U.S. patent application number 14/721439 was filed with the patent office on 2015-09-10 for method of evaluating pancreatic cancer, pancreatic cancer-evaluating apparatus, pancreatic cancer-evaluating method, pancreatic cancer-evaluating program product, pancreatic cancer-evaluating system, and information communication terminal apparatus.
This patent application is currently assigned to Ajinomoto Co., Inc.. The applicant listed for this patent is Ajinomoto Co., Inc.. Invention is credited to Nobuyasu Fukutake, Masahiko Higashiyama, Kazuhiro Katayama, Shinya Kikuchi, Yohei Miyagi, Takahiko Muramatsu, Shinichi Ohkawa, Naoyuki Okamoto, Nobukazu Ono, Atsuko Shinhara, Koichi Shiraishi, Makoto Ueno, Hiroshi Yamamoto.
Application Number | 20150254411 14/721439 |
Document ID | / |
Family ID | 50827922 |
Filed Date | 2015-09-10 |
United States Patent
Application |
20150254411 |
Kind Code |
A1 |
Ono; Nobukazu ; et
al. |
September 10, 2015 |
METHOD OF EVALUATING PANCREATIC CANCER, PANCREATIC
CANCER-EVALUATING APPARATUS, PANCREATIC CANCER-EVALUATING METHOD,
PANCREATIC CANCER-EVALUATING PROGRAM PRODUCT, PANCREATIC
CANCER-EVALUATING SYSTEM, AND INFORMATION COMMUNICATION TERMINAL
APPARATUS
Abstract
A method of evaluating pancreatic cancer includes (I) an
obtaining step of obtaining amino acid concentration data on a
concentration value of an amino acid in blood collected from a
subject to be evaluated, and (II) an evaluating step of evaluating
a state of pancreatic cancer in the subject by calculating a value
of a formula using the amino acid concentration data of the subject
obtained at the obtaining step and the formula previously
established for evaluating the state of pancreatic cancer,
including an explanatory variable to be substituted with the
concentration value of the amino acid. The amino acid concentration
data includes the concentration values of at least two amino acids
of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro,
Orn, Ile, Leu, Phe, Ser, and Gln, and the formula includes at least
two explanatory variables to be substituted with the concentration
values of at least two amino acids of Asn, His, Thr, Ala, Cit, Arg,
Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and
Gln.
Inventors: |
Ono; Nobukazu; (Kanagawa,
JP) ; Shinhara; Atsuko; (Kanagawa, JP) ;
Muramatsu; Takahiko; (Kanagawa, JP) ; Kikuchi;
Shinya; (Kanagawa, JP) ; Yamamoto; Hiroshi;
(Kanagawa, JP) ; Shiraishi; Koichi; (Kanagawa,
JP) ; Katayama; Kazuhiro; (Osaka, JP) ;
Fukutake; Nobuyasu; (Osaka, JP) ; Higashiyama;
Masahiko; (Osaka, JP) ; Ohkawa; Shinichi;
(Kanagawa, JP) ; Ueno; Makoto; (Kanagawa, JP)
; Miyagi; Yohei; (Kanagawa, JP) ; Okamoto;
Naoyuki; (Kanagawa, JP) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Ajinomoto Co., Inc. |
Tokyo |
|
JP |
|
|
Assignee: |
Ajinomoto Co., Inc.
Tokyo
JP
|
Family ID: |
50827922 |
Appl. No.: |
14/721439 |
Filed: |
May 26, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
PCT/JP2013/081981 |
Nov 27, 2013 |
|
|
|
14721439 |
|
|
|
|
Current U.S.
Class: |
702/19 |
Current CPC
Class: |
G16B 99/00 20190201;
G01N 33/6806 20130101; G16H 50/20 20180101; G01N 33/57438
20130101 |
International
Class: |
G06F 19/00 20060101
G06F019/00 |
Foreign Application Data
Date |
Code |
Application Number |
Nov 27, 2012 |
JP |
2012-259167 |
Claims
1. A method of evaluating pancreatic cancer, comprising: an
obtaining step of obtaining amino acid concentration data on a
concentration value of an amino acid in blood collected from a
subject to be evaluated; and an evaluating step of evaluating a
state of pancreatic cancer in the subject by calculating a value of
a formula using (i) the amino acid concentration data of the
subject obtained at the obtaining step and (ii) the formula
previously established for evaluating the state of pancreatic
cancer, including an explanatory variable to be substituted with
the concentration value of the amino acid, wherein the amino acid
concentration data includes the concentration values of at least
two amino acids of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met,
Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln, and the
formula includes at least two explanatory variables to be
substituted with the concentration values of at least two amino
acids of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp,
Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln.
2. The method of evaluating pancreatic cancer according to claim 1,
wherein the state of pancreatic cancer is the degree of the
possibility of being affected with pancreatic cancer, and
evaluating the state of pancreatic cancer in the subject is
evaluating the degree of the possibility that the subject is
affected with pancreatic cancer.
3. The method of evaluating pancreatic cancer according to claim 2,
wherein a plurality of categories defined considering at least the
degree of the possibility of being affected with pancreatic cancer,
and one or more thresholds are previously established, and
evaluating the degree of the possibility that the subject is
affected with pancreatic cancer is classifying the subject into any
one of the categories using the value of the formula and the
threshold.
4. The method of evaluating pancreatic cancer according to claim 3,
wherein the categories include at least one category defined
considering at least the degree of the possibility of being
affected with pancreatic cancer and the degree of the possibility
of being affected with a cancer other than pancreatic cancer.
5. The method of evaluating pancreatic cancer according to claim 3,
wherein the categories include a category to which a subject with a
high possibility of being affected with pancreatic cancer belongs
and a category to which a subject with a low possibility of being
affected with pancreatic cancer belongs.
6. The method of evaluating pancreatic cancer according to claim 5,
wherein the category to which a subject with a low possibility of
being affected with pancreatic cancer belongs is a healthy category
to which a subject with a high possibility of being healthy
belongs, other cancer category to which a subject with a high
possibility of being affected with a cancer other than pancreatic
cancer belongs, or a healthy/other cancer category to which a
subject with a high possibility of being healthy and a subject with
a high possibility of being affected with a cancer other than
pancreatic cancer belong.
7. The method of evaluating pancreatic cancer according to claim 5,
wherein the category to which a subject with a low possibility of
being affected with pancreatic cancer belongs includes a healthy
category to which a subject with a high possibility of being
healthy belongs and other cancer category to which a subject with a
high possibility of being affected with a cancer other than
pancreatic cancer belongs.
8. The method of evaluating pancreatic cancer according to claim 1,
wherein the formula is any one of a logistic regression equation, a
fractional expression, a linear discriminant, a multiple regression
equation, a formula prepared by a support vector machine, a formula
prepared by a Mahalanobis' generalized distance method, a formula
prepared by canonical discriminant analysis, and a formula prepared
by a decision tree.
9. A pancreatic cancer-evaluating apparatus comprising a control
unit and a memory unit to evaluate a state of pancreatic cancer in
a subject to be evaluated, wherein the control unit includes: an
evaluating unit that evaluates the state of pancreatic cancer in
the subject by calculating a value of a formula using (i)
previously obtained amino acid concentration data of the subject on
a concentration value of an amino acid and (ii) the formula
previously stored in the memory unit for evaluating the state of
pancreatic cancer, including an explanatory variable to be
substituted with the concentration value of the amino acid, wherein
the amino acid concentration data includes the concentration values
of at least two amino acids of Asn, His, Thr, Ala, Cit, Arg, Tyr,
Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln, and
the formula includes at least two explanatory variables to be
substituted with the concentration values of at least two amino
acids of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp,
Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln.
10. A pancreatic cancer-evaluating method of evaluating a state of
pancreatic cancer in a subject to be evaluated, which method is
carried out with an information processing apparatus including a
control unit and a memory unit, the method comprising: an
evaluating step of evaluating the state of pancreatic cancer in the
subject by calculating a value of a formula using (i) previously
obtained amino acid concentration data of the subject on a
concentration value of an amino acid and (ii) the formula
previously stored in the memory unit for evaluating the state of
pancreatic cancer, including an explanatory variable to be
substituted with the concentration value of the amino acid, wherein
the amino acid concentration data includes the concentration values
of at least two amino acids of Asn, His, Thr, Ala, Cit, Arg, Tyr,
Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln, the
formula includes at least two explanatory variables to be
substituted with the concentration values of at least two amino
acids of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp,
Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln, and the evaluating step
is executed by the control unit.
11. A pancreatic cancer-evaluating program product having a
non-transitory computer readable medium including programmed
instructions for making an information processing apparatus
including a control unit and a memory unit execute a method of
evaluating a state of pancreatic cancer in a subject to be
evaluated, the method comprising: an evaluating step of evaluating
the state of pancreatic cancer in the subject by calculating a
value of a formula using (i) previously obtained amino acid
concentration data of the subject on a concentration value of an
amino acid and (ii) the formula previously stored in the memory
unit for evaluating the state of pancreatic cancer, including an
explanatory variable to be substituted with the concentration value
of the amino acid, wherein the amino acid concentration data
includes the concentration values of at least two amino acids of
Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro,
Orn, Ile, Leu, Phe, Ser, and Gln, the formula includes at least two
explanatory variables to be substituted with the concentration
values of at least two amino acids of Asn, His, Thr, Ala, Cit, Arg,
Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and
Gln, and the evaluating step is executed by the control unit.
12. A pancreatic cancer-evaluating system comprising (I) a
pancreatic cancer-evaluating apparatus including a control unit and
a memory unit to evaluate a state of pancreatic cancer in a subject
to be evaluated and (II) an information communication terminal
apparatus including a control unit to provide amino acid
concentration data of the subject on a concentration value of an
amino acid that are connected to each other communicatively via a
network, wherein the control unit of the information communication
terminal apparatus includes: an amino acid concentration
data-sending unit that transmits the amino acid concentration data
of the subject to the pancreatic cancer-evaluating apparatus; and
an evaluation result-receiving unit that receives an evaluation
result on the state of pancreatic cancer in the subject,
transmitted from the pancreatic cancer-evaluating apparatus, and
the control unit of the pancreatic cancer-evaluating apparatus
includes: an amino acid concentration data-receiving unit that
receives the amino acid concentration data of the subject
transmitted from the information communication terminal apparatus;
an evaluating unit that evaluates the state of pancreatic cancer in
the subject by calculating a value of a formula using (i) the amino
acid concentration data of the subject received by the amino acid
concentration data-receiving unit and (ii) the formula previously
stored in the memory unit for evaluating the state of pancreatic
cancer, including an explanatory variable to be substituted with
the concentration value of the amino acid; and an evaluation
result-sending unit that transmits the evaluation result of the
subject obtained by the evaluating unit to the information
communication terminal apparatus, wherein the amino acid
concentration data includes the concentration values of at least
two amino acids of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met,
Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln, and the
formula includes at least two explanatory variables to be
substituted with the concentration values of at least two amino
acids of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp,
Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln.
13. An information communication terminal apparatus comprising a
control unit to provide amino acid concentration data of a subject
to be evaluated on a concentration value of an amino acid, being
connected communicatively via a network to a pancreatic
cancer-evaluating apparatus that evaluates a state of pancreatic
cancer in the subject, wherein the control unit includes: an amino
acid concentration data-sending unit that transmits the amino acid
concentration data of the subject to the pancreatic
cancer-evaluating apparatus; and an evaluation result-receiving
unit that receives an evaluation result on the state of pancreatic
cancer in the subject, transmitted from the pancreatic
cancer-evaluating apparatus, wherein the evaluation result is the
result of (I) receiving the amino acid concentration data of the
subject transmitted from the information communication terminal
apparatus and (II) evaluating the state of pancreatic cancer in the
subject by calculating a value of a formula using (i) the received
amino acid concentration data of the subject and (ii) the formula
previously stored in the pancreatic cancer-evaluating apparatus for
evaluating the state of pancreatic cancer, including an explanatory
variable to be substituted with the concentration value of the
amino acid, wherein the (I) and (II) are executed by the pancreatic
cancer-evaluating apparatus, wherein the amino acid concentration
data includes the concentration values of at least two amino acids
of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro,
Orn, Ile, Leu, Phe, Ser, and Gln, and the formula includes at least
two explanatory variables to be substituted with the concentration
values of at least two amino acids of Asn, His, Thr, Ala, Cit, Arg,
Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and
Gln.
14. A pancreatic cancer-evaluating apparatus comprising a control
unit and a memory unit to evaluate a state of pancreatic cancer in
a subject to be evaluated, being connected communicatively via a
network to an information communication terminal apparatus that
provides amino acid concentration data of the subject on a
concentration value of an amino acid, wherein the control unit
includes: an amino acid concentration data-receiving unit that
receives the amino acid concentration data of the subject
transmitted from the information communication terminal apparatus;
an evaluating unit that evaluates the state of pancreatic cancer in
the subject by calculating a value of a formula using (i) the amino
acid concentration data of the subject received by the amino acid
concentration data-receiving unit and (ii) the formula previously
stored in the memory unit for evaluating the state of pancreatic
cancer, including an explanatory variable to be substituted with
the concentration value of the amino acid; and an evaluation
result-sending unit that transmits an evaluation result on the
state of pancreatic cancer in the subject obtained by the
evaluating unit to the information communication terminal
apparatus, wherein the amino acid concentration data includes the
concentration values of at least two amino acids of Asn, His, Thr,
Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu,
Phe, Ser, and Gln, and the formula includes at least two
explanatory variables to be substituted with the concentration
values of at least two amino acids of Asn, His, Thr, Ala, Cit, Arg,
Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and
Gln.
Description
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This application is based upon and claims the benefit of
priority from PCT Application PCT/JP2013/081981, filed Nov. 27,
2013, which claims priority from Japanese Patent Application No.
2012-259167, filed Nov. 27, 2012, the entire contents of which are
incorporated herein by reference.
BACKGROUND OF THE INVENTION
[0002] 1. Field of the Invention
[0003] The present invention relates to a method of evaluating
pancreatic cancer, a pancreatic cancer-evaluating apparatus, a
pancreatic cancer-evaluating method, a pancreatic cancer-evaluating
program product, a pancreatic cancer-evaluating system, and an
information communication terminal apparatus.
[0004] 2. Description of the Related Art
[0005] In Japan, the number of male deaths from pancreatic cancer
in 2009 is 14094, which ranks fifth in the total number of male
deaths from cancer and the number of female deaths from pancreatic
cancer in 2009 is 12697, which ranks fourth in the total number of
female deaths from cancer. The lifetime incidence rate of
pancreatic cancer is 2%.
[0006] Pancreatic cancer has few symptoms in some cancer sites and
is often found at an advanced stage. Even when detected at a size
of 2 cm or smaller using image diagnosis, pancreatic cancer has
often spread to adjacent tissues outside the pancreas and has an
extremely poor prognosis. It is desired that pancreatic cancer
should be found at an operable earlier stage.
[0007] Pancreatic cancer is diagnosed using abdominal
ultrasonography, CT (computed tomography), or MRI (magnetic
resonance imaging), in all of which the detection rate is not
high.
[0008] Serum tumor markers include CA19-9, CEA, SPan-1, DUPAN-2,
and the like. These markers have relatively high sensitivity and
specificity for advanced cancer but have a low positive rate for
early cancer and may be positive even in cancers other than
pancreatic cancer.
[0009] Image diagnosis using an endoscopy, such as ERCP (endoscopic
retrograde cholangiopancreatography) and EUS (endoscopic
ultrasonography), is known to be effective with a high detection
rate for pancreatic cancer but increases the patient's physical
burden and is unsuitable for population screening and may have a
risk of bleeding. Histologic diagnosis by biopsy provides a
definite diagnosis, but is a highly invasive test. Performing a
biopsy at the screening is not practical.
[0010] It is therefore desirable from the viewpoints of a physical
burden imposed on patients and of cost-benefit performance to
narrow down the target range of subjects with a high possibility of
onset of pancreatic cancer and to subject those people to
treatment. Specifically, it is desirable to narrow the target range
of subjects by selecting subjects in accordance with a less
invasive method and subjecting the selected subjects to image
diagnosis, and to treat the subjects who are definitively diagnosed
as having pancreatic cancer.
[0011] It is known that the concentrations of amino acids in blood
change as a result of onset of cancer. For example, Cynober
("Cynober, L. ed., Metabolic and therapeutic aspects of amino acids
in clinical nutrition. 2nd ed., CRC Press") has reported that the
amount of consumption increases in cancer cells, for glutamine
mainly as an oxidation energy source, for arginine as a precursor
of nitrogen oxide and polyamine, and for methionine through the
activation of the ability of cancer cells to take in methionine.
Schrader et al. ("Schrader H, Menge B A, Belyaev O, Uhl W, Schmidt
W E, Meier J J., Amino acid malnutrition in patients with chronic
pancreatitis and pancreatic carcinoma. Pancreas. 2009 May;
38(4):416-21.") and Vissers et al. ("Vissers Y L, Dejong C H,
Luiking Y C, Fearon K C, von Meyenfeldt M F, Deutz N E. Plasma
arginine concentrations are reduced in cancer patients: evidence
for arginine deficiency? Am J Clin Nutr. 2005 May; 81(5):1142-6.")
have reported that the amino acid composition in plasma in
pancreatic cancer patients is different from that of healthy
subjects.
[0012] JP-A-2011-247869 discloses that "of biogenic substances in a
sample collected from a subject, a specified finite number of
analysis object substances are selected, the quantity is
determined, a multivariate analysis is performed to perform
metabolome analysis, and the analysis result is compared with the
analysis results of a healthy subject group and a disease patient
group obtained beforehand. Thus, the inspections of specific
diseases, such as early diagnosis, determination of therapeutic
effect and prognosis for instance, can be easily performed." The
example described in JP-A-2011-247869 describes that "a
multivariate analysis using 61 components is performed using
SIMCA-P+ (Umetrics). The difference is examined using the score
plot of principal component analysis (PCA). Of, in total, 61
analyzed biomoleculars, PC1(t[1]), PC2(t[2]), and PC3(t[3]) are of
20 (32.3%), 15 (24.7%), and 7 (12.0%), respectively, in the 61
components (A=3, R2X=0.69). It is thus confirmed that the
distributions of analyzed biomoleculars in pancreatic cancer
patients and healthy subjects are different," on data of serum
metabolomes measured by GCMS (gas chromatography and mass
spectroscopy) for healthy subjects and pancreatic cancer.
[0013] WO 2004/052191, WO 2006/098192, and WO 2009/054351 related
to a method of relating an amino acid concentration and a
biological state are disclosed as previous patents. WO 2008/016111
related to a method of evaluating a state of lung cancer using an
amino acid concentration, WO 2008/075662 related to a method of
evaluating a state of breast cancer using an amino acid
concentration, WO 2008/075663 related to a method of evaluating a
state of colorectal cancer using an amino acid concentration, WO
2008/075664 related to a method of evaluating a state of cancer
using an amino acid concentration, WO 2009/099005 related to a
method of evaluating a state of gastric cancer using an amino acid
concentration, WO 2009/110517 related to a method of evaluating a
cancer type using an amino acid concentration, WO 2009/154296
related to a method of evaluating a state of female genital cancer
using an amino acid concentration, and WO 2009/154297 related to a
method of evaluating a state of prostatic disease including at
least one of prostatic cancer and prostatic hypertrophy using an
amino acid concentration are disclosed as previous patents.
[0014] However, neither "Schrader H, Menge B A, Belyaev O, Uhl W,
Schmidt W E, Meier J J., Amino acid malnutrition in patients with
chronic pancreatitis and pancreatic carcinoma. Pancreas. 2009 May;
38(4):416-21." nor "Vissers Y L, Dejong C H, Luiking Y C, Fearon K
C, von Meyenfeldt M F, Deutz N E. Plasma arginine concentrations
are reduced in cancer patients: evidence for arginine deficiency?
Am J Clin Nutr. 2005 May; 81(5):1142-6." search for a combination
of biomoleculars or an index formula using multivariate analysis
optimum for evaluating a state of pancreatic cancer.
[0015] The example described in JP-A-2011-247869 merely shows the
tendency of general components of a large number of analyzed
biomolecular components using the principal component analysis,
which is one of multivariate analyses, and does not search for a
combination of biomoleculars or an index formula using multivariate
analysis optimum for evaluating a state of pancreatic cancer.
[0016] Even when the index formulae disclosed in WO 2004/052191, WO
2006/098192, WO 2009/054351, WO 2008/016111, WO 2008/075662, WO
2008/075663, WO 2008/075664, WO 2009/099005, WO 2009/110517, WO
2009/154296, and WO 2009/154297 are used for evaluating a state of
pancreatic cancer, evaluation results having sufficient reliability
cannot be obtained because diseases to be evaluated are different.
In particular, WO 2009/110517 describes a method of evaluating a
cancer type but does not describe a blood marker or an index
formula specifically suitable for classification into subjects with
a high possibility of being affected with pancreatic cancer and
subjects with a high possibility of being affected with cancers
other than pancreatic cancer. WO 2009/110517 does not describe an
index formula that accurately classifies subjects into subjects
with a high possibility of being affected with pancreatic cancer
and subjects with a low possibility of being affected with
pancreatic cancer and that is suitable for classification into
subjects with a high possibility of being affected with pancreatic
cancer and subjects with a high possibility of being affected with
cancers other than pancreatic cancer.
[0017] No blood marker has been reported for classification into
subjects with a high possibility of being affected with pancreatic
cancer and subjects with a high possibility of being affected with
cancers other than pancreatic cancer, such as colorectal cancer,
lung cancer, breast cancer, prostatic cancer, gastric cancer,
uterine cancer (cervical cancer, endometrial cancer), and ovarian
cancer.
[0018] There is a problem that a method of evaluating a state of
pancreatic cancer using a formula including at least two
explanatory variables to be substituted with the concentration
values of at least two amino acids has not been developed nor put
into practice.
SUMMARY OF THE INVENTION
[0019] It is an object of the present invention to at least
partially solve the problems in the conventional technology.
[0020] The present invention has been made in view of the problems
described above, and an object of the present invention is to
provide a method of evaluating pancreatic cancer, a pancreatic
cancer-evaluating apparatus, a pancreatic cancer-evaluating method,
a pancreatic cancer-evaluating program product, a pancreatic
cancer-evaluating system, and an information communication terminal
apparatus, which can provide reliable information that may be
helpful in knowing a state of pancreatic cancer.
[0021] To solve the problem and achieve the object described above,
a method of evaluating pancreatic cancer according to one aspect of
the present invention includes an obtaining step of obtaining amino
acid concentration data on a concentration value of an amino acid
in blood collected from a subject to be evaluated, and an
evaluating step of evaluating a state of pancreatic cancer in the
subject by calculating a value of a formula (hereinafter referred
sometimes as the value of the evaluation formula or the evaluation
value) using the amino acid concentration data of the subject
obtained at the obtaining step and the formula (hereinafter
referred sometimes as the evaluation formula) previously
established for evaluating the state of pancreatic cancer,
including an explanatory variable to be substituted with the
concentration value of the amino acid, wherein the amino acid
concentration data includes the concentration values of at least
two amino acids of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met,
Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln, and the
formula includes at least two explanatory variables to be
substituted with the concentration values of at least two amino
acids of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp,
Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln.
[0022] In the present specification, various amino acids are mainly
written in abbreviations, the formal names of these are as
follows.
TABLE-US-00001 (Abbreviation) (Formal name) Ala Alanine Arg
Arginine Asn Asparagine Cit Citrulline Gln Glutamine Gly Glycine
His Histidine Ile Isoleucine Leu Leucine Lys Lysine Met Methionine
Orn Ornithine Phe Phenylalanine Pro Proline Ser Serine Thr
Threonine Trp Tryptophan Tyr Tyrosine Val Valine
[0023] The method of evaluating pancreatic cancer according to
another aspect of the present invention is the method of evaluating
pancreatic cancer, wherein the state of pancreatic cancer is the
degree of the possibility of being affected with pancreatic cancer,
and evaluating the state of pancreatic cancer in the subject is
evaluating the degree of the possibility that the subject is
affected with pancreatic cancer.
[0024] In the present specification, as an example of the state of
pancreatic cancer, for example, the degree of progress of
pancreatic cancer is included in addition to the degree of the
possibility being affected with pancreatic cancer.
[0025] The method of evaluating pancreatic cancer according to
still another aspect of the present invention is the method of
evaluating pancreatic cancer, wherein a plurality of categories
defined considering at least the degree of the possibility of being
affected with pancreatic cancer, and one or more thresholds are
previously established, and evaluating the degree of the
possibility that the subject is affected with pancreatic cancer is
classifying the subject into any one of the categories using the
value of the formula and the threshold.
[0026] The method of evaluating pancreatic cancer according to
still another aspect of the present invention is the method of
evaluating pancreatic cancer, wherein the categories include at
least one category defined considering at least the degree of the
possibility of being affected with pancreatic cancer and the degree
of the possibility of being affected with a cancer other than
pancreatic cancer.
[0027] The method of evaluating pancreatic cancer according to
still another aspect of the present invention is the method of
evaluating pancreatic cancer, wherein the categories include a
category (hereinafter, also referred to as the category X) to which
a subject with a high possibility of being affected with pancreatic
cancer (for example, a subject assumed to be affected with
pancreatic cancer) belongs and a category (hereinafter, also
referred to as the category Y) to which a subject with a low
possibility of being affected with pancreatic cancer (for example,
a subject assumed to be not affected with pancreatic cancer)
belongs.
[0028] The method of evaluating pancreatic cancer according to
still another aspect of the present invention is the method of
evaluating pancreatic cancer, wherein the category to which a
subject with a low possibility of being affected with pancreatic
cancer belongs, includes a healthy category to which a subject with
a high possibility of being healthy (for example, a subject assumed
to be healthy) belongs, other cancer category to which a subject
with a high possibility of being affected with a cancer other than
pancreatic cancer (for example, a subject assumed to be affected
with a cancer other than pancreatic cancer) belongs, or a
healthy/other cancer category to which a subject with a high
possibility of being healthy and a subject with a high possibility
of being affected with a cancer other than pancreatic cancer
belong.
[0029] The method of evaluating pancreatic cancer according to
still another aspect of the present invention is the method of
evaluating pancreatic cancer, wherein the category to which a
subject with a low possibility of being affected with pancreatic
cancer belongs includes the healthy category to which a subject
with a high possibility of being healthy belongs and the other
cancer category to which a subject with a high possibility of being
affected with a cancer other than pancreatic cancer belongs.
[0030] The method of evaluating pancreatic cancer according to
still another aspect of the present invention is the method of
evaluating pancreatic cancer, wherein the formula is any one of a
logistic regression equation, a fractional expression, a linear
discriminant, a multiple regression equation, a formula prepared by
a support vector machine, a formula prepared by a Mahalanobis'
generalized distance method, a formula prepared by canonical
discriminant analysis, and a formula prepared by a decision
tree.
[0031] The method of evaluating pancreatic cancer according to
still another aspect of the present invention may be the method of
evaluating pancreatic cancer, wherein evaluating the state of
pancreatic cancer in the subject is deciding that the value of the
formula reflects the state of pancreatic cancer in the subject.
[0032] The method of evaluating pancreatic cancer according to
still another aspect of the present invention may be the method of
evaluating pancreatic cancer, wherein at the evaluating step, the
value of the formula is converted by a predetermined method, and it
is decided that the converted value reflects the state of
pancreatic cancer in the subject.
[0033] The method of evaluating pancreatic cancer according to
still another aspect of the present invention may be the method of
evaluating pancreatic cancer, wherein at the evaluating step, a
positional information about a position of a predetermined mark
corresponding to the value of the formula or the converted value is
generated on a predetermined scale visually presented on a display
device such as a monitor or a physical medium such as paper for
evaluating the state of pancreatic cancer, using the value of the
formula or the converted value, and it is decided that the
generated positional information reflects the state of pancreatic
cancer in the subject.
[0034] The method of evaluating pancreatic cancer according to
still another aspect of the present invention may be the method of
evaluating pancreatic cancer, wherein at the evaluating step, the
value of the formula is converted by a predetermined method, and
the subject is classified into any one of the categories using the
converted value.
[0035] The method of evaluating pancreatic cancer according to
still another aspect of the present invention may be the method of
evaluating pancreatic cancer, wherein the categories are the
category X and the category Y, and at the evaluating step, the
subject is classified into one of the category X and the category
Y. When the classification is executed, the category X may be
written as for example, a pancreatic cancer category, and the
category Y may be written as for example, a pancreatic cancer-free
category.
[0036] The method of evaluating pancreatic cancer according to
still another aspect of the present invention may be the method of
evaluating pancreatic cancer, wherein (I) the formula is named as a
first formula, a second formula that is different from the first
formula and includes at least two explanatory variables to be
substituted with the concentration values of at least two amino
acids of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp,
Gly, Pro, Orn, Ile, Leu, Phe, Ser, Gln is previously established,
and (II) at the evaluating step, the value of the first formula and
the value of the second formula are calculated, and the subject is
classified into one of the category X and the category Y using the
calculated values of the first formula and the second formula.
[0037] The method of evaluating pancreatic cancer according to
still another aspect of the present invention may be the method of
evaluating pancreatic cancer, wherein (I) the category Y includes
the healthy category to which a subject with a high possibility of
being healthy belongs and the other cancer category to which a
subject with a high possibility of being affected with a cancer
other than pancreatic cancer belongs, the first formula is a
formula for classifying a subject into one of the category X and
the healthy category, the second formula is a formula for
classifying a subject into one of the category X and the other
cancer category, and (II) at the evaluating step, (i) the value of
the first formula is first calculated, (ii) the subject is
classified into one of the category X and the healthy category
using the calculated value of the first formula, (iii) then if the
classification result is the category X, the value of the second
formula is calculated, (iv) the subject classified in the category
X using the value of the first formula is further classified into
one of the category X and the other cancer category using the
calculated value of the second formula, and then (v) the subject
classified in the healthy category and the subject classified in
the other cancer category is finally classified into the category
Y.
[0038] The method of evaluating pancreatic cancer according to
still another aspect of the present invention may be the method of
evaluating pancreatic cancer, wherein at the evaluating step, the
subject is classified into one of the category X and the healthy
category. When the classification is executed, the category X may
be written as for example, the pancreatic cancer category.
[0039] The method of evaluating pancreatic cancer according to
still another aspect of the present invention may be the method of
evaluating pancreatic cancer, wherein at the evaluating step, the
subject is classified into one of the category X and the other
cancer category. When the classification is executed, the category
X may be written as for example, the pancreatic cancer
category.
[0040] The method of evaluating pancreatic cancer according to
still another aspect of the present invention may be the method of
evaluating pancreatic cancer, wherein at the evaluating step, the
subject is classified into one of the category X and the
healthy/other cancer category. When the classification is executed,
the category X may be written as for example, the pancreatic cancer
category.
[0041] The method of evaluating pancreatic cancer according to
still another aspect of the present invention may be the method of
evaluating pancreatic cancer, wherein at the evaluating step, the
subject is classified into any one of the category X, the healthy
category, and the other cancer category. When the classification is
executed, the category X may be written as for example, the
pancreatic cancer category.
[0042] The method of evaluating pancreatic cancer according to
still another aspect of the present invention may be the method of
evaluating pancreatic cancer, wherein (I) the formula is named as a
first formula, a second formula that is different from the first
formula and includes at least two explanatory variables to be
substituted with the concentration values of at least two amino
acids of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp,
Gly, Pro, Orn, Ile, Leu, Phe, Ser, Gln is previously established,
and (II) at the evaluating step, the value of the first formula and
the value of the second formula are calculated, and the subject is
classified into any one of the category X, the healthy category,
and the other cancer category using the calculated values of the
first formula and the second formula.
[0043] The method of evaluating pancreatic cancer according to
still another aspect of the present invention may be the method of
evaluating pancreatic cancer, wherein (I) the first formula is a
formula for classifying a subject into one of the category X and
the healthy category, the second formula is a formula for
classifying a subject into one of the category X and the other
cancer category, and (II) at the evaluating step, (i) the value of
the first formula is first calculated, (ii) the subject is
classified into one of the category X and the healthy category
using the calculated value of the first formula, (iii) then if the
classification result is the category X, the value of the second
formula is calculated, (iv) the subject classified in the category
X using the value of the first formula is further classified into
one of the category X and the other cancer category using the
calculated value of the second formula, and then (v) the subject
classified in the category X using the value of the first formula
and classified in the other cancer category using the value of the
second formula is finally classified into the other cancer
category.
[0044] A pancreatic cancer-evaluating apparatus according to one
aspect of the present invention includes a control unit and a
memory unit to evaluate a state of pancreatic cancer in a subject
to be evaluated, wherein the control unit includes an evaluating
unit that evaluates the state of pancreatic cancer in the subject
by calculating a value of a formula using previously obtained amino
acid concentration data of the subject on a concentration value of
an amino acid and the formula previously stored in the memory unit
for evaluating the state of pancreatic cancer, including an
explanatory variable to be substituted with the concentration value
of the amino acid, wherein the amino acid concentration data
includes the concentration values of at least two amino acids of
Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro,
Orn, Ile, Leu, Phe, Ser, and Gln, and the formula includes at least
two explanatory variables to be substituted with the concentration
values of at least two amino acids of Asn, His, Thr, Ala, Cit, Arg,
Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and
Gln.
[0045] The pancreatic cancer-evaluating apparatus according to
another aspect of the present invention may be the pancreatic
cancer-evaluating apparatus, wherein (I) the control unit further
includes an evaluation formula-preparing unit that prepares the
evaluation formula stored in the memory unit, based on prostatic
cancer state information stored in the memory unit, including the
amino acid concentration data and prostatic cancer state index data
on an index for indicating the state of prostatic cancer, wherein
(II) the evaluation formula-preparing unit further includes (i) a
candidate formula-preparing unit that prepares a candidate formula
that is a candidate of the evaluation formula, based on a
predetermined formula-preparing method from the pancreatic cancer
state information, (ii) a candidate formula-verifying unit that
verifies the candidate formula prepared by the candidate
formula-preparing unit, based on a predetermined verifying method,
and (iii) an explanatory variable-selecting unit that selects the
explanatory variable of the candidate formula based on a
predetermined explanatory variable-selecting method thereby
selecting a combination of the amino acid concentration data
included in the pancreatic cancer state information used in
preparing the candidate formula, and (iv) the evaluation
formula-preparing unit prepares the evaluation formula by selecting
the candidate formula used as the evaluation formula, from a
plurality of the candidate formulae, based on the verification
results accumulated by repeatedly executing the candidate
formula-preparing unit, the candidate formula-verifying unit, and
the explanatory variable-selecting unit.
[0046] A pancreatic cancer-evaluating method according to one
aspect of the present invention is a method of evaluating a state
of pancreatic cancer in a subject to be evaluated, which method is
carried out with an information processing apparatus including a
control unit and a memory unit, wherein the method includes an
evaluating step of evaluating the state of pancreatic cancer in the
subject by calculating a value of a formula using previously
obtained amino acid concentration data of the subject on a
concentration value of an amino acid and the formula previously
stored in the memory unit for evaluating the state of pancreatic
cancer, including an explanatory variable to be substituted with
the concentration value of the amino acid, wherein the amino acid
concentration data includes the concentration values of at least
two amino acids of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met,
Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln, the formula
includes at least two explanatory variables to be substituted with
the concentration values of at least two amino acids of Asn, His,
Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile,
Leu, Phe, Ser, and Gln, and the evaluating step is executed by the
control unit.
[0047] A pancreatic cancer-evaluating program product according to
one aspect of the present invention has a non-transitory computer
readable medium including programmed instructions for making an
information processing apparatus including a control unit and a
memory unit execute a method of evaluating a state of pancreatic
cancer in a subject to be evaluated, wherein the method includes an
evaluating step of evaluating the state of pancreatic cancer in the
subject by calculating a value of a formula using previously
obtained amino acid concentration data of the subject on a
concentration value of an amino acid and the formula previously
stored in the memory unit for evaluating the state of pancreatic
cancer, including an explanatory variable to be substituted with
the concentration value of the amino acid, wherein the amino acid
concentration data includes the concentration values of at least
two amino acids of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met,
Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln, the formula
includes at least two explanatory variables to be substituted with
the concentration values of at least two amino acids of Asn, His,
Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile,
Leu, Phe, Ser, and Gln, and the evaluating step is executed by the
control unit.
[0048] A non-transitory computer-readable recording medium
according to one aspect of the present invention includes the
programmed instructions for making an information processing
apparatus execute the pancreatic cancer-evaluating method.
[0049] A pancreatic cancer-evaluating system according to one
aspect of the present invention includes (I) a pancreatic
cancer-evaluating apparatus including a control unit and a memory
unit to evaluate a state of pancreatic cancer in a subject to be
evaluated and (II) an information communication terminal apparatus
including a control unit to provide amino acid concentration data
of the subject on a concentration value of an amino acid that are
connected to each other communicatively via a network, wherein
(III) the control unit of the information communication terminal
apparatus includes an amino acid concentration data-sending unit
that transmits the amino acid concentration data of the subject to
the pancreatic cancer-evaluating apparatus and an evaluation
result-receiving unit that receives an evaluation result on the
state of pancreatic cancer in the subject, transmitted from the
pancreatic cancer-evaluating apparatus, and (IV) the control unit
of the pancreatic cancer-evaluating apparatus includes an amino
acid concentration data-receiving unit that receives the amino acid
concentration data of the subject transmitted from the information
communication terminal apparatus, an evaluating unit that evaluates
the state of pancreatic cancer in the subject by calculating a
value of a formula using the amino acid concentration data of the
subject received by the amino acid concentration data-receiving
unit and the formula previously stored in the memory unit for
evaluating the state of pancreatic cancer, including an explanatory
variable to be substituted with the concentration value of the
amino acid, and an evaluation result-sending unit that transmits
the evaluation result of the subject obtained by the evaluating
unit to the information communication terminal apparatus, wherein
(V) the amino acid concentration data includes the concentration
values of at least two amino acids of Asn, His, Thr, Ala, Cit, Arg,
Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and
Gln, and the formula includes at least two explanatory variables to
be substituted with the concentration values of at least two amino
acids of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp,
Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln.
[0050] An information communication terminal apparatus according to
one aspect of the present invention includes a control unit to
provide amino acid concentration data of a subject to be evaluated
on a concentration value of an amino acid, being connected
communicatively via a network to a pancreatic cancer-evaluating
apparatus that evaluates a state of pancreatic cancer in the
subject, wherein the control unit includes an amino acid
concentration data-sending unit that transmits the amino acid
concentration data of the subject to the pancreatic
cancer-evaluating apparatus, and an evaluation result-receiving
unit that receives an evaluation result on the state of pancreatic
cancer in the subject, transmitted from the pancreatic
cancer-evaluating apparatus, wherein the evaluation result is the
result of (I) receiving the amino acid concentration data of the
subject transmitted from the information communication terminal
apparatus and (II) evaluating the state of pancreatic cancer in the
subject by calculating a value of a formula using the received
amino acid concentration data of the subject and the formula
previously stored in the pancreatic cancer-evaluating apparatus for
evaluating the state of pancreatic cancer, including an explanatory
variable to be substituted with the concentration value of the
amino acid, wherein the (I) and (II) are executed by the pancreatic
cancer-evaluating apparatus, wherein the amino acid concentration
data includes the concentration values of at least two amino acids
of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro,
Orn, Ile, Leu, Phe, Ser, and Gln, and the formula includes at least
two explanatory variables to be substituted with the concentration
values of at least two amino acids of Asn, His, Thr, Ala, Cit, Arg,
Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and
Gln. An information communication terminal apparatus according to
one aspect of the present invention includes a control unit to
provide amino acid concentration data of a subject to be evaluated
on a concentration value of an amino acid, wherein the control unit
includes an evaluation result-receiving unit that receives an
evaluation result on a state of pancreatic cancer in the subject,
wherein the evaluation result is the result of evaluating the state
of pancreatic cancer in the subject by calculating a value of a
formula using the amino acid concentration data of the subject and
the formula for evaluating the state of pancreatic cancer,
including an explanatory variable to be substituted with the
concentration value of the amino acid, wherein the amino acid
concentration data includes the concentration values of at least
two amino acids of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met,
Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln, and the
formula includes at least two explanatory variables to be
substituted with the concentration values of at least two amino
acids of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp,
Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln.
[0051] A pancreatic cancer-evaluating apparatus according to one
aspect of the present invention includes a control unit and a
memory unit to evaluate a state of pancreatic cancer in a subject
to be evaluated, being connected communicatively via a network to
an information communication terminal apparatus that provides amino
acid concentration data of the subject on a concentration value of
an amino acid, wherein the control unit includes an amino acid
concentration data-receiving unit that receives the amino acid
concentration data of the subject transmitted from the information
communication terminal apparatus, an evaluating unit that evaluates
the state of pancreatic cancer in the subject by calculating a
value of a formula using the amino acid concentration data of the
subject received by the amino acid concentration data-receiving
unit and the formula previously stored in the memory unit for
evaluating the state of pancreatic cancer, including an explanatory
variable to be substituted with the concentration value of the
amino acid, and an evaluation result-sending unit that transmits an
evaluation result on the state of pancreatic cancer in the subject
obtained by the evaluating unit to the information communication
terminal apparatus, wherein the amino acid concentration data
includes the concentration values of at least two amino acids of
Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro,
Orn, Ile, Leu, Phe, Ser, and Gln, and the formula includes at least
two explanatory variables to be substituted with the concentration
values of at least two amino acids of Asn, His, Thr, Ala, Cit, Arg,
Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and
Gln.
[0052] A method of searching for preventing/ameliorating substance
for pancreatic cancer according to one aspect of the present
invention includes (I) an obtaining step of obtaining amino acid
concentration data on a concentration value of an amino acid in
blood collected from a subject to be evaluated to which a desired
substance group consisting of one or more substances has been
administered, (II) an evaluating step of evaluating a state of
pancreatic cancer in the subject by calculating a value of a
formula using the amino acid concentration data of the subject
obtained at the obtaining step and the formula previously
established for evaluating the state of pancreatic cancer,
including an explanatory variable to be substituted with the
concentration value of the amino acid, and (III) a judging step of
judging whether or not the desired substance group prevents
pancreatic cancer or ameliorates the state of pancreatic cancer,
using an evaluation result obtained at the evaluating step, wherein
the amino acid concentration data includes the concentration values
of at least two amino acids of Asn, His, Thr, Ala, Cit, Arg, Tyr,
Val, Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln, and
the formula includes at least two explanatory variables to be
substituted with the concentration values of at least two amino
acids of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp,
Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln.
[0053] According to the present invention, (I) the amino acid
concentration data on the concentration value of the amino acid in
blood collected from the subject (the one including the
concentration values of at least two amino acids of the 19 kinds of
amino acids composed of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val,
Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln) is
obtained, and (II) the state of pancreatic cancer in the subject is
evaluated by calculating the value of the formula using the
obtained amino acid concentration data of the subject and the
formula previously established for evaluating the state of
pancreatic cancer, including the explanatory variable to be
substituted with the concentration value of the amino acid (the one
including at least two explanatory variables to be substituted with
the concentration values of at least two amino acids of the 19
kinds of amino acids). Hence, reliable information that may be
helpful in knowing the state of pancreatic cancer can be provided.
Both improvement in reliability of the information and reduction in
various burdens imposed on users (for example, mental, physical,
temporal, financial, or other burdens) can be achieved.
[0054] According to the present invention, the state of pancreatic
cancer is the degree of the possibility of being affected with
pancreatic cancer, and evaluating the state of pancreatic cancer in
the subject is evaluating the degree of the possibility that the
subject is affected with pancreatic cancer. Hence, reliable
information that may be helpful in knowing the degree of the
possibility of being affected with pancreatic cancer can be
provided.
[0055] According to the present invention, the categories defined
considering at least the degree of the possibility of being
affected with pancreatic cancer, and one or more thresholds are
previously established, and evaluating the degree of the
possibility that the subject is affected with pancreatic cancer is
classifying the subject into any one of the categories using the
value of the formula and the threshold. Hence, reliable information
that may be helpful in knowing the degree of the possibility of
being affected with pancreatic cancer can be provided in easily
understandable form.
[0056] According to the present invention, the categories include
at least one category defined considering at least the degree of
the possibility of being affected with pancreatic cancer and the
degree of the possibility of being affected with a cancer other
than pancreatic cancer. Hence, reliable information can be provided
in easily understandable form, which may be helpful in knowing not
only the degree of the possibility of being affected with
pancreatic cancer but also the degree of the possibility of being
affected with a cancer other than pancreatic cancer.
[0057] According to the present invention, the categories include
the category X and the category Y. Hence, reliable information that
may be helpful in knowing whether the possibility of being affected
with pancreatic cancer is high or low can be provided in easily
understandable form.
[0058] According to the present invention, the category Y includes
the healthy category to which a subject with a high possibility of
being healthy belongs, the other cancer category to which a subject
with a high possibility of being affected with a cancer other than
pancreatic cancer (for example, lung cancer, colorectal cancer,
prostatic cancer, breast cancer, gastric cancer, uterine cancer
(cervical cancer, endometrial cancer), ovarian cancer, or the like)
belongs, or the healthy/other cancer category to which a subject
with a high possibility of being healthy and a subject with a high
possibility of being affected with a cancer other than pancreatic
cancer belong. Hence, reliable information can be provided in
easily understandable form, which may be helpful in knowing not
only whether the possibility of being affected with pancreatic
cancer is high but also whether the possibility of being healthy is
high, whether the possibility of being affected with a cancer other
than pancreatic cancer is high, or whether the possibility of being
healthy or being affected with a cancer other than pancreatic
cancer is high.
[0059] According to the present invention, the category Y includes
the healthy category to which a subject with a high possibility of
being healthy belongs and the other cancer category to which a
subject with a high possibility of being affected with a cancer
other than pancreatic cancer belongs. Hence, reliable information
can be provided in easily understandable form, which may be helpful
in knowing not only whether the possibility of being affected with
pancreatic cancer is high but also whether the possibility of being
healthy is high and whether the possibility of being affected with
a cancer other than pancreatic cancer is high.
[0060] According to the present invention, the formula is any one
of a logistic regression equation, a fractional expression, a
linear discriminant, a multiple regression equation, a formula
prepared by a support vector machine, a formula prepared by a
Mahalanobis' generalized distance method, a formula prepared by
canonical discriminant analysis, and a formula prepared by a
decision tree. Hence, further improvement in reliability of
information that may be helpful in knowing the state of pancreatic
cancer can be achieved.
[0061] According to the present invention, evaluating the state of
pancreatic cancer in the subject may be deciding that the value of
the formula reflects the state of pancreatic cancer in the subject.
Hence, reliable information that may be helpful in knowing the
state of pancreatic cancer can be provided.
[0062] According to the present invention, the value of the formula
may be converted by the predetermined method, and it may be decided
that the converted value reflects the state of pancreatic cancer in
the subject. Hence, reliable information that may be helpful in
knowing the state of pancreatic cancer can be provided.
[0063] According to the present invention, the positional
information about the position of the predetermined mark (for
example, a circle sign or a star sign) corresponding to the value
of the formula or the converted value may be generated on the
predetermined scale (for example, a graduated scale at least marked
with graduations corresponding to the upper limit value and the
lower limit value in the possible range of the value of the formula
or the converted value, or part of the range) visually presented on
the display device such as a monitor or the physical medium such as
paper for evaluating the state of pancreatic cancer, using the
value of the formula or the converted value, and it may be decided
that the generated positional information reflects the state of
pancreatic cancer in the subject. Hence, reliable information that
may be helpful in knowing the state of pancreatic cancer can be
provided.
[0064] According to the present invention, the value of the formula
may be converted by the predetermined method, and the subject may
be classified into any one of the categories using the converted
value. Hence, reliable information that may be helpful in knowing
the state of pancreatic cancer can be provided.
[0065] According to the present invention, the categories may be
the category X and the category Y, and the subject may be
classified into one of the category X and the category Y. Hence,
reliable information that may be helpful in knowing whether the
possibility of being affected with pancreatic cancer is high or low
can be provided in easily understandable form.
[0066] According to the present invention, (I) the formula may be
named as the first formula, the second formula that is different
from the first formula and includes at least two explanatory
variables to be substituted with the concentration values of at
least two amino acids of the 19 kinds of amino acids may be
previously established, and (II) the value of the first formula and
the value of the second formula may be calculated, and the subject
may be classified into one of the category X and the category Y
using the calculated values of the first formula and the second
formula. Hence, further improvement in reliability of information
that may be helpful in knowing whether the possibility of being
affected with pancreatic cancer is high or low can be achieved.
[0067] According to the present invention, (I) the category Y may
include the healthy category and the other cancer category, the
first formula may be a formula for classifying a subject into one
of the category X and the healthy category, the second formula may
be a formula for classifying a subject into one of the category X
and the other cancer category, and (II) (i) the value of the first
formula may be first calculated, (ii) the subject may be classified
into one of the category X and the healthy category using the
calculated value of the first formula, (iii) then if the
classification result is the category X, the value of the second
formula may be calculated, (iv) the subject classified in the
category X using the value of the first formula may be further
classified into one of the category X and the other cancer category
using the calculated value of the second formula, and then (v) the
subject classified in the healthy category and the subject
classified in the other cancer category may be finally classified
into the category Y. Hence, further improvement in reliability of
information that may be helpful in knowing whether the possibility
of being affected with pancreatic cancer is high or low can be
achieved.
[0068] According to the present invention, the subject may be
classified into one of the category X and the healthy category.
Hence, reliable information that may be helpful in knowing whether
the possibility of being affected with pancreatic cancer is high or
the possibility of being healthy is high can be provided in easily
understandable form.
[0069] According to the present invention, the subject may be
classified into one of the category X and the other cancer
category. Hence, reliable information that may be helpful in
knowing whether the possibility of being affected with pancreatic
cancer is high or whether the possibility of being affected with a
cancer other than pancreatic cancer is high can be provided in
easily understandable form.
[0070] According to the present invention, the subject may be
classified into one of the category X and the healthy/other cancer
category. Hence, reliable information that may be helpful in
knowing whether the possibility of being affected with pancreatic
cancer is high or whether the possibility of being healthy or being
affected with a cancer other than pancreatic cancer is high can be
provided in easily understandable form.
[0071] According to the present invention, the category Y may
include the healthy category and the other cancer category, and the
subject may be classified into any one of the category X, the
healthy category, and the other cancer category. Hence, reliable
information that may be helpful in knowing whether the possibility
of being affected with pancreatic cancer is high, whether the
possibility of being healthy is high, or whether the possibility of
being affected with a cancer other than pancreatic cancer is high
can be provided in easily understandable form.
[0072] According to the present invention, (I) the formula may be
named as the first formula, the second formula that is different
from the first formula and includes at least two explanatory
variables to be substituted with the concentration values of at
least two amino acids of the 19 kinds of amino acids may be
previously established, and (II) the value of the first formula and
the value of the second formula may be calculated, and the subject
may be classified into any one of the category X, the healthy
category, and the other cancer category using the calculated values
of the first formula and the second formula. This leads to further
improvement in reliability of information that may be helpful in
knowing whether the possibility of being affected with pancreatic
cancer is high, whether the possibility of being healthy is high,
or whether the possibility of being affected with a cancer other
than pancreatic cancer is high.
[0073] According to the present invention, (I) the first formula
may be a formula for classifying a subject into one of the category
X and the healthy category, the second formula may be a formula for
classifying a subject into one of the category X and the other
cancer category, and (II) (i) the value of the first formula may be
first calculated, (ii) the subject may be classified into one of
the category X and the healthy category using the calculated value
of the first formula, (iii) then if the classification result is
the category X, the value of the second formula may be calculated,
(iv) the subject classified in the category X using the value of
the first formula may be further classified into one of the
category X and the other cancer category using the calculated value
of the second formula, and then (v) the subject classified in the
category X using the value of the first formula and classified in
the other cancer category using the value of the second formula may
be finally classified into the other cancer category. This leads to
further improvement in reliability of information that may be
helpful in knowing whether the possibility of being affected with
pancreatic cancer is high, whether the possibility of being healthy
is high, or whether the possibility of being affected with a cancer
other than pancreatic cancer is high.
[0074] According to the present invention, the evaluation formula
may be prepared based on the pancreatic cancer state information
previously stored in the memory unit including the amino acid
concentration data and the pancreatic cancer state index data on
the index for indicating the state of pancreatic cancer.
Specifically, (I) the candidate formula may be prepared based on
the predetermined formula-preparing method from the pancreatic
cancer state information, (II) the prepared candidate formula may
be verified based on the predetermined verifying method, (III) the
explanatory variables of the candidate formula may be selected
based on the predetermined explanatory variable-selecting method,
thereby selecting the combination of the amino acid concentration
data contained in the pancreatic cancer state information used in
preparing of the candidate formula, and (IV) the candidate formula
used as the evaluation formula may be selected from a plurality of
the candidate formulae based on the verification results
accumulated by repeatedly executing the (I), (II) and (III),
thereby preparing the evaluation formula. Hence, the evaluation
formula most appropriate for evaluating the state of pancreatic
cancer can be prepared.
[0075] According to the present invention, (I) the amino acid
concentration data on the concentration value of the amino acid in
blood collected from the subject to which the desired substance
group consisting of one or more substances has been administered
(the one including the concentration values of at least two amino
acids of the 19 kinds of amino acids) may be obtained, (II) the
state of pancreatic cancer in the subject may be evaluated by
calculating the value of the formula using the obtained amino acid
concentration data of the subject and the formula previously
established for evaluating the state of pancreatic cancer,
including the explanatory variable to be substituted with the
concentration value of the amino acid (the one including at least
two explanatory variables to be substituted with the concentration
values of at least two amino acids of the 19 kinds of amino acids),
and (III) whether or not the desired substance group prevents
pancreatic cancer or ameliorates the state of pancreatic cancer may
be judged using the obtained evaluation result. Hence, reliable
information on a substance preventing pancreatic cancer or a
substance ameliorating the state of pancreatic cancer can be
provided by applying the method of evaluating pancreatic cancer
which can provide reliable information that may be helpful in
knowing the state of pancreatic cancer. Both improvement in
reliability of the information and reduction in various burdens
imposed on users can be achieved. An existing animal model
partially reflecting the state of progress of pancreatic cancer or
a clinically effective chemical at an early stage can be selected
by using typical data on variation patterns of the concentration
values of amino acids of an individual being affected with
pancreatic cancer and the formula appropriate for evaluating the
state of pancreatic cancer.
[0076] In the present invention, when the state of pancreatic
cancer is evaluated, the concentration value of an amino acid other
than the 19 kinds of amino acids may be additionally used. In the
present invention, when the state of pancreatic cancer is
evaluated, a value of other biological information (for example,
the values listed in 1. through 5. below) may be used in addition
to the concentration values of amino acids. In the present
invention, the formula described above may additionally include one
or more explanatory variables to be substituted with the
concentration value of an amino acid other than the 19 kinds of
amino acids. In the present invention, the formula described above
may additionally include one or more explanatory variables to be
substituted with the value of other biological information (for
example, the values listed in 1. through 5. below), in addition to
the explanatory variables to be substituted with the concentration
values of amino acids.
[0077] 1. the concentration values of metabolites in blood other
than amino acids (amino acid metabolites, carbohydrates, lipids,
and the like), proteins, peptides, minerals, hormones, and the
like
[0078] 2. the values of tumor markers in blood (CA19-9, CEA, CA125,
SPan-1, DUPAN-2, SLX, SCC, CYFRA, ProGRP, p53, elastase, and the
like)
[0079] 3. blood test values such as albumin, total protein,
triglyceride, HbAlc, LDL cholesterol, HDL cholesterol, amylase,
total bilirubin, and uric acid
[0080] 4. the values obtained from image information of
ultrasonography, X rays, CT, MRI, and the like
[0081] 5. the values of biological indices such as age, height,
weight, BMI, blood pressure, gender, smoking information, dietary
information, drinking information, exercise information, stress
information, sleeping information, family medical history, disease
history information (diabetes, pancreatitis, and the like)
[0082] The above and other objects, features, advantages and
technical and industrial significance of this invention will be
better understood by reading the following detailed description of
presently preferred embodiments of the invention, when considered
in connection with the accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
[0083] FIG. 1 is a principle configurational diagram showing a
basic principle of a first embodiment;
[0084] FIG. 2 is a flowchart showing an example of a method of
evaluating pancreatic cancer according to the first embodiment;
[0085] FIG. 3 is a principle configurational diagram showing a
basic principle of a second embodiment;
[0086] FIG. 4 is a diagram showing an example of an entire
configuration of a present system;
[0087] FIG. 5 is a diagram showing another example of an entire
configuration of the present system;
[0088] FIG. 6 is a block diagram showing an example of a
configuration of a pancreatic cancer-evaluating apparatus 100 in
the present system;
[0089] FIG. 7 is a chart showing an example of information stored
in a user information file 106a;
[0090] FIG. 8 is a chart showing an example of information stored
in an amino acid concentration data file 106b;
[0091] FIG. 9 is a chart showing an example of information stored
in a pancreatic cancer state information file 106c;
[0092] FIG. 10 is a chart showing an example of information stored
in a designated pancreatic cancer state information file 106d;
[0093] FIG. 11 is a chart showing an example of information stored
in a candidate formula file 106e1;
[0094] FIG. 12 is a chart showing an example of information stored
in a verification result file 106e2;
[0095] FIG. 13 is a chart showing an example of information stored
in a selected pancreatic cancer state information file 106e3;
[0096] FIG. 14 is a chart showing an example of information stored
in an evaluation formula file 106e4;
[0097] FIG. 15 is a chart showing an example of information stored
in an evaluation result file 106f;
[0098] FIG. 16 is a block diagram showing a configuration of an
evaluation formula-preparing part 102h;
[0099] FIG. 17 is a block diagram showing a configuration of an
evaluating part 102i;
[0100] FIG. 18 is a block diagram showing an example of a
configuration of a client apparatus 200 in the present system;
[0101] FIG. 19 is a block diagram showing an example of a
configuration of a database apparatus 400 in the present
system;
[0102] FIG. 20 is a flowchart showing an example of a pancreatic
cancer evaluation service processing performed in the present
system; and
[0103] FIG. 21 is a flowchart showing an example of a evaluation
formula-preparing processing performed in the pancreatic
cancer-evaluating apparatus 100 in the present system.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0104] Hereinafter, an embodiment (first embodiment) of the method
of evaluating pancreatic cancer according to the present invention
and an embodiment (second embodiment) of the pancreatic
cancer-evaluating apparatus, the pancreatic cancer-evaluating
method, the pancreatic cancer-evaluating program, the recording
medium, the pancreatic cancer-evaluating system, and the
information communication terminal apparatus according to the
present invention are described in detail with reference to the
drawings. The present invention is not limited to these
embodiments.
First Embodiment
1-1. Outline of First Embodiment
[0105] Here, an outline of the first embodiment will be described
with reference to FIG. 1. FIG. 1 is a principle configurational
diagram showing a basic principle of the first embodiment.
[0106] Amino acid concentration data on a concentration value of an
amino acid (the one including concentration values of at least two
amino acids of the 19 kinds of amino acids composed of Asn, His,
Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile,
Leu, Phe, Ser, and Gln) in blood (including, for example, plasma or
serum) collected from a subject to be evaluated (for example, an
individual such as animal or human) is obtained (step S11).
[0107] In step S11, for example, the amino acid concentration data
determined by a company or the like that performs amino acid
concentration value measurements may be obtained, or the amino acid
concentration data may be obtained by determining the concentration
value of the amino acid by a measurement method such as, for
example, the following method (A) or (B) from blood collected from
the subject. Here, the unit of the concentration value of the amino
acid may be, for example, a molar concentration, a weight
concentration, or one obtained by addition, subtraction,
multiplication, and division of any constant with these
concentrations.
[0108] (A) Plasma is separated from blood by centrifuging a
collected blood sample. All plasma samples are frozen and stored at
-80.degree. C. until an amino acid concentration value is measured.
At the time of measuring an amino acid concentration value,
acetonitrile is added to perform a protein removal treatment,
pre-column derivatization is then performed using a labeled reagent
(3-aminopyridyl-N-hydroxysuccinimidyl carbamate), and an amino acid
concentration value is analyzed by liquid chromatograph mass
spectrometer (LC/MS) (see International Publication WO 2003/069328
and International Publication WO 2005/116629).
[0109] (B) Plasma is separated from blood by centrifuging a
collected blood sample. All plasma samples are frozen and stored at
-80.degree. C. until an amino acid concentration value is measured.
At the time of measuring an amino acid concentration value,
sulfosalicylic acid is added to perform a protein removal
treatment, and an amino acid concentration value is analyzed by an
amino acid analyzer based on post-column derivatization using a
ninhydrin reagent.
[0110] A state of pancreatic cancer in the subject is evaluated
using, as evaluation values for evaluating a state of pancreatic
cancer, the concentration values of at least two amino acids of the
19 kinds of amino acids included in the amino acid concentration
data obtained in step S11 (step S12). Before step S12 is executed,
data such as defective and outliers may be removed from the amino
acid concentration data obtained in step S11.
[0111] According to the first embodiment described above, in step
S11, the amino acid concentration data of the subject is obtained,
and in step S12, the state of pancreatic cancer in the subject is
evaluated using, as the evaluation values, the concentration values
of at least two amino acids of the 19 kinds of amino acids included
in the amino acid concentration data of the subject obtained in
step S11. Hence, reliable information that may be helpful in
knowing the state of pancreatic cancer can be provided. Both
improvement in reliability of the information and reduction in
various burdens imposed on users (for example, mental burden,
physical burden, temporal burden, or financial burden) can be
achieved.
[0112] The state of pancreatic cancer may be the degree of the
possibility of being affected with pancreatic cancer. Evaluating
the state of pancreatic cancer in the subject may be evaluating the
degree of the possibility that the subject is affected with
pancreatic cancer. Hence, reliable information that may be helpful
in knowing the degree of the possibility of being affected with
pancreatic cancer can be provided.
[0113] In step S12, it may be decided that the concentration values
of at least two amino acids of the 19 kinds of amino acids included
in the amino acid concentration data of the subject obtained at
step S11 reflect the state of pancreatic cancer in the subject. The
concentration values may be converted, for example, by the methods
listed below, and it may be decided that the converted values
reflect the state of pancreatic cancer in the subject. In other
words, in step S12, the concentration values or the converted
values may be treated per se as the evaluation result on the state
of pancreatic cancer in the subject. Hence, reliable information
that may be helpful in knowing the state of pancreatic cancer can
be provided.
[0114] The concentration value may be converted such that the
possible range of the concentration value falls within a
predetermined range (for example, the range from 0.0 to 1.0, the
range from 0.0 to 10.0, the range from 0.0 to 100.0, or the range
from -10.0 to 10.0), for example, by addition, subtraction,
multiplication, and division of any given value with the
concentration value, by conversion of the concentration value by a
predetermined conversion method (for example, index transformation,
logarithm transformation, angular transformation, square root
transformation, probit transformation, or reciprocal
transformation), or by performing a combination of these
computations on the concentration value. For example, the value of
an exponential function with the concentration value as an exponent
and Napier constant as the base (specifically, the value of p/(1-p)
where a natural logarithm ln(p/(1-p)) is equal to the concentration
value when the probability p of being affected with pancreatic
cancer is defined) may be further calculated, and a value
(specifically, the value of probability p) may be further
calculated by dividing the calculated value of exponential function
by the sum of 1 and the value of exponential function.
[0115] The concentration value may be converted such that the
converted value is particular value when a particular condition is
met. For example, the concentration value may be converted such
that the converted value is 5.0 when the specificity is 80% and the
converted value is 8.0 when the specificity is 95%.
[0116] In step S12, the positional information about the position
of a predetermined mark (for example, a circle sign or a star sign)
corresponding to the concentration value or the converted value may
be generated on a predetermined scale (for example, a graduated
scale at least marked with graduations corresponding to the upper
limit value and the lower limit value in the possible range of the
concentration value or the converted value, or part of the range)
visually presented on a display device such as a monitor or a
physical medium such as paper for evaluating the state of
pancreatic cancer, using the concentration values of at least two
amino acids of the 19 kinds of amino acids included in the amino
acid concentration data of the subject obtained in step S11 or, if
the concentration values are converted, the converted values. Then
it may be decided that the generated positional information
reflects the state of pancreatic cancer. Hence, reliable
information that may be helpful in knowing the state of pancreatic
cancer can be provided.
[0117] In step S12, the state of pancreatic cancer in the subject
may be evaluated by calculating the value of the evaluation formula
using the amino acid concentration data of the subject and the
previously established formula for evaluating the state of
pancreatic cancer, including the explanatory variable to be
substituted with the concentration value of the amino acid (the one
including at least two explanatory variables to be substituted with
the concentration values of at least two amino acids of the 19
kinds of amino acids). Hence, reliable information that may be
helpful in knowing the state of pancreatic cancer can be
provided.
[0118] In step S12, it may be decided that the calculated value of
the formula reflects the state of pancreatic cancer in the subject.
The value of the formula may be converted, for example, by the
methods listed below, and it may be decided that the converted
value reflects the state of pancreatic cancer in the subject. In
other words, in step S12, the value of the formula or the converted
value may be treated per se as the evaluation result on the state
of pancreatic cancer in the subject. Hence, reliable information
that may be helpful in knowing the state of pancreatic cancer can
be provided.
[0119] The value of the evaluation formula may be converted such
that the possible range of the value of the evaluation formula
falls within a predetermined range (for example, the range from 0.0
to 1.0, the range from 0.0 to 10.0, the range from 0.0 to 100.0, or
the range from -10.0 to 10.0), for example, by addition,
subtraction, multiplication, and division of any given number with
the value of the evaluation formula, by conversion of the value of
the evaluation formula by a predetermined conversion method (for
example, index transformation, logarithm transformation, angular
transformation, square root transformation, probit transformation,
or reciprocal transformation), or by performing a combination of
these computations on the value of the evaluation formula. For
example, the value of an exponential function with the value of the
evaluation formula as an exponent and Napier constant as the base
(specifically, the value of p/(1-p) where a natural logarithm
ln(p/(1-p)) is equal to the value of the evaluation formula when
the probability p of being affected with pancreatic cancer is
defined) may be further calculated, and a value (specifically, the
value of probability p) may be calculated by dividing the
calculated value of exponential function by the sum of 1 and the
value of exponential function.
[0120] The value of the evaluation formula may be converted such
that the converted value is a particular value when a particular
condition is met. For example, the value of the evaluation formula
may be converted such that the converted value is 5.0 when the
specificity is 80% and the converted value is 8.0 when the
specificity is 95%.
[0121] In step S12, the positional information about the position
of a predetermined mark (for example, a circle sign or a star sign)
corresponding to the value of the formula or the converted value
may be generated on a predetermined scale (for example, a graduated
scale at least marked with graduations corresponding to the upper
limit value and the lower limit value in the possible range of the
value of the formula or the converted value, or part of the range)
visually presented on a display device such as a monitor or a
physical medium such as paper for evaluating the state of
pancreatic cancer, using the value of the formula or, if the value
of the formula is converted, the converted value. Then it may be
decided that the generated positional information reflects the
state of pancreatic cancer in the subject. Hence, reliable
information that may be helpful in knowing the state of pancreatic
cancer can be provided.
[0122] When a plurality of categories defined considering at least
the degree of the possibility of being affected with pancreatic
cancer, and one or more thresholds are previously established, in
step S12, the subject may be classified into any one of the
categories using the concentration values of at least two amino
acids of the 19 kinds of amino acids or, if the concentration
values are converted, the converted values, and a threshold.
[0123] Alternatively, the subject may be classified into any one of
the categories using the value of the formula or, if the value of
the formula is converted, the converted value, and a threshold.
Hence, reliable information that may be helpful in knowing the
degree of the possibility of being affected with pancreatic cancer
can be provided in easily understandable form.
[0124] The categories may include at least one category defined
considering at least the degree of the possibility of being
affected with pancreatic cancer and the degree of the possibility
of being affected with a cancer other than pancreatic cancer (for
example, lung cancer, colorectal cancer, prostatic cancer, breast
cancer, gastric cancer, uterine cancer (cervical cancer,
endometrial cancer), or ovarian cancer). Hence, reliable
information that may be helpful in knowing not only the degree of
the possibility of being affected with pancreatic cancer but also
the degree of the possibility of being affected with a cancer other
than pancreatic cancer can be provided.
[0125] In a set of the concentration values of at least two amino
acids of the 19 kinds of amino acids included in the amino acid
concentration data of a plurality of test subjects proved to be not
affected with pancreatic cancer (for example, to be healthy), the
boundary value when the specificity is a predetermined value (for
example 80 or 95) may be established as a threshold. In a set of a
plurality of values of the evaluation formula calculated for each
test subject using the amino acid concentration data and the
evaluation formula, the boundary value when the specificity is a
predetermined value may be established as a threshold.
[0126] In a set of the concentration values of at least two amino
acids of the 19 kinds of amino acids included in the amino acid
concentration data of a plurality of test subjects proved to be
affected with pancreatic cancer, the boundary value when the
sensitivity is a predetermined value (for example, 80 or 95) may be
established as a threshold. In a set of a plurality of values of
the evaluation formula calculated for each test subject using the
amino acid concentration data and the evaluation formula, the
boundary value when the sensitivity is a predetermined value may be
established as a threshold.
[0127] The categories may include a category X to which a subject
with a high possibility of being affected with pancreatic cancer
belongs and a category Y to which a subject with a low possibility
of being affected with pancreatic cancer belongs. Hence, reliable
information that may be helpful in knowing whether the possibility
of being affected with pancreatic cancer is high or low can be
provided in easily understandable form.
[0128] The category Y may include a healthy category to which a
subject with a high possibility of being healthy belongs, other
cancer category to which a subject with a high possibility of being
affected with a cancer other than pancreatic cancer belongs, or a
healthy/other cancer category to which a subject with a high
possibility of being healthy and a subject with a high possibility
of being affected with a cancer other than pancreatic cancer
belong. Hence, reliable information can be provided in easily
understandable form, which may be helpful in knowing not only
whether the possibility of being affected with pancreatic cancer is
high but also whether the possibility of being healthy is high,
whether the possibility of being affected with a cancer other than
pancreatic cancer is high, or whether the possibility of being
healthy or being affected with a cancer other than pancreatic
cancer is high.
[0129] The category Y may include the healthy category and the
other cancer category. Hence, reliable information can be provided
in easily understandable form, which may be helpful in knowing not
only whether the possibility of being affected with pancreatic
cancer is high but also whether the possibility of being healthy is
high and whether the possibility of being affected with a cancer
other than pancreatic cancer is high.
[0130] When the categories are the category X and the category Y,
in step S12, the subject may be classified into one of the category
X and the category Y, using the concentration values of at least
two amino acids of the 19 kinds of amino acids or, if the
concentration values are converted, the converted values, and a
threshold. Alternatively, the subject may be classified into one of
the category X and the category Y, using the value of the formula
or, if the value of the formula is converted, the converted value,
and a threshold. Hence, reliable information that may be helpful in
knowing whether the possibility of being affected with pancreatic
cancer is high or low can be provided in easily understandable
form.
[0131] When a first formula and a second formula that are different
from each other and each include at least two explanatory variables
to be substituted with the concentration values of at least two
amino acids of the 19 kinds of amino acids are previously
established as evaluation formulae, in step S12, the value of the
first formula and the value of the second formula may be
calculated, and the subject may be classified into one of the
category X and the category Y using the calculated values of the
first formula and the second formula. This leads to further
improvement in reliability of information that may be helpful in
knowing whether the possibility of being affected with pancreatic
cancer is high or low.
[0132] Specifically, when the healthy category and the other cancer
category are previously established as the category Y, a formula
for classifying a subject into one of the category X and the
healthy category is previously established as the first formula,
and a formula for classifying a subject into one of the category X
and the other cancer category is previously established as the
second formula, in step S12, the value of the first formula may be
first calculated, and the subject may be classified into one of the
category X and the healthy category using the calculated value of
the first formula. Then if the classification result is the
category X, the value of the second formula may be calculated, and
the subject classified in the category X using the value of the
first formula may be further classified into one of the category X
and the other cancer category using the calculated value of the
second formula. Then the subject classified in the healthy category
and the subject classified in the other cancer category may be
finally classified into the category Y.
[0133] When the healthy category is previously established as the
category Y, in step S12, the subject may be classified into one of
the category X and the healthy category, using the concentration
values of at least two amino acids of the 19 kinds of amino acids
or, if the concentration values are converted, the converted
values, and a threshold. Alternatively, the subject may be
classified into one of the category X and the healthy category
using the value of the formula or, if the value of the formula is
converted, the converted value, and a threshold. Hence, reliable
information that may be helpful in knowing whether the possibility
of being affected with pancreatic cancer is high or whether the
possibility of being healthy is high can be provided in easily
understandable form.
[0134] When the other cancer category is previously established as
the category Y, in step S12, the subject may be classified into one
of the category X and the other cancer category using the
concentration values of at least two amino acids of the 19 kinds of
amino acids or, if the concentration values are converted, the
converted values, and a threshold. Alternatively, the subject may
be classified into one of the category X and the other cancer
category using the value of the formula or, if the value of the
formula is converted, the converted value, and a threshold. Hence,
reliable information that may be helpful in knowing whether the
possibility of being affected with pancreatic cancer is high or
whether the possibility of being affected with a cancer other than
pancreatic cancer is high can be provided in easily understandable
form.
[0135] When the healthy/other cancer category is previously
established as the category Y, in step S12, the subject may be
classified into one of the category X and the healthy/other cancer
category using the concentration values of at least two amino acids
of the 19 kinds of amino acids or, if the concentration values are
converted, the converted values, and a threshold. Alternatively,
the subject may be classified into one of the category X and the
healthy/other cancer category using the value of the formula or, if
the value of the formula is converted, the converted value, and a
threshold. Hence, reliable information that may be helpful in
knowing whether the possibility of being affected with pancreatic
cancer is high or whether the possibility of being healthy or being
affected with a cancer other than pancreatic cancer is high can be
provided in easily understandable form.
[0136] When the healthy category and the other cancer category are
previously established as the category Y, in step S12, the subject
may be classified into any one of the category X, the healthy
category, and the other cancer category using the concentration
values of at least two amino acids of the 19 kinds of amino acids
or, if the concentration values are converted, the converted
values, and a threshold. Alternatively, the subject may be
classified into any one of the category X, the healthy category,
and the other cancer category using the value of the formula or, if
the value of the formula is converted, the converted value, and a
threshold. Hence, reliable information that may be helpful in
knowing whether the possibility of being affected with pancreatic
cancer is high, whether the possibility of being healthy is high,
or whether the possibility of being affected with a cancer other
than pancreatic cancer is high can be provided in easily
understandable form.
[0137] When the first formula and the second formula that are
different from each other and each include at least two explanatory
variables to be substituted with the concentration values of at
least two amino acids of the 19 kinds of amino acids are previously
established as evaluation formulae, in step S12, the value of the
first formula and the value of the second formula may be
calculated, and the subject may be classified into any one of the
category X, the healthy category, and the other cancer category
using the calculated values of the first formula and the second
formula. This leads to further improvement in reliability of
information that may be helpful in knowing whether the possibility
of being affected with pancreatic cancer is high, whether the
possibility of being healthy is high, or whether the possibility of
being affected with a cancer other than pancreatic cancer is
high.
[0138] Specifically, when a formula for classifying a subject into
one of the category X and the healthy category is previously
established as the first formula, and a formula for classifying a
subject into one of the category X and the other cancer category is
previously established as the second formula, in step S12, the
value of the first formula may be first calculated, and the subject
may be classified into one of the category X and the healthy
category using the calculated value of the first formula. Then if
the classification result is the category X, the value of the
second formula may be calculated, and the subject classified in the
category X using the value of the first formula may be further
classified into one of the category X and the other cancer category
using the calculated value of the second formula. Then the subject
classified in the category X using the value of the first formula
and classified in the other cancer category using the value of the
second formula may be finally classified into the other cancer
category.
[0139] The evaluation formula may be any one of the logistic
regression equation, the fractional expression, the linear
discriminant, the multiple regression equation, the formula
prepared by the support vector machine, the formula prepared by the
Mahalanobis' generalized distance method, the formula prepared by
the canonical discriminant analysis, and the formula prepared by
the decision tree. This leads to further improvement in reliability
of information that may be helpful in knowing the state of
pancreatic cancer.
[0140] In addition to the formulae described in the present
specification, the formulae described in the international patent
applications, filed by the present applicant, WO 2008/016111, WO
2008/075662, WO 2008/075663, WO 2009/099005, WO 2009/154296, and WO
2009/154297 can be additionally employed as evaluation formulae to
evaluate the state of pancreatic cancer.
[0141] The formula employed as the evaluation formula may be
prepared by a method described in WO 2004/052191 that is an
international application filed by the present applicant or by a
method described in WO 2006/098192 that is an international
application filed by the present applicant. Any formulae obtained
by these methods can be preferably used in the evaluation of the
state of pancreatic cancer, regardless of the unit of the amino
acid concentration value in the amino acid concentration data as
input data.
[0142] The formula employed as the evaluation formula refers to a
form of equation used generally in multivariate analysis and
includes, for example, fractional expression, multiple regression
equation, multiple logistic regression equation, linear
discriminant function, Mahalanobis' generalized distance, canonical
discriminant function, support vector machine, decision tree, and
an equation shown by the sum of different forms of equations. In
the multiple regression equation, the multiple logistic regression
equation, and the canonical discriminant function, a coefficient
and a constant term are added to each explanatory variable, and the
coefficient and the constant term may be preferably real numbers,
more preferably values in the range of 99% confidence interval for
the coefficient and the constant term obtained from data for the
various kinds of classifications described above, more preferably
in the range of 95% confidence interval for the coefficient and the
constant term obtained from data for the various kinds of
classifications described above. The value of each coefficient and
the confidence interval thereof may be those multiplied by a real
number, and the value of the constant term and the confidence
interval thereof may be those having an arbitrary actual constant
added or subtracted or those multiplied or divided by an arbitrary
actual constant. When an expression such as a logistic regression,
a linear discriminant, and a multiple regression analysis is used
as an evaluation formula, a linear transformation of the expression
(addition of a constant and multiplication by a constant) and a
monotonic increasing (decreasing) transformation (for example, a
logit transformation) of the expression do not alter evaluation
performance and thus are equivalent to before transformation.
Therefore, the expression includes an expression that is subjected
to a linear transformation and a monotonic increasing (decreasing)
transformation.
[0143] In the fractional expression, the numerator of the
fractional expression is expressed by the sum of the amino acids A,
B, C etc. and the denominator of the fractional expression is
expressed by the sum of the amino acids a, b, c etc. The fractional
expression also includes the sum of the fractional expressions
.alpha., .beta., .gamma. etc. (for example, .alpha.+.beta.) having
such constitution. The fractional expression also includes divided
fractional expressions. The amino acids used in the numerator or
denominator may have suitable coefficients respectively. The amino
acids used in the numerator or denominator may appear repeatedly.
Each fractional expression may have a suitable coefficient. A value
of a coefficient for each explanatory variable and a value for a
constant term may be any real numbers. In a fractional expression
and the one in which explanatory variables in the numerator and
explanatory variables in the denominator in the fractional
expression are switched with each other, the positive and negative
signs are generally reversed in correlation with objective
explanatory variables, but because their correlation is maintained,
the evaluation performance can be assumed to be equivalent. The
fractional expression therefore also includes the one in which
explanatory variables in the numerator and explanatory variables in
the denominator in the fractional expression are switched with each
other.
[0144] In the first embodiment, when the state of pancreatic cancer
is evaluated, the concentration value of an amino acid other than
the 19 kinds of amino acids may be additionally used. In the first
embodiment, when the state of pancreatic cancer is evaluated, a
value of other biological information (for example, the values
listed in 1. through 5. below) may be used in addition to the
concentration values of amino acids. In the first embodiment, the
formula employed as the evaluation formula may additionally include
one or more explanatory variables to be substituted with the
concentration value of an amino acid other than the 19 kinds of
amino acids. In the first embodiment, the formula employed as the
evaluation formula may additionally include one or more explanatory
variables to be substituted with the value of other biological
information (for example, the values listed in 1. through 5.
below), in addition to the explanatory variables to be substituted
with the concentration values of amino acids.
[0145] 1. the concentration values of metabolites in blood other
than amino acids (amino acid metabolites, carbohydrates, lipids,
and the like), proteins, peptides, minerals, hormones, and the
like
[0146] 2. the values of tumor markers in blood (CA19-9, CEA, CA125,
SPan-1, DUPAN-2, SLX, SCC, CYFRA, ProGRP, p53, elastase, and the
like)
[0147] 3. blood test values such as albumin, total protein,
triglyceride, HbAlc, LDL cholesterol, HDL cholesterol, amylase,
total bilirubin, and uric acid
[0148] 4. the values obtained from image information of
ultrasonography, X rays, CT, MRI, and the like
[0149] 5. the values of biological indices such as age, height,
weight, BMI, blood pressure, gender, smoking information, dietary
information, drinking information, exercise information, stress
information, sleeping information, family medical history, disease
history information (diabetes, pancreatitis, and the like)
[0150] When, before step S11 is executed, a desired substance group
consisting of one or more substances is administered to the
subject, and then blood is collected from the subject, and in step
S11, the amino acid concentration data of the subject is obtained,
a substance preventing pancreatic cancer or a substance
ameliorating the state of pancreatic cancer may be searched by
judging whether or not the administered substance group prevents
pancreatic cancer or ameliorates the state of pancreatic cancer,
using the evaluation result obtained in step S12. Hence, reliable
information on a substance preventing pancreatic cancer or a
substance ameliorating the state of pancreatic cancer can be
provided by applying the method of evaluating pancreatic cancer
which can provide reliable information that may be helpful in
knowing the state of pancreatic cancer.
[0151] Before step S11 is executed, a suitable combination of an
existing drug, amino acid, food and supplement capable of
administration to humans (for example, a suitable combination of
drugs known to be effective in prevention or amelioration of
pancreatic cancer (for example, gemcitabine, erlotinib, and TS-1))
may be administered over a predetermined period (for example in the
range of 1 day to 12 months) in a predetermined amount at
predetermined frequency and timing (for example 3 times per day,
after food) by a predetermined administration method (for example,
oral administration). The administration method, dose, and dosage
form may be suitably combined depending on the condition of a
patient. The dosage form may be determined based on known
techniques. The dose is not particularly limited, and for example,
a drug containing 1 .mu.g to 100 g active ingredient may be
given.
[0152] When the judgement result that the administered substance
group prevents pancreatic cancer or ameliorates the state of
pancreatic cancer is obtained, the administered substance group may
be searched as a substance preventing pancreatic cancer or a
substance ameliorating the state of pancreatic cancer. The
substance group searched by the searching method includes, for
example, the amino acid group including at least two amino acids of
the 19 kinds of amino acids.
[0153] Substances that restore normal value to the concentration
values of the amino acid group including at least two amino acids
of the 19 kinds of amino acids or the value of the evaluation
formula can be selected using the method of evaluating pancreatic
cancer in the first embodiment or the pancreatic cancer-evaluating
apparatus in the second embodiment.
[0154] Searching for a substance preventing pancreatic cancer or a
substance ameliorating the state of pancreatic cancer includes not
only discovery of a novel substance effective in preventing and
ameliorating pancreatic cancer, but also (i) new discovery of use
of a known substance in preventing and ameliorating pancreatic
cancer, (ii) discovery of a novel composition consisting of a
combination of existing drugs, supplements etc. having efficacy
expectable for prevention and amelioration of pancreatic cancer,
(iii) discovery of the suitable usage, dose and combination
described above to form them into a kit, (iv) presentation of a
preventing and therapeutic menu including a diet, exercise etc.,
and (v) presentation of a necessary change in menu for each
individual by monitoring the effect of the preventing and
therapeutic menu.
1-2. Specific Example of the First Embodiment
[0155] Here, a specific example of the first embodiment will be
described with reference to FIG. 2. FIG. 2 is a flowchart showing
the specific example of the first embodiment.
[0156] The amino acid concentration data on the concentration
values of the amino acids in blood collected from an individual
such as animal or human (the one including the concentration values
of at least two amino acids of the 19 kinds of amino acids) is
obtained (step SA11). In step SA11, for example, the amino acid
concentration data determined by a company or the like that
performs amino acid concentration value measurements may be
obtained, or the amino acid concentration data may be obtained by
determining the concentration values of the amino acids by the
measurement method such as, for example, the above described (A) or
(B) from blood collected from the individual.
[0157] Data such as defective and outliers is then removed from the
amino acid concentration data of the individual obtained in step
SA11 (step SA12).
[0158] The value of the formula is calculated using (i) the amino
acid concentration data of the individual from which the data such
as the defective and the outliers have been removed in step SA12
and (ii) the formula previously established as an evaluation
formula, including at least two explanatory variables to be
substituted with the concentration values of at least two amino
acids of the 19 kinds of amino acids. Any one of the
classifications of 1. through 6. below is then executed using the
calculated value of the formula (evaluation value) and a previously
established threshold (step SA13).
[0159] 1. When a plurality of categories defined considering at
least the degree of the possibility that a subject is affected with
pancreatic cancer (the categories may include at least one category
defined considering at least the degree of the possibility that a
subject is affected with pancreatic cancer and the degree of the
possibility that a subject is affected with a cancer other than
pancreatic cancer), and one or more thresholds are previously
established, the individual is classified into any one of the
categories using the evaluation value and the threshold(s).
[0160] 2. When the pancreatic cancer category and the pancreatic
cancer-free category, and a threshold are previously established,
the individual is classified into one of the pancreatic cancer
category and the pancreatic cancer-free category using the
evaluation value and the threshold.
[0161] When the first formula and the second formula different from
each other are previously established as evaluation formulae, the
value of the first formula and the value of the second formula may
be calculated, and the individual may be classified into one of the
pancreatic cancer category and the pancreatic cancer-free category
using the calculated values of the first formula and the second
formula.
[0162] When the healthy category and the other cancer category are
previously established as the pancreatic cancer-free category, a
formula for classifying a subject into one of the pancreatic cancer
category and the healthy category is previously established as the
first formula, and a formula for classifying a subject into one of
the pancreatic cancer category and the other cancer category is
previously established as the second formula, the value of the
first formula may be first calculated, and the individual may be
classified into one of the pancreatic cancer category and the
healthy category using the calculated value of the first formula.
Then if the classification result is the pancreatic cancer
category, the value of the second formula may be calculated, and
the individual classified in the pancreatic cancer category using
the value of the first formula may be further classified into one
of the pancreatic cancer category and the other cancer category
using the calculated value of the second formula. Then the
individual classified in the healthy category and the individual
classified in the other cancer category may be finally classified
into the pancreatic cancer-free category. The individual classified
into the pancreatic cancer category using the value of the first
formula and classified into the pancreatic cancer category using
the value of the second formula is finally classified into the
pancreatic cancer category, as a matter of course.
[0163] 3. When the pancreatic cancer category and the healthy
category, and a threshold are previously established, the
individual is classified into one of the pancreatic cancer category
and the healthy category using the evaluation value and the
threshold.
[0164] 4. When the pancreatic cancer category and the other cancer
category, and a threshold are previously established, the
individual is classified into one of the pancreatic cancer category
and the other cancer category using the evaluation value and the
threshold.
[0165] 5. When the pancreatic cancer category and the healthy/other
cancer category, and a threshold are previously established, the
individual is classified into one of the pancreatic cancer category
and the healthy/other cancer category using the evaluation value
and the threshold.
[0166] 6. When the pancreatic cancer category, the healthy
category, and the other cancer category, and a threshold are
previously established, the individual is classified into any one
of the pancreatic cancer category, the healthy category, and the
other cancer category using the evaluation values and the
threshold.
[0167] When the first formula and the second formula that are
different from each other are previously established as evaluation
formulae, the value of the first formula and the value of the
second formula may be calculated, and the individual may be
classified into any one of the pancreatic cancer category, the
healthy category, and the other cancer category using the
calculated values of the first formula and the second formula.
[0168] when a formula for classifying a subject into one of the
pancreatic cancer category and the healthy category is previously
established as the first formula, and a formula for classifying a
subject into one of the pancreatic cancer category and the other
cancer category is previously established as the second formula,
the value of the first formula may be first calculated, and the
individual may be classified into one of the pancreatic cancer
category and the healthy category using the calculated value of the
first formula. Then if the classification result is the pancreatic
cancer category, the value of the second formula may be calculated,
and the individual classified in the pancreatic cancer category
using the value of the first formula may be further classified into
one of the pancreatic cancer category and the other cancer category
using the calculated value of the second formula. Then the
individual classified in the pancreatic cancer category using the
value of the first formula and classified in the other cancer
category using the value of the second formula may be finally
classified into the other cancer category. The individual
classified in the healthy category using the value of the first
formula is finally classified into the healthy category, as a
matter of course, and the individual classified in the pancreatic
cancer category using the value of the first formula and classified
in the pancreatic cancer category using the value of the second
formula is finally classified into the pancreatic cancer category,
as a matter of course.
Second Embodiment
2-1. Outline of the Second Embodiment
[0169] Here, outlines of the second embodiment will be described in
detail with reference to FIG. 3. FIG. 3 is a principle
configurational diagram showing a basic principle of the second
embodiment.
[0170] A control device evaluates a state of pancreatic cancer in a
subject to be evaluated (for example, an individual such as animal
or human) by calculating a value of a formula using (i) the
concentration values of at least two amino acids of the 19 kinds of
amino acids composed of Asn, His, Thr, Ala, Cit, Arg, Tyr, Val,
Met, Lys, Trp, Gly, Pro, Orn, Ile, Leu, Phe, Ser, and Gln,
including previously obtained amino acid concentration data of the
subject on the concentration value of an amino acid and (ii) the
formula previously stored in a memory device for evaluating the
state of pancreatic cancer, including an explanatory variable to be
substituted with the concentration value of the amino acid (the one
including at least two explanatory variables to be substituted with
the concentration values of at least two amino acids of the 19
kinds of amino acids) (step S21).
[0171] According to the second embodiment described above, in step
S21, the state of pancreatic cancer in the subject is evaluated by
calculating the value of the evaluation formula using the amino
acid concentration data of the subject and the formula stored in
the memory device as the evaluation formula. Hence, reliable
information that may be helpful in knowing the state of pancreatic
cancer can be provided. Both improvement in reliability of the
information and reduction in various burdens imposed on users (for
example, mental burden, physical burden, temporal burden, or
financial burden) can be achieved.
[0172] The state of pancreatic cancer may be the degree of the
possibility of being affected with pancreatic cancer. Evaluating
the state of pancreatic cancer in the subject may be evaluating the
degree of the possibility that the subject is affected with
pancreatic cancer. Hence, reliable information that may be helpful
in knowing the degree of the possibility of being affected with
pancreatic cancer can be provided.
[0173] In step S21, it may be decided that the calculated value of
the formula reflects the state of pancreatic cancer in the subject.
The value of the formula may be converted, for example, by the
methods listed below, and it may be decided that the converted
value reflects the state of pancreatic cancer in the subject. In
other words, in step S21, the value of the formula or the converted
value may be treated per se as the evaluation result on the state
of pancreatic cancer in the subject. Hence, reliable information
that may be helpful in knowing the state of pancreatic cancer can
be provided.
[0174] The value of the evaluation formula may be converted such
that the possible range of the value of the evaluation formula
falls within a predetermined range (for example, the range from 0.0
to 1.0, the range from 0.0 to 10.0, the range from 0.0 to 100.0, or
the range from -10.0 to 10.0), for example, by addition,
subtraction, multiplication, and division of any given number with
the value of the evaluation formula, by conversion of the value of
the evaluation formula by a predetermined conversion method (for
example, index transformation, logarithm transformation, angular
transformation, square root transformation, probit transformation,
or reciprocal transformation), or by performing a combination of
these computations on the value of the evaluation formula. For
example, the value of an exponential function with the value of the
evaluation formula as an exponent and Napier constant as the base
(specifically, the value of p/(1-p) where a natural logarithm
ln(p/(1-p)) is equal to the value of the evaluation formula when
the probability p of being affected with pancreatic cancer is
defined) may be further calculated, and a value (specifically, the
value of probability p) may be calculated by dividing the
calculated value of exponential function by the sum of 1 and the
value of exponential function.
[0175] The value of the evaluation formula may be converted such
that the converted value is a particular value when a particular
condition is met. For example, the value of the evaluation formula
may be converted such that the converted value is 5.0 when the
specificity is 80% and the converted value is 8.0 when the
specificity is 95%.
[0176] In step S21, the positional information about the position
of a predetermined mark (for example, a circle sign or a star sign)
corresponding to the value of the formula or the converted value
may be generated on a predetermined scale (for example, a graduated
scale at least marked with graduations corresponding to the upper
limit value and the lower limit value in the possible range of the
value of the formula or the converted value, or part of the range)
visually presented on a display device such as a monitor or a
physical medium such as paper for evaluating the state of
pancreatic cancer, using the value of the formula or, if the value
of the formula is converted, the converted value. Then it may be
decided that the generated positional information reflects the
state of pancreatic cancer in the subject. Hence, reliable
information that may be helpful in knowing the state of pancreatic
cancer can be provided.
[0177] When a plurality of categories defined considering at least
the degree of the possibility of being affected with pancreatic
cancer, and one or more thresholds are previously established, in
step S21, the subject may be classified into any one of the
categories using the value of the formula or, if the value of the
formula is converted, the converted value, and a threshold. Hence,
reliable information that may be helpful in knowing the degree of
the possibility of being affected with pancreatic cancer can be
provided in easily understandable form.
[0178] The categories may include at least one category defined
considering at least the degree of the possibility of being
affected with pancreatic cancer and the degree of the possibility
of being affected with a cancer other than pancreatic cancer (for
example, lung cancer, colorectal cancer, prostatic cancer, breast
cancer, gastric cancer, uterine cancer (cervical cancer,
endometrial cancer), or ovarian cancer). Hence, reliable
information that may be helpful in knowing not only the degree of
the possibility of being affected with pancreatic cancer but also
the degree of the possibility of being affected with a cancer other
than pancreatic cancer can be provided.
[0179] In a set of a plurality of values of the evaluation formula
calculated for each test subject using the amino acid concentration
data of the plurality of test subjects proved to be not affected
with pancreatic cancer (for example, to be healthy) and the
evaluation formula, the boundary value when the specificity is a
predetermined value (for example 80 or 95) may be established as a
threshold.
[0180] In a set of a plurality of values of the evaluation formula
calculated for each test subject using the amino acid concentration
data of the plurality of test subjects proved to be affected with
pancreatic cancer and the evaluation formula, the boundary value
when the sensitivity is a predetermined value (for example, 80 or
95) may be established as a threshold.
[0181] The categories may include a category X to which a subject
with a high possibility of being affected with pancreatic cancer
belongs and a category Y to which a subject with a low possibility
of being affected with pancreatic cancer belongs. Hence, reliable
information that may be helpful in knowing whether the possibility
of being affected with pancreatic cancer is high or low can be
provided in easily understandable form.
[0182] The category Y may include a healthy category to which a
subject with a high possibility of being healthy belongs, other
cancer category to which a subject with a high possibility of being
affected with a cancer other than pancreatic cancer belongs, or a
healthy/other cancer category to which a subject with a high
possibility of being healthy and a subject with a high possibility
of being affected with a cancer other than pancreatic cancer
belong. Hence, reliable information can be provided in easily
understandable form, which may be helpful in knowing not only
whether the possibility of being affected with pancreatic cancer is
high but also whether the possibility of being healthy is high,
whether the possibility of being affected with a cancer other than
pancreatic cancer is high, or whether the possibility of being
healthy or being affected with a cancer other than pancreatic
cancer is high.
[0183] The category Y may include the healthy category and the
other cancer category. Hence, reliable information can be provided
in easily understandable form, which may be helpful in knowing not
only whether the possibility of being affected with pancreatic
cancer is high but also whether the possibility of being healthy is
high and whether the possibility of being affected with a cancer
other than pancreatic cancer is high.
[0184] When the categories are the category X and the category Y,
in step S21, the subject may be classified into one of the category
X and the category Y, using the value of the formula or, if the
value of the formula is converted, the converted value, and a
threshold. Hence, reliable information that may be helpful in
knowing whether the possibility of being affected with pancreatic
cancer is high or low can be provided in easily understandable
form.
[0185] When a first formula and a second formula that are different
from each other and each include at least two explanatory variables
to be substituted with the concentration values of at least two
amino acids of the 19 kinds of amino acids are previously
established as evaluation formulae, in step S21, the value of the
first formula and the value of the second formula may be
calculated, and the subject may be classified into one of the
category X and the category Y using the calculated values of the
first formula and the second formula. This leads to further
improvement in reliability of information that may be helpful in
knowing whether the possibility of being affected with pancreatic
cancer is high or low.
[0186] Specifically, when the healthy category and the other cancer
category are previously established as the category Y, a formula
for classifying a subject into one of the category X and the
healthy category is previously established as the first formula,
and a formula for classifying a subject into one of the category X
and the other cancer category is previously established as the
second formula, in step S21, the value of the first formula may be
first calculated, and the subject may be classified into one of the
category X and the healthy category using the calculated value of
the first formula. Then if the classification result is the
category X, the value of the second formula may be calculated, and
the subject classified in the category X using the value of the
first formula may be further classified into one of the category X
and the other cancer category using the calculated value of the
second formula. Then the subject classified in the healthy category
and the subject classified in the other cancer category may be
finally classified into the category Y.
[0187] When the healthy category is previously established as the
category Y, in step S21, the subject may be classified into one of
the category X and the healthy category using the value of the
formula or, if the value of the formula is converted, the converted
value, and a threshold. Hence, reliable information that may be
helpful in knowing whether the possibility of being affected with
pancreatic cancer is high or whether the possibility of being
healthy is high can be provided in easily understandable form.
[0188] When the other cancer category is previously established as
the category Y, in step S21, the subject may be classified into one
of the category X and the other cancer category using the value of
the formula or, if the value of the formula is converted, the
converted value, and a threshold. Hence, reliable information that
may be helpful in knowing whether the possibility of being affected
with pancreatic cancer is high or whether the possibility of being
affected with a cancer other than pancreatic cancer is high can be
provided in easily understandable form.
[0189] When the healthy/other cancer category is previously
established as the category Y, in step S21, the subject may be
classified into one of the category X and the healthy/other cancer
category using the value of the formula or, if the value of the
formula is converted, the converted value, and a threshold. Hence,
reliable information that may be helpful in knowing whether the
possibility of being affected with pancreatic cancer is high or
whether the possibility of being healthy or being affected with a
cancer other than pancreatic cancer is high can be provided in
easily understandable form.
[0190] When the healthy category and the other cancer category are
previously established as the category Y, in step S21, the subject
may be classified into any one of the category X, the healthy
category, and the other cancer category using the value of the
formula or, if the value of the formula is converted, the converted
value, and a threshold. Hence, reliable information that may be
helpful in knowing whether the possibility of being affected with
pancreatic cancer is high, whether the possibility of being healthy
is high, or whether the possibility of being affected with a cancer
other than pancreatic cancer is high can be provided in easily
understandable form.
[0191] When the first formula and the second formula that are
different from each other and each include at least two explanatory
variables to be substituted with the concentration values of at
least two amino acids of the 19 kinds of amino acids are previously
established as evaluation formulae, in step S21, the value of the
first formula and the value of the second formula may be
calculated, and the subject may be classified into any one of the
category X, the healthy category, and the other cancer category
using the calculated values of the first formula and the second
formula. This leads to further improvement in reliability of
information that may be helpful in knowing whether the possibility
of being affected with pancreatic cancer is high, whether the
possibility of being healthy is high, or whether the possibility of
being affected with a cancer other than pancreatic cancer is
high.
[0192] Specifically, when a formula for classifying a subject into
one of the category X and the healthy category is previously
established as the first formula, and a formula for classifying a
subject into one of the category X and the other cancer category is
previously established as the second formula, in step S21, the
value of the first formula may be first calculated, and the subject
may be classified into one of the category X and the healthy
category using the calculated value of the first formula. Then if
the classification result is the category X, the value of the
second formula may be calculated, and the subject classified in the
category X using the value of the first formula may be further
classified into one of the category X and the other cancer category
using the calculated value of the second formula. Then the subject
classified in the category X using the value of the first formula
and classified in the other cancer category using the value of the
second formula may be finally classified into the other cancer
category.
[0193] The evaluation formula may be any one of the logistic
regression equation, the fractional expression, the linear
discriminant, the multiple regression equation, the formula
prepared by the support vector machine, the formula prepared by the
Mahalanobis' generalized distance method, the formula prepared by
the canonical discriminant analysis, and the formula prepared by
the decision tree. This leads to further improvement in reliability
of information that may be helpful in knowing the state of
pancreatic cancer.
[0194] In addition to the formulae described in the present
specification, the formulae described in the international patent
applications, filed by the present applicant, WO 2008/016111, WO
2008/075662, WO 2008/075663, WO 2009/099005, WO 2009/154296, and WO
2009/154297 can be additionally employed to evaluate the state of
pancreatic cancer.
[0195] The formula employed as the evaluation formula may be
prepared by a method described in WO 2004/052191 that is an
international application filed by the present applicant or by a
method described in WO 2006/098192 that is an international
application filed by the present applicant. Any formulae obtained
by these methods can be preferably used in the evaluation of the
state of pancreatic cancer, regardless of the unit of the amino
acid concentration value in the amino acid concentration data as
input data.
[0196] The formula employed as the evaluation formula refers to a
form of equation used generally in multivariate analysis and
includes, for example, fractional expression, multiple regression
equation, multiple logistic regression equation, linear
discriminant function, Mahalanobis' generalized distance, canonical
discriminant function, support vector machine, decision tree, and
an equation shown by the sum of different forms of equations. In
the multiple regression equation, the multiple logistic regression
equation, and the canonical discriminant function, a coefficient
and a constant term are added to each explanatory variable, and the
coefficient and the constant term may be preferably real numbers,
more preferably values in the range of 99% confidence interval for
the coefficient and the constant term obtained from data for the
various kinds of classifications described above, more preferably
in the range of 95% confidence interval for the coefficient and the
constant term obtained from data for the various kinds of
classifications described above. The value of each coefficient and
the confidence interval thereof may be those multiplied by a real
number, and the value of the constant term and the confidence
interval thereof may be those having an arbitrary actual constant
added or subtracted or those multiplied or divided by an arbitrary
actual constant.
[0197] When an expression such as a logistic regression, a linear
discriminant, and a multiple regression analysis is used as an
evaluation formula, a linear transformation of the expression
(addition of a constant and multiplication by a constant) and a
monotonic increasing (decreasing) transformation (for example, a
logit transformation) of the expression do not alter evaluation
performance and thus are equivalent to before transformation.
Therefore, the expression includes an expression that is subjected
to a linear transformation and a monotonic increasing (decreasing)
transformation.
[0198] In the fractional expression, the numerator of the
fractional expression is expressed by the sum of the amino acids A,
B, C etc. and the denominator of the fractional expression is
expressed by the sum of the amino acids a, b, c etc. The fractional
expression also includes the sum of the fractional expressions
.alpha., .beta., .gamma. etc. (for example, .alpha.+.beta.) having
such constitution. The fractional expression also includes divided
fractional expressions. The amino acids used in the numerator or
denominator may have suitable coefficients respectively. The amino
acids used in the numerator or denominator may appear repeatedly.
Each fractional expression may have a suitable coefficient. A value
of a coefficient for each explanatory variable and a value for a
constant term may be any real numbers. In a fractional expression
and the one in which explanatory variables in the numerator and
explanatory variables in the denominator in the fractional
expression are switched with each other, the positive and negative
signs are generally reversed in correlation with objective
explanatory variables, but because their correlation is maintained,
the evaluation performance can be assumed to be equivalent. The
fractional expression therefore also includes the one in which
explanatory variables in the numerator and explanatory variables in
the denominator in the fractional expression are switched with each
other.
[0199] In the second embodiment, when the state of pancreatic
cancer is evaluated, the concentration value of an amino acid other
than the 19 kinds of amino acids may be additionally used. In the
second embodiment, when the state of pancreatic cancer is
evaluated, a value of other biological information (for example,
the values listed in 1. through 5. below) may be used in addition
to the concentration values of amino acids. In the second
embodiment, the formula employed as the evaluation formula may
additionally include one or more explanatory variables to be
substituted with the concentration value of an amino acid other
than the 19 kinds of amino acids. In the second embodiment, the
formula employed as the evaluation formula may additionally include
one or more explanatory variables to be substituted with the value
of other biological information (for example, the values listed in
1. through 5. below), in addition to the explanatory variables to
be substituted with the concentration values of amino acids.
[0200] 1. the concentration values of metabolites in blood other
than amino acids (amino acid metabolites, carbohydrates, lipids,
and the like), proteins, peptides, minerals, hormones, and the
like
[0201] 2. the values of tumor markers in blood (CA19-9, CEA, CA125,
SPan-1, DUPAN-2, SLX, SCC, CYFRA, ProGRP, p53, elastase, and the
like)
[0202] 3. blood test values such as albumin, total protein,
triglyceride, HbAlc, LDL cholesterol, HDL cholesterol, amylase,
total bilirubin, and uric acid
[0203] 4. the values obtained from image information of
ultrasonography, X rays, CT, MRI, and the like
[0204] 5. the values of biological indices such as age, height,
weight, BMI, blood pressure, gender, smoking information, dietary
information, drinking information, exercise information, stress
information, sleeping information, family medical history, disease
history information (diabetes, pancreatitis, and the like)
[0205] Here, the summary of the evaluation formula-preparing
processing (steps 1 to 4) is described in detail. The processing
described below is merely one example, and the method of preparing
the evaluation formula is not limited thereto.
[0206] First, the control device prepares a candidate formula
(e.g., y=a.sub.1x.sub.1+a.sub.2x.sub.2+ . . . +a.sub.nx.sub.n, y:
pancreatic cancer state index data, x.sub.1: amino acid
concentration data, a.sub.1: constant, i=1, 2, . . . , n) that is a
candidate for the evaluation formula, based on a predetermined
formula-preparing method from pancreatic cancer state information
previously stored in the memory device containing the amino acid
concentration data and pancreatic cancer state index data on an
index for indicating the state of pancreatic cancer (step 1). Data
containing defective and outliers may be removed in advance from
the pancreatic cancer state information.
[0207] In step 1, a plurality of the candidate formulae may be
prepared from the pancreatic cancer state information by using a
plurality of the different formula-preparing methods (including
those for multivariate analysis such as principal component
analysis, discriminant analysis, support vector machine, multiple
regression analysis, logistic regression analysis, k-means method,
cluster analysis, and decision tree). Specifically, a plurality of
the candidate formulae may be prepared simultaneously and
concurrently by using a plurality of different algorithms with the
pancreatic cancer state information which is multivariate data
composed of the amino acid concentration data and the pancreatic
cancer state index data obtained by analyzing blood obtained from a
large number of healthy groups and pancreatic cancer groups. For
example, the two different candidate formulae may be formed by
performing discriminant analysis and logistic regression analysis
simultaneously with the different algorithms. Alternatively, the
candidate formula may be formed by converting the pancreatic cancer
state information with the candidate formula prepared by performing
principal component analysis and then performing discriminant
analysis of the converted pancreatic cancer state information. In
this way, it is possible to finally prepare the most suitable
evaluation formula.
[0208] The candidate formula prepared by principal component
analysis is a linear expression including each amino acid
explanatory variable maximizing the variance of all amino acid
concentration data. The candidate formula prepared by discriminant
analysis is a high-powered expression (including exponential and
logarithmic expressions) including each amino acid explanatory
variable minimizing the ratio of the sum of the variances in
respective groups to the variance of all amino acid concentration
data. The candidate formula prepared by using support vector
machine is a high-powered expression (including kernel function)
including each amino acid explanatory variable maximizing the
boundary between groups. The candidate formula prepared by multiple
regression analysis is a high-powered expression including each
amino acid explanatory variable minimizing the sum of the distances
from all amino acid concentration data. The candidate formula
prepared by logistic regression analysis is a linear model
expressing logarithmic odds of probability, and a linear expression
including each amino acid explanatory variable maximizing the
likelihood of the probability. The k-means method is a method of
searching k pieces of neighboring amino acid concentration data in
various groups, designating the group containing the greatest
number of the neighboring points as its data-belonging group, and
selecting the amino acid explanatory variable that makes the group
to which input amino acid concentration data belong agree well with
the designated group. The cluster analysis is a method of
clustering (grouping) the points closest in entire amino acid
concentration data. The decision tree is a method of ordering amino
acid explanatory variables and predicting the group of amino acid
concentration data from the pattern possibly held by the
higher-ordered amino acid explanatory variable.
[0209] Returning to the description of the evaluation
formula-preparing processing, the control device verifies the
candidate formula prepared in step 1 based on a particular
verifying method (step 2). The verification of the candidate
formula is performed on each other to each candidate formula
prepared in step 1.
[0210] In step 2, at least one of discrimination rate, sensitivity,
specificity, information criterion, ROC_AUC (area under the curve
in a receiver operating characteristic curve), and the like of the
candidate formula may be verified by at least one of the bootstrap
method, holdout method, N-fold method, leave-one-out method, and
the like. In this way, it is possible to prepare the candidate
formula higher in predictability or reliability, by taking the
pancreatic cancer state information and the evaluation condition
into consideration.
[0211] The discrimination rate is the rate of the states of
pancreatic cancer judged correct according to the present
embodiment in all input data. The sensitivity is the rate of the
states of pancreatic cancer judged correct according to the present
embodiment in the states of pancreatic cancer declared pancreatic
cancer in the input data. The specificity is the rate of the states
of pancreatic cancer judged correct according to the present
embodiment in the states of pancreatic cancer declared healthy in
the input data. The information criterion is the sum of the number
of the amino acid explanatory variables in the candidate formula
prepared in step 1 and the difference in number between the states
of pancreatic cancer evaluated according to the present embodiment
and those declared in input data. ROC_AUC (area under the curve in
a receiver operating characteristic curve) is defined as an area
under the curve in a receiver operating characteristic curve (ROC)
which is a curve prepared by plotting (x,y)=(1-specificity,
sensitivity) on a two-dimensional coordinate, the value of ROC_AUC
is equal to 1 for perfect discrimination, and discrimination
performance becomes higher as the value becomes closer to 1. The
predictability is the average of the discrimination rate,
sensitivity, or specificity obtained by repeating verification of
the candidate formula. Alternatively, the reliability is the
variance of the discrimination rate, sensitivity, or specificity
obtained by repeating verification of the candidate formula.
[0212] Returning to the description of the evaluation
formula-preparing processing, the control device selects a
combination of the amino acid concentration data contained in the
pancreatic cancer state information used in preparing the candidate
formula, by selecting the explanatory variable of the candidate
formula based on a predetermined explanatory variable-selecting
method (step 3). The selection of the amino acid explanatory
variable may be performed on each candidate formula prepared in
step 1. In this way, it is possible to select the amino acid
explanatory variable of the candidate formula properly. The step 1
is executed once again by using the pancreatic cancer state
information including the amino acid concentration data selected in
step 3.
[0213] In step 3, the amino acid explanatory variable of the
candidate formula may be selected based on at least one of the
stepwise method, best path method, local search method, and genetic
algorithm from the verification result obtained in step 2.
[0214] The best path method is a method of selecting an amino acid
explanatory variable by optimizing an evaluation index of the
candidate formula while eliminating the amino acid explanatory
variables contained in the candidate formula one by one.
[0215] Returning to the description of the evaluation
formula-preparing processing, the control device prepares the
evaluation formula by repeatedly performing the steps 1, 2 and 3,
and based on verification results thus accumulated, selecting the
candidate formula used as the evaluation formula from a plurality
of the candidate formulae (step 4). In the selection of the
candidate formula, there are cases where the optimum formula is
selected from the candidate formulae prepared in the same
formula-preparing method or the optimum formula is selected from
all candidate formulae.
[0216] As described above, in the evaluation formula-preparing
processing, the processing for the preparation of the candidate
formulae, the verification of the candidate formulae, and the
selection of the explanatory variables in the candidate formulae
are performed based on the pancreatic cancer state information in a
series of operations in a systematized manner, whereby the
evaluation formula most appropriate for evaluating the state of
pancreatic cancer can be prepared. In other words, in the
evaluation formula-preparing processing, the amino acid
concentration is used in multivariate statistical analysis, and for
selecting the optimum and robust combination of the explanatory
variables, the explanatory variable-selecting method is combined
with cross-validation to extract the evaluation formula having high
evaluation performance.
[0217] Logistic regression equation, linear discriminant, support
vector machine, Mahalanobis' generalized distance method, multiple
regression analysis, cluster analysis, Cox proportional-hazards
model, and the like can be used as the evaluation formula.
2-2. System Configuration
[0218] Hereinafter, the configuration of the pancreatic
cancer-evaluating system according to the second embodiment
(hereinafter referred to sometimes as the present system) will be
described with reference to FIGS. 4 to 19. This system is merely
one example, and the present invention is not limited thereto.
[0219] First, an entire configuration of the present system will be
described with reference to FIGS. 4 and 5. FIG. 4 is a diagram
showing an example of the entire configuration of the present
system. FIG. 5 is a diagram showing another example of the entire
configuration of the present system. As shown in FIG. 4, the
present system is constituted in which the pancreatic
cancer-evaluating apparatus 100 that evaluates the state of
pancreatic cancer in the individual as the subject, and the client
apparatus 200 (corresponding to the information communication
terminal apparatus of the present invention) that provides the
amino acid concentration data of the individual on the
concentration values of amino acids, are communicatively connected
to each other via a network 300.
[0220] In the present system as shown in FIG. 5, in addition to the
pancreatic cancer-evaluating apparatus 100 and the client apparatus
200, the database apparatus 400 storing, for example, the
pancreatic cancer state information used in preparing the
evaluation formula and the evaluation formula used in evaluating
the state of pancreatic cancer in the pancreatic cancer-evaluating
apparatus 100, may be communicatively connected via the network
300. In this configuration, reliable information that may be
helpful in knowing the state of pancreatic cancer, or the like is
provided via the network 300 from the pancreatic cancer-evaluating
apparatus 100 to the client apparatuses 200 and the database
apparatus 400, or from the client apparatuses 200 and the database
apparatus 400 to the pancreatic cancer-evaluating apparatus 100.
The reliable information that may be helpful in knowing the state
of pancreatic cancer is, for example, information on the measured
values of particular items as to the state of pancreatic cancer of
organisms including human. The reliable information that may be
helpful in knowing the state of pancreatic cancer is generated in
the pancreatic cancer-evaluating apparatus 100, client apparatus
200, or other apparatuses (e.g., various measuring apparatuses) and
stored mainly in the database apparatus 400.
[0221] Now, the configuration of the pancreatic cancer-evaluating
apparatus 100 in the present system will be described with
reference to FIGS. 6 to 17. FIG. 6 is a block diagram showing an
example of the configuration of the pancreatic cancer-evaluating
apparatus 100 in the present system, showing conceptually only the
region relevant to the present invention.
[0222] The pancreatic cancer-evaluating apparatus 100 includes (I)
a control device 102, such as CPU (Central Processing Unit), that
integrally controls the pancreatic cancer-evaluating apparatus,
(II) a communication interface 104 that connects the pancreatic
cancer-evaluating apparatus to the network 300 communicatively via
communication apparatuses such as a router and wired or wireless
communication lines such as a private line, (III) a memory device
106 that stores various databases, tables, files and others, and
(IV) an input/output interface 108 connected to an input device 112
and an output device 114, and these parts are connected to each
other communicatively via any communication channel. The pancreatic
cancer-evaluating apparatus 100 may be present together with
various analyzers (e.g., amino acid analyzer) in a same
housing.
[0223] The memory device 106 is a storage means, and examples
thereof include memory apparatuses such as RAM (Random Access
Memory) and ROM (Read Only Memory), fixed disk drives such as a
hard disk, a flexible disk, an optical disk, and the like. The
memory device 106 stores computer programs giving instructions to
the CPU for various processings, together with OS (Operating
System). As shown in the figure, the memory device 106 stores the
user information file 106a, the amino acid concentration data file
106b, the pancreatic cancer state information file 106c, the
designated pancreatic cancer state information file 106d, an
evaluation formula-related information database 106e, and the
evaluation result file 106f.
[0224] The user information file 106a stores user information on
users. FIG. 7 is a chart showing an example of information stored
in the user information file 106a. As shown in FIG. 7, the
information stored in the user information file 106a includes user
ID (identification) for identifying a user uniquely, user password
for authentication of the user, user name, organization ID for
uniquely identifying an organization of the user, department ID for
uniquely identifying a department of the user organization,
department name, and electronic mail address of the user that are
correlated to one another.
[0225] Returning to FIG. 6, the amino acid concentration data file
106b stores the amino acid concentration data on the concentration
values of amino acids. FIG. 8 is a chart showing an example of
information stored in the amino acid concentration data file 106b.
As shown in FIG. 8, the information stored in the amino acid
concentration data file 106b includes individual number for
uniquely identifying an individual (sample) as a subject to be
evaluated and amino acid concentration data that are correlated to
one another. In FIG. 8, the amino acid concentration data is
assumed to be numerical values, i.e., on a continuous scale, but
the amino acid concentration data may be expressed on a nominal
scale or an ordinal scale. In the case of the nominal or ordinal
scale, any number may be allocated to each state for analysis. The
amino acid concentration data may be combined with the
concentration value of an amino acid other than the 19 kinds of
amino acids or the value of other biological information (for
example, the values listed in 1. through 5. below).
[0226] 1. the concentration values of metabolites in blood other
than amino acids (amino acid metabolites, carbohydrates, lipids,
and the like), proteins, peptides, minerals, hormones, and the
like
[0227] 2. the values of tumor markers in blood (CA19-9, CEA, CA125,
SPan-1, DUPAN-2, SLX, SCC, CYFRA, ProGRP, p53, elastase, and the
like)
[0228] 3. blood test values such as albumin, total protein,
triglyceride, HbAlc, LDL cholesterol, HDL cholesterol, amylase,
total bilirubin, and uric acid
[0229] 4. the values obtained from image information of
ultrasonography, X rays, CT, MRI, and the like
[0230] 5. the values of biological indices such as age, height,
weight, BMI, blood pressure, gender, smoking information, dietary
information, drinking information, exercise information, stress
information, sleeping information, family medical history, disease
history information (diabetes, pancreatitis, and the like)
[0231] Returning to FIG. 6, the pancreatic cancer state information
file 106c stores the pancreatic cancer state information used in
preparing the evaluation formula. FIG. 9 is a chart showing an
example of information stored in the pancreatic cancer state
information file 106c. As shown in FIG. 9, the information stored
in the pancreatic cancer state information file 106c includes
individual (sample) number, pancreatic cancer state index data (T)
on index (index T.sub.1, index T.sub.2, index T.sub.3 . . . ) for
indicating the state of pancreatic cancer, and amino acid
concentration data that are correlated to one another. In FIG. 9,
the pancreatic cancer state index data and the amino acid
concentration data are assumed to be numerical values, i.e., on a
continuous scale, but the pancreatic cancer state index data and
the amino acid concentration data may be expressed on a nominal
scale or an ordinal scale. In the case of the nominal or ordinal
scale, any number may be allocated to each state for analysis. The
pancreatic cancer state index data is a single known condition
index serving as a marker of the state of pancreatic cancer, and
numerical data may be used.
[0232] Returning to FIG. 6, the designated pancreatic cancer state
information file 106d stores the pancreatic cancer state
information designated in a pancreatic cancer state
information-designating part 102g described below. FIG. 10 is a
chart showing an example of information stored in the designated
pancreatic cancer state information file 106d. As shown in FIG. 10,
the information stored in the designated pancreatic cancer state
information file 106d includes individual number, designated
pancreatic cancer state index data, and designated amino acid
concentration data that are correlated to one another.
[0233] Returning to FIG. 6, the evaluation formula-related
information database 106e is composed of (I) the candidate formula
file 106e1 storing the candidate formula prepared in a candidate
formula-preparing part 102h1 described below, (II) the verification
result file 106e2 storing the verification results obtained in a
candidate formula-verifying part 102h2 described below, (III) the
selected pancreatic cancer state information file 106e3 storing the
pancreatic cancer state information containing the combination of
the amino acid concentration data selected in an explanatory
variable-selecting part 102h3 described below, and (IV) the
evaluation formula file 106e4 storing the evaluation formula
prepared in the evaluation formula-preparing part 102h described
below.
[0234] The candidate formula file 106e1 stores the candidate
formulae prepared in the candidate formula-preparing part 102h1
described below. FIG. 11 is a chart showing an example of
information stored in the candidate formula file 106e1. As shown in
FIG. 11, the information stored in the candidate formula file 106e1
includes rank, and candidate formula (e.g., F.sub.1 (Gly, Leu, Phe,
. . . ), F.sub.2 (Gly, Leu, Phe, . . . ), or F.sub.3 (Gly, Leu,
Phe, . . . ) in FIG. 11) that are correlated to each other.
[0235] Returning to FIG. 6, the verification result file 106e2
stores the verification results obtained in the candidate
formula-verifying part 102h2 described below. FIG. 12 is a chart
showing an example of information stored in the verification result
file 106e2. As shown in FIG. 12, the information stored in the
verification result file 106e2 includes rank, candidate formula
(e.g., F.sub.k (Gly, Leu, Phe, . . . ), F.sub.m (Gly, Leu, Phe, . .
. ), F.sub.1 (Gly, Leu, Phe, . . . ) in FIG. 12), and verification
result of each candidate formula (e.g., evaluation value of each
candidate formula) that are correlated to one another.
[0236] Returning to FIG. 6, the selected pancreatic cancer state
information file 106e3 stores the pancreatic cancer state
information including the combination of the amino acid
concentration data corresponding to the explanatory variables
selected in the explanatory variable-selecting part 102h3 described
below. FIG. 13 is a chart showing an example of information stored
in the selected pancreatic cancer state information file 106e3. As
shown in FIG. 13, the information stored in the selected pancreatic
cancer state information file 106e3 includes individual number,
pancreatic cancer state index data designated in the pancreatic
cancer state information-designating part 102g described below, and
amino acid concentration data selected in the explanatory
variable-selecting part 102h3 described below that are correlated
to one another.
[0237] Returning to FIG. 6, the evaluation formula file 106e4
stores the evaluation formulae prepared in the evaluation
formula-preparing part 102h described below. FIG. 14 is a chart
showing an example of information stored in the evaluation formula
file 106e4. As shown in FIG. 14, the information stored in the
evaluation formula file 106e4 includes rank, evaluation formula
(e.g., F.sub.p (Phe, . . . ), F.sub.p (Gly, Leu, Phe), F.sub.k
(Gly, Leu, Phe, . . . ) in FIG. 14), a threshold corresponding to
each formula-preparing method, and verification result of each
evaluation formula (e.g., evaluation value of each evaluation
formula) that are correlated to one another.
[0238] Returning to FIG. 6, the evaluation result file 106f stores
the evaluation results obtained in the evaluating part 102i
described below. FIG. 15 is a chart showing an example of
information stored in the evaluation result file 106f. The
information stored in the evaluation result file 106f includes
individual number for uniquely identifying the individual (sample)
as the subject, previously obtained amino acid concentration data
of the individual, and evaluation result on the state of pancreatic
cancer (for example, the value of the evaluation formula calculated
by a calculating part 102i1 described below, the converted value of
the evaluation formula by a converting part 102i2 described below,
the positional information generated by a generating part 102i3
described below, or the classification result obtained by a
classifying part 102i4 described below), that are correlated to one
another.
[0239] Returning to FIG. 6, the memory device 106 stores various
Web data for providing the client apparatuses 200 with web site
information, CGI programs, and others as information other than the
information described above. The Web data include data for
displaying the Web pages described below and others, and the data
are generated as, for example, a HTML (HyperText Markup Language)
or XML (Extensible Markup Language) text file. Files for components
and files for operation for generation of the Web data, and other
temporary files, and the like are also stored in the memory device
106. In addition, the memory device 106 may store as needed sound
files of sounds for transmission to the client apparatuses 200 in
WAVE format or AIFF (Audio Interchange File Format) format and
image files of still images or motion pictures in JPEG (Joint
Photographic Experts Group) format or MPEG2 (Moving Picture Experts
Group phase 2) format.
[0240] The communication interface 104 allows communication between
the pancreatic cancer-evaluating apparatus 100 and the network 300
(or communication apparatus such as a router). Thus, the
communication interface 104 has a function to communicate data via
a communication line with other terminals.
[0241] The input/output interface 108 is connected to the input
device 112 and the output device 114. A monitor (including a home
television), a speaker, or a printer may be used as the output
device 114 (hereinafter, the output device 114 may be described as
a monitor 114). A keyboard, a mouse, a microphone, or a monitor
functioning as a pointing device together with a mouse may be used
as the input device 112.
[0242] The control device 102 has an internal memory storing
control programs such as OS (Operating System), programs for
various processing procedures, and other needed data, and performs
various information processings according to these programs. As
shown in the figure, the control device 102 includes mainly a
request-interpreting part 102a, a browsing processing part 102b, an
authentication-processing part 102c, an electronic mail-generating
part 102d, a Web page-generating part 102e, a receiving part 102f,
the pancreatic cancer state information-designating part 102g, the
evaluation formula-preparing part 102h, the evaluating part 102i, a
result outputting part 102j and a sending part 102k. The control
device 102 performs data processings such as removal of data
including defective, removal of data including many outliers, and
removal of explanatory variables for the defective-including data
in the pancreatic cancer state information transmitted from the
database apparatus 400 and in the amino acid concentration data
transmitted from the client apparatus 200.
[0243] The request-interpreting part 102a interprets the requests
transmitted from the client apparatus 200 or the database apparatus
400 and sends the requests to other parts in the control device 102
according to results of interpreting the requests. Upon receiving
browsing requests for various screens transmitted from the client
apparatus 200, the browsing processing part 102b generates and
transmits web data for these screens. Upon receiving authentication
requests transmitted from the client apparatus 200 or the database
apparatus 400, the authentication-processing part 102c performs
authentication. The electronic mail-generating part 102d generates
electronic mails including various kinds of information. The Web
page-generating part 102e generates Web pages for users to browse
with the client apparatus 200.
[0244] The receiving part 102f receives, via the network 300,
information (specifically, the amino acid concentration data, the
pancreatic cancer state information, the evaluation formula, etc.)
transmitted from the client apparatus 200 and the database
apparatus 400. The pancreatic cancer state information-designating
part 102g designates objective pancreatic cancer state index data
and objective amino acid concentration data in preparing the
evaluation formula.
[0245] The evaluation formula-preparing part 102h generates the
evaluation formula based on the pancreatic cancer state information
received in the receiving part 102f and the pancreatic cancer state
information designated in the pancreatic cancer state
information-designating part 102g. Specifically, the evaluation
formula-preparing part 102h generates the evaluation formula by
selecting the candidate formula used as the evaluation formula from
a plurality of the candidate formulae, based on verification
results accumulated by repeating processings in the candidate
formula-preparing part 102h1, the candidate formula-verifying part
102h2, and the explanatory variable-selecting part 102h3 from the
pancreatic cancer state information.
[0246] If the evaluation formulae are stored previously in a
predetermined region of the memory device 106, the evaluation
formula-preparing part 102h may generate the evaluation formula by
selecting the desired evaluation formula out of the memory device
106. Alternatively, the evaluation formula-preparing part 102h may
generate the evaluation formula by selecting and downloading the
desired evaluation formula from the evaluation formulae previously
stored in another computer apparatus (e.g., the database apparatus
400).
[0247] Hereinafter, a configuration of the evaluation
formula-preparing part 102h will be described with reference to
FIG. 16. FIG. 16 is a block diagram showing the configuration of
the evaluation formula-preparing part 102h, and only a part in the
configuration related to the present invention is shown
conceptually. The evaluation formula-preparing part 102h includes
the candidate formula-preparing part 102h1, the candidate
formula-verifying part 102h2, and the explanatory
variable-selecting part 102h3, additionally. The candidate
formula-preparing part 102h1 generates the candidate formula that
is a candidate of the evaluation formula, from the pancreatic
cancer state information based on a predetermined formula-preparing
method. The candidate formula-preparing part 102h1 may generate a
plurality of the candidate formulae from the pancreatic cancer
state information, by using a plurality of the different
formula-preparing methods. The candidate formula-verifying part
102h2 verifies the candidate formula prepared by the candidate
formula-preparing part 102h1 based on a particular verifying
method. The candidate formula-verifying part 102h2 may verify at
least one of the discrimination rate, sensitivity, specificity,
information criterion, and ROC_AUC (area under the curve in a
receiver operating characteristic curve) of the candidate formulae
based on at least one of the bootstrap method, holdout method,
N-fold method, and leave-one-out method. The explanatory
variable-selecting part 102h3 selects the combination of the amino
acid concentration data contained in the pancreatic cancer state
information used in preparing the candidate formula, by selecting
the explanatory variables of the candidate formula based on a
particular explanatory variable-selecting method. The explanatory
variable-selecting part 102h3 may select the explanatory variables
of the candidate formula based on at least one of the stepwise
method, best path method, local search method, and genetic
algorithm from the verification results.
[0248] Returning to FIG. 6, the evaluating part 102i evaluates the
state of pancreatic cancer in the individual by calculating the
value of the evaluation formula using the previously obtained
formula (for example, the evaluation formula prepared by the
evaluation formula-preparing part 102h or the evaluation formula
received by the receiving part 102f) and the amino acid
concentration data received by the receiving part 102f.
[0249] Hereinafter, a configuration of the evaluating part 102i
will be described with reference to FIG. 17. FIG. 17 is a block
diagram showing the configuration of the evaluating part 102i, and
only a part in the configuration related to the present invention
is shown conceptually. The evaluating part 102i includes the
calculating part 102i1, the converting part 102i2, the generating
part 102i3, and the classifying part 102i4, additionally.
[0250] The calculating part 102i1 calculates the value of the
evaluation formula using (i) the concentration values of at least
two amino acids of the 19 kinds of amino acids, including the amino
acid concentration data and (ii) the evaluation formula including
at least two explanatory variables to be substituted with the
concentration values of at least two amino acids of the 19 kinds of
amino acids. The evaluating part 102i stores the value of the
evaluation formula calculated by the calculating part 102i1 as an
evaluation result in a predetermined region of the evaluation
result file 106f. The evaluation formula may be any one of a
logistic regression equation, a fractional expression, a linear
discriminant, a multiple regression equation, a formula prepared by
a support vector machine, a formula prepared by a Mahalanobis'
generalized distance method, a formula prepared by canonical
discriminant analysis, and a formula prepared by a decision
tree.
[0251] The converting part 102i2 converts the value of the
evaluation formula calculated by the calculating part 102i1, for
example, by the conversion method described above. The evaluating
part 102i stores the converted value by the converting part 102i2
as an evaluation result in a predetermined region of the evaluation
result file 106f.
[0252] The generating part 102i3 generates the positional
information about the position of a predetermined mark (for
example, a circle sign or a star sign) corresponding to the value
of the formula or the converted value on a predetermined scale (for
example, a graduated scale at least marked with graduations
corresponding to the upper limit value and the lower limit value in
the possible range of the value of the formula or the converted
value, or part of the range) visually presented on a display device
such as a monitor or a physical medium such as paper for evaluating
the state of pancreatic cancer, using the value of the formula
calculated by the calculating part 102i1 or the converted value by
the converting part 102i2. The evaluating part 102i stores the
positional information generated by the generating part 102i3 as an
evaluation result in a predetermined region of the evaluation
result file 106f.
[0253] The classifying part 102i4 classifies the individual into
any one of a plurality of categories previously defined considering
at least the degree of the possibility of being affected with
pancreatic cancer, using the value of the evaluation formula
calculated by the calculating part 102i1 or the converted value by
the converting part 102i2.
[0254] The categories may include at least one category defined
considering at least the degree of the possibility that a subject
is affected with pancreatic cancer and the degree of the
possibility that a subject is affected with a cancer other than
pancreatic cancer.
[0255] When the category X and the category Y are previously
established as the categories, the classifying part 102i4
classifies the individual into one of the category X and the
category Y using the evaluation value and a threshold. When the
first formula and the second formula that are different from each
other are previously established as evaluation formulae, the
calculating part 102i1 may calculate the value of the first formula
and the value of the second formula, and the classifying part 102i4
may classify the individual into one of the category X and the
category Y using the values of the first formula and the second
formula. When the healthy category and the other cancer category
are previously established as the category Y, a formula for
classifying a subject into one of the category X and the healthy
category is previously established as the first formula, and a
formula for classifying a subject into one of the category X and
the other cancer category is previously established as the second
formula, the calculating part 102i1 may first calculate the value
of the first formula, and the classifying part 102i4 may classify
the individual into one of the category X and the healthy category
using the calculated value of the first formula. Then if the
classification result is the category X, the calculating part 102i1
may calculate the value of the second formula, and the classifying
part 102i4 may further classify the individual classified in the
category X using the value of the first formula into one of the
category X and the other cancer category, using the calculated
value of the second formula. Then the classifying part 102i4 may
finally classify the individual classified in the healthy category
and the individual classified in the other cancer category into the
category Y.
[0256] When the category X and the healthy category are previously
established as the categories, the classifying part 102i4
classifies the individual into one of the category X and the
healthy category using the evaluation value and a threshold.
[0257] When the category X and the other cancer category are
previously established as the categories, the classifying part
102i4 classifies the individual into one of the category X and the
other cancer category using the evaluation value and a
threshold.
[0258] When the category X and the healthy/other cancer category
are previously established as the categories, the classifying part
102i4 classifies the individual into one of the category X and the
healthy/other cancer category using the evaluation value and a
threshold.
[0259] When the category X, the healthy category, and the other
cancer category are previously established as the categories, the
classifying part 102i4 classifies the individual into any one of
the category X, the healthy category, and the other cancer
category, using the evaluation value and a threshold. When the
first formula and the second formula that are different from each
other are previously established as the evaluation formulae, the
calculating part 102i1 may calculate the value of the first formula
and the value of the second formula, and the classifying part 102i4
may classify the individual into any one of the category X, the
healthy category, and the other cancer category, using the
calculated values of the first formula and the second formula. When
a formula for classifying a subject into one of the category X and
the healthy category is previously established as the first
formula, and a formula for classifying a subject into one of the
category X and the other cancer category is previously established
as the second formula, the calculating part 102i1 may first
calculate the value of the first formula, and the classifying part
102i4 may classify the individual into one of the category X and
the healthy category using the calculated value of the first
formula. Then if the classification result is the category X, the
calculating part 102i1 may calculate the value of the second
formula, and the classifying part 102i4 may further classify the
individual classified in the category X using the value of the
first formula into one of the category X and the other cancer
category, using the calculated value of the second formula. Then
the classifying part 102i4 may finally classify the individual
classified in the category X using the value of the first formula
and classified in the other cancer category using the value of the
second formula into the other cancer category.
[0260] Returning to FIG. 6, the result outputting part 102j
outputs, into the output device 114, the processing results in each
processing part in the control device 102 (including the evaluation
results obtained by the evaluating part 102i) etc.
[0261] The sending part 102k transmits the evaluation results to
the client apparatus 200 that is a sender of the amino acid
concentration data of the individual, and transmits the evaluation
formulae prepared in the pancreatic cancer-evaluating apparatus 100
and the evaluation results to the database apparatus 400.
[0262] Hereinafter, a configuration of the client apparatus 200 in
the present system will be described with reference to FIG. 18.
FIG. 18 is a block diagram showing an example of the configuration
of the client apparatus 200 in the present system, and only the
part in the configuration relevant to the present invention is
shown conceptually.
[0263] The client apparatus 200 includes a control device 210, ROM
220, HD (Hard Disk) 230, RAM 240, an input device 250, an output
device 260, an input/output IF 270, and a communication IF 280 that
are connected communicatively to one another through a
communication channel.
[0264] The control device 210 has a Web browser 211, an electronic
mailer 212, a receiving part 213, and a sending part 214. The Web
browser 211 performs browsing processings of interpreting Web data
and displaying the interpreted Web data on a monitor 261 described
below. The Web browser 211 may have various plug-in softwares, such
as stream player, having functions to receive, display and feedback
streaming screen images. The electronic mailer 212 sends and
receives electronic mails using a particular protocol (e.g., SMTP
(Simple Mail Transfer Protocol) or POPS (Post Office Protocol
version 3)). The receiving part 213 receives various kinds of
information, such as the evaluation results transmitted from the
pancreatic cancer-evaluating apparatus 100, via the communication
IF 280. The sending part 214 sends various kinds of information
such as the amino acid concentration data of the individual, via
the communication IF 280, to the pancreatic cancer-evaluating
apparatus 100.
[0265] The input device 250 is for example a keyboard, a mouse or a
microphone. The monitor 261 described below also functions as a
pointing device together with a mouse. The output device 260 is an
output means for outputting information received via the
communication IF 280, and includes the monitor 261 (including home
television) and a printer 262. In addition, the output device 260
may have a speaker or the like additionally. The input/output IF
270 is connected to the input device 250 and the output device
260.
[0266] The communication IF 280 connects the client apparatus 200
to the network 300 (or communication apparatus such as a router)
communicatively. In other words, the client apparatuses 200 are
connected to the network 300 via a communication apparatus such as
a modem, TA (Terminal Adapter) or a router, and a telephone line,
or a private line. In this way, the client apparatuses 200 can
access to the pancreatic cancer-evaluating apparatus 100 by using a
particular protocol.
[0267] The client apparatus 200 may be realized by installing
softwares (including programs, data and others) for a Web
data-browsing function and an electronic mail-processing function
to an information processing apparatus (for example, an information
processing terminal such as a known personal computer, a
workstation, a family computer, Internet TV (Television), PHS
(Personal Handyphone System) terminal, a mobile phone terminal, a
mobile unit communication terminal or PDA (Personal Digital
Assistants)) connected as needed with peripheral devices such as a
printer, a monitor, and an image scanner.
[0268] All or a part of processings of the control device 210 in
the client apparatus 200 may be performed by CPU and programs read
and executed by the CPU. Computer programs for giving instructions
to the CPU and executing various processings together with the OS
(Operating System) are recorded in the ROM 220 or HD 230. The
computer programs, which are executed as they are loaded in the RAM
240, constitute the control device 210 with the CPU. The computer
programs may be stored in application program servers connected via
any network to the client apparatus 200, and the client apparatus
200 may download all or a part of them as needed. All or any part
of processings of the control device 210 may be realized by
hardware such as wired-logic.
[0269] The control device 210 may include an evaluating part 210a
(including a calculating part 210a1, a converting part 210a2, a
generating part 210a3, and a classifying part 210a4) having the
same functions as the functions of the evaluating part 102i in the
control device 102 of the pancreatic cancer-evaluating apparatus
100. When the control device 210 includes the evaluating part 210a,
the evaluating part 210a may convert the value of the formula in
the converting part 210a2, generate the positional information
corresponding to the value of the formula or the converted value in
the generating part 210a3, and classify the individual into any one
of the categories using the value of the formula or the converted
value in the classifying part 210a4, in accordance with information
included in the evaluation result transmitted from the pancreatic
cancer-evaluating apparatus 100.
[0270] Hereinafter, the network 300 in the present system will be
described with reference to FIGS. 4 and 5. The network 300 has a
function to connect the pancreatic cancer-evaluating apparatus 100,
the client apparatuses 200, and the database apparatus 400
mutually, communicatively to one another, and is for example the
Internet, an intranet, or LAN (Local Area Network (including both
wired and wireless)). The network 300 may be VAN (Value Added
Network), a personal computer communication network, a public
telephone network (including both analog and digital), a leased
line network (including both analog and digital), CATV (Community
Antenna Television) network, a portable switched network or a
portable packet-switched network (including IMT2000 (International
Mobile Telecommunication 2000) system, GSM (registered trademark)
(Global System for Mobile Communications) system, or PDC (Personal
Digital Cellular)/PDC-P system), a wireless calling network, a
local wireless network such as Bluetooth (registered trademark),
PHS network, a satellite communication network (including CS
(Communication Satellite), BS (Broadcasting Satellite), ISDB
(Integrated Services Digital Broadcasting), and the like), or the
like.
[0271] Hereinafter, the configuration of the database apparatus 400
in the present system will be described with reference to FIG. 19.
FIG. 19 is a block diagram showing an example of the configuration
of the database apparatus 400 in the present system, showing
conceptually only the region relevant to the present invention.
[0272] The database apparatus 400 has functions to store, for
example, the pancreatic cancer state information used in preparing
the evaluation formulae in the pancreatic cancer-evaluating
apparatus 100 or in the database apparatus, the evaluation formulae
prepared in the pancreatic cancer-evaluating apparatus 100, and the
evaluation results obtained in the pancreatic cancer-evaluating
apparatus 100. As shown in FIG. 19, the database apparatus 400
includes (I) a control device 402, such as CPU, which integrally
controls the entire database apparatus, (II) a communication
interface 404 connecting the database apparatus to the network 300
communicatively via a communication apparatus such as a router and
via wired or wireless communication circuits such as a private
line, (III) a memory device 406 storing various databases, tables
and files (for example, files for Web pages), and (IV) an
input/output interface 408 connected to an input device 412 and an
output device 414, and these parts are connected communicatively to
each other via any communication channel.
[0273] The memory device 406 is a storage means, and may be, for
example, memory apparatus such as RAM or ROM, a fixed disk drive
such as a hard disk, a flexible disk, an optical disk, and the
like. The memory device 406 stores, for example, various programs
used in various processings. The communication interface 404 allows
communication between the database apparatus 400 and the network
300 (or a communication apparatus such as a router). Thus, the
communication interface 404 has a function to communicate data via
a communication line with other terminals. The input/output
interface 408 is connected to the input device 412 and the output
device 414. A monitor (including a home television), a speaker, or
a printer may be used as the output device 414 (hereinafter, the
output device 414 may be described as a monitor 414). A keyboard, a
mouse, a microphone, or a monitor functioning as a pointing device
together with a mouse may be used as the input device 412.
[0274] The control device 402 has an internal memory storing
control programs such as OS (Operating System), programs for
various processing procedures, and other needed data, and performs
various information processings according to these programs. As
shown in the figure, the control device 402 includes mainly a
request-interpreting part 402a, a browsing processing part 402b, an
authentication-processing part 402c, an electronic mail-generating
part 402d, a Web page-generating part 402e, and a sending part
402f.
[0275] The request-interpreting part 402a interprets the requests
transmitted from the pancreatic cancer-evaluating apparatus 100 and
sends the requests to other parts in the control device 402
according to results of interpreting the requests. Upon receiving
browsing requests for various screens transmitted from the
pancreatic cancer-evaluating apparatus 100, the browsing processing
part 402b generates and transmits web data for these screens. Upon
receiving authentication requests transmitted from the pancreatic
cancer-evaluating apparatus 100, the authentication-processing part
402c performs authentication. The electronic mail-generating part
402d generates electronic mails including various kinds of
information. The Web page-generating part 402e generates Web pages
for users to browse with the client apparatus 200. The sending part
402f transmits various kinds of information such as the pancreatic
cancer state information and the evaluation formulae to the
pancreatic cancer-evaluating apparatus 100.
2-3. Specific Example of the Second Embodiment
[0276] Here, a specific example of the second embodiment will be
described with reference to FIG. 20. FIG. 20 is a flowchart showing
the example of the pancreatic cancer evaluation service processing
according to the second embodiment.
[0277] The amino acid concentration data used in the present
processing is data concerning the concentration values of amino
acids obtained by analyzing, by professionals or ourselves, blood
(including, for example, plasma or serum) previously collected from
an individual by the measurement method such as the following (A)
or (B). Here, the unit of the amino acid concentration may be, for
example, a molar concentration, a weight concentration, or one
obtained by addition, subtraction, multiplication, and division of
any constant with these concentrations.
[0278] (A) Plasma is separated from blood by centrifuging a
collected blood sample. All plasma samples are frozen and stored at
-80.degree. C. until an amino acid concentration is measured. At
the time of measuring an amino acid concentration, acetonitrile is
added to perform a protein removal treatment, pre-column
derivatization is then performed using a labeled reagent
(3-aminopyridyl-N-hydroxysuccinimidyl carbamate), and an amino acid
concentration is analyzed by liquid chromatograph mass spectrometer
(LC/MS) (see International Publication WO 2003/069328 and
International Publication WO 2005/116629).
[0279] (B) Plasma is separated from blood by centrifuging a
collected blood sample. All plasma samples are frozen and stored at
-80.degree. C. until an amino acid concentration is measured. At
the time of measuring an amino acid concentration, sulfosalicylic
acid is added to perform a protein removal treatment, and an amino
acid concentration is analyzed by an amino acid analyzer based on
post-column derivatization using a ninhydrin reagent.
[0280] First, the client apparatus 200 accesses the pancreatic
cancer-evaluating apparatus 100 when the user specifies the Web
site address (such as URL) provided from the pancreatic
cancer-evaluating apparatus 100, via the input device 250 on the
screen displaying the Web browser 211. Specifically, when the user
instructs update of the Web browser 211 screen on the client
apparatus 200, the Web browser 211 sends the Web site address
provided from the pancreatic cancer-evaluating apparatus 100 by a
particular protocol to the pancreatic cancer-evaluating apparatus
100, thereby transmitting requests demanding a transmission of Web
page corresponding to an amino acid concentration data transmission
screen to the pancreatic cancer-evaluating apparatus 100 based on a
routing of the address.
[0281] Then, upon receipt of the request transmitted from the
client apparatus 200, the request-interpreting part 102a in the
pancreatic cancer-evaluating apparatus 100 analyzes the transmitted
requests and sends the requests to other parts in the control
device 102 according to analytical results. Specifically, when the
transmitted requests are requests to send the Web page
corresponding to the amino acid concentration data transmission
screen, mainly the browsing processing part 102b in the pancreatic
cancer-evaluating apparatus 100 obtains the Web data for display of
the Web page stored in a predetermined region of the memory device
106 and sends the obtained Web data to the client apparatus 200.
More specifically, upon receiving the requests to transmit the Web
page corresponding to the amino acid concentration data
transmission screen by the user, the control device 102 in the
pancreatic cancer-evaluating apparatus 100 demands inputs of user
ID and user password from the user. If the user ID and password are
input, the authentication-processing part 102c in the pancreatic
cancer-evaluating apparatus 100 examines the input user ID and
password by comparing them with the user ID and user password
stored in the user information file 106a for authentication. Only
when the user is authenticated, the browsing processing part 102b
in the pancreatic cancer-evaluating apparatus 100 sends the Web
data for displaying the Web page corresponding to the amino acid
concentration data transmission screen to the client apparatus 200.
The client apparatus 200 is identified with the IP (Internet
Protocol) address transmitted from the client apparatus 200
together with the transmission requests.
[0282] Then, the client apparatus 200 receives, in the receiving
part 213, the Web data (for displaying the Web page corresponding
to the amino acid concentration data transmission screen)
transmitted from the pancreatic cancer-evaluating apparatus 100,
interprets the received Web data with the Web browser 211, and
displays the amino acid concentration data transmission screen on
the monitor 261.
[0283] When the user inputs and selects, via the input device 250,
for example the amino acid concentration data of the individual on
the amino acid concentration data transmission screen displayed on
the monitor 261, the sending part 214 of the client apparatus 200
transmits an identifier for identifying input information and
selected items to the pancreatic cancer-evaluating apparatus 100,
thereby transmitting the amino acid concentration data of the
individual to the pancreatic cancer-evaluating apparatus 100 (step
SA21). In step SA21, the transmission of the amino acid
concentration data may be realized for example by using an existing
file transfer technology such as FTP (File Transfer Protocol).
[0284] Then, the request-interpreting part 102a of the pancreatic
cancer-evaluating apparatus 100 interprets the identifier
transmitted from the client apparatus 200 thereby interpreting the
requests from the client apparatus 200, and requests the database
apparatus 400 to send the evaluation formula.
[0285] Then, the request-interpreting part 402a in the database
apparatus 400 interprets the transmission requests from the
pancreatic cancer-evaluating apparatus 100 and transmits, to the
pancreatic cancer-evaluating apparatus 100, the evaluation formula
(for example, the updated newest evaluation formula) stored in a
predetermined region of the memory device 406 (step SA22).
Specifically, in step SA22, one or more evaluation formulae
including at least two explanatory variables to be substituted with
the concentration values of at least two amino acids of the 19
kinds of amino acids (for example, any one of a logistic regression
equation, a fractional expression, a linear discriminant, a
multiple regression equation, a formula prepared by a support
vector machine, a formula prepared by a Mahalanobis' generalized
distance method, a formula prepared by canonical discriminant
analysis, and a formula prepared by a decision tree) are
transmitted to the pancreatic cancer-evaluating apparatus 100.
[0286] Then, the pancreatic cancer-evaluating apparatus 100
receives, in the receiving part 102f, the amino acid concentration
data of the individual transmitted from the client apparatuses 200
and the evaluation formula transmitted from the database apparatus
400, and stores the received amino acid concentration data in a
predetermined memory region of the amino acid concentration data
file 106b and the received evaluation formula in a predetermined
memory region of the evaluation formula file 106e4 (step SA23).
[0287] Then, the control device 102 in the pancreatic
cancer-evaluating apparatus 100 removes data such as defective and
outliers from the amino acid concentration data of the individual
received in step SA23 (step SA24).
[0288] The evaluating part 102i then uses the amino acid
concentration data of the individual from which the data such as
defective and outliers has been removed in step SA24 and one or
more evaluation formulae received in step SA23 to calculate one or
more values of the evaluation formula(e) in the calculating part
102i1 (step SA25).
[0289] When the first formula and the second formula different from
each other are received as evaluation formulae in step SA23, the
evaluating part 102i may calculate the value of the first formula
and the value of the second formula in the calculating part
102i1.
[0290] When the first formula for classifying a subject into one of
the pancreatic cancer category and the healthy category and the
second formula for classifying a subject into one of the pancreatic
cancer category and the other cancer category are received in step
SA23, the evaluating part 102i may first calculate the value of the
first formula in the calculating part 102i1, and, if the
classification result obtained in the classifying part 102i4 is the
pancreatic cancer category, may calculate the value of the second
formula.
[0291] The evaluating part 102i then executes any one of the
classifications of 1. through 6. below using the value of the
evaluation formula (evaluation value) calculated in step SA25 and
the previously established threshold in the classifying part 102i4
and stores the obtained classification result into a predetermined
storage area of the evaluation result file 106f (step SA26).
[0292] 1. When a plurality of categories defined considering at
least the degree of the possibility that a subject is affected with
pancreatic cancer (the categories may include at least one category
defined considering the degree of the possibility that a subject is
affected with pancreatic cancer and the degree of the possibility
that a subject is affected with a cancer other than pancreatic
cancer), and one or more thresholds are previously established, the
evaluating part 102i classifies the individual into any one of the
categories using the evaluation value and the threshold(s) in the
classifying part 102i4.
[0293] 2. When the pancreatic cancer category and the pancreatic
cancer-free category, and a threshold are previously established,
the evaluating part 102i classifies the individual into one of the
pancreatic cancer category and the pancreatic cancer-free category
using the evaluation value and the threshold in the classifying
part 102i4.
[0294] When the first formula and the second formula different from
each other are received as evaluation formulae in step SA23, the
evaluating part 102i may classify the individual into one of the
pancreatic cancer category and the pancreatic cancer-free category,
using the value of the first formula and the value of the second
formula calculated in the calculating part 102i1, in the
classifying part 102i4.
[0295] When the healthy category and the other cancer category are
previously established as the pancreatic cancer-free category, and
the first formula for classifying a subject into one of the
pancreatic cancer category and the healthy category and the second
formula for classifying a subject into one of the pancreatic cancer
category and the other cancer category are received in step SA23,
the evaluating part 102i may classify the individual into one of
the pancreatic cancer category and the healthy category using the
value of the first formula calculated in the calculating part 102i1
in the classifying part 102i4. If the classification result is the
pancreatic cancer category, the evaluating part 102i may further
classify the individual classified in the pancreatic cancer
category using the value of the first formula into one of the
pancreatic cancer category and the other cancer category using the
value of the second formula calculated in the calculating part 102i
in the classifying part 102i4. The evaluating part 102i may finally
classify the individual classified in the healthy category and the
individual classified in the other cancer category into the
pancreatic cancer-free category in the classifying part 102i4. The
individual classified into the pancreatic cancer category using the
value of the first formula and classified into the pancreatic
cancer category using the value of the second formula is finally
classified into the pancreatic cancer category, as a matter of
course.
[0296] 3. When the pancreatic cancer category and the healthy
category, and a threshold are previously established, the
evaluating part 102i classifies the individual into one of the
pancreatic cancer category and the healthy category, using the
evaluation value and the threshold in the classifying part
102i4.
[0297] 4. When the pancreatic cancer category and the other cancer
category, and a threshold are previously established, the
evaluating part 102i classifies the individual into one of the
pancreatic cancer category and the other cancer category, using the
evaluation value and the threshold in the classifying part
102i4.
[0298] 5. When the pancreatic cancer category and the healthy/other
cancer category, and a threshold are previously established, the
evaluating part 102i classifies the individual into one of the
pancreatic cancer category and the healthy/other cancer category,
using the evaluation value and the threshold in the classifying
part 102i4.
[0299] 6. When the pancreatic cancer category, the healthy
category, and the other cancer category, and a threshold are
previously established, the evaluating part 102i classifies the
individual into one of the pancreatic cancer category, the healthy
category, and the other cancer category, using the evaluation
values and the threshold in the classifying part 102i4.
[0300] When the first formula and the second formula different from
each other are received as evaluation formulae in step SA23, the
evaluating part 102i may classify the individual into one of the
pancreatic cancer category, the healthy category, and the other
cancer category, using the value of the first formula and the value
of the second formula calculated in the calculating part 102i1, in
the classifying part 102i4.
[0301] When the first formula for classifying a subject into one of
the pancreatic cancer category and the healthy category and the
second formula for classifying a subject into one of the pancreatic
cancer category and the other cancer category are received in step
SA23, the evaluating part 102i may classify the individual into one
of the pancreatic cancer category and the healthy category using
the value of the first formula calculated in the calculating part
102i1, in the classifying part 102i4. If the classification result
is the pancreatic cancer category, the evaluating part 102i may
further classify the individual classified in the pancreatic cancer
category using the value of the first formula into one of the
pancreatic cancer category and the other cancer category, using the
value of the second formula calculated in the calculating part
102i, in the classifying part 102i4. The evaluating part 102i may
finally classify the individual classified in the pancreatic cancer
category using the value of the first formula and classified in the
other cancer category using the value of the second formula, into
the other cancer category, in the classifying part 102i4. The
individual classified in the healthy category using the value of
the first formula is finally classified into the healthy category,
as a matter of course, and the individual classified in the
pancreatic cancer category using the value of the first formula and
classified in the pancreatic cancer category using the value of the
second formula is finally classified into the pancreatic cancer
category, as a matter of course.
[0302] Returning to the description of FIG. 20, the sending part
102k in the pancreatic cancer-evaluating apparatus 100 sends, to
the client apparatus 200 that has sent the amino acid concentration
data and to the database apparatus 400, the classification results
obtained in step SA26 (step SA27). Specifically, the pancreatic
cancer-evaluating apparatus 100 first generates a Web page for
displaying the classification results in the Web page-generating
part 102e and stores the Web data corresponding to the generated
Web page in a predetermined memory region of the memory device 106.
Then, the user is authenticated as described above by inputting a
predetermined URL (Uniform Resource Locator) into the Web browser
211 of the client apparatus 200 via the input device 250, and the
client apparatus 200 sends a Web page browsing request to the
pancreatic cancer-evaluating apparatus 100. The pancreatic
cancer-evaluating apparatus 100 then interprets the browsing
request transmitted from the client apparatus 200 in the browsing
processing part 102b and reads the Web data corresponding to the
Web page for displaying the classification results, out of the
predetermined memory region of the memory device 106. The sending
part 102k in the pancreatic cancer-evaluating apparatus 100 then
sends the read-out Web data to the client apparatus 200 and
simultaneously sends the Web data or the classification results to
the database apparatus 400.
[0303] In step SA27, the control device 102 in the pancreatic
cancer-evaluating apparatus 100 may notify the classification
results to the user client apparatus 200 by electronic mail.
Specifically, the electronic mail-generating part 102d in the
pancreatic cancer-evaluating apparatus 100 first acquires the user
electronic mail address by referencing the user information stored
in the user information file 106a based on the user ID and the like
at the transmission timing. The electronic mail-generating part
102d in the pancreatic cancer-evaluating apparatus 100 then
generates electronic mail data with the acquired electronic mail
address as its mail address, including the user name and the
classification results. The sending part 102k in the pancreatic
cancer-evaluating apparatus 100 then sends the generated electronic
mail data to the user client apparatus 200.
[0304] Also in step SA27, the pancreatic cancer-evaluating
apparatus 100 may send the classification results to the user
client apparatus 200 by using, for example, an existing file
transfer technology such as FTP.
[0305] Returning to the description of FIG. 20, the control device
402 in the database apparatus 400 receives the classification
results or the Web data transmitted from the pancreatic
cancer-evaluating apparatus 100 and stores (accumulates) the
received classification results or the received Web data in a
predetermined memory region of the memory device 406 (step
SA28).
[0306] The receiving part 213 of the client apparatus 200 receives
the Web data transmitted from the pancreatic cancer-evaluating
apparatus 100, and the received Web data is interpreted with the
Web browser 211, to display on the monitor 261 the Web page screen
displaying the classification results of the individual (step
SA29). When the classification results are sent from the pancreatic
cancer-evaluating apparatus 100 by electronic mail, the electronic
mail transmitted from the pancreatic cancer-evaluating apparatus
100 is received at any timing, and the received electronic mail is
displayed on the monitor 261 with the known function of the
electronic mailer 212 in the client apparatus 200.
[0307] In this way, the user can confirm the classification results
by browsing the Web page displayed on the monitor 261. The user may
print out the content of the Web page displayed on the monitor 261
by the printer 262.
[0308] When the classification results are transmitted by
electronic mail from the pancreatic cancer-evaluating apparatus
100, the user reads the electronic mail displayed on the monitor
261, whereby the user can confirm the classification results. The
user may print out the content of the electronic mail displayed on
the monitor 261 by the printer 262.
[0309] As described in detail above, the client apparatus 200
transmits the amino acid concentration data of the individual to
the pancreatic cancer-evaluating apparatus 100. Upon receiving a
request from the pancreatic cancer-evaluating apparatus 100, the
database apparatus 400 transmits the evaluation formula to the
pancreatic cancer-evaluating apparatus 100. The pancreatic
cancer-evaluating apparatus 100 (i) receives the amino acid
concentration data from the client apparatus 200 and receives the
evaluation formula from the database apparatus 400, (ii) calculates
the evaluation value using the received amino acid concentration
data and evaluation formula, (iii) executes any one of the
classifications 1. through 6. using the calculated evaluation value
and the threshold, and (iv) transmits the obtained classification
result to the client apparatus 200 and the database apparatus 400.
The client apparatus 200 then receives and displays the
classification result transmitted from the pancreatic
cancer-evaluating apparatus 100. The database apparatus 400
receives and stores the classification result transmitted from the
pancreatic cancer-evaluating apparatus 100.
[0310] Hence, reliable information that may be helpful in knowing
the degree of the possibility of being affected with pancreatic
cancer can be provided in easily understandable form. Reliable
information that may be helpful in knowing not only the degree of
the possibility of being affected with pancreatic cancer but also
the degree of the possibility of being affected with a cancer other
than pancreatic cancer can be provided in easily understandable
form.
[0311] Reliable information that may be helpful in knowing whether
the possibility of being affected with pancreatic cancer is high or
low can be provided in easily understandable form.
[0312] Reliable information that may be helpful in knowing whether
the possibility of being affected with pancreatic cancer is high or
whether the possibility of being healthy is high can be provided in
easily understandable form.
[0313] Reliable information that may be helpful in knowing whether
the possibility of being affected with pancreatic cancer is high or
whether the possibility of being affected with a cancer other than
pancreatic cancer is high can be provided in easily understandable
form.
[0314] Reliable information that may be helpful in knowing whether
the possibility of being affected with pancreatic cancer is high or
whether the possibility of being healthy or being affected with a
cancer other than pancreatic cancer is high can be provided in
easily understandable form.
[0315] Reliable information that may be helpful in knowing whether
the possibility of being affected with pancreatic cancer is high,
whether the possibility of being healthy is high, or whether the
possibility of being affected with a cancer other than pancreatic
cancer is high can be provided in easily understandable form.
[0316] Given the foregoing description, the explanation of the
pancreatic cancer evaluation service processing is finished.
[0317] In the present description, the pancreatic cancer-evaluating
apparatus 100 executes the reception of the amino acid
concentration data, the calculation of the value of the evaluation
formula, the classification of the individual into the category,
and the transmission of the classification result, and the client
apparatus 200 executes the reception of the classification result,
by way of example. However, when the client apparatus 200 includes
the evaluating part 210a, the pancreatic cancer-evaluating
apparatus 100 only has to execute the calculation of the value of
the evaluation formula, and, for example, the execution of
conversion of the value of the evaluation formula, the generation
of the positional information, and the classification of the
individual into the category, and the like may be appropriately
shared between the pancreatic cancer-evaluating apparatus 100 and
the client apparatus 200.
[0318] For example, when the client apparatus 200 receives the
value of the formula from the pancreatic cancer-evaluating
apparatus 100, the evaluating part 210a may convert the value of
the formula in the converting part 210a2, generate the positional
information corresponding to the value of the formula or the
converted value in the generating part 210a3, and classify the
individual into any one of the plurality of categories using the
value of the formula or the converted value in the classifying part
210a4.
[0319] When the client apparatus 200 receives the converted value
from the pancreatic cancer-evaluating apparatus 100, the evaluating
part 210a may generate the positional information corresponding to
the converted value in the generating part 210a3 and classify the
individual into one of the plurality of categories using the
converted value in the classifying part 210a4.
[0320] When the client apparatus 200 receives the value of the
formula or the converted value and the positional information from
the pancreatic cancer-evaluating apparatus 100, the evaluating part
210a may classify the individual into one of the plurality of
categories using the value of the formula or the converted value in
the classifying part 210a4.
2-4. Other Embodiments
[0321] In addition to the second embodiment described above, the
pancreatic cancer-evaluating apparatus, the pancreatic
cancer-evaluating method, the pancreatic cancer-evaluating program
product, the pancreatic cancer-evaluating system, and the
information communication terminal apparatus according to the
present invention can be practiced in various different embodiments
within the technological scope of the claims.
[0322] Of the processings described in the second embodiment, all
or a part of the processings described as automatically performed
ones may be manually performed, or all or a part of the processings
described as manually performed ones may be also automatically
performed by known methods.
[0323] In addition, the processing procedures, the control
procedures, the specific names, the information including
parameters such as registered data of various processings and
retrieval conditions, the screen examples, and the database
configuration shown in the description and the drawings may be
arbitrarily modified unless otherwise specified.
[0324] The components of the pancreatic cancer-evaluating apparatus
100 shown in the figures are functionally conceptual and therefore
not be physically configured as shown in the figures.
[0325] For example, for the operational functions provided in the
pancreatic cancer-evaluating apparatus 100, in particular, for the
operational functions performed in the control device 102, all or
part thereof may be implemented by a CPU (Central Processing Unit)
and programs interpreted and executed in the CPU, or may be
implemented by wired-logic hardware. The program is recorded in a
non-transitory computer-readable recording medium including
programmed instructions for making an information processing
apparatus execute the pancreatic cancer-evaluating method according
to the present invention, and is mechanically read as needed by the
pancreatic cancer-evaluating apparatus 100. More specifically,
computer programs to give instructions to the CPU in cooperation
with an OS (operating system) to perform various processes are
recorded in the memory device 106 such as ROM or a HDD (hard disk
drive). The computer programs are executed by being loaded to RAM,
and form the control unit in cooperation with the CPU.
[0326] The computer programs may be stored in an application
program server connected to the pancreatic cancer-evaluating
apparatus 100 via an arbitrary network, and all or part thereof can
be downloaded as necessary.
[0327] The pancreatic cancer-evaluating program according to the
present invention may be stored in the non-transitory
computer-readable recording medium, or can be configured as a
program product. The "recording medium" mentioned here includes any
"portable physical medium" such as a memory card, a USB (universal
serial bus) memory, an SD (secure digital) card, a flexible disk, a
magneto-optical disc, ROM, EPROM (erasable programmable read only
memory), EEPROM (electronically erasable and programmable read only
memory), CD-ROM (compact disk read only memory), MO
(magneto-optical disk), DVD (digital versatile disk), and a Blu-ray
Disc.
[0328] The "program" mentioned here is a data processing method
described in an arbitrary language or description method, and
therefore any form such as a source code and a binary code is
acceptable. The "program" is not necessarily limited to a program
configured as a single unit, and, therefore, includes those
dispersively configured as a plurality of modules and libraries and
those in which the function of the program is achieved in
cooperation with separate programs represented as OS (operating
system). Any known configuration and procedures can be used as a
specific configuration and reading procedure to read a recording
medium by each apparatus shown in the embodiments or as an
installation procedure after the reading, or the like.
[0329] The various databases and the like stored in the memory
device 106 is a storage unit which is a memory device such as RAM
and ROM, a fixed disk drive such as a hard disk, a flexible disk,
and an optical disc, or the like. The memory device 106 stores
therein various programs, tables, databases, files for Web (World
Wide Web) pages, and the like used to perform various processes and
to provide Web sites.
[0330] The pancreatic cancer-evaluating apparatus 100 may be
configured as an information processing apparatus such as known
personal computer and work station, or may be configured as the
information processing apparatus connected to an arbitrary
peripheral device. The pancreatic cancer-evaluating apparatus 100
may be provided by installing software (including the programs and
the data, etc.) to cause the information processing apparatus to
implement the pancreatic cancer-evaluating method according to the
present invention.
[0331] Furthermore, a specific configuration of dispersion or
integration of the apparatuses is not limited to the shown one. The
apparatuses can be configured by functionally or physically
dispersing or integrating all or part of the apparatuses in
arbitrary units according to various types of additions or the like
or according to functional loads. In other words, the embodiments
may be implemented in arbitrary combinations thereof or an
embodiment may be selectively implemented.
[0332] Finally, an example of the evaluation formula-preparing
processing performed in the pancreatic cancer-evaluating apparatus
100 is described in detail with reference to FIG. 21. The
processing described below is merely one example, and the method of
preparing evaluation formula is not limited thereto. FIG. 21 is a
flowchart showing an example of the evaluation formula-preparing
processing. The evaluation formula-preparing processing may be
performed in the database apparatus 400 handling the pancreatic
cancer state information.
[0333] In the present description, the pancreatic cancer-evaluating
apparatus 100 stores the pancreatic cancer state information
previously obtained from the database apparatus 400 in a
predetermined memory region of the pancreatic cancer state
information file 106c. The pancreatic cancer-evaluating apparatus
100 shall store, in a predetermined memory region of the designated
pancreatic cancer state information file 106d, the pancreatic
cancer state information including the pancreatic cancer state
index data and the amino acid concentration data (the one including
the concentration values of the 19 kinds of amino acids) designated
previously in the pancreatic cancer state information-designating
part 102g.
[0334] The candidate formula-preparing part 102h1 in the evaluation
formula-preparing part 102h first prepares the candidate formulae
based on a predetermined formula-preparing method from the
pancreatic cancer state information stored in a predetermine memory
region of the designated pancreatic cancer state information file
106d, and stores the prepared candidate formulae in a predetermined
memory region of the candidate formula file 106e1 (step SB21).
Specifically, the candidate formula-preparing part 102h1 in the
evaluation formula-preparing part 102h first selects a desired
method out of a plurality of different formula-preparing methods
(including those for multivariate analysis such as principal
component analysis, discriminant analysis, support vector machine,
multiple regression analysis, logistic regression analysis, k-means
method, cluster analysis, and decision tree) and determines the
form of the candidate formula to be prepared (the form of formula)
based on the selected formula-preparing method. The candidate
formula-preparing part 102h1 in the evaluation formula-preparing
part 102h then performs various calculation corresponding to the
selected formula-selecting method (e.g., average or variance),
based on the pancreatic cancer state information. The candidate
formula-preparing part 102h1 in the evaluation formula-preparing
part 102h then determines the parameters for the calculation result
and the determined candidate formula. In this way, the candidate
formula is generated based on the selected formula-preparing
method. When the candidate formulae are generated simultaneously
and concurrently (in parallel) by using a plurality of different
formula-preparing methods in combination, the processings described
above may be executed concurrently for each selected
formula-preparing method. Alternatively when the candidate formulae
are generated in series by using a plurality of different
formula-preparing methods in combination, for example, the
candidate formulae may be generated by converting the pancreatic
cancer state information with the candidate formulae prepared by
performing principal component analysis and performing discriminant
analysis of the converted pancreatic cancer state information.
[0335] The candidate formula-verifying part 102h2 in the evaluation
formula-preparing part 102h verifies (mutually verifies) the
candidate formula prepared in step SB21 according to a particular
verifying method and stores the verification result in a
predetermined memory region of the verification result file 106e2
(step SB22). Specifically, the candidate formula-verifying part
102h2 in the evaluation formula-preparing part 102h first generates
the verification data to be used in verification of the candidate
formula, based on the pancreatic cancer state information stored in
a predetermined memory region of the designated pancreatic cancer
state information file 106d, and verifies the candidate formula
according to the generated verification data. If a plurality of the
candidate formulae is generated by using a plurality of different
formula-preparing methods in step SB21, the candidate
formula-verifying part 102h2 in the evaluation formula-preparing
part 102h verifies each candidate formula corresponding to each
formula-preparing method according to a particular verifying
method. Here in step SB22, at least one of the discrimination rate,
sensitivity, specificity, information criterion, ROC_AUC (area
under the curve in a receiver operating characteristic curve), and
the like of the candidate formula may be verified based on at least
one method of the bootstrap method, holdout method, N-fold method,
leave-one-out method, and the like. Thus, it is possible to select
the candidate formula higher in predictability or reliability, by
taking the pancreatic cancer state information and evaluation
condition into consideration.
[0336] Then, the explanatory variable-selecting part 102h3 in the
evaluation formula-preparing part 102h selects the combination of
the amino acid concentration data contained in the pancreatic
cancer state information used in preparing the candidate formula by
selecting the explanatory variable of the candidate formula
according to a predetermined explanatory variable-selecting method,
and stores the pancreatic cancer state information including the
selected combination of the amino acid concentration data in a
predetermined memory region of the selected pancreatic cancer state
information file 106e3 (step SB23). When a plurality of the
candidate formulae is generated by using a plurality of different
formula-preparing methods in step SB21 and each candidate formula
corresponding to each formula-preparing method is verified
according to a predetermined verifying method in step SB22, the
explanatory variable-selecting part 102h3 in the evaluation
formula-preparing part 102h may select the explanatory variable of
the candidate formula for each candidate formula according to a
predetermined explanatory variable-selecting method in step SB23.
Here in step SB23, the explanatory variable of the candidate
formula may be selected from the verification results according to
at least one of the stepwise method, best path method, local search
method, and genetic algorithm. The best path method is a method of
selecting an explanatory variable by optimizing an evaluation index
of the candidate formula while eliminating the explanatory
variables contained in the candidate formula one by one. In step
SB23, the explanatory variable-selecting part 102h3 in the
evaluation formula-preparing part 102h may select the combination
of the amino acid concentration data based on the pancreatic cancer
state information stored in a predetermined memory region of the
designated pancreatic cancer state information file 106d.
[0337] The evaluation formula-preparing part 102h then judges
whether all combinations of the amino acid concentration data
contained in the pancreatic cancer state information stored in a
predetermined memory region of the designated pancreatic cancer
state information file 106d are processed, and if the judgment
result is "End" (Yes in step SB24), the processing advances to the
next step (step SB25), and if the judgment result is not "End" (No
in step SB24), it returns to step SB21. The evaluation
formula-preparing part 102h may judge whether the processing is
performed a predetermined number of times, and if the judgment
result is "End" (Yes in step SB24), the processing may advance to
the next step (step SB25), and if the judgment result is not "End"
(No in step SB24), it may return to step SB21. The evaluation
formula-preparing part 102h may judge whether the combination of
the amino acid concentration data selected in step SB23 is the same
as the combination of the amino acid concentration data contained
in the pancreatic cancer state information stored in a
predetermined memory region of the designated pancreatic cancer
state information file 106d or the combination of the amino acid
concentration data selected in the previous step SB23, and if the
judgment result is "the same" (Yes in step SB24), the processing
may advance to the next step (step SB25) and if the judgment result
is not "the same" (No in step SB24), it may return to step SB21. If
the verification result is specifically the evaluation value for
each candidate formula, the evaluation formula-preparing part 102h
may advance to step SB25 or return to step SB21, based on the
comparison of the evaluation value with a particular threshold
corresponding to each formula-preparing method.
[0338] Then, the evaluation formula-preparing part 102h determines
the evaluation formula by selecting the candidate formula used as
the evaluation formula based on the verification results from a
plurality of the candidate formulae, and stores the determined
formula (the selected candidate formula) in particular memory
region of the evaluation formula file 106e4 (step SB25). Here, in
step SB25, for example, there are cases where the optimal
evaluation formula is selected from the candidate formulae prepared
in the same formula-preparing method or the optimal evaluation
formula is selected from all candidate formulae.
[0339] Given the foregoing description, the explanation of the
evaluation formula-preparing processing is finished.
Example 1
[0340] In the present Example 1 and the following examples, data of
the concentration values of amino acids (nmol/ml) in plasma
measured using the amino acid analysis method from a blood sample
in each of the groups below is used. Pancreatic cancer patients (51
people) with definite diagnosis of pancreatic cancer are divided
into a pancreatic cancer group. Healthy individuals with no
anamnesis or history of cancer are divided into a healthy group
(255 people). The cancer patients with definite diagnosis of lung
cancer, colorectal cancer, prostatic cancer, and breast cancer are
divided into a lung cancer group (320 people), a colorectal cancer
group (252 people), a prostatic cancer group (87 people), and a
breast cancer group (121 people), respectively, and these four
groups form the other cancers group (780 people).
[0341] The capability of discriminating between the pancreatic
cancer group and the healthy group for each amino acid is evaluated
with ROC_AUC (the area under the curve in a receiver operating
characteristic curve). Amino acids with significant ROC_AUC
(p<0.05) in examination with a null hypothesis of "ROC_AUC=0.5"
under the assumption of non-parametric are Asn, His, Thr, Ala, Cit,
Arg, Tyr, Val, Met, Lys, and Trp. These amino acids significantly
decreased in the pancreatic cancer group. The concentration values
of these amino acids are thought to be useful in evaluation of the
state of pancreatic cancer with consideration of the healthy state,
because ROC_AUC is significant.
Example 2
[0342] The sample data used in Example 1 is used. A multivariate
discriminant (multivariate function) including an explanatory
variable to be substituted with the concentration value of an amino
acid in plasma is obtained for discriminating between two groups:
the pancreatic cancer group and the healthy group. As for the
obtained multivariate discriminant, the capability of
discriminating between the pancreatic cancer group and the other
cancers group, between the pancreatic cancer group and the lung
cancer group, between the pancreatic cancer group and the
colorectal cancer group, between the pancreatic cancer group and
the prostatic cancer group, and between the pancreatic cancer group
and the breast cancer group is also shown.
[0343] A logistic regression equation is used as a multivariate
discriminant. The 19 kinds of amino acids (specifically, Asn, His,
Thr, Ala, Cit, Arg, Tyr, Val, Met, Lys, Trp, Gly, Pro, Orn, Ile,
Leu, Phe, Ser, and Gln) are searched for a combination of six or
less explanatory variables to be included in the logistic
regression equation. The Leave-One-Out method is employed as
validation to explore a logistic regression equation having a good
capability of discriminating between the pancreatic cancer group
and the healthy group.
[0344] List of Logistic Regression Equations Searched in Example 2
(ROC_AUC value: 0.500 or greater) provided later shows (i) a list
of logistic regression equations with two explanatory variables
where the ROC_AUC value for the pancreatic cancer group and the
healthy group with validation is equal to or greater than 0.500,
(ii) a list of logistic regression equations with three explanatory
variables where the ROC_AUC value for the pancreatic cancer group
and the healthy group with validation is equal to or greater than
0.500, (iii) a list of logistic regression equations with four
explanatory variables where the ROC_AUC value for the pancreatic
cancer group and the healthy group with validation is equal to or
greater than 0.500, (iv) a list of logistic regression equations
with five explanatory variables where the ROC_AUC value for the
pancreatic cancer group and the healthy group with validation is
equal to or greater than 0.500, and (v) a list of logistic
regression equations with six explanatory variables where the
ROC_AUC value for the pancreatic cancer group and the healthy group
with validation is equal to or greater than 0.500. These logistic
regression equations are thought to be useful in the evaluation
because the ROC_AUC value is high.
[0345] The logistic regression equations where the ROC_AUC value
for the pancreatic cancer group and the healthy group with
validation is equal to or greater than 0.750 are shown later in
List (1) of Logistic Regression Equations Searched in Example 2.
These logistic regression equations are thought to be useful in the
evaluation because the ROC_AUC value is extremely high. When the
amino acid explanatory variables included in these logistic
regression equations are listed in the descending order of
occurrence frequency from the highest to the tenth, they are
arranged in the following order: Met, Phe, Trp, Ile, Ser, Val, His,
Thr, Asn, Ala (see Table 1 below). These amino acids are thought to
be useful in the evaluation as with the equations because they are
explanatory variables included in the equations thought to be
useful in the evaluation. For these logistic regression equations,
the average value of the ROC_AUC values for the pancreatic cancer
group and the lung cancer group, for the pancreatic cancer group
and the colorectal cancer group, for the pancreatic cancer group
and the prostatic cancer group, and for the pancreatic cancer group
and the breast cancer group is equal to or greater than 0.775, and
the capability of discriminating between the pancreatic cancer
group and a variety of other cancer groups is good. These logistic
regression equations are thought to be useful in evaluation of the
state of pancreatic cancer with additional consideration of the
state of cancers other than pancreatic cancer, because the ROC_AUC
value is extremely high. Among these logistic regression equations,
for example, the index formula 1
"(-1.3217)+(0.0545)Ser+(-0.0544)Val+(-0.3973)Met+(0.1922)Ile+(0.1506)Phe+-
(-0.1179)Trp" having a set of explanatory variables "Ser, Val, Met,
Ile, Phe, Trp" (the multivariate discriminant including Ser, Val,
Met, Ile, Phe, Trp as explanatory variables) has a good
discriminating capability with ROC_AUC(Validation)=0.902,
ROC_AUC(No Validation)=0.923, sensitivity=0.902, specificity=0.804.
The sensitivity and the specificity are the values when the maximum
discriminate point, where the average of sensitivity and
specificity is highest, is a cutoff value.
TABLE-US-00002 TABLE 1 Pancreatic cancer group vs Healthy group
Logistic regression equation Linear discriminant Average of Average
of Healthy other Healthy other Amino acid Univariate group cancers
group cancers Ser 66 70 Asn O 13 75 23 79 Gly Gln 100 98 His O 45
24 46 28 Thr O 38 38 Ala O 11 36 33 Cit O 52 10 58 Arg O Pro Tyr O
23 Val O 54 23 47 28 Met O 90 46 81 38 Orn Lys O 17 Ile 66 61 17
Leu Phe 79 48 90 45 Trp O 75 100 71 100 (O indicates the amino acid
that varies significantly. The numeral indicates the frequency of
occurrence of the amino acid explanatory variable.)
[0346] The value of the formula is calculated using the index
formula 1 and the amino acid concentration values (.mu.mol/L) of
the pancreatic cancer group, and each case in the pancreatic cancer
group is classified into any one of a plurality of categories
established as shown below, using the calculated value of the
formula and a previously established cutoff value. As candidates
for the cutoff value, the value of the formula when the specificity
is 80% and the value of the formula when the specificity is 95% are
found to be -2.002 and -0.528, respectively. When these values are
set as cutoff values, the sensitivities are 86% and 71%,
respectively.
[0347] The amino acid concentration values of a case having the
highest value of the formula are Ser:166.3, Val:149.9, Met:18.5,
Ile:69.0, Phe:44.1, Trp:33.6, and the value of the formula in this
case is 8.2. The relational expression "logarithm odds
ln(p/(1-p))=value of formula" (where p is the probability of
cancer) is defined, and the odds p/(1-p), calculated from the value
8.2 of this formula, are 3508.0. The probability p, calculated from
the odds, is 1.0.
[0348] When the value -0.528 of the formula when the specificity is
95% is established as a cutoff value, and when the value of the
formula higher than the cutoff value is defined positive
(equivalent to the pancreatic cancer category), and when the value
of the formula lower than the cutoff value is defined negative
(equivalent to the healthy category), then the case in which the
value of the formula is 8.2 is classified either as positive or as
negative.
[0349] This case is classified as positive because the value of the
formula is higher than the cutoff value.
[0350] When the value -2.002 of the formula when the specificity is
80% is established as a first cutoff value, and the value -0.528 of
the formula when the specificity is 95% is established as a second
cutoff value, and when the value of the formula lower than the
first cutoff value is defined rank A (the category meaning that the
possibility (probability, risk) of pancreatic cancer is low), when
the value of the formula higher than the first cutoff value and
lower than the second cutoff value is defined rank B (the category
that means the possibility of having pancreatic cancer is
moderate), and when the value of the formula higher than the second
cutoff value is defined rank C (the category meaning that the
possibility of pancreatic cancer is high), then the case in which
the value of the formula is 8.2 is classified into any one of the
three ranks. This case is classified into the rank C because the
value of the formula is higher than the second cutoff value.
[0351] A linear discriminant is used as a multivariate
discriminant. The 19 kinds of amino acids are searched for a
combination of six or less explanatory variables to be included in
the linear discriminant, and the bootstrap method is employed as
validation to explore a linear discriminant with a good capability
of discriminating between the pancreatic cancer group and the
healthy group.
[0352] A list of linear discriminants where the ROC_AUC value for
the pancreatic cancer group and the healthy group with validation
is equal to or greater than 0.750 is shown later in List (1) of
Linear Discriminants Searched in Example 2. These linear
discriminants are thought to be useful in evaluation of the state
of pancreatic cancer with consideration of the healthy state,
because the ROC_AUC value is extremely high. When the amino acid
explanatory variables included in these linear discriminants are
listed in the descending order of occurrence frequency from the
highest to the tenth, they are arranged in the following order:
Phe, Met, Trp, Ser, Ile, Val, His, Thr, Asn, Cit (see Table 1
above). The concentration values of these amino acids are thought
to be useful in the evaluation as with the formula, because they
are explanatory variables included in the formula thought to be
useful in the evaluation. As for these linear discriminants, the
average value of the ROC_AUC values for the pancreatic cancer group
and the lung cancer group, for the pancreatic cancer group and the
colorectal cancer group, for the pancreatic cancer group and the
prostatic cancer group, and for the pancreatic cancer group and the
breast cancer group is equal to or greater than 0.762, and the
capability of discriminating between the pancreatic cancer group
and a variety of other cancer groups is good. These linear
discriminants are thought to be useful in evaluation of the state
of pancreatic cancer with additional consideration of the state of
cancers other than pancreatic cancer, because the ROC_AUC value is
extremely high. Among these linear discriminants, for example, the
index formula 2
"(-1.0207)+(0.0564)Ser+(-0.0410)Val+(-0.4144)Met+(0.1407)Ile+(0.1786)Phe+-
(-0.1154)Trp" having a set of explanatory variables "Ser, Val, Met,
Ile, Phe, Trp" (the multivariate discriminant including Ser, Val,
Met, Ile, Phe, Trp as explanatory variables) has a good
discriminating capability with ROC_AUC(Validation)=0.912,
ROC_AUC(No Validation)=0.926, sensitivity=0.800, and
specificity=0.902. The sensitivity and the specificity are the
values when the maximum discriminate point, where the average of
sensitivity and specificity is the highest, is a cutoff value.
[0353] The value of the formula is calculated using the index
formula 2 and the amino acid concentration values (.mu.mol/L) of
the pancreatic cancer group, and each case in the pancreatic cancer
group is classified into any one of a plurality of categories
established as shown below, using the calculated value of the
formula and a previously established cutoff value. As candidates
for the cutoff value, the value of the formula when the specificity
is 80% and the value of the formula when the specificity is 95% are
found to be -0.434 and 1.093, respectively. When these values are
set as cutoff values, the sensitivities are 90% and 69%,
respectively.
[0354] The amino acid concentration values in a case having the
highest value of the formula are Ser:166.3, Val:149.9, Met:18.5,
Ile:69.0, Phe:44.1, Trp:33.6, and the value of the formula in this
case is 8.2.
[0355] When the value 1.093 of the formula when the specificity is
95% is established as a cutoff value, and when the value of the
formula higher than the cutoff value is defined positive, and when
the value of the formula lower than the cutoff value is defined
negative, then the case in which the value of the formula is 8.2 is
classified either as positive or negative. This case is classified
as positive because the value of the formula is higher than the
cutoff value.
[0356] In addition, when the value -0.434 of the formula when the
specificity is 80% is established as a first cutoff value, and the
value 1.093 of the formula when the specificity is 95% is
established as a second cutoff value, and when the value of the
formula lower than the first cutoff value is defined rank A, when
the value of the formula higher than the first cutoff value and
lower than the second cutoff value is defined rank B, and when the
value of the formula higher than the second cutoff value is defined
rank C, then the case in which the value of the formula is 8.2 is
classified into any one of the three ranks. This case is classified
into rank C because the value of the formula is higher than the
second cutoff value.
[0357] List (2) of Logistic Regression Equations Searched in
Example 2 provided later shows a list of logistic regression
equations in which the ROC_AUC value for the pancreatic cancer
group and the healthy group with validation is equal to or greater
than 0.750 and the capability of discriminating between the
pancreatic cancer group and a variety of other cancer groups is
also good. These logistic regression equations are thought to be
useful in evaluation of the state of pancreatic cancer with
consideration of both the healthy state and the state of cancers
other than pancreatic cancer, because the ROC_AUC value is
extremely high. When the amino acid explanatory variables included
in these logistic regression equations are listed in the descending
order of occurrence frequency from the highest to the tenth, they
are arranged in the following order: Trp, Gln, Asn, Cit, Phe, Met,
Ala, His, Val, Tyr (see Table 1 above). The concentration values of
these amino acids are thought to be useful in the evaluation as
with the formula because they are explanatory variables included in
the formula thought to be useful in the evaluation. Among these
logistic regression equations, for example, the index formula 3
"(2.2508)+(0.0135)Gln+(-0.1156)His+(-0.0544)Cit+(-0.1821)Met+(0.1518)Phe+-
(-0.1151)Trp" having a set of explanatory variables "Gln, His, Cit,
Met, Phe, Trp" (the multivariate discriminant including Gln, His,
Cit, Met, Phe, Trp as explanatory variables) has a good
discriminating capability with ROC_AUC(Validation)=0.862,
ROC_AUC(No Validation)=0.894, sensitivity=0.831, and
specificity=0.843. The sensitivity and the specificity are the
values when the maximum discriminate point, where the average of
sensitivity and specificity is the highest, is a cutoff value.
[0358] The value of the formula is calculated using the index
formula 3 and the amino acid concentration values (.mu.mol/L) of
the pancreatic cancer group, and each case in the pancreatic cancer
group is classified into any one of a plurality of categories
established as shown below, using the calculated value of the
formula and a previously established cutoff value. As candidates
for the cutoff value, the value of the formula when the specificity
is 80% and the value of the formula when the specificity is 95% are
found to be -1.659 and -0.288, respectively. When these values are
set as cutoff values, the sensitivities are 84% and 57%,
respectively.
[0359] The amino acid concentration values of a case having the
highest value of the formula are Gln:484.6, His:32.4, Cit:17.7,
Met:18.4, Phe:56.6, Trp:30.4, and the value of the formula in this
case is 5.8. The odds, calculated from the value 5.8 of this
formula, are 341.5. The probability p, calculated from the odds, is
1.0.
[0360] When the value -0.288 of the formula when the specificity is
95% is established as a cutoff value, and when the value of the
formula higher than the cutoff value is defined positive, and when
the value of the formula lower than the cutoff value is defined
negative, then the case in which the value of the formula is 5.8 is
classified either as positive or negative. This case is classified
into a positive because the value of the formula is higher than the
cutoff value.
[0361] When classifying each case either as positive or negative
using the amino acid concentration values of the other cancers
group when the value -1.659 of the formula when the specificity is
80% is established as a cutoff value and when the value -0.288 of
the formula when the specificity is 95% is established as a cutoff
value, then the false positive rates for the other cancers group
are 24% and 10%, respectively. These values are lower than the
false positive rates of 40% and 22% for the other cancers group
when the index formula 1 is used. The index formula 3 is therefore
useful in evaluation of the state of pancreatic cancer with
consideration of both the healthy state and the state of cancers
other than pancreatic cancer.
[0362] When the value -1.659 of the formula when the specificity is
80% is established as a first cutoff value, and the value -0.288 of
the formula when the specificity is 95% is established as a second
cutoff value, and when the value of the formula lower than the
first cutoff value is defined rank A, when the value of the formula
higher than the first cutoff value and lower than the second cutoff
value is defined rank B, and when the value of the formula higher
than the second cutoff value is defined rank C, then the case in
which the value of the formula is 5.8 is classified into any one of
the three ranks. This case is classified into the rank C because
the value of the formula is higher than the second cutoff
value.
[0363] List (2) of Linear Discriminants Searched in Example 2
provided later shows a list of linear discriminants in which the
ROC_AUC value for the pancreatic cancer group and the healthy group
with validation is equal to or greater than 0.750 and the
capability of discriminating between the pancreatic cancer group
and a variety of other cancer groups is also good. These linear
discriminants are thought to be useful in evaluation of the state
of pancreatic cancer with consideration of both the healthy state
and the state of cancers other than pancreatic cancer, because the
ROC_AUC value is extremely high. When the amino acid explanatory
variables included in these linear discriminants are listed in the
descending order of occurrence frequency from the highest to the
tenth, they are arranged in the following order: Trp, Gln, Asn,
Cit, Phe, Met, Ala, Val, His, Ile, Lys, in total eleven (see Table
1 above). The concentration values of these amino acids are thought
to be useful in the evaluation as with the formula because they are
explanatory variables included in the formula thought to be useful
in the evaluation. Among these linear discriminants, for example,
the index formula 4
"(2.6773)+(0.0131)Gln+(-0.0833)His+(-0.0369)Cit+(-0.1942)Met+(0.1325)Phe+-
(-0.1189)Trp" having a set of explanatory variables "Gln, His, Cit,
Met, Phe, Trp" (the multivariate discriminant including Gln, His,
Cit, Met, Phe, Trp as explanatory variables) has a good
discriminating capability with ROC_AUC(Validation)=0.876,
ROC_AUC(No Validation)=0.897, sensitivity=0.831, specificity=0.804.
The sensitivity and the specificity are the values when the maximum
discriminate point, where the average of sensitivity and
specificity is the highest, is a cutoff value.
[0364] The value of the formula is calculated using the index
formula 4 and the amino acid concentration values (.mu.mol/L) of
the pancreatic cancer group, and each case in the pancreatic cancer
group is classified into any one of a plurality of categories
established as shown below, using the calculated value of the
formula and a previously established cutoff value. As candidates
for the cutoff value, the value of the formula when the specificity
is 80% and the value of the formula when the specificity is 95% are
found to be -0.092 and 1.103, respectively. When these values are
set as cutoff values, the sensitivities are 80% and 55%,
respectively.
[0365] The amino acid concentration values of a case with the
highest value of the formula are Gln:484.6, His:32.4, Cit:17.7,
Met:18.4, Phe:56.6, Trp:30.4, and the value of the formula in this
case is 6.0.
[0366] When the value 1.103 of the formula when the specificity is
95% is established as a cutoff value, and when the value of the
formula higher than the cutoff value is defined positive, and when
the value of the formula lower than the cutoff value is defined
negative, then the case in which the value of the formula is 6.0 is
classified either as positive or negative. This case is classified
as positive because the value of the formula is higher than the
cutoff value.
[0367] When each case is classified either as positive or negative
using the amino acid concentration values of the other cancers
group when the value -0.092 of the formula when the specificity is
80% is established as a cutoff value and when the value 1.103 of
the formula when the specificity is 95% is established as a cutoff
value, then the false positive rates for the other cancers group
are 23% and 10%, respectively. These values are lower than the
false positive rates of 40% and 20% for the other cancers group
when the index formula 2 is used. The index formula 4 is therefore
useful in evaluation of the state of pancreatic cancer with
consideration of both the healthy state and the state of cancers
other than pancreatic cancer.
[0368] When the value -0.092 of the formula when the specificity is
80% is established as a first cutoff value, and the value 1.103 of
the formula when the specificity is 95% is established as a second
cutoff value, and when the value of the formula lower than the
first cutoff value is defined rank A, when the value of the formula
higher than the first cutoff value and lower than the second cutoff
value is defined rank B, and when the value of the formula higher
than the second cutoff value is defined rank C, then the case in
which the value of the formula is 6.0 is classified into any one of
the three ranks. This case is classified into the rank C because
the value of the formula is higher than the second cutoff
value.
Example 3
[0369] The sample data used in Example 1 is used. The capability of
discriminating between the pancreatic cancer group and the other
cancers group for each amino acid is evaluated with ROC_AUC. Amino
acids with significant ROC_AUC (p<0.05) in examination with a
null hypothesis of "ROC_AUC=0.5" under the assumption of
non-parametric are Asn, Gly, His, Thr, Ala, Cit, Arg, Pro, Tyr,
Val, Met, Orn, Lys, Ile, Leu, Phe, and Trp. These amino acids
significantly decreased in the pancreatic cancer group.
[0370] The concentration values of these amino acids are thought to
be useful in evaluation of the state of pancreatic cancer with
consideration of the state of cancers other than pancreatic cancer,
because ROC_AUC is significant.
[0371] The capability of discriminating between the pancreatic
cancer group and the lung cancer group for each amino acid is
evaluated with ROC_AUC. Amino acids with significant ROC_AUC
(p<0.05) in examination with a null hypothesis of "ROC_AUC=0.5"
under the assumption of non-parametric are Ser, Asn, Gly, His, Thr,
Ala, Cit, Arg, Pro, Tyr, Val, Met, Orn, Lys, Ile, Leu, Phe, and
Trp. These amino acids significantly decreased in the pancreatic
cancer group. The concentration values of these amino acids are
thought to be useful in evaluation of the state of pancreatic
cancer with consideration of the state of lung cancer, because
ROC_AUC is significant.
[0372] The capability of discriminating between the pancreatic
cancer group and the colorectal cancer group for each amino acid is
evaluated with ROC_AUC. Amino acids with significant ROC_AUC
(p<0.05) in examination with a null hypothesis of "ROC_AUC=0.5"
under the assumption of non-parametric are Asn, Gly, Gln, His, Thr,
Ala, Cit, Arg, Pro, Tyr, Val, Met, Lys, Ile, Leu, Phe, and Trp.
These amino acids significantly decreased in the pancreatic cancer
group. The concentration values of these amino acids are thought to
be useful in evaluation of the state of pancreatic cancer with
consideration of the state of colorectal cancer, because ROC_AUC is
significant.
[0373] The capability of discriminating between the pancreatic
cancer group and the prostatic cancer group for each amino acid is
evaluated with ROC_AUC. Amino acids with significant ROC_AUC
(p<0.05) in examination with a null hypothesis of "ROC_AUC=0.5"
under the assumption of non-parametric are Asn, His, Thr, Ala, Cit,
Arg, Pro, Tyr, Val, Met, Lys, Leu, Phe, and Trp. These amino acids
significantly decreased in the pancreatic cancer group. The
concentration values of these amino acids are thought to be useful
in evaluation of the state of pancreatic cancer with consideration
of the state of prostatic cancer, because ROC_AUC is
significant.
[0374] The capability of discriminating between the pancreatic
cancer group and the breast cancer group for each amino acid is
evaluated with ROC_AUC. Amino acids with significant ROC_AUC
(p<0.05) in examination with a null hypothesis of "ROC_AUC=0.5"
under the assumption of non-parametric are Ser, Asn, Gly, His, Thr,
Ala, Val, Met, Lys, Ile, and Trp. These amino acids significantly
decreased in the pancreatic cancer group. The concentration values
of these amino acids are thought to be useful in evaluation of the
state of pancreatic cancer with consideration of the state of
breast cancer, because ROC_AUC is significant.
Example 4
[0375] The sample data used in Example 1 is used. A multivariate
discriminant (multivariate function) including an explanatory
variable to be substituted with the concentration value of an amino
acid in plasma is obtained for discriminating between two groups:
the pancreatic cancer group and the other cancers group. As for the
obtained multivariate discriminant, the capability of
discriminating between the pancreatic cancer group and the healthy
group is also shown.
[0376] A logistic regression equation is used as a multivariate
discriminant. The 19 kinds of amino acids are searched for a
combination of six or less explanatory variables to be included in
the logistic regression equation. The Leave-One-Out method is
employed as validation to explore a logistic regression equation
having a good capability of discriminating between the pancreatic
cancer group and the other cancers group.
[0377] The logistic regression equations where the ROC_AUC value
for the pancreatic cancer group and the other cancers group with
validation is equal to or greater than 0.750 are shown later in
List (1) of Logistic Regression Equations Searched in Example 4.
These logistic regression equations are thought to be useful in
evaluation of the state of pancreatic cancer with consideration of
the state of cancers other than pancreatic cancer because the
ROC_AUC value is extremely high. When the amino acid explanatory
variables included in these logistic regression equations are
listed in the descending order of occurrence frequency from the
highest to the tenth, they are arranged in the following order:
Trp, Gln, Asn, Cit, Ala, Phe, Gly, Val, Met, Pro (see Table 2
below). These amino acids are thought to be useful in the
evaluation as with the equations because they are explanatory
variables included in the equations thought to be useful in the
evaluation. For these logistic regression equations, the ROC_AUC
value for the pancreatic cancer group and the healthy group is
equal to or greater than 0.760, and the capability of
discriminating between the pancreatic cancer group and the healthy
group is good. These logistic regression equations are thought to
be useful in evaluation of the state of pancreatic cancer with
additional consideration of the healthy state, because the ROC_AUC
value is extremely high. Among these logistic regression equations,
for example, the index formula 5
"(1.7072)+(-0.0985)Asn+(0.0115)Gln+(-0.0063)Ala+(-0.0582)Cit+(0.0212)Phe+-
(-0.0792)Trp" having a set of explanatory variables "Asn, Gln, Ala,
Cit, Phe, Trp" (the multivariate discriminant including Asn, Gln,
Ala, Cit, Phe, Trp as explanatory variables) has a good
discriminating capability with ROC_AUC(Validation)=0.854,
ROC_AUC(No Validation)=0.873, sensitivity=0.740, specificity=0.882.
The sensitivity and the specificity are the values when the maximum
discriminate point, where the average of sensitivity and
specificity is highest, is a cutoff value.
TABLE-US-00003 TABLE 2 Pancreatic cancer group vs Other cancers
group Logistic regression equation Linear discriminant Other Other
cancers Healthy cancers Healthy Amino acid Univariate group group
group group Ser 47 Asn O 95 20 97 31 Gly O 32 41 Gln 100 84 100 38
His O 80 61 Thr O Ala O 39 41 Cit O 54 27 48 23 Arg O Pro O 18 18
Tyr O Val O 29 26 27 20 Met O 18 41 22 73 Orn O Lys O Ile O 37 26
Leu O 23 Phe O 37 78 36 99 Trp O 100 100 100 99 (O indicates the
amino acid that varies significantly. The numeral indicates the
frequency of occurrence of the amino acid explanatory
variable.)
[0378] The value of the formula is calculated using the index
formula 5 and the amino acid concentration values (.mu.mol/L) of
the pancreatic cancer group, and each case in the pancreatic cancer
group is classified into any one of a plurality of categories
established as shown below, using the calculated value of the
formula and a previously established cutoff value. As candidates
for the cutoff value, the value of the formula when the specificity
is 80% and the value of the formula when the specificity is 95% are
found to be -2.650 and -1.316, respectively. When these values are
set as cutoff values, the sensitivities are 76% and 39%,
respectively.
[0379] The amino acid concentration values of a case having the
highest value of the formula are Asn:35.2, Gln:697.3, Ala:249.3,
Cit:26.0, Phe:44.1, Trp:33.6, and the value of the formula in this
case is 1.5. The odds, calculated from the value 1.5 of this
formula, are 4.3. The probability p, calculated from the odds, is
0.8.
[0380] When the value -1.316 of the formula when the specificity is
95% is established as a cutoff value, and when the value of the
formula higher than the cutoff value is defined positive
(equivalent to the pancreatic cancer category), and when the value
of the formula lower than the cutoff value is defined negative
(equivalent to the other cancer category), then the case in which
the value of the formula is 1.5 is classified either as positive or
as negative. This case is classified as positive because the value
of the formula is higher than the cutoff value.
[0381] When the value -2.650 of the formula when the specificity is
80% is established as a first cutoff value, and the value -1.316 of
the formula when the specificity is 95% is established as a second
cutoff value, and when the value of the formula lower than the
first cutoff value is defined rank A (the category meaning that the
possibility of pancreatic cancer is low and the possibility of a
cancer other than pancreatic cancer is high), when the value of the
formula higher than the first cutoff value and lower than the
second cutoff value is defined rank B (the category that means both
the possibility of having pancreatic cancer and the possibility of
having a cancer other than pancreatic cancer are moderate), and
when the value of the formula higher than the second cutoff value
is defined rank C (the category meaning that the possibility of
pancreatic cancer is high and the possibility of a cancer other
than pancreatic cancer is low), then the case in which the value of
the formula is 1.5 is classified into any one of the three ranks.
This case is classified into the rank C because the value of the
formula is higher than the second cutoff value.
[0382] A linear discriminant is used as a multivariate
discriminant. The 19 kinds of amino acids are searched for a
combination of six or less explanatory variables to be included in
the linear discriminant, and the bootstrap method is employed as
validation to explore a linear discriminant with a good capability
of discriminating between the pancreatic cancer group and the other
cancers group.
[0383] A list of linear discriminants where the ROC_AUC value for
the pancreatic cancer group and the other cancers group with
validation is equal to or greater than 0.750 is shown later in List
(1) of Linear Discriminants Searched in Example 4. These linear
discriminants are thought to be useful in evaluation of the state
of pancreatic cancer with consideration of the state of cancers
other than pancreatic cancer, because the ROC_AUC value is
extremely high. When the amino acid explanatory variables included
in these linear discriminants are listed in the descending order of
occurrence frequency from the highest to the tenth, they are
arranged in the following order: Trp, Gln, Asn, Cit, Gly, Ala, Phe,
Val, Met, Pro (see Table 2 above). The concentration values of
these amino acids are thought to be useful in the evaluation as
with the formula, because they are explanatory variables included
in the formula thought to be useful in the evaluation. As for these
linear discriminants, the ROC_AUC value for the pancreatic cancer
group and the healthy group is equal to or greater than 0.784, and
the capability of discriminating between the pancreatic cancer
group and the healthy group is good. These linear discriminants are
thought to be useful in evaluation of the state of pancreatic
cancer with additional consideration of the healthy state, because
the ROC_AUC value is extremely high. Among these linear
discriminants, for example, the index formula 6
"(5.4468)+(-0.1111)Asn+(0.0122)Gln+(-0.0083)Ala+(-0.0524)Cit+(0-
.0345)Phe+(-0.1015)Trp" having a set of explanatory variables "Asn,
Gln, Ala, Cit, Phe, Trp" (the multivariate discriminant including
Asn, Gln, Ala, Cit, Phe, Trp as explanatory variables) has a good
discriminating capability with ROC_AUC(Validation)=0.859,
ROC_AUC(No Validation)=0.874, sensitivity=0.742, and
specificity=0.902. The sensitivity and the specificity are the
values when the maximum discriminate point, where the average of
sensitivity and specificity is the highest, is a cutoff value.
[0384] The value of the formula is calculated using the index
formula 6 and the amino acid concentration values (.mu.mol/L) of
the pancreatic cancer group, and each case in the pancreatic cancer
group is classified into any one of a plurality of categories
established as shown below, using the calculated value of the
formula and a previously established cutoff value. As candidates
for the cutoff value, the value of the formula when the specificity
is 80% and the value of the formula when the specificity is 95% are
found to be 0.109 and 1.780, respectively. When these values are
set as cutoff values, the sensitivities are 73% and 37%,
respectively.
[0385] The amino acid concentration values in a case having the
highest value of the formula are Asn:35.2, Gln:697.3, Ala:249.3,
Cit:26.0, Phe:44.1, Trp:33.6, and the value of the formula in this
case is 4.7.
[0386] When the value 1.780 of the formula when the specificity is
95% is established as a cutoff value, and when the value of the
formula higher than the cutoff value is defined positive, and when
the value of the formula lower than the cutoff value is defined
negative, then the case in which the value of the formula is 4.7 is
classified either as positive or negative. This case is classified
as positive because the value of the formula is higher than the
cutoff value.
[0387] In addition, when the value 0.109 of the formula when the
specificity is 80% is established as a first cutoff value, and the
value 1.780 of the formula when the specificity is 95% is
established as a second cutoff value, and when the value of the
formula lower than the first cutoff value is defined rank A, when
the value of the formula higher than the first cutoff value and
lower than the second cutoff value is defined rank B, and when the
value of the formula higher than the second cutoff value is defined
rank C, then the case in which the value of the formula is 4.7 is
classified into any one of the three ranks. This case is classified
into rank C because the value of the formula is higher than the
second cutoff value.
[0388] List (2) of Logistic Regression Equations Searched in
Example 4 provided later shows a list of logistic regression
equations in which the ROC_AUC value for the pancreatic cancer
group and the other cancers group with validation is equal to or
greater than 0.750 and the capability of discriminating between the
pancreatic cancer group and the healthy group is also good. These
logistic regression equations are thought to be useful in
evaluation of the state of pancreatic cancer with consideration of
both the healthy state and the state of cancers other than
pancreatic cancer, because the ROC_AUC value is extremely high.
When the amino acid explanatory variables included in these
logistic regression equations are listed in the descending order of
occurrence frequency from the highest to the tenth, they are
arranged in the following order: Trp, Gln, His, Phe, Met, Ile, Cit,
Val, Leu, Asn (see Table 2 above). The concentration values of
these amino acids are thought to be useful in the evaluation as
with the formula because they are explanatory variables included in
the formula thought to be useful in the evaluation. Among these
logistic regression equations, for example, the index formula 7
"(0.8883)+(0.0101)Gln+(-0.0453)His+(-0.1983)Met+(0.0032)Ile+(0.0304)Phe+(-
-0.0647)Trp" having a set of explanatory variables "Gln, His, Met,
Ile, Phe, Trp" (the multivariate discriminant including Gln, His,
Met, Ile, Phe, Trp as explanatory variables) has a good
discriminating capability with ROC_AUC(Validation)=0.832,
ROC_AUC(No Validation)=0.854, sensitivity=0.690, and
specificity=0.902. The sensitivity and the specificity are the
values when the maximum discriminate point, where the average of
sensitivity and specificity is the highest, is a cutoff value.
[0389] The value of the formula is calculated using the index
formula 7 and the amino acid concentration values (.mu.mol/L) of
the pancreatic cancer group, and each case in the pancreatic cancer
group is classified into any one of a plurality of categories
established as shown below, using the calculated value of the
formula and a previously established cutoff value. As candidates
for the cutoff value, the value of the formula when the specificity
is 80% and the value of the formula when the specificity is 95% are
found to be -2.626 and -1.306, respectively. When these values are
set as cutoff values, the sensitivities are 75% and 43%,
respectively.
[0390] The amino acid concentration values of a case having the
highest value of the formula are Gln:697.3, His:54.0, Met:18.5,
Ile:69.0, Phe:44.1, Trp:33.6, and the value of the formula in this
case is 1.2. The odds, calculated from the value 1.2 of this
formula, are 3.3. The probability p, calculated from the odds, is
0.8.
[0391] When the value -1.306 of the formula when the specificity is
95% is established as a cutoff value, and when the value of the
formula higher than the cutoff value is defined positive, and when
the value of the formula lower than the cutoff value is defined
negative, then the case in which the value of the formula is 1.2 is
classified either as positive or negative. This case is classified
into a positive because the value of the formula is higher than the
cutoff value.
[0392] When classifying each case either as positive or negative
using the amino acid concentration values of the healthy group when
the value -2.626 of the formula when the specificity is 80% is
established as a cutoff value and when the value -1.306 of the
formula when the specificity is 95% is established as a cutoff
value, then the false positive rates for the healthy group are 22%
and 2%, respectively. These values are lower than the false
positive rates of 28% and 5% for the healthy group when the index
formula 5 is used. The index formula 7 is therefore useful in
evaluation of the state of pancreatic cancer with consideration of
both the healthy state and the state of cancers other than
pancreatic cancer.
[0393] When the value -2.626 of the formula when the specificity is
80% is established as a first cutoff value, and the value -1.306 of
the formula when the specificity is 95% is established as a second
cutoff value, and when the value of the formula lower than the
first cutoff value is defined rank A, when the value of the formula
higher than the first cutoff value and lower than the second cutoff
value is defined rank B, and when the value of the formula higher
than the second cutoff value is defined rank C, then the case in
which the value of the formula is 1.2 is classified into any one of
the three ranks. This case is classified into the rank C because
the value of the formula is higher than the second cutoff
value.
[0394] List (2) of Linear Discriminants Searched in Example 4
provided later shows a list of linear discriminants in which the
ROC_AUC value for the pancreatic cancer group and the other cancers
group with validation is equal to or greater than 0.750 and the
capability of discriminating between the pancreatic cancer group
and the healthy group is also good. These linear discriminants are
thought to be useful in evaluation of the state of pancreatic
cancer with consideration of both the healthy state and the state
of cancers other than pancreatic cancer, because the ROC_AUC value
is extremely high. When the amino acid explanatory variables
included in these linear discriminants are listed in the descending
order of occurrence frequency from the highest to the tenth, they
are arranged in the following order: Trp, Phe, Met, His, Ser, Gln,
Asn, Ile, Cit, Val (see Table 2 above). The concentration values of
these amino acids are thought to be useful in the evaluation as
with the formula because they are explanatory variables included in
the formula thought to be useful in the evaluation. Among these
linear discriminants, for example, the index formula 8
"(5.7313)+(0.0114)Ser+(-0.0226)Val+(-0.2232)Met+(0.0489)Ile+(0.0676)Phe+(-
-0.0795)Trp" having a set of explanatory variables "Ser, Val, Met,
Ile, Phe, Trp" (the multivariate discriminant including Ser, Val,
Met, Ile, Phe, Trp as explanatory variables) has a good
discriminating capability with ROC_AUC(Validation)=0.833,
ROC_AUC(No Validation)=0.849, sensitivity=0.837, specificity=0.784.
The sensitivity and the specificity are the values when the maximum
discriminate point, where the average of sensitivity and
specificity is the highest, is a cutoff value.
[0395] The value of the formula is calculated using the index
formula 8 and the amino acid concentration values (.mu.mol/L) of
the pancreatic cancer group, and each case in the pancreatic cancer
group is classified into any one of a plurality of categories
established as shown below, using the calculated value of the
formula and a previously established cutoff value. As candidates
for the cutoff value, the value of the formula when the specificity
is 80% and the value of the formula when the specificity is 95% are
found to be 0.019 and 1.739, respectively. When these values are
set as cutoff values, the sensitivities are 78% and 31%,
respectively.
[0396] The amino acid concentration values of a case with the
highest value of the formula are Ser:166.3, Gln:697.3, Asn:35.2,
Ile:69.0, Cit:26.0, Val:149.9, and the value of the formula in this
case is 3.8.
[0397] When the value 1.739 of the formula when the specificity is
95% is established as a cutoff value, and when the value of the
formula higher than the cutoff value is defined positive, and when
the value of the formula lower than the cutoff value is defined
negative, then the case in which the value of the formula is 3.8 is
classified either as positive or negative. This case is classified
as positive because the value of the formula is higher than the
cutoff value.
[0398] When each case is classified either as positive or negative
using the amino acid concentration values of the healthy group when
the value 0.019 of the formula when the specificity is 80% is
established as a cutoff value and when the value 1.739 of the
formula when the specificity is 95% is established as a cutoff
value, then the false positive rates for the healthy group are 17%
and 1%, respectively. These values are lower than the false
positive rates of 28% and 4% for the healthy group when the index
formula 6 is used. The index formula 8 is therefore useful in
evaluation of the state of pancreatic cancer with consideration of
both the healthy state and the state of cancers other than
pancreatic cancer.
[0399] When the value 0.019 of the formula when the specificity is
80% is established as a first cutoff value, and the value 1.739 of
the formula when the specificity is 95% is established as a second
cutoff value, and when the value of the formula lower than the
first cutoff value is defined rank A, when the value of the formula
higher than the first cutoff value and lower than the second cutoff
value is defined rank B, and when the value of the formula higher
than the second cutoff value is defined rank C, then the case in
which the value of the formula is 3.8 is classified into any one of
the three ranks. This case is classified into the rank C because
the value of the formula is higher than the second cutoff
value.
Example 5
[0400] The sample data used in Example 1 is used. A multivariate
discriminant (multivariate function) including an explanatory
variable to be substituted with the concentration value of an amino
acid in plasma is obtained for discriminating between two groups:
the pancreatic cancer group and the lung cancer group.
[0401] A logistic regression equation is used as a multivariate
discriminant. The 19 kinds of amino acids are searched for a
combination of six or less explanatory variables to be included in
the logistic regression equation. The Leave-One-Out method is
employed as validation to explore a logistic regression equation
having a good capability of discriminating between the pancreatic
cancer group and the lung cancer group.
[0402] The logistic regression equations where the ROC_AUC value
for the pancreatic cancer group and the lung cancer group with
validation is equal to or greater than 0.750 are shown later in
List (1) of Logistic Regression Equations Searched in Example 5.
These logistic regression equations are thought to be useful in
evaluation of the state of pancreatic cancer with consideration of
the state of lung cancer because the ROC_AUC value is extremely
high. When the amino acid explanatory variables included in these
logistic regression equations are listed in the descending order of
occurrence frequency from the highest to the tenth, they are
arranged in the following order: Gln, Asn, Trp, Val, Ala, Phe, Cit,
Arg, Pro, Leu (see Table 3 below). These amino acids are thought to
be useful in the evaluation as with the equations because they are
explanatory variables included in the equations thought to be
useful in the evaluation. For these logistic regression equations,
the ROC_AUC value for the pancreatic cancer group and the healthy
group is equal to or greater than 0.725, and the capability of
discriminating between the pancreatic cancer group and the healthy
group is good.
[0403] These logistic regression equations are thought to be useful
in evaluation of the state of pancreatic cancer with additional
consideration of the healthy state, because the ROC_AUC value is
extremely high. Among these logistic regression equations, for
example, the index formula 9
"(2.5017)+(-0.1544)Asn+(0.0144)Gln+(-0.0136)Pro+(-0.0179)Val+(0.0647)Phe+-
(-0.0751)Trp" having a set of explanatory variables "Asn, Gln, Pro,
Val, Phe, Trp" (the multivariate discriminant including Asn, Gln,
Pro, Val, Phe, Trp as explanatory variables) has a good
discriminating capability with ROC_AUC(Validation)=0.879,
ROC_AUC(No Validation)=0.901, sensitivity=0.831, specificity=0.902.
The sensitivity and the specificity are the values when the maximum
discriminate point, where the average of sensitivity and
specificity is highest, is a cutoff value.
TABLE-US-00004 TABLE 3 Pancreatic cancer group vs Lung cancer group
Logistic regression equation Linear discriminant Lung cancer
Healthy Lung cancer Healthy Amino acid Univariate group group group
group Ser O 44 66 Asn O 97 40 92 40 Gly O Gln 100 43 100 32 His O
35 38 Thr O Ala O 46 50 Cit O 23 42 18 29 Arg O 22 12 Pro O 21 25
Tyr O 14 Val O 67 65 Met O 66 19 73 Orn O Lys O 16 15 Ile O 12 Leu
O 15 22 Phe O 31 98 28 98 Trp O 96 100 98 100 (O indicates the
amino acid that varies significantly. The numeral indicates the
frequency of occurrence of the amino acid explanatory
variable.)
[0404] The value of the formula can be calculated using the index
formula 9 as with Example 4, and each case can be classified using
the calculated value of the formula and a previously established
cutoff value as with Example 4.
[0405] A linear discriminant is used as a multivariate
discriminant. The 19 kinds of amino acids are searched for a
combination of six or less explanatory variables to be included in
the linear discriminant, and the bootstrap method is employed as
validation to explore a linear discriminant with a good capability
of discriminating between the pancreatic cancer group and the lung
cancer group.
[0406] A list of linear discriminants where the ROC_AUC value for
the pancreatic cancer group and the lung cancer group with
validation is equal to or greater than 0.750 is shown later in List
(1) of Linear Discriminants Searched in Example 5. These linear
discriminants are thought to be useful in evaluation of the state
of pancreatic cancer with consideration of the state of lung
cancer, because the ROC_AUC value is extremely high. When the amino
acid explanatory variables included in these linear discriminants
are listed in the descending order of occurrence frequency from the
highest to the tenth, they are arranged in the following order:
Gln, Trp, Asn, Val, Ala, Phe, Pro, Leu, Met, Cit (see Table 3
above). The concentration values of these amino acids are thought
to be useful in the evaluation as with the formula, because they
are explanatory variables included in the formula thought to be
useful in the evaluation. As for these linear discriminants, the
ROC_AUC value for the pancreatic cancer group and the healthy group
is equal to or greater than 0.727, and the capability of
discriminating between the pancreatic cancer group and the healthy
group is good.
[0407] These linear discriminants are thought to be useful in
evaluation of the state of pancreatic cancer with additional
consideration of the healthy state, because the ROC_AUC value is
extremely high. Among these linear discriminants, for example, the
index formula 10
"(5.6262)+(-0.1579)Asn+(0.0147)Gln+(-0.0133)Pro+(-0.0175)Val+(0.0680)Phe+-
(-0.1047)Trp" having a set of explanatory variables "Asn, Gln, Pro,
Val, Phe, Trp" (the multivariate discriminant including Asn, Gln,
Pro, Val, Phe, Trp as explanatory variables) has a good
discriminating capability with ROC_AUC(Validation)=0.889,
ROC_AUC(No Validation)=0.900, sensitivity=0.828, and
specificity=0.882. The sensitivity and the specificity are the
values when the maximum discriminate point, where the average of
sensitivity and specificity is the highest, is a cutoff value.
[0408] The value of the formula can be calculated using the index
formula 10 as with Example 4, and each case can be classified using
the calculated value of the formula and a previously established
cutoff value as with Example 4.
[0409] List (2) of Logistic Regression Equations Searched in
Example 5 provided later shows a list of logistic regression
equations in which the ROC_AUC value for the pancreatic cancer
group and the lung cancer group with validation is equal to or
greater than 0.750 and the capability of discriminating between the
pancreatic cancer group and the healthy group is also good. These
logistic regression equations are thought to be useful in
evaluation of the state of pancreatic cancer with consideration of
both the healthy state and the state of lung cancer, because the
ROC_AUC value is extremely high. When the amino acid explanatory
variables included in these logistic regression equations are
listed in the descending order of occurrence frequency from the
highest to the tenth, they are arranged in the following order:
Trp, Phe, Met, Ser, Gln, Cit, Asn, His, Lys, Ile, Arg, in total
eleven (see Table 3 above). The concentration values of these amino
acids are thought to be useful in the evaluation as with the
formula because they are explanatory variables included in the
formula thought to be useful in the evaluation. Among these
logistic regression equations, for example, the index formula 11
"(0.7428)+(-0.0948)Asn+(0.0147)Gln+(-0.0250)His+(-0.1901)Met+(0.0579)Phe+-
(-0.0741)Trp" having a set of explanatory variables "Asn, Gln, His,
Met, Phe, Trp" (the multivariate discriminant including Asn, Gln,
His, Met, Phe, Trp as explanatory variables) has a good
discriminating capability with ROC_AUC(Validation)=0.858,
ROC_AUC(No Validation)=0.882, sensitivity=0.747, and
specificity=0.902. The sensitivity and the specificity are the
values when the maximum discriminate point, where the average of
sensitivity and specificity is the highest, is a cutoff value.
[0410] The value of the formula can be calculated using the index
formula 11 as with Example 4, and each case can be classified using
the calculated value of the formula and a previously established
cutoff value as with Example 4.
[0411] List (2) of Linear Discriminants Searched in Example 5
provided later shows a list of linear discriminants in which the
ROC_AUC value for the pancreatic cancer group and the lung cancer
group with validation is equal to or greater than 0.750 and the
capability of discriminating between the pancreatic cancer group
and the healthy group is also good. These linear discriminants are
thought to be useful in evaluation of the state of pancreatic
cancer with consideration of both the healthy state and the state
of lung cancer, because the ROC_AUC value is extremely high. When
the amino acid explanatory variables included in these linear
discriminants are listed in the descending order of occurrence
frequency from the highest to the tenth, they are arranged in the
following order: Trp, Phe, Met, Ser, Asn, His, Gln, Cit, Lys, Tyr
(see Table 3 above). The concentration values of these amino acids
are thought to be useful in the evaluation as with the formula
because they are explanatory variables included in the formula
thought to be useful in the evaluation. Among these linear
discriminants, for example, the index formula 12
"(6.6327)+(0.0159)Ser+(-0.0688)Asn+(-0.0166)Cit+(-0.1442)Met+(0.0618)Phe+-
(-0.0996)Trp" having a set of explanatory variables "Ser, Asn, Cit,
Met, Phe, Trp" (the multivariate discriminant including Ser, Asn,
Cit, Met, Phe, Trp as explanatory variables) has a good
discriminating capability with ROC_AUC(Validation)=0.841,
ROC_AUC(No Validation)=0.858, sensitivity=0.825, specificity=0.804.
The sensitivity and the specificity are the values when the maximum
discriminate point, where the average of sensitivity and
specificity is the highest, is a cutoff value.
[0412] The value of the formula can be calculated using the index
formula 12 as with Example 4, and each case can be classified using
the calculated value of the formula and a previously established
cutoff value as with Example 4.
Example 6
[0413] The sample data used in Example 1 is used. A multivariate
discriminant (multivariate function) including an explanatory
variable to be substituted with the concentration value of an amino
acid in plasma is obtained for discriminating between two groups:
the pancreatic cancer group and the colorectal cancer group.
[0414] A logistic regression equation is used as a multivariate
discriminant. The 19 kinds of amino acids are searched for a
combination of six or less explanatory variables to be included in
the logistic regression equation. The Leave-One-Out method is
employed as validation to explore a logistic regression equation
having a good capability of discriminating between the pancreatic
cancer group and the colorectal cancer group.
[0415] The logistic regression equations where the ROC_AUC value
for the pancreatic cancer group and the colorectal cancer group
with validation is equal to or greater than 0.750 are shown later
in List (1) of Logistic Regression Equations Searched in Example 6.
These logistic regression equations are thought to be useful in
evaluation of the state of pancreatic cancer with consideration of
the state of colorectal cancer because the ROC_AUC value is
extremely high. When the amino acid explanatory variables included
in these logistic regression equations are listed in the descending
order of occurrence frequency from the highest to the tenth, they
are arranged in the following order: Trp, Cit, Tyr, Met, Asn, Orn,
Gln, Pro, Ala, Gly (see Table 4 below). These amino acids are
thought to be useful in the evaluation as with the equations
because they are explanatory variables included in the equations
thought to be useful in the evaluation. For these logistic
regression equations, the ROC_AUC value for the pancreatic cancer
group and the healthy group is equal to or greater than 0.803, and
the capability of discriminating between the pancreatic cancer
group and the healthy group is good.
[0416] These logistic regression equations are thought to be useful
in evaluation of the state of pancreatic cancer with additional
consideration of the healthy state, because the ROC_AUC value is
extremely high. Among these logistic regression equations, for
example, the index formula 13
"(5.6692)+(-0.0719)Asn+(0.0072)Gln+(-0.0715)Cit+(0.0674)Tyr+(-0.1878)Met+-
(-0.1103)Trp" having a set of explanatory variables "Asn, Gln, Cit,
Tyr, Met, Trp" (the multivariate discriminant including Asn, Gln,
Cit, Tyr, Met, Trp as explanatory variables) has a good
discriminating capability with ROC_AUC(Validation)=0.851,
ROC_AUC(No Validation)=0.874, sensitivity=0.889, specificity=0.804.
The sensitivity and the specificity are the values when the maximum
discriminate point, where the average of sensitivity and
specificity is highest, is a cutoff value.
TABLE-US-00005 TABLE 4 Pancreatic cancer group vs Colorectal cancer
group Logistic regression equation Linear discriminant Colorectal
Healthy Colorectal Healthy Amino acid Univariate cancer group group
cancer group group Ser 12 37 Asn O 43 32 41 21 Gly O 14 13 Gln O 24
83 33 42 His O 89 61 Thr O 22 12 40 Ala O 14 Cit O 100 19 97 25 Arg
O Pro O 16 Tyr O 99 96 Val O Met O 70 39 75 82 Orn 27 19 21 Lys O
Ile O 16 Leu O 22 Phe O 77 20 97 Trp O 100 100 100 100 (O indicates
the amino acid that varies significantly. The numeral indicates the
frequency of occurrence of the amino acid explanatory
variable.)
[0417] The value of the formula can be calculated using the index
formula 13 as with Example 4, and each case can be classified using
the calculated value of the formula and a previously established
cutoff value as with Example 4.
[0418] A linear discriminant is used as a multivariate
discriminant. The 19 kinds of amino acids are searched for a
combination of six or less explanatory variables to be included in
the linear discriminant, and the bootstrap method is employed as
validation to explore a linear discriminant with a good capability
of discriminating between the pancreatic cancer group and the
colorectal cancer group.
[0419] A list of linear discriminants where the ROC_AUC value for
the pancreatic cancer group and the colorectal cancer group with
validation is equal to or greater than 0.750 is shown later in List
(1) of Linear Discriminants Searched in Example 6. These linear
discriminants are thought to be useful in evaluation of the state
of pancreatic cancer with consideration of the state of colorectal
cancer, because the ROC_AUC value is extremely high. When the amino
acid explanatory variables included in these linear discriminants
are listed in the descending order of occurrence frequency from the
highest to the tenth, they are arranged in the following order:
Trp, Cit, Tyr, Met, Asn, Gln, Orn, Phe, Gly, Thr, Ser, in total
eleven (see Table 4 above). The concentration values of these amino
acids are thought to be useful in the evaluation as with the
formula, because they are explanatory variables included in the
formula thought to be useful in the evaluation. As for these linear
discriminants, the ROC_AUC value for the pancreatic cancer group
and the healthy group is equal to or greater than 0.793, and the
capability of discriminating between the pancreatic cancer group
and the healthy group is good. These linear discriminants are
thought to be useful in evaluation of the state of pancreatic
cancer with additional consideration of the healthy state, because
the ROC_AUC value is extremely high. Among these linear
discriminants, for example, the index formula 14
"(6.7413)+(-0.0941)Asn+(0.0093)Gln+(-0.0666)Cit+(0.0561)Tyr+(-0.1268)Met+-
(-0.1224)Trp" having a set of explanatory variables "Asn, Gln, Cit,
Tyr, Met, Trp" (the multivariate discriminant including Asn, Gln,
Cit, Tyr, Met, Trp as explanatory variables) has a good
discriminating capability with ROC_AUC(Validation)=0.862,
ROC_AUC(No Validation)=0.876, sensitivity=0.861, and
specificity=0.824. The sensitivity and the specificity are the
values when the maximum discriminate point, where the average of
sensitivity and specificity is the highest, is a cutoff value.
[0420] The value of the formula can be calculated using the index
formula 14 as with Example 4, and each case can be classified using
the calculated value of the formula and a previously established
cutoff value as with Example 4.
[0421] List (2) of Logistic Regression Equations Searched in
Example 6 provided later shows a list of logistic regression
equations in which the ROC_AUC value for the pancreatic cancer
group and the colorectal cancer group with validation is equal to
or greater than 0.750 and the capability of discriminating between
the pancreatic cancer group and the healthy group is also good.
These logistic regression equations are thought to be useful in
evaluation of the state of pancreatic cancer with consideration of
both the healthy state and the state of colorectal cancer, because
the ROC_AUC value is extremely high. When the amino acid
explanatory variables included in these logistic regression
equations are listed in the descending order of occurrence
frequency from the highest to the tenth, they are arranged in the
following order: Trp, His, Gln, Phe, Met, Asn, Leu, Thr, Cit, Orn
(see Table 4 above). The concentration values of these amino acids
are thought to be useful in the evaluation as with the formula
because they are explanatory variables included in the formula
thought to be useful in the evaluation. Among these logistic
regression equations, for example, the index formula 15
"(4.0457)+(0.0070)Gln+(-0.0515)His+(0.0059)Thr+(-0.1935)Met+(0.0373)Phe+(-
-0.0815)Trp" having a set of explanatory variables "Gln, His, Thr,
Met, Phe, Trp" (the multivariate discriminant including Gln, His,
Thr, Met, Phe, Trp as explanatory variables) has a good
discriminating capability with ROC_AUC(Validation)=0.822,
ROC_AUC(No Validation)=0.849, sensitivity=0.762, and
specificity=0.843. The sensitivity and the specificity are the
values when the maximum discriminate point, where the average of
sensitivity and specificity is the highest, is a cutoff value.
[0422] The value of the formula can be calculated using the index
formula 15 as with Example 4, and each case can be classified using
the calculated value of the formula and a previously established
cutoff value as with Example 4.
[0423] List (2) of Linear Discriminants Searched in Example 6
provided later shows a list of linear discriminants in which the
ROC_AUC value for the pancreatic cancer group and the colorectal
cancer group with validation is equal to or greater than 0.750 and
the capability of discriminating between the pancreatic cancer
group and the healthy group is also good. These linear
discriminants are thought to be useful in evaluation of the state
of pancreatic cancer with consideration of both the healthy state
and the state of colorectal cancer, because the ROC_AUC value is
extremely high. When the amino acid explanatory variables included
in these linear discriminants are listed in the descending order of
occurrence frequency from the highest to the tenth, they are
arranged in the following order: Trp, Phe, Met, His, Gln, Thr, Ser,
Cit, Asn, Ile (see Table 4 above). The concentration values of
these amino acids are thought to be useful in the evaluation as
with the formula because they are explanatory variables included in
the formula thought to be useful in the evaluation. Among these
linear discriminants, for example, the index formula 16
"(4.7750)+(0.0066)Gln+(-0.0466)His+(0.0084)Thr+(-0.1967)Met+(0.0666)Phe+(-
-0.1057)Trp" having a set of explanatory variables "Gln, His, Thr,
Met, Phe, Trp" (the multivariate discriminant including Gln, His,
Thr, Met, Phe, Trp as explanatory variables) has a good
discriminating capability with ROC_AUC(Validation)=0.835,
ROC_AUC(No Validation)=0.856, sensitivity=0.730, specificity=0.882.
The sensitivity and the specificity are the values when the maximum
discriminate point, where the average of sensitivity and
specificity is the highest, is a cutoff value.
[0424] The value of the formula can be calculated using the index
formula 16 as with Example 4, and each case can be classified using
the calculated value of the formula and a previously established
cutoff value as with Example 4.
Example 7
[0425] Among the sample data used in Example 1, only the sample
data of males is used. A multivariate discriminant (multivariate
function) including an explanatory variable to be substituted with
the concentration value of an amino acid in plasma is obtained for
discriminating between two groups: the pancreatic cancer group and
the prostatic cancer group.
[0426] A logistic regression equation is used as a multivariate
discriminant. The 19 kinds of amino acids are searched for a
combination of six or less explanatory variables to be included in
the logistic regression equation. The Leave-One-Out method is
employed as validation to explore a logistic regression equation
having a good capability of discriminating between the pancreatic
cancer group and the prostatic cancer group.
[0427] The logistic regression equations where the ROC_AUC value
for the pancreatic cancer group and the prostatic cancer group with
validation is equal to or greater than 0.750 are shown later in
List (1) of Logistic Regression Equations Searched in Example 7.
These logistic regression equations are thought to be useful in
evaluation of the state of pancreatic cancer with consideration of
the state of prostatic cancer because the ROC_AUC value is
extremely high. When the amino acid explanatory variables included
in these logistic regression equations are listed in the descending
order of occurrence frequency from the highest to the tenth, they
are arranged in the following order: Ile, Val, Ala, Ser, Met, Cit,
Gln, Asn, Pro, Thr (see Table 5 below). These amino acids are
thought to be useful in the evaluation as with the equations
because they are explanatory variables included in the equations
thought to be useful in the evaluation. For these logistic
regression equations, the ROC_AUC value for the pancreatic cancer
group and the healthy group is equal to or greater than 0.816, and
the capability of discriminating between the pancreatic cancer
group and the healthy group is good. These logistic regression
equations are thought to be useful in evaluation of the state of
pancreatic cancer with additional consideration of the healthy
state, because the ROC_AUC value is extremely high. Among these
logistic regression equations, for example, the index formula 17
"(3.0499)+(0.0406)Ser+(-0.0121)Ala+(-0.0402)Val+(-0.1789)Met+(0.1361)Ile"
having a set of explanatory variables "Ser, Ala, Val, Met, Ile"
(the multivariate discriminant including Ser, Ala, Val, Met, Ile as
explanatory variables) has a good discriminating capability with
ROC_AUC(Validation)=0.877, ROC_AUC(No Validation)=0.907,
sensitivity=0.828, specificity=0.903. The sensitivity and the
specificity are the values when the maximum discriminate point,
where the average of sensitivity and specificity is highest, is a
cutoff value.
TABLE-US-00006 TABLE 5 Pancreatic cancer group vs Prostatic cancer
group Logistic regression equation Linear discriminant Prostatic
Healthy Prostatic Healthy Amino acid Univariate cancer group group
cancer group group Ser 61 100 99 Asn O 23 15 Gly Gln 33 20 His O
Thr O 17 30 15 Ala O 81 92 Cit O 41 21 Arg O 15 8 15 Pro O 17 25
Tyr O 14 8 15 Val O 91 45 96 32 Met O 54 100 41 100 Orn 14 Lys O 19
Ile 100 81 100 35 Leu O 9 14 Phe O 43 93 Trp O 65 86 (O indicates
the amino acid that varies significantly. The numeral indicates the
frequency of occurrence of the amino acid explanatory
variable.)
[0428] The value of the formula can be calculated using the index
formula 17 as with Example 4, and each case can be classified using
the calculated value of the formula and a previously established
cutoff value as with Example 4.
[0429] A linear discriminant is used as a multivariate
discriminant. The 19 kinds of amino acids are searched for a
combination of six or less explanatory variables to be included in
the linear discriminant, and the bootstrap method is employed as
validation to explore a linear discriminant with a good capability
of discriminating between the pancreatic cancer group and the
prostatic cancer group.
[0430] A list of linear discriminants where the ROC_AUC value for
the pancreatic cancer group and the prostatic cancer group with
validation is equal to or greater than 0.750 is shown later in List
(1) of Linear Discriminants Searched in Example 7. These linear
discriminants are thought to be useful in evaluation of the state
of pancreatic cancer with consideration of the state of prostatic
cancer, because the ROC_AUC value is extremely high. When the amino
acid explanatory variables included in these linear discriminants
are listed in the descending order of occurrence frequency from the
highest to the tenth, they are arranged in the following order:
Ile, Val, Ala, Met, Pro, Cit, Gln, Asn, Leu, Arg, Tyr, in total
eleven (see Table 5 above). The concentration values of these amino
acids are thought to be useful in the evaluation as with the
formula, because they are explanatory variables included in the
formula thought to be useful in the evaluation. As for these linear
discriminants, the ROC_AUC value for the pancreatic cancer group
and the healthy group is equal to or greater than 0.818, and the
capability of discriminating between the pancreatic cancer group
and the healthy group is good. These linear discriminants are
thought to be useful in evaluation of the state of pancreatic
cancer with additional consideration of the healthy state, because
the ROC_AUC value is extremely high. Among these linear
discriminants, for example, the index formula 18
"(5.0859)+(0.0109)Gln+(-0.0171)Ala+(-0.0452)Cit+(-0.0389)Val+(-0.1548)Met-
+(0.1284)Ile" having a set of explanatory variables "Gln, Ala, Cit,
Val, Met, Ile" (the multivariate discriminant including Gln, Ala,
Cit, Val, Met, Ile as explanatory variables) has a good
discriminating capability with ROC_AUC(Validation)=0.889,
ROC_AUC(No Validation)=0.914, sensitivity=0.862, and
specificity=0.871. The sensitivity and the specificity are the
values when the maximum discriminate point, where the average of
sensitivity and specificity is the highest, is a cutoff value.
[0431] The value of the formula can be calculated using the index
formula 18 as with Example 4, and each case can be classified using
the calculated value of the formula and a previously established
cutoff value as with Example 4.
[0432] List (2) of Logistic Regression Equations Searched in
Example 7 provided later shows a list of logistic regression
equations in which the ROC_AUC value for the pancreatic cancer
group and the prostatic cancer group with validation is equal to or
greater than 0.750 and the capability of discriminating between the
pancreatic cancer group and the healthy group is also good. These
logistic regression equations are thought to be useful in
evaluation of the state of pancreatic cancer with consideration of
both the healthy state and the state of prostatic cancer, because
the ROC_AUC value is extremely high. When the amino acid
explanatory variables included in these logistic regression
equations are listed in the descending order of occurrence
frequency from the highest to the tenth, they are arranged in the
following order: Met, Ser, Ile, Trp, Val, Phe, Thr, Lys, Arg, Tyr
(see Table 5 above). The concentration values of these amino acids
are thought to be useful in the evaluation as with the formula
because they are explanatory variables included in the formula
thought to be useful in the evaluation. Among these logistic
regression equations, for example, the index formula 19
"(-0.4061)+(0.0399)Ser+(-0.2141)Met+(0.1298)Ile+(-0.0658)Leu+(0.0402)Phe+-
(-0.0539)Trp" having a set of explanatory variables "Ser, Met, Ile,
Leu, Phe, Trp" (the multivariate discriminant including Ser, Met,
Ile, Leu, Phe, Trp as explanatory variables) has a good
discriminating capability with ROC_AUC(Validation)=0.787,
ROC_AUC(No Validation)=0.856, sensitivity=0.851, and
specificity=0.774. The sensitivity and the specificity are the
values when the maximum discriminate point, where the average of
sensitivity and specificity is the highest, is a cutoff value.
[0433] The value of the formula can be calculated using the index
formula 19 as with Example 4, and each case can be classified using
the calculated value of the formula and a previously established
cutoff value as with Example 4.
[0434] List (2) of Linear Discriminants Searched in Example 7
provided later shows a list of linear discriminants in which the
ROC_AUC value for the pancreatic cancer group and the prostatic
cancer group with validation is equal to or greater than 0.750 and
the capability of discriminating between the pancreatic cancer
group and the healthy group is also good. These linear
discriminants are thought to be useful in evaluation of the state
of pancreatic cancer with consideration of both the healthy state
and the state of prostatic cancer, because the ROC_AUC value is
extremely high. When the amino acid explanatory variables included
in these linear discriminants are listed in the descending order of
occurrence frequency from the highest to the tenth, they are
arranged in the following order: Met, Ser, Phe, Trp, Ile, Val, Tyr,
Arg, Thr, Orn, Leu, in total eleven (see Table 5 above). The
concentration values of these amino acids are thought to be useful
in the evaluation as with the formula because they are explanatory
variables included in the formula thought to be useful in the
evaluation. Among these linear discriminants, for example, the
index formula 20
"(1.6394)+(0.0387)Ser+(-0.0455)Val+(-0.2545)Met+(0.1283)Ile+(0.0546)Phe+(-
-0.0299)Trp" having a set of explanatory variables "Ser, Val, Met,
Ile, Phe, Trp" (the multivariate discriminant including Ser, Val,
Met, Ile, Phe, Trp as explanatory variables) has a good
discriminating capability with ROC_AUC(Validation)=0.859,
ROC_AUC(No Validation)=0.885, sensitivity=0.908, specificity=0.742.
The sensitivity and the specificity are the values when the maximum
discriminate point, where the average of sensitivity and
specificity is the highest, is a cutoff value.
[0435] The value of the formula can be calculated using the index
formula 20 as with Example 4, and each case can be classified using
the calculated value of the formula and a previously established
cutoff value as with Example 4.
Example 8
[0436] Among the sample data used in Example 1, only the sample
data of females is used. A multivariate discriminant (multivariate
function) including an explanatory variable to be substituted with
the concentration value of an amino acid in plasma is obtained for
discriminating between two groups: the pancreatic cancer group and
the breast cancer group.
[0437] A logistic regression equation is used as a multivariate
discriminant. The 19 kinds of amino acids are searched for a
combination of six or less explanatory variables to be included in
the logistic regression equation. The Leave-One-Out method is
employed as validation to explore a logistic regression equation
having a good capability of discriminating between the pancreatic
cancer group and the breast cancer group.
[0438] The logistic regression equations where the ROC_AUC value
for the pancreatic cancer group and the breast cancer group with
validation is equal to or greater than 0.750 are shown later in
List (1) of Logistic Regression Equations Searched in Example 8.
These logistic regression equations are thought to be useful in
evaluation of the state of pancreatic cancer with consideration of
the state of breast cancer because the ROC_AUC value is extremely
high. When the amino acid explanatory variables included in these
logistic regression equations are listed in the descending order of
occurrence frequency from the highest to the tenth, they are
arranged in the following order: Tyr, Trp, Gly, Ala, Asn, Lys, Met,
Val, Orn, Leu (see Table 6 below).
[0439] These amino acids are thought to be useful in the evaluation
as with the equations because they are explanatory variables
included in the equations thought to be useful in the evaluation.
For these logistic regression equations, the ROC_AUC value for the
pancreatic cancer group and the healthy group is equal to or
greater than 0.796, and the capability of discriminating between
the pancreatic cancer group and the healthy group is good. These
logistic regression equations are thought to be useful in
evaluation of the state of pancreatic cancer with additional
consideration of the healthy state, because the ROC_AUC value is
extremely high. Among these logistic regression equations, for
example, the index formula 21
"(19.7721)+(-0.1860)Asn+(-0.0214)Gly+(-0.0294)Arg+(0.1519)Tyr+(-0.0325)Va-
l+(-0.1932)Trp" having a set of explanatory variables "Asn, Gly,
Arg, Tyr, Val, Trp" (the multivariate discriminant including Asn,
Gly, Arg, Tyr, Val, Trp as explanatory variables) has a good
discriminating capability with ROC_AUC(Validation)=0.945,
ROC_AUC(No Validation)=0.965, sensitivity=0.851, specificity=1.000.
The sensitivity and the specificity are the values when the maximum
discriminate point, where the average of sensitivity and
specificity is highest, is a cutoff value.
TABLE-US-00007 TABLE 6 Pancreatic cancer group vs Breast cancer
group Logistic regression equation Linear discriminant Breast
Healthy Breast Healthy Amino acid Univariate cancer group group
cancer group group Ser O Asn O 48 55 Gly O 84 80 16 Gln 37 28 His O
100 14 98 Thr O Ala O 61 63 Cit 34 31 Arg 60 69 Pro Tyr 100 33 100
23 Val O 26 26 Met O 30 32 Orn 17 18 Lys O 32 30 27 31 Ile O 69 94
Leu 16 34 21 Phe 34 Trp O 100 94 100 100 (O indicates the amino
acid that varies significantly. The numeral indicates the frequency
of occurrence of the amino acid explanatory variable.)
[0440] The value of the formula can be calculated using the index
formula 21 as with Example 4, and each case can be classified using
the calculated value of the formula and a previously established
cutoff value as with Example 4.
[0441] A linear discriminant is used as a multivariate
discriminant. The 19 kinds of amino acids are searched for a
combination of six or less explanatory variables to be included in
the linear discriminant, and the bootstrap method is employed as
validation to explore a linear discriminant with a good capability
of discriminating between the pancreatic cancer group and the
breast cancer group.
[0442] A list of linear discriminants where the ROC_AUC value for
the pancreatic cancer group and the breast cancer group with
validation is equal to or greater than 0.750 is shown later in List
(1) of Linear Discriminants Searched in Example 8. These linear
discriminants are thought to be useful in evaluation of the state
of pancreatic cancer with consideration of the state of breast
cancer, because the ROC_AUC value is extremely high. When the amino
acid explanatory variables included in these linear discriminants
are listed in the descending order of occurrence frequency from the
highest to the tenth, they are arranged in the following order:
Tyr, Trp, Gly, Ala, Asn, Met, Lys, Val, Orn, His (see Table 6
above). The concentration values of these amino acids are thought
to be useful in the evaluation as with the formula, because they
are explanatory variables included in the formula thought to be
useful in the evaluation. As for these linear discriminants, the
ROC_AUC value for the pancreatic cancer group and the healthy group
is equal to or greater than 0.800, and the capability of
discriminating between the pancreatic cancer group and the healthy
group is good.
[0443] These linear discriminants are thought to be useful in
evaluation of the state of pancreatic cancer with additional
consideration of the healthy state, because the ROC_AUC value is
extremely high. Among these linear discriminants, for example, the
index formula 22
"(16.5080)+(-0.1847)Asn+(-0.0136)Gly+(0.1059)Tyr+(-0.0166)Val+(-0.0144)Ly-
s+(-0.1261)Trp" having a set of explanatory variables "Asn, Gly,
Tyr, Val, Lys, Trp" (the multivariate discriminant including Asn,
Gly, Tyr, Val, Lys, Trp as explanatory variables) has a good
discriminating capability with ROC_AUC(Validation)=0.947,
ROC_AUC(No Validation)=0.963, sensitivity=0.851, and
specificity=1.000. The sensitivity and the specificity are the
values when the maximum discriminate point, where the average of
sensitivity and specificity is the highest, is a cutoff value.
[0444] The value of the formula can be calculated using the index
formula 22 as with Example 4, and each case can be classified using
the calculated value of the formula and a previously established
cutoff value as with Example 4.
[0445] List (2) of Logistic Regression Equations Searched in
Example 8 provided later shows a list of logistic regression
equations in which the ROC_AUC value for the pancreatic cancer
group and the breast cancer group with validation is equal to or
greater than 0.750 and the capability of discriminating between the
pancreatic cancer group and the healthy group is also good. These
logistic regression equations are thought to be useful in
evaluation of the state of pancreatic cancer with consideration of
both the healthy state and the state of breast cancer, because the
ROC_AUC value is extremely high. When the amino acid explanatory
variables included in these logistic regression equations are
listed in the descending order of occurrence frequency from the
highest to the tenth, they are arranged in the following order:
His, Trp, Ile, Arg, Gln, Phe, Cit, Leu, Tyr, Lys (see Table 6
above). The concentration values of these amino acids are thought
to be useful in the evaluation as with the formula because they are
explanatory variables included in the formula thought to be useful
in the evaluation. Among these logistic regression equations, for
example, the index formula 23
"(9.6001)+(0.0010)Gln+(-0.1052)His+(-0.0386)Arg+(0.0762)Tyr+(0.0049)Ile+(-
-0.1257)Trp" having a set of explanatory variables "Gln, His, Arg,
Tyr, Ile, Trp" (the multivariate discriminant including Gln, His,
Arg, Tyr, Ile, Trp as explanatory variables) has a good
discriminating capability with ROC_AUC(Validation)=0.878,
ROC_AUC(No Validation)=0.923, sensitivity=0.876, and
specificity=0.900. The sensitivity and the specificity are the
values when the maximum discriminate point, where the average of
sensitivity and specificity is the highest, is a cutoff value.
[0446] The value of the formula can be calculated using the index
formula 23 as with Example 4, and each case can be classified using
the calculated value of the formula and a previously established
cutoff value as with Example 4.
[0447] List (2) of Linear Discriminants Searched in Example 8
provided later shows a list of linear discriminants in which the
ROC_AUC value for the pancreatic cancer group and the breast cancer
group with validation is equal to or greater than 0.750 and the
capability of discriminating between the pancreatic cancer group
and the healthy group is also good. These linear discriminants are
thought to be useful in evaluation of the state of pancreatic
cancer with consideration of both the healthy state and the state
of breast cancer, because the ROC_AUC value is extremely high. When
the amino acid explanatory variables included in these linear
discriminants are listed in the descending order of occurrence
frequency from the highest to the tenth, they are arranged in the
following order: Trp, His, Ile, Arg, Lys, Cit, Gln, Tyr, Leu, Gly
(see Table 6 above). The concentration values of these amino acids
are thought to be useful in the evaluation as with the formula
because they are explanatory variables included in the formula
thought to be useful in the evaluation. Among these linear
discriminants, for example, the index formula 24
"(10.5615)+(0.0037)Gln+(-0.1087)His+(-0.0445)Arg+(0.0653)Tyr+(0.0380)Ile+-
(-0.1489)Trp" having a set of explanatory variables "Gln, His, Arg,
Tyr, Ile, Trp" (the multivariate discriminant including Gln, His,
Arg, Tyr, Ile, Trp as explanatory variables) has a good
discriminating capability with ROC_AUC(Validation)=0.896,
ROC_AUC(No Validation)=0.924, sensitivity=0.843, specificity=0.950.
The sensitivity and the specificity are the values when the maximum
discriminate point, where the average of sensitivity and
specificity is the highest, is a cutoff value.
[0448] The value of the formula can be calculated using the index
formula 24 as with Example 4, and each case can be classified using
the calculated value of the formula and a previously established
cutoff value as with Example 4.
Example 9
[0449] The sample data used in Example 1 is used. First, the index
formula 1 obtained in Example 2 is established as the first
formula, and each case in each group is classified either as
positive (equivalent to the pancreatic cancer category) or as
negative (equivalent to the healthy category) using the amino acid
concentration values of the pancreatic cancer group (51 cases), the
healthy group (255 cases), and the other cancers group (780 cases),
and the first formula. When the specificity (the percentage of
cases in the healthy group correctly classified into the healthy
category) is 95%, the positive rate for each group is as follows:
71% for the pancreatic cancer group (36 positive cases), 5% for the
healthy group (13 positive cases), and 22% for the other cancers
group (170 cases).
[0450] The index formula 5 obtained in Example 4 is established as
the second formula, and each case in each group is classified
either as positive (equivalent to the pancreatic cancer category)
or as negative (equivalent to the other cancer category) using the
amino acid concentration values of the cases in each group found
positive with the index formula 1 (the pancreatic cancer group (36
cases), the healthy group (13 cases), the other cancers group (170
cases)) and the second formula. When the specificity (the
percentage of cases in the other cancers group correctly classified
into the other cancer category) is 95%, the positive rate for each
group is as follows: 33% (17 positive cases) for the pancreatic
cancer group, 2% (4 positive cases) for the healthy group, and 4%
(32 cases) for the other cancers group. When the specificity is
80%, the positive rate for each group is as follows: 59% (30
positive cases) for the pancreatic cancer group, 4% (9 positive
cases) for the healthy group, and 10% (78 cases) for the other
cancers group.
[0451] As described above, a plurality of formulae can be used to
reduce the false positive rate for the other cancers group without
noticeably reducing the true positive rate for the pancreatic
cancer group.
[0452] Based on the results described above, the cases that are
positive with the first formula and also positive with the second
formula may be classified into the pancreatic cancer category, and
the other cases may be classified into the pancreatic cancer-free
category.
[0453] The cases that are positive with the first formula and also
positive with the second formula may be classified into the
pancreatic cancer category, the cases that are positive with the
first formula and negative with the second formula may be
classified into the other cancer category, and the cases that are
negative with the first formula may be classified into the healthy
category. The case classified in the pancreatic cancer category may
be established as rank C, which is a category meaning that the
possibility of having pancreatic cancer is high (for example, a
category meaning that the possibility of having pancreatic cancer
is high and the possibility of having a cancer other than
pancreatic cancer is not high), the case classified in the other
cancer category may be established as rank B, which is a category
meaning that the possibility of having pancreatic cancer is
moderate (for example, a category meaning that the possibility of
having pancreatic cancer is moderate and the possibility of having
a cancer other than pancreatic cancer is not low), and the case
classified in the healthy category may be established as rank A,
which is a category meaning that the possibility of having
pancreatic cancer is low.
[0454] With the index formula 1 established as the first formula,
each case in each group may be classified either as positive
(equivalent to the pancreatic cancer category) or as negative
(equivalent to the healthy category), using the amino acid
concentration values of the pancreatic cancer group (51 cases), the
healthy group (255 cases), and the other cancers group (780 cases),
and the first formula. In addition, with the index formula 5
established as the second formula, each case in each group may be
classified either as positive (equivalent to the pancreatic cancer
category) or as negative (equivalent to the other cancer category),
using the amino acid concentration values of the pancreatic cancer
group (51 cases), the healthy group (255 cases), and the other
cancers group (780 cases), and the second formula. Those
classification results may be comprehensively considered to make a
final classification.
[0455] List (1) of Logistic Regression Equations Searched in
Example 2
[0456] The logistic regression equations searched in Example 2
above are listed below. Before each equation, "the value of ROC_AUC
for the pancreatic cancer group and the healthy group with
validation", "the value of ROC_AUC for the pancreatic cancer group
and the healthy group without validation", "the value of ROC_AUC
for the pancreatic cancer group and the other cancers group", "the
value of ROC_AUC for the pancreatic cancer group and the lung
cancer group", "the value of ROC_AUC for the pancreatic cancer
group and the colorectal cancer group", "the value of ROC_AUC for
the pancreatic cancer group and the prostatic cancer group", "the
value of ROC_AUC for the pancreatic cancer group and the breast
cancer group", and "the average value of the value of ROC_AUC for
the pancreatic cancer group and the lung cancer group, the value of
ROC_AUC for the pancreatic cancer group and the colorectal cancer
group, the value of ROC_AUC for the pancreatic cancer group and the
prostatic cancer group, and the value of ROC_AUC for the pancreatic
cancer group and the breast cancer group" obtained for the equation
are additionally listed.
[0457] 0.902, 0.923, 0.809, 0.790, 0.778, 0.870, 0.878, 0.829,
(-1.32 17)+(0.0545)Ser+(-0.0544)Val+(-0.3973)Met+(0.1922)Ile+(0.15
06)Phe+(-0.1179)Trp; 0.900, 0.919, 0.800, 0.780, 0.815, 0.860, 0.7
77, 0.808, (1.1114)+(0.0530)Ser+(-0.1384)His+(0.0420)Thr+(-0.
3641)Met+(0.1993)Phe+(-0.1237)Trp; 0.899, 0.917, 0.812, 0.798, 0.
789, 0.854, 0.864, 0.826, (2.2454)+(0.0452)Thr+(-0.0612)Val+(-0.
4741)Met+(0.2021)Ile+(0.1569)Phe+(-0.1267)Trp; 0.894, 0.918, 0.
783, 0.749, 0.760, 0.870, 0.859, 0.810, (-1.8219)+(0.0622)Ser+(-0.
1003)His+(-0.0447)Val+(-0.4105)Met+(0.1701)Ile+(0.1621)Phe; 0.891,
0.913, 0.825, 0.813, 0.822, 0.870, 0.830, 0.834,
(-0.7646)+(0.0539)Ser+(0.0080)Gln+(-0.1367)His+(-0.2716)Met+(0.1766)P
he+(-0.1028)Trp; 0.891, 0.910, 0.793, 0.765, 0.776, 0.856, 0.858,
0. 814, (2.3264)+(-0.0966)His+(0.0489)Thr+(-0.0552)Val+(-0.489
6)Met+(0.1897)Ile+(0.1580)Phe; 0.890, 0.916, 0.807, 0.794, 0.791,
0.854, 0.841, 0.820, (-1.8334)+(0.0536)Ser+(-0.3463)Met+(0.173
5)Ile+(-0.0820)Leu+(0.1380)Phe+(-0.1330)Trp; 0.890, 0.912, 0.7 85,
0.765, 0.749, 0.870, 0.849, 0.808, (-3.2110)+(0.0409)Ser+(0.0
284)Thr+(-0.0697)Val+(-0.5814)Met+(0.2181)Ile+(0.1512)Phe; 0. 890,
0.914, 0.791, 0.754, 0.794, 0.854, 0.836, 0.810, (-0.4856)+(0.
0659)Ser+(-0.1214)His+(-0.2902)Met+(0.0720)Ile+(0.1503)Phe+(-0.1121)Trp;
0.889, 0.910, 0.831, 0.819, 0.840, 0.854, 0.829, 0.83 5,
(2.1791)+(0.0103)Gln+(-0.1446)His+(0.0467)Thr+(-0.3603)Me
t+(0.1795)Phe+(-0.1251)Trp; 0.888, 0.909, 0.797, 0.783, 0.752, 0.
872, 0.876, 0.821, (-2.0528)+(0.0623)Ser+(-0.1191)Asn+(-0.067
1)Val+(-0.3897)Met+(0.2086)Ile+(0.1559)Phe; 0.887, 0.911, 0.79 4,
0.768, 0.802, 0.853, 0.801, 0.806, (0.2218)+(0.0663)Ser+(-0.11
76)His+(0.0128)Pro+(-0.2882)Met+(0.1713)Phe+(-0.1063)Trp; 0. 885,
0.906, 0.770, 0.736, 0.762, 0.850, 0.821, 0.792, (-2.1269)+(0.
0641)Ser+(-0.1326)His+(-0.3520)Met+(0.1518)Ile+(-0.0632)Leu
+(0.1622)Phe; 0.885, 0.904, 0.807, 0.790, 0.811, 0.859, 0.806, 0.81
6, (0.7826)+(0.0620)Ser+(-0.1170)His+(-0.2419)Met+(0.1752)Ph
e+(-0.1023)Trp; 0.885, 0.908, 0.812, 0.789, 0.821, 0.865, 0.815, 0.
822,
(0.6585)+(0.0637)Ser+(-0.1191)His+(0.0234)Tyr+(-0.2771)Met+(0.1715)Phe+(--
0.1085)Trp; 0.884, 0.906, 0.805, 0.777, 0.785, 0.883, 0.862, 0.827,
(2.1234)+(0.0509)Ser+(0.0590)Tyr+(-0.048
8)Val+(-0.3619)Met+(0.1995)Ile+(-0.1244)Trp; 0.884, 0.905, 0.8 10,
0.795, 0.815, 0.858, 0.807, 0.819, (1.0354)+(0.0642)Ser+(-0.0
298)Asn+(-0.1127)His+(-0.2223)Met+(0.1737)Phe+(-0.1009)Trp; 0.884,
0.909, 0.795, 0.777, 0.745, 0.877, 0.887, 0.821,
(-3.0328)+(0.0510)Ser+(-0.0050)Ala+(-0.0625)Val+(-0.4487)Met+(0.2107)Ile+-
(0.1401)Phe; 0.883, 0.907, 0.791, 0.769, 0.747, 0.865, 0.888, 0.
817, (-3.0576)+(0.0592)Ser+(-0.0056)Gly+(-0.0640)Val+(-0.478
3)Met+(0.2055)Ile+(0.1405)Phe; 0.882, 0.903, 0.805, 0.787, 0.810,
0.855, 0.804, 0.814, (0.7088)+(0.0622)Ser+(-0.1177)His+(0.000
9)Ala+(-0.2474)Met+(0.1748)Phe+(-0.1026)Trp; 0.882, 0.906, 0.8 04,
0.785, 0.812, 0.858, 0.803, 0.814, (0.7718)+(0.0609)Ser+(-0.1
195)His+(-0.2422)Met+(0.0111)Orn+(0.1700)Phe+(-0.1017)Trp; 0. 882,
0.905, 0.799, 0.771, 0.809, 0.852, 0.813, 0.811, (0.5016)+(0.0
636)Ser+(-0.1239)His+(-0.2582)Met+(0.0196)Leu+(0.1610)Phe+(-0.1091)Trp;
0.881, 0.904, 0.787, 0.767, 0.743, 0.868, 0.870, 0.81 2,
(-3.2208)+(0.0511)Ser+(-0.0642)Val+(-0.4837)Met+(0.2047)I
le+(0.1423)Phe; 0.881, 0.904, 0.802, 0.772, 0.819, 0.829, 0.825, 0.
811,
(4.6013)+(-0.1241)His+(0.0491)Thr+(-0.3361)Met+(0.0575)Ile+(0.1484)Phe+(--
0.1339)Trp; 0.881, 0.904, 0.805, 0.787, 0.811, 0.852, 0.806, 0.814,
(0.5622)+(0.0605)Ser+(-0.1208)His+(-0.262
7)Met+(0.0083)Lys+(0.1749)Phe+(-0.1088)Trp; 0.881, 0.906, 0.79 0,
0.769, 0.755, 0.871, 0.860, 0.814, (-2.7772)+(0.0534)Ser+(-0.0
583)Cit+(-0.0611)Val+(-0.4725)Met+(0.2025)Ile+(0.1483)Phe; 0. 881,
0.903, 0.805, 0.784, 0.812, 0.856, 0.807, 0.815, (0.7259)+(0.0
625)Ser+(-0.1217)His+(0.0048)Val+(-0.2448)Met+(0.1692)Phe+(-0.1064)Trp;
0.881, 0.902, 0.798, 0.784, 0.760, 0.859, 0.869, 0.81 8,
(1.4747)+(-0.0872)Asn+(0.0451)Thr+(-0.0745)Val+(-0.4746)M
et+(0.2248)Ile+(0.1468)Phe; 0.880, 0.904, 0.810, 0.792, 0.812, 0.
857, 0.817, 0.819,
(0.8210)+(0.0648)Ser+(-0.0022)Gly+(-0.1140)His+(-0.2398)Met+(0.1738)Phe+(-
-0.1039)Trp; 0.880, 0.905, 0.809, 0.792, 0.817, 0.858, 0.800,
0.817, (0.8548)+(0.0627)Ser+(-0.103
0)His+(-0.0434)Cit+(-0.2268)Met+(0.1810)Phe+(-0.1120)Trp; 0. 880,
0.902, 0.804, 0.783, 0.783, 0.880, 0.849, 0.824, (3.5594)+(0.0
437)Ser+(-0.0504)Cit+(-0.0373)Val+(-0.2208)Met+(0.1758)Ile+(-0.1170)Trp;
0.880, 0.901, 0.798, 0.783, 0.774, 0.878, 0.833, 0.81 7,
(3.5083)+(0.0341)Ser+(0.0217)Thr+(-0.0447)Val+(-0.3282)Me
t+(0.1883)Ile+(-0.1110)Trp; 0.880, 0.900, 0.831, 0.825, 0.800, 0.
853, 0.898, 0.844,
(1.6131)+(0.0057)Gln+(-0.0525)Val+(-0.3431)Met+(0.1808)Ile+(0.1304)Phe+(--
0.1173)Trp; 0.880, 0.904, 0.789, 0.773, 0.750, 0.855, 0.866, 0.811,
(1.3300)+(0.0530)Ser+(-0.178
7)Asn+(-0.0502)Val+(0.1586)Ile+(0.1013)Phe+(-0.1205)Trp; 0.8 79,
0.903, 0.784, 0.768, 0.742, 0.863, 0.861, 0.808, (-3.3275)+(0.0
510)Ser+(-0.0566)Val+(-0.4745)Met+(0.2287)Ile+(-0.0295)Leu+(0.1461)Phe;
0.879, 0.906, 0.789, 0.765, 0.751, 0.871, 0.874, 0.815,
(-3.4771)+(0.0531)Ser+(0.0228)Tyr+(-0.0672)Val+(-0.5232)Met
+(0.2117)Ile+(0.1378)Phe; 0.878, 0.897, 0.812, 0.796, 0.830, 0.83
2, 0.800, 0.815, (5.1467)+(-0.1179)His+(0.0505)Thr+(-0.3103)Me
t+(0.1690)Phe+(-0.1253)Trp; 0.878, 0.903, 0.801, 0.777, 0.813, 0.
835, 0.817, 0.811, (-1.3020)+(0.0581)Ser+(-0.0917)Cit+(-0.311
8)Met+(0.0708)Ile+(0.1355)Phe+(-0.1702)Trp; 0.878, 0.905, 0.78 2,
0.763, 0.741, 0.862, 0.860, 0.807, (-3.2369)+(0.0521)Ser+(0.00
53)Pro+(-0.0643)Val+(-0.4981)Met+(0.1980)Ile+(0.1419)Phe; 0. 878,
0.904, 0.807, 0.792, 0.812, 0.857, 0.802, 0.816, (0.8772)+(0.0
632)Ser+(-0.1150)His+(-0.0075)Arg+(-0.2326)Met+(0.1756)Phe+(-0.1014)Trp;
0.878, 0.898, 0.758, 0.725, 0.747, 0.823, 0.821, 0.77 9,
(1.1231)+(0.0472)Ser+(-0.1274)His+(0.1065)Ile+(-0.0390)Le
u+(0.1044)Phe+(-0.1281)Trp; 0.877, 0.903, 0.807, 0.797, 0.795, 0.
855, 0.824, 0.818, (1.0488)+(0.0524)Ser+(-0.1170)Asn+(0.0077)G
ln+(-0.1332)His+(0.1277)Phe+(-0.1078)Trp; 0.877, 0.900, 0.754,
0.707, 0.768, 0.840, 0.783, 0.775, (-1.3972)+(0.0567)Ser+(-0.169
9)His+(0.0295)Thr+(-0.4330)Met+(0.0672)Ile+(0.1506)Phe; 0.87 7,
0.904, 0.782, 0.761, 0.740, 0.865, 0.866, 0.808, (-2.9436)+(0.05
28)Ser+(-0.0012)Gln+(-0.0642)Val+(-0.4767)Met+(0.2056)Ile+(0.1425)Phe;
0.877, 0.900, 0.812, 0.798, 0.791, 0.876, 0.848, 0.828,
(6.5712)+(0.0336)Thr+(-0.0519)Cit+(-0.0438)Val+(-0.2732)Met
+(0.1832)Ile+(-0.1144)Trp; 0.877, 0.903, 0.819, 0.801, 0.795, 0.8
49, 0.894, 0.835,
(4.9139)+(-0.0543)His+(-0.0452)Val+(-0.2526)Met+(0.1687)Ile+(0.1312)Phe+(-
-0.0958)Trp; 0.877, 0.900, 0.797, 0.784, 0.755, 0.863, 0.875,
0.819, (0.3843)+(0.0393)Thr+(-0.004
2)Ala+(-0.0697)Val+(-0.5055)Met+(0.2222)Ile+(0.1346)Phe; 0.8 77,
0.899, 0.803, 0.787, 0.768, 0.879, 0.865, 0.824, (3.2446)+(0.04
17)Ser+(-0.0046)Ala+(-0.0407)Val+(-0.2260)Met+(0.1885)Ile+(-0.1079)Trp;
0.877, 0.896, 0.806, 0.783, 0.828, 0.827, 0.804, 0.81 1,
(5.1385)+(-0.1262)His+(0.0512)Thr+(-0.3199)Met+(0.0154)Le
u+(0.1582)Phe+(-0.1315)Trp; 0.877, 0.895, 0.811, 0.802, 0.778, 0.
873, 0.862, 0.828,
(6.3171)+(0.0318)Thr+(-0.0048)Ala+(-0.0466)Val+(-0.2706)Met+(0.1948)Ile+(-
-0.1108)Trp; 0.877, 0.901, 0.770, 0.737, 0.753, 0.844, 0.841,
0.794, (1.5645)+(0.0502)Ser+(-0.133
1)His+(-0.0071)Ala+(0.0682)Ile+(0.1022)Phe+(-0.1303)Trp; 0.8 77,
0.904, 0.787, 0.767, 0.744, 0.867, 0.870, 0.812, (-3.2265)+(0.0
513)Ser+(-0.0640)Val+(-0.4840)Met+(-0.0021)Orn+(0.2050)Ile+(0.1430)Phe;
0.876, 0.899, 0.796, 0.776, 0.772, 0.871, 0.847, 0.817,
(3.1391)+(0.0431)Ser+(0.0063)Pro+(-0.0420)Val+(-0.2707)Met+(0.1750)Ile+(--
0.1119)Trp; 0.876, 0.896, 0.800, 0.782, 0.782, 0.85 9, 0.843,
0.817, (7.1237)+(-0.0566)His+(0.0346)Thr+(-0.0375)Va
l+(-0.2613)Met+(0.1722)Ile+(-0.0947)Trp; 0.876, 0.900, 0.789, 0.
772, 0.802, 0.820, 0.788, 0.796, (-1.7780)+(0.0469)Ser+(0.0220)T
hr+(-0.4185)Met+(0.0601)Ile+(0.1200)Phe+(-0.1623)Trp; 0.876, 0.900,
0.814, 0.814, 0.828, 0.840, 0.768, 0.812,
(0.3731)+(0.0463)Ser+(-0.0799)Asn+(0.0272)Thr+(-0.3209)Met+(0.1461)Phe+(--
0.1 531)Trp; 0.876, 0.898, 0.813, 0.799, 0.830, 0.833, 0.801,
0.816, (5.
1380)+(-0.1164)His+(0.0508)Thr+(-0.0016)Val+(-0.3109)Met+(0.
1713)Phe+(-0.1240)Trp; 0.876, 0.898, 0.781, 0.748, 0.787, 0.859, 0.
796, 0.798, (4.0210)+(0.0445)Ser+(-0.1021)His+(0.0220)Thr+(-0.
2402)Met+(0.0941)Ile+(-0.1075)Trp; 0.876, 0.898, 0.804, 0.786, 0.
774, 0.882, 0.856, 0.824, (3.7945)+(0.0469)Ser+(-0.0611)Asn+(-0.
0421)Val+(-0.2051)Met+(0.1806)Ile+(-0.1024)Trp; 0.876, 0.899,
0.803, 0.783, 0.772, 0.871, 0.868, 0.824,
(3.1847)+(0.0513)Ser+(-0.0059)Gly+(-0.0407)Val+(-0.2496)Met+(0.1795)Ile+(-
-0.1110)T rp; 0.876, 0.898, 0.815, 0.806, 0.785, 0.847, 0.882,
0.830, (3.0411)
+(0.0040)Gly+(-0.0542)Val+(-0.3097)Met+(0.1869)Ile+(0.1305)Phe+(-
-0.1123)Trp; 0.876, 0.899, 0.777, 0.739, 0.777, 0.852, 0.825,
0.798, (-3.0222)+(0.0578)Ser+(0.0068)Gln+(-0.1683)His+(-0.36
16)Met+(0.0626)Ile+(0.1415)Phe; 0.876, 0.900, 0.792, 0.772, 0.76 5,
0.863, 0.851, 0.813, (0.6553)+(0.0436)Thr+(-0.0620)Cit+(-0.0
694)Val+(-0.5305)Met+(0.2201)Ile+(0.1426)Phe; 0.875, 0.898, 0. 808,
0.802, 0.833, 0.838, 0.750, 0.806, (0.0690)+(0.0437)Ser+(0.0
320)Thr+(-0.0895)Cit+(-0.3650)Met+(0.1686)Phe+(-0.1704)Trp; 0.875,
0.896, 0.820, 0.810, 0.789, 0.844, 0.895, 0.835,
(3.7150)+(-0.0537)Val+(-0.2954)Met+(0.1852)Ile+(0.1259)Phe+(-0.1109)Tr
p; 0.875, 0.895, 0.789, 0.774, 0.751, 0.853, 0.860, 0.810,
(0.1159)+(0.0397)Thr+(-0.0717)Val+(-0.5387)Met+(0.2196)Ile+(0.1380)P
he; 0.875, 0.898, 0.810, 0.795, 0.828, 0.831, 0.799, 0.813,
(5.0416)
+(0.0077)Asn+(-0.1194)His+(0.0503)Thr+(-0.3161)Met+(0.1699)Phe+(-0.1255)T-
rp; 0.875, 0.899, 0.825, 0.817, 0.787, 0.854, 0.906, 0.841,
(3.9291)+(-0.0044)Ala+(-0.0534)Val+(-0.2665)Met+(0.19
20)Ile+(0.1248)Phe+(-0.1088)Trp; 0.875, 0.897, 0.794, 0.778, 0.7
63, 0.875, 0.845, 0.815, (4.6063)+(0.0465)Ser+(-0.1092)Asn+(-0.
0635)Cit+(-0.0374)Val+(0.1596)Ile+(-0.1266)Trp; 0.875, 0.899,
0.781, 0.761, 0.783, 0.844, 0.786, 0.793,
(2.7059)+(0.0543)Ser+(-0.1114)Asn+(-0.1258)His+(0.0185)Thr+(0.1304)Phe+(--
0.1179)Tr p; 0.875, 0.903, 0.785, 0.768, 0.746, 0.863, 0.855,
0.808, (-3.1220)
+(0.0548)Ser+(-0.0162)Arg+(-0.0640)Val+(-0.4578)Met+(0.205
3)Ile+(0.1464)Phe; 0.875, 0.898, 0.806, 0.793, 0.824, 0.832, 0.786,
0.809, (4.7360)+(0.0034)Gly+(-0.1236)His+(0.0487)Thr+(-0.315
1)Met+(0.1724)Phe+(-0.1208)Trp; 0.875, 0.904, 0.786, 0.767, 0.74 3,
0.868, 0.870, 0.812, (-3.2133)+(0.0512)Ser+(-0.0641)Val+(-0.
4828)Met+(-0.0003)Lys+(0.2046)Ile+(0.1423)Phe; 0.875, 0.895, 0.
798, 0.781, 0.770, 0.873, 0.849, 0.818, (3.1269)+(0.0422)Ser+(-0.
0412)Val+(-0.2543)Met+(0.1807)Ile+(-0.1110)Trp; 0.875, 0.895,
0.792, 0.776, 0.753, 0.867, 0.864, 0.815,
(3.8125)+(0.0350)Ser+(-0.0086)Ala+(-0.0759)Cit+(-0.0342)Val+(0.1732)Ile+(-
-0.1444)T rp; 0.875, 0.898, 0.808, 0.792, 0.825, 0.827, 0.799,
0.811, (5.0167)
+(-0.1163)His+(0.0493)Thr+(0.0042)Pro+(-0.3173)Met+(0.1656)Phe+(-
-0.1257)Trp; 0.874, 0.892, 0.811, 0.795, 0.789, 0.870, 0.856,
0.827, (5.8798)+(0.0306)Thr+(0.0275)Tyr+(-0.0494)Val+(-0.331
2)Met+(0.1907)Ile+(-0.1191)Trp; 0.874, 0.898, 0.811, 0.797, 0.82 9,
0.831, 0.799, 0.814, (5.1472)+(-0.1179)His+(0.0507)Thr+(-0.0
017)Tyr+(-0.3085)Met+(0.1695)Phe+(-0.1249)Trp; 0.874, 0.898, 0.
788, 0.761, 0.770, 0.865, 0.842, 0.810, (3.8623)+(0.0473)Ser+(-0.
0629)His+(-0.0301)Val+(-0.2091)Met+(0.1648)Ile+(-0.0919)Tr p;
0.874, 0.898, 0.792, 0.790, 0.806, 0.814, 0.751, 0.790, (-1.0344)
+(0.0456)Ser+(0.0230)Thr+(0.0098)Pro+(-0.4138)Met+(0.1413)P
he+(-0.1577)Trp; 0.874, 0.895, 0.788, 0.774, 0.751, 0.854, 0.859,
0. 809, (0.0531)+(0.0005)Gly+(0.0394)Thr+(-0.0716)Val+(-0.5394)
Met+(0.2193)Ile+(0.1383)Phe; 0.874, 0.897, 0.812, 0.798, 0.830, 0.
831, 0.801, 0.815,
(5.1552)+(-0.1177)His+(0.0509)Thr+(-0.3113)Met+(-0.0016)Orn+(0.1700)Phe+(-
-0.1256)Trp; 0.874, 0.896, 0.754, 0.722, 0.735, 0.823, 0.828,
0.777, (1.3999)+(0.0456)Ser+(-0.118
7)His+(-0.0254)Val+(0.1124)Ile+(0.1002)Phe+(-0.1271)Trp; 0.8 74,
0.895, 0.768, 0.727, 0.765, 0.852, 0.820, 0.791, (-1.5196)+(0.0
660)Ser+(-0.1481)His+(-0.0042)Ala+(-0.3256)Met+(0.0732)Ile+(0.1382)Phe;
0.873, 0.897, 0.812, 0.814, 0.827, 0.835, 0.756, 0.808,
(-0.1619)+(0.0395)Ser+(0.0286)Thr+(-0.0081)Val+(-0.3801)Met
+(0.1583)Phe+(-0.1520)Trp; 0.873, 0.895, 0.802, 0.787, 0.773, 0.8
76, 0.850, 0.821, (3.6154)+(0.0371)Ser+(-0.0090)Ala+(-0.0871)C
it+(0.1770)Ile+(-0.0599)Leu+(-0.1475)Trp; 0.873, 0.897, 0.812,
0.798, 0.829, 0.832, 0.800, 0.815, (5.1575)+(-0.1177)His+(0.050
5)Thr+(-0.0002)Ala+(-0.3093)Met+(0.1691)Phe+(-0.1253)Trp; 0. 873,
0.896, 0.799, 0.783, 0.771, 0.872, 0.851, 0.819, (3.0224)+(0.0
410)Ser+(-0.0428)Val+(-0.2747)Met+(0.0061)Lys+(0.1815)Ile+(-0.1138)Trp;
0.873, 0.891, 0.804, 0.793, 0.778, 0.865, 0.845, 0.82 0,
(6.1068)+(0.0314)Thr+(-0.0472)Val+(-0.2968)Met+(0.1870)Il
e+(-0.1123)Trp; 0.873, 0.897, 0.810, 0.795, 0.829, 0.825, 0.801, 0.
812,
(4.9661)+(-0.1202)His+(0.0488)Thr+(-0.3182)Met+(0.0049)Lys+(0.1679)Phe+(--
0.1273)Trp; 0.873, 0.896, 0.821, 0.812, 0.790, 0.844, 0.896, 0.836,
(3.8662)+(-0.0081)Asn+(-0.0538)Val+(-0.28
81)Met+(0.1849)Ile+(0.1257)Phe+(-0.1096)Trp; 0.873, 0.897, 0.8 11,
0.799, 0.833, 0.830, 0.787, 0.812, (5.5816)+(-0.1144)His+(0.0
550)Thr+(-0.0157)Arg+(-0.3019)Met+(0.1705)Phe+(-0.1270)Trp; 0.873,
0.896, 0.801, 0.784, 0.773, 0.874, 0.851, 0.821, (2.9282)+(0.
0409)Ser+(0.0009)Gln+(-0.0410)Val+(-0.2589)Met+(0.1794)Ile+(-0.1121)Trp;
0.873, 0.898, 0.818, 0.808, 0.788, 0.842, 0.891, 0.83 2,
(3.7193)+(0.0050)Pro+(-0.0540)Val+(-0.3080)Met+(0.1806)Il
e+(0.1269)Phe+(-0.1125)Trp; 0.873, 0.900, 0.837, 0.818, 0.833, 0.
859, 0.882, 0.848,
(2.0349)+(0.0121)Gln+(-0.1284)His+(-0.2378)Met+(0.0584)Ile+(0.1200)Phe+(--
0.1165)Trp; 0.873, 0.894, 0.802, 0.801, 0.821, 0.824, 0.749, 0.799,
(-0.5508)+(0.0412)Ser+(0.025
5)Thr+(-0.3787)Met+(0.1449)Phe+(-0.1587)Trp; 0.873, 0.894, 0.7 96,
0.777, 0.771, 0.871, 0.843, 0.816, (3.1019)+(0.0405)Ser+(-0.0
430)Val+(-0.2624)Met+(0.0147)Orn+(0.1798)Ile+(-0.1110)Trp; 0. 873,
0.898, 0.769, 0.735, 0.765, 0.837, 0.822, 0.790, (1.7038)+(0.0
588)Ser+(-0.0844)Asn+(-0.1247)His+(0.0537)Ile+(0.1038)Phe+(-0.1227)Trp;
0.872, 0.895, 0.789, 0.774, 0.751, 0.853, 0.860, 0.80 9,
(0.1187)+(0.0392)Thr+(-0.0702)Val+(-0.5356)Met+(0.2227)Il
e+(-0.0048)Leu+(0.1384)Phe; 0.872, 0.897, 0.808, 0.807, 0.808, 0.
826, 0.795, 0.809,
(-0.3872)+(0.0586)Ser+(-0.0695)Asn+(0.0110)Pro+(-0.2845)Met+(0.1316)Phe+(-
-0.1409)Trp
[0458] List (1) of Linear Discriminants Searched in Example 2
[0459] The linear discriminants searched in Example 2 above are
listed below. Before each equation, "the value of ROC_AUC for the
pancreatic cancer group and the healthy group with validation",
"the value of ROC_AUC for the pancreatic cancer group and the
healthy group without validation", "the value of ROC_AUC for the
pancreatic cancer group and the other cancers group", "the value of
ROC_AUC for the pancreatic cancer group and the lung cancer group",
"the value of ROC_AUC for the pancreatic cancer group and the
colorectal cancer group", "the value of ROC_AUC for the pancreatic
cancer group and the prostatic cancer group", "the value of ROC_AUC
for the pancreatic cancer group and the breast cancer group", and
"the average value of the value of ROC_AUC for the pancreatic
cancer group and the lung cancer group, the value of ROC_AUC for
the pancreatic cancer group and the colorectal cancer group, the
value of ROC_AUC for the pancreatic cancer group and the prostatic
cancer group, and the value of ROC_AUC for the pancreatic cancer
group and the breast cancer group" obtained for the equation are
additionally listed.
[0460] 0.912, 0.926, 0.816, 0.798, 0.795, 0.864, 0.874, 0.833,
(-1.02 07)+(0.0564)Ser+(-0.0410)Val+(-0.4144)Met+(0.1407)Ile+(0.17
86)Phe+(-0.1154)Trp; 0.910, 0.923, 0.800, 0.780, 0.816, 0.856, 0.7
76, 0.807, (1.2502)+(0.0519)Ser+(-0.1044)His+(0.0391)Thr+(-0.
3808)Met+(0.2058)Phe+(-0.1332)Trp; 0.906, 0.919, 0.815, 0.803, 0.
802, 0.853, 0.847, 0.826, (2.7689)+(0.0555)Thr+(-0.0511)Val+(-0.
5140)Met+(0.1555)Ile+(0.1792)Phe+(-0.1223)Trp; 0.904, 0.920, 0.
812, 0.798, 0.800, 0.846, 0.847, 0.823, (-1.2604)+(0.0530)Ser+(-0.
3551)Met+(0.1373)Ile+(-0.0676)Leu+(0.1759)Phe+(-0.1399)Trp; 0.903,
0.919, 0.782, 0.749, 0.760, 0.870, 0.853, 0.808,
(-1.6453)+(0.0604)Ser+(-0.0790)His+(-0.0373)Val+(-0.4011)Met+(0.1385)
Ile+(0.1636)Phe; 0.902, 0.918, 0.796, 0.762, 0.801, 0.856, 0.831,
0. 813, (-0.1304)+(0.0660)Ser+(-0.0940)His+(-0.3073)Met+(0.054
3)Ile+(0.1677)Phe+(-0.1190)Trp; 0.901, 0.917, 0.781, 0.760, 0.75 3,
0.860, 0.839, 0.803, (-2.7861)+(0.0400)Ser+(0.0326)Thr+(-0.0
608)Val+(-0.5850)Met+(0.1830)Ile+(0.1702)Phe; 0.900, 0.914, 0. 824,
0.813, 0.821, 0.868, 0.828, 0.833, (-0.3399)+(0.0555)Ser+(0.
0065)Gln+(-0.0993)His+(-0.2838)Met+(0.1822)Phe+(-0.1212)Tr p;
0.898, 0.912, 0.789, 0.763, 0.776, 0.851, 0.839, 0.807,
(2.3150)+(-0.0751)His+(0.0555)Thr+(-0.0488)Val+(-0.4979)Met+(0.1558)
Ile+(0.1591)Phe; 0.897, 0.911, 0.828, 0.820, 0.837, 0.842, 0.822,
0. 830, (2.6477)+(0.0093)Gln+(-0.1101)His+(0.0480)Thr+(-0.3592)
Met+(0.1701)Phe+(-0.1325)Trp; 0.896, 0.909, 0.814, 0.800, 0.818,
0.858, 0.809, 0.821, (1.4707)+(0.0650)Ser+(-0.0399)Asn+(-0.082
8)His+(-0.2276)Met+(0.1831)Phe+(-0.1217)Trp; 0.895, 0.908, 0.8 07,
0.791, 0.813, 0.856, 0.804, 0.816, (1.0068)+(0.0630)Ser+(-0.0
875)His+(-0.2579)Met+(0.1830)Phe+(-0.1207)Trp; 0.895, 0.911, 0.
813, 0.791, 0.824, 0.864, 0.814, 0.823, (0.7601)+(0.0642)Ser+(-0.
0885)His+(0.0236)Tyr+(-0.2880)Met+(0.1795)Phe+(-0.1278)Trp; 0.895,
0.911, 0.812, 0.801, 0.783, 0.855, 0.870, 0.827, (2.8531)+(0.
0444)Ser+(-0.1615)Asn+(-0.0336)Val+(0.0949)Ile+(0.1195)Phe+(-0.1303)Trp;
0.895, 0.910, 0.798, 0.781, 0.751, 0.878, 0.886, 0.82 4,
(-2.2067)+(0.0513)Ser+(-0.0059)Ala+(-0.0514)Val+(-0.4276)
Met+(0.1741)Ile+(0.1473)Phe; 0.895, 0.911, 0.801, 0.780, 0.808, 0.
853, 0.805, 0.812, (0.6315)+(0.0639)Ser+(-0.0888)His+(0.0082)P
ro+(-0.2857)Met+(0.1818)Phe+(-0.1202)Trp; 0.894, 0.912, 0.798,
0.783, 0.758, 0.867, 0.869, 0.819, (-1.5328)+(0.0563)Ser+(-0.081
8)Asn+(-0.0541)Val+(-0.3937)Met+(0.1667)Ile+(0.1569)Phe; 0.8 94,
0.909, 0.811, 0.796, 0.817, 0.858, 0.802, 0.818, (1.1779)+(0.06
34)Ser+(-0.0818)His+(-0.0228)Cit+(-0.2535)Met+(0.1837)Phe+(-0.1223)Trp;
0.894, 0.908, 0.808, 0.792, 0.813, 0.856, 0.804, 0.81 6,
(1.0402)+(0.0632)Ser+(-0.0871)His+(-0.2558)Met+(-0.0009)L
ys+(0.1834)Phe+(-0.1204)Trp; 0.893, 0.908, 0.806, 0.789, 0.813, 0.
852, 0.800, 0.814, (0.9480)+(0.0631)Ser+(-0.0881)His+(0.0006)A
la+(-0.2617)Met+(0.1834)Phe+(-0.1213)Trp; 0.893, 0.909, 0.800,
0.777, 0.808, 0.853, 0.807, 0.811, (0.7256)+(0.0651)Ser+(-0.095
2)His+(-0.2689)Met+(0.0129)Leu+(0.1735)Phe+(-0.1209)Trp; 0.8 93,
0.908, 0.806, 0.788, 0.813, 0.856, 0.804, 0.815, (0.9375)+(0.06
34)Ser+(-0.0899)His+(0.0018)Val+(-0.2577)Met+(0.1809)Phe+(-0.1216)Trp;
0.893, 0.908, 0.811, 0.795, 0.815, 0.855, 0.815, 0.820,
(1.1251)+(0.0658)Ser+(-0.0023)Gly+(-0.0856)His+(-0.2575)Met
+(0.1816)Phe+(-0.1211)Trp; 0.892, 0.909, 0.791, 0.767, 0.752, 0.8
60, 0.887, 0.816, (-2.4043)+(0.0586)Ser+(-0.0057)Gly+(-0.0530)
Val+(-0.4602)Met+(0.1686)Ile+(0.1487)Phe; 0.892, 0.908, 0.815,
0.804, 0.804, 0.854, 0.838, 0.825, (2.1627)+(0.0471)Ser+(-0.116
8)Asn+(0.0059)Gln+(-0.0954)His+(0.1334)Phe+(-0.1287)Trp; 0.8 92,
0.907, 0.784, 0.762, 0.748, 0.860, 0.860, 0.807, (-2.7343)+(0.0
512)Ser+(-0.0535)Val+(-0.4634)Met+(0.1686)Ile+(0.1515)Phe; 0. 892,
0.908, 0.784, 0.764, 0.748, 0.860, 0.857, 0.807, (-2.7747)+(0.
0506)Ser+(-0.0498)Val+(-0.4593)Met+(0.1763)Ile+(-0.0120)Leu
+(0.1538)Phe; 0.892, 0.908, 0.808, 0.793, 0.814, 0.856, 0.801, 0.81
6, (1.0417)+(0.0637)Ser+(-0.0871)His+(-0.0031)Arg+(-0.2535)M
et+(0.1829)Phe+(-0.1201)Trp; 0.891, 0.909, 0.805, 0.788, 0.811, 0.
856, 0.802, 0.814,
(0.8987)+(0.0622)Ser+(-0.0896)His+(-0.2581)Met+(0.0100)Orn+(0.1790)Phe+(--
0.1200)Trp; 0.890, 0.908, 0.781, 0.760, 0.746, 0.858, 0.858, 0.805,
(-2.7988)+(0.0513)Ser+(0.002
3)Pro+(-0.0534)Val+(-0.4692)Met+(0.1662)Ile+(0.1516)Phe; 0.8 89,
0.908, 0.785, 0.761, 0.753, 0.863, 0.857, 0.809, (-2.4869)+(0.0
531)Ser+(-0.0401)Cit+(-0.0510)Val+(-0.4534)Met+(0.1694)Ile+(0.1506)Phe;
0.889, 0.909, 0.785, 0.760, 0.752, 0.865, 0.865, 0.810,
(-2.9300)+(0.0517)Ser+(0.0129)Tyr+(-0.0546)Val+(-0.4830)Met
+(0.1714)Ile+(0.1491)Phe; 0.888, 0.906, 0.780, 0.758, 0.745, 0.85
8, 0.859, 0.805, (-2.4649)+(0.0528)Ser+(-0.0012)Gln+(-0.0535)V
al+(-0.4582)Met+(0.1693)Ile+(0.1524)Phe; 0.888, 0.906, 0.785, 0.
765, 0.747, 0.859, 0.862, 0.808,
(-2.7176)+(0.0518)Ser+(-0.0532)Val+(-0.4646)Met+(-0.0055)Orn+(0.1704)Ile+-
(0.1529)Phe; 0.888, 0.903, 0.799, 0.788, 0.760, 0.864, 0.864,
0.819,
(1.2361)+(0.0468)Thr+(-0.0057)Ala+(-0.0605)Val+(-0.5055)Met+(0.1871)Ile+(-
0.1 435)Phe; 0.887, 0.903, 0.799, 0.785, 0.770, 0.856, 0.854,
0.816, (2.
0233)+(-0.0687)Asn+(0.0503)Thr+(-0.0636)Val+(-0.4866)Met+(0.
1810)Ile+(0.1515)Phe; 0.887, 0.903, 0.810, 0.804, 0.789, 0.834, 0.
849, 0.819, (2.1560)+(0.0423)Ser+(-0.1386)Asn+(0.1029)Ile+(-0.
0610)Leu+(0.1253)Phe+(-0.1484)Trp; 0.887, 0.904, 0.814, 0.790, 0.
798, 0.885, 0.861, 0.834, (3.2556)+(0.0393)Ser+(0.0476)Tyr+(-0.
0321)Val+(-0.3074)Met+(0.1395)Ile+(-0.0999)Trp; 0.887, 0.905,
0.802, 0.781, 0.813, 0.833, 0.812, 0.810,
(-0.7602)+(0.0589)Ser+(-0.0644)Cit+(-0.3340)Met+(0.0567)Ile+(0.1461)Phe+(-
-0.1536)Trp; 0.887, 0.904, 0.766, 0.728, 0.761, 0.848, 0.817,
0.788, (-1.862
9)+(0.0597)Ser+(-0.1027)His+(-0.3399)Met+(0.1177)Ile+(-0.04
70)Leu+(0.1542)Phe; 0.887, 0.907, 0.784, 0.763, 0.750, 0.861, 0.85
5, 0.807, (-2.5250)+(0.0533)Ser+(-0.0519)Val+(-0.4475)Met+(-0.
0066)Lys+(0.1685)Ile+(0.1528)Phe; 0.887, 0.903, 0.795, 0.767, 0.
815, 0.822, 0.807, 0.803, (4.6094)+(-0.0974)His+(0.0547)Thr+(-0.
3593)Met+(0.0451)Ile+(0.1510)Phe+(-0.1313)Trp; 0.887, 0.901, 0.
806, 0.803, 0.819, 0.831, 0.769, 0.806, (0.8909)+(0.0495)Ser+(-0.
0804)Asn+(0.0274)Thr+(-0.3250)Met+(0.1731)Phe+(-0.1660)Trp; 0.887,
0.902, 0.804, 0.791, 0.784, 0.886, 0.823, 0.821, (4.4196)+(0.
0274)Ser+(0.0224)Thr+(-0.0324)Val+(-0.3009)Met+(0.1397)Ile+(-0.0907)Trp;
0.886, 0.905, 0.844, 0.843, 0.816, 0.856, 0.897, 0.85 3,
(2.0355)+(0.0066)Gln+(-0.0397)Val+(-0.3168)Met+(0.1284)Il
e+(0.1311)Phe+(-0.1090)Trp; 0.886, 0.900, 0.804, 0.806, 0.818, 0.
825, 0.758, 0.802, (0.4259)+(0.0430)Ser+(0.0297)Thr+(-0.0105)V
al+(-0.3931)Met+(0.1880)Phe+(-0.1582)Trp; 0.886, 0.899, 0.796,
0.778, 0.794, 0.846, 0.812, 0.808, (3.1351)+(0.0540)Ser+(-0.100
2)Asn+(-0.0861)His+(0.1369)Phe+(-0.1276)Trp; 0.886, 0.902, 0.8 09,
0.789, 0.793, 0.883, 0.841, 0.827, (4.2488)+(0.0388)Ser+(-0.0
459)Cit+(-0.0260)Val+(-0.2229)Met+(0.1326)Ile+(-0.0884)Trp; 0.885,
0.901, 0.787, 0.767, 0.767, 0.855, 0.831, 0.805, (1.0928)+(0.
0508)Thr+(-0.0475)Cit+(-0.0603)Val+(-0.5411)Met+(0.1843)Ile
+(0.1481)Phe; 0.885, 0.902, 0.803, 0.795, 0.827, 0.833, 0.749, 0.80
1, (0.5012)+(0.0459)Ser+(0.0317)Thr+(-0.0619)Cit+(-0.3861)Me
t+(0.1783)Phe+(-0.1682)Trp; 0.885, 0.903, 0.778, 0.748, 0.758, 0.
852, 0.842, 0.800,
(2.1169)+(0.0446)Ser+(-0.1004)His+(-0.0073)Ala+(0.0451)Ile+(0.1020)Phe+(--
0.1174)Trp; 0.885, 0.898, 0.786, 0.772, 0.756, 0.849, 0.842, 0.805,
(0.7111)+(0.0469)Thr+(-0.062
5)Val+(-0.5409)Met+(0.1818)Ile+(0.1477)Phe; 0.885, 0.905, 0.78 3,
0.764, 0.750, 0.858, 0.849, 0.805, (-2.5667)+(0.0542)Ser+(-0.0
117)Arg+(-0.0530)Val+(-0.4456)Met+(0.1685)Ile+(0.1517)Phe; 0. 885,
0.902, 0.793, 0.775, 0.794, 0.844, 0.803, 0.804, (3.5394)+(0.0
482)Ser+(-0.1125)Asn+(-0.0924)His+(0.0136)Thr+(0.1363)Phe+(-0.1331)Trp;
0.885, 0.901, 0.813, 0.800, 0.800, 0.883, 0.826, 0.82 7,
(6.9234)+(0.0383)Thr+(-0.0519)Cit+(-0.0325)Val+(-0.2896)M
et+(0.1428)Ile+(-0.0934)Trp; 0.885, 0.902, 0.787, 0.769, 0.803, 0.
816, 0.782, 0.793, (-1.1723)+(0.0475)Ser+(0.0242)Thr+(-0.4228)
Met+(0.0442)Ile+(0.1547)Phe+(-0.1668)Trp; 0.885, 0.900, 0.788,
0.782, 0.805, 0.809, 0.754, 0.788, (-0.4771)+(0.0461)Ser+(0.024
5)Thr+(0.0063)Pro+(-0.4030)Met+(0.1676)Phe+(-0.1663)Trp; 0.8 84,
0.898, 0.786, 0.772, 0.756, 0.850, 0.842, 0.805, (0.7556)+(-0.0
003)Gly+(0.0471)Thr+(-0.0625)Val+(-0.5408)Met+(0.1819)Ile+(0.1475)Phe;
0.884, 0.901, 0.762, 0.726, 0.760, 0.832, 0.808, 0.782,
(2.0817)+(0.0488)Ser+(-0.1010)His+(-0.0148)Lys+(0.0398)Ile+(0.1108)Phe+(--
0.1212)Trp; 0.884, 0.901, 0.786, 0.772, 0.761, 0.84 9, 0.828,
0.803, (1.1646)+(0.0531)Thr+(-0.0168)Arg+(-0.0631)Va
l+(-0.5324)Met+(0.1839)Ile+(0.1497)Phe; 0.884, 0.900, 0.785, 0.
772, 0.756, 0.842, 0.843, 0.803, (0.8173)+(0.0536)Thr+(-0.0628)V
al+(-0.5701)Met+(-0.0240)Orn+(0.1923)Ile+(0.1576)Phe; 0.884, 0.900,
0.807, 0.800, 0.807, 0.814, 0.821, 0.811,
(2.6359)+(0.0383)Thr+(-0.3763)Met+(0.1339)Ile+(-0.0707)Leu+(0.1592)Phe+(--
0.1 470)Trp; 0.884, 0.901, 0.844, 0.832, 0.839, 0.854, 0.880,
0.851, (2.
0499)+(0.0118)Gln+(-0.0940)His+(-0.2274)Met+(0.0420)Ile+(0.
1165)Phe+(-0.1146)Trp; 0.884, 0.900, 0.765, 0.736, 0.756, 0.822, 0.
820, 0.783, (1.7752)+(0.0391)Ser+(-0.0937)His+(0.0719)Ile+(-0.
0325)Leu+(0.1113)Phe+(-0.1251)Trp; 0.884, 0.898, 0.804, 0.790, 0.
826, 0.817, 0.786, 0.805, (5.3455)+(-0.0929)His+(0.0545)Thr+(-0.
3233)Met+(0.1661)Phe+(-0.1329)Trp; 0.884, 0.899, 0.788, 0.775, 0.
757, 0.849, 0.843, 0.806, (0.4472)+(0.0008)Gln+(0.0460)Thr+(-0.
0623)Val+(-0.5433)Met+(0.1812)Ile+(0.1473)Phe; 0.883, 0.899, 0.
804, 0.789, 0.796, 0.857, 0.820, 0.816, (3.2583)+(0.0541)Ser+(-0.
0948)Asn+(-0.0836)His+(-0.0025)Ala+(0.1386)Phe+(-0.1244)Tr p;
0.883, 0.901, 0.784, 0.757, 0.780, 0.839, 0.824, 0.800,
(2.6411)+(0.0537)Ser+(-0.1017)Asn+(-0.0912)His+(0.0314)Ile+(0.1210)P
he+(-0.1273)Trp; 0.883, 0.900, 0.797, 0.782, 0.795, 0.846, 0.809,
0. 808, (3.2209)+(0.0557)Ser+(-0.0944)Asn+(-0.0840)His+(-0.005
5)Lys+(0.1410)Phe+(-0.1256)Trp; 0.883, 0.899, 0.798, 0.782, 0.79 4,
0.848, 0.812, 0.809, (3.1873)+(0.0539)Ser+(-0.1013)Asn+(-0.0
845)His+(-0.0011)Val+(0.1384)Phe+(-0.1271)Trp; 0.883, 0.899, 0.
814, 0.800, 0.780, 0.890, 0.869, 0.835, (4.1970)+(0.0368)Ser+(-0.
0056)Ala+(-0.0282)Val+(-0.2090)Met+(0.1393)Ile+(-0.0803)Tr p;
0.883, 0.898, 0.794, 0.776, 0.791, 0.844, 0.811, 0.806,
(3.0890)+(0.0538)Ser+(-0.1016)Asn+(-0.0866)His+(0.0020)Pro+(0.1351)P
he+(-0.1277)Trp; 0.883, 0.898, 0.798, 0.782, 0.819, 0.815, 0.786,
0. 800, (5.1658)+(-0.0933)His+(0.0540)Thr+(0.0051)Pro+(-0.3376)
Met+(0.1643)Phe+(-0.1324)Trp; 0.883, 0.900, 0.762, 0.729, 0.754,
0.826, 0.821, 0.782, (1.9680)+(0.0396)Ser+(-0.0956)His+(-0.012
3)Val+(0.0554)Ile+(0.1032)Phe+(-0.1204)Trp; 0.883, 0.898, 0.78 4,
0.757, 0.792, 0.862, 0.785, 0.799, (5.0116)+(0.0365)Ser+(-0.08
16)His+(0.0226)Thr+(-0.2202)Met+(0.0714)Ile+(-0.0924)Trp; 0. 883,
0.901, 0.792, 0.773, 0.791, 0.847, 0.806, 0.804, (3.0109)+(0.0
532)Ser+(-0.1029)Asn+(-0.0884)His+(0.0136)Orn+(0.1319)Phe+(-0.1267)Trp;
0.883, 0.900, 0.786, 0.770, 0.757, 0.851, 0.841, 0.80 5,
(1.0460)+(0.0493)Thr+(-0.0614)Val+(-0.5303)Met+(-0.0066)L
ys+(0.1825)Ile+(0.1493)Phe; 0.883, 0.903, 0.829, 0.818, 0.807, 0.
849, 0.892, 0.842, (5.0397)+(-0.0326)His+(-0.0343)Val+(-0.233
6)Met+(0.1210)Ile+(0.1267)Phe+(-0.0933)Trp; 0.882, 0.899, 0.78 5,
0.773, 0.754, 0.849, 0.837, 0.803, (0.7801)+(0.0474)Thr+(-0.00
75)Tyr+(-0.0620)Val+(-0.5326)Met+(0.1806)Ile+(0.1498)Phe; 0. 882,
0.898, 0.786, 0.772, 0.756, 0.849, 0.842, 0.805, (0.7094)+(0.0
469)Thr+(0.0001)Pro+(-0.0625)Val+(-0.5411)Met+(0.1817)Ile+(0.1477)Phe;
0.882, 0.899, 0.786, 0.771, 0.756, 0.849, 0.842, 0.805,
(0.7287)+(0.0475)Thr+(-0.0642)Val+(-0.5450)Met+(0.1789)Ile+(0.0050)Leu+(0-
.1471)Phe; 0.882, 0.899, 0.805, 0.789, 0.807, 0.829, 0.823, 0.812,
(-0.2954)+(0.0595)Ser+(-0.0653)Asn+(-0.2876)Met
+(0.0433)Ile+(0.1463)Phe+(-0.1537)Trp; 0.882, 0.900, 0.819, 0.8 14,
0.793, 0.847, 0.868, 0.830, (3.2539)+(0.0061)Gly+(-0.0409)Va
l+(-0.2897)Met+(0.1335)Ile+(0.1368)Phe+(-0.1032)Trp; 0.882, 0. 898,
0.798, 0.780, 0.795, 0.846, 0.817, 0.809, (3.2007)+(0.0557)Se
r+(-0.0993)Asn+(-0.0015)Gly+(-0.0850)His+(0.1359)Phe+(-0.12 79)Trp;
0.882, 0.900, 0.741, 0.695, 0.759, 0.833, 0.763, 0.762, (-1.
5427)+(0.0550)Ser+(-0.1392)His+(0.0297)Thr+(-0.4182)Met+(0.
0553)Ile+(0.1512)Phe; 0.882, 0.895, 0.805, 0.788, 0.782, 0.876, 0.
844, 0.823, (3.9518)+(0.0364)Ser+(-0.0291)Val+(-0.2346)Met+(0.
1321)Ile+(-0.0863)Trp; 0.882, 0.896, 0.757, 0.720, 0.757, 0.824, 0.
805, 0.776, (1.8875)+(0.0428)Ser+(-0.1075)His+(0.0302)Ile+(0.
1017)Phe+(-0.1267)Trp; 0.882, 0.897, 0.821, 0.819, 0.827, 0.839, 0.
801, 0.821,
(1.3070)+(0.0603)Ser+(-0.0728)Asn+(-0.0484)Cit+(-0.2247)Met+(0.165-
1)Phe+(-0.1517)Trp; 0.882, 0.896, 0.808, 0.803, 0.811, 0.825,
0.804, 0.811,
(0.4379)+(0.0587)Ser+(-0.0718)Asn+(0.0068)Pro+(-0.2643)Met+(0.1589-
)Phe+(-0.1529)Trp; 0.882, 0.8 98, 0.811, 0.798, 0.786, 0.876,
0.849, 0.827, (5.8199)+(0.0366)Ser
+(-0.1098)Asn+(-0.0498)Cit+(-0.0238)Val+(0.1071)Ile+(-0.102 3)Trp;
0.882, 0.896, 0.794, 0.791, 0.813, 0.811, 0.753, 0.792, (-0.1
750)+(0.0452)Ser+(0.0255)Thr+(-0.3843)Met+(0.1693)Phe+(-0.1
668)Trp; 0.882, 0.899, 0.797, 0.784, 0.820, 0.822, 0.766, 0.798,
(4. 7434)+(0.0043)Gly+(-0.0969)His+(0.0516)Thr+(-0.3247)Met+(0.
1714)Phe+(-0.1316)Trp; 0.882, 0.899, 0.793, 0.774, 0.792, 0.844, 0.
812, 0.805, (3.0641)+(0.0543)Ser+(-0.0998)Asn+(-0.0887)His+(0.
0040)Leu+(0.1330)Phe+(-0.1277)Trp; 0.882, 0.898, 0.805, 0.791, 0.
826, 0.821, 0.786, 0.806, (5.4643)+(-0.0922)His+(0.0554)Thr+(-0.
3198)Met+(-0.0024)Lys+(0.1671)Phe+(-0.1324)Trp; 0.882, 0.896,
0.804, 0.790, 0.791, 0.865, 0.823, 0.817,
(7.3957)+(-0.0482)His+(0.0382)Thr+(-0.0270)Val+(-0.2600)Met+(0.1258)Ile+(-
-0.0800) Trp; 0.881, 0.895, 0.817, 0.809, 0.786, 0.885, 0.853,
0.834, (6.688
7)+(0.0341)Thr+(-0.0054)Ala+(-0.0345)Val+(-0.2668)Met+(0.14
78)Ile+(-0.0845)Trp; 0.881, 0.897, 0.798, 0.794, 0.816, 0.823, 0.7
51, 0.796, (0.2587)+(0.0471)Ser+(0.0290)Thr+(-0.3706)Met+(-0.
0105)Lys+(0.1761)Phe+(-0.1636)Trp; 0.881, 0.898, 0.805, 0.797, 0.
817, 0.827, 0.786, 0.807, (-0.0129)+(0.0566)Ser+(-0.0507)Cit+(0.
0079)Pro+(-0.3110)Met+(0.1611)Phe+(-0.1531)Trp; 0.881, 0.897,
0.806, 0.792, 0.828, 0.819, 0.789, 0.807,
(5.5754)+(-0.0149)Asn+(-0.0911)His+(0.0549)Thr+(-0.3115)Met+(0.1657)Phe+(-
-0.1333) Trp; 0.881, 0.899, 0.834, 0.829, 0.808, 0.848, 0.894,
0.845, (4.945
4)+(-0.0295)Asn+(-0.0406)Val+(-0.2362)Met+(0.1316)Ile+(0.12
66)Phe+(-0.0995)Trp
[0461] List (2) of Logistic Regression Equations Searched in
Example 2
[0462] The logistic regression equations searched in Example 2
above are listed below. Before each equation, "the value of ROC_AUC
for the pancreatic cancer group and the healthy group with
validation", "the value of ROC_AUC for the pancreatic cancer group
and the healthy group without validation", "the value of ROC_AUC
for the pancreatic cancer group and the other cancers group", "the
value of ROC_AUC for the pancreatic cancer group and the lung
cancer group", "the value of ROC_AUC for the pancreatic cancer
group and the colorectal cancer group", "the value of ROC_AUC for
the pancreatic cancer group and the prostatic cancer group", "the
value of ROC_AUC for the pancreatic cancer group and the breast
cancer group", and "the average value of the value of ROC_AUC for
the pancreatic cancer group and the lung cancer group, the value of
ROC_AUC for the pancreatic cancer group and the colorectal cancer
group, the value of ROC_AUC for the pancreatic cancer group and the
prostatic cancer group, and the value of ROC_AUC for the pancreatic
cancer group and the breast cancer group" obtained for the equation
are additionally listed.
[0463] 0.862, 0.894, 0.855, 0.850, 0.855, 0.863, 0.864, 0.858,
(2.250 8)+(0.0135)Gln+(-0.1156)His+(-0.0544)Cit+(-0.1821)Met+(0.15
18)Phe+(-0.1151)Trp; 0.809, 0.842, 0.860, 0.862, 0.869, 0.866, 0.8
30, 0.857, (5.7676)+(-0.0593)Asn+(0.0090)Gln+(-0.0683)Cit+(0.
0235)Tyr+(-0.0892)Met+(-0.1426)Trp; 0.805, 0.839, 0.859, 0.866,
0.861, 0.867, 0.831, 0.856,
(6.0629)+(-0.0739)Asn+(0.0084)Gln+(-0.0022)Ala+(-0.0714)Cit+(0.0130)Tyr+(-
-0.1421)Trp; 0.861, 0. 892, 0.852, 0.845, 0.851, 0.860, 0.867,
0.856, (2.3965)+(0.0128)Gl
n+(-0.1297)His+(0.0154)Tyr+(-0.2172)Met+(0.1374)Phe+(-0.109 4)Trp;
0.826, 0.858, 0.859, 0.874, 0.841, 0.836, 0.870, 0.855, (3.32
10)+(-0.0919)Asn+(0.0062)Gln+(-0.0041)Ala+(-0.0060)Val+(0.0
931)Phe+(-0.1458)Trp; 0.865, 0.892, 0.852, 0.849, 0.848, 0.857, 0.
864, 0.854,
(2.5117)+(-0.0105)Asn+(0.0128)Gln+(-0.1258)His+(-0.1885)Met+(0.139-
1)Phe+(-0.1051)Trp; 0.832, 0.863, 0.856, 0.865, 0.848, 0.848,
0.856, 0.854,
(3.4918)+(-0.0812)Asn+(0.0083)Gln+(-0.0048)Ala+(-0.0926)Cit+(0.104-
4)Phe+(-0.1577)Trp; 0.838, 0. 869, 0.859, 0.865, 0.865, 0.838,
0.846, 0.854, (2.2614)+(-0.0481)A
sn+(0.0098)Gln+(-0.0872)Cit+(-0.1772)Met+(0.1247)Phe+(-0.15 33)Trp;
0.859, 0.890, 0.851, 0.849, 0.847, 0.857, 0.859, 0.853, (2.4
884)+(0.0134)Gln+(-0.1272)His+(-0.0096)Arg+(-0.1820)Met+(0.
1400)Phe+(-0.1049)Trp; 0.867, 0.892, 0.850, 0.846, 0.846, 0.857, 0.
862, 0.853, (2.4271)+(0.0126)Gln+(-0.1275)His+(-0.1955)Met+(0.
1405)Phe+(-0.1055)Trp; 0.864, 0.892, 0.849, 0.846, 0.846, 0.856, 0.
861, 0.852, (2.4120)+(0.0126)Gln+(-0.1277)His+(0.0002)Ala+(-0.
1968)Met+(0.1405)Phe+(-0.1055)Trp; 0.863, 0.892, 0.849, 0.844, 0.
846, 0.853, 0.863, 0.851, (2.4047)+(0.0126)Gln+(-0.1304)His+(0.
0029)Val+(-0.1969)Met+(0.1366)Phe+(-0.1080)Trp; 0.835, 0.865,
0.859, 0.875, 0.857, 0.820, 0.854, 0.851,
(2.1650)+(-0.0499)Asn+(0.0079)Gln+(-0.0068)Val+(-0.2042)Met+(0.1209)Phe+(-
-0.1369) Trp; 0.857, 0.889, 0.846, 0.840, 0.841, 0.860, 0.862,
0.851, (3.487
6)+(-0.0572)Asn+(0.0125)Gln+(-0.1139)His+(-0.0612)Cit+(0.11
71)Phe+(-0.1225)Trp; 0.865, 0.893, 0.845, 0.835, 0.844, 0.857, 0.8
67, 0.851, (2.3748)+(0.0127)Gln+(-0.1335)His+(-0.2057)Met+(0.
0145)Leu+(0.1299)Phe+(-0.1120)Trp; 0.820, 0.855, 0.855, 0.869, 0.
845, 0.833, 0.855, 0.850, (3.1828)+(-0.0751)Asn+(0.0067)Gln+(-0.
0048)Ala+(-0.0135)Arg+(0.0888)Phe+(-0.1544)Trp; 0.805, 0.839,
0.853, 0.857, 0.860, 0.863, 0.821, 0.850,
(5.3506)+(0.0073)Gln+(-0.0019)Ala+(-0.0665)Cit+(0.0274)Tyr+(-0.1208)Met+(-
-0.1440)T rp; 0.805, 0.839, 0.854, 0.866, 0.852, 0.861, 0.821,
0.850, (6.1032)
+(-0.0730)Asn+(0.0085)Gln+(-0.0017)Ala+(-0.0706)Cit+(0.003
0)Arg+(-0.1376)Trp; 0.810, 0.839, 0.854, 0.867, 0.853, 0.861, 0.81
9, 0.850, (6.1036)+(-0.0709)Asn+(0.0086)Gln+(-0.0016)Ala+(-0.
0689)Cit+(-0.1374)Trp; 0.810, 0.839, 0.855, 0.868, 0.854, 0.861, 0.
817, 0.850,
(5.9973)+(-0.0607)Asn+(0.0090)Gln+(-0.0008)Ala+(-0.0658)Cit+(-0.04-
47)Met+(-0.1345)Trp; 0.825, 0.853, 0.852, 0.86 4, 0.838, 0.830,
0.865, 0.849, (3.1978)+(-0.0869)Asn+(0.0061)Gln
+(-0.0051)Ala+(0.0844)Phe+(-0.1536)Trp; 0.826, 0.862, 0.855, 0.
868, 0.850, 0.823, 0.855, 0.849, (2.1377)+(-0.0445)Asn+(0.0075)G
ln+(-0.0022)Ala+(-0.1950)Met+(0.1113)Phe+(-0.1437)Trp; 0.827,
0.863, 0.857, 0.872, 0.855, 0.823, 0.847, 0.849, (3.2812)+(-0.088
6)Asn+(0.0069)Gln+(-0.0139)Arg+(-0.0078)Val+(0.0929)Phe+(-0.
1487)Trp; 0.817, 0.853, 0.852, 0.864, 0.838, 0.829, 0.865, 0.849,
(3. 1937)+(-0.0876)Asn+(0.0060)Gln+(-0.0051)Ala+(0.0004)Lys+(0.
0841)Phe+(-0.1538)Trp; 0.862, 0.892, 0.846, 0.841, 0.843, 0.853, 0.
858, 0.849, (2.4961)+(0.0121)Gln+(-0.1282)His+(-0.1947)Met+(0.
0089)Orn+(0.1359)Phe+(-0.1050)Trp; 0.808, 0.840, 0.853, 0.865, 0.
854, 0.859, 0.816, 0.849, (5.9367)+(-0.0631)Asn+(0.0089)Gln+(-0.
0682)Cit+(0.0039)Arg+(-0.0539)Met+(-0.1360)Trp; 0.842, 0.868,
0.838, 0.828, 0.823, 0.866, 0.876, 0.848,
(4.8214)+(-0.0550)Asn+(0.0081)Gln+(-0.0076)Ala+(-0.0880)Cit+(0.0799)Ile+(-
-0.1627) Trp; 0.828, 0.856, 0.846, 0.845, 0.844, 0.866, 0.837,
0.848, (6.267
4)+(-0.0542)Asn+(0.0120)Gln+(-0.0952)His+(-0.0395)Cit+(0.02
20)Tyr+(-0.1092)Trp; 0.858, 0.885, 0.843, 0.841, 0.829, 0.856, 0.8
66, 0.848, (3.7749)+(-0.0504)Asn+(0.0112)Gln+(-0.1257)His+(-0.
0027)Ala+(0.1070)Phe+(-0.1122)Trp; 0.813, 0.839, 0.853, 0.866, 0.
853, 0.859, 0.814, 0.848, (5.9487)+(-0.0612)Asn+(0.0091)Gln+(-0.
0660)Cit+(-0.0511)Met+(-0.1357)Trp; 0.873, 0.900, 0.837, 0.818,
0.833, 0.859, 0.882, 0.848,
(2.0349)+(0.0121)Gln+(-0.1284)His+(-0.2378)Met+(0.0584)Ile+(0.1200)Phe+(--
0.1165)Trp; 0.818, 0.8 53, 0.851, 0.863, 0.836, 0.828, 0.865,
0.848, (3.1849)+(-0.0865)As
n+(0.0060)Gln+(-0.0052)Ala+(0.0017)Leu+(0.0830)Phe+(-0.154 8)Trp;
0.807, 0.836, 0.852, 0.864, 0.850, 0.858, 0.819, 0.848, (5.97
89)+(-0.0773)Asn+(0.0083)Gln+(-0.0018)Ala+(-0.0686)Cit+(0.0
044)Lys+(-0.1405)Trp; 0.834, 0.865, 0.852, 0.858, 0.855, 0.835, 0.
843, 0.848,
(2.0349)+(0.0082)Gln+(-0.0027)Ala+(-0.0866)Cit+(-0.1904)Met+(0.130-
0)Phe+(-0.1549)Trp; 0.823, 0.855, 0.845, 0.841, 0.845, 0.870,
0.834, 0.848,
(5.8022)+(0.0115)Gln+(-0.0987)His+(-0.0345)Cit+(0.0344)Tyr+(-0.096-
9)Met+(-0.1080)Trp; 0.832, 0. 863, 0.852, 0.860, 0.850, 0.835,
0.845, 0.848, (3.5427)+(-0.0934)A
sn+(0.0083)Gln+(-0.0913)Cit+(-0.0035)Val+(0.0985)Phe+(-0.15 88)Trp;
0.832, 0.863, 0.854, 0.868, 0.847, 0.820, 0.856, 0.848, (3.3
020)+(-0.1020)Asn+(0.0061)Gln+(-0.0083)Val+(0.0893)Phe+(-0.
1476)Trp; 0.809, 0.835, 0.852, 0.860, 0.857, 0.854, 0.818, 0.848,
(5. 9745)+(-0.0783)Asn+(0.0085)Gln+(-0.0724)Cit+(0.0081)Tyr+(-0.
1447)Trp; 0.795, 0.830, 0.852, 0.866, 0.845, 0.852, 0.827, 0.848,
(5. 1777)+(-0.0531)Asn+(0.0075)Gln+(-0.0015)Ala+(0.0202)Tyr+(-0.
1137)Met+(-0.1356)Trp; 0.864, 0.892, 0.844, 0.840, 0.841, 0.848, 0.
860, 0.847, (2.0904)+(0.0121)Gln+(-0.1342)His+(-0.2275)Met+(0.
0111)Lys+(0.1425)Phe+(-0.1118)Trp; 0.802, 0.835, 0.852, 0.860, 0.
856, 0.854, 0.819, 0.847, (5.9724)+(-0.0793)Asn+(0.0084)Gln+(-0.
0731)Cit+(0.0014)Arg+(0.0078)Tyr+(-0.1447)Trp; 0.821, 0.854, 0.
850, 0.862, 0.836, 0.831, 0.861, 0.847, (3.0860)+(-0.0887)Asn+(0.
0010)Gly+(0.0059)Gln+(-0.0051)Ala+(0.0855)Phe+(-0.1536)Trp; 0.819,
0.852, 0.849, 0.861, 0.834, 0.831, 0.861, 0.847,
(3.2964)+(-0.0890)Asn+(0.0057)Gln+(-0.0053)Ala+(0.0094)Orn+(0.0792)Phe
+(-0.1521)Trp; 0.825, 0.855, 0.846, 0.851, 0.839, 0.868, 0.829, 0.8
47, (6.3495)+(-0.0438)Asn+(0.0121)Gln+(-0.0878)His+(-0.0359)
Cit+(-0.0188)Met+(-0.0982)Trp; 0.807, 0.836, 0.851, 0.859, 0.852,
0.856, 0.819, 0.847, (5.8630)+(-0.0663)Asn+(0.0085)Gln+(-0.002
7)Ala+(-0.0747)Cit+(0.0053)Val+(-0.1459)Trp; 0.832, 0.862, 0.8 50,
0.856, 0.852, 0.836, 0.843, 0.847, (3.5137)+(-0.0865)Asn+(0.0
084)Gln+(-0.0950)Cit+(-0.0029)Lys+(0.0955)Phe+(-0.1631)Trp; 0.830,
0.857, 0.843, 0.842, 0.838, 0.866, 0.839, 0.846,
(5.9220)+(-0.0347)Asn+(0.0121)Gln+(-0.1045)His+(0.0317)Tyr+(-0.0819)Me
t+(-0.1044)Trp; 0.842, 0.868, 0.836, 0.824, 0.827, 0.864, 0.868, 0.
846, (4.3742)+(0.0074)Gln+(-0.0067)Ala+(-0.0814)Cit+(-0.107
6)Met+(0.0844)Ile+(-0.1569)Trp; 0.802, 0.839, 0.845, 0.851, 0.83 0,
0.847, 0.856, 0.846, (5.2638)+(-0.0625)Asn+(0.0077)Gln+(-0.0
271)Val+(-0.1255)Met+(0.0579)Leu+(-0.1291)Trp; 0.866, 0.895, 0.
843, 0.838, 0.841, 0.846, 0.859, 0.846, (2.3031)+(0.0124)Gln+(-0.
1264)His+(0.0070)Pro+(-0.2170)Met+(0.1381)Phe+(-0.1083)Trp; 0.814,
0.838, 0.850, 0.862, 0.851, 0.855, 0.816, 0.846,
(6.0237)+(-0.0754)Asn+(0.0086)Gln+(-0.0705)Cit+(-0.1410)Trp; 0.828,
0.86 3, 0.852, 0.866, 0.843, 0.822, 0.851, 0.845,
(3.1762)+(-0.1039)Asn
+(0.0010)Gly+(0.0060)Gln+(-0.0083)Val+(0.0907)Phe+(-0.1474) Trp;
0.812, 0.846, 0.844, 0.845, 0.841, 0.849, 0.847, 0.845, (5.822
5)+(-0.0862)Asn+(0.0084)Gln+(-0.0688)Cit+(-0.0187)Val+(0.04
45)Leu+(-0.1483)Trp; 0.799, 0.833, 0.842, 0.850, 0.819, 0.851, 0.8
61, 0.845, (5.5360)+(-0.0888)Asn+(0.0066)Gln+(-0.0032)Ala+(-0.
0254)Val+(0.0532)Leu+(-0.1346)Trp; 0.809, 0.841, 0.850, 0.865, 0.
847, 0.865, 0.804, 0.845, (5.9980)+(-0.0739)Asn+(0.0019)Gly+(0.
0084)Gln+(-0.0016)Ala+(-0.0714)Cit+(-0.1371)Trp; 0.808, 0.838,
0.851, 0.863, 0.852, 0.851, 0.813, 0.845,
(5.7387)+(-0.0657)Asn+(0.0087)Gln+(-0.0647)Cit+(-0.0687)Met+(0.0064)Lys+(-
-0.1396) Trp; 0.828, 0.854, 0.844, 0.849, 0.837, 0.865, 0.828,
0.845, (6.375
0)+(-0.0487)Asn+(0.0120)Gln+(-0.0891)His+(0.0001)Ala+(-0.03
70)Cit+(-0.0999)Trp; 0.830, 0.854, 0.844, 0.850, 0.837, 0.865, 0.8
28, 0.845, (6.3815)+(-0.0485)Asn+(0.0120)Gln+(-0.0889)His+(-0.
0370)Cit+(-0.0997)Trp; 0.808, 0.838, 0.849, 0.861, 0.850, 0.854, 0.
814, 0.845, (6.0191)+(-0.0769)Asn+(0.0085)Gln+(-0.0717)Cit+(0.
0021)Arg+(-0.1413)Trp; 0.824, 0.861, 0.851, 0.866, 0.843, 0.816, 0.
855, 0.845, (3.2955)+(-0.1079)Asn+(0.0060)Gln+(-0.0091)Val+(0.
0032)Lys+(0.0884)Phe+(-0.1481)Trp; 0.849, 0.882, 0.838, 0.832, 0.
827, 0.859, 0.861, 0.845, (3.3973)+(0.0107)Gln+(-0.1187)His+(-0.
0036)Ala+(-0.0613)Cit+(0.1236)Phe+(-0.1262)Trp; 0.801, 0.838,
0.848, 0.853, 0.858, 0.856, 0.812, 0.845,
(5.2374)+(0.0073)Gln+(-0.0668)Cit+(0.0001)Arg+(0.0253)Tyr+(-0.1322)Met+(--
0.1461)Tr p; 0.807, 0.839, 0.848, 0.853, 0.858, 0.856, 0.811,
0.844,
(5.2385)+(0.0073)Gln+(-0.0667)Cit+(0.0253)Tyr+(-0.1321)Met+(-0.1460)
Trp; 0.861, 0.885, 0.829, 0.818, 0.801, 0.875, 0.883, 0.844, (4.913
4)+(0.0066)Gln+(-0.0570)Cit+(-0.0378)Val+(-0.1870)Met+(0.16
70)Ile+(-0.1228)Trp; 0.833, 0.861, 0.848, 0.854, 0.849, 0.831, 0.8
42, 0.844, (3.4802)+(-0.0912)Asn+(0.0082)Gln+(-0.0940)Cit+(0.
0930)Phe+(-0.1645)Trp; 0.788, 0.824, 0.848, 0.864, 0.835, 0.847, 0.
831, 0.844,
(5.4817)+(-0.0765)Asn+(-0.0006)Gly+(0.0068)Gln+(-0.0028)Ala+(0.002-
6)Tyr+(-0.1349)Trp; 0.803, 0.835, 0.849, 0.858, 0.853, 0.849,
0.816, 0.844,
(5.8759)+(-0.0832)Asn+(0.0083)Gln+(-0.0719)Cit+(0.0063)Tyr+(0.0034-
)Lys+(-0.1467)Trp; 0.807, 0.8 37, 0.849, 0.857, 0.856, 0.851,
0.813, 0.844, (5.6996)+(-0.0573)As
n+(0.0089)Gln+(-0.0708)Cit+(0.0045)Val+(-0.0602)Met+(-0.143 5)Trp;
0.831, 0.865, 0.844, 0.852, 0.829, 0.820, 0.876, 0.844, (3.50
14)+(-0.1103)Asn+(0.0060)Gln+(-0.0296)Val+(0.0453)Leu+(0.08
50)Phe+(-0.1518)Trp; 0.827, 0.861, 0.853, 0.866, 0.855, 0.812, 0.8
43, 0.844, (2.0627)+(-0.0417)Asn+(0.0081)Gln+(-0.0089)Arg+(-0.
2034)Met+(0.1115)Phe+(-0.1455)Trp; 0.809, 0.840, 0.845, 0.849, 0.
845, 0.848, 0.834, 0.844, (5.6309)+(-0.0669)Asn+(0.0083)Gln+(-0.
0036)Ala+(-0.0762)Cit+(0.0191)Leu+(-0.1522)Trp; 0.880, 0.900,
0.831, 0.825, 0.800, 0.853, 0.898, 0.844,
(1.6131)+(0.0057)Gln+(-0.0525)Val+(-0.3431)Met+(0.1808)Ile+(0.1304)Phe+(--
0.1173)Tr p; 0.829, 0.861, 0.848, 0.854, 0.849, 0.831, 0.842,
0.844,
(3.4795)+(-0.0908)Asn+(0.0082)Gln+(-0.0937)Cit+(-0.0005)Arg+(0.0930)
Phe+(-0.1645)Trp; 0.824, 0.852, 0.843, 0.850, 0.837, 0.865, 0.824,
0.844, (6.3859)+(-0.0451)Asn+(0.0123)Gln+(-0.0902)His+(-0.03
40)Cit+(-0.0043)Arg+(-0.0988)Trp; 0.817, 0.847, 0.844, 0.850, 0.
839, 0.858, 0.828, 0.844, (6.2658)+(-0.0673)Asn+(0.0081)Gln+(-0.
0054)Ala+(-0.0773)Cit+(0.0130)Pro+(-0.1416)Trp; 0.824, 0.861,
0.852, 0.864, 0.852, 0.812, 0.847, 0.844,
(2.0112)+(-0.0454)Asn+(0.0076)Gln+(0.0016)Tyr+(-0.2134)Met+(0.1094)Phe+(--
0.1459)T rp; 0.810, 0.841, 0.849, 0.863, 0.849, 0.860, 0.802,
0.844, (5.8487)
+(-0.0641)Asn+(0.0019)Gly+(0.0089)Gln+(-0.0685)Cit+(-0.050
2)Met+(-0.1355)Trp; 0.836, 0.869, 0.845, 0.851, 0.836, 0.820, 0.86
7, 0.844, (1.7715)+(0.0065)Gln+(-0.0319)Val+(-0.2619)Met+(0.0
539)Leu+(0.1213)Phe+(-0.1461)Trp; 0.854, 0.879, 0.828, 0.821, 0.
791, 0.876, 0.886, 0.844, (5.6074)+(-0.0967)Asn+(0.0077)Gln+(-0.
0706)Cit+(-0.0363)Val+(0.1494)Ile+(-0.1313)Trp; 0.866, 0.894,
0.840, 0.838, 0.836, 0.858, 0.841, 0.843, (2.0299)+(0.0044)Gly+(0.
0119)Gln+(-0.1319)His+(-0.2072)Met+(0.1476)Phe+(-0.1045)Tr p;
0.786, 0.824, 0.848, 0.866, 0.837, 0.847, 0.822, 0.843,
(5.4570)+(-0.0712)Asn+(0.0072)Gln+(-0.0026)Ala+(-0.0084)Arg+(0.0048)
Tyr+(-0.1345)Trp; 0.829, 0.860, 0.847, 0.852, 0.849, 0.831, 0.842,
0.843, (3.4683)+(-0.0911)Asn+(0.0082)Gln+(-0.0942)Cit+(0.001
8)Leu+(0.0913)Phe+(-0.1660)Trp; 0.833, 0.861, 0.851, 0.863, 0.85 2,
0.811, 0.846, 0.843, (2.0143)+(-0.0455)Asn+(0.0076)Gln+(-0.2
109)Met+(0.1098)Phe+(-0.1455)Trp; 0.793, 0.831, 0.848, 0.862, 0.
846, 0.844, 0.821, 0.843, (5.1177)+(-0.0542)Asn+(-0.0002)Gly+(0.
0076)Gln+(0.0182)Tyr+(-0.1223)Met+(-0.1367)Trp; 0.837, 0.865,
0.838, 0.826, 0.840, 0.853, 0.853, 0.843,
(4.5403)+(-0.0428)Asn+(0.0087)Gln+(-0.0781)Cit+(-0.1229)Met+(0.0689)Ile+(-
-0.1589) Trp; 0.830, 0.863, 0.849, 0.863, 0.844, 0.821, 0.845,
0.843, (3.481
6)+(-0.1074)Asn+(0.0056)Gln+(-0.0101)Val+(0.0148)Orn+(0.084
6)Phe+(-0.1431)Trp; 0.835, 0.865, 0.850, 0.856, 0.858, 0.826, 0.83
3, 0.843, (1.8996)+(0.0083)Gln+(-0.0849)Cit+(-0.0021)Val+(-0.
2102)Met+(0.1306)Phe+(-0.1546)Trp; 0.828, 0.865, 0.849, 0.854, 0.
859, 0.826, 0.833, 0.843, (1.8779)+(0.0083)Gln+(-0.0865)Cit+(0.
0037)Tyr+(-0.2157)Met+(0.1267)Phe+(-0.1580)Trp; 0.820, 0.849,
0.848, 0.859, 0.853, 0.872, 0.788, 0.843,
(6.7018)+(-0.0985)Asn+(0.0072)Gln+(0.0206)Thr+(-0.0028)Ala+(-0.0740)Cit+(-
-0.1456) Trp; 0.788, 0.823, 0.847, 0.865, 0.834, 0.845, 0.829,
0.843, (5.495
1)+(-0.0756)Asn+(-0.0007)Gly+(0.0069)Gln+(-0.0027)Ala+(0.00
02)Val+(-0.1344)Trp; 0.796, 0.824, 0.847, 0.865, 0.834, 0.845, 0.8
29, 0.843, (5.5074)+(-0.0757)Asn+(-0.0007)Gly+(0.0069)Gln+(-0.
0027)Ala+(-0.1341)Trp; 0.787, 0.825, 0.847, 0.863, 0.834, 0.847, 0.
827, 0.843, (5.4224)+(-0.0774)Asn+(0.0067)Gln+(-0.0028)Ala+(0.
0030)Tyr+(0.0001)Val+(-0.1351)Trp; 0.841, 0.866, 0.832, 0.819, 0.
816, 0.863, 0.874, 0.843, (4.7910)+(0.0072)Gln+(-0.0086)Ala+(-0.
0936)Cit+(-0.0102)Lys+(0.0909)Ile+(-0.1638)Trp; 0.794, 0.825,
0.846, 0.863, 0.834, 0.847, 0.827, 0.843,
(5.4282)+(-0.0775)Asn+(0.0067)Gln+(-0.0028)Ala+(0.0031)Tyr+(-0.1350)Trp;
0.790, 0.8 29, 0.849, 0.863, 0.849, 0.844, 0.815, 0.843,
(5.1494)+(-0.0511)As
n+(0.0079)Gln+(-0.0070)Arg+(0.0196)Tyr+(-0.1191)Met+(-0.135 8)Trp;
0.827, 0.861, 0.851, 0.863, 0.851, 0.811, 0.846, 0.843, (2.00
69)+(-0.0454)Asn+(0.0076)Gln+(-0.2115)Met+(0.0008)Leu+(0.10
92)Phe+(-0.1460)Trp; 0.798, 0.831, 0.848, 0.861, 0.846, 0.844, 0.8
20, 0.843, (5.0998)+(-0.0544)Asn+(0.0075)Gln+(0.0184)Tyr+(-0.
1226)Met+(-0.1367)Trp; 0.804, 0.836, 0.847, 0.854, 0.855, 0.848, 0.
814, 0.843, (5.8144)+(-0.0763)Asn+(0.0084)Gln+(-0.0758)Cit+(0.
0057)Tyr+(0.0032)Val+(-0.1501)Trp; 0.851, 0.875, 0.833, 0.828, 0.
814, 0.868, 0.860, 0.843, (4.8479)+(-0.0763)Asn+(0.0085)Gln+(-0.
0834)Cit+(0.1455)Ile+(-0.0584)Leu+(-0.1487)Trp; 0.856, 0.885,
0.840, 0.838, 0.833, 0.848, 0.851, 0.843,
(3.6081)+(-0.0403)Asn+(0.0126)Gln+(-0.1304)His+(-0.0168)Arg+(0.1065)Phe+(-
-0.1131)Trp
[0464] List (2) of Linear Discriminants Searched in Example 2
[0465] The linear discriminants searched in Example 2 above are
listed below. Before each equation, "the value of ROC_AUC for the
pancreatic cancer group and the healthy group with validation",
"the value of ROC_AUC for the pancreatic cancer group and the
healthy group without validation", "the value of ROC_AUC for the
pancreatic cancer group and the other cancers group", "the value of
ROC_AUC for the pancreatic cancer group and the lung cancer group",
"the value of ROC_AUC for the pancreatic cancer group and the
colorectal cancer group", "the value of ROC_AUC for the pancreatic
cancer group and the prostatic cancer group", "the value of ROC_AUC
for the pancreatic cancer group and the breast cancer group", and
"the average value of the value of ROC_AUC for the pancreatic
cancer group and the lung cancer group, the value of ROC_AUC for
the pancreatic cancer group and the colorectal cancer group, the
value of ROC_AUC for the pancreatic cancer group and the prostatic
cancer group, and the value of ROC_AUC for the pancreatic cancer
group and the breast cancer group" obtained for the equation are
additionally listed.
[0466] 0.876, 0.897, 0.863, 0.862, 0.862, 0.864, 0.866, 0.864,
(2.677 3)+(0.0131)Gln+(-0.0833)His+(-0.0369)Cit+(-0.1942)Met+(0.13
25)Phe+(-0.1189)Trp; 0.815, 0.839, 0.865, 0.874, 0.862, 0.879, 0.8
39, 0.864, (6.3554)+(-0.0849)Asn+(0.0097)Gln+(-0.0031)Ala+(-0.
0554)Cit+(0.0122)Tyr+(-0.1240)Trp; 0.875, 0.897, 0.861, 0.858, 0.
856, 0.868, 0.871, 0.863, (4.1845)+(-0.0886)Asn+(0.0124)Gln+(-0.
0795)His+(-0.0439)Cit+(0.1039)Phe+(-0.1254)Trp; 0.844, 0.868,
0.866, 0.876, 0.856, 0.852, 0.867, 0.863,
(4.2725)+(-0.1063)Asn+(0.0099)Gln+(-0.0038)Ala+(-0.0633)Cit+(0.0905)Phe+(-
-0.1475) Trp; 0.818, 0.842, 0.865, 0.869, 0.870, 0.872, 0.837,
0.862, (5.815
8)+(-0.0671)Asn+(0.0103)Gln+(-0.0536)Cit+(0.0213)Tyr+(-0.08
88)Met+(-0.1263)Trp; 0.852, 0.873, 0.867, 0.875, 0.870, 0.842, 0.8
60, 0.862, (2.9709)+(-0.0695)Asn+(0.0114)Gln+(-0.0601)Cit+(-0.
1650)Met+(0.1155)Phe+(-0.1481)Trp; 0.877, 0.895, 0.861, 0.862, 0.
858, 0.856, 0.870, 0.861, (3.0012)+(-0.0367)Asn+(0.0128)Gln+(-0.
0871)His+(-0.1691)Met+(0.1301)Phe+(-0.1171)Trp; 0.849, 0.871,
0.866, 0.877, 0.860, 0.843, 0.863, 0.861,
(4.4184)+(-0.1197)Asn+(0.0097)Gln+(-0.0558)Cit+(-0.0076)Val+(0.1001)Phe+(-
-0.1461) Trp; 0.846, 0.865, 0.851, 0.844, 0.833, 0.878, 0.888,
0.861, (5.401
4)+(-0.0795)Asn+(0.0089)Gln+(-0.0071)Ala+(-0.0725)Cit+(0.06
02)Ile+(-0.1221)Trp; 0.850, 0.871, 0.863, 0.870, 0.862, 0.847, 0.8
59, 0.860, (4.1784)+(-0.1095)Asn+(0.0102)Gln+(-0.0648)Cit+(-0.
0050)Lys+(0.0905)Phe+(-0.1510)Trp; 0.874, 0.895, 0.858, 0.856, 0.
856, 0.855, 0.870, 0.859, (2.5573)+(0.0121)Gln+(-0.0909)His+(0.
0123)Tyr+(-0.2108)Met+(0.1287)Phe+(-0.1198)Trp; 0.817, 0.839,
0.863, 0.878, 0.856, 0.874, 0.827, 0.859,
(6.2806)+(-0.0688)Asn+(0.0103)Gln+(-0.0018)Ala+(-0.0528)Cit+(-0.0466)Met+-
(-0.116 1)Trp; 0.816, 0.839, 0.861, 0.875, 0.852, 0.873, 0.833,
0.858, (6.55
10)+(-0.0865)Asn+(0.0094)Gln+(-0.0028)Ala+(-0.0594)Cit+(0.0
068)Arg+(-0.1198)Trp; 0.816, 0.841, 0.859, 0.868, 0.853, 0.869, 0.
843, 0.858,
(6.0813)+(-0.0835)Asn+(0.0098)Gln+(-0.0036)Ala+(-0.0596)Cit+(0.010-
5)Leu+(-0.1236)Trp; 0.820, 0.838, 0.861, 0.875, 0.855, 0.872,
0.830, 0.858,
(6.4488)+(-0.0822)Asn+(0.0098)Gln+(-0.0026)Ala+(-0.0545)Cit+(-0.11-
89)Trp; 0.815, 0.838, 0.861, 0. 875, 0.854, 0.872, 0.830, 0.858,
(6.4299)+(-0.0829)Asn+(0.0098)G
ln+(-0.0026)Ala+(-0.0545)Cit+(0.0006)Lys+(-0.1193)Trp; 0.863,
0.881, 0.846, 0.844, 0.814, 0.886, 0.888, 0.858, (6.0987)+(-0.105
9)Asn+(0.0079)Gln+(-0.0561)Cit+(-0.0246)Val+(0.1006)Ile+(-0.
1051)Trp; 0.838, 0.861, 0.862, 0.879, 0.845, 0.838, 0.871, 0.858,
(4. 5654)+(-0.1123)Asn+(0.0076)Gln+(-0.0024)Ala+(-0.0100)Val+(0.
1002)Phe+(-0.1400)Trp; 0.816, 0.838, 0.861, 0.873, 0.856, 0.871, 0.
831, 0.858,
(6.2809)+(-0.0810)Asn+(0.0098)Gln+(-0.0030)Ala+(-0.0574)Cit+(0.002-
3)Val+(-0.1217)Trp; 0.848, 0.868, 0.865, 0.880, 0.860, 0.826,
0.863, 0.857,
(3.3302)+(-0.0714)Asn+(0.0094)Gln+(-0.0103)Val+(-0.1688)Met+(0.128-
0)Phe+(-0.1379)Trp; 0.821, 0. 844, 0.858, 0.865, 0.851, 0.863,
0.849, 0.857, (6.2656)+(-0.1002)A
sn+(0.0095)Gln+(-0.0522)Cit+(-0.0132)Val+(0.0269)Leu+(-0.12 04)Trp;
0.813, 0.838, 0.859, 0.867, 0.859, 0.872, 0.831, 0.857, (5.3
275)+(0.0086)Gln+(-0.0027)Ala+(-0.0507)Cit+(0.0266)Tyr+(-0.
1304)Met+(-0.1249)Trp; 0.870, 0.890, 0.853, 0.855, 0.840, 0.857, 0.
876, 0.857,
(4.2458)+(-0.0784)Asn+(0.0110)Gln+(-0.0865)His+(-0.0023)Ala+(0.102-
6)Phe+(-0.1193)Trp; 0.846, 0.869, 0.862, 0.872, 0.861, 0.839,
0.853, 0.856,
(4.1950)+(-0.1153)Asn+(0.0098)Gln+(-0.0611)Cit+(-0.0087)Leu+(0.097-
3)Phe+(-0.1515)Trp; 0.871, 0. 894, 0.855, 0.856, 0.851, 0.852,
0.865, 0.856, (2.6471)+(0.0123)Gl
n+(-0.0905)His+(-0.0020)Arg+(-0.1937)Met+(0.1307)Phe+(-0.11 58)Trp;
0.834, 0.855, 0.855, 0.863, 0.845, 0.878, 0.837, 0.856, (6.7
550)+(-0.0609)Asn+(0.0118)Gln+(-0.0620)His+(-0.0012)Ala+(-0.
0377)Cit+(-0.0952)Trp; 0.877, 0.896, 0.853, 0.850, 0.850, 0.854, 0.
868, 0.856, (2.5522)+(0.0122)Gln+(-0.0940)His+(-0.2001)Met+(0.
0059)Leu+(0.1259)Phe+(-0.1162)Trp; 0.874, 0.893, 0.854, 0.854, 0.
850, 0.852, 0.865, 0.855, (2.6456)+(0.0121)Gln+(-0.0905)His+(-0.
0000)Ala+(-0.1962)Met+(0.1311)Phe+(-0.1162)Trp; 0.820, 0.843,
0.857, 0.868, 0.849, 0.868, 0.836, 0.855,
(6.4530)+(-0.0810)Asn+(0.0091)Gln+(-0.0041)Ala+(-0.0552)Cit+(0.0059)Pro+(-
-0.1177)Trp; 0.876, 0.893, 0.854, 0.854, 0.850, 0.852, 0.865,
0.855, (2.644
5)+(0.0121)Gln+(-0.0905)His+(-0.1963)Met+(0.1311)Phe+(-0.11 62)Trp;
0.874, 0.893, 0.854, 0.855, 0.849, 0.852, 0.864, 0.855, (2.6
523)+(0.0121)Gln+(-0.0902)His+(-0.0002)Val+(-0.1963)Met+(0.
1314)Phe+(-0.1161)Trp; 0.836, 0.858, 0.854, 0.857, 0.851, 0.872, 0.
840, 0.855,
(6.5444)+(-0.0675)Asn+(0.0117)Gln+(-0.0648)His+(-0.0387)Cit+(0.013-
1)Tyr+(-0.1028)Trp; 0.808, 0.832, 0.853, 0.866, 0.829, 0.864,
0.860, 0.855,
(6.4282)+(-0.0939)Asn+(0.0075)Gln+(-0.0029)Ala+(-0.0179)Val+(0.032-
6)Leu+(-0.1132)Trp; 0.843, 0. 866, 0.858, 0.872, 0.844, 0.831,
0.873, 0.855, (4.6216)+(-0.1240)A
sn+(0.0075)Gln+(-0.0187)Val+(0.0156)Leu+(0.0954)Phe+(-0.139 1)Trp;
0.872, 0.893, 0.854, 0.853, 0.849, 0.852, 0.863, 0.855, (2.65
00)+(0.0119)Gln+(-0.0907)His+(-0.1957)Met+(0.0024)Orn+(0.13
02)Phe+(-0.1160)Trp; 0.836, 0.857, 0.855, 0.863, 0.848, 0.875, 0.8
32, 0.855, (6.5627)+(-0.0499)Asn+(0.0122)Gln+(-0.0619)His+(-0.
0363)Cit+(-0.0430)Met+(-0.0935)Trp; 0.874, 0.894, 0.854, 0.853,
0.850, 0.850, 0.864, 0.855,
(2.5315)+(0.0119)Gln+(-0.0916)His+(-0.2033)Met+(0.0029)Lys+(0.1306)Phe+(--
0.1171)Trp; 0.821, 0.8 40, 0.859, 0.873, 0.856, 0.867, 0.822,
0.854, (6.1205)+(-0.0704)As
n+(0.0103)Gln+(-0.0531)Cit+(-0.0570)Met+(-0.1186)Trp; 0.803, 0.830,
0.857, 0.871, 0.848, 0.859, 0.840, 0.854, (5.7371)+(-0.059
2)Asn+(0.0082)Gln+(-0.0024)Ala+(0.0223)Tyr+(-0.0910)Met+(-0.
1242)Trp; 0.833, 0.857, 0.853, 0.852, 0.853, 0.876, 0.836, 0.854,
(5. 7659)+(0.0113)Gln+(-0.0684)His+(-0.0335)Cit+(0.0279)Tyr+(-0.
1168)Met+(-0.1013)Trp; 0.844, 0.868, 0.859, 0.867, 0.858, 0.837, 0.
855, 0.854,
(4.0726)+(-0.1158)Asn+(0.0098)Gln+(-0.0646)Cit+(-0.0003)Pro+(0.087-
6)Phe+(-0.1537)Trp; 0.850, 0.868, 0.859, 0.866, 0.858, 0.837,
0.856, 0.854,
(4.0736)+(-0.1158)Asn+(0.0098)Gln+(-0.0646)Cit+(0.0874)Phe+(-0.153-
7)Trp; 0.832, 0.855, 0.859, 0.8 75, 0.845, 0.832, 0.865, 0.854,
(4.2884)+(-0.1042)Asn+(0.0075)Gl
n+(-0.0033)Ala+(-0.0103)Leu+(0.0951)Phe+(-0.1460)Trp; 0.832, 0.856,
0.857, 0.870, 0.842, 0.834, 0.870, 0.854, (4.2512)+(-0.098
3)Asn+(0.0076)Gln+(-0.0040)Ala+(-0.0036)Lys+(0.0857)Phe+(-0.
1455)Trp; 0.850, 0.870, 0.845, 0.837, 0.831, 0.873, 0.876, 0.854,
(4. 3443)+(0.0086)Gln+(-0.0065)Ala+(-0.0699)Cit+(-0.1457)Met+(0.
0719)Ile+(-0.1159)Trp; 0.839, 0.861, 0.849, 0.842, 0.845, 0.865, 0.
863, 0.854,
(5.3657)+(-0.0871)Asn+(0.0095)Gln+(-0.0723)Cit+(-0.0074)Lys+(0.050-
6)Ile+(-0.1284)Trp; 0.841, 0.864, 0.860, 0.876, 0.849, 0.828,
0.861, 0.853,
(4.4599)+(-0.1165)Asn+(0.0079)Gln+(-0.0038)Arg+(-0.0112)Val+(0.100-
3)Phe+(-0.1418)Trp; 0.816, 0. 839, 0.854, 0.867, 0.835, 0.857,
0.855, 0.853, (5.9653)+(-0.0715)A
sn+(0.0085)Gln+(-0.0217)Val+(-0.1018)Met+(0.0410)Leu+(-0.10 85)Trp;
0.817, 0.840, 0.857, 0.870, 0.852, 0.867, 0.825, 0.853, (6.2
031)+(-0.0741)Asn+(0.0099)Gln+(-0.0582)Cit+(0.0072)Arg+(-0.
0613)Met+(-0.1196)Trp; 0.852, 0.871, 0.838, 0.841, 0.787, 0.885, 0.
901, 0.853,
(6.3239)+(-0.0898)Asn+(0.0056)Gln+(-0.0062)Ala+(-0.0277)Val+(0.112-
1)Ile+(-0.0928)Trp; 0.812, 0.838, 0.858, 0.867, 0.860, 0.860,
0.827, 0.853,
(6.1992)+(-0.0911)Asn+(0.0097)Gln+(-0.0564)Cit+(0.0078)Tyr+(-0.000-
7)Lys+(-0.1273)Trp; 0.873, 0. 893, 0.852, 0.852, 0.844, 0.849,
0.868, 0.853, (4.0710)+(-0.0792)A
sn+(0.0116)Gln+(-0.0890)His+(-0.0058)Arg+(0.1011)Phe+(-0.12 09)Trp;
0.868, 0.886, 0.840, 0.833, 0.815, 0.884, 0.881, 0.853, (4.7
899)+(0.0075)Gln+(-0.0516)Cit+(-0.0267)Val+(-0.2009)Met+(0.
1234)Ile+(-0.0924)Trp; 0.816, 0.838, 0.857, 0.867, 0.859, 0.859, 0.
828, 0.853, (6.1771)+(-0.0919)Asn+(0.0096)Gln+(-0.0564)Cit+(0.
0076)Tyr+(-0.1277)Trp; 0.814, 0.839, 0.858, 0.870, 0.857, 0.864, 0.
822, 0.853, (5.9708)+(-0.0693)Asn+(0.0104)Gln+(-0.0552)Cit+(0.
0016)Val+(-0.0603)Met+(-0.1209)Trp; 0.886, 0.905, 0.844, 0.843,
0.816, 0.856, 0.897, 0.853,
(2.0355)+(0.0066)Gln+(-0.0397)Val+(-0.3168)Met+(0.1284)Ile+(0.1311)Phe+(--
0.1090)Trp; 0.818, 0.8 40, 0.856, 0.873, 0.848, 0.877, 0.814,
0.853, (6.3593)+(-0.0845)As
n+(0.0024)Gly+(0.0095)Gln+(-0.0027)Ala+(-0.0576)Cit+(-0.118 1)Trp;
0.814, 0.838, 0.857, 0.867, 0.859, 0.859, 0.827, 0.853, (6.16
78)+(-0.0919)Asn+(0.0096)Gln+(-0.0565)Cit+(0.0075)Tyr+(0.00
01)Val+(-0.1278)Trp; 0.873, 0.892, 0.851, 0.852, 0.842, 0.848, 0.8
70, 0.853, (4.2347)+(-0.0860)Asn+(0.0110)Gln+(-0.0853)His+(-0.
0024)Val+(0.1046)Phe+(-0.1211)Trp; 0.837, 0.858, 0.851, 0.854, 0.
847, 0.868, 0.841, 0.853, (6.0881)+(-0.0392)Asn+(0.0112)Gln+(-0.
0715)His+(0.0254)Tyr+(-0.0882)Met+(-0.0993)Trp; 0.873, 0.893,
0.844, 0.848, 0.810, 0.852, 0.899, 0.852,
(4.5526)+(-0.1319)Asn+(0.0058)Gln+(-0.0339)Val+(0.0933)Ile+(0.0918)Phe+(--
0.1225)T rp; 0.845, 0.867, 0.842, 0.833, 0.823, 0.873, 0.880,
0.852, (5.0406)
+(0.0070)Gln+(-0.0086)Ala+(-0.0741)Cit+(-0.0113)Lys+(0.069
1)Ile+(-0.1191)Trp; 0.817, 0.839, 0.857, 0.872, 0.854, 0.862, 0.82
1, 0.852, (6.0399)+(-0.0717)Asn+(0.0102)Gln+(-0.0530)Cit+(-0.
0614)Met+(0.0019)Lys+(-0.1196)Trp; 0.851, 0.873, 0.851, 0.847, 0.
850, 0.840, 0.873, 0.852, (3.7665)+(-0.1162)Asn+(0.0093)Gln+(-0.
0729)Cit+(0.0294)Ile+(0.0726)Phe+(-0.1544)Trp; 0.834, 0.855, 0.
852, 0.859, 0.845, 0.871, 0.834, 0.852, (6.6903)+(-0.0647)Asn+(0.
0118)Gln+(-0.0630)His+(-0.0389)Cit+(0.0013)Arg+(-0.0973)Tr p;
0.871, 0.891, 0.850, 0.849, 0.842, 0.848, 0.870, 0.852,
(4.1249)+(-0.0832)Asn+(0.0111)Gln+(-0.0888)His+(-0.0006)Pro+(0.1016)Phe+(-
-0.1222)Trp; 0.838, 0.855, 0.852, 0.860, 0.845, 0.871, 0.833,
0.852, (6.6752)+(-0.0637)Asn+(0.0119)Gln+(-0.0633)His+(-0.03
79)Cit+(-0.0969)Trp; 0.876, 0.897, 0.851, 0.850, 0.846, 0.848, 0.8
64, 0.852, (2.6021)+(0.0118)Gln+(-0.0903)His+(0.0036)Pro+(-0.
2057)Met+(0.1298)Phe+(-0.1159)Trp; 0.844, 0.865, 0.847, 0.838, 0.
846, 0.862, 0.861, 0.852, (4.6128)+(-0.0559)Asn+(0.0100)Gln+(-0.
0691)Cit+(-0.1294)Met+(0.0581)Ile+(-0.1234)Trp; 0.872, 0.892,
0.849, 0.849, 0.841, 0.847, 0.870, 0.852,
(4.1478)+(-0.0822)Asn+(0.0111)Gln+(-0.0885)His+(-0.0011)Lys+(0.1016)Phe+(-
-0.1218)Trp; 0.812, 0.837, 0.855, 0.865, 0.855, 0.857, 0.830,
0.852, (6.250
1)+(-0.0955)Asn+(0.0093)Gln+(-0.0602)Cit+(0.0052)Arg+(0.007
0)Tyr+(-0.1284)Trp; 0.876, 0.892, 0.849, 0.848, 0.841, 0.848, 0.86
9, 0.852, (4.1266)+(-0.0834)Asn+(0.0110)Gln+(-0.0889)His+(0.1
011)Phe+(-0.1222)Trp; 0.832, 0.855, 0.855, 0.869, 0.841, 0.830, 0.
866, 0.852,
(4.1494)+(-0.1004)Asn+(0.0076)Gln+(-0.0041)Ala+(-0.0032)Arg+(0.083-
5)Phe+(-0.1466)Trp; 0.873, 0.892, 0.849, 0.848, 0.842, 0.848,
0.869, 0.851,
(4.1304)+(-0.0835)Asn+(0.0110)Gln+(-0.0887)His+(-0.0003)Leu+(0.101-
4)Phe+(-0.1222)Trp; 0.842, 0. 864, 0.857, 0.873, 0.847, 0.825,
0.861, 0.851, (4.5031)+(-0.1189)A
sn+(0.0076)Gln+(-0.0113)Val+(-0.0002)Lys+(0.1006)Phe+(-0.14 25)Trp;
0.847, 0.864, 0.857, 0.873, 0.847, 0.825, 0.861, 0.851, (4.5
012)+(-0.1192)Asn+(0.0076)Gln+(-0.0114)Val+(0.1005)Phe+(-0.
1425)Trp; 0.819, 0.843, 0.855, 0.863, 0.856, 0.858, 0.830, 0.851,
(5. 6067)+(-0.0680)Asn+(0.0105)Gln+(-0.0579)Cit+(-0.0775)Met+(0.
0109)Leu+(-0.1237)Trp; 0.814, 0.839, 0.855, 0.863, 0.855, 0.857, 0.
831, 0.851,
(5.9974)+(-0.0889)Asn+(0.0099)Gln+(-0.0600)Cit+(-0.0026)Lys+(0.008-
4)Leu+(-0.1273)Trp; 0.856, 0.875, 0.843, 0.840, 0.825, 0.875,
0.865, 0.851,
(5.6391)+(-0.0894)Asn+(0.0081)Gln+(-0.0686)Cit+(0.1097)Ile+(-0.044-
7)Leu+(-0.1169)Trp; 0.813, 0. 838, 0.855, 0.866, 0.851, 0.860,
0.828, 0.851, (6.4138)+(-0.0916)A
sn+(0.0095)Gln+(-0.0606)Cit+(0.0068)Arg+(-0.0019)Lys+(-0.12 38)Trp;
0.884, 0.901, 0.844, 0.832, 0.839, 0.854, 0.880, 0.851, (2.0
499)+(0.0118)Gln+(-0.0940)His+(-0.2274)Met+(0.0420)Ile+(0.1
165)Phe+(-0.1146)Trp; 0.833, 0.854, 0.852, 0.857, 0.855, 0.876, 0.
816, 0.851,
(6.3446)+(-0.0858)Asn+(0.0085)Gln+(-0.0036)Ala+(-0.0827)Cit+(0.039-
9)Orn+(-0.1185)Trp; 0.844, 0.867, 0.855, 0.861, 0.854, 0.831,
0.859, 0.851,
(4.1532)+(-0.1213)Asn+(0.0093)Gln+(-0.0701)Cit+(0.0073)Arg+(0.0880-
)Phe+(-0.1552)Trp; 0.812, 0.8 38, 0.854, 0.861, 0.857, 0.855,
0.832, 0.851, (5.9157)+(-0.0939)As
n+(0.0096)Gln+(-0.0597)Cit+(0.0054)Tyr+(0.0067)Leu+(-0.130 9)Trp;
0.846, 0.868, 0.857, 0.868, 0.857, 0.832, 0.847, 0.851, (2.45
49)+(0.0096)Gln+(-0.0020)Ala+(-0.0570)Cit+(-0.2059)Met+(0.1
155)Phe+(-0.1458)Trp; 0.842, 0.863, 0.857, 0.871, 0.851, 0.820, 0.
862, 0.851,
(2.9539)+(-0.0618)Asn+(0.0090)Gln+(-0.0018)Ala+(-0.1665)Met+(0.110-
5)Phe+(-0.1453)Trp; 0.859, 0.878, 0.839, 0.838, 0.806, 0.876,
0.883, 0.851,
(5.5211)+(-0.0556)Asn+(0.0071)Gln+(-0.0306)Val+(-0.1601)Met+(0.122-
1)Ile+(-0.0872)Trp; 0.872, 0. 890, 0.837, 0.835, 0.795, 0.862,
0.911, 0.851, (6.1834)+(-0.0880)A
sn+(-0.0059)Ala+(-0.0341)Val+(0.1111)Ile+(0.0892)Phe+(-0.10 65)Trp;
0.861, 0.879, 0.831, 0.811, 0.804, 0.880, 0.907, 0.851, (6.6
747)+(-0.0060)Ala+(0.0404)Tyr+(-0.0328)Val+(-0.1943)Met+(0.
1415)Ile+(-0.0867)Trp; 0.801, 0.827, 0.853, 0.869, 0.840, 0.856, 0.
838, 0.851, (6.3135)+(-0.0839)Asn+(0.0075)Gln+(-0.0030)Ala+(0.
0105)Tyr+(-0.0021)Val+(-0.1222)Trp; 0.834, 0.853, 0.853, 0.866,
0.838, 0.829, 0.868, 0.850,
(4.1858)+(-0.1024)Asn+(0.0073)Gln+(-0.0042)Ala+(0.0836)Phe+(-0.1471)Trp;
0.835, 0.856, 0.850, 0.8 57, 0.845, 0.867, 0.833, 0.850,
(6.5698)+(-0.0676)Asn+(0.0116)Gl
n+(-0.0647)His+(-0.0376)Cit+(0.0032)Lys+(-0.0986)Trp; 0.821, 0.844,
0.854, 0.863, 0.853, 0.860, 0.824, 0.850, (5.9896)+(-0.067
4)Asn+(0.0099)Gln+(-0.0535)Cit+(0.0049)Pro+(-0.0736)Met+(-0.
1185)Trp; 0.818, 0.838, 0.855, 0.868, 0.852, 0.860, 0.820, 0.850,
(6.
2676)+(-0.0890)Asn+(0.0098)Gln+(-0.0557)Cit+(-0.0003)Lys+(-0.1237)Trp;
0.861, 0.878, 0.835, 0.833, 0.794, 0.879, 0.894, 0.850,
(5.1510)+(0.0056)Gln+(-0.0053)Ala+(-0.0295)Val+(-0.1808)Met
+(0.1311)Ile+(-0.0826)Trp; 0.822, 0.838, 0.854, 0.868, 0.852, 0.8
59, 0.821, 0.850, (6.2580)+(-0.0894)Asn+(0.0097)Gln+(-0.0557)C
it+(-0.1239)Trp; 0.806, 0.830, 0.854, 0.867, 0.850, 0.853, 0.830,
0. 850,
(5.7845)+(-0.0635)Asn+(0.0083)Gln+(0.0215)Tyr+(-0.0025)Val+(-0.0978)Met+(-
-0.1237)Trp; 0.835, 0.861, 0.852, 0.860, 0.843, 0.847, 0.848,
0.850, (3.9364)+(0.0067)Gln+(-0.0053)Ala+(-0.061
0)Cit+(-0.0089)Lys+(0.0823)Phe+(-0.1445)Trp; 0.814, 0.837, 0.8 54,
0.868, 0.853, 0.858, 0.821, 0.850, (6.2188)+(-0.0885)Asn+(0.0
098)Gln+(-0.0566)Cit+(0.0007)Val+(-0.0006)Lys+(-0.1245)Trp; 0.814,
0.837, 0.854, 0.868, 0.853, 0.858, 0.821, 0.850,
(6.2188)+(-0.0885)Asn+(0.0098)Gln+(-0.0566)Cit+(0.0007)Val+(-0.0006)Ly
s+(-0.1245)Trp
[0467] List (1) of Logistic Regression Equations Searched in
Example 4
[0468] The logistic regression equations searched in Example 4
above are listed below. Before each equation, "the value of ROC_AUC
for the pancreatic cancer group and the other cancers group with
validation", "the value of ROC_AUC for the pancreatic cancer group
and the other cancers group without validation", "the value of
ROC_AUC for the pancreatic cancer group and the healthy group",
"the value of ROC_AUC for the pancreatic cancer group and the lung
cancer group", "the value of ROC_AUC for the pancreatic cancer
group and the colorectal cancer group", "the value of ROC_AUC for
the pancreatic cancer group and the prostatic cancer group", "the
value of ROC_AUC for the pancreatic cancer group and the breast
cancer group", and "the average value of the value of ROC_AUC for
the pancreatic cancer group and the lung cancer group, the value of
ROC_AUC for the pancreatic cancer group and the colorectal cancer
group, the value of ROC_AUC for the pancreatic cancer group and the
prostatic cancer group, and the value of ROC_AUC for the pancreatic
cancer group and the breast cancer group" obtained for the equation
are additionally listed.
[0469] 0.854, 0.873, 0.835, 0.891, 0.849, 0.888, 0.863, 0.873,
(1.707 2)+(-0.0985)Asn+(0.0115)Gln+(-0.0063)Ala+(-0.0582)Cit+(0.02
12)Phe+(-0.0792)Trp; 0.852, 0.871, 0.832, 0.884, 0.849, 0.896, 0.8
67, 0.874, (2.3113)+(-0.1017)Asn+(0.0110)Gln+(-0.0063)Ala+(-0.
0568)Cit+(0.0111)Ile+(-0.0719)Trp; 0.851, 0.869, 0.820, 0.889, 0.
845, 0.892, 0.850, 0.869, (2.6006)+(-0.1002)Asn+(0.0111)Gln+(-0.
0058)Ala+(-0.0561)Cit+(-0.0706)Trp; 0.850, 0.872, 0.823, 0.887,
0.851, 0.892, 0.863, 0.873,
(2.3468)+(-0.1053)Asn+(0.0111)Gln+(-0.0063)Ala+(-0.0570)Cit+(0.0137)Tyr+(-
-0.0747)Trp; 0.849, 0. 870, 0.846, 0.884, 0.866, 0.869, 0.842,
0.865, (1.2353)+(-0.0844)A
sn+(0.0123)Gln+(-0.0572)Cit+(-0.1339)Met+(0.0312)Phe+(-0.08 16)Trp;
0.849, 0.870, 0.808, 0.894, 0.845, 0.892, 0.842, 0.868, (2.7
671)+(-0.0984)Asn+(0.0120)Gln+(-0.0048)Ala+(-0.0551)Cit+(-0.
0068)Pro+(-0.0739)Trp; 0.849, 0.869, 0.784, 0.884, 0.857, 0.847, 0.
870, 0.865,
(3.8383)+(-0.0962)Asn+(-0.0121)Gly+(0.0143)Gln+(-0.0492)Cit+(-0.01-
12)Pro+(-0.0942)Trp; 0.848, 0.870, 0.819, 0.89 2, 0.845, 0.893,
0.849, 0.870, (2.7323)+(-0.0997)Asn+(0.0111)Gln
+(-0.0055)Ala+(-0.0544)Cit+(-0.0019)Val+(-0.0677)Trp; 0.848, 0.870,
0.820, 0.889, 0.846, 0.892, 0.850, 0.869, (2.5966)+(-0.099
0)Asn+(0.0112)Gln+(-0.0058)Ala+(-0.0560)Cit+(-0.0008)Lys+(-0.0698)Trp;
0.848, 0.869, 0.821, 0.888, 0.846, 0.891, 0.851, 0.869,
(2.5842)+(-0.1004)Asn+(0.0110)Gln+(-0.0058)Ala+(-0.0575)Cit
+(0.0021)Orn+(-0.0706)Trp; 0.848, 0.869, 0.821, 0.887, 0.846, 0.8
91, 0.853, 0.869, (2.5115)+(-0.1010)Asn+(0.0112)Gln+(-0.0060)A
la+(-0.0567)Cit+(0.0021)Leu+(-0.0722)Trp; 0.847, 0.871, 0.820,
0.890, 0.849, 0.892, 0.850, 0.870, (2.5117)+(-0.0856)Asn+(0.011
8)Gln+(-0.0051)Ala+(-0.0536)Cit+(-0.0683)Met+(-0.0633)Trp; 0. 847,
0.872, 0.836, 0.889, 0.848, 0.900, 0.855, 0.873, (2.5945)+(-0.
0937)Asn+(0.0118)Gln+(-0.0223)His+(-0.0050)Ala+(-0.0487)Cit
+(-0.0610)Trp; 0.847, 0.867, 0.816, 0.894, 0.829, 0.878, 0.866, 0.8
67,
(2.2693)+(-0.1096)Asn+(0.0092)Gln+(-0.0060)Ala+(-0.0061)Val+(0.0201)Phe+(-
-0.0668)Trp; 0.847, 0.868, 0.804, 0.890, 0.844, 0.880, 0.850,
0.866, (2.9468)+(-0.0090)Ser+(-0.0912)Asn+(0.012
1)Gln+(-0.0062)Ala+(-0.0562)Cit+(-0.0724)Trp; 0.846, 0.867, 0. 805,
0.889, 0.841, 0.882, 0.855, 0.867, (2.4617)+(-0.0897)Asn+(0.
0121)Gln+(-0.0093)Thr+(-0.0056)Ala+(-0.0575)Cit+(-0.0664)Tr p;
0.846, 0.869, 0.838, 0.886, 0.858, 0.874, 0.842, 0.865,
(2.3818)+(-0.1068)Asn+(0.0100)Gln+(-0.0557)Cit+(-0.0062)Val+(0.0189)
Phe+(-0.0831)Trp; 0.846, 0.868, 0.793, 0.881, 0.849, 0.859, 0.882,
0.868, (3.3740)+(-0.0924)Asn+(-0.0110)Gly+(0.0134)Gln+(-0.00
52)Ala+(-0.0504)Cit+(-0.0788)Trp; 0.845, 0.867, 0.823, 0.888, 0.
858, 0.865, 0.833, 0.861, (2.0486)+(-0.1048)Asn+(0.0120)Gln+(-0.
0596)Cit+(-0.0115)Pro+(0.0223)Phe+(-0.0965)Trp; 0.845, 0.868,
0.845, 0.882, 0.852, 0.886, 0.852, 0.868,
(2.8826)+(-0.1094)Asn+(0.0093)Gln+(-0.0522)Cit+(-0.0094)Val+(0.0189)Ile+(-
-0.0729) Trp; 0.845, 0.865, 0.828, 0.888, 0.820, 0.892, 0.878,
0.869, (2.713
6)+(-0.1154)Asn+(0.0087)Gln+(-0.0058)Ala+(-0.0098)Val+(0.02
38)Ile+(-0.0565)Trp; 0.844, 0.868, 0.813, 0.890, 0.845, 0.885, 0.8
42, 0.866, (2.5586)+(-0.0968)Asn+(0.0118)Gln+(-0.0057)Ala+(-0.
0484)Cit+(-0.0106)Arg+(-0.0667)Trp; 0.844, 0.867, 0.858, 0.875,
0.859, 0.877, 0.856, 0.867,
(1.9144)+(-0.0985)Asn+(0.0116)Gln+(-0.0373)His+(-0.0484)Cit+(0.0186)Phe+(-
-0.0747)Trp; 0.844, 0. 866, 0.760, 0.888, 0.843, 0.840, 0.874,
0.861, (4.8087)+(-0.1039)A
sn+(-0.0144)Gly+(0.0131)Gln+(-0.0103)Pro+(-0.0097)Val+(-0.0
762)Trp; 0.844, 0.864, 0.788, 0.884, 0.842, 0.828, 0.884, 0.860,
(4. 1888)+(-0.1114)Asn+(-0.0146)Gly+(0.0118)Gln+(-0.0126)Val+(0.
0169)Phe+(-0.0789)Trp; 0.844, 0.865, 0.835, 0.886, 0.847, 0.873, 0.
844, 0.863,
(0.6243)+(0.0108)Gln+(-0.0056)Ala+(-0.0583)Cit+(-0.1610)Met+(0.033-
6)Phe+(-0.0779)Trp; 0.844, 0.866, 0.807, 0.872, 0.861, 0.838,
0.879, 0.862,
(3.0000)+(-0.1069)Asn+(-0.0115)Gly+(0.0129)Gln+(-0.0551)Cit+(0.014-
7)Phe+(-0.0994)Trp; 0.844, 0.8 65, 0.837, 0.882, 0.859, 0.865,
0.832, 0.860, (2.2031)+(-0.1074)As
n+(0.0101)Gln+(-0.0594)Cit+(-0.0084)Leu+(0.0218)Phe+(-0.087 0)Trp;
0.843, 0.864, 0.838, 0.875, 0.861, 0.863, 0.840, 0.860, (2.09
25)+(-0.1115)Asn+(0.0100)Gln+(-0.0612)Cit+(0.0157)Phe+(-0.0
921)Trp; 0.843, 0.866, 0.788, 0.881, 0.849, 0.844, 0.877, 0.863,
(4.
3296)+(-0.0996)Asn+(-0.0132)Gly+(0.0130)Gln+(-0.0442)Cit+(-0.0091)Val+(-0-
.0775)Trp; 0.843, 0.865, 0.846, 0.882, 0.836, 0.879, 0.873, 0.867,
(1.9077)+(-0.1020)Asn+(0.0111)Gln+(-0.0396)His+(-0.0051)Ala+(0.0197)Phe+(-
-0.0605)Trp; 0.843, 0.862, 0.797, 0.8 69, 0.857, 0.840, 0.871,
0.860, (3.5957)+(-0.1052)Asn+(-0.0118)G
ly+(0.0126)Gln+(-0.0529)Cit+(-0.0929)Trp; 0.843, 0.866, 0.837,
0.878, 0.860, 0.866, 0.843, 0.862, (1.9994)+(-0.1037)Asn+(0.010
7)Gln+(-0.0608)Cit+(-0.0051)Lys+(0.0174)Phe+(-0.0879)Trp; 0. 843,
0.861, 0.815, 0.885, 0.827, 0.866, 0.864, 0.860, (1.9633)+(-0.
1140)Asn+(0.0092)Gln+(-0.0066)Ala+(0.0175)Phe+(-0.0750)Trp; 0.843,
0.865, 0.828, 0.894, 0.845, 0.856, 0.838, 0.858,
(1.9014)+(-0.0885)Asn+(0.0107)Gln+(-0.0091)Val+(-0.1551)Met+(0.0330)Ph
e+(-0.0629)Trp; 0.843, 0.865, 0.800, 0.891, 0.833, 0.868, 0.860, 0.
863, (2.0354)+(-0.1115)Asn+(0.0104)Gln+(-0.0053)Ala+(-0.008
6)Pro+(0.0203)Phe+(-0.0792)Trp; 0.843, 0.865, 0.776, 0.886, 0.83 4,
0.853, 0.883, 0.864, (4.3559)+(-0.1025)Asn+(-0.0135)Gly+(0.0
121)Gln+(-0.0040)Ala+(-0.0090)Val+(-0.0661)Trp; 0.843, 0.864,
0.822, 0.888, 0.837, 0.865, 0.858, 0.862,
(1.2887)+(-0.0886)Asn+(0.0111)Gln+(-0.0052)Ala+(-0.1275)Met+(0.0289)Phe+(-
-0.0671) Trp; 0.842, 0.862, 0.809, 0.884, 0.852, 0.869, 0.821,
0.856, (2.944
4)+(-0.1069)Asn+(0.0115)Gln+(-0.0567)Cit+(-0.0100)Pro+(-0.0
861)Trp; 0.842, 0.864, 0.773, 0.882, 0.850, 0.820, 0.878, 0.858,
(3. 4727)+(-0.1125)Asn+(-0.0128)Gly+(0.0130)Gln+(-0.0131)Pro+(0.
0163)Phe+(-0.1001)Trp; 0.842, 0.865, 0.810, 0.882, 0.859, 0.871, 0.
827, 0.860,
(2.7620)+(-0.1110)Asn+(0.0115)Gln+(-0.0572)Cit+(-0.0106)Pro+(0.011-
2)Tyr+(-0.0905)Trp; 0.842, 0.860, 0.776, 0.880, 0.839, 0.831,
0.876, 0.856,
(4.7447)+(-0.1110)Asn+(-0.0145)Gly+(0.0116)Gln+(-0.0116)Val+(-0.07-
27)Trp; 0.842, 0.866, 0.803, 0.8 94, 0.844, 0.863, 0.840, 0.860,
(2.6868)+(-0.1155)Asn+(0.0097)Gl
n+(-0.0111)Pro+(-0.0071)Val+(0.0204)Phe+(-0.0795)Trp; 0.842, 0.859,
0.825, 0.885, 0.840, 0.850, 0.836, 0.853, (2.7694)+(-0.121
1)Asn+(0.0079)Gln+(-0.0087)Val+(0.0162)Phe+(-0.0747)Trp; 0.8 42,
0.865, 0.857, 0.877, 0.854, 0.863, 0.853, 0.862, (1.4326)+(-0.0
806)Asn+(0.0122)Gln+(-0.0417)His+(-0.1327)Met+(0.0285)Phe+(-0.0597)Trp;
0.842, 0.865, 0.790, 0.876, 0.856, 0.841, 0.867, 0.86 0,
(4.0160)+(-0.0989)Asn+(-0.0126)Gly+(0.0126)Gln+(-0.0502)C
it+(-0.0085)Leu+(-0.0855)Trp; 0.842, 0.862, 0.828, 0.879, 0.856,
0.871, 0.824, 0.858, (2.6469)+(-0.0905)Asn+(0.0110)Gln+(-0.054
7)Cit+(-0.0953)Met+(-0.0724)Trp; 0.842, 0.859, 0.830, 0.873, 0.8
53, 0.865, 0.831, 0.855, (2.7424)+(-0.1124)Asn+(0.0099)Gln+(-0.
0593)Cit+(-0.0850)Trp; 0.842, 0.862, 0.791, 0.879, 0.840, 0.841, 0.
881, 0.860, (4.4765)+(0.0106)Ser+(-0.1173)Asn+(-0.0166)Gly+(0.
0111)Gln+(-0.0116)Val+(-0.0712)Trp; 0.842, 0.862, 0.840, 0.882,
0.837, 0.868, 0.859, 0.861,
(2.6309)+(-0.1229)Asn+(0.0075)Gln+(-0.0125)Val+(0.0183)Ile+(0.0140)Phe+(--
0.0711)Trp; 0.842, 0.8 66, 0.764, 0.886, 0.842, 0.843, 0.878,
0.862, (3.8741)+(-0.1013)As
n+(-0.0126)Gly+(0.0130)Gln+(-0.0040)Ala+(-0.0094)Pro+(-0.08 31)Trp;
0.842, 0.864, 0.816, 0.889, 0.830, 0.870, 0.862, 0.863, (2.0
567)+(-0.1122)Asn+(0.0092)Gln+(-0.0063)Ala+(-0.0049)Leu+(0.
0206)Phe+(-0.0720)Trp; 0.842, 0.864, 0.807, 0.869, 0.858, 0.844, 0.
876, 0.862, (3.3874)+(0.0083)Ser+(-0.1115)Asn+(-0.0134)Gly+(0.
0122)Gln+(-0.0519)Cit+(-0.0914)Trp; 0.842, 0.864, 0.802, 0.886,
0.831, 0.882, 0.861, 0.865,
(2.8366)+(-0.1181)Asn+(0.0090)Gln+(-0.0057)Ala+(0.0141)Tyr+(-0.0059)Val+(-
-0.0636)Trp; 0.841, 0. 861, 0.822, 0.865, 0.851, 0.839, 0.889,
0.861, (3.1733)+(-0.1020)A
sn+(-0.0120)Gly+(0.0133)Gln+(-0.0464)His+(0.0135)Phe+(-0.07 57)Trp;
0.841, 0.860, 0.803, 0.889, 0.823, 0.879, 0.850, 0.860, (3.0
004)+(-0.1129)Asn+(0.0090)Gln+(-0.0055)Ala+(-0.0050)Val+(-0.
0602)Trp; 0.841, 0.862, 0.793, 0.878, 0.833, 0.844, 0.891, 0.861,
(4. 4905)+(-0.1142)Asn+(-0.0146)Gly+(0.0114)Gln+(-0.0160)Val+(0.
0206)Ile+(-0.0692)Trp; 0.841, 0.867, 0.830, 0.875, 0.868, 0.873, 0.
838, 0.864, (2.2861)+(-0.0896)Asn+(0.0110)Gln+(-0.0546)Cit+(0.
0182)Tyr+(-0.1193)Met+(-0.0774)Trp; 0.841, 0.865, 0.799, 0.876,
0.857, 0.846, 0.864, 0.861,
(3.4698)+(-0.0755)Asn+(-0.0117)Gly+(0.0135)Gln+(-0.0485)Cit+(-0.0992)Met+-
(-0.0816)Trp; 0.841, 0. 864, 0.815, 0.888, 0.830, 0.882, 0.860,
0.865, (2.9758)+(-0.1205)A
sn+(0.0094)Gln+(-0.0134)Pro+(-0.0128)Val+(0.0353)Ile+(-0.06 80)Trp;
0.841, 0.862, 0.789, 0.878, 0.838, 0.840, 0.887, 0.861, (3.0
725)+(-0.1084)Asn+(-0.0117)Gly+(0.0120)Gln+(-0.0057)Ala+(0.
0132)Phe+(-0.0835)Trp; 0.841, 0.864, 0.836, 0.881, 0.846, 0.869, 0.
853, 0.862,
(2.2038)+(-0.1030)Asn+(0.0119)Gln+(-0.0465)His+(-0.0109)Pro+(0.021-
5)Phe+(-0.0702)Trp; 0.841, 0.862, 0.781, 0.880, 0.836, 0.835,
0.887, 0.859,
(4.5981)+(-0.1133)Asn+(-0.0147)Gly+(0.0120)Gln+(-0.0199)Val+(0.016-
8)Leu+(-0.0749)Trp; 0.841, 0.8 62, 0.798, 0.874, 0.842, 0.846,
0.881, 0.861, (4.4317)+(-0.0987)As
n+(-0.0137)Gly+(0.0130)Gln+(-0.0332)His+(-0.0082)Val+(-0.06 18)Trp;
0.841, 0.865, 0.792, 0.876, 0.848, 0.848, 0.880, 0.863, (4.0
089)+(-0.0908)Asn+(-0.0127)Gly+(0.0142)Gln+(-0.0390)His+(-0.
0108)Pro+(-0.0739)Trp; 0.841, 0.862, 0.810, 0.875, 0.856, 0.831, 0.
864, 0.856,
(2.0237)+(-0.0118)Gly+(0.0125)Gln+(-0.0536)Cit+(-0.1846)Met+(0.026-
2)Phe+(-0.0934)Trp; 0.841, 0.856, 0.800, 0.881, 0.821, 0.871,
0.852, 0.856,
(2.6648)+(-0.1149)Asn+(0.0090)Gln+(-0.0062)Ala+(-0.0680)Trp; 0.841,
0.858, 0.812, 0.863, 0.846, 0.8 42, 0.882, 0.858,
(3.7353)+(-0.0993)Asn+(-0.0124)Gly+(0.0130)G
ln+(-0.0445)His+(-0.0709)Trp; 0.841, 0.866, 0.819, 0.878, 0.855,
0.884, 0.847, 0.866, (1.5472)+(0.0097)Gln+(-0.0061)Ala+(-0.056
0)Cit+(0.0283)Tyr+(-0.1648)Met+(-0.0744)Trp; 0.841, 0.866, 0.8 27,
0.884, 0.853, 0.882, 0.836, 0.864, (2.9297)+(-0.0966)Asn+(0.0
124)Gln+(-0.0298)His+(-0.0464)Cit+(-0.0091)Pro+(-0.0702)Tr p;
0.841, 0.865, 0.804, 0.874, 0.843, 0.859, 0.889, 0.866,
(3.5734)+(-0.0925)Asn+(-0.0119)Gly+(0.0133)Gln+(-0.0357)His+(-0.004
2)Ala+(-0.0643)Trp; 0.841, 0.862, 0.819, 0.882, 0.837, 0.871, 0.85
4, 0.861, (2.7968)+(-0.0916)Asn+(0.0109)Gln+(-0.0255)Val+(-0.
1691)Met+(0.0379)Leu+(-0.0530)Trp; 0.841, 0.861, 0.844, 0.870, 0.
852, 0.877, 0.843, 0.860, (2.7090)+(-0.1006)Asn+(0.0112)Gln+(-0.
0339)His+(-0.0474)Cit+(-0.0674)Trp; 0.841, 0.863, 0.804, 0.877,
0.854, 0.820, 0.874, 0.856,
(2.6558)+(-0.0831)Asn+(-0.0119)Gly+(0.0128)Gln+(-0.1449)Met+(0.0233)Phe+(-
-0.0864)Trp; 0.841, 0.8 62, 0.825, 0.882, 0.850, 0.870, 0.826,
0.857, (3.0838)+(-0.1087)As
n+(0.0098)Gln+(-0.0545)Cit+(-0.0051)Val+(-0.0762)Trp; 0.841, 0.860,
0.779, 0.877, 0.834, 0.842, 0.881, 0.859, (3.6115)+(-0.105
8)Asn+(-0.0121)Gly+(0.0118)Gln+(-0.0055)Ala+(-0.0788)Trp; 0. 841,
0.864, 0.813, 0.868, 0.856, 0.849, 0.882, 0.864, (3.5123)+(-0.
0906)Asn+(-0.0116)Gly+(0.0138)Gln+(-0.0336)His+(-0.0414)Cit
+(-0.0760)Trp; 0.841, 0.863, 0.828, 0.875, 0.860, 0.856, 0.838, 0.8
58, (2.3351)+(-0.0052)Ser+(-0.1066)Asn+(0.0105)Gln+(-0.0614)
Cit+(0.0147)Phe+(-0.0933)Trp; 0.841, 0.864, 0.797, 0.872, 0.858,
0.842, 0.872, 0.861, (3.5957)+(-0.1014)Asn+(-0.0117)Gly+(0.012
8)Gln+(-0.0525)Cit+(-0.0022)Lys+(-0.0909)Trp; 0.840, 0.865, 0. 809,
0.889, 0.852, 0.878, 0.818, 0.859, (3.1554)+(-0.1054)Asn+(0.
0114)Gln+(-0.0536)Cit+(-0.0093)Pro+(-0.0034)Val+(-0.0801)Tr p;
0.840, 0.861, 0.763, 0.880, 0.846, 0.824, 0.871, 0.855,
(4.1032)+(-0.1091)Asn+(-0.0132)Gly+(0.0127)Gln+(-0.0122)Pro+(-0.093
7)Trp; 0.840, 0.863, 0.820, 0.879, 0.853, 0.870, 0.836, 0.859,
(2.57 64)+(-0.1086)Asn+(0.0115)Gln+(-0.0578)Cit+(-0.0123)Pro+(0.0
157)Ile+(-0.0898)Trp; 0.840, 0.863, 0.835, 0.877, 0.859, 0.862, 0.
836, 0.858,
(2.1404)+(-0.1108)Asn+(0.0101)Gln+(-0.0611)Cit+(-0.0034)Ile+(0.016-
6)Phe+(-0.0918)Trp; 0.840, 0.865, 0.837, 0.876, 0.860, 0.872,
0.838, 0.862,
(2.3981)+(-0.0898)Asn+(0.0108)Gln+(-0.0551)Cit+(-0.1062)Met+(0.009-
6)Ile+(-0.0728)Trp; 0.840, 0. 864, 0.821, 0.884, 0.854, 0.877,
0.821, 0.859, (2.9704)+(-0.0901)A
sn+(0.0110)Gln+(-0.0504)Cit+(-0.0048)Val+(-0.0906)Met+(-0.0
644)Trp; 0.840, 0.864, 0.828, 0.882, 0.850, 0.875, 0.839, 0.861,
(2. 9830)+(-0.1095)Asn+(0.0099)Gln+(-0.0531)Cit+(-0.0103)Val+(0.
0105)Leu+(-0.0777)Trp; 0.840, 0.862, 0.813, 0.888, 0.819, 0.883, 0.
867, 0.865,
(2.8107)+(-0.1126)Asn+(0.0093)Gln+(-0.0058)Ala+(-0.0129)Val+(0.016-
9)Leu+(-0.0631)Trp; 0.840, 0.862, 0.804, 0.887, 0.826, 0.860,
0.871, 0.861,
(1.8017)+(-0.1065)Asn+(0.0101)Gln+(-0.0086)Thr+(-0.0064)Ala+(0.018-
9)Phe+(-0.0711)Trp; 0.840, 0. 864, 0.808, 0.886, 0.853, 0.873,
0.820, 0.858, (2.9330)+(-0.1036)A
sn+(0.0117)Gln+(-0.0563)Cit+(-0.0098)Pro+(-0.0023)Lys+(-0.0
838)Trp; 0.840, 0.862, 0.815, 0.886, 0.828, 0.867, 0.864, 0.861,
(1. 9363)+(-0.1104)Asn+(0.0096)Gln+(-0.0065)Ala+(-0.0026)Lys+(0.
0179)Phe+(-0.0729)Trp; 0.840, 0.859, 0.830, 0.877, 0.829, 0.881, 0.
859, 0.861,
(2.7153)+(-0.1033)Asn+(0.0106)Gln+(-0.0369)His+(-0.0048)Ala+(-0.05-
30)Trp; 0.840, 0.861, 0.828, 0.876, 0.855, 0.870, 0.830, 0.857,
(2.7362)+(-0.1068)Asn+(0.0103)Gln+(-0.0587)Cit+(-0.0038)Lys+(-0.0812)Trp;
0.840, 0.862, 0.791, 0.872, 0.857, 0.8 33, 0.867, 0.857,
(3.7777)+(-0.1036)Asn+(-0.0120)Gly+(0.0128)G
ln+(-0.0523)Cit+(-0.0061)Ile+(-0.0918)Trp; 0.840, 0.861, 0.791,
0.887, 0.837, 0.825, 0.869, 0.854, (3.0237)+(-0.0139)Gly+(0.011
4)Gln+(-0.0117)Val+(-0.1910)Met+(0.0295)Phe+(-0.0774)Trp; 0. 840,
0.860, 0.818, 0.882, 0.826, 0.865, 0.867, 0.860, (1.8745)+(-0.
1149)Asn+(0.0092)Gln+(-0.0068)Ala+(0.0049)Ile+(0.0165)Phe+(-0.0754)Trp;
0.840, 0.863, 0.852, 0.883, 0.836, 0.878, 0.856, 0.86 3,
(0.8547)+(0.0106)Gln+(-0.0386)His+(-0.0043)Ala+(-0.1722)M
et+(0.0308)Phe+(-0.0594)Trp; 0.840, 0.861, 0.786, 0.879, 0.848, 0.
811, 0.873, 0.853, (3.8030)+(-0.1144)Asn+(-0.0137)Gly+(0.0112)
Gln+(-0.0143)Leu+(0.0193)Phe+(-0.0882)Trp; 0.840, 0.859, 0.831,
0.873, 0.854, 0.865, 0.831, 0.856, (2.7159)+(-0.1126)Asn+(0.009
8)Gln+(-0.0594)Cit+(0.0010)Ile+(-0.0852)Trp; 0.840, 0.860, 0.8 04,
0.889, 0.831, 0.859, 0.840, 0.855, (1.7534)+(-0.1031)Asn+(0.0
114)Gln+(-0.0064)Ala+(-0.0225)Arg+(0.0201)Phe+(-0.0691)Trp; 0.839,
0.862, 0.839, 0.879, 0.836, 0.879, 0.857, 0.863,
(2.7140)+(-0.0976)Asn+(0.0093)Gln+(-0.0150)Val+(-0.1446)Met+(0.0379)Il
e+(-0.0438)Trp
[0470] List (1) of Linear Discriminants Searched in Example 4
[0471] The linear discriminants searched in Example 4 above are
listed below. Before each equation, "the value of ROC_AUC for the
pancreatic cancer group and the other cancers group with
validation", "the value of ROC_AUC for the pancreatic cancer group
and the other cancers group without validation", "the value of
ROC_AUC for the pancreatic cancer group and the healthy group",
"the value of ROC_AUC for the pancreatic cancer group and the lung
cancer group", "the value of ROC_AUC for the pancreatic cancer
group and the colorectal cancer group", "the value of ROC_AUC for
the pancreatic cancer group and the prostatic cancer group", "the
value of ROC_AUC for the pancreatic cancer group and the breast
cancer group", and "the average value of the value of ROC_AUC for
the pancreatic cancer group and the lung cancer group, the value of
ROC_AUC for the pancreatic cancer group and the colorectal cancer
group, the value of ROC_AUC for the pancreatic cancer group and the
prostatic cancer group, and the value of ROC_AUC for the pancreatic
cancer group and the breast cancer group" obtained for the equation
are additionally listed.
[0472] 0.859, 0.874, 0.841, 0.890, 0.853, 0.883, 0.868, 0.873,
(5.446 8)+(-0.1111)Asn+(0.0122)Gln+(-0.0083)Ala+(-0.0524)Cit+(0.03
45)Phe+(-0.1015)Trp; 0.859, 0.874, 0.808, 0.889, 0.852, 0.878, 0.8
78, 0.874, (6.8056)+(-0.0977)Asn+(-0.0069)Gly+(0.0132)Gln+(-0.
0072)Ala+(-0.0462)Cit+(-0.0919)Trp; 0.858, 0.874, 0.848, 0.892,
0.863, 0.868, 0.854, 0.869,
(5.6035)+(-0.1337)Asn+(0.0116)Gln+(-0.0452)Cit+(-0.0098)Val+(0.0408)Phe+(-
-0.1050)Trp; 0.858, 0. 872, 0.849, 0.895, 0.857, 0.859, 0.854,
0.866, (4.8108)+(-0.0961)A
sn+(0.0115)Gln+(-0.0125)Val+(-0.1461)Met+(0.0663)Phe+(-0.09 71)Trp;
0.858, 0.871, 0.811, 0.894, 0.844, 0.895, 0.848, 0.870, (6.5
042)+(-0.1023)Asn+(0.0128)Gln+(-0.0067)Ala+(-0.0490)Cit+(-0.
0066)Pro+(-0.0903)Trp; 0.857, 0.869, 0.822, 0.890, 0.843, 0.891, 0.
854, 0.869,
(6.4072)+(-0.1027)Asn+(0.0120)Gln+(-0.0080)Ala+(-0.0507)Cit+(-0.08-
76)Trp; 0.857, 0.872, 0.800, 0.888, 0.861, 0.855, 0.864, 0.867,
(6.7332)+(-0.1105)Asn+(-0.0083)Gly+(0.0144)Gln+(-0.0439)Cit+(-0.0102)Pro+-
(-0.1075)Trp; 0.857, 0.874, 0.857, 0. 886, 0.869, 0.867, 0.853,
0.869, (4.0729)+(-0.0942)Asn+(0.0132)G
ln+(-0.0523)Cit+(-0.1417)Met+(0.0541)Phe+(-0.1117)Trp; 0.856,
0.870, 0.833, 0.885, 0.844, 0.894, 0.868, 0.873, (6.1244)+(-0.105
0)Asn+(0.0118)Gln+(-0.0087)Ala+(-0.0540)Cit+(0.0138)Ile+(-0.
0889)Trp; 0.856, 0.871, 0.823, 0.891, 0.846, 0.894, 0.852, 0.871,
(6.
2462)+(-0.0877)Asn+(0.0125)Gln+(-0.0073)Ala+(-0.0497)Cit+(-0.0524)Met+(-0-
.0833)Trp; 0.856, 0.872, 0.835, 0.890, 0.845, 0.901, 0.860, 0.874,
(6.4966)+(-0.0951)Asn+(0.0128)Gln+(-0.0248)His+(-0.0074)Ala+(-0.0456)Cit+-
(-0.0771)Trp; 0.856, 0.870, 0.823, 0. 896, 0.850, 0.858, 0.851,
0.864, (5.8194)+(-0.1324)Asn+(0.0113)G
ln+(-0.0106)Pro+(-0.0108)Val+(0.0473)Phe+(-0.1078)Trp; 0.855,
0.869, 0.829, 0.895, 0.833, 0.878, 0.871, 0.869, (5.9985)+(-0.117
2)Asn+(0.0101)Gln+(-0.0073)Ala+(-0.0092)Val+(0.0417)Phe+(-0.
0931)Trp; 0.855, 0.870, 0.795, 0.892, 0.838, 0.868, 0.880, 0.870,
(7.
5122)+(-0.1003)Asn+(-0.0083)Gly+(0.0116)Gln+(-0.0061)Ala+(-0.0076)Val+(-0-
.0835)Trp; 0.855, 0.872, 0.824, 0.885, 0.851, 0.890, 0.868, 0.873,
(6.2747)+(-0.1094)Asn+(0.0117)Gln+(-0.0086)Ala+(-0.0521)Cit+(0.0214)Tyr+(-
-0.0981)Trp; 0.855, 0.869, 0.821, 0.8 90, 0.843, 0.891, 0.853,
0.869, (6.4558)+(-0.1023)Asn+(0.0119)Gl
n+(-0.0079)Ala+(-0.0503)Cit+(-0.0012)Leu+(-0.0868)Trp; 0.855,
0.871, 0.867, 0.879, 0.863, 0.872, 0.864, 0.870, (5.1147)+(-0.121
3)Asn+(0.0130)Gln+(-0.0367)His+(-0.0468)Cit+(0.0353)Phe+(-0.
1017)Trp; 0.855, 0.870, 0.815, 0.891, 0.844, 0.889, 0.855, 0.870,
(6.
5195)+(-0.0041)Ser+(-0.0995)Asn+(0.0124)Gln+(-0.0080)Ala+(-0.0513)Cit+(-0-
.0879)Trp; 0.855, 0.871, 0.819, 0.892, 0.845, 0.896, 0.850, 0.871,
(6.5601)+(-0.0953)Asn+(0.0126)Gln+(-0.0077)Ala+(-0.0510)Cit+(-0.0059)Lys+-
(-0.0835)Trp; 0.855, 0.872, 0.828, 0. 879, 0.869, 0.845, 0.876,
0.867, (5.7732)+(-0.1237)Asn+(-0.0073)
Gly+(0.0129)Gln+(-0.0488)Cit+(0.0224)Phe+(-0.1163)Trp; 0.855,
0.870, 0.814, 0.890, 0.842, 0.890, 0.858, 0.870, (6.2561)+(-0.096
1)Asn+(0.0126)Gln+(-0.0058)Thr+(-0.0078)Ala+(-0.0496)Cit+(-0.0857)Trp;
0.855, 0.870, 0.845, 0.887, 0.866, 0.860, 0.843, 0.864,
(5.3112)+(-0.1294)Asn+(0.0115)Gln+(-0.0500)Cit+(-0.0135)Leu
+(0.0430)Phe+(-0.1112)Trp; 0.855, 0.871, 0.815, 0.881, 0.864, 0.8
58, 0.864, 0.867, (6.2662)+(-0.0895)Asn+(-0.0081)Gly+(0.0138)G
ln+(-0.0452)Cit+(-0.0844)Met+(-0.0980)Trp; 0.855, 0.868, 0.814,
0.875, 0.865, 0.848, 0.867, 0.864, (6.4563)+(-0.1169)Asn+(-0.008
1)Gly+(0.0129)Gln+(-0.0471)Cit+(-0.1070)Trp; 0.854, 0.870, 0.8 32,
0.888, 0.862, 0.863, 0.845, 0.865, (5.1434)+(-0.1290)Asn+(0.0
132)Gln+(-0.0512)Cit+(-0.0113)Pro+(0.0381)Phe+(-0.1204)Trp; 0.854,
0.870, 0.807, 0.887, 0.855, 0.856, 0.868, 0.866,
(7.1793)+(-0.1140)Asn+(-0.0086)Gly+(0.0129)Gln+(-0.0388)Cit+(-0.0081)V
al+(-0.0938)Trp; 0.854, 0.870, 0.818, 0.890, 0.850, 0.834, 0.880,
0. 864, (6.6708)+(-0.1247)Asn+(-0.0086)Gly+(0.0115)Gln+(-0.012
9)Val+(0.0332)Phe+(-0.1013)Trp; 0.854, 0.870, 0.821, 0.893, 0.84 2,
0.892, 0.851, 0.870, (6.6454)+(-0.1031)Asn+(0.0119)Gln+(-0.0
075)Ala+(-0.0478)Cit+(-0.0031)Val+(-0.0833)Trp; 0.854, 0.869,
0.819, 0.891, 0.844, 0.888, 0.852, 0.869,
(6.3509)+(-0.1005)Asn+(0.0122)Gln+(-0.0079)Ala+(-0.0480)Cit+(-0.0040)Arg+-
(-0.086 8)Trp; 0.854, 0.868, 0.785, 0.890, 0.841, 0.861, 0.873,
0.866, (7.05
17)+(-0.0993)Asn+(-0.0082)Gly+(0.0125)Gln+(-0.0058)Ala+(-0.
0081)Pro+(-0.0971)Trp; 0.854, 0.871, 0.844, 0.882, 0.869, 0.872, 0.
848, 0.868,
(5.2217)+(-0.1212)Asn+(0.0126)Gln+(-0.0549)Cit+(-0.0099)Lys+(0.035-
1)Phe+(-0.1109)Trp; 0.854, 0.869, 0.810, 0.885, 0.842, 0.857,
0.889, 0.868,
(6.1928)+(-0.1069)Asn+(-0.0070)Gly+(0.0112)Gln+(-0.0077)Ala+(0.024-
3)Phe+(-0.1030)Trp; 0.854, 0.8 69, 0.846, 0.883, 0.850, 0.887,
0.859, 0.870, (6.4355)+(-0.1302)As
n+(0.0110)Gln+(-0.0463)Cit+(-0.0135)Val+(0.0270)Ile+(-0.087 1)Trp;
0.853, 0.867, 0.846, 0.878, 0.865, 0.857, 0.850, 0.862, (5.07
82)+(-0.1336)Asn+(0.0116)Gln+(-0.0542)Cit+(0.0302)Phe+(-0.1
166)Trp; 0.853, 0.869, 0.849, 0.886, 0.838, 0.886, 0.877, 0.872,
(5. 5655)+(-0.1034)Asn+(0.0115)Gln+(-0.0376)His+(-0.0077)Ala+(0.
0371)Phe+(-0.0878)Trp; 0.853, 0.869, 0.817, 0.882, 0.842, 0.875, 0.
886, 0.871,
(7.0111)+(-0.0902)Asn+(-0.0076)Gly+(0.0127)Gln+(-0.0318)His+(-0.00-
66)Ala+(-0.0799)Trp; 0.853, 0.870, 0.826, 0.89 0, 0.845, 0.891,
0.853, 0.870, (6.3910)+(-0.1037)Asn+(0.0118)Gln
+(-0.0080)Ala+(-0.0544)Cit+(0.0051)Orn+(-0.0878)Trp; 0.853, 0. 866,
0.794, 0.884, 0.838, 0.860, 0.879, 0.865, (6.9138)+(-0.1003)A
sn+(-0.0078)Gly+(0.0113)Gln+(-0.0073)Ala+(-0.0936)Trp; 0.853,
0.868, 0.807, 0.883, 0.861, 0.849, 0.859, 0.863, (6.9047)+(-0.111
0)Asn+(-0.0086)Gly+(0.0129)Gln+(-0.0434)Cit+(-0.0093)Leu+(-0.0997)Trp;
0.853, 0.869, 0.874, 0.880, 0.860, 0.865, 0.863, 0.867,
(4.2094)+(-0.0824)Asn+(0.0129)Gln+(-0.0437)His+(-0.1432)Met
+(0.0582)Phe+(-0.0944)Trp; 0.853, 0.866, 0.818, 0.884, 0.840, 0.8
59, 0.881, 0.866, (7.3959)+(-0.1216)Asn+(-0.0093)Gly+(0.0111)G
ln+(-0.0164)Val+(0.0236)Ile+(-0.0865)Trp; 0.853, 0.869, 0.835,
0.873, 0.873, 0.872, 0.845, 0.866, (5.4341)+(-0.0983)Asn+(0.012
3)Gln+(-0.0521)Cit+(0.0295)Tyr+(-0.1187)Met+(-0.1073)Trp; 0. 853,
0.869, 0.784, 0.892, 0.847, 0.846, 0.866, 0.863, (7.5590)+(-0.
1102)Asn+(-0.0095)Gly+(0.0129)Gln+(-0.0095)Pro+(-0.0086)Val
+(-0.0949)Trp; 0.853, 0.868, 0.849, 0.882, 0.854, 0.863, 0.862, 0.8
65,
(5.2900)+(-0.1174)Asn+(0.0130)Gln+(-0.0434)His+(-0.0116)Pro+(0.0422)Phe+(-
-0.1034)Trp; 0.853, 0.867, 0.842, 0.878, 0.862, 0.874, 0.843,
0.864, (5.4579)+(-0.0978)Asn+(0.0123)Gln+(-0.053
3)Cit+(-0.0961)Met+(0.0109)Ile+(-0.0958)Trp; 0.852, 0.869, 0.8 11,
0.880, 0.862, 0.854, 0.865, 0.866, (6.6439)+(-0.1073)Asn+(-0.
0078)Gly+(0.0136)Gln+(-0.0476)Cit+(-0.0071)Lys+(-0.1013)Tr p;
0.852, 0.868, 0.837, 0.888, 0.841, 0.867, 0.872, 0.867,
(4.7054)+(-0.0857)Asn+(0.0111)Gln+(-0.0073)Ala+(-0.1151)Met+(0.0507)
Phe+(-0.1001)Trp; 0.852, 0.865, 0.831, 0.880, 0.860, 0.871, 0.829,
0.860, (5.7466)+(-0.0986)Asn+(0.0123)Gln+(-0.0508)Cit+(-0.08
27)Met+(-0.0949)Trp; 0.852, 0.867, 0.835, 0.894, 0.852, 0.859, 0.8
35, 0.860, (5.5823)+(-0.1259)Asn+(0.0113)Gln+(-0.0161)Arg+(-0.
0125)Val+(0.0434)Phe+(-0.0987)Trp; 0.852, 0.868, 0.800, 0.889, 0.
848, 0.849, 0.865, 0.863, (7.2108)+(-0.0903)Asn+(-0.0095)Gly+(0.
0123)Gln+(-0.0096)Val+(-0.0783)Met+(-0.0846)Trp; 0.852, 0.867,
0.848, 0.880, 0.860, 0.881, 0.842, 0.866,
(5.9090)+(-0.0895)Asn+(0.0133)Gln+(-0.0300)His+(-0.0446)Cit+(-0.0765)Met+-
(-0.081 6)Trp; 0.852, 0.866, 0.816, 0.889, 0.835, 0.871, 0.864,
0.865, (5.55
82)+(-0.1148)Asn+(0.0110)Gln+(-0.0070)Ala+(-0.0086)Pro+(0.0
373)Phe+(-0.1075)Trp; 0.852, 0.865, 0.834, 0.888, 0.817, 0.899, 0.
879, 0.871,
(6.8490)+(-0.1135)Asn+(0.0094)Gln+(-0.0080)Ala+(-0.0143)Val+(0.034-
1)Ile+(-0.0726)Trp; 0.852, 0.867, 0.798, 0.885, 0.840, 0.862,
0.877, 0.866,
(6.7264)+(-0.0818)Asn+(-0.0079)Gly+(0.0120)Gln+(-0.0065)Ala+(-0.06-
37)Met+(-0.0885)Trp; 0.852, 0. 867, 0.807, 0.882, 0.839, 0.867,
0.885, 0.868, (6.7520)+(0.0088)Se
r+(-0.1060)Asn+(-0.0093)Gly+(0.0106)Gln+(-0.0071)Ala+(-0.09 37)Trp;
0.852, 0.866, 0.790, 0.886, 0.836, 0.859, 0.880, 0.865, (6.9
225)+(-0.0986)Asn+(-0.0076)Gly+(0.0117)Gln+(-0.0073)Ala+(-0.
0072)Orn+(-0.0931)Trp; 0.852, 0.867, 0.793, 0.888, 0.838, 0.861, 0.
875, 0.865,
(7.2368)+(-0.0971)Asn+(-0.0083)Gly+(0.0114)Gln+(-0.0067)Ala+(-0.00-
75)Leu+(-0.0889)Trp; 0.851, 0.866, 0.816, 0.88 0, 0.842, 0.883,
0.865, 0.867, (5.9813)+(-0.0886)Asn+(0.0102)Gln
+(-0.0078)Ala+(0.0314)Tyr+(-0.0958)Met+(-0.0966)Trp; 0.851, 0. 869,
0.799, 0.887, 0.856, 0.830, 0.873, 0.862, (6.0449)+(-0.1207)A
sn+(-0.0084)Gly+(0.0128)Gln+(-0.0119)Pro+(0.0274)Phe+(-0.12 08)Trp;
0.851, 0.867, 0.843, 0.878, 0.865, 0.856, 0.849, 0.862, (5.1
230)+(-0.0012)Ser+(-0.1325)Asn+(0.0117)Gln+(-0.0544)Cit+(0.
0298)Phe+(-0.1166)Trp; 0.851, 0.864, 0.799, 0.885, 0.845, 0.842, 0.
867, 0.860,
(7.4786)+(-0.1154)Asn+(-0.0095)Gly+(0.0115)Gln+(-0.0106)Val+(-0.09-
13)Trp; 0.851, 0.868, 0.825, 0.875, 0.862, 0.854, 0.871, 0.866,
(6.3238)+(0.0080)Ser+(-0.1217)Asn+(-0.0094)Gly+(0.0122)Gln+(-0.0451)Cit+(-
-0.1068)Trp; 0.851, 0.868, 0.845, 0.8 87, 0.846, 0.877, 0.856,
0.866, (3.8638)+(0.0111)Gln+(-0.0080)Al
a+(-0.0523)Cit+(-0.1680)Met+(0.0550)Phe+(-0.1007)Trp; 0.851, 0.864,
0.850, 0.885, 0.839, 0.861, 0.864, 0.863, (5.8647)+(-0.141
5)Asn+(0.0093)Gln+(-0.0178)Val+(0.0218)Ile+(0.0387)Phe+(-0.
0969)Trp; 0.851, 0.866, 0.804, 0.885, 0.843, 0.849, 0.875, 0.863,
(7. 4605)+(-0.1204)Asn+(-0.0092)Gly+(0.0116)Gln+(-0.0167)Val+(0.
0117)Leu+(-0.0904)Trp; 0.851, 0.866, 0.826, 0.890, 0.834, 0.869, 0.
864, 0.864,
(5.7369)+(-0.1126)Asn+(0.0098)Gln+(-0.0078)Ala+(-0.0113)Leu+(0.042-
5)Phe+(-0.0985)Trp; 0.851, 0.868, 0.817, 0.875, 0.866, 0.851,
0.868, 0.865,
(6.4428)+(-0.1177)Asn+(-0.0081)Gly+(0.0127)Gln+(-0.0500)Cit+(0.004-
0)Orn+(-0.1073)Trp; 0.851, 0.8 69, 0.828, 0.875, 0.861, 0.861,
0.873, 0.868, (6.5996)+(-0.1055)As
n+(-0.0079)Gly+(0.0140)Gln+(-0.0311)His+(-0.0407)Cit+(-0.09 25)Trp;
0.851, 0.867, 0.830, 0.884, 0.855, 0.882, 0.837, 0.865, (6.3
333)+(-0.1084)Asn+(0.0139)Gln+(-0.0305)His+(-0.0434)Cit+(-0.
0096)Pro+(-0.0899)Trp; 0.851, 0.866, 0.817, 0.880, 0.848, 0.855, 0.
874, 0.864,
(7.3317)+(-0.1066)Asn+(-0.0091)Gly+(0.0125)Gln+(-0.0265)His+(-0.00-
76)Val+(-0.0836)Trp; 0.851, 0.867, 0.842, 0.87 9, 0.865, 0.854,
0.846, 0.861, (5.1442)+(-0.1324)Asn+(0.0116)Gln
+(-0.0530)Cit+(-0.0053)Ile+(0.0323)Phe+(-0.1164)Trp; 0.851, 0. 865,
0.824, 0.887, 0.834, 0.874, 0.869, 0.866, (5.6780)+(-0.1058)A
sn+(0.0105)Gln+(-0.0082)Ala+(-0.0075)Lys+(0.0355)Phe+(-0.09 81)Trp;
0.851, 0.867, 0.799, 0.884, 0.853, 0.841, 0.869, 0.862, (6.6
764)+(0.0097)Ser+(-0.1188)Asn+(-0.0107)Gly+(0.0119)Gln+(-0.
0107)Pro+(-0.1090)Trp; 0.851, 0.868, 0.815, 0.874, 0.867, 0.850, 0.
871, 0.865,
(6.4098)+(-0.1188)Asn+(-0.0079)Gly+(0.0128)Gln+(-0.0476)Cit+(0.004-
4)Tyr+(-0.1093)Trp; 0.851, 0.864, 0.814, 0.885, 0.854, 0.868,
0.827, 0.858,
(6.1918)+(-0.1194)Asn+(0.0128)Gln+(-0.0497)Cit+(-0.0099)Pro+(-0.10-
41)Trp; 0.851, 0.866, 0.794, 0. 887, 0.841, 0.859, 0.869, 0.864,
(6.7304)+(-0.0935)Asn+(-0.0075)Gly+(0.0123)Gln+(-0.0071)Ala+(-0.0112)Arg+-
(-0.0910)Trp; 0.85 1, 0.867, 0.832, 0.889, 0.855, 0.846, 0.849,
0.860, (4.3755)+(-0.09
86)Asn+(0.0122)Gln+(-0.0101)Pro+(-0.1241)Met+(0.0556)Phe+(-0.1163)Trp;
0.850, 0.864, 0.827, 0.885, 0.851, 0.871, 0.830, 0.859,
(6.5123)+(-0.1234)Asn+(0.0114)Gln+(-0.0460)Cit+(-0.0068)Val
+(-0.0925)Trp; 0.850, 0.866, 0.793, 0.884, 0.838, 0.863, 0.876, 0.8
65, (7.0363)+(-0.0941)Asn+(-0.0077)Gly+(0.0117)Gln+(-0.0071)
Ala+(-0.0050)Lys+(-0.0900)Trp; 0.850, 0.866, 0.844, 0.872, 0.857,
0.844, 0.885, 0.865, (5.9570)+(-0.1120)Asn+(-0.0078)Gly+(0.012
7)Gln+(-0.0419)His+(0.0257)Phe+(-0.0997)Trp; 0.850, 0.865, 0.8 46,
0.886, 0.857, 0.843, 0.842, 0.857, (4.4720)+(-0.0960)Asn+(0.0
109)Gln+(-0.1334)Met+(-0.0129)Leu+(0.0625)Phe+(-0.1073)Trp; 0.850,
0.865, 0.827, 0.887, 0.839, 0.874, 0.852, 0.863,
(6.3928)+(-0.1011)Asn+(0.0112)Gln+(-0.0255)Val+(-0.1199)Met+(0.0330)Le
u+(-0.0768)Trp; 0.850, 0.866, 0.812, 0.890, 0.852, 0.877, 0.825, 0.
861, (6.5916)+(-0.1185)Asn+(0.0127)Gln+(-0.0451)Cit+(-0.009
1)Pro+(-0.0050)Val+(-0.0959)Trp; 0.850, 0.866, 0.814, 0.884, 0.8
56, 0.820, 0.871, 0.858, (6.3242)+(-0.1193)Asn+(-0.0088)Gly+(0.
0111)Gln+(-0.0179)Leu+(0.0357)Phe+(-0.1095)Trp; 0.850, 0.866,
0.796, 0.884, 0.838, 0.859, 0.881, 0.866,
(6.8599)+(-0.1008)Asn+(-0.0077)Gly+(0.0112)Gln+(-0.0075)Ala+(0.0024)Ile+(-
-0.0938)Trp; 0.850, 0.864, 0.851, 0.882, 0.836, 0.883, 0.859,
0.865, (6.258
3)+(-0.0987)Asn+(0.0101)Gln+(-0.0189)Val+(-0.1205)Met+(0.04
38)Ile+(-0.0702)Trp; 0.850, 0.868, 0.810, 0.878, 0.864, 0.847, 0.8
64, 0.863, (6.3784)+(-0.1133)Asn+(-0.0080)Gly+(0.0133)Gln+(-0.
0433)Cit+(-0.0057)Arg+(-0.1056)Trp; 0.850, 0.866, 0.808, 0.881,
0.851, 0.852, 0.871, 0.864,
(6.9842)+(-0.0997)Asn+(-0.0088)Gly+(0.0142)Gln+(-0.0358)His+(-0.0104)Pro+-
(-0.0923)Trp; 0.850, 0. 867, 0.789, 0.887, 0.852, 0.843, 0.863,
0.861, (6.6608)+(-0.0924)A
sn+(-0.0092)Gly+(0.0132)Gln+(-0.0095)Pro+(-0.0657)Met+(-0.1
023)Trp; 0.850, 0.865, 0.801, 0.883, 0.847, 0.844, 0.870, 0.861,
(7. 4326)+(-0.1188)Asn+(-0.0092)Gly+(0.0113)Gln+(0.0083)Tyr+(-0.
0111)Val+(-0.0950)Trp; 0.850, 0.866, 0.821, 0.879, 0.849, 0.888, 0.
854, 0.868, (5.2240)+(0.0101)Gln+(-0.0086)Ala+(-0.0521)Cit+(0.
0339)Tyr+(-0.1490)Met+(-0.0969)Trp; 0.850, 0.866, 0.809, 0.886,
0.834, 0.884, 0.865, 0.867,
(6.8770)+(-0.1141)Asn+(0.0095)Gln+(-0.0078)Ala+(0.0231)Tyr+(-0.0073)Val+(-
-0.0901)Trp; 0.850, 0. 867, 0.830, 0.881, 0.860, 0.828, 0.876,
0.861, (4.9495)+(-0.0883)A
sn+(-0.0078)Gly+(0.0124)Gln+(-0.1375)Met+(0.0427)Phe+(-0.11 20)Trp;
0.850, 0.866, 0.797, 0.881, 0.841, 0.860, 0.881, 0.866, (6.8
237)+(-0.1039)Asn+(-0.0073)Gly+(0.0110)Gln+(-0.0077)Ala+(0.
0102)Tyr+(-0.0983)Trp; 0.850, 0.864, 0.855, 0.882, 0.847, 0.858, 0.
855, 0.861,
(5.6934)+(-0.1257)Asn+(0.0110)Gln+(-0.0323)His+(-0.0091)Val+(0.042-
6)Phe+(-0.0931)Trp; 0.850, 0.867, 0.824, 0.880, 0.862, 0.875,
0.841, 0.864,
(6.4621)+(-0.1301)Asn+(0.0111)Gln+(-0.0462)Cit+(0.0181)Tyr+(-0.007-
9)Val+(-0.1007)Trp; 0.850, 0. 867, 0.861, 0.884, 0.840, 0.881,
0.871, 0.869, (4.0370)+(0.0111)Gl
n+(-0.0441)His+(-0.0071)Ala+(-0.1656)Met+(0.0590)Phe+(-0.08 44)Trp;
0.850, 0.864, 0.825, 0.888, 0.830, 0.882, 0.855, 0.864, (6.7
756)+(-0.1299)Asn+(0.0106)Gln+(-0.0118)Pro+(-0.0170)Val+(0.
0396)Ile+(-0.0859)Trp; 0.850, 0.862, 0.824, 0.883, 0.829, 0.868, 0.
871, 0.863, (5.5825)+(-0.1143)Asn+(0.0098)Gln+(-0.0086)Ala+(0.
0320)Phe+(-0.1018)Trp; 0.850, 0.864, 0.822, 0.889, 0.851, 0.846, 0.
840, 0.856,
(5.4733)+(-0.1287)Asn+(0.0109)Gln+(-0.0108)Pro+(-0.0127)Leu+(0.047-
4)Phe+(-0.1157)Trp
[0473] List (2) of Logistic Regression Equations Searched in
Example 4
[0474] The logistic regression equations searched in Example 4
above are listed below. Before each equation, "the value of ROC_AUC
for the pancreatic cancer group and the other cancers group with
validation", "the value of ROC_AUC for the pancreatic cancer group
and the other cancers group without validation", "the value of
ROC_AUC for the pancreatic cancer group and the healthy group",
"the value of ROC_AUC for the pancreatic cancer group and the lung
cancer group", "the value of ROC_AUC for the pancreatic cancer
group and the colorectal cancer group", "the value of ROC_AUC for
the pancreatic cancer group and the prostatic cancer group", "the
value of ROC_AUC for the pancreatic cancer group and the breast
cancer group", and "the average value of the value of ROC_AUC for
the pancreatic cancer group and the lung cancer group, the value of
ROC_AUC for the pancreatic cancer group and the colorectal cancer
group, the value of ROC_AUC for the pancreatic cancer group and the
prostatic cancer group, and the value of ROC_AUC for the pancreatic
cancer group and the breast cancer group" obtained for the equation
are additionally listed.
[0475] 0.832, 0.854, 0.860, 0.867, 0.842, 0.862, 0.842, 0.853,
(0.888 3)+(0.0101)Gln+(-0.0453)His+(-0.1983)Met+(0.0032)Ile+(0.030
4)Phe+(-0.0647)Trp; 0.811, 0.827, 0.859, 0.830, 0.819, 0.841, 0.82
2, 0.828, (1.4317)+(0.0059)Gln+(-0.0615)His+(0.0176)Phe+(-0.0
796)Trp; 0.838, 0.862, 0.859, 0.873, 0.856, 0.875, 0.834, 0.859,
(0. 7688)+(0.0114)Gln+(-0.0347)His+(-0.0488)Cit+(-0.1734)Met+(0.
0327)Phe+(-0.0727)Trp; 0.832, 0.855, 0.859, 0.868, 0.842, 0.863, 0.
839, 0.853, (0.9479)+(0.0102)Gln+(-0.0459)His+(-0.1951)Met+(0.
0005)Leu+(0.0306)Phe+(-0.0647)Trp; 0.835, 0.855, 0.858, 0.869, 0.
842, 0.863, 0.838, 0.853, (0.9606)+(0.0101)Gln+(-0.0456)His+(-0.
1946)Met+(0.0308)Phe+(-0.0646)Trp; 0.830, 0.854, 0.858, 0.868, 0.
842, 0.862, 0.837, 0.852, (0.9492)+(0.0100)Gln+(-0.0463)His+(-0.
1974)Met+(0.0010)Lys+(0.0310)Phe+(-0.0651)Trp; 0.832, 0.856, 0.
858, 0.867, 0.846, 0.864, 0.843, 0.855, (0.8859)+(0.0101)Gln+(-0.
0449)His+(0.0079)Tyr+(-0.2036)Met+(0.0287)Phe+(-0.0666)Trp; 0.844,
0.867, 0.858, 0.875, 0.859, 0.877, 0.856, 0.867,
(1.9144)+(-0.0985)Asn+(0.0116)Gln+(-0.0373)His+(-0.0484)Cit+(0.0186)Ph
e+(-0.0747)Trp; 0.810, 0.833, 0.858, 0.844, 0.822, 0.847, 0.820, 0.
833, (1.4444)+(0.0069)Gln+(-0.0551)His+(-0.0066)Lys+(-0.001
2)Leu+(0.0192)Phe+(-0.0744)Trp; 0.813, 0.834, 0.858, 0.842, 0.82 3,
0.848, 0.822, 0.834, (1.4226)+(0.0070)Gln+(-0.0556)His+(-0.0
070)Lys+(0.0185)Phe+(-0.0747)Trp; 0.801, 0.824, 0.857, 0.836, 0.
809, 0.834, 0.814, 0.823, (1.5132)+(0.0064)Gln+(-0.0614)His+(-0.
0170)Tyr+(0.0240)Phe+(-0.0738)Trp; 0.838, 0.858, 0.857, 0.878, 0.
831, 0.868, 0.853, 0.857, (0.8895)+(0.0079)Gln+(-0.0176)Val+(-0.
2523)Met+(0.0391)Ile+(0.0373)Phe+(-0.0600)Trp; 0.842, 0.865, 0.
857, 0.877, 0.854, 0.863, 0.853, 0.862, (1.4326)+(-0.0806)Asn+(0.
0122)Gln+(-0.0417)His+(-0.1327)Met+(0.0285)Phe+(-0.0597)Tr p;
0.810, 0.828, 0.857, 0.837, 0.820, 0.838, 0.814, 0.827,
(1.5141)+(0.0058)Gln+(-0.0585)His+(-0.0046)Leu+(0.0205)Phe+(-0.0777)Trp;
0.813, 0.835, 0.856, 0.838, 0.835, 0.855, 0.815, 0.836, (1.269
3)+(0.0080)Gln+(-0.0481)His+(-0.0557)Cit+(0.0201)Phe+(-0.08 74)Trp;
0.820, 0.844, 0.856, 0.852, 0.841, 0.864, 0.818, 0.844, (1.2
255)+(0.0092)Gln+(-0.0419)His+(-0.0565)Cit+(-0.0074)Lys+(0.
0216)Phe+(-0.0828)Trp; 0.803, 0.830, 0.856, 0.844, 0.813, 0.844, 0.
815, 0.829,
(1.4926)+(0.0073)Gln+(-0.0562)His+(-0.0143)Tyr+(-0.0061)Lys+(0.023-
6)Phe+(-0.0704)Trp; 0.800, 0.824, 0.855, 0.838, 0.810, 0.834,
0.808, 0.823,
(1.5624)+(0.0064)Gln+(-0.0594)His+(-0.0159)Tyr+(-0.0031)Leu+(0.025-
5)Phe+(-0.0730)Trp; 0.832, 0. 854, 0.855, 0.865, 0.840, 0.859,
0.851, 0.854, (2.1707)+(-0.1074)A
sn+(0.0104)Gln+(-0.0506)His+(-0.0033)Tyr+(0.0180)Phe+(-0.06 52)Trp;
0.838, 0.855, 0.855, 0.865, 0.843, 0.858, 0.852, 0.854, (2.1
490)+(-0.1092)Asn+(0.0104)Gln+(-0.0504)His+(0.0170)Phe+(-0.
0662)Trp; 0.821, 0.844, 0.854, 0.850, 0.833, 0.860, 0.835, 0.845,
(3. 9190)+(-0.0317)Cit+(-0.0149)Val+(-0.1434)Met+(0.0414)Ile+(0.
0240)Phe+(-0.0598)Trp; 0.835, 0.855, 0.853, 0.866, 0.842, 0.859, 0.
853, 0.855,
(2.1356)+(-0.1071)Asn+(0.0106)Gln+(-0.0493)His+(-0.0017)Lys+(0.017-
3)Phe+(-0.0654)Trp; 0.813, 0.837, 0.853, 0.844, 0.835, 0.858,
0.806, 0.836,
(1.3628)+(0.0079)Gln+(-0.0444)His+(-0.0557)Cit+(-0.0054)Leu+(0.023-
7)Phe+(-0.0854)Trp; 0.832, 0. 856, 0.853, 0.874, 0.847, 0.864,
0.822, 0.852, (1.0094)+(0.0114)Gl
n+(-0.0439)His+(-0.0175)Arg+(-0.1644)Met+(0.0294)Phe+(-0.06 34)Trp;
0.801, 0.824, 0.853, 0.841, 0.806, 0.837, 0.810, 0.823, (1.6
890)+(0.0062)Gln+(-0.0559)His+(-0.0132)Tyr+(-0.0043)Val+(0.
0252)Phe+(-0.0711)Trp; 0.837, 0.856, 0.853, 0.868, 0.843, 0.859, 0.
850, 0.855,
(2.2231)+(-0.1084)Asn+(0.0103)Gln+(-0.0483)His+(-0.0033)Leu+(0.019-
0)Phe+(-0.0649)Trp; 0.836, 0.855, 0.852, 0.867, 0.843, 0.857,
0.848, 0.854,
(2.2347)+(-0.1077)Asn+(0.0105)Gln+(-0.0506)His+(-0.0045)Ile+(0.018-
0)Phe+(-0.0656)Trp; 0.840, 0. 863, 0.852, 0.883, 0.836, 0.878,
0.856, 0.863, (0.8547)+(0.0106)Gl
n+(-0.0386)His+(-0.0043)Ala+(-0.1722)Met+(0.0308)Phe+(-0.05 94)Trp;
0.820, 0.841, 0.852, 0.853, 0.823, 0.854, 0.838, 0.842, (3.4
029)+(0.0020)Ser+(-0.0158)Val+(-0.1764)Met+(0.0402)Ile+(0.0
268)Phe+(-0.0567)Trp; 0.807, 0.833, 0.852, 0.845, 0.826, 0.850, 0.
807, 0.832,
(1.3754)+(0.0084)Gln+(-0.0483)His+(-0.0548)Cit+(-0.0155)Tyr+(0.025-
4)Phe+(-0.0821)Trp; 0.804, 0.825, 0.852, 0.835, 0.807, 0.843,
0.821, 0.827,
(1.7109)+(0.0059)Gln+(-0.0552)His+(-0.0101)Val+(0.0099)Leu+(0.0178-
)Phe+(-0.0744)Trp; 0.813, 0.8 37, 0.851, 0.846, 0.831, 0.858,
0.808, 0.836, (1.4770)+(0.0078)Gln
+(-0.0429)His+(-0.0539)Cit+(-0.0043)Val+(0.0228)Phe+(-0.083 7)Trp;
0.835, 0.857, 0.851, 0.877, 0.840, 0.866, 0.835, 0.854, (1.22
10)+(0.0100)Gln+(-0.0383)His+(-0.0054)Val+(-0.1938)Met+(0.0
342)Phe+(-0.0607)Trp; 0.809, 0.836, 0.851, 0.855, 0.826, 0.848, 0.
797, 0.832,
(1.4109)+(0.0092)Gln+(-0.0555)His+(-0.0276)Arg+(-0.0080)Tyr+(0.022-
6)Phe+(-0.0720)Trp; 0.819, 0.840, 0.851, 0.854, 0.821, 0.847,
0.839, 0.840,
(3.2389)+(-0.0194)Val+(-0.2122)Met+(0.0097)Lys+(0.0427)Ile+(0.0309-
)Phe+(-0.0610)Trp; 0.810, 0.82 8, 0.851, 0.840, 0.813, 0.840,
0.817, 0.827,
(1.6683)+(0.0058)Gln+(-0.0547)His+(-0.0054)Val+(0.0212)Phe+(-0.074-
6)Trp; 0.810, 0. 833, 0.851, 0.846, 0.820, 0.849, 0.817, 0.833,
(1.6012)+(0.0066)Gl
n+(-0.0516)His+(-0.0041)Val+(-0.0055)Lys+(0.0210)Phe+(-0.07 20)Trp;
0.816, 0.837, 0.851, 0.853, 0.830, 0.849, 0.799, 0.833, (1.3
773)+(0.0091)Gln+(-0.0556)His+(-0.0286)Arg+(0.0199)Phe+(-0.
0745)Trp; 0.839, 0.857, 0.850, 0.872, 0.838, 0.863, 0.852, 0.856,
(2. 4322)+(-0.1072)Asn+(0.0102)Gln+(-0.0444)His+(-0.0050)Val+(0.
0189)Phe+(-0.0612)Trp; 0.816, 0.842, 0.850, 0.852, 0.840, 0.858, 0.
806, 0.839,
(1.2382)+(0.0096)Gln+(-0.0473)His+(-0.0416)Cit+(-0.0197)Arg+(0.021-
4)Phe+(-0.0817)Trp; 0.835, 0.859, 0.850, 0.869, 0.847, 0.886,
0.836, 0.860,
(2.1595)+(0.0080)Gln+(-0.0500)Cit+(-0.0125)Val+(-0.1881)Met+(0.036-
8)Ile+(-0.0598)Trp; 0.811, 0. 838, 0.850, 0.855, 0.830, 0.851,
0.801, 0.835, (1.3783)+(0.0092)Gl
n+(-0.0549)His+(-0.0280)Arg+(-0.0010)Lys+(0.0199)Phe+(-0.07 39)Trp;
0.818, 0.838, 0.850, 0.843, 0.840, 0.849, 0.813, 0.836, (3.6
030)+(-0.0400)Cit+(-0.1257)Met+(0.0411)Ile+(-0.0228)Leu+(0.
0269)Phe+(-0.0700)Trp; 0.824, 0.846, 0.850, 0.851, 0.832, 0.862, 0.
851, 0.849, (3.4958)+(0.0197)Tyr+(-0.0169)Val+(-0.1900)Met+(0.
0398)Ile+(0.0212)Phe+(-0.0598)Trp; 0.828, 0.855, 0.849, 0.863, 0.
850, 0.877, 0.826, 0.854, (1.9611)+(0.0097)Gln+(-0.0329)His+(-0.
0475)Cit+(-0.1561)Met+(0.0101)Ile+(-0.0631)Trp; 0.827, 0.849,
0.849, 0.861, 0.823, 0.868, 0.855, 0.852,
(3.6056)+(-0.0029)Ala+(-0.0139)Val+(-0.1476)Met+(0.0386)Ile+(0.0243)Phe+(-
-0.0529)Trp; 0.832, 0.858, 0.849, 0.873, 0.838, 0.883, 0.844,
0.860, (1.094
5)+(0.0090)Gln+(-0.0329)His+(-0.0066)Ala+(-0.0546)Cit+(0.02
24)Phe+(-0.0770)Trp; 0.810, 0.832, 0.849, 0.845, 0.822, 0.843, 0.8
11, 0.830, (1.6167)+(0.0072)Gln+(-0.0573)His+(-0.0057)Lys+(-0.
0092)Ile+(0.0202)Phe+(-0.0740)Trp; 0.801, 0.824, 0.848, 0.841, 0.
810, 0.832, 0.801, 0.821, (1.7185)+(0.0069)Gln+(-0.0622)His+(-0.
0146)Tyr+(-0.0106)Ile+(0.0253)Phe+(-0.0729)Trp; 0.812, 0.836,
0.848, 0.844, 0.836, 0.852, 0.805, 0.834,
(1.4235)+(0.0083)Gln+(-0.0485)His+(-0.0547)Cit+(-0.0084)Ile+(0.0221)Phe+(-
-0.0860)T rp; 0.811, 0.824, 0.848, 0.831, 0.815, 0.846, 0.809,
0.825, (2.1163) +(0.0056)Gln+(-0.0577)His+(-0.0737)Trp; 0.809,
0.824, 0.848, 0. 832, 0.815, 0.846, 0.809, 0.825,
(2.1319)+(0.0056)Gln+(-0.0574)H is+(-0.0004)Leu+(-0.0735)Trp;
0.833, 0.858, 0.848, 0.879, 0.840, 0.853, 0.847, 0.855,
(0.9592)+(0.0121)Gln+(-0.0472)His+(-0.192
0)Met+(-0.0243)Orn+(0.0373)Phe+(-0.0657)Trp; 0.815, 0.838, 0.8 48,
0.858, 0.828, 0.851, 0.797, 0.833, (1.4616)+(0.0090)Gln+(-0.0
524)His+(-0.0286)Arg+(-0.0046)Leu+(0.0226)Phe+(-0.0727)Trp; 0.806,
0.833, 0.848, 0.840, 0.827, 0.847, 0.819, 0.833, (1.3150)+(0.
0086)Gln+(-0.0506)His+(-0.0475)Cit+(-0.0116)Orn+(0.0226)Phe
+(-0.0866)Trp; 0.808, 0.827, 0.848, 0.839, 0.819, 0.834, 0.807, 0.8
25, (1.6962)+(0.0065)Gln+(-0.0624)His+(-0.0126)Ile+(0.0203)P
he+(-0.0774)Trp; 0.821, 0.840, 0.848, 0.852, 0.823, 0.849, 0.836,
0. 840,
(3.5940)+(-0.0158)Val+(-0.1719)Met+(0.0401)Ile+(0.0260)Phe+(-0.0568)Trp;
0.817, 0.839, 0.847, 0.852, 0.822, 0.848, 0.836, 0.840,
(3.5883)+(0.0003)His+(-0.0159)Val+(-0.1724)Met+(0.040
3)Ile+(0.0261)Phe+(-0.0568)Trp; 0.830, 0.852, 0.847, 0.868, 0.83 9,
0.855, 0.838, 0.850, (1.2919)+(-0.0059)Ser+(0.0107)Gln+(-0.0
456)His+(-0.1879)Met+(0.0293)Phe+(-0.0657)Trp; 0.807, 0.828, 0.
847, 0.842, 0.814, 0.838, 0.810, 0.826, (1.7332)+(0.0061)Gln+(-0.
0570)His+(-0.0039)Val+(-0.0062)Ile+(0.0215)Phe+(-0.0749)Tr p;
0.835, 0.857, 0.847, 0.872, 0.841, 0.854, 0.856, 0.855,
(2.1735)+(-0.1012)Asn+(0.0115)Gln+(-0.0525)His+(-0.0183)Orn+(0.0209)Phe+(-
-0.0669)Trp; 0.824, 0.844, 0.847, 0.855, 0.825, 0.855, 0.845,
0.845, (4.1964)+(-0.0366)Asn+(-0.0156)Val+(-0.1313)Met+(0.03
98)Ile+(0.0227)Phe+(-0.0531)Trp; 0.822, 0.841, 0.847, 0.848, 0.8
39, 0.849, 0.824, 0.840, (4.4190)+(-0.0614)Asn+(-0.0403)Cit+(0.
0345)Ile+(-0.0238)Leu+(0.0191)Phe+(-0.0731)Trp; 0.822, 0.849,
0.847, 0.856, 0.842, 0.865, 0.834, 0.849,
(1.7543)+(0.0088)Gln+(-0.0415)His+(0.0185)Tyr+(-0.2011)Met+(0.0057)Ile+(--
0.0612)Tr p; 0.804, 0.822, 0.847, 0.833, 0.811, 0.844, 0.804,
0.823, (2.2437)+(0.0057)Gln+(-0.0571)His+(-0.0067)Tyr+(-0.0705)Trp;
0.838, 0. 861, 0.847, 0.870, 0.853, 0.877, 0.844, 0.861,
(2.6610)+(-0.1010)A
sn+(0.0111)Gln+(-0.0339)His+(-0.0475)Cit+(0.0018)Ile+(-0.06 78)Trp;
0.801, 0.822, 0.847, 0.832, 0.810, 0.844, 0.805, 0.823, (2.2
188)+(0.0057)Gln+(-0.0578)His+(-0.0072)Tyr+(0.0008)Leu+(-0.
0708)Trp; 0.827, 0.848, 0.846, 0.862, 0.815, 0.876, 0.858, 0.853,
(1. 2964)+(0.0071)Gln+(-0.0476)His+(-0.0067)Ala+(0.0194)Phe+(-0.
0686)Trp; 0.818, 0.839, 0.846, 0.852, 0.822, 0.848, 0.836, 0.840,
(3. 5995)+(-0.0002)Thr+(-0.0158)Val+(-0.1712)Met+(0.0401)Ile+(0.
0259)Phe+(-0.0567)Trp; 0.824, 0.848, 0.846, 0.863, 0.827, 0.874, 0.
835, 0.850,
(2.2081)+(0.0080)Gln+(-0.0295)His+(-0.0082)Val+(-0.1935)Met+(0.023-
6)Ile+(-0.0479)Trp; 0.843, 0.865, 0.846, 0.882, 0.836, 0.879,
0.873, 0.867,
(1.9077)+(-0.1020)Asn+(0.0111)Gln+(-0.0396)His+(-0.0051)Ala+(0.019-
7)Phe+(-0.0605)Trp; 0.826, 0. 852, 0.846, 0.869, 0.816, 0.878,
0.858, 0.856, (1.2862)+(0.0078)Gl
n+(-0.0444)His+(-0.0064)Ala+(-0.0050)Lys+(0.0198)Phe+(-0.06 50)Trp;
0.822, 0.849, 0.846, 0.855, 0.842, 0.864, 0.834, 0.849, (1.7
216)+(0.0091)Gln+(-0.0451)His+(0.0175)Tyr+(-0.1988)Met+(0.0
045)Leu+(-0.0625)Trp; 0.818, 0.840, 0.846, 0.852, 0.820, 0.851, 0.
840, 0.841, (3.7058)+(-0.0188)Val+(-0.1737)Met+(0.0369)Ile+(0.
0073)Leu+(0.0243)Phe+(-0.0565)Trp; 0.849, 0.870, 0.846, 0.884, 0.
866, 0.869, 0.842, 0.865, (1.2353)+(-0.0844)Asn+(0.0123)Gln+(-0.
0572)Cit+(-0.1339)Met+(0.0312)Phe+(-0.0816)Trp; 0.827, 0.853,
0.846, 0.861, 0.851, 0.872, 0.823, 0.852,
(1.9652)+(0.0102)Gln+(-0.0374)His+(-0.0467)Cit+(-0.1531)Met+(0.0058)Leu+(-
-0.0647)T rp; 0.806, 0.828, 0.846, 0.837, 0.818, 0.850, 0.811,
0.829, (2.0237)
+(0.0067)Gln+(-0.0541)His+(-0.0073)Lys+(0.0032)Leu+(-0.069 9)Trp;
0.822, 0.845, 0.846, 0.858, 0.831, 0.862, 0.825, 0.844, (2.05
96)+(0.0087)Gln+(-0.0426)His+(-0.1785)Met+(0.0077)Ile+(-0.0
551)Trp; 0.838, 0.861, 0.845, 0.870, 0.852, 0.877, 0.844, 0.861,
(2. 6642)+(-0.1008)Asn+(0.0112)Gln+(-0.0346)His+(-0.0474)Cit+(0.
0010)Leu+(-0.0680)Trp; 0.804, 0.826, 0.845, 0.837, 0.819, 0.833, 0.
807, 0.824, (1.7177)+(0.0067)Gln+(-0.0653)His+(-0.0171)Ile+(0.
0040)Leu+(0.0188)Phe+(-0.0782)Trp; 0.817, 0.845, 0.845, 0.858, 0.
831, 0.862, 0.825, 0.844, (2.0573)+(0.0087)Gln+(-0.0424)His+(-0.
1778)Met+(-0.0003)Lys+(0.0078)Ile+(-0.0550)Trp; 0.825, 0.848,
0.845, 0.864, 0.814, 0.876, 0.853, 0.852,
(1.3320)+(0.0071)Gln+(-0.0466)His+(-0.0066)Ala+(-0.0020)Leu+(0.0207)Phe+(-
-0.0677)T rp; 0.815, 0.838, 0.845, 0.858, 0.831, 0.848, 0.795,
0.833, (1.5171)
+(0.0093)Gln+(-0.0560)His+(-0.0277)Arg+(-0.0073)Ile+(0.021
3)Phe+(-0.0735)Trp; 0.838, 0.862, 0.845, 0.870, 0.855, 0.877, 0.84
5, 0.862, (2.6256)+(-0.1026)Asn+(0.0111)Gln+(-0.0338)His+(-0.
0476)Cit+(0.0045)Tyr+(-0.0693)Trp; 0.829, 0.853, 0.845, 0.869, 0.
836, 0.856, 0.842, 0.850, (0.9474)+(0.0108)Gln+(-0.0459)His+(-0.
0074)Thr+(-0.1743)Met+(0.0289)Phe+(-0.0619)Trp; 0.817, 0.841,
0.845, 0.854, 0.821, 0.847, 0.845, 0.842,
(3.7672)+(-0.0158)Val+(-0.1671)Met+(-0.0097)Orn+(0.0439)Ile+(0.0270)Phe+(-
-0.0574)Trp; 0.821, 0.844, 0.845, 0.856, 0.833, 0.858, 0.825,
0.843, (1.986
6)+(0.0092)Gln+(-0.0476)His+(-0.1771)Met+(0.0064)Leu+(-0.05 76)Trp;
0.819, 0.845, 0.845, 0.864, 0.810, 0.874, 0.848, 0.849, (1.3
242)+(0.0074)Gln+(-0.0483)His+(-0.0064)Ala+(-0.0097)Tyr+(0.
0233)Phe+(-0.0659)Trp; 0.824, 0.847, 0.845, 0.854, 0.829, 0.879, 0.
843, 0.851,
(4.5234)+(-0.0035)Ala+(-0.0342)Cit+(-0.0106)Val+(-0.1031)Met+(0.03-
85)Ile+(-0.0523)Trp; 0.823, 0.845, 0.845, 0.8 66, 0.831, 0.842,
0.822, 0.840, (0.8426)+(0.0071)Gln+(-0.2328)Me
t+(0.0264)Ile+(-0.0171)Leu+(0.0352)Phe+(-0.0745)Trp; 0.845, 0. 868,
0.845, 0.882, 0.852, 0.886, 0.852, 0.868, (2.8826)+(-0.1094)A
sn+(0.0093)Gln+(-0.0522)Cit+(-0.0094)Val+(0.0189)Ile+(-0.07 29)Trp;
0.818, 0.844, 0.844, 0.857, 0.833, 0.857, 0.825, 0.843, (1.9
930)+(0.0092)Gln+(-0.0479)His+(-0.1765)Met+(-0.0009)Ile+(0.
0068)Leu+(-0.0577)Trp; 0.841, 0.861, 0.844, 0.870, 0.852, 0.877, 0.
843, 0.860,
(2.7090)+(-0.1006)Asn+(0.0112)Gln+(-0.0339)His+(-0.0474)Cit+(-0.06-
74)Trp; 0.806, 0.830, 0.844, 0.835, 0.831, 0.838, 0.810, 0.829,
(3.5322)+(0.0038)Ser+(-0.0221)His+(-0.1374)Met+(0.0091)Ile+(0.0199)Phe+(--
0.0684)Trp; 0.816, 0.840, 0.844, 0.86 3, 0.825, 0.855, 0.798,
0.835, (1.5894)+(0.0090)Gln+(-0.0487)His
+(-0.0284)Arg+(-0.0051)Val+(0.0232)Phe+(-0.0702)Trp; 0.824, 0. 847,
0.844, 0.867, 0.811, 0.875, 0.850, 0.851, (1.4335)+(0.0070)Gl
n+(-0.0441)His+(-0.0064)Ala+(-0.0035)Val+(0.0220)Phe+(-0.06 55)Trp;
0.835, 0.854, 0.844, 0.866, 0.842, 0.852, 0.852, 0.853, (2.3
932)+(-0.0049)Ser+(-0.1052)Asn+(0.0109)Gln+(-0.0504)His+(0.
0160)Phe+(-0.0671)Trp; 0.828, 0.847, 0.844, 0.855, 0.831, 0.875, 0.
840, 0.850,
(3.4379)+(-0.0060)Ala+(-0.0470)Cit+(0.0336)Ile+(-0.0206)Leu+(0.021-
1)Phe+(-0.0711)Trp; 0.829, 0.853, 0.844, 0.867, 0.854, 0.850,
0.815, 0.847,
(0.6734)+(0.0097)Gln+(-0.0603)Cit+(-0.2015)Met+(0.0053)Ile+(0.0327-
)Phe+(-0.0882)Trp; 0.839, 0.8 62, 0.844, 0.872, 0.852, 0.878,
0.843, 0.861, (2.7071)+(-0.0988)As
n+(0.0113)Gln+(-0.0330)His+(-0.0475)Cit+(-0.0013)Lys+(-0.06
65)Trp
[0476] List (2) of Linear Discriminants Searched in Example 4
[0477] The linear discriminants searched in Example 4 above are
listed below. Before each equation, "the value of ROC_AUC for the
pancreatic cancer group and the other cancers group with
validation", "the value of ROC_AUC for the pancreatic cancer group
and the other cancers group without validation", "the value of
ROC_AUC for the pancreatic cancer group and the healthy group",
"the value of ROC_AUC for the pancreatic cancer group and the lung
cancer group", "the value of ROC_AUC for the pancreatic cancer
group and the colorectal cancer group", "the value of ROC_AUC for
the pancreatic cancer group and the prostatic cancer group", "the
value of ROC_AUC for the pancreatic cancer group and the breast
cancer group", and "the average value of the value of ROC_AUC for
the pancreatic cancer group and the lung cancer group, the value of
ROC_AUC for the pancreatic cancer group and the colorectal cancer
group, the value of ROC_AUC for the pancreatic cancer group and the
prostatic cancer group, and the value of ROC_AUC for the pancreatic
cancer group and the breast cancer group" obtained for the equation
are additionally listed.
[0478] 0.833, 0.849, 0.880, 0.860, 0.830, 0.861, 0.852, 0.851,
(5.731 3)+(0.0114)Ser+(-0.0226)Val+(-0.2232)Met+(0.0489)Ile+(0.067
6)Phe+(-0.0795)Trp; 0.843, 0.860, 0.879, 0.871, 0.852, 0.863, 0.84
9, 0.859, (3.2393)+(0.0037)Ser+(0.0106)Gln+(-0.0517)His+(-0.2
085)Met+(0.0643)Phe+(-0.0934)Trp; 0.847, 0.866, 0.875, 0.874, 0.
863, 0.873, 0.848, 0.865, (3.3463)+(0.0126)Gln+(-0.0436)His+(-0.
0447)Cit+(-0.1986)Met+(0.0623)Phe+(-0.0962)Trp; 0.831, 0.849,
0.875, 0.860, 0.832, 0.859, 0.847, 0.849,
(6.5393)+(0.0075)Thr+(-0.0236)Val+(-0.2243)Met+(0.0503)Ile+(0.0644)Phe+(--
0.0798)Tr p; 0.831, 0.848, 0.875, 0.846, 0.855, 0.862, 0.829,
0.848,
(5.6907)+(0.0141)Ser+(-0.0317)His+(0.0235)Tyr+(-0.1891)Met+(0.0540)P
he+(-0.1005)Trp; 0.845, 0.862, 0.874, 0.868, 0.858, 0.859, 0.858,
0. 861, (3.3530)+(0.0109)Gln+(-0.0510)His+(0.0190)Tyr+(-0.2214)
Met+(0.0579)Phe+(-0.1003)Trp; 0.853, 0.869, 0.874, 0.880, 0.860,
0.865, 0.863, 0.867, (4.2094)+(-0.0824)Asn+(0.0129)Gln+(-0.043
7)His+(-0.1432)Met+(0.0582)Phe+(-0.0944)Trp; 0.847, 0.860, 0.8 74,
0.871, 0.851, 0.858, 0.851, 0.858, (3.4357)+(0.0110)Gln+(-0.0
515)His+(-0.2021)Met+(0.0618)Phe+(-0.0934)Trp; 0.843, 0.862, 0.
873, 0.875, 0.854, 0.860, 0.846, 0.859, (3.3761)+(0.0122)Gln+(-0.
0510)His+(-0.0129)Arg+(-0.1828)Met+(0.0603)Phe+(-0.0912)Tr p;
0.827, 0.842, 0.873, 0.852, 0.837, 0.846, 0.824, 0.840,
(5.1029)+(0.0103)Ser+(-0.1930)Met+(0.0483)Ile+(-0.0349)Leu+(0.0703)P
he+(-0.0947)Trp; 0.842, 0.860, 0.873, 0.871, 0.851, 0.858, 0.851,
0. 858, (3.4428)+(0.0110)Gln+(-0.0515)His+(-0.2017)Met+(-0.000
4)Ile+(0.0619)Phe+(-0.0934)Trp; 0.831, 0.847, 0.873, 0.854, 0.84 7,
0.858, 0.822, 0.845, (6.5948)+(0.0166)Ser+(-0.0568)Asn+(-0.0
244)His+(-0.1212)Met+(0.0564)Phe+(-0.0924)Trp; 0.823, 0.841, 0.
873, 0.845, 0.845, 0.852, 0.813, 0.839, (5.9004)+(0.0127)Ser+(-0.
0325)His+(0.0022)Thr+(-0.1690)Met+(0.0591)Phe+(-0.0924)Trp; 0.821,
0.840, 0.872, 0.842, 0.842, 0.851, 0.818, 0.838, (5.7918)+(0.
0136)Ser+(-0.0319)His+(-0.1675)Met+(0.0041)Ile+(0.0574)Phe+(-0.0919)Trp;
0.843, 0.861, 0.872, 0.873, 0.851, 0.860, 0.851, 0.85 9,
(3.5849)+(0.0113)Gln+(-0.0496)His+(-0.1909)Met+(-0.0042)L
ys+(0.0619)Phe+(-0.0920)Trp; 0.849, 0.863, 0.872, 0.883, 0.834, 0.
865, 0.868, 0.862, (3.5810)+(0.0087)Gln+(-0.0238)Val+(-0.2622)
Met+(0.0473)Ile+(0.0706)Phe+(-0.0865)Trp; 0.841, 0.860, 0.871,
0.871, 0.850, 0.857, 0.852, 0.857, (3.4364)+(0.0111)Gln+(-0.051
1)His+(-0.0013)Thr+(-0.1980)Met+(0.0611)Phe+(-0.0931)Trp; 0. 825,
0.840, 0.870, 0.844, 0.843, 0.850, 0.813, 0.838, (5.8961)+(0.0
135)Ser+(-0.0317)His+(-0.1628)Met+(0.0582)Phe+(-0.0919)Trp; 0.824,
0.843, 0.870, 0.846, 0.850, 0.857, 0.809, 0.841, (6.1358)+(0.
0136)Ser+(-0.0254)His+(-0.0246)Cit+(-0.1553)Met+(0.0573)Phe
+(-0.0933)Trp; 0.843, 0.860, 0.870, 0.875, 0.850, 0.858, 0.846, 0.8
57, (3.5663)+(0.0108)Gln+(-0.0477)His+(-0.1968)Met+(-0.0060)
Leu+(0.0661)Phe+(-0.0927)Trp; 0.822, 0.840, 0.870, 0.845, 0.844,
0.850, 0.812, 0.838, (5.9269)+(0.0139)Ser+(-0.0312)His+(-0.002
5)Arg+(-0.1585)Met+(0.0579)Phe+(-0.0915)Trp; 0.822, 0.840, 0.8 69,
0.845, 0.843, 0.852, 0.814, 0.838, (5.9641)+(0.0138)Ser+(-0.0
308)His+(-0.1585)Met+(-0.0016)Lys+(0.0583)Phe+(-0.0914)Trp; 0.847,
0.865, 0.868, 0.880, 0.851, 0.854, 0.863, 0.862, (3.3457)+(0.
0126)Gln+(-0.0513)His+(-0.2042)Met+(-0.0199)Orn+(0.0685)Phe
+(-0.0938)Trp; 0.847, 0.864, 0.868, 0.881, 0.847, 0.865, 0.850, 0.8
61, (3.8166)+(0.0108)Gln+(-0.0403)His+(-0.0082)Val+(-0.2049)
Met+(0.0696)Phe+(-0.0882)Trp; 0.836, 0.851, 0.867, 0.857, 0.857,
0.857, 0.818, 0.847, (6.6277)+(0.0157)Ser+(-0.0622)Asn+(-0.028
0)Cit+(-0.1182)Met+(0.0533)Phe+(-0.1019)Trp; 0.823, 0.842, 0.8 67,
0.847, 0.844, 0.851, 0.817, 0.840, (5.9967)+(0.0140)Ser+(-0.0
306)His+(-0.1613)Met+(-0.0068)Orn+(0.0602)Phe+(-0.0920)Trp; 0.838,
0.855, 0.867, 0.858, 0.842, 0.863, 0.870, 0.858, (6.6808)+(0.
0304)Tyr+(-0.0240)Val+(-0.2256)Met+(0.0495)Ile+(0.0541)Phe+(-0.0870)Trp;
0.855, 0.871, 0.867, 0.879, 0.863, 0.872, 0.864, 0.87 0,
(5.1147)+(-0.1213)Asn+(0.0130)Gln+(-0.0367)His+(-0.0468)C
it+(0.0353)Phe+(-0.1017)Trp; 0.831, 0.848, 0.866, 0.845, 0.863, 0.
854, 0.821, 0.846, (5.5721)+(0.0124)Ser+(-0.0334)Cit+(0.0250)T
yr+(-0.1942)Met+(0.0498)Phe+(-0.1139)Trp; 0.837, 0.854, 0.866,
0.856, 0.861, 0.854, 0.836, 0.852, (6.1112)+(0.0162)Ser+(-0.069
3)Asn+(0.0246)Tyr+(-0.1529)Met+(0.0489)Phe+(-0.1123)Trp; 0.8 23,
0.841, 0.865, 0.843, 0.849, 0.847, 0.812, 0.838, (5.5939)+(0.01
21)Ser+(-0.0340)Cit+(-0.1749)Met+(0.0079)Ile+(0.0527)Phe+(-0.1049)Trp;
0.823, 0.841, 0.865, 0.850, 0.843, 0.850, 0.806, 0.837,
(6.0598)+(0.0126)Ser+(-0.0268)His+(-0.1552)Met+(-0.0084)Leu
+(0.0638)Phe+(-0.0910)Trp; 0.832, 0.849, 0.864, 0.857, 0.835, 0.8
60, 0.849, 0.850,
(7.0685)+(-0.0221)Cit+(-0.0209)Val+(-0.1817)Met+(0.0477)Ile+(0.0568)Phe+(-
-0.0783)Trp; 0.830, 0.849, 0.864, 0.848, 0.849, 0.843, 0.855,
0.849, (6.4939)+(0.0249)Ser+(-0.009
0)Gly+(-0.0267)His+(-0.1616)Met+(0.0530)Phe+(-0.0933)Trp; 0. 836,
0.852, 0.864, 0.869, 0.840, 0.843, 0.838, 0.847, (3.2359)+(0.0
076)Gln+(-0.2239)Met+(0.0412)Ile+(-0.0322)Leu+(0.0708)Phe+(-0.1031)Trp;
0.842, 0.859, 0.863, 0.869, 0.848, 0.852, 0.856, 0.85 7,
(5.2008)+(0.0008)Ser+(-0.1224)Asn+(0.0111)Gln+(-0.0451)Hi
s+(0.0345)Phe+(-0.0989)Trp; 0.826, 0.844, 0.862, 0.858, 0.840, 0.
854, 0.809, 0.840,
(6.3284)+(0.0121)Ser+(-0.0201)His+(-0.0086)Val+(-0.1642)Met+(0.0656)Phe+(-
-0.0865)Trp; 0.842, 0.859, 0.862, 0.869, 0.850, 0.852, 0.858,
0.857, (5.2386)+(-0.1225)Asn+(0.011
1)Gln+(-0.0451)His+(0.0025)Tyr+(0.0332)Phe+(-0.0998)Trp; 0.8 45,
0.859, 0.862, 0.870, 0.849, 0.851, 0.856, 0.856, (5.2312)+(-0.1
218)Asn+(0.0112)Gln+(-0.0451)His+(0.0342)Phe+(-0.0988)Trp; 0. 829,
0.846, 0.862, 0.859, 0.826, 0.851, 0.849, 0.846, (6.7116)+(-0.
0200)Val+(-0.1902)Met+(0.0516)Ile+(-0.0070)Leu+(0.0608)Phe+(-0.0785)Trp;
0.824, 0.841, 0.862, 0.847, 0.850, 0.844, 0.804, 0.83 6,
(5.7739)+(0.0112)Ser+(0.0015)Thr+(-0.0327)Cit+(-0.1711)Me
t+(0.0548)Phe+(-0.1054)Trp; 0.829, 0.845, 0.862, 0.852, 0.846, 0.
843, 0.823, 0.841, (6.2199)+(0.0156)Ser+(-0.0681)Asn+(-0.1302)
Met+(0.0034)Ile+(0.0527)Phe+(-0.1034)Trp; 0.831, 0.845, 0.862,
0.853, 0.848, 0.844, 0.819, 0.841, (6.3132)+(0.0149)Ser+(-0.069
0)Asn+(0.0018)Thr+(-0.1309)Met+(0.0540)Phe+(-0.1040)Trp; 0.8 28,
0.846, 0.861, 0.859, 0.826, 0.851, 0.851, 0.847, (6.8200)+(-0.0
004)His+(-0.0224)Val+(-0.1919)Met+(0.0475)Ile+(0.0589)Phe+(-0.0777)Trp;
0.829, 0.846, 0.861, 0.859, 0.826, 0.852, 0.852, 0.84 7,
(6.6545)+(-0.0232)Val+(-0.2023)Met+(0.0028)Lys+(0.0480)Il
e+(0.0598)Phe+(-0.0786)Trp; 0.850, 0.867, 0.861, 0.884, 0.840, 0.
881, 0.871, 0.869, (4.0370)+(0.0111)Gln+(-0.0441)His+(-0.0071)
Ala+(-0.1656)Met+(0.0590)Phe+(-0.0844)Trp; 0.847, 0.864, 0.861,
0.880, 0.851, 0.865, 0.850, 0.862, (3.6131)+(0.0121)Gln+(-0.050
5)His+(-0.0094)Pro+(-0.1825)Met+(0.0649)Phe+(-0.0977)Trp; 0. 833,
0.846, 0.861, 0.859, 0.826, 0.852, 0.850, 0.847, (6.8122)+(-0.
0225)Val+(-0.1923)Met+(0.0477)Ile+(0.0589)Phe+(-0.0778)Trp; 0.835,
0.851, 0.861, 0.864, 0.832, 0.857, 0.854, 0.852,
(7.8537)+(-0.0508)Asn+(-0.0220)Val+(-0.1418)Met+(0.0466)Ile+(0.0553)Ph
e+(-0.0753)Trp; 0.835, 0.852, 0.861, 0.862, 0.835, 0.879, 0.842, 0.
854, (6.5739)+(0.0127)Ser+(-0.0243)His+(-0.0067)Ala+(-0.125
4)Met+(0.0548)Phe+(-0.0833)Trp; 0.826, 0.845, 0.861, 0.854, 0.84 6,
0.846, 0.818, 0.841, (6.3177)+(0.0157)Ser+(-0.0674)Asn+(-0.0
012)Arg+(-0.1247)Met+(0.0533)Phe+(-0.1030)Trp; 0.826, 0.843, 0.
861, 0.850, 0.842, 0.847, 0.824, 0.841, (6.5117)+(-0.0332)Cit+(-0.
1536)Met+(0.0533)Ile+(-0.0359)Leu+(0.0612)Phe+(-0.0907)Trp; 0.823,
0.841, 0.861, 0.847, 0.849, 0.844, 0.804, 0.836, (5.7692)+(0.
0117)Ser+(-0.0329)Cit+(-0.1666)Met+(0.0008)Orn+(0.0540)Phe+(-0.1049)Trp;
0.821, 0.838, 0.860, 0.842, 0.838, 0.852, 0.819, 0.83 8,
(4.4648)+(0.0082)Gln+(-0.0521)His+(-0.0472)Cit+(0.0240)Ph
e+(-0.1033)Trp; 0.824, 0.842, 0.860, 0.845, 0.845, 0.851, 0.820, 0.
840, (7.6321)+(0.0112)Ser+(-0.0847)Asn+(-0.0205)His+(-0.026
2)Cit+(0.0345)Phe+(-0.0975)Trp; 0.832, 0.845, 0.860, 0.854, 0.84 7,
0.843, 0.820, 0.841, (6.3080)+(0.0155)Ser+(-0.0680)Asn+(-0.1
264)Met+(0.0534)Phe+(-0.1033)Trp; 0.816, 0.827, 0.860, 0.832, 0.
821, 0.836, 0.821, 0.828, (4.5801)+(0.0064)Gln+(-0.0606)His+(0.
0228)Phe+(-0.1005)Trp; 0.809, 0.826, 0.860, 0.835, 0.817, 0.836, 0.
817, 0.826, (4.5675)+(0.0066)Gln+(-0.0604)His+(-0.0091)Tyr+(0.
0265)Phe+(-0.0969)Trp; 0.828, 0.846, 0.860, 0.859, 0.826, 0.852, 0.
851, 0.847,
(6.8341)+(-0.0007)Arg+(-0.0225)Val+(-0.1907)Met+(0.0477)Ile+(0.058-
8)Phe+(-0.0776)Trp; 0.816, 0.838, 0.860, 0.84 5, 0.834, 0.852,
0.818, 0.837, (4.4559)+(0.0084)Gln+(-0.0520)His
+(-0.0468)Cit+(-0.0071)Tyr+(0.0269)Phe+(-0.1005)Trp; 0.825, 0. 841,
0.860, 0.850, 0.843, 0.854, 0.808, 0.839, (6.2539)+(0.0133)Se
r+(-0.0296)His+(-0.0058)Pro+(-0.1457)Met+(0.0590)Phe+(-0.09 45)Trp;
0.846, 0.862, 0.860, 0.873, 0.852, 0.858, 0.859, 0.860, (5.3
365)+(-0.1137)Asn+(0.0118)Gln+(-0.0420)His+(-0.0073)Lys+(0.
0373)Phe+(-0.0959)Trp; 0.825, 0.842, 0.860, 0.849, 0.850, 0.848, 0.
802, 0.837,
(5.9599)+(0.0126)Ser+(-0.0319)Cit+(-0.1558)Met+(-0.0037)Lys+(0.054-
8)Phe+(-0.1027)Trp; 0.828, 0.841, 0.860, 0.847, 0.849, 0.843,
0.804, 0.836,
(5.7741)+(0.0118)Ser+(-0.0322)Cit+(-0.1667)Met+(0.0543)Phe+(-0.104-
8)Trp; 0.831, 0.847, 0.860, 0.8 59, 0.827, 0.852, 0.854, 0.848,
(6.8895)+(-0.0222)Val+(-0.1915)M
et+(-0.0055)Orn+(0.0496)Ile+(0.0595)Phe+(-0.0778)Trp; 0.845, 0.863,
0.859, 0.877, 0.854, 0.857, 0.850, 0.860, (4.9605)+(-0.110
9)Asn+(0.0129)Gln+(-0.0448)His+(-0.0163)Arg+(0.0359)Phe+(-0.
0953)Trp; 0.830, 0.850, 0.859, 0.859, 0.844, 0.867, 0.827, 0.849,
(4. 7362)+(0.0100)Gln+(-0.0440)His+(-0.0493)Cit+(-0.0136)Lys+(0.
0313)Phe+(-0.0978)Trp; 0.823, 0.845, 0.859, 0.854, 0.842, 0.858, 0.
817, 0.843,
(4.2587)+(0.0100)Gln+(-0.0524)His+(-0.0345)Cit+(-0.0181)Arg+(0.026-
7)Phe+(-0.0985)Trp; 0.831, 0.846, 0.859, 0.856, 0.847, 0.844,
0.820, 0.842,
(6.3562)+(0.0158)Ser+(-0.0655)Asn+(-0.1269)Met+(-0.0048)Orn+(0.054-
9)Phe+(-0.1031)Trp; 0.818, 0. 838, 0.859, 0.846, 0.837, 0.841,
0.814, 0.834, (7.4338)+(0.0120)Se
r+(-0.0844)Asn+(-0.0261)His+(-0.0053)Arg+(0.0350)Phe+(-0.09 49)Trp;
0.823, 0.841, 0.859, 0.846, 0.849, 0.842, 0.806, 0.836, (5.7
600)+(0.0112)Ser+(-0.0349)Cit+(0.0033)Arg+(-0.1716)Met+(0.0
546)Phe+(-0.1056)Trp; 0.831, 0.846, 0.859, 0.855, 0.847, 0.846, 0.
820, 0.842,
(6.3922)+(0.0159)Ser+(-0.0665)Asn+(-0.1215)Met+(-0.0021)Lys+(0.053-
7)Phe+(-0.1022)Trp; 0.819, 0.840, 0.859, 0.855, 0.831, 0.849,
0.811, 0.837,
(4.2627)+(0.0095)Gln+(-0.0580)His+(-0.0238)Arg+(-0.0038)Tyr+(0.028-
4)Phe+(-0.0936)Trp; 0.844, 0. 861, 0.859, 0.873, 0.849, 0.849,
0.864, 0.859, (5.1561)+(-0.1186)A
sn+(0.0122)Gln+(-0.0454)His+(-0.0148)Orn+(0.0385)Phe+(-0.09 92)Trp;
0.822, 0.842, 0.859, 0.843, 0.855, 0.846, 0.809, 0.838, (7.1
177)+(-0.0245)His+(0.0071)Thr+(-0.0262)Cit+(-0.1480)Met+(0.
0513)Phe+(-0.0948)Trp; 0.823, 0.840, 0.859, 0.853, 0.833, 0.848, 0.
812, 0.837, (4.2643)+(0.0095)Gln+(-0.0580)His+(-0.0241)Arg+(0.
0269)Phe+(-0.0950)Trp; 0.819, 0.839, 0.859, 0.846, 0.836, 0.844, 0.
820, 0.836,
(7.5330)+(0.0121)Ser+(-0.0841)Asn+(-0.0248)His+(-0.0042)Lys+(0.036-
4)Phe+(-0.0944)Trp; 0.838, 0.853, 0.858, 0.855, 0.853, 0.841,
0.859, 0.852,
(6.9057)+(0.0270)Ser+(-0.0612)Asn+(-0.0091)Gly+(-0.1277)Met+(0.048-
8)Phe+(-0.1027)Trp; 0.834, 0. 850, 0.858, 0.852, 0.854, 0.839,
0.847, 0.848, (6.3156)+(0.0231)Se
r+(-0.0087)Gly+(-0.0233)Cit+(-0.1668)Met+(0.0499)Phe+(-0.10 44)Trp;
0.823, 0.836, 0.858, 0.843, 0.834, 0.837, 0.821, 0.834, (7.4
516)+(0.0109)Ser+(-0.0888)Asn+(-0.0270)His+(0.0342)Phe+(-0.
0962)Trp; 0.835, 0.851, 0.858, 0.852, 0.854, 0.834, 0.855, 0.849,
(5. 8771)+(0.0234)Ser+(-0.0091)Gly+(0.0152)Tyr+(-0.1942)Met+(0.
0470)Phe+(-0.1114)Trp; 0.818, 0.837, 0.858, 0.841, 0.844, 0.837, 0.
815, 0.834, (6.8189)+(-0.0308)His+(0.0060)Thr+(-0.1554)Met+(0.
0031)Ile+(0.0508)Phe+(-0.0930)Trp; 0.846, 0.862, 0.858, 0.878, 0.
849, 0.851, 0.853, 0.858, (5.4093)+(-0.1206)Asn+(0.0110)Gln+(-0.
0380)His+(-0.0110)Leu+(0.0437)Phe+(-0.0973)Trp; 0.837, 0.851,
0.858, 0.868, 0.844, 0.854, 0.818, 0.846,
(7.0621)+(0.0148)Ser+(-0.0652)Asn+(-0.0106)Val+(-0.1219)Met+(0.0642)Phe+(-
-0.0901)T rp; 0.821, 0.839, 0.858, 0.842, 0.847, 0.836, 0.819,
0.836, (5.0497)
+(0.0117)Ser+(0.0233)Tyr+(-0.2099)Met+(0.0021)Ile+(0.0498)P
he+(-0.1154)Trp; 0.823, 0.842, 0.858, 0.845, 0.851, 0.840, 0.814,
0. 837,
(5.1803)+(0.0126)Ser+(-0.0051)Arg+(0.0239)Tyr+(-0.1988)Met+(0.0497)Phe+(--
0.1142)Trp; 0.844, 0.860, 0.858, 0.874, 0.850, 0.849, 0.850, 0.856,
(5.3633)+(-0.1193)Asn+(0.0115)Gln+(-0.044
8)His+(-0.0111)Ile+(0.0387)Phe+(-0.0985)Trp; 0.822, 0.843, 0.8 57,
0.857, 0.833, 0.856, 0.814, 0.840, (4.4823)+(0.0098)Gln+(-0.0
544)His+(-0.0190)Arg+(-0.0074)Lys+(0.0300)Phe+(-0.0931)Trp; 0.806,
0.828, 0.857, 0.839, 0.798, 0.870, 0.835, 0.835, (4.9288)+(0.
0110)Ser+(-0.0175)His+(-0.0279)Val+(-0.2471)Met+(0.0594)Ile
+(0.0520)Phe; 0.825, 0.843, 0.857, 0.840, 0.854, 0.844, 0.825, 0.84
1, (6.7583)+(-0.0303)His+(0.0055)Thr+(0.0214)Tyr+(-0.1732)Me
t+(0.0469)Phe+(-0.1008)Trp; 0.820, 0.839, 0.857, 0.850, 0.832, 0.
855, 0.816, 0.838,
(4.7194)+(0.0078)Gln+(-0.0458)His+(-0.0439)Cit+(-0.0051)Val+(0.0284)Phe+(-
-0.1000)Trp; 0.841, 0.857, 0.857, 0.869, 0.823, 0.882, 0.875,
0.862, (7.3604)+(-0.0067)Ala+(-0.019
9)Val+(-0.1555)Met+(0.0506)Ile+(0.0532)Phe+(-0.0690)Trp; 0.8 20,
0.836, 0.857, 0.847, 0.825, 0.847, 0.822, 0.835, (4.8410)+(0.00
80)Gln+(-0.0534)His+(-0.0128)Lys+(0.0296)Phe+(-0.0951)Trp; 0. 827,
0.844, 0.857, 0.848, 0.850, 0.838, 0.821, 0.839, (7.6779)+(-0.
0494)Asn+(-0.0244)His+(0.0079)Thr+(-0.1163)Met+(0.0491)Phe+(-0.0939)Trp;
0.835, 0.851, 0.857, 0.866, 0.826, 0.879, 0.843, 0.85 3,
(5.3914)+(0.0086)Gln+(-0.0274)His+(-0.0137)Val+(-0.1738)M
et+(0.0347)Ile+(-0.0669)Trp; 0.857, 0.874, 0.857, 0.886, 0.869, 0.
867, 0.853, 0.869,
(4.0729)+(-0.0942)Asn+(0.0132)Gln+(-0.0523)Cit+(-0.1417)Met+(0.0541)Phe+(-
-0.1117)Trp; 0.818, 0.837, 0.857, 0.844, 0.834, 0.837, 0.821,
0.834, (7.4828)+(0.0111)Ser+(-0.087
4)Asn+(-0.0267)His+(-0.0032)Orn+(0.0351)Phe+(-0.0962)Trp; 0. 817,
0.838, 0.857, 0.843, 0.846, 0.835, 0.809, 0.833, (6.9264)+(-0.
0304)His+(0.0064)Thr+(-0.0019)Arg+(-0.1497)Met+(0.0513)Phe+(-0.0928)Trp;
0.831, 0.846, 0.857, 0.861, 0.825, 0.856, 0.843, 0.84 6,
(7.8869)+(0.0080)Ser+(-0.1053)Asn+(-0.0174)Val+(0.0268)Il
e+(0.0379)Phe+(-0.0882)Trp; 0.827, 0.842, 0.856, 0.848, 0.847, 0.
846, 0.814, 0.839,
(7.4518)+(0.0099)Ser+(-0.0955)Asn+(-0.0369)Cit+(0.0065)Orn+(0.0297)Phe+(--
0.1064)Trp
[0479] List (1) of Logistic Regression Equations Searched in
Example 5
[0480] The logistic regression equations searched in Example 5
above are listed below. Before each equation, "the value of ROC_AUC
for the pancreatic cancer group and the lung cancer group with
validation", "the value of ROC_AUC for the pancreatic cancer group
and the lung cancer group without validation", "the value of
ROC_AUC for the pancreatic cancer group and the healthy group",
"the value of ROC_AUC for the pancreatic cancer group and the other
cancers group", "the value of ROC_AUC for the pancreatic cancer
group and the colorectal cancer group", "the value of ROC_AUC for
the pancreatic cancer group and the prostatic cancer group", "the
value of ROC_AUC for the pancreatic cancer group and the breast
cancer group", and "the average value of the value of ROC_AUC for
the pancreatic cancer group and the lung cancer group, the value of
ROC_AUC for the pancreatic cancer group and the colorectal cancer
group, the value of ROC_AUC for the pancreatic cancer group and the
prostatic cancer group, and the value of ROC_AUC for the pancreatic
cancer group and the breast cancer group" obtained for the equation
are additionally listed.
[0481] 0.879, 0.901, 0.799, 0.867, 0.834, 0.859, 0.850, 0.861,
(2.501 7)+(-0.1544)Asn+(0.0144)Gln+(-0.0136)Pro+(-0.0179)Val+(0.06
47)Phe+(-0.0751)Trp; 0.879, 0.900, 0.825, 0.868, 0.840, 0.855, 0.8
49, 0.861, (1.5408)+(-0.1050)Asn+(0.0143)Gln+(-0.0196)Val+(-0.
1804)Met+(0.0788)Phe+(-0.0595)Trp; 0.879, 0.899, 0.808, 0.865, 0.
818, 0.870, 0.869, 0.864, (2.4184)+(-0.1460)Asn+(0.0137)Gln+(-0.
0063)Ala+(-0.0174)Val+(0.0542)Phe+(-0.0581)Trp; 0.878, 0.899,
0.806, 0.859, 0.832, 0.846, 0.822, 0.850,
(2.3121)+(-0.1378)Asn+(0.0149)Gln+(-0.0291)Arg+(-0.0209)Val+(0.0646)Phe+(-
-0.0644)Trp; 0.877, 0.896, 0.794, 0.863, 0.820, 0.895, 0.843,
0.864, (3.054
6)+(-0.1157)Asn+(0.0150)Gln+(-0.0065)Ala+(-0.0363)Cit+(-0.0
103)Val+(-0.0537)Trp; 0.877, 0.899, 0.770, 0.854, 0.809, 0.880, 0.
810, 0.849,
(3.2431)+(-0.0996)Asn+(0.0151)Gln+(-0.0064)Ala+(-0.0237)Arg+(-0.01-
22)Val+(-0.0440)Trp; 0.876, 0.898, 0.829, 0.87 0, 0.844, 0.865,
0.854, 0.865, (2.0985)+(-0.1578)Asn+(0.0147)Gln
+(-0.0434)Cit+(-0.0184)Val+(0.0625)Phe+(-0.0746)Trp; 0.876, 0. 893,
0.817, 0.860, 0.829, 0.849, 0.847, 0.854, (2.9307)+(-0.1647)A
sn+(0.0124)Gln+(-0.0209)Val+(0.0566)Phe+(-0.0686)Trp; 0.875, 0.892,
0.780, 0.854, 0.803, 0.884, 0.840, 0.855, (3.6223)+(-0.122
0)Asn+(0.0132)Gln+(-0.0067)Ala+(-0.0129)Val+(-0.0490)Trp; 0. 874,
0.894, 0.805, 0.860, 0.830, 0.841, 0.846, 0.853, (3.2658)+(-0.
0073)Ser+(-0.1562)Asn+(0.0131)Gln+(-0.0209)Val+(0.0537)Phe+(-0.0697)Trp;
0.874, 0.894, 0.806, 0.860, 0.825, 0.846, 0.851, 0.85 4,
(2.7168)+(-0.1504)Asn+(0.0132)Gln+(-0.0088)Thr+(-0.0197)V
al(0.0537)Phe+(-0.0663)Trp; 0.874, 0.898, 0.766, 0.857, 0.808, 0.
880, 0.836, 0.855,
(3.5580)+(-0.1181)Asn+(0.0142)Gln+(-0.0057)Ala+(-0.0086)Pro+(-0.0110)Val+-
(-0.0528)Trp; 0.873, 0.891, 0.80 7, 0.864, 0.828, 0.888, 0.853,
0.865, (2.2278)+(-0.1175)Asn+(0.01
54)Gln+(-0.0077)Ala+(-0.0464)Cit+(-0.0694)Trp; 0.873, 0.894, 0.
766, 0.854, 0.820, 0.865, 0.816, 0.849, (3.9874)+(-0.1306)Asn+(0.
0133)Gln+(-0.0113)Pro+(-0.0132)Val+(-0.0617)Trp; 0.873, 0.894,
0.798, 0.863, 0.827, 0.893, 0.838, 0.863,
(2.7457)+(-0.1095)Asn+(0.0149)Gln+(-0.0072)Ala+(-0.0424)Cit+(-0.0107)Leu+-
(-0.061 5)Trp; 0.873, 0.893, 0.789, 0.856, 0.803, 0.886, 0.850,
0.858, (3.53
53)+(-0.1236)Asn+(0.0131)Gln+(-0.0068)Ala+(-0.0146)Val+(0.0
076)Ile+(-0.0475)Trp; 0.873, 0.896, 0.810, 0.855, 0.811, 0.855, 0.
840, 0.850,
(0.6642)+(0.0125)Gln+(-0.0052)Ala+(-0.0163)Val+(-0.2337)Met+(0.070-
6)Phe+(-0.0564)Trp; 0.873, 0.895, 0.767, 0.856, 0.801, 0.880,
0.851, 0.857,
(3.3049)+(-0.1056)Asn+(0.0142)Gln+(-0.0107)Thr+(-0.0066)Ala+(-0.01-
19)Val+(-0.0475)Trp; 0.873, 0. 893, 0.769, 0.851, 0.813, 0.873,
0.806, 0.846, (2.9725)+(-0.0932)A
sn+(0.0146)Gln+(-0.0074)Ala+(-0.0245)Arg+(-0.0128)Leu+(-0.0
524)Trp; 0.873, 0.894, 0.805, 0.860, 0.819, 0.859, 0.860, 0.858,
(2. 1851)+(-0.1339)Asn+(0.0128)Gln+(-0.0075)Ala+(-0.0221)Leu+(0.
0535)Phe+(-0.0678)Trp; 0.872, 0.896, 0.789, 0.865, 0.829, 0.890, 0.
844, 0.865,
(2.3256)+(-0.1109)Asn+(0.0163)Gln+(-0.0063)Ala+(-0.0432)Cit+(-0.00-
95)Pro+(-0.0722)Trp; 0.872, 0.893, 0.756, 0.85 2, 0.799, 0.866,
0.840, 0.850, (4.0269)+(-0.0137)Ser+(-0.1075)As
n+(0.0146)Gln+(-0.0071)Ala+(-0.0129)Val+(-0.0515)Trp; 0.872, 0.891,
0.793, 0.860, 0.828, 0.879, 0.833, 0.858, (2.1632)+(-0.103
9)Asn+(0.0161)Gln+(-0.0077)Ala+(-0.0331)Cit+(-0.0180)Arg+(-0.0639)Trp;
0.872, 0.896, 0.760, 0.854, 0.825, 0.869, 0.793, 0.846,
(3.6419)+(-0.1091)Asn+(0.0151)Gln+(-0.0226)Arg+(-0.0101)Pro
+(-0.0129)Val+(-0.0571)Trp; 0.872, 0.891, 0.819, 0.860, 0.825, 0.
852, 0.856, 0.856,
(2.9395)+(-0.1699)Asn+(0.0128)Gln+(-0.0274)Val+(0.0126)Leu+(0.0531)Phe+(--
0.0668)Trp; 0.872, 0.896, 0.785, 0.861, 0.821, 0.877, 0.837, 0.858,
(3.7526)+(-0.1329)Asn+(0.013
3)Gln+(-0.0127)Pro+(-0.0174)Val+(0.0198)Ile+(-0.0589)Trp; 0. 872,
0.891, 0.822, 0.860, 0.829, 0.851, 0.849, 0.855, (2.8423)+(-0.
1619)Asn+(0.0127)Gln+(-0.0065)His+(-0.0202)Val+(0.0568)Phe+(-0.0667)Trp;
0.871, 0.892, 0.780, 0.854, 0.802, 0.883, 0.841, 0.85 5,
(3.6590)+(-0.1254)Asn+(0.0130)Gln+(-0.0067)Ala+(-0.0134)V
al+(0.0017)Lys+(-0.0493)Trp; 0.871, 0.892, 0.818, 0.859, 0.828, 0.
847, 0.846, 0.853,
(2.9627)+(-0.1677)Asn+(0.0123)Gln+(-0.0214)Val+(0.0014)Lys+(0.0567)Phe+(--
0.0687)Trp; 0.871, 0.893, 0.832, 0.870, 0.859, 0.859, 0.836, 0.862,
(1.8582)+(-0.1462)Asn+(0.013
9)Gln+(-0.0518)Cit+(-0.0240)Leu+(0.0618)Phe+(-0.0862)Trp; 0. 871,
0.892, 0.778, 0.853, 0.801, 0.883, 0.838, 0.854, (3.6602)+(-0.
1232)Asn+(0.0130)Gln+(0.0034)His+(-0.0068)Ala+(-0.0132)Val+(-0.0498)Trp;
0.871, 0.893, 0.818, 0.860, 0.829, 0.849, 0.848, 0.85 5,
(2.9200)+(-0.1649)Asn+(0.0124)Gln+(-0.0211)Val+(0.0010)Il
e+(0.0566)Phe+(-0.0684)Trp; 0.871, 0.897, 0.783, 0.863, 0.836, 0.
878, 0.821, 0.858,
(3.4654)+(-0.1234)Asn+(0.0150)Gln+(-0.0357)Cit+(-0.0107)Pro+(-0.0106)Val+-
(-0.0669)Trp; 0.871, 0.894, 0.75 7, 0.855, 0.818, 0.862, 0.823,
0.849, (3.6841)+(-0.1155)Asn+(0.01
42)Gln+(-0.0099)Thr+(-0.0107)Pro+(-0.0124)Val+(-0.0608)Trp; 0.871,
0.885, 0.788, 0.848, 0.815, 0.858, 0.814, 0.843,
(4.2016)+(-0.1395)Asn+(0.0118)Gln+(-0.0164)Val+(-0.0598)Trp; 0.871,
0.89 2, 0.786, 0.856, 0.800, 0.884, 0.855, 0.858,
(3.5356)+(-0.1318)Asn
+(0.0137)Gln+(-0.0064)Ala+(-0.0223)Val+(0.0172)Leu+(-0.047 6)Trp;
0.871, 0.895, 0.783, 0.856, 0.809, 0.883, 0.834, 0.855, (3.31
96)+(-0.0940)Asn+(0.0137)Gln+(-0.0059)Ala+(-0.0119)Val+(-0.
0813)Met+(-0.0441)Trp; 0.871, 0.894, 0.827, 0.871, 0.836, 0.883, 0.
878, 0.873,
(0.9598)+(-0.1351)Asn+(0.0160)Gln+(-0.0078)Ala+(-0.0520)Cit+(0.041-
2)Phe+(-0.0816)Trp; 0.871, 0.893, 0.764, 0.853, 0.815, 0.869,
0.816, 0.848,
(2.4550)+(-0.0982)Asn+(0.0161)Gln+(-0.0067)Ala+(-0.0235)Arg+(-0.00-
96)Pro+(-0.0644)Trp; 0.871, 0. 892, 0.776, 0.849, 0.793, 0.878,
0.831, 0.848, (3.8206)+(-0.1186)A
sn+(0.0132)Gln+(-0.0064)Ala+(-0.0133)Tyr+(-0.0124)Val+(-0.0
433)Trp; 0.870, 0.895, 0.747, 0.856, 0.822, 0.855, 0.821, 0.849,
(4.
3566)+(-0.0117)Ser+(-0.1182)Asn+(0.0145)Gln+(-0.0114)Pro+(-0.0134)Val+(-0-
.0652)Trp; 0.870, 0.894, 0.798, 0.863, 0.843, 0.845, 0.839, 0.855,
(2.2275)+(-0.1449)Asn+(0.0134)Gln+(-0.0143)Pro+(-0.0207)Leu+(0.0611)Phe+(-
-0.0880)Trp; 0.870, 0.888, 0.802, 0.8 58, 0.833, 0.870, 0.821,
0.853, (3.6506)+(-0.1325)Asn+(0.0136)Gl
n+(-0.0376)Cit+(-0.0136)Val+(-0.0640)Trp; 0.870, 0.891, 0.757,
0.847, 0.810, 0.861, 0.796, 0.840, (2.9262)+(-0.0988)Asn+(0.015
0)Gln+(-0.0074)Ala+(-0.0240)Arg+(-0.0184)Ile+(-0.0589)Trp; 0. 870,
0.893, 0.804, 0.866, 0.829, 0.892, 0.853, 0.867, (2.2383)+(-0.
1100)Asn+(0.0157)Gln+(-0.0076)Ala+(-0.0462)Cit+(-0.0036)Lys
+(-0.0673)Trp; 0.870, 0.891, 0.785, 0.856, 0.820, 0.878, 0.825, 0.8
54, (2.7544)+(-0.1122)Asn+(0.0154)Gln+(-0.0070)Ala+(-0.0444)
Cit+(-0.0185)Ile+(-0.0670)Trp; 0.870, 0.889, 0.779, 0.853, 0.807,
0.876, 0.838, 0.852, (3.3036)+(-0.1156)Asn+(0.0126)Gln+(-0.007
7)Ala+(-0.0137)Leu+(-0.0579)Trp; 0.870, 0.891, 0.793, 0.864, 0.8
32, 0.829, 0.885, 0.859, (3.9221)+(-0.1340)Asn+(-0.0131)Gly+(0.
0158)Gln+(-0.0219)Val+(0.0448)Phe+(-0.0796)Trp; 0.870, 0.887,
0.777, 0.851, 0.812, 0.868, 0.825, 0.848,
(2.4154)+(-0.1035)Asn+(0.0149)Gln+(-0.0082)Ala+(-0.0250)Arg+(-0.0605)Trp;
0.870, 0. 887, 0.776, 0.846, 0.817, 0.862, 0.787, 0.838,
(3.8220)+(-0.1157)A
sn+(0.0139)Gln+(-0.0248)Arg+(-0.0159)Val+(-0.0531)Trp; 0.869,
0.894, 0.769, 0.855, 0.820, 0.865, 0.818, 0.849, (3.9537)+(-0.129
2)Asn+(0.0135)Gln+(-0.0032)His+(-0.0113)Pro+(-0.0129)Val+(-0.0608)Trp;
0.869, 0.886, 0.770, 0.848, 0.817, 0.844, 0.818, 0.841,
(4.5838)+(-0.0110)Ser+(-0.1288)Asn+(0.0129)Gln+(-0.0166)Val
+(-0.0625)Trp; 0.869, 0.892, 0.809, 0.859, 0.826, 0.841, 0.852, 0.8
53,
(2.7855)+(-0.1607)Asn+(0.0136)Gln+(-0.0189)Val+(-0.0174)Orn+(0.0584)Phe+(-
-0.0730)Trp; 0.869, 0.890, 0.784, 0.858, 0.833, 0.859, 0.825,
0.852, (4.0173)+(-0.0107)Ser+(-0.1216)Asn+(0.014
7)Gln+(-0.0370)Cit+(-0.0139)Val+(-0.0667)Trp; 0.869, 0.892, 0. 812,
0.847, 0.806, 0.831, 0.825, 0.839, (3.0304)+(-0.1605)Asn+(0.
0130)Gln+(-0.0378)Tyr+(-0.0203)Val+(0.0723)Phe+(-0.0542)Tr p;
0.869, 0.889, 0.769, 0.854, 0.808, 0.874, 0.846, 0.854,
(2.7396)+(-0.1199)Asn+(0.0143)Gln+(-0.0068)Ala+(-0.0106)Pro+(-0.070
1)Trp; 0.869, 0.893, 0.809, 0.867, 0.835, 0.891, 0.848, 0.867,
(2.09 80)+(-0.0922)Asn+(0.0156)Gln+(-0.0068)Ala+(-0.0424)Cit+(-0.
0745)Met+(-0.0643)Trp; 0.869, 0.893, 0.766, 0.854, 0.819, 0.864, 0.
816, 0.848,
(4.0000)+(-0.1318)Asn+(0.0133)Gln+(-0.0113)Pro+(-0.0134)Val+(0.000-
5)Lys+(-0.0618)Trp; 0.869, 0.891, 0.751, 0.863, 0.833, 0.841,
0.868, 0.858,
(4.7039)+(-0.0974)Asn+(-0.0145)Gly+(0.0172)Gln+(-0.0123)Pro+(-0.01-
50)Val+(-0.0765)Trp; 0.869, 0. 891, 0.808, 0.850, 0.827, 0.843,
0.797, 0.839, (0.5776)+(0.0144)Gl
n+(-0.0263)Arg+(-0.0188)Val+(-0.2381)Met+(0.0788)Phe+(-0.06 05)Trp;
0.869, 0.891, 0.802, 0.858, 0.817, 0.884, 0.836, 0.857, (2.5
560)+(-0.1120)Asn+(0.0154)Gln+(-0.0071)Ala+(-0.0471)Cit+(-0.
0183)Tyr+(-0.0614)Trp; 0.869, 0.895, 0.775, 0.858, 0.816, 0.872, 0.
837, 0.855,
(3.8763)+(-0.1432)Asn+(0.0143)Gln+(-0.0124)Pro+(-0.0277)Val+(0.027-
4)Leu+(-0.0606)Trp; 0.869, 0.890, 0.804, 0.854, 0.844, 0.836,
0.794, 0.841,
(2.2097)+(-0.1272)Asn+(0.0134)Gln+(-0.0300)Arg+(-0.0274)Leu+(0.063-
1)Phe+(-0.0756)Trp; 0.868, 0. 883, 0.790, 0.852, 0.806, 0.872,
0.853, 0.853, (2.6780)+(-0.1261)A
sn+(0.0130)Gln+(-0.0085)Ala+(-0.0678)Trp; 0.868, 0.892, 0.790,
0.863, 0.823, 0.878, 0.860, 0.863, (1.8784)+(-0.0968)Asn+(0.016
9)Gln+(-0.0135)Thr+(-0.0073)Ala+(-0.0476)Cit+(-0.0673)Trp; 0. 868,
0.890, 0.793, 0.861, 0.821, 0.858, 0.867, 0.859, (1.5610)+(-0.
1371)Asn+(0.0149)Gln+(-0.0067)Ala+(-0.0125)Pro+(0.0418)Phe+(-0.0840)Trp;
0.868, 0.891, 0.803, 0.862, 0.838, 0.881, 0.818, 0.85 7,
(3.2905)+(-0.0971)Asn+(0.0142)Gln+(-0.0331)Cit+(-0.0121)V
al+(-0.0973)Met+(-0.0571)Trp; 0.868, 0.891, 0.765, 0.854, 0.804,
0.873, 0.848, 0.854, (2.9967)+(-0.0973)Asn+(0.0138)Gln+(-0.012
4)Thr+(-0.0074)Ala+(-0.0126)Leu+(-0.0556)Trp; 0.868, 0.886, 0. 725,
0.831, 0.773, 0.867, 0.778, 0.826, (2.8819)+(-0.1086)Asn+(0.
0152)Gln+(-0.0074)Ala+(-0.0259)Arg+(-0.0170)Val; 0.868, 0.890,
0.767, 0.863, 0.821, 0.859, 0.879, 0.862,
(4.3460)+(-0.1007)Asn+(-0.0129)Gly+(0.0163)Gln+(-0.0053)Ala+(-0.0153)Val+-
(-0.061 5)Trp; 0.868, 0.892, 0.770, 0.852, 0.798, 0.876, 0.841,
0.852, (3.46
83)+(-0.1172)Asn+(0.0145)Gln+(-0.0070)Ala+(-0.0105)Val+(-0.
0181)Orn+(-0.0524)Trp; 0.868, 0.884, 0.818, 0.856, 0.842, 0.832, 0.
826, 0.846, (2.7211)+(-0.1542)Asn+(0.0111)Gln+(-0.0265)Leu+(0.
0551)Phe+(-0.0827)Trp; 0.868, 0.890, 0.760, 0.858, 0.827, 0.838, 0.
853, 0.852,
(4.5717)+(-0.0861)Asn+(-0.0138)Gly+(0.0171)Gln+(-0.0230)Arg+(-0.01-
76)Val+(-0.0683)Trp; 0.868, 0.889, 0.784, 0.86 2, 0.826, 0.874,
0.854, 0.861, (2.5701)+(-0.0129)Ser+(-0.1025)As
n+(0.0167)Gln+(-0.0081)Ala+(-0.0454)Cit+(-0.0725)Trp; 0.868, 0.891,
0.764, 0.844, 0.790, 0.853, 0.824, 0.839, (1.1007)+(-0.103
5)Asn+(0.0148)Gln+(-0.0057)Ala+(-0.0213)Val+(-0.1699)Met+(0.
0641)Phe; 0.868, 0.886, 0.775, 0.849, 0.811, 0.854, 0.824, 0.844,
(3.
8432)+(-0.1227)Asn+(0.0129)Gln+(-0.0113)Thr+(-0.0152)Val+(-0.0579)Trp;
0.868, 0.885, 0.794, 0.850, 0.816, 0.861, 0.819, 0.845,
(4.1486)+(-0.1405)Asn+(0.0117)Gln+(-0.0175)Val+(0.0051)Ile+(-0.0589)Trp;
0.867, 0.889, 0.763, 0.846, 0.816, 0.852, 0.789, 0.83 7,
(4.1138)+(-0.0085)Ser+(-0.1076)Asn+(0.0146)Gln+(-0.0237)A
rg+(-0.0160)Val+(-0.0558)Trp; 0.867, 0.889, 0.802, 0.858, 0.820,
0.878, 0.843, 0.857, (3.3758)+(-0.0996)Asn+(0.0143)Gln+(-0.033
0)Val+(-0.1527)Met+(0.0356)Leu+(-0.0467)Trp; 0.867, 0.889, 0.7 78,
0.846, 0.817, 0.858, 0.787, 0.838, (3.9146)+(-0.1262)Asn+(0.0
135)Gln+(-0.0276)Arg+(-0.0178)Val+(0.0066)Lys+(-0.0538)Trp; 0.867,
0.890, 0.786, 0.857, 0.825, 0.865, 0.829, 0.852,
(3.1465)+(-0.1133)Asn+(0.0153)Gln+(-0.0128)Thr+(-0.0413)Cit+(-0.0123)V
al+(-0.0627)Trp; 0.867, 0.887, 0.791, 0.853, 0.823, 0.868, 0.811,
0. 847, (3.6993)+(-0.0978)Asn+(0.0128)Gln+(-0.0144)Val+(-0.112
7)Met+(-0.0514)Trp; 0.867, 0.892, 0.787, 0.859, 0.826, 0.815, 0.87
2, 0.851, (2.2295)+(-0.0139)Gly+(0.0160)Gln+(-0.0198)Val+(-0.
2375)Met+(0.0599)Phe+(-0.0726)Trp; 0.867, 0.891, 0.787, 0.852, 0.
826, 0.867, 0.794, 0.845, (3.5652)+(-0.1161)Asn+(0.0146)Gln+(-0.
0224)Cit+(-0.0204)Arg+(-0.0143)Val+(-0.0567)Trp; 0.867, 0.888,
0.801, 0.855, 0.819, 0.850, 0.846, 0.851,
(1.3118)+(-0.1192)Asn+(0.0154)Gln+(-0.0083)Ala+(-0.0274)Arg+(0.0394)Phe+(-
-0.0721)Trp; 0.867, 0.893, 0.764, 0.848, 0.809, 0.858, 0.805,
0.841, (4.169
0)+(-0.1271)Asn+(0.0134)Gln+(-0.0105)Pro+(-0.0136)Tyr+(-0.0
129)Val+(-0.0553)Trp; 0.867, 0.889, 0.767, 0.852, 0.808, 0.863, 0.
836, 0.849,
(2.2550)+(-0.0915)Asn+(0.0156)Gln+(-0.0097)Thr+(-0.0079)Ala+(-0.02-
22)Arg+(-0.0592)Trp; 0.867, 0.890, 0.813, 0.86 9, 0.853, 0.861,
0.850, 0.864, (1.0150)+(-0.1443)Asn+(0.0168)Gln
+(-0.0547)Cit+(-0.0161)Pro+(0.0524)Phe+(-0.1028)Trp; 0.867, 0. 889,
0.742, 0.835, 0.778, 0.850, 0.804, 0.830, (1.7622)+(-0.1296)A
sn+(0.0158)Gln+(-0.0071)Ala+(-0.0283)Arg+(-0.0220)Val+(0.04 71)Phe;
0.867, 0.886, 0.768, 0.859, 0.827, 0.836, 0.869, 0.855, (4.9
691)+(-0.1110)Asn+(-0.0143)Gly+(0.0155)Gln+(-0.0184)Val+(-0.
0725)Trp; 0.867, 0.889, 0.751, 0.840, 0.778, 0.881, 0.809, 0.839,
(2. 6674)+(-0.1110)Asn+(0.0152)Gln+(-0.0075)Ala+(-0
0.0266)Arg+(-0.0212)Val+(0.0204)Ile; 0.867, 0.891, 0.758, 0.855,
0.805, 0.871, 0.855, 0.855,
(2.5140)+(-0.1026)Asn+(0.0153)Gln+(-0.0113)Thr+(-0.0066)Ala+(-0.0097)Pro+-
(-0.0680)Trp; 0.867, 0.891, 0.804, 0. 864, 0.827, 0.888, 0.853,
0.865, (2.2343)+(-0.1182)Asn+(0.0153)G
ln+(0.0022)His+(-0.0078)Ala+(-0.0472)Cit+(-0.0702)Trp; 0.867,
0.890, 0.824, 0.861, 0.848, 0.837, 0.832, 0.852, (1.4661)+(-0.101
1)Asn+(0.0128)Gln+(-0.1673)Met+(-0.0215)Leu+(0.0716)Phe+(-0.
0740)Trp; 0.867, 0.893, 0.761, 0.852, 0.816, 0.855, 0.816, 0.845,
(3.
8915)+(-0.1273)Asn+(0.0141)Gln+(-0.0109)Pro+(-0.0117)Val+(-0.0127)Orn+(-0-
.0647)Trp; 0.866, 0.891, 0.792, 0.858, 0.815, 0.877, 0.849, 0.858,
(2.3274)+(-0.1132)Asn+(0.0163)Gln+(-0.0077)Ala+(-0.0368)Cit+(-0.0186)Orn+-
(-0.0697)Trp; 0.866, 0.891, 0.769, 0. 848, 0.813, 0.860, 0.797,
0.840, (3.6054)+(-0.1070)Asn+(0.0144)G
ln+(-0.0076)Thr+(-0.0224)Arg+(-0.0151)Val+(-0.0524)Trp; 0.86 6,
0.884, 0.794, 0.849, 0.817, 0.859, 0.816, 0.844, (4.1462)+(-0.13
74)Asn+(0.0120)Gln+(-0.0048)His+(-0.0158)Val+(-0.0585)Trp; 0. 866,
0.888, 0.782, 0.848, 0.816, 0.865, 0.797, 0.842, (3.7457)+(-0.
1167)Asn+(0.0138)Gln+(-0.0250)Arg+(-0.0176)Val+(0.0070)Ile+(-0.0518)Trp;
0.866, 0.889, 0.801, 0.857, 0.835, 0.830, 0.836, 0.84 7,
(2.4800)+(-0.1360)Asn+(0.0123)Gln+(-0.0118)Thr+(-0.0248)L
eu+(0.0514)Phe+(-0.0784)Trp
[0482] List (1) of Linear Discriminants Searched in Example 5
[0483] The linear discriminants searched in Example 5 above are
listed below. Before each equation, "the value of ROC_AUC for the
pancreatic cancer group and the lung cancer group with validation",
"the value of ROC_AUC for the pancreatic cancer group and the lung
cancer group without validation", "the value of ROC_AUC for the
pancreatic cancer group and the healthy group", "the value of
ROC_AUC for the pancreatic cancer group and the other cancers
group", "the value of ROC_AUC for the pancreatic cancer group and
the colorectal cancer group", "the value of ROC_AUC for the
pancreatic cancer group and the prostatic cancer group", "the value
of ROC_AUC for the pancreatic cancer group and the breast cancer
group", and "the average value of the value of ROC_AUC for the
pancreatic cancer group and the lung cancer group, the value of
ROC_AUC for the pancreatic cancer group and the colorectal cancer
group, the value of ROC_AUC for the pancreatic cancer group and the
prostatic cancer group, and the value of ROC_AUC for the pancreatic
cancer group and the breast cancer group" obtained for the equation
are additionally listed.
[0484] 0.889, 0.900, 0.816, 0.870, 0.844, 0.860, 0.856, 0.865,
(5.626 2)+(-0.1579)Asn+(0.0147)Gln+(-0.0133)Pro+(-0.0175)Val+(0.06
80)Phe+(-0.1047)Trp; 0.888, 0.899, 0.843, 0.872, 0.850, 0.857, 0.8
55, 0.865, (4.4024)+(-0.1075)Asn+(0.0147)Gln+(-0.0196)Val+(-0.
1775)Met+(0.0888)Phe+(-0.0925)Trp; 0.887, 0.899, 0.821, 0.868, 0.
824, 0.876, 0.872, 0.868, (5.7041)+(-0.1372)Asn+(0.0135)Gln+(-0.
0082)Ala+(-0.0168)Val+(0.0597)Phe+(-0.0875)Trp; 0.887, 0.899,
0.823, 0.866, 0.842, 0.856, 0.832, 0.857,
(5.4488)+(-0.1451)Asn+(0.0149)Gln+(-0.0236)Arg+(-0.0202)Val+(0.0627)Phe+(-
-0.0933)Trp; 0.885, 0.897, 0.781, 0.860, 0.816, 0.883, 0.839,
0.859, (6.932
6)+(-0.1143)Asn+(0.0143)Gln+(-0.0069)Ala+(-0.0094)Pro+(-0.0
106)Val+(-0.0772)Trp; 0.884, 0.894, 0.781, 0.858, 0.829, 0.869, 0.
819, 0.853,
(6.9669)+(-0.1335)Asn+(0.0140)Gln+(-0.0121)Pro+(-0.0128)Val+(-0.08-
70)Trp; 0.884, 0.895, 0.765, 0.858, 0.828, 0.857, 0.819, 0.850,
(7.2847)+(-0.0106)Ser+(-0.1228)Asn+(0.0152)Gln+(-0.0123)Pro+(-0.0133)Val+-
(-0.0882)Trp; 0.884, 0.897, 0.786, 0. 861, 0.827, 0.872, 0.832,
0.857, (6.9854)+(-0.1425)Asn+(0.0145)G
ln+(-0.0126)Pro+(-0.0230)Val+(0.0187)Leu+(-0.0849)Trp; 0.884,
0.895, 0.787, 0.866, 0.823, 0.876, 0.873, 0.867, (7.2130)+(-0.102
6)Asn+(-0.0072)Gly+(0.0146)Gln+(-0.0076)Ala+(-0.0133)Val+(-0.0770)Trp;
0.883, 0.895, 0.795, 0.860, 0.815, 0.888, 0.841, 0.860,
(6.5615)+(-0.0887)Asn+(0.0138)Gln+(-0.0076)Ala+(-0.0114)Val
+(-0.0771)Met+(-0.0674)Trp; 0.883, 0.897, 0.840, 0.872, 0.851, 0.
867, 0.857, 0.868,
(5.3307)+(-0.1611)Asn+(0.0143)Gln+(-0.0346)Cit+(-0.0181)Val+(0.0628)Phe+(-
-0.0999)Trp; 0.883, 0.896, 0.786, 0.858, 0.816, 0.887, 0.823,
0.856, (6.6882)+(-0.1000)Asn+(0.015
0)Gln+(-0.0080)Ala+(-0.0211)Arg+(-0.0123)Val+(-0.0677)Trp; 0. 883,
0.897, 0.820, 0.860, 0.819, 0.864, 0.848, 0.857, (3.8867)+(0.0
128)Gln+(-0.0077)Ala+(-0.0159)Val+(-0.2229)Met+(0.0786)Phe+(-0.0839)Trp;
0.883, 0.897, 0.804, 0.867, 0.826, 0.897, 0.850, 0.86 7,
(6.5607)+(-0.1130)Asn+(0.0146)Gln+(-0.0084)Ala+(-0.0332)C
it+(-0.0101)Val+(-0.0731)Trp; 0.883, 0.896, 0.774, 0.867, 0.839,
0.852, 0.859, 0.861, (7.3561)+(-0.1163)Asn+(-0.0086)Gly+(0.016
0)Gln+(-0.0122)Pro+(-0.0136)Val+(-0.0918)Trp; 0.882, 0.897, 0. 774,
0.858, 0.832, 0.868, 0.802, 0.850, (6.7631)+(-0.1177)Asn+(0.
0160)Gln+(-0.0215)Arg+(-0.0116)Pro+(-0.0128)Val+(-0.0819)Tr p;
0.882, 0.892, 0.795, 0.858, 0.812, 0.884, 0.846, 0.858,
(6.8850)+(-0.1147)Asn+(0.0131)Gln+(-0.0083)Ala+(-0.0123)Val+(-0.072
1)Trp; 0.882, 0.895, 0.793, 0.864, 0.840, 0.878, 0.825, 0.859,
(6.64 55)+(-0.1319)Asn+(0.0155)Gln+(-0.0329)Cit+(-0.0121)Pro+(-0.
0107)Val+(-0.0880)Trp; 0.882, 0.895, 0.781, 0.859, 0.809, 0.882, 0.
852, 0.859,
(6.5441)+(-0.1000)Asn+(0.0143)Gln+(-0.0107)Thr+(-0.0081)Ala+(-0.01-
18)Val+(-0.0706)Trp; 0.882, 0.894, 0.804, 0.86 4, 0.828, 0.894,
0.841, 0.864, (6.2603)+(-0.1068)Asn+(0.0144)Gln
+(-0.0090)Ala+(-0.0386)Cit+(-0.0116)Leu+(-0.0788)Trp; 0.882, 0.893,
0.820, 0.863, 0.825, 0.864, 0.862, 0.861, (5.3683)+(-0.125
6)Asn+(0.0128)Gln+(-0.0090)Ala+(-0.0224)Leu+(0.0598)Phe+(-0.
0956)Trp; 0.882, 0.895, 0.773, 0.859, 0.828, 0.862, 0.825, 0.852,
(6.
6445)+(-0.1193)Asn+(0.0151)Gln+(-0.0100)Thr+(-0.0115)Pro+(-0.0124)Val+(-0-
.0851)Trp; 0.882, 0.895, 0.820, 0.870, 0.844, 0.842, 0.877, 0.864,
(6.2093)+(-0.1451)Asn+(-0.0066)Gly+(0.0141)Gln+(-0.0201)Val+(0.0505)Phe+(-
-0.0993)Trp; 0.882, 0.894, 0.780, 0.8 59, 0.824, 0.873, 0.829,
0.855, (5.9832)+(-0.1014)Asn+(0.0159)Gl
n+(-0.0077)Ala+(-0.0201)Arg+(-0.0106)Pro+(-0.0877)Trp; 0.882,
0.894, 0.800, 0.862, 0.827, 0.878, 0.839, 0.860, (6.9095)+(-0.139
2)Asn+(0.0139)Gln+(-0.0134)Pro+(-0.0188)Val+(0.0238)Ile+(-0.
0821)Trp; 0.882, 0.893, 0.817, 0.862, 0.832, 0.848, 0.853, 0.857,
(5. 4208)+(-0.1462)Asn+(0.0139)Gln+(-0.0104)Thr+(-0.0195)Val+(0.
0586)Phe+(-0.0960)Trp; 0.882, 0.893, 0.813, 0.865, 0.849, 0.842, 0.
842, 0.857,
(5.2374)+(-0.1489)Asn+(0.0139)Gln+(-0.0137)Pro+(-0.0218)Leu+(0.066-
1)Phe+(-0.1155)Trp; 0.882, 0.895, 0.784, 0.860, 0.832, 0.871,
0.817, 0.854,
(6.6358)+(-0.1060)Asn+(0.0146)Gln+(-0.0108)Pro+(-0.0120)Val+(-0.07-
70)Met+(-0.0810)Trp; 0.881, 0. 895, 0.794, 0.868, 0.833, 0.895,
0.847, 0.868, (5.9674)+(-0.1130)A
sn+(0.0160)Gln+(-0.0077)Ala+(-0.0415)Cit+(-0.0105)Pro+(-0.0
895)Trp; 0.881, 0.894, 0.779, 0.858, 0.828, 0.865, 0.819, 0.852,
(6.
8969)+(-0.1322)Asn+(0.0143)Gln+(-0.0119)Pro+(-0.0121)Val+(-0.0051)Orn+(-0-
.0876)Trp; 0.881, 0.892, 0.830, 0.863, 0.837, 0.852, 0.849, 0.858,
(5.6927)+(-0.1623)Asn+(0.0127)Gln+(-0.0203)Val+(0.0616)Phe+(-0.0985)Trp;
0.881, 0.894, 0.781, 0.858, 0.829, 0.86 9, 0.819, 0.853,
(6.9665)+(-0.1335)Asn+(0.0140)Gln+(-0.0121)Pr
o+(0.0001)Tyr+(-0.0128)Val+(-0.0870)Trp; 0.881, 0.893, 0.806, 0.
861, 0.809, 0.893, 0.859, 0.863, (6.8469)+(-0.1179)Asn+(0.0129)G
ln+(-0.0085)Ala+(-0.0159)Val+(0.0141)Ile+(-0.0686)Trp; 0.881,
0.892, 0.793, 0.856, 0.806, 0.884, 0.842, 0.856, (6.9147)+(-0.113
0)Asn+(0.0131)Gln+(-0.0083)Ala+(-0.0060)Tyr+(-0.0120)Val+(-0.0693)Trp;
0.881, 0.893, 0.778, 0.857, 0.809, 0.877, 0.847, 0.856,
(7.1932)+(-0.0103)Ser+(-0.1041)Asn+(0.0142)Gln+(-0.0084)Ala
+(-0.0127)Val+(-0.0730)Trp; 0.881, 0.893, 0.823, 0.863, 0.835, 0.
846, 0.850, 0.856, (5.8716)+(-0.0044)Ser+(-0.1570)Asn+(0.0131)
Gln+(-0.0203)Val+(0.0591)Phe+(-0.0983)Trp; 0.880, 0.894, 0.820,
0.856, 0.835, 0.842, 0.810, 0.845, (3.5425)+(0.0140)Gln+(-0.021
4)Arg+(-0.0191)Val+(-0.2368)Met+(0.0827)Phe+(-0.0894)Trp; 0. 880,
0.893, 0.811, 0.869, 0.834, 0.897, 0.854, 0.870, (5.9734)+(-0.
1014)Asn+(0.0154)Gln+(-0.0094)Ala+(-0.0431)Cit+(-0.0076)Lys
+(-0.0818)Trp; 0.880, 0.892, 0.797, 0.859, 0.808, 0.888, 0.854, 0.8
60, (6.8944)+(-0.1203)Asn+(0.0133)Gln+(-0.0082)Ala+(-0.0181)
Val+(0.0104)Leu+(-0.0710)Trp; 0.880, 0.892, 0.830, 0.864, 0.838,
0.856, 0.848, 0.859, (5.7140)+(-0.1570)Asn+(0.0130)Gln+(-0.019
5)Val+(-0.0034)Lys+(0.0620)Phe+(-0.0978)Trp; 0.880, 0.892, 0.7 99,
0.862, 0.828, 0.885, 0.839, 0.861, (6.0615)+(-0.1104)Asn+(0.0
148)Gln+(-0.0090)Ala+(-0.0399)Cit+(-0.0128)Ile+(-0.0850)Tr p;
0.880, 0.894, 0.780, 0.858, 0.829, 0.869, 0.817, 0.852,
(6.9990)+(-0.1276)Asn+(0.0143)Gln+(-0.0122)Pro+(-0.0119)Val+(-0.003
7)Lys+(-0.0862)Trp; 0.880, 0.892, 0.831, 0.863, 0.835, 0.853, 0.85
3, 0.858, (5.7311)+(-0.1642)Asn+(0.0128)Gln+(-0.0231)Val+(0.0
052)Leu+(0.0599)Phe+(-0.0974)Trp; 0.880, 0.892, 0.811, 0.863, 0.
842, 0.879, 0.820, 0.858, (6.2140)+(-0.1028)Asn+(0.0145)Gln+(-0.
0295)Cit+(-0.0124)Val+(-0.0968)Met+(-0.0767)Trp; 0.880, 0.892,
0.790, 0.857, 0.808, 0.880, 0.846, 0.857,
(6.7511)+(-0.1117)Asn+(0.0137)Gln+(-0.0085)Ala+(-0.0108)Val+(-0.0099)Orn+-
(-0.073 0)Trp; 0.880, 0.892, 0.792, 0.858, 0.812, 0.887, 0.843,
0.859, (6.91
06)+(-0.1099)Asn+(0.0133)Gln+(-0.0084)Ala+(-0.0115)Val+(-0.
0030)Lys+(-0.0713)Trp; 0.880, 0.894, 0.814, 0.863, 0.835, 0.824, 0.
870, 0.856,
(4.4168)+(-0.0089)Gly+(0.0146)Gln+(-0.0189)Val+(-0.2484)Met+(0.070-
9)Phe+(-0.0943)Trp; 0.880, 0.893, 0.799, 0.867, 0.841, 0.858,
0.860, 0.863,
(7.0140)+(-0.1230)Asn+(-0.0077)Gly+(0.0151)Gln+(-0.0252)Cit+(-0.01-
49)Val+(-0.0879)Trp; 0.880, 0. 892, 0.783, 0.863, 0.824, 0.865,
0.866, 0.862, (6.9325)+(-0.0931)A
sn+(-0.0076)Gly+(0.0142)Gln+(-0.0083)Ala+(-0.0170)Leu+(-0.0
843)Trp; 0.880, 0.894, 0.777, 0.859, 0.814, 0.865, 0.857, 0.857,
(6.
3357)+(-0.0095)Gly+(0.0145)Gln+(-0.0072)Ala+(-0.0121)Val+(-0.1494)Met+(-0-
.0731)Trp; 0.880, 0.892, 0.827, 0.864, 0.837, 0.850, 0.853, 0.858,
(5.5559)+(-0.1603)Asn+(0.0132)Gln+(-0.0191)Val+(-0.0089)Orn+(0.0624)Phe+(-
-0.0998)Trp; 0.879, 0.893, 0.804, 0.8 65, 0.833, 0.886, 0.843,
0.864, (5.6813)+(-0.1039)Asn+(0.0155)Gl
n+(-0.0094)Ala+(-0.0330)Cit+(-0.0146)Arg+(-0.0837)Trp; 0.879,
0.893, 0.791, 0.865, 0.837, 0.854, 0.858, 0.861, (6.8301)+(-0.078
3)Asn+(-0.0092)Gly+(0.0155)Gln+(-0.0149)Val+(-0.1177)Met+(-0.0794)Trp;
0.879, 0.893, 0.839, 0.871, 0.862, 0.859, 0.839, 0.863,
(4.8814)+(-0.1511)Asn+(0.0138)Gln+(-0.0433)Cit+(-0.0242)Leu
+(0.0637)Phe+(-0.1101)Trp; 0.879, 0.890, 0.814, 0.865, 0.830, 0.8
89, 0.855, 0.866, (5.7663)+(-0.1134)Asn+(0.0147)Gln+(-0.0096)A
la+(-0.0435)Cit+(-0.0861)Trp; 0.879, 0.893, 0.833, 0.864, 0.836,
0.853, 0.852, 0.859, (5.6873)+(-0.1634)Asn+(0.0126)Gln+(-0.021
5)Val+(0.0047)Ile+(0.0612)Phe+(-0.0973)Trp; 0.879, 0.890, 0.79 3,
0.862, 0.832, 0.850, 0.861, 0.858, (7.2952)+(-0.1227)Asn+(-0.0
085)Gly+(0.0142)Gln+(-0.0166)Val+(-0.0876)Trp; 0.879, 0.892, 0.
815, 0.867, 0.834, 0.892, 0.853, 0.868, (5.5186)+(-0.0871)Asn+(0.
0153)Gln+(-0.0088)Ala+(-0.0400)Cit+(-0.0784)Met+(-0.0804)Tr p;
0.879, 0.894, 0.784, 0.863, 0.836, 0.856, 0.846, 0.858,
(7.0712)+(-0.1079)Asn+(-0.0079)Gly+(0.0161)Gln+(-0.0213)Arg+(-0.016
4)Val+(-0.0823)Trp; 0.879, 0.893, 0.831, 0.857, 0.825, 0.840, 0.84
0, 0.849, (5.5862)+(-0.1584)Asn+(0.0131)Gln+(-0.0256)Tyr+(-0.
0196)Val+(0.0733)Phe+(-0.0894)Trp; 0.879, 0.892, 0.792, 0.857, 0.
810, 0.884, 0.846, 0.858, (6.9019)+(-0.1155)Asn+(0.0130)Gln+(0.
0022)His+(-0.0084)Ala+(-0.0125)Val+(-0.0726)Trp; 0.879, 0.891,
0.779, 0.859, 0.819, 0.882, 0.842, 0.858,
(6.3848)+(-0.1030)Asn+(0.0148)Gln+(-0.0078)Ala+(-0.0109)Pro+(-0.0077)Lys+-
(-0.087 6)Trp; 0.879, 0.892, 0.833, 0.872, 0.840, 0.885, 0.879,
0.874, (4.71
27)+(-0.1290)Asn+(0.0150)Gln+(-0.0098)Ala+(-0.0476)Cit+(0.0
408)Phe+(-0.1005)Trp; 0.879, 0.892, 0.782, 0.855, 0.819, 0.876, 0.
818, 0.851,
(6.3732)+(-0.0919)Asn+(0.0146)Gln+(-0.0087)Ala+(-0.0218)Arg+(-0.01-
48)Leu+(-0.0745)Trp; 0.879, 0.893, 0.771, 0.86 4, 0.844, 0.838,
0.850, 0.856, (7.0000)+(-0.1097)Asn+(-0.0090)Gl
y+(0.0155)Gln+(-0.0127)Pro+(-0.0160)Leu+(-0.1017)Trp; 0.878, 0.890,
0.793, 0.852, 0.826, 0.861, 0.798, 0.844, (6.6960)+(-0.122
4)Asn+(0.0144)Gln+(-0.0230)Arg+(-0.0156)Val+(-0.0775)Trp; 0. 878,
0.893, 0.801, 0.867, 0.828, 0.884, 0.864, 0.867, (5.4919)+(-0.
0996)Asn+(0.0158)Gln+(-0.0102)Thr+(-0.0093)Ala+(-0.0405)Cit
+(-0.0843)Trp; 0.878, 0.894, 0.785, 0.859, 0.830, 0.867, 0.820, 0.8
53, (6.9384)+(-0.1319)Asn+(0.0142)Gln+(-0.0038)His+(-0.0121)
Pro+(-0.0124)Val+(-0.0860)Trp; 0.878, 0.892, 0.831, 0.864, 0.838,
0.853, 0.850, 0.858, (5.6808)+(-0.1616)Asn+(0.0127)Gln+(-0.001
6)His+(-0.0201)Val+(0.0616)Phe+(-0.0980)Trp; 0.878, 0.892, 0.7 82,
0.855, 0.813, 0.867, 0.835, 0.852, (5.7538)+(-0.0967)Asn+(0.0
156)Gln+(-0.0096)Ala+(-0.0200)Arg+(-0.0165)Orn+(-0.0827)Tr p;
0.878, 0.890, 0.811, 0.861, 0.829, 0.877, 0.838, 0.858,
(6.3792)+(-0.1045)Asn+(0.0142)Gln+(-0.0279)Val+(-0.1311)Met+(0.0255)
Leu+(-0.0702)Trp; 0.878, 0.890, 0.793, 0.856, 0.818, 0.875, 0.835,
0.854, (5.7816)+(-0.1013)Asn+(0.0146)Gln+(-0.0096)Ala+(-0.02
11)Arg+(-0.0842)Trp; 0.878, 0.890, 0.795, 0.860, 0.837, 0.860, 0.8
26, 0.853, (6.8735)+(-0.0096)Ser+(-0.1285)Asn+(0.0147)Gln+(-0.
0331)Cit+(-0.0141)Val+(-0.0849)Trp; 0.878, 0.885, 0.801, 0.852,
0.823, 0.859, 0.819, 0.847,
(6.9114)+(-0.1396)Asn+(0.0122)Gln+(-0.0158)Val+(-0.0828)Trp; 0.878,
0.891, 0.817, 0.856, 0.820, 0.8 55, 0.838, 0.851,
(3.7293)+(0.0120)Gln+(-0.0088)Ala+(-0.1992)M
et+(-0.0195)Leu+(0.0739)Phe+(-0.0925)Trp; 0.878, 0.891, 0.775,
0.853, 0.817, 0.871, 0.812, 0.848, (6.1747)+(-0.0969)Asn+(0.014
9)Gln+(-0.0088)Ala+(-0.0208)Arg+(-0.0180)Ile+(-0.0824)Trp; 0. 878,
0.889, 0.790, 0.855, 0.812, 0.879, 0.838, 0.854, (6.5522)+(-0.
1074)Asn+(0.0126)Gln+(-0.0091)Ala+(-0.0142)Leu+(-0.0794)Tr p;
0.878, 0.892, 0.778, 0.866, 0.831, 0.868, 0.869, 0.865,
(6.4265)+(-0.1040)Asn+(-0.0068)Gly+(0.0156)Gln+(-0.0073)Ala+(-0.011
5)Pro+(-0.0982)Trp; 0.878, 0.890, 0.783, 0.854, 0.809, 0.875, 0.84
0, 0.853, (6.4197)+(-0.1045)Asn+(0.0135)Gln+(-0.0092)Ala+(-0.
0136)Orn+(-0.0117)Leu+(-0.0795)Trp; 0.878, 0.889, 0.776, 0.855,
0.816, 0.873, 0.835, 0.853,
(6.3761)+(-0.1128)Asn+(0.0142)Gln+(-0.0077)Ala+(-0.0100)Pro+(-0.0099)Ile+-
(-0.0907)Trp; 0.878, 0. 892, 0.778, 0.858, 0.819, 0.881, 0.834,
0.856, (6.5926)+(-0.1089)A
sn+(0.0139)Gln+(-0.0076)Ala+(-0.0096)Pro+(-0.0109)Leu+(-0.0
845)Trp; 0.878, 0.891, 0.787, 0.863, 0.827, 0.867, 0.861, 0.862,
(5.
9954)+(-0.0924)Asn+(-0.0058)Gly+(0.0157)Gln+(-0.0091)Ala+(-0.0200)Arg+(-0-
.0896)Trp; 0.878, 0.891, 0.820, 0.860, 0.850, 0.842, 0.808, 0.848,
(5.0158)+(-0.1329)Asn+(0.0141)Gln+(-0.0251)Arg+(-0.0276)Leu+(0.0632)Phe+(-
-0.1045)Trp; 0.878, 0.891, 0.816, 0.8 67, 0.852, 0.823, 0.865,
0.858, (5.8682)+(-0.1317)Asn+(-0.0074)G
ly+(0.0133)Gln+(-0.0277)Leu+(0.0496)Phe+(-0.1107)Trp; 0.878, 0.892,
0.763, 0.845, 0.786, 0.866, 0.829, 0.843, (4.0631)+(-0.094
6)Asn+(0.0139)Gln+(-0.0085)Ala+(-0.0210)Val+(-0.1618)Met+(0.
0588)Phe; 0.878, 0.890, 0.776, 0.855, 0.808, 0.874, 0.845, 0.854,
(6.
2087)+(-0.0904)Asn+(0.0140)Gln+(-0.0123)Thr+(-0.0087)Ala+(-0.0144)Leu+(-0-
.0769)Trp; 0.877, 0.891, 0.818, 0.857, 0.834, 0.843, 0.822, 0.848,
(3.6186)+(0.0132)Gln+(-0.0103)Pro+(-0.0170)Val+(-0.2461)Met+(0.0860)Phe+(-
-0.0991)Trp; 0.877, 0.891, 0.794, 0.8 52, 0.826, 0.859, 0.799,
0.844, (6.6475)+(-0.1264)Asn+(0.0143)Gl
n+(-0.0250)Arg+(-0.0165)Val+(0.0035)Lys+(-0.0779)Trp; 0.877, 0.888,
0.804, 0.856, 0.830, 0.866, 0.818, 0.851, (6.4700)+(-0.101
4)Asn+(0.0133)Gln+(-0.0142)Val+(-0.1045)Met+(-0.0752)Trp; 0. 877,
0.890, 0.774, 0.857, 0.813, 0.880, 0.848, 0.858, (6.1290)+(-0.
1107)Asn+(0.0150)Gln+(-0.0081)Ala+(-0.0101)Pro+(-0.0146)Orn
+(-0.0902)Trp; 0.877, 0.891, 0.795, 0.856, 0.813, 0.881, 0.838, 0.8
56, (6.2061)+(-0.0850)Asn+(0.0132)Gln+(-0.0085)Ala+(-0.0709)
Met+(-0.0116)Leu+(-0.0757)Trp; 0.877, 0.892, 0.773, 0.848, 0.805,
0.880, 0.800, 0.844, (5.7439)+(0.0138)Gln+(-0.0083)Ala+(-0.021
6)Arg+(-0.0111)Val+(-0.1216)Met+(-0.0645)Trp; 0.877, 0.889, 0. 786,
0.857, 0.822, 0.841, 0.853, 0.851, (7.4364)+(-0.1144)Asn+(-0.
0094)Gly+(0.0147)Gln+(-0.0197)Tyr+(-0.0155)Val+(-0.0789)Tr p;
0.877, 0.888, 0.727, 0.835, 0.774, 0.878, 0.791, 0.833,
(5.8092)+(-0.1082)Asn+(0.0145)Gln+(-0.0095)Ala+(-0.0245)Arg+(-0.017
5)Val; 0.877, 0.887, 0.784, 0.851, 0.821, 0.849, 0.821, 0.844,
(7.19 34)+(-0.0094)Ser+(-0.1302)Asn+(0.0132)Gln+(-0.0162)Val+(-0.
0838)Trp; 0.877, 0.889, 0.814, 0.860, 0.833, 0.872, 0.832, 0.857,
(6. 6160)+(-0.1436)Asn+(0.0139)Gln+(-0.0312)Cit+(-0.0198)Val+(0.
0110)Leu+(-0.0825)Trp; 0.877, 0.890, 0.840, 0.865, 0.853, 0.840, 0.
841, 0.856,
(4.0702)+(-0.1032)Asn+(0.0135)Gln+(-0.1606)Met+(-0.0231)Leu+(0.082-
2)Phe+(-0.1055)Trp; 0.877, 0.891, 0.806, 0.871, 0.840, 0.883,
0.875, 0.872,
(5.9695)+(-0.1050)Asn+(-0.0052)Gly+(0.0156)Gln+(-0.0092)Ala+(-0.03-
93)Cit+(-0.0909)Trp; 0.877, 0. 889, 0.790, 0.849, 0.795, 0.884,
0.830, 0.849, (5.7019)+(0.0122)Gl
n+(-0.0082)Ala+(-0.0197)Val+(-0.1701)Met+(0.0163)Leu+(-0.06 49)Trp;
0.877, 0.890, 0.784, 0.862, 0.819, 0.859, 0.877, 0.861, (6.1
519)+(-0.1002)Asn+(-0.0061)Gly+(0.0151)Gln+(-0.0094)Ala+(-0.
0174)Orn+(-0.0921)Trp
[0485] List (2) of Logistic Regression Equations Searched in
Example 5
[0486] The logistic regression equations searched in Example 5
above are listed below. Before each equation, "the value of ROC_AUC
for the pancreatic cancer group and the lung cancer group with
validation", "the value of ROC_AUC for the pancreatic cancer group
and the lung cancer group without validation", "the value of
ROC_AUC for the pancreatic cancer group and the healthy group",
"the value of ROC_AUC for the pancreatic cancer group and the other
cancers group", "the value of ROC_AUC for the pancreatic cancer
group and the colorectal cancer group", "the value of ROC_AUC for
the pancreatic cancer group and the prostatic cancer group", "the
value of ROC_AUC for the pancreatic cancer group and the breast
cancer group", and "the average value of the value of ROC_AUC for
the pancreatic cancer group and the lung cancer group, the value of
ROC_AUC for the pancreatic cancer group and the colorectal cancer
group, the value of ROC_AUC for the pancreatic cancer group and the
prostatic cancer group, and the value of ROC_AUC for the pancreatic
cancer group and the breast cancer group" obtained for the equation
are additionally listed.
[0487] 0.858, 0.882, 0.854, 0.866, 0.854, 0.854, 0.858, 0.862,
(0.742 8)+(-0.0948)Asn+(0.0147)Gln+(-0.0250)His+(-0.1901)Met+(0.05
79)Phe+(-0.0741)Trp; 0.850, 0.872, 0.854, 0.852, 0.838, 0.842, 0.8
35, 0.847, (0.1340)+(0.0125)Gln+(-0.0287)His+(-0.2660)Met+(0.
0561)Phe+(-0.0760)Trp; 0.849, 0.877, 0.853, 0.859, 0.851, 0.853, 0.
835, 0.854,
(-0.3557)+(0.0142)Gln+(-0.0176)His+(-0.0454)Cit+(-0.2515)Met+(0.05-
95)Phe+(-0.0844)Trp; 0.829, 0.855, 0.852, 0.8 47, 0.854, 0.845,
0.814, 0.842, (4.2366)+(0.0090)Ser+(-0.0506)As
n+(-0.0181)Cit+(-0.1342)Met+(0.0480)Phe+(-0.0762)Trp; 0.847, 0.874,
0.852, 0.854, 0.839, 0.849, 0.837, 0.849,
(0.1888)+(0.0131)Gln+(-0.0262)His+(-0.2534)Met+(-0.0053)Lys+(0.0573)Phe+(-
-0. 0743)Trp; 0.814, 0.834, 0.851, 0.825, 0.816, 0.835, 0.816,
0.825, (1. 8629)+(0.0072)Gln+(-0.0495)His+(0.0085)Phe+(-0.0904)Trp;
0.8 15, 0.842, 0.850, 0.835, 0.834, 0.846, 0.812, 0.833,
(1.0816)+(0.00
96)Gln+(-0.0322)His+(-0.0580)Cit+(0.0197)Phe+(-0.1039)Trp; 0. 862,
0.887, 0.849, 0.872, 0.863, 0.864, 0.853, 0.867, (0.4080)+(-0.
1010)Asn+(0.0158)Gln+(-0.0511)Cit+(-0.1773)Met+(0.0598)Phe+(-0.0872)Trp;
0.854, 0.882, 0.849, 0.872, 0.865, 0.869, 0.860, 0.86 9,
(1.3668)+(-0.1519)Asn+(0.0150)Gln+(-0.0162)His+(-0.0523)C
it+(0.0410)Phe+(-0.0924)Trp; 0.842, 0.869, 0.848, 0.843, 0.822, 0.
833, 0.821, 0.836, (0.3205)+(0.0127)Gln+(-0.0317)His+(-0.0234)
Tyr+(-0.2412)Met+(0.0628)Phe+(-0.0681)Trp; 0.842, 0.866, 0.847,
0.844, 0.824, 0.854, 0.821, 0.841, (4.0284)+(0.0066)Ser+(-0.021
5)Val+(-0.1905)Met+(0.0235)Ile+(0.0641)Phe+(-0.0531)Trp; 0.8 51,
0.877, 0.846, 0.854, 0.846, 0.843, 0.819, 0.846, (-0.0588)+(0.0
148)Gln+(-0.0282)His+(-0.0253)Arg+(-0.2362)Met+(0.0598)Phe+(-0.0718)Trp;
0.828, 0.853, 0.845, 0.841, 0.846, 0.834, 0.800, 0.83 3,
(4.2868)+(0.0091)Ser+(-0.0489)Asn+(-0.0098)Arg+(-0.1330)M
et+(0.0480)Phe+(-0.0729)Trp; 0.819, 0.849, 0.844, 0.841, 0.846, 0.
833, 0.817, 0.836, (5.0808)+(0.0052)Ser+(-0.0891)Asn+(-0.0263)
Cit+(-0.0008)Lys+(0.0305)Phe+(-0.0861)Trp; 0.849, 0.870, 0.844,
0.858, 0.845, 0.844, 0.859, 0.855, (1.9743)+(-0.1549)Asn+(0.013
2)Gln+(-0.0321)His+(0.0345)Phe+(-0.0834)Trp; 0.827, 0.854, 0.8 44,
0.850, 0.850, 0.836, 0.847, 0.847, (4.6405)+(0.0158)Ser+(-0.0
352)Asn+(-0.0068)Gly+(-0.1493)Met+(0.0411)Phe+(-0.0800)Trp; 0.847,
0.873, 0.844, 0.845, 0.816, 0.831, 0.842, 0.841,
(2.1375)+(-0.1449)Asn+(0.0136)Gln+(-0.0342)His+(-0.0424)Tyr+(0.0534)Ph
e+(-0.0658)Trp; 0.825, 0.848, 0.844, 0.841, 0.846, 0.832, 0.817, 0.
836, (5.0770)+(0.0049)Ser+(-0.0907)Asn+(-0.0265)Cit+(0.0301)
Phe+(-0.0866)Trp; 0.825, 0.857, 0.844, 0.845, 0.839, 0.858, 0.817,
0.843, (0.8822)+(0.0124)Gln+(-0.0225)His+(-0.0628)Cit+(-0.01
58)Lys+(0.0326)Phe+(-0.0992)Trp; 0.818, 0.833, 0.843, 0.823, 0.8
12, 0.839, 0.808, 0.823, (2.1373)+(0.0072)Gln+(-0.0478)His+(-0.
0877)Trp; 0.848, 0.875, 0.843, 0.860, 0.845, 0.850, 0.859, 0.857,
(1. 9446)+(-0.1433)Asn+(0.0137)Gln+(-0.0299)His+(-0.0060)Lys+(0.
0365)Phe+(-0.0810)Trp; 0.824, 0.852, 0.843, 0.841, 0.843, 0.831, 0.
815, 0.835, (4.1715)+(0.0078)Ser+(-0.0549)Asn+(-0.1513)Met+(0.
0019)Lys+(0.0463)Phe+(-0.0764)Trp; 0.828, 0.852, 0.842, 0.841, 0.
844, 0.833, 0.812, 0.835, (4.2086)+(0.0081)Ser+(-0.0527)Asn+(-0.
1471)Met+(0.0468)Phe+(-0.0754)Trp; 0.841, 0.865, 0.842, 0.854, 0.
842, 0.863, 0.841, 0.853, (4.3533)+(0.0072)Ser+(-0.0423)Asn+(-0.
0047)Ala+(-0.1106)Met+(0.0440)Phe+(-0.0678)Trp; 0.821, 0.846,
0.842, 0.836, 0.845, 0.829, 0.798, 0.829,
(3.8441)+(0.0056)Ser+(-0.0198)Cit+(-0.1786)Met+(0.0461)Phe+(-0.0797)Trp;
0.824, 0.85 1, 0.841, 0.846, 0.849, 0.829, 0.841, 0.843,
(4.4498)+(0.0145)Ser+(-0.0073)Gly+(-0.0108)Cit+(-0.1718)Met+(0.0398)Phe+(-
-0.082 7)Trp; 0.816, 0.846, 0.841, 0.836, 0.845, 0.828, 0.798,
0.829, (3.82
69)+(0.0055)Ser+(-0.0199)Cit+(-0.1805)Met+(0.0006)Lys+(0.04
59)Phe+(-0.0801)Trp; 0.821, 0.849, 0.841, 0.819, 0.794, 0.828, 0.7
84, 0.814, (1.0434)+(0.0113)Gln+(-0.0327)His+(-0.0618)Cit+(-0.
0563)Tyr+(0.0498)Phe+(-0.0851)Trp; 0.839, 0.864, 0.841, 0.854, 0.
839, 0.873, 0.845, 0.855, (5.0156)+(0.0046)Ser+(-0.0661)Asn+(-0.
0057)Ala+(-0.0191)Cit+(0.0314)Phe+(-0.0739)Trp; 0.850, 0.873,
0.840, 0.853, 0.847, 0.839, 0.821, 0.845,
(-0.2044)+(0.0133)Gln+(-0.0518)Cit+(-0.2611)Met+(0.0571)Phe+(-0.0912)Trp;
0.824, 0. 858, 0.840, 0.840, 0.836, 0.849, 0.796, 0.835,
(0.8827)+(0.0125)Gl
n+(-0.0379)His+(-0.0341)Cit+(-0.0328)Arg+(0.0302)Phe+(-0.09 28)Trp;
0.828, 0.854, 0.840, 0.842, 0.845, 0.829, 0.813, 0.835, (4.2
894)+(0.0094)Ser+(-0.0460)Asn+(-0.1485)Met+(-0.0127)Orn+(0.
0512)Phe+(-0.0757)Trp; 0.823, 0.849, 0.840, 0.832, 0.817, 0.842, 0.
815, 0.831, (1.7645)+(0.0094)Gln+(-0.0404)His+(-0.0142)Lys+(0.
0181)Phe+(-0.0838)Trp; 0.835, 0.861, 0.840, 0.851, 0.843, 0.862, 0.
831, 0.849,
(4.0445)+(0.0049)Ser+(-0.0049)Ala+(-0.0146)Cit+(-0.1341)Met+(0.043-
6)Phe+(-0.0704)Trp; 0.825, 0.852, 0.839, 0.840, 0.842, 0.831,
0.813, 0.834,
(4.2041)+(0.0089)Ser+(-0.0500)Asn+(-0.0026)Thr+(-0.1429)Met+(0.046-
2)Phe+(-0.0746)Trp; 0.817, 0. 847, 0.839, 0.833, 0.840, 0.828,
0.789, 0.826, (3.9284)+(0.0063)Se
r+(-0.0128)Cit+(-0.0083)Arg+(-0.1698)Met+(0.0466)Phe+(-0.07 70)Trp;
0.819, 0.847, 0.838, 0.838, 0.842, 0.825, 0.817, 0.832, (5.1
270)+(0.0052)Ser+(-0.0889)Asn+(-0.0228)Cit+(-0.0054)Orn+(0.
0310)Phe+(-0.0868)Trp; 0.845, 0.870, 0.838, 0.848, 0.833, 0.829, 0.
835, 0.842,
(0.6178)+(-0.0085)Ser+(0.0134)Gln+(-0.0277)His+(-0.2538)Met+(0.051-
3)Phe+(-0.0776)Trp; 0.815, 0.845, 0.838, 0.834, 0.843, 0.823,
0.795, 0.826,
(3.8019)+(0.0052)Ser+(0.0065)His+(-0.0227)Cit+(-0.1841)Met+(0.0460-
)Phe+(-0.0827)Trp; 0.818, 0.84 6, 0.838, 0.846, 0.850, 0.828,
0.849, 0.843,
(5.4768)+(0.0107)Ser+(-0.0790)Asn+(-0.0056)Gly+(-0.0201)Cit+(0.023-
6)Phe+(-0.090 4)Trp; 0.819, 0.842, 0.838, 0.833, 0.831, 0.853,
0.800, 0.831, (1.74
23)+(0.0093)Gln+(-0.0296)His+(-0.0545)Cit+(-0.0967)Trp; 0.84 9,
0.875, 0.838, 0.856, 0.849, 0.849, 0.824, 0.849, (-0.1630)+(0.01
42)Gln+(-0.0518)Cit+(-0.2409)Met+(-0.0071)Lys+(0.0593)Phe+(-0.0880)Trp;
0.823, 0.852, 0.838, 0.839, 0.843, 0.825, 0.808, 0.83 2,
(4.1903)+(0.0078)Ser+(-0.0549)Asn+(0.0046)His+(-0.1504)Me
t+(0.0467)Phe+(-0.0772)Trp; 0.820, 0.845, 0.837, 0.824, 0.816, 0.
814, 0.790, 0.816, (5.2767)+(0.0061)Ser+(-0.0846)Asn+(-0.0270)
Cit+(-0.0375)Tyr+(0.0493)Phe+(-0.0740)Trp; 0.817, 0.839, 0.837,
0.807, 0.776, 0.811, 0.782, 0.802, (1.9795)+(0.0084)Gln+(-0.050
2)His+(-0.0534)Tyr+(0.0358)Phe+(-0.0708)Trp; 0.817, 0.846, 0.8 37,
0.838, 0.845, 0.822, 0.814, 0.832, (5.0582)+(0.0046)Ser+(-0.0
958)Asn+(0.0082)His+(-0.0304)Cit+(0.0301)Phe+(-0.0905)Trp; 0. 857,
0.881, 0.837, 0.852, 0.827, 0.840, 0.834, 0.845, (1.5102)+(-0.
1492)Asn+(0.0153)Gln+(-0.0648)Cit+(-0.0467)Tyr+(0.0627)Phe+(-0.0839)Trp;
0.825, 0.852, 0.837, 0.844, 0.846, 0.828, 0.832, 0.84 0,
(4.5273)+(0.0152)Ser+(-0.0074)Gly+(-0.0089)Arg+(-0.1647)M
et+(0.0400)Phe+(-0.0798)Trp; 0.859, 0.883, 0.837, 0.871, 0.866, 0.
872, 0.853, 0.868, (1.4133)+(-0.1411)Asn+(0.0151)Gln+(-0.0593)
Cit+(-0.0077)Lys+(0.0430)Phe+(-0.0961)Trp; 0.819, 0.848, 0.837,
0.839, 0.841, 0.830, 0.818, 0.834, (4.9911)+(0.0070)Ser+(-0.082
2)Asn+(-0.0055)Thr+(-0.0251)Cit+(0.0299)Phe+(-0.0844)Trp; 0. 854,
0.879, 0.837, 0.850, 0.835, 0.836, 0.816, 0.841, (0.5649)+(0.0
116)Gln+(-0.0186)His+(-0.2464)Met+(-0.0179)Leu+(0.0691)Phe+(-0.0718)Trp;
0.852, 0.877, 0.837, 0.857, 0.847, 0.845, 0.835, 0.85 1,
(1.5634)+(-0.1301)Asn+(0.0151)Gln+(-0.0298)His+(-0.0280)A
rg+(0.0417)Phe+(-0.0789)Trp; 0.830, 0.860, 0.836, 0.825, 0.801, 0.
835, 0.777, 0.818, (1.3370)+(0.0122)Gln+(-0.0471)His+(-0.0339)
Arg+(-0.0423)Tyr+(0.0450)Phe+(-0.0690)Trp; 0.829, 0.854, 0.836,
0.834, 0.825, 0.840, 0.792, 0.828, (1.2668)+(0.0117)Gln+(-0.046
9)His+(-0.0386)Arg+(0.0258)Phe+(-0.0838)Trp; 0.816, 0.846, 0.8 36,
0.835, 0.841, 0.826, 0.799, 0.828, (3.8669)+(0.0070)Ser+(-0.0
040)Thr+(-0.0185)Cit+(-0.1691)Met+(0.0450)Phe+(-0.0781)Trp; 0.820,
0.847, 0.835, 0.837, 0.845, 0.827, 0.801, 0.830, (5.0812)+(0.
0060)Ser+(-0.0840)Asn+(-0.0173)Cit+(-0.0112)Arg+(0.0323)Phe
+(-0.0829)Trp; 0.841, 0.870, 0.835, 0.848, 0.830, 0.846, 0.828, 0.8
43, (5.3439)+(-0.0433)Asn+(-0.0210)Val+(-0.1218)Met+(0.0202)
Ile+(0.0593)Phe+(-0.0510)Trp; 0.845, 0.871, 0.835, 0.846, 0.833,
0.848, 0.805, 0.839, (4.9169)+(0.0093)Ser+(-0.0553)Asn+(-0.016
5)Val+(-0.1210)Met+(0.0656)Phe+(-0.0552)Trp; 0.831, 0.861, 0.8 35,
0.852, 0.840, 0.849, 0.855, 0.851, (4.5027)+(0.0121)Ser+(-0.0
062)Gly+(-0.0041)Ala+(-0.1428)Met+(0.0381)Phe+(-0.0742)Trp; 0.837,
0.866, 0.835, 0.842, 0.822, 0.843, 0.818, 0.837, (4.6202)+(0.
0010)Thr+(-0.0212)Val+(-0.1756)Met+(0.0220)Ile+(0.0604)Phe+(-0.0539)Trp;
0.858, 0.879, 0.835, 0.867, 0.861, 0.859, 0.851, 0.86 3,
(1.5215)+(-0.1583)Asn+(0.0143)Gln+(-0.0586)Cit+(0.0393)Ph
e+(-0.0991)Trp; 0.856, 0.877, 0.835, 0.857, 0.847, 0.835, 0.843, 0.
850, (1.0599)+(-0.1017)Asn+(0.0131)Gln+(-0.2016)Met+(0.0547)
Phe+(-0.0825)Trp; 0.858, 0.884, 0.835, 0.856, 0.848, 0.842, 0.807,
0.845, (0.1226)+(0.0129)Gln+(-0.0471)Cit+(-0.2338)Met+(-0.01
87)Leu+(0.0725)Phe+(-0.0833)Trp; 0.826, 0.849, 0.834, 0.843, 0.8
42, 0.824, 0.842, 0.839, (4.4781)+(0.0146)Ser+(-0.0079)Gly+(-0.
1791)Met+(0.0385)Phe+(-0.0826)Trp; 0.853, 0.878, 0.834, 0.859, 0.
848, 0.840, 0.844, 0.852, (1.0584)+(-0.0965)Asn+(0.0134)Gln+(-0.
1950)Met+(-0.0040)Lys+(0.0558)Phe+(-0.0810)Trp; 0.842, 0.873,
0.834, 0.842, 0.828, 0.826, 0.801, 0.832,
(-0.0812)+(0.0137)Gln+(-0.0559)Cit+(-0.0258)Tyr+(-0.2345)Met+(0.0654)Phe+-
(-0.085 3)Trp; 0.838, 0.865, 0.834, 0.841, 0.823, 0.842, 0.816,
0.836, (4.57
68)+(-0.0192)Val+(-0.1714)Met+(0.0246)Ile+(-0.0048)Leu+(0.0
609)Phe+(-0.0537)Trp; 0.823, 0.849, 0.834, 0.843, 0.842, 0.821, 0.
842, 0.839, (4.4515)+(0.0144)Ser+(-0.0080)Gly+(-0.1833)Met+(0.
0013)Lys+(0.0380)Phe+(-0.0835)Trp; 0.860, 0.885, 0.834, 0.858, 0.
823, 0.862, 0.859, 0.857, (0.0513)+(0.0130)Gln+(-0.0179)His+(-0.
0065)Ala+(-0.2216)Met+(0.0524)Phe+(-0.0679)Trp; 0.836, 0.865,
0.834, 0.840, 0.820, 0.833, 0.825, 0.835,
(4.2506)+(-0.0254)Val+(-0.2105)Met+(0.0096)Lys+(0.0272)Ile+(0.0623)Phe+(--
0.0545)T rp; 0.863, 0.886, 0.834, 0.853, 0.823, 0.845, 0.837,
0.848, (0.6071)
+(0.0117)Gln+(-0.0226)Val+(-0.2849)Met+(0.0182)Ile+(0.0760)
Phe+(-0.0599)Trp; 0.817, 0.849, 0.834, 0.834, 0.839, 0.819, 0.795,
0.825, (3.9336)+(0.0070)Ser+(-0.0110)Cit+(-0.1814)Met+(-0.01
23)Orn+(0.0500)Phe+(-0.0793)Trp; 0.829, 0.857, 0.834, 0.834, 0.8
30, 0.826, 0.787, 0.825, (3.8834)+(0.0037)Ser+(-0.1711)Met+(0.0
188)Ile+(-0.0302)Leu+(0.0639)Phe+(-0.0667)Trp; 0.864, 0.889, 0.
833, 0.864, 0.838, 0.867, 0.852, 0.861, (-0.3713)+(0.0143)Gln+(-0.
0066)Ala+(-0.0470)Cit+(-0.2090)Met+(0.0545)Phe+(-0.0788)Tr p;
0.865, 0.885, 0.833, 0.860, 0.843, 0.841, 0.840, 0.852,
(2.4858)+(-0.1478)Asn+(0.0122)Gln+(-0.0184)His+(-0.0240)Leu+(0.0557)
Phe+(-0.0765)Trp; 0.823, 0.853, 0.833, 0.844, 0.844, 0.820, 0.839,
0.839, (4.5097)+(0.0151)Ser+(-0.0071)Gly+(-0.1764)Met+(-0.01
07)Orn+(0.0427)Phe+(-0.0818)Trp; 0.834, 0.867, 0.833, 0.843, 0.8
23, 0.844, 0.818, 0.838, (4.6666)+(-0.0029)Cit+(-0.0208)Val+(-0.
1692)Met+(0.0218)Ile+(0.0596)Phe+(-0.0540)Trp; 0.848, 0.876, 0.
833, 0.852, 0.846, 0.839, 0.809, 0.843, (-0.2120)+(0.0143)Gln+(-0.
0394)Cit+(-0.0184)Arg+(-0.2462)Met+(0.0592)Phe+(-0.0864)Tr p;
0.836, 0.863, 0.833, 0.847, 0.836, 0.856, 0.819, 0.843,
(4.1396)+(0.0054)Ser+(-0.0050)Ala+(-0.0095)Arg+(-0.1284)Met+(0.0433)
Phe+(-0.0674)Trp; 0.840, 0.866, 0.833, 0.842, 0.822, 0.841, 0.818,
0.837, (4.6547)+(-0.0210)Val+(-0.1721)Met+(0.0221)Ile+(0.059
7)Phe+(-0.0535)Trp; 0.857, 0.882, 0.833, 0.854, 0.830, 0.823, 0.85
3, 0.847, (-0.3303)+(0.0173)Gln+(-0.0335)His+(-0.2786)Met+(-0.
0450)Orn+(0.0737)Phe+(-0.0766)Trp; 0.821, 0.853, 0.832, 0.817, 0.
784, 0.825, 0.788, 0.812, (1.9308)+(0.0100)Gln+(-0.0423)His+(-0.
0473)Tyr+(-0.0118)Lys+(0.0402)Phe+(-0.0675)Trp; 0.871, 0.893,
0.832, 0.870, 0.859, 0.859, 0.836, 0.862,
(1.8582)+(-0.1462)Asn+(0.0139)Gln+(-0.0518)Cit+(-0.0240)Leu+(0.0618)Phe+(-
-0.0862) Trp; 0.817, 0.847, 0.832, 0.826, 0.822, 0.813, 0.788,
0.817, (4.551
3)+(0.0078)Ser+(-0.0595)Asn+(-0.0244)Tyr+(-0.1146)Met+(0.05
42)Phe+(-0.0692)Trp; 0.814, 0.841, 0.832, 0.828, 0.831, 0.818, 0.7
95, 0.821, (3.8053)+(0.0045)Ser+(-0.0007)His+(-0.1948)Met+(0.
0002)Lys+(0.0445)Phe+(-0.0786)Trp; 0.836, 0.867, 0.832, 0.843, 0.
824, 0.844, 0.818, 0.838,
(4.7117)+(-0.0207)Val+(-0.1706)Met+(-0.0044)Orn+(0.0233)Ile+(0.0602)Phe+(-
-0.0539)Trp; 0.846, 0.873, 0.832, 0.850, 0.823, 0.863, 0.838,
0.849,
(4.7306)+(-0.0034)Ala+(-0.0191)Val+(-0.1422)Met+(0.0208)Ile+(0.0562)Phe+(-
-0.0487) Trp; 0.803, 0.819, 0.832, 0.814, 0.819, 0.816, 0.791,
0.811, (4.302 0)+(-0.0257)His+(0.0072)Phe+(-0.0900)Trp; 0.817,
0.841, 0.831, 0.828, 0.831, 0.819, 0.794, 0.821,
(3.8098)+(0.0046)Ser+(-0.000
6)His+(-0.1943)Met+(0.0445)Phe+(-0.0785)Trp; 0.830, 0.858, 0.8 31,
0.838, 0.839, 0.833, 0.788, 0.830, (4.2940)+(-0.0156)Cit+(-0.
1464)Met+(0.0203)Ile+(-0.0305)Leu+(0.0622)Phe+(-0.0677)Trp; 0.823,
0.841, 0.831, 0.828, 0.831, 0.818, 0.793, 0.821, (3.8056)+(0.
0045)Ser+(-0.1950)Met+(0.0445)Phe+(-0.0788)Trp; 0.820, 0.850,
0.831, 0.842, 0.850, 0.831, 0.810, 0.835,
(4.9150)+(-0.0416)Asn+(0.0005)Thr+(-0.0162)Cit+(-0.1231)Met+(0.0424)Phe+(-
-0.0776) Trp; 0.828, 0.857, 0.831, 0.844, 0.846, 0.838, 0.806,
0.837, (4.383
7)+(0.0085)Ser+(-0.0498)Asn+(-0.0070)Pro+(-0.1239)Met+(0.04
93)Phe+(-0.0762)Trp; 0.820, 0.841, 0.831, 0.828, 0.831, 0.817, 0.7
93, 0.821, (3.8018)+(0.0045)Ser+(-0.1954)Met+(0.0001)Lys+(0.0
444)Phe+(-0.0789)Trp; 0.822, 0.846, 0.831, 0.830, 0.835, 0.823, 0.
782, 0.821, (3.9368)+(0.0059)Ser+(-0.0112)Arg+(-0.1754)Met+(0.
0460)Phe+(-0.0756)Trp; 0.821, 0.849, 0.831, 0.842, 0.841, 0.821, 0.
841, 0.838,
(4.4750)+(0.0155)Ser+(-0.0076)Gly+(-0.0031)Thr+(-0.1713)Met+(0.037-
9)Phe+(-0.0813)Trp; 0.835, 0.863, 0.831, 0.852, 0.845, 0.856,
0.836, 0.850,
(4.9570)+(-0.0325)Asn+(-0.0046)Ala+(-0.0121)Cit+(-0.0899)Met+(0.03-
99)Phe+(-0.0692)Trp; 0.847, 0. 872, 0.831, 0.848, 0.826, 0.836,
0.842, 0.844, (0.1066)+(0.0142)Gl
n+(-0.0273)His+(-0.0135)Thr+(-0.2376)Met+(0.0514)Phe+(-0.07 20)Trp;
0.825, 0.845, 0.831, 0.838, 0.846, 0.821, 0.816, 0.832, (5.4
144)+(-0.0821)Asn+(-0.0252)Cit+(0.0280)Phe+(-0.0873)Trp; 0.8 21,
0.846, 0.831, 0.838, 0.846, 0.821, 0.815, 0.832, (5.4178)+(-0.0
818)Asn+(-0.0252)Cit+(-0.0002)Lys+(0.0280)Phe+(-0.0872)Trp
[0488] List (2) of Linear Discriminants Searched in Example 5
[0489] The linear discriminants searched in Example 5 above are
listed below. Before each equation, "the value of ROC_AUC for the
pancreatic cancer group and the lung cancer group with validation",
"the value of ROC_AUC for the pancreatic cancer group and the lung
cancer group without validation", "the value of ROC_AUC for the
pancreatic cancer group and the healthy group", "the value of
ROC_AUC for the pancreatic cancer group and the other cancers
group", "the value of ROC_AUC for the pancreatic cancer group and
the colorectal cancer group", "the value of ROC_AUC for the
pancreatic cancer group and the prostatic cancer group", "the value
of ROC_AUC for the pancreatic cancer group and the breast cancer
group", and "the average value of the value of ROC_AUC for the
pancreatic cancer group and the lung cancer group, the value of
ROC_AUC for the pancreatic cancer group and the colorectal cancer
group, the value of ROC_AUC for the pancreatic cancer group and the
prostatic cancer group, and the value of ROC_AUC for the pancreatic
cancer group and the breast cancer group" obtained for the equation
are additionally listed.
[0490] 0.841, 0.858, 0.864, 0.850, 0.855, 0.851, 0.818, 0.846,
(6.632 7)+(0.0159)Ser+(-0.0688)Asn+(-0.0166)Cit+(-0.1442)Met+(0.06
18)Phe+(-0.0996)Trp; 0.857, 0.877, 0.864, 0.864, 0.858, 0.859, 0.8
44, 0.859, (2.5401)+(0.0145)Gln+(-0.0299)His+(-0.0372)Cit+(-0.
2512)Met+(0.0650)Phe+(-0.1008)Trp; 0.867, 0.883, 0.863, 0.868, 0.
858, 0.855, 0.860, 0.864, (3.5162)+(-0.0924)Asn+(0.0149)Gln+(-0.
0277)His+(-0.1837)Met+(0.0640)Phe+(-0.1019)Trp; 0.858, 0.873,
0.863, 0.856, 0.843, 0.848, 0.843, 0.852,
(2.7828)+(0.0132)Gln+(-0.0366)His+(-0.2574)Met+(0.0629)Phe+(-0.0988)Trp;
0.855, 0.87 3, 0.861, 0.854, 0.839, 0.844, 0.840, 0.849,
(2.8178)+(0.0132)Gln+(-0.0372)His+(-0.0084)Tyr+(-0.2479)Met+(0.0654)Phe+(-
-0.095 8)Trp; 0.856, 0.873, 0.861, 0.856, 0.842, 0.847, 0.844,
0.851, (2.84
77)+(-0.0011)Ser+(0.0133)Gln+(-0.0364)His+(-0.2551)Met+(0.0
620)Phe+(-0.0989)Trp; 0.838, 0.856, 0.860, 0.847, 0.848, 0.846, 0.
821, 0.843,
(6.5646)+(0.0156)Ser+(-0.0681)Asn+(-0.0039)His+(-0.1509)Met+(0.061-
3)Phe+(-0.0989)Trp; 0.858, 0.874, 0.859, 0.857, 0.844, 0.853,
0.845, 0.854,
(3.0539)+(0.0137)Gln+(-0.0339)His+(-0.2375)Met+(-0.0072)Lys+(0.063-
6)Phe+(-0.0971)Trp; 0.851, 0. 867, 0.859, 0.847, 0.829, 0.856,
0.827, 0.845, (6.5527)+(0.0108)Se
r+(-0.0243)Val+(-0.2233)Met+(0.0285)Ile+(0.0820)Phe+(-0.076 2)Trp;
0.842, 0.858, 0.859, 0.853, 0.853, 0.842, 0.849, 0.851, (6.85
06)+(0.0218)Ser+(-0.0580)Asn+(-0.0055)Gly+(-0.1580)Met+(0.0
561)Phe+(-0.1003)Trp; 0.838, 0.854, 0.859, 0.846, 0.849, 0.842, 0.
819, 0.841, (6.5378)+(0.0149)Ser+(-0.0710)Asn+(0.0015)Thr+(-0.
1556)Met+(0.0612)Phe+(-0.1009)Trp; 0.860, 0.878, 0.858, 0.858, 0.
849, 0.851, 0.832, 0.853, (2.8002)+(0.0151)Gln+(-0.0362)His+(-0.
0210)Arg+(-0.2272)Met+(0.0605)Phe+(-0.0951)Trp; 0.840, 0.856,
0.858, 0.847, 0.848, 0.846, 0.819, 0.842,
(6.6275)+(0.0159)Ser+(-0.0679)Asn+(-0.1463)Met+(-0.0025)Lys+(0.0613)Phe+(-
-0.0995)T rp; 0.839, 0.856, 0.857, 0.846, 0.848, 0.843, 0.814,
0.841, (6.5993)
+(0.0164)Ser+(-0.0669)Asn+(-0.0061)Arg+(-0.1444)Met+(0.060
3)Phe+(-0.0990)Trp; 0.828, 0.847, 0.857, 0.839, 0.846, 0.837, 0.80
3, 0.833, (6.0634)+(0.0114)Ser+(-0.0078)His+(-0.0158)Cit+(-0.
1960)Met+(0.0583)Phe+(-0.0978)Trp; 0.840, 0.854, 0.857, 0.845, 0.
847, 0.842, 0.820, 0.841, (6.5342)+(0.0154)Ser+(-0.0700)Asn+(-0.
1518)Met+(0.0607)Phe+(-0.1005)Trp; 0.840, 0.857, 0.856, 0.846, 0.
847, 0.841, 0.820, 0.842, (6.5852)+(0.0160)Ser+(-0.0647)Asn+(-0.
1539)Met+(-0.0093)Orn+(0.0641)Phe+(-0.0997)Trp; 0.866, 0.882,
0.855, 0.871, 0.865, 0.867, 0.861, 0.869,
(4.4728)+(-0.1505)Asn+(0.0148)Gln+(-0.0207)His+(-0.0467)Cit+(0.0398)Phe+(-
-0.1103) Trp; 0.834, 0.854, 0.855, 0.841, 0.842, 0.837, 0.813,
0.836, (6.612
9)+(0.0151)Ser+(-0.0715)Asn+(-0.0076)Tyr+(-0.1412)Met+(0.06
26)Phe+(-0.0979)Trp; 0.828, 0.845, 0.854, 0.836, 0.840, 0.834, 0.8
06, 0.831, (6.0074)+(0.0112)Ser+(-0.0117)His+(-0.2017)Met+(0.
0579)Phe+(-0.0970)Trp; 0.864, 0.882, 0.854, 0.860, 0.843, 0.838, 0.
855, 0.855,
(2.4700)+(0.0158)Gln+(-0.0382)His+(-0.2621)Met+(-0.0290)Orn+(0.074-
7)Phe+(-0.0977)Trp; 0.825, 0.845, 0.854, 0.836, 0.839, 0.834,
0.806, 0.831,
(6.0072)+(0.0113)Ser+(-0.0116)His+(-0.0002)Thr+(-0.2011)Met+(0.057-
8)Phe+(-0.0969)Trp; 0.832, 0. 851, 0.854, 0.843, 0.847, 0.844,
0.815, 0.839, (7.7895)+(0.0114)Se
r+(-0.1007)Asn+(-0.0221)Cit+(-0.0059)Lys+(0.0400)Phe+(-0.10 25)Trp;
0.832, 0.851, 0.854, 0.846, 0.846, 0.833, 0.840, 0.842, (6.4
730)+(0.0196)Ser+(-0.0067)Gly+(-0.0067)His+(-0.2004)Met+(0.
0524)Phe+(-0.0985)Trp; 0.829, 0.848, 0.853, 0.837, 0.840, 0.837, 0.
803, 0.832,
(6.1598)+(0.0121)Ser+(-0.0100)His+(-0.1917)Met+(-0.0038)Lys+(0.058-
8)Phe+(-0.0960)Trp; 0.828, 0.847, 0.853, 0.836, 0.840, 0.835,
0.801, 0.831,
(6.1210)+(0.0127)Ser+(-0.0104)His+(-0.0083)Arg+(-0.1890)Met+(0.057-
5)Phe+(-0.0954)Trp; 0.834, 0. 852, 0.853, 0.846, 0.847, 0.834,
0.837, 0.842, (6.4343)+(0.0190)Se
r+(-0.0064)Gly+(-0.0098)Cit+(-0.1997)Met+(0.0521)Phe+(-0.10 08)Trp;
0.872, 0.887, 0.853, 0.874, 0.868, 0.864, 0.855, 0.869, (3.3
147)+(-0.1054)Asn+(0.0157)Gln+(-0.0455)Cit+(-0.1736)Met+(0.
0639)Phe+(-0.1118)Trp; 0.842, 0.858, 0.853, 0.839, 0.835, 0.836, 0.
799, 0.832, (6.0315)+(0.0091)Ser+(-0.1951)Met+(0.0271)Ile+(-0.
0355)Leu+(0.0809)Phe+(-0.0915)Trp; 0.830, 0.848, 0.852, 0.839, 0.
846, 0.840, 0.798, 0.833, (6.1744)+(0.0119)Ser+(-0.0177)Cit+(-0.
1875)Met+(-0.0043)Lys+(0.0584)Phe+(-0.0991)Trp; 0.857, 0.871,
0.852, 0.850, 0.841, 0.850, 0.815, 0.844,
(7.5269)+(0.0155)Ser+(-0.0710)Asn+(-0.0171)Val+(-0.1394)Met+(0.0851)Phe+(-
-0.0823)T rp; 0.833, 0.847, 0.852, 0.838, 0.845, 0.833, 0.800,
0.831, (5.9829)
+(0.0107)Ser+(-0.0181)Cit+(-0.1997)Met+(0.0571)Phe+(-0.101 0)Trp;
0.829, 0.847, 0.852, 0.838, 0.846, 0.833, 0.799, 0.831, (5.98
27)+(0.0107)Ser+(0.0001)Thr+(-0.0181)Cit+(-0.2000)Met+(0.05
71)Phe+(-0.1010)Trp; 0.846, 0.864, 0.852, 0.846, 0.831, 0.851, 0.8
25, 0.843, (7.3153)+(0.0069)Thr+(-0.0250)Val+(-0.2210)Met+(0.
0290)Ile+(0.0782)Phe+(-0.0768)Trp; 0.830, 0.849, 0.852, 0.838, 0.
841, 0.831, 0.808, 0.832, (6.1249)+(0.0124)Ser+(-0.0104)His+(-0.
1996)Met+(-0.0122)Orn+(0.0627)Phe+(-0.0963)Trp; 0.829, 0.848,
0.852, 0.840, 0.843, 0.837, 0.818, 0.836,
(7.6702)+(0.0097)Ser+(-0.1087)Asn+(-0.0011)His+(-0.0228)Cit+(0.0364)Phe+(-
-0.1051)T rp; 0.822, 0.844, 0.852, 0.834, 0.837, 0.830, 0.803,
0.828, (6.0498)
+(0.0110)Ser+(-0.0120)His+(-0.0046)Tyr+(-0.1959)Met+(0.059
1)Phe+(-0.0953)Trp; 0.854, 0.874, 0.851, 0.855, 0.838, 0.847, 0.84
6, 0.851, (2.7951)+(0.0138)Gln+(-0.0346)His+(-0.0069)Thr+(-0.
2353)Met+(0.0586)Phe+(-0.0981)Trp; 0.826, 0.843, 0.851, 0.837, 0.
836, 0.851, 0.813, 0.836, (4.0419)+(0.0093)Gln+(-0.0422)His+(-0.
0437)Cit+(0.0123)Phe+(-0.1087)Trp; 0.833, 0.848, 0.851, 0.840, 0.
843, 0.837, 0.817, 0.836, (7.6646)+(0.0096)Ser+(-0.1092)Asn+(-0.
0231)Cit+(0.0363)Phe+(-0.1055)Trp; 0.829, 0.848, 0.851, 0.837, 0.
845, 0.833, 0.795, 0.830, (6.0430)+(0.0117)Ser+(-0.0135)Cit+(-0.
0058)Arg+(-0.1926)Met+(0.0566)Phe+(-0.0997)Trp; 0.828, 0.848,
0.851, 0.836, 0.843, 0.831, 0.796, 0.829,
(6.0141)+(0.0105)Ser+(-0.0180)Cit+(-0.0037)Tyr+(-0.1951)Met+(0.0580)Phe+(-
-0.0997)T rp; 0.854, 0.868, 0.850, 0.856, 0.838, 0.877, 0.849,
0.858, (7.2167)
+(0.0136)Ser+(-0.0539)Asn+(-0.0075)Ala+(-0.1121)Met+(0.056
5)Phe+(-0.0877)Trp; 0.864, 0.880, 0.850, 0.854, 0.839, 0.840, 0.82
6, 0.846, (3.1852)+(0.0124)Gln+(-0.0243)His+(-0.2406)Met+(-0.
0196)Leu+(0.0799)Phe+(-0.0976)Trp; 0.856, 0.871, 0.850, 0.858, 0.
847, 0.845, 0.857, 0.855, (4.8183)+(-0.1481)Asn+(0.0129)Gln+(-0.
0298)His+(0.0351)Phe+(-0.1080)Trp; 0.862, 0.878, 0.850, 0.860, 0.
850, 0.836, 0.850, 0.853, (3.4141)+(0.0034)Ser+(-0.1051)Asn+(0.
0133)Gln+(-0.1917)Met+(0.0626)Phe+(-0.1123)Trp; 0.835, 0.853,
0.849, 0.845, 0.844, 0.834, 0.833, 0.841,
(6.5724)+(0.0202)Ser+(-0.0068)Gly+(-0.1935)Met+(-0.0038)Lys+(0.0522)Phe+(-
-0.0997)T rp; 0.833, 0.852, 0.849, 0.845, 0.844, 0.830, 0.837,
0.841, (6.4109)
+(0.0190)Ser+(-0.0070)Gly+(0.0011)Thr+(-0.2079)Met+(0.0513)
Phe+(-0.1017)Trp; 0.822, 0.834, 0.849, 0.825, 0.816, 0.833, 0.816,
0.824, (4.3714)+(0.0076)Gln+(-0.0504)His+(0.0082)Phe+(-0.106 5)Trp;
0.858, 0.875, 0.849, 0.851, 0.827, 0.839, 0.846, 0.847, (4.71
14)+(-0.1427)Asn+(0.0136)Gln+(-0.0313)His+(-0.0327)Tyr+(0.0
516)Phe+(-0.0951)Trp; 0.834, 0.852, 0.848, 0.845, 0.845, 0.831, 0.
832, 0.840,
(6.4904)+(0.0202)Ser+(-0.0066)Gly+(-0.0067)Arg+(-0.1937)Met+(0.051-
0)Phe+(-0.0996)Trp; 0.837, 0.851, 0.848, 0.844, 0.844, 0.829,
0.837, 0.840,
(6.4094)+(0.0193)Ser+(-0.0069)Gly+(-0.2044)Met+(0.0510)Phe+(-0.101-
4)Trp; 0.831, 0.848, 0.848, 0.8 40, 0.843, 0.835, 0.816, 0.836,
(7.6782)+(0.0097)Ser+(-0.1082)As
n+(-0.0210)Cit+(-0.0027)Orn+(0.0369)Phe+(-0.1054)Trp; 0.830, 0.849,
0.848, 0.833, 0.828, 0.830, 0.800, 0.827, (7.6726)+(0.0102)
Ser+(-0.1049)Asn+(-0.0215)Cit+(-0.0224)Tyr+(0.0475)Phe+(-0.
0967)Trp; 0.832, 0.850, 0.848, 0.840, 0.843, 0.834, 0.809, 0.834,
(7. 6642)+(0.0108)Ser+(-0.1044)Asn+(-0.0174)Cit+(-0.0070)Arg+(0.
0365)Phe+(-0.1038)Trp; 0.849, 0.864, 0.848, 0.845, 0.844, 0.839, 0.
802, 0.837,
(7.0742)+(0.0143)Ser+(-0.0698)Asn+(-0.1241)Met+(-0.0229)Leu+(0.081-
9)Phe+(-0.0937)Trp; 0.858, 0.876, 0.848, 0.862, 0.850, 0.853,
0.855, 0.859,
(4.9806)+(-0.1348)Asn+(0.0137)Gln+(-0.0266)His+(-0.0098)Lys+(0.039-
3)Phe+(-0.1048)Trp; 0.831, 0. 851, 0.848, 0.829, 0.810, 0.842,
0.800, 0.825, (3.9499)+(0.0103)Gl
n+(-0.0433)His+(-0.0418)Cit+(-0.0382)Tyr+(0.0326)Phe+(-0.09 35)Trp;
0.873, 0.887, 0.847, 0.858, 0.828, 0.854, 0.849, 0.854, (3.3
435)+(0.0120)Gln+(-0.0255)Val+(-0.2885)Met+(0.0255)Ile+(0.0
864)Phe+(-0.0863)Trp; 0.831, 0.849, 0.847, 0.840, 0.840, 0.837, 0.
819, 0.836,
(7.5743)+(0.0115)Ser+(-0.1038)Asn+(-0.0042)Thr+(-0.0212)Cit+(0.036-
3)Phe+(-0.1040)Trp; 0.831, 0.848, 0.847, 0.845, 0.848, 0.832,
0.842, 0.842,
(7.8998)+(0.0136)Ser+(-0.1031)Asn+(-0.0038)Gly+(-0.0187)Cit+(0.031-
7)Phe+(-0.1058)Trp; 0.828, 0. 847, 0.846, 0.827, 0.817, 0.817,
0.802, 0.821, (7.6595)+(0.0096)Se
r+(-0.1051)Asn+(-0.0073)His+(-0.0238)Tyr+(0.0464)Phe+(-0.09 46)Trp;
0.856, 0.872, 0.846, 0.853, 0.849, 0.837, 0.822, 0.845, (2.4
879)+(0.0131)Gln+(-0.0435)Cit+(-0.2623)Met+(0.0609)Phe+(-0.
1121)Trp; 0.838, 0.860, 0.846, 0.848, 0.840, 0.862, 0.819, 0.845,
(4. 3920)+(0.0116)Gln+(-0.0329)His+(-0.0451)Cit+(-0.0175)Lys+(0.
0243)Phe+(-0.1033)Trp; 0.835, 0.852, 0.846, 0.845, 0.855, 0.831, 0.
813, 0.838,
(7.6871)+(-0.0588)Asn+(0.0069)Thr+(-0.0175)Cit+(-0.1369)Met+(0.052-
8)Phe+(-0.1008)Trp; 0.832, 0.847, 0.846, 0.834, 0.836, 0.829,
0.797, 0.827,
(6.0647)+(0.0113)Ser+(-0.1961)Met+(-0.0045)Lys+(0.0571)Phe+(-0.100-
0)Trp; 0.828, 0.847, 0.846, 0.8 34, 0.836, 0.829, 0.797, 0.827,
(6.0645)+(0.0113)Ser+(-0.0001)Th
r+(-0.1960)Met+(-0.0045)Lys+(0.0571)Phe+(-0.1000)Trp; 0.830, 0.849,
0.846, 0.837, 0.842, 0.828, 0.800, 0.830, (6.0387)+(0.0115)
Ser+(-0.0099)Cit+(-0.2015)Met+(-0.0101)Orn+(0.0606)Phe+(-0.
1004)Trp; 0.863, 0.880, 0.846, 0.862, 0.852, 0.851, 0.841, 0.856,
(4. 5737)+(-0.1307)Asn+(0.0152)Gln+(-0.0300)His+(-0.0239)Arg+(0.
0364)Phe+(-0.1027)Trp; 0.848, 0.864, 0.846, 0.844, 0.827, 0.844, 0.
827, 0.840,
(7.4275)+(-0.0203)Val+(-0.1885)Met+(0.0335)Ile+(-0.0100)Leu+(0.075-
3)Phe+(-0.0765)Trp; 0.852, 0.870, 0.845, 0.851, 0.833, 0.849,
0.838, 0.848,
(8.4985)+(-0.0543)Asn+(-0.0239)Val+(-0.1338)Met+(0.0268)Ile+(0.073-
0)Phe+(-0.0742)Trp; 0.828, 0.8 47, 0.845, 0.833, 0.837, 0.831,
0.792, 0.827, (6.1009)+(0.0123)Ser
+(-0.0073)Arg+(-0.1892)Met+(-0.0028)Lys+(0.0564)Phe+(-0.098 9)Trp;
0.834, 0.854, 0.845, 0.845, 0.843, 0.828, 0.836, 0.840, (6.46
99)+(0.0196)Ser+(-0.0064)Gly+(-0.2025)Met+(-0.0097)Orn+(0.0
553)Phe+(-0.1005)Trp; 0.848, 0.865, 0.845, 0.852, 0.836, 0.875, 0.
836, 0.853,
(6.8606)+(0.0100)Ser+(-0.0080)Ala+(-0.0146)Cit+(-0.1446)Met+(0.053-
6)Phe+(-0.0870)Trp; 0.827, 0.847, 0.845, 0.833, 0.838, 0.828,
0.791, 0.826,
(6.0008)+(0.0117)Ser+(0.0005)Thr+(-0.0090)Arg+(-0.1960)Met+(0.0557-
)Phe+(-0.0998)Trp; 0.827, 0.84 8, 0.845, 0.836, 0.838, 0.832,
0.805, 0.831,
(7.6599)+(0.0112)Ser+(-0.1015)Asn+(-0.0057)His+(-0.0108)Arg+(0.035-
6)Phe+(-0.101 5)Trp; 0.832, 0.844, 0.845, 0.832, 0.835, 0.824,
0.798, 0.825, (5.86
28)+(0.0101)Ser+(-0.2090)Met+(0.0557)Phe+(-0.1020)Trp; 0.832,
0.847, 0.845, 0.833, 0.837, 0.828, 0.792, 0.826, (6.0006)+(0.0118)
Ser+(-0.0088)Arg+(-0.1946)Met+(0.0555)Phe+(-0.0997)Trp; 0.86 2,
0.878, 0.844, 0.862, 0.845, 0.842, 0.867, 0.858, (4.5811)+(-0.14
27)Asn+(0.0147)Gln+(-0.0321)His+(-0.0226)Orn+(0.0425)Phe+(-0.1072)Trp;
0.865, 0.879, 0.844, 0.859, 0.849, 0.834, 0.849, 0.853,
(3.5861)+(-0.1025)Asn+(0.0136)Gln+(-0.1869)Met+(0.0599)Phe+(-0.1124)Trp;
0.854, 0.872, 0.844, 0.858, 0.847, 0.843, 0.857, 0.85 5,
(4.9507)+(-0.0032)Ser+(-0.1444)Asn+(0.0132)Gln+(-0.0296)H
is+(0.0332)Phe+(-0.1080)Trp; 0.826, 0.847, 0.844, 0.837, 0.837, 0.
834, 0.814, 0.833, (7.7612)+(0.0107)Ser+(-0.1025)Asn+(-0.0046)
His+(-0.0061)Lys+(0.0376)Phe+(-0.1021)Trp; 0.830, 0.845, 0.844,
0.835, 0.836, 0.825, 0.818, 0.831, (7.6449)+(0.0090)Ser+(-0.110
1)Asn+(-0.0071)His+(0.0341)Phe+(-0.1042)Trp; 0.852, 0.873, 0.8 44,
0.852, 0.846, 0.835, 0.822, 0.844, (2.5096)+(0.0130)Gln+(-0.0
435)Cit+(-0.0052)Tyr+(-0.2566)Met+(0.0624)Phe+(-0.1103)Trp; 0.828,
0.848, 0.844, 0.834, 0.839, 0.823, 0.796, 0.826, (6.0007)+(0.
0108)Ser+(0.0017)Thr+(-0.2113)Met+(-0.0133)Orn+(0.0618)Phe+(-0.1012)Trp;
0.832, 0.844, 0.844, 0.835, 0.832, 0.854, 0.807, 0.83 4,
(4.3936)+(0.0093)Gln+(-0.0402)His+(-0.0427)Cit+(-0.1045)T rp;
0.829, 0.850, 0.844, 0.840, 0.837, 0.822, 0.831, 0.835, (6.5152)
+(0.0193)Ser+(-0.0073)Gly+(-0.0096)Tyr+(-0.1925)Met+(0.053
1)Phe+(-0.0981)Trp; 0.853, 0.869, 0.844, 0.848, 0.842, 0.838, 0.81
0, 0.840, (8.5266)+(-0.0643)Asn+(0.0095)Thr+(-0.0179)Val+(-0.
1409)Met+(0.0792)Phe+(-0.0835)Trp; 0.828, 0.846, 0.844, 0.832, 0.
834, 0.829, 0.793, 0.826, (6.1049)+(0.0111)Ser+(-0.0044)Tyr+(-0.
1906)Met+(-0.0046)Lys+(0.0582)Phe+(-0.0985)Trp; 0.824, 0.846,
0.844, 0.831, 0.835, 0.825, 0.789, 0.824,
(6.0241)+(0.0117)Ser+(-0.0087)Arg+(-0.0030)Tyr+(-0.1911)Met+(0.0562)Phe+(-
-0.0987)T rp; 0.831, 0.850, 0.843, 0.835, 0.839, 0.827, 0.794,
0.828, (6.0950)
+(0.0127)Ser+(-0.0069)Arg+(-0.1950)Met+(-0.0114)Orn+(0.060
2)Phe+(-0.0991)Trp; 0.825, 0.841, 0.843, 0.816, 0.794, 0.823, 0.79
3, 0.813, (4.2614)+(0.0087)Gln+(-0.0512)His+(-0.0397)Tyr+(0.0
295)Phe+(-0.0908)Trp; 0.824, 0.834, 0.843, 0.824, 0.813, 0.837, 0.
808, 0.823, (4.6044)+(0.0076)Gln+(-0.0489)His+(-0.1037)Trp; 0. 831,
0.850, 0.843, 0.835, 0.837, 0.828, 0.800, 0.829, (6.1095)+(0.0
120)Ser+(-0.1986)Met+(-0.0116)Orn+(-0.0027)Lys+(0.0613)Phe+(-0.0997)Trp;
0.848, 0.865, 0.843, 0.843, 0.824, 0.843, 0.828, 0.84 0,
(8.5066)+(0.0090)Ser+(-0.1145)Asn+(-0.0209)Val+(0.0118)Il
e+(0.0597)Phe+(-0.0848)Trp; 0.825, 0.843, 0.843, 0.830, 0.833, 0.
820, 0.794, 0.823, (5.8951)+(0.0099)Ser+(-0.0038)Tyr+(-0.2043)
Met+(0.0567)Phe+(-0.1007)Trp; 0.858, 0.876, 0.843, 0.858, 0.853,
0.849, 0.829, 0.852, (2.8311)+(0.0139)Gln+(-0.0442)Cit+(-0.235
3)Met+(-0.0092)Lys+(0.0623)Phe+(-0.1087)Trp; 0.828, 0.844, 0.8 43,
0.831, 0.833, 0.823, 0.797, 0.824, (5.8677)+(0.0106)Ser+(-0.0
013)Thr+(-0.2051)Met+(0.0553)Phe+(-0.1016)Trp; 0.888, 0.899, 0.
843, 0.872, 0.850, 0.857, 0.855, 0.865, (4.4024)+(-0.1075)Asn+(0.
0147)Gln+(-0.0196)Val+(-0.1775)Met+(0.0888)Phe+(-0.0925)Tr p;
0.848, 0.865, 0.843, 0.854, 0.837, 0.866, 0.851, 0.855,
(7.0521)+(0.0156)Ser+(-0.0046)Gly+(-0.0074)Ala+(-0.1536)Met+(0.0496)
Phe+(-0.0886)Trp
[0491] List (1) of Logistic Regression Equations Searched in
Example 6
[0492] The logistic regression equations searched in Example 6
above are listed below. Before each equation, "the value of ROC_AUC
for the pancreatic cancer group and the colorectal cancer group
with validation", "the value of ROC_AUC for the pancreatic cancer
group and the colorectal cancer group without validation", "the
value of ROC_AUC for the pancreatic cancer group and the healthy
group", "the value of ROC_AUC for the pancreatic cancer group and
the other cancers group", "the value of ROC_AUC for the pancreatic
cancer group and the lung cancer group", "the value of ROC_AUC for
the pancreatic cancer group and the prostatic cancer group", "the
value of ROC_AUC for the pancreatic cancer group and the breast
cancer group", and "the average value of the value of ROC_AUC for
the pancreatic cancer group and the lung cancer group, the value of
ROC_AUC for the pancreatic cancer group and the colorectal cancer
group, the value of ROC_AUC for the pancreatic cancer group and the
prostatic cancer group, and the value of ROC_AUC for the pancreatic
cancer group and the breast cancer group" obtained for the equation
are additionally listed.
[0493] 0.851, 0.874, 0.831, 0.855, 0.845, 0.857, 0.841, 0.854,
(5.669 2)+(-0.0719)Asn+(0.0072)Gln+(-0.0715)Cit+(0.0674)Tyr+(-0.18
78)Met+(-0.1103)Trp; 0.850, 0.871, 0.830, 0.836, 0.811, 0.833, 0.8
34, 0.837, (7.7617)+(-0.0729)Asn+(-0.0057)Gly+(-0.0829)Cit+(0.
0409)Tyr+(0.0296)Orn+(-0.1265)Trp; 0.850, 0.873, 0.814, 0.859, 0.
857, 0.861, 0.832, 0.856, (6.1359)+(-0.1088)Asn+(0.0071)Gln+(-0.
0672)Cit+(-0.0111)Pro+(0.0505)Tyr+(-0.1271)Trp; 0.849, 0.870,
0.846, 0.846, 0.832, 0.854, 0.826, 0.846,
(5.7474)+(-0.1127)Asn+(0.0047)Gln+(-0.0872)Cit+(0.0428)Tyr+(0.0250)Orn+(--
0.1255)T rp; 0.849, 0.867, 0.838, 0.831, 0.809, 0.840, 0.808,
0.831, (7.0356)
+(-0.0849)Asn+(-0.0858)Cit+(0.0454)Tyr+(0.0272)Orn+(-0.127 2)Trp;
0.849, 0.870, 0.835, 0.836, 0.815, 0.852, 0.811, 0.837, (7.16
56)+(-0.0396)Asn+(-0.0827)Cit+(0.0644)Tyr+(-0.1539)Met+(0.0
221)Orn+(-0.1154)Trp; 0.849, 0.871, 0.816, 0.851, 0.844, 0.858, 0.
824, 0.849, (5.8529)+(0.0054)Gln+(-0.0752)Cit+(-0.0083)Pro+(0.
0729)Tyr+(-0.2227)Met+(-0.1204)Trp; 0.848, 0.868, 0.825, 0.837,
0.821, 0.852, 0.807, 0.837,
(7.1319)+(-0.0848)Cit+(-0.0074)Pro+(0.0688)Tyr+(-0.1769)Met+(0.0215)Orn+(-
-0.1210)Trp; 0.848, 0.8 68, 0.841, 0.839, 0.818, 0.853, 0.822,
0.840, (7.0943)+(-0.0793)As
n+(-0.0024)Ala+(-0.0860)Cit+(0.0480)Tyr+(0.0271)Orn+(-0.120 8)Trp;
0.848, 0.869, 0.826, 0.836, 0.819, 0.844, 0.805, 0.835, (7.55
34)+(-0.0758)Asn+(-0.0856)Cit+(-0.0091)Pro+(0.0501)Tyr+(0.0
291)Orn+(-0.1282)Trp; 0.848, 0.868, 0.817, 0.839, 0.827, 0.848, 0.
801, 0.836, (7.4652)+(0.0076)Thr+(-0.0677)Cit+(-0.0072)Pro+(0.
0744)Tyr+(-0.2094)Met+(-0.1239)Trp; 0.847, 0.869, 0.839, 0.832,
0.811, 0.841, 0.809, 0.832,
(7.1085)+(-0.0806)Asn+(-0.0868)Cit+(0.0455)Tyr+(0.0281)Orn+(-0.0020)Lys+(-
-0.1251)Trp; 0.847, 0.8 68, 0.803, 0.842, 0.829, 0.839, 0.827,
0.841, (8.0010)+(-0.0032)Gl
y+(-0.0628)Cit+(-0.0063)Pro+(0.0706)Tyr+(-0.1728)Met+(-0.12 09)Trp;
0.847, 0.871, 0.814, 0.857, 0.846, 0.838, 0.869, 0.856, (6.3
888)+(-0.1064)Asn+(-0.0072)Gly+(0.0069)Gln+(-0.0612)Cit+(0.
0393)Tyr+(-0.1215)Trp; 0.847, 0.868, 0.825, 0.840, 0.824, 0.843, 0.
820, 0.839,
(7.1977)+(-0.0275)Asn+(-0.0640)Cit+(0.0662)Tyr+(-0.1707)Met+(0.010-
4)Phe+(-0.1193)Trp; 0.847, 0.868, 0.826, 0.837, 0.820, 0.847,
0.812, 0.837,
(7.4013)+(-0.0324)Asn+(0.0064)Thr+(-0.0658)Cit+(0.0704)Tyr+(-0.189-
5)Met+(-0.1172)Trp; 0.847, 0. 866, 0.817, 0.837, 0.821, 0.842,
0.816, 0.836, (7.5014)+(-0.0300)A
sn+(-0.0653)Cit+(0.0703)Tyr+(-0.1702)Met+(-0.1157)Trp; 0.847,
0.867, 0.837, 0.831, 0.810, 0.839, 0.807, 0.831, (7.0571)+(-0.084
6)Asn+(-0.0859)Cit+(0.0455)Tyr+(0.0275)Orn+(-0.0010)Ile+(-0.
1269)Trp; 0.846, 0.866, 0.809, 0.838, 0.826, 0.844, 0.809, 0.836,
(7.
5613)+(-0.0672)Cit+(-0.0065)Pro+(0.0737)Tyr+(-0.1847)Met+(-0.1211)Trp;
0.846, 0.867, 0.827, 0.849, 0.839, 0.849, 0.836, 0.848,
(5.8545)+(-0.1092)Asn+(0.0053)Gln+(-0.0674)Cit+(0.0456)Tyr+(-0.1244)Trp;
0.846, 0.866, 0.824, 0.837, 0.822, 0.841, 0.813, 0.83 5,
(6.7689)+(-0.0672)Cit+(0.0662)Tyr+(-0.1984)Met+(0.0116)Ph
e+(-0.1210)Trp; 0.846, 0.870, 0.818, 0.850, 0.838, 0.842, 0.846, 0.
849, (5.9813)+(-0.0053)Gly+(0.0055)Gln+(-0.0705)Cit+(0.0640)
Tyr+(-0.2246)Met+(-0.1145)Trp; 0.846, 0.867, 0.811, 0.836, 0.821,
0.839, 0.808, 0.834, (7.3261)+(-0.0705)Cit+(-0.0066)Pro+(0.073
4)Tyr+(0.0041)Val+(-0.1901)Met+(-0.1275)Trp; 0.846, 0.868, 0.8 32,
0.837, 0.821, 0.845, 0.811, 0.836, (6.6000)+(0.0065)Thr+(-0.0
678)Cit+(0.0657)Tyr+(-0.2208)Met+(0.0132)Phe+(-0.1230)Trp; 0. 846,
0.868, 0.810, 0.841, 0.829, 0.845, 0.814, 0.839, (7.9033)+(-0.
0256)Asn+(-0.0642)Cit+(-0.0061)Pro+(0.0731)Tyr+(-0.1593)Met
+(-0.1197)Trp; 0.846, 0.869, 0.835, 0.830, 0.810, 0.836, 0.799, 0.8
28, (7.1058)+(-0.0739)Asn+(-0.0798)Cit+(-0.0100)Arg+(0.0471)
Tyr+(0.0272)Orn+(-0.1256)Trp; 0.846, 0.867, 0.838, 0.831, 0.809,
0.840, 0.808, 0.831, (7.0362)+(-0.0849)Asn+(-0.0858)Cit+(0.045
4)Tyr+(0.0273)Orn+(-0.0000)Leu+(-0.1272)Trp; 0.846, 0.867, 0.8 39,
0.831, 0.810, 0.840, 0.808, 0.831, (7.0210)+(-0.0847)Asn+(-0.
0857)Cit+(0.0452)Tyr+(0.0272)Orn+(0.0006)Phe+(-0.1275)Trp; 0. 846,
0.869, 0.816, 0.842, 0.830, 0.845, 0.814, 0.839, (7.2685)+(-0.
0656)Cit+(-0.0062)Pro+(0.0694)Tyr+(-0.1834)Met+(0.0102)Phe+(-0.1240)Trp;
0.846, 0.868, 0.838, 0.848, 0.838, 0.853, 0.829, 0.84 7,
(4.8590)+(0.0051)Gln+(-0.0738)Cit+(0.0627)Tyr+(-0.2409)Me
t+(0.0172)Phe+(-0.1200)Trp; 0.846, 0.869, 0.826, 0.837, 0.817, 0.
842, 0.823, 0.838, (7.2825)+(-0.0044)Gly+(-0.0825)Cit+(0.0609)
Tyr+(-0.1763)Met+(0.0222)Orn+(-0.1180)Trp; 0.846, 0.868, 0.818,
0.839, 0.821, 0.838, 0.825, 0.838, (7.5424)+(-0.0041)Gly+(0.007
1)Thr+(-0.0647)Cit+(0.0670)Tyr+(-0.2093)Met+(-0.1194)Trp; 0. 846,
0.865, 0.830, 0.832, 0.813, 0.847, 0.804, 0.832, (6.6662)+(-0.
0848)Cit+(0.0660)Tyr+(-0.1954)Met+(0.0189)Orn+(-0.1170)Trp; 0.846,
0.866, 0.818, 0.839, 0.823, 0.845, 0.819, 0.838,
(7.5068)+(-0.0280)Asn+(-0.0009)Ala+(-0.0654)Cit+(0.0711)Tyr+(-0.1674)M
et+(-0.1139)Trp; 0.846, 0.868, 0.817, 0.849, 0.841, 0.842, 0.835,
0. 846, (6.1483)+(-0.0060)Ser+(-0.1031)Asn+(0.0058)Gln+(-0.068
7)Cit+(0.0451)Tyr+(-0.1261)Trp; 0.846, 0.867, 0.836, 0.828, 0.80 5,
0.835, 0.805, 0.828, (6.9378)+(-0.0858)Asn+(-0.0874)Cit+(0.0
446)Tyr+(0.0024)Val+(0.0267)Orn+(-0.1316)Trp; 0.846, 0.866, 0. 834,
0.830, 0.809, 0.839, 0.807, 0.830, (7.1787)+(-0.0020)Ser+(-0.
0817)Asn+(-0.0862)Cit+(0.0453)Tyr+(0.0274)Orn+(-0.1279)Trp; 0.845,
0.862, 0.817, 0.833, 0.817, 0.841, 0.806, 0.832,
(7.0767)+(-0.0690)Cit+(0.0710)Tyr+(-0.2009)Met+(-0.1171)Trp; 0.845,
0.86 8, 0.829, 0.849, 0.840, 0.847, 0.838, 0.848,
(5.7352)+(-0.1079)Asn
+(0.0053)Gln+(-0.0671)Cit+(0.0445)Tyr+(0.0039)Phe+(-0.1263)Trp;
0.845, 0.867, 0.833, 0.837, 0.818, 0.854, 0.813, 0.838, (6.722
9)+(-0.0016)Ala+(-0.0851)Cit+(0.0669)Tyr+(-0.1865)Met+(0.01
96)Orn+(-0.1135)Trp; 0.845, 0.863, 0.819, 0.836, 0.821, 0.846, 0.8
13, 0.836, (7.1306)+(-0.0013)Ala+(-0.0689)Cit+(0.0719)Tyr+(-0.
1938)Met+(-0.1143)Trp; 0.845, 0.864, 0.822, 0.833, 0.816, 0.845, 0.
803, 0.832, (6.9630)+(0.0056)Thr+(-0.0697)Cit+(0.0711)Tyr+(-0.
2203)Met+(-0.1186)Trp; 0.845, 0.867, 0.817, 0.840, 0.824, 0.833, 0.
831, 0.839,
(7.2884)+(-0.0032)Gly+(-0.0631)Cit+(0.0635)Tyr+(-0.1857)Met+(0.010-
5)Phe+(-0.1213)Trp; 0.845, 0.865, 0.825, 0.843, 0.831, 0.851,
0.821, 0.842,
(5.5455)+(0.0045)Gln+(-0.0759)Cit+(0.0697)Tyr+(-0.2378)Met+(-0.114-
8)Trp; 0.845, 0.867, 0.823, 0.8 38, 0.820, 0.848, 0.817, 0.838,
(7.2506)+(0.0034)Ser+(-0.0336)As
n+(-0.0652)Cit+(0.0711)Tyr+(-0.1743)Met+(-0.1147)Trp; 0.845, 0.864,
0.810, 0.837, 0.820, 0.833, 0.828, 0.836, (7.5972)+(-0.003
5)Gly+(-0.0645)Cit+(0.0676)Tyr+(-0.1872)Met+(-0.1176)Trp; 0. 845,
0.866, 0.833, 0.831, 0.809, 0.839, 0.810, 0.831, (7.1163)+(-0.
0798)Asn+(-0.0043)Thr+(-0.0870)Cit+(0.0468)Tyr+(0.0282)Orn+(-0.1251)Trp;
0.845, 0.867, 0.825, 0.840, 0.825, 0.847, 0.820, 0.84 0,
(6.8272)+(-0.0012)Ala+(-0.0671)Cit+(0.0672)Tyr+(-0.1919)M
et+(0.0114)Phe+(-0.1183)Trp; 0.845, 0.866, 0.821, 0.842, 0.825, 0.
841, 0.836, 0.842, (7.1813)+(0.0076)Ser+(-0.0052)Gly+(-0.0629)
Cit+(0.0674)Tyr+(-0.1982)Met+(-0.1156)Trp; 0.845, 0.866, 0.819,
0.837, 0.819, 0.838, 0.820, 0.836, (7.2585)+(-0.0418)Asn+(-0.065
9)Cit+(0.0720)Tyr+(-0.1918)Met+(0.0078)Lys+(-0.1212)Trp; 0.8 44,
0.866, 0.809, 0.837, 0.824, 0.839, 0.808, 0.834, (7.2430)+(-0.0
686)Cit+(-0.0070)Pro+(0.0757)Tyr+(-0.2111)Met+(0.0065)Lys+(-0.1265)Trp;
0.844, 0.866, 0.810, 0.840, 0.823, 0.837, 0.833, 0.84 0,
(7.8866)+(-0.0257)Asn+(-0.0030)Gly+(-0.0617)Cit+(0.0674)T
yr+(-0.1627)Met+(-0.1162)Trp; 0.844, 0.866, 0.809, 0.839, 0.826,
0.846, 0.811, 0.838, (7.5711)+(-0.0005)Ala+(-0.0672)Cit+(-0.00
63)Pro+(0.0741)Tyr+(-0.1825)Met+(-0.1199)Trp; 0.844, 0.867, 0. 827,
0.846, 0.834, 0.842, 0.833, 0.844, (5.7895)+(-0.1098)Asn+(0.
0052)Gln+(-0.0695)Cit+(0.0448)Tyr+(0.0024)Val+(-0.1287)Trp; 0.844,
0.865, 0.817, 0.833, 0.814, 0.837, 0.814, 0.832,
(7.2967)+(-0.0308)Asn+(-0.0689)Cit+(0.0699)Tyr+(0.0041)Val+(-0.1751)Me
t+(-0.1225)Trp; 0.844, 0.865, 0.832, 0.832, 0.814, 0.848, 0.801, 0.
832, (6.7648)+(-0.0807)Cit+(-0.0054)Arg+(0.0662)Tyr+(-0.185
4)Met+(0.0192)Orn+(-0.1170)Trp; 0.844, 0.865, 0.813, 0.835, 0.81 9,
0.839, 0.814, 0.834, (7.2574)+(-0.0687)Cit+(-0.0065)Pro+(0.0
745)Tyr+(-0.2011)Met+(0.0089)Leu+(-0.1272)Trp; 0.844, 0.866, 0.
835, 0.832, 0.812, 0.850, 0.802, 0.833, (6.6142)+(0.0042)Thr+(-0.
0840)Cit+(0.0664)Tyr+(-0.2108)Met+(0.0176)Orn+(-0.1180)Trp; 0.844,
0.866, 0.828, 0.838, 0.824, 0.845, 0.814, 0.837, (6.5164)+(0.
0026)Ser+(-0.0673)Cit+(0.0664)Tyr+(-0.2045)Met+(0.0125)Phe+(-0.1204)Trp;
0.844, 0.865, 0.823, 0.836, 0.820, 0.848, 0.812, 0.83 6,
(7.0140)+(0.0055)Thr+(-0.0013)Ala+(-0.0695)Cit+(0.0720)Ty
r+(-0.2132)Met+(-0.1160)Trp; 0.844, 0.865, 0.813, 0.838, 0.827, 0.
846, 0.807, 0.836, (7.3279)+(0.0029)Ser+(-0.0675)Cit+(-0.0067)
Pro+(0.0746)Tyr+(-0.1908)Met+(-0.1206)Trp; 0.844, 0.867, 0.827,
0.848, 0.837, 0.856, 0.832, 0.848, (5.5554)+(0.0047)Gln+(-0.001
8)Ala+(-0.0757)Cit+(0.0709)Tyr+(-0.2296)Met+(-0.1111)Trp; 0. 844,
0.866, 0.835, 0.835, 0.817, 0.850, 0.809, 0.836, (6.4516)+(-0.
0822)Cit+(0.0626)Tyr+(-0.1933)Met+(0.0176)Orn+(0.0090)Phe+(-0.1202)Trp;
0.844, 0.868, 0.827, 0.851, 0.842, 0.853, 0.837, 0.85 0,
(5.8878)+(-0.1052)Asn+(0.0056)Gln+(-0.0679)Cit+(0.0458)Ty
r+(-0.0030)Lys+(-0.1214)Trp; 0.844, 0.868, 0.830, 0.857, 0.850, 0.
863, 0.851, 0.858, (5.8704)+(-0.1056)Asn+(0.0055)Gln+(-0.0027)
Ala+(-0.0676)Cit+(0.0486)Tyr+(-0.1173)Trp; 0.844, 0.864, 0.824,
0.833, 0.816, 0.834, 0.812, 0.831, (6.5818)+(-0.0706)Cit+(0.066
1)Tyr+(0.0037)Val+(-0.2037)Met+(0.0110)Phe+(-0.1270)Trp; 0.8 43,
0.866, 0.811, 0.838, 0.827, 0.844, 0.807, 0.836, (7.6240)+(-0.0
643)Cit+(-0.0036)Arg+(-0.0064)Pro+(0.0739)Tyr+(-0.1790)Met+(-0.1208)Trp;
0.843, 0.866, 0.832, 0.840, 0.826, 0.854, 0.813, 0.84 0,
(5.4494)+(0.0038)Gln+(-0.0864)Cit+(0.0660)Tyr+(-0.2286)Me
t+(0.0142)Orn+(-0.1149)Trp; 0.843, 0.867, 0.830, 0.849, 0.838, 0.
848, 0.838, 0.848, (5.7917)+(-0.1101)Asn+(0.0052)Gln+(-0.0676)
Cit+(0.0452)Tyr+(0.0033)Ile+(-0.1253)Trp; 0.843, 0.867, 0.826,
0.849, 0.840, 0.849, 0.836, 0.848, (5.8645)+(-0.1092)Asn+(0.005
3)Gln+(-0.0673)Cit+(0.0456)Tyr+(-0.0004)Leu+(-0.1240)Trp; 0. 843,
0.864, 0.831, 0.829, 0.809, 0.843, 0.801, 0.829, (6.5154)+(-0.
0867)Cit+(0.0658)Tyr+(0.0031)Val+(-0.1992)Met+(0.0178)Orn+(-0.1221)Trp;
0.843, 0.865, 0.811, 0.840, 0.824, 0.838, 0.831, 0.83 9,
(7.6202)+(-0.0033)Gly+(-0.0011)Ala+(-0.0645)Cit+(0.0685)T
yr+(-0.1815)Met+(-0.1151)Trp; 0.843, 0.865, 0.831, 0.855, 0.852,
0.845, 0.849, 0.853, (6.4883)+(-0.0903)Asn+(-0.0089)Gly+(0.006
9)Gln+(-0.0800)Cit+(0.0290)Orn+(-0.1034)Trp; 0.843, 0.863, 0.8 18,
0.833, 0.817, 0.843, 0.806, 0.832, (6.9632)+(0.0013)Ser+(-0.0
691)Cit+(0.0713)Tyr+(-0.2039)Met+(-0.1167)Trp; 0.843, 0.863, 0.
816, 0.829, 0.811, 0.833, 0.806, 0.828, (6.8562)+(-0.0726)Cit+(0.
0706)Tyr+(0.0040)Val+(-0.2062)Met+(-0.1236)Trp; 0.843, 0.865,
0.826, 0.840, 0.826, 0.846, 0.817, 0.839,
(5.4601)+(0.0042)Gln+(-0.0781)Cit+(0.0694)Tyr+(0.0027)Val+(-0.2395)Met+(--
0.1190)Tr p; 0.843, 0.859, 0.813, 0.831, 0.815, 0.830, 0.814,
0.830, (7.3478)+(-0.0782)Asn+(-0.0635)Cit+(0.0492)Tyr+(-0.1269)Trp;
0.843, 0. 864, 0.820, 0.835, 0.816, 0.841, 0.818, 0.835,
(6.8704)+(-0.0023)A
la+(-0.0735)Cit+(0.0723)Tyr+(0.0053)Val+(-0.1964)Met+(-0.12 11)Trp;
0.843, 0.866, 0.816, 0.837, 0.821, 0.842, 0.816, 0.836, (7.5
175)+(-0.0283)Asn+(-0.0638)Cit+(-0.0021)Arg+(0.0705)Tyr+(-0.
1682)Met+(-0.1157)Trp; 0.843, 0.868, 0.819, 0.847, 0.841, 0.838, 0.
825, 0.843,
(5.7314)+(-0.1002)Asn+(0.0063)Gln+(-0.0577)Cit+(-0.0159)Arg+(0.048-
0)Tyr+(-0.1216)Trp; 0.843, 0.865, 0.831, 0.832, 0.813, 0.847,
0.804, 0.832,
(6.6496)+(0.0002)Ser+(-0.0848)Cit+(0.0660)Tyr+(-0.1959)Met+(0.0189-
)Orn+(-0.1169)Trp; 0.843, 0.8 64, 0.822, 0.833, 0.816, 0.845,
0.803, 0.832, (6.9687)+(-0.0001)Se
r+(0.0057)Thr+(-0.0697)Cit+(0.0711)Tyr+(-0.2202)Met+(-0.118 6)Trp;
0.842, 0.864, 0.820, 0.837, 0.821, 0.847, 0.814, 0.837, (7.03
79)+(0.0010)Ser+(-0.0013)Ala+(-0.0690)Cit+(0.0722)Tyr+(-0.1
963)Met+(-0.1141)Trp; 0.842, 0.864, 0.829, 0.831, 0.812, 0.845, 0.
803, 0.831, (6.5223)+(-0.0839)Cit+(0.0673)Tyr+(-0.2097)Met+(0.
0170)Orn+(0.0032)Lys+(-0.1193)Trp; 0.842, 0.866, 0.824, 0.844, 0.
836, 0.847, 0.818, 0.842, (5.5207)+(0.0051)Gln+(-0.0681)Cit+(-0.
0105)Arg+(0.0701)Tyr+(-0.2261)Met+(-0.1140)Trp; 0.842, 0.863,
0.816, 0.833, 0.819, 0.840, 0.804, 0.831,
(7.1673)+(-0.0653)Cit+(-0.0046)Arg+(0.0712)Tyr+(-0.1930)Met+(-0.1170)Trp;
0.842, 0. 865, 0.819, 0.834, 0.813, 0.838, 0.820, 0.834,
(7.2332)+(-0.0306)A
sn+(-0.0672)Cit+(0.0712)Tyr+(-0.1868)Met+(0.0092)Leu+(-0.12 26)Trp;
0.842, 0.864, 0.823, 0.832, 0.816, 0.839, 0.806, 0.831, (6.7
337)+(0.0046)Thr+(-0.0706)Cit+(0.0721)Tyr+(-0.2354)Met+(0.0
045)Lys+(-0.1217)Trp; 0.842, 0.866, 0.823, 0.837, 0.822, 0.841, 0.
811, 0.835,
(6.8536)+(-0.0645)Cit+(-0.0034)Arg+(0.0666)Tyr+(-0.1925)Met+(0.011-
0)Phe+(-0.1208)Trp; 0.842, 0.864, 0.822, 0.830, 0.811, 0.837,
0.802, 0.829,
(6.7648)+(0.0052)Thr+(-0.0730)Cit+(0.0706)Tyr+(0.0036)Val+(-0.2233-
)Met+(-0.1243)Trp; 0.842, 0.8 60, 0.819, 0.831, 0.813, 0.828,
0.819, 0.830, (7.2067)+(-0.0803)As
n+(-0.0639)Cit+(0.0484)Tyr+(0.0059)Ile+(-0.1284)Trp; 0.842, 0. 864,
0.827, 0.838, 0.818, 0.846, 0.830, 0.840, (6.8917)+(-0.0701)C
it+(-0.0075)Pro+(0.0749)Tyr+(-0.2193)Met+(0.0275)Ile+(-0.12 24)Trp;
0.842, 0.866, 0.829, 0.842, 0.829, 0.852, 0.818, 0.841, (5.5
687)+(0.0042)Gln+(0.0031)Thr+(-0.0759)Cit+(0.0698)Tyr+(-0.2
462)Met+(-0.1160)Trp; 0.842, 0.867, 0.818, 0.851, 0.843, 0.845, 0.
843, 0.849,
(5.8268)+(-0.1085)Asn+(0.0063)Gln+(-0.0072)Thr+(-0.0685)Cit+(0.047-
8)Tyr+(-0.1208)Trp; 0.842, 0.860, 0.816, 0.838, 0.824, 0.841,
0.827, 0.838,
(7.4134)+(-0.0734)Asn+(-0.0023)Ala+(-0.0637)Cit+(0.0521)Tyr+(-0.12-
07)Trp; 0.842, 0.862, 0.817, 0.8 32, 0.816, 0.834, 0.809, 0.830,
(6.7789)+(-0.0703)Cit+(0.0723)Ty
r+(-0.2235)Met+(0.0053)Lys+(-0.1210)Trp; 0.842, 0.865, 0.811, 0.
834, 0.816, 0.826, 0.825, 0.833, (7.3813)+(-0.0034)Gly+(-0.0679)
Cit+(0.0672)Tyr+(0.0038)Val+(-0.1928)Met+(-0.1240)Trp; 0.842,
0.862, 0.806, 0.835, 0.817, 0.818, 0.840, 0.834, (8.0200)+(-0.068
7)Asn+(-0.0050)Gly+(-0.0581)Cit+(0.0458)Tyr+(-0.1260)Trp; 0. 841,
0.863, 0.832, 0.828, 0.806, 0.842, 0.807, 0.829, (6.4594)+(-0.
0855)Cit+(0.0670)Tyr+(-0.2087)Met+(0.0174)Orn+(0.0076)Leu+(-0.1227)Trp;
0.841, 0.864, 0.817, 0.837, 0.822, 0.844, 0.813, 0.83 6,
(7.2172)+(-0.0013)Ala+(-0.0653)Cit+(-0.0044)Arg+(0.0722)T
yr+(-0.1864)Met+(-0.1143)Trp
[0494] List (1) of Linear Discriminants Searched in Example 6
[0495] The linear discriminants searched in Example 6 above are
listed below. Before each equation, "the value of ROC_AUC for the
pancreatic cancer group and the colorectal cancer group with
validation", "the value of ROC_AUC for the pancreatic cancer group
and the colorectal cancer group without validation", "the value of
ROC_AUC for the pancreatic cancer group and the healthy group",
"the value of ROC_AUC for the pancreatic cancer group and the other
cancers group", "the value of ROC_AUC for the pancreatic cancer
group and the lung cancer group", "the value of ROC_AUC for the
pancreatic cancer group and the prostatic cancer group", "the value
of ROC_AUC for the pancreatic cancer group and the breast cancer
group", and "the average value of the value of ROC_AUC for the
pancreatic cancer group and the lung cancer group, the value of
ROC_AUC for the pancreatic cancer group and the colorectal cancer
group, the value of ROC_AUC for the pancreatic cancer group and the
prostatic cancer group, and the value of ROC_AUC for the pancreatic
cancer group and the breast cancer group" obtained for the equation
are additionally listed.
[0496] 0.862, 0.876, 0.836, 0.862, 0.854, 0.866, 0.850, 0.862,
(6.741 3)+(-0.0941)Asn+(0.0093)Gln+(-0.0666)Cit+(0.0561)Tyr+(-0.12
68)Met+(-0.1224)Trp; 0.861, 0.876, 0.840, 0.849, 0.834, 0.843, 0.8
36, 0.847, (8.2510)+(-0.0469)Asn+(-0.0498)Cit+(0.0525)Tyr+(-0.
1388)Met+(0.0356)Phe+(-0.1294)Trp; 0.860, 0.874, 0.859, 0.845, 0.
831, 0.848, 0.818, 0.843, (6.9429)+(0.0121)Thr+(-0.0594)Cit+(0.
0463)Tyr+(-0.2151)Met+(0.0479)Phe+(-0.1367)Trp; 0.860, 0.871,
0.841, 0.839, 0.820, 0.854, 0.814, 0.840,
(8.8283)+(-0.0615)Asn+(-0.0708)Cit+(0.0534)Tyr+(-0.1019)Met+(0.0231)Orn+(-
-0.1179)Trp; 0.858, 0.871, 0.842, 0.845, 0.832, 0.840, 0.828,
0.843, (7.229
1)+(-0.0552)Cit+(0.0477)Tyr+(-0.1719)Met+(0.0417)Phe+(-0.13 18)Trp;
0.857, 0.871, 0.832, 0.840, 0.825, 0.849, 0.808, 0.838, (9.1
087)+(-0.0640)Asn+(0.0112)Thr+(-0.0561)Cit+(0.0564)Tyr+(-0.
1303)Met+(-0.1204)Trp; 0.857, 0.873, 0.836, 0.849, 0.841, 0.843, 0.
829, 0.846,
(7.6157)+(-0.0525)Cit+(-0.0057)Pro+(0.0502)Tyr+(-0.1580)Met+(0.041-
7)Phe+(-0.1349)Trp; 0.857, 0.875, 0.820, 0.865, 0.865, 0.868,
0.838, 0.862,
(7.2197)+(-0.1137)Asn+(0.0090)Gln+(-0.0613)Cit+(-0.0095)Pro+(0.045-
2)Tyr+(-0.1360)Trp; 0.856, 0. 874, 0.857, 0.857, 0.853, 0.851,
0.841, 0.855, (4.7009)+(0.0070)Gl
n+(-0.0685)Cit+(0.0441)Tyr+(-0.2171)Met+(0.0506)Phe+(-0.138 4)Trp;
0.856, 0.872, 0.845, 0.853, 0.841, 0.857, 0.843, 0.853, (7.50
89)+(-0.0029)Ala+(-0.0544)Cit+(0.0496)Tyr+(-0.1581)Met+(0.0
411)Phe+(-0.1274)Trp; 0.856, 0.870, 0.861, 0.849, 0.837, 0.854, 0.
831, 0.848, (6.2989)+(0.0102)Ser+(-0.0563)Cit+(0.0477)Tyr+(-0.
1949)Met+(0.0483)Phe+(-0.1330)Trp; 0.855, 0.871, 0.852, 0.843, 0.
828, 0.848, 0.821, 0.842, (7.0492)+(-0.0679)Cit+(0.0457)Tyr+(-0.
1714)Met+(0.0151)Orn+(0.0379)Phe+(-0.1306)Trp; 0.855, 0.872, 0.
842, 0.846, 0.835, 0.843, 0.825, 0.844, (7.3230)+(-0.0543)Cit+(0.
0474)Tyr+(-0.1681)Met+(-0.0034)Leu+(0.0436)Phe+(-0.1303)Tr p;
0.855, 0.871, 0.843, 0.844, 0.831, 0.840, 0.828, 0.842,
(7.1567)+(-0.0553)Cit+(0.0479)Tyr+(-0.1754)Met+(0.0010)Lys+(0.0418)P
he+(-0.1326)Trp; 0.855, 0.867, 0.818, 0.840, 0.826, 0.842, 0.821,
0. 839, (9.1261)+(-0.0569)Asn+(-0.0525)Cit+(0.0565)Tyr+(-0.099
9)Met+(-0.1178)Trp; 0.855, 0.872, 0.828, 0.855, 0.847, 0.847, 0.84
8, 0.853, (6.5246)+(-0.0045)Gly+(0.0065)Gln+(-0.0666)Cit+(0.0
437)Tyr+(-0.1509)Met+(-0.1216)Trp; 0.854, 0.869, 0.836, 0.843, 0.
828, 0.857, 0.821, 0.844, (8.5671)+(0.0088)Ser+(-0.0642)Asn+(-0.
0532)Cit+(0.0577)Tyr+(-0.1104)Met+(-0.1169)Trp; 0.854, 0.868,
0.819, 0.841, 0.825, 0.842, 0.822, 0.840,
(8.9561)+(-0.0599)Asn+(-0.0525)Cit+(0.0575)Tyr+(-0.1093)Met+(0.0031)Lys+(-
-0.1203)Trp; 0.854, 0.870, 0.831, 0.839, 0.820, 0.832, 0.833,
0.839, (9.296
4)+(-0.0799)Asn+(-0.0043)Gly+(-0.0645)Cit+(0.0360)Tyr+(0.02
35)Orn+(-0.1248)Trp; 0.854, 0.867, 0.822, 0.847, 0.835, 0.854, 0.8
33, 0.847, (9.2762)+(-0.0536)Asn+(-0.0023)Ala+(-0.0523)Cit+(0.
0577)Tyr+(-0.0913)Met+(-0.1145)Trp; 0.853, 0.868, 0.819, 0.840,
0.825, 0.843, 0.822, 0.839,
(9.0817)+(-0.0567)Asn+(-0.0527)Cit+(0.0566)Tyr+(-0.1018)Met+(0.0010)Leu+(-
-0.1185)Trp; 0.853, 0.8 71, 0.841, 0.846, 0.834, 0.838, 0.835,
0.844, (7.4809)+(-0.0015)Gl
y+(-0.0531)Cit+(0.0461)Tyr+(-0.1652)Met+(0.0405)Phe+(-0.131 4)Trp;
0.853, 0.868, 0.830, 0.840, 0.820, 0.846, 0.833, 0.842, (8.71
18)+(-0.0562)Asn+(-0.0553)Cit+(0.0576)Tyr+(-0.1194)Met+(0.0
147)Ile+(-0.1189)Trp; 0.853, 0.873, 0.821, 0.863, 0.857, 0.847, 0.
870, 0.862,
(7.5590)+(-0.1142)Asn+(-0.0066)Gly+(0.0091)Gln+(-0.0565)Cit+(0.033-
7)Tyr+(-0.1305)Trp; 0.853, 0.864, 0.832, 0.834, 0.821, 0.846,
0.796, 0.832,
(7.9167)+(0.0081)Thr+(-0.0631)Cit+(0.0509)Tyr+(-0.1581)Met+(-0.120-
3)Trp; 0.853, 0.867, 0.818, 0.8 40, 0.826, 0.843, 0.821, 0.839,
(9.1439)+(-0.0569)Asn+(-0.0523)C
it+(0.0566)Tyr+(-0.0002)Val+(-0.0998)Met+(-0.1175)Trp; 0.853,
0.869, 0.857, 0.868, 0.879, 0.860, 0.841, 0.863, (5.6045)+(-0.072
8)Asn+(0.0103)Gln+(-0.0613)Cit+(-0.1429)Met+(0.0505)Phe+(-0.
1170)Trp; 0.853, 0.868, 0.834, 0.857, 0.851, 0.866, 0.842, 0.857,
(6. 3677)+(0.0059)Gln+(-0.0034)Ala+(-0.0708)Cit+(0.0512)Tyr+(-0.
1486)Met+(-0.1166)Trp; 0.853, 0.870, 0.823, 0.854, 0.851, 0.862, 0.
823, 0.852, (6.3261)+(0.0066)Gln+(-0.0697)Cit+(-0.0076)Pro+(0.
0521)Tyr+(-0.1493)Met+(-0.1260)Trp; 0.852, 0.870, 0.828, 0.858,
0.855, 0.860, 0.840, 0.856,
(7.1920)+(-0.1090)Asn+(0.0084)Gln+(-0.0643)Cit+(0.0397)Tyr+(-0.0067)Lys+(-
-0.1252)Trp; 0.852, 0. 872, 0.841, 0.859, 0.855, 0.855, 0.845,
0.857, (6.6480)+(-0.1169)A
sn+(0.0077)Gln+(-0.0620)Cit+(0.0359)Tyr+(0.0126)Phe+(-0.136 7)Trp;
0.852, 0.869, 0.827, 0.857, 0.857, 0.858, 0.833, 0.854, (7.24
09)+(-0.1157)Asn+(0.0077)Gln+(-0.0619)Cit+(0.0405)Tyr+(-0.0
060)Leu+(-0.1268)Trp; 0.852, 0.868, 0.850, 0.843, 0.826, 0.842, 0.
836, 0.843, (6.9305)+(-0.0575)Cit+(0.0488)Tyr+(-0.1861)Met+(0.
0121)Ile+(0.0401)Phe+(-0.1322)Trp; 0.852, 0.868, 0.834, 0.865, 0.
864, 0.872, 0.857, 0.865, (7.2186)+(-0.1085)Asn+(0.0078)Gln+(-0.
0040)Ala+(-0.0631)Cit+(0.0432)Tyr+(-0.1247)Trp; 0.852, 0.864,
0.838, 0.833, 0.816, 0.848, 0.803, 0.833,
(7.6916)+(-0.0762)Cit+(0.0484)Tyr+(-0.1372)Met+(0.0201)Orn+(-0.1184)Trp;
0.852, 0.8 66, 0.834, 0.848, 0.840, 0.855, 0.825, 0.846,
(6.1119)+(0.0057)Gln
+(-0.0714)Cit+(0.0491)Tyr+(-0.1632)Met+(-0.1214)Trp; 0.852, 0. 868,
0.813, 0.843, 0.832, 0.843, 0.819, 0.841, (9.4226)+(-0.0544)A
sn+(-0.0504)Cit+(-0.0051)Pro+(0.0585)Tyr+(-0.0890)Met+(-0.1
206)Trp; 0.852, 0.869, 0.832, 0.855, 0.851, 0.853, 0.839, 0.853,
(6. 9872)+(-0.1169)Asn+(0.0077)Gln+(-0.0630)Cit+(0.0393)Tyr+(-0.
1315)Trp; 0.852, 0.870, 0.828, 0.857, 0.854, 0.853, 0.842, 0.855,
(6. 9009)+(-0.1142)Asn+(0.0081)Gln+(-0.0036)Thr+(-0.0626)Cit+(0.
0405)Tyr+(-0.1301)Trp; 0.852, 0.868, 0.817, 0.842, 0.827, 0.839, 0.
832, 0.842,
(9.4049)+(-0.0556)Asn+(-0.0020)Gly+(-0.0498)Cit+(0.0541)Tyr+(-0.09-
33)Met+(-0.1177)Trp; 0.852, 0.870, 0.844, 0.8 46, 0.836, 0.844,
0.828, 0.844, (7.3607)+(-0.0531)Cit+(0.0482)Ty
r+(-0.0022)Val+(-0.1726)Met+(0.0432)Phe+(-0.1290)Trp; 0.851, 0.863,
0.830, 0.836, 0.822, 0.846, 0.807, 0.835,
(7.6885)+(0.0043)Ser+(-0.0606)Cit+(0.0517)Tyr+(-0.1403)Met+(-0.1180)Trp;
0.85 1, 0.866, 0.842, 0.843, 0.828, 0.862, 0.822, 0.845,
(7.9827)+(-0.00
33)Ala+(-0.0760)Cit+(0.0503)Tyr+(-0.1224)Met+(0.0209)Orn+(-0.1137)Trp;
0.851, 0.870, 0.830, 0.867, 0.871, 0.842, 0.866, 0.863,
(7.2500)+(-0.1025)Asn+(-0.0076)Gly+(0.0097)Gln+(-0.0528)Cit
+(0.0206)Phe+(-0.1235)Trp; 0.851, 0.869, 0.844, 0.845, 0.834, 0.8
60, 0.815, 0.845, (6.0208)+(0.0052)Gln+(-0.0832)Cit+(0.0469)Ty
r+(-0.1637)Met+(0.0157)Orn+(-0.1212)Trp; 0.851, 0.867, 0.829, 0.
838, 0.826, 0.842, 0.806, 0.836,
(9.1413)+(-0.0785)Asn+(-0.0693)Cit+(-0.0081)Pro+(0.0443)Tyr+(0.0264)Orn+(-
-0.1291)Trp; 0.851, 0.865, 0.839, 0.835, 0.818, 0.838, 0.812,
0.833, (8.6994)+(-0.085
7)Asn+(-0.0692)Cit+(0.0394)Tyr+(0.0222)Orn+(-0.1261)Trp; 0.8 51,
0.867, 0.830, 0.840, 0.826, 0.839, 0.820, 0.838, (8.4478)+(-0.0
037)Gly+(0.0101)Thr+(-0.0586)Cit+(0.0465)Tyr+(-0.1508)Met+(-0.1206)Trp;
0.851, 0.865, 0.844, 0.834, 0.817, 0.855, 0.795, 0.83 3,
(7.6431)+(0.0061)Thr+(-0.0770)Cit+(0.0483)Tyr+(-0.1555)Me
t+(0.0180)Orn+(-0.1199)Trp; 0.851, 0.866, 0.824, 0.837, 0.829, 0.
849, 0.790, 0.834,
(8.3241)+(0.0093)Thr+(-0.0606)Cit+(-0.0063)Pro+(0.0535)Tyr+(-0.1467)Met+(-
-0.1240)Trp; 0.851, 0.867, 0.830, 0.837, 0.824, 0.852, 0.798,
0.835, (8.0977)+(-0.0759)Cit+(-0.006
9)Pro+(0.0508)Tyr+(-0.1211)Met+(0.0237)Orn+(-0.1221)Trp; 0.8 51,
0.870, 0.825, 0.856, 0.853, 0.852, 0.841, 0.854, (7.1163)+(-0.0
039)Ser+(-0.1149)Asn+(0.0081)Gln+(-0.0635)Cit+(0.0392)Tyr+(-0.1319)Trp;
0.851, 0.861, 0.815, 0.834, 0.822, 0.829, 0.814, 0.83 1,
(8.9887)+(-0.0809)Asn+(-0.0516)Cit+(0.0427)Tyr+(-0.1259)T rp;
0.851, 0.866, 0.843, 0.846, 0.827, 0.859, 0.848, 0.850, (7.8294)
+(-0.0040)Ala+(-0.0625)Cit+(0.0555)Tyr+(-0.1420)Met+(0.020
8)Ile+(-0.1141)Trp; 0.850, 0.868, 0.845, 0.860, 0.862, 0.842, 0.85
1, 0.856, (5.1235)+(-0.0933)Asn+(0.0077)Gln+(0.0473)Tyr+(-0.1
702)Met+(0.0469)Phe+(-0.1384)Trp; 0.850, 0.866, 0.837, 0.847, 0.
838, 0.853, 0.827, 0.846, (5.9727)+(0.0058)Gln+(-0.0721)Cit+(0.
0493)Tyr+(-0.1686)Met+(0.0031)Leu+(-0.1234)Trp; 0.850, 0.866,
0.832, 0.834, 0.820, 0.838, 0.801, 0.831,
(8.9450)+(-0.0838)Asn+(-0.0698)Cit+(0.0401)Tyr+(0.0251)Orn+(-0.0095)Ile+(-
-0.1244)Trp; 0.850, 0.867, 0.839, 0.836, 0.819, 0.845, 0.808,
0.835, (9.009
1)+(-0.0761)Asn+(-0.0727)Cit+(0.0394)Tyr+(0.0265)Orn+(-0.00
63)Lys+(-0.1198)Trp; 0.850, 0.866, 0.834, 0.848, 0.840, 0.856, 0.8
25, 0.847, (6.1246)+(0.0057)Gln+(-0.0713)Cit+(0.0492)Tyr+(-0.
0002)Val+(-0.1632)Met+(-0.1211)Trp; 0.850, 0.862, 0.824, 0.834,
0.820, 0.840, 0.811, 0.833,
(7.9490)+(-0.0602)Cit+(0.0516)Tyr+(-0.1365)Met+(0.0020)Leu+(-0.1197)Trp;
0.850, 0.865, 0.839, 0.8 34, 0.817, 0.853, 0.802, 0.834,
(7.8845)+(-0.0776)Cit+(0.0473)Ty
r+(-0.1264)Met+(0.0224)Orn+(-0.0032)Lys+(-0.1160)Trp; 0.850, 0.867,
0.834, 0.837, 0.819, 0.843, 0.820, 0.837, (8.1249)+(-0.003
0)Gly+(-0.0727)Cit+(0.0448)Tyr+(-0.1265)Met+(0.0210)Orn+(-0.
1183)Trp; 0.850, 0.862, 0.823, 0.835, 0.822, 0.841, 0.811, 0.834,
(8. 0278)+(-0.0598)Cit+(0.0515)Tyr+(-0.1332)Met+(-0.1184)Trp; 0.
850, 0.870, 0.826, 0.856, 0.855, 0.850, 0.833, 0.852, (6.8089)+(-0.
1125)Asn+(0.0086)Gln+(-0.0566)Cit+(-0.0112)Arg+(0.0406)Tyr+(-0.1280)Trp;
0.850, 0.868, 0.832, 0.862, 0.863, 0.852, 0.855, 0.86 0,
(7.7324)+(-0.1031)Asn+(-0.0079)Gly+(0.0091)Gln+(-0.0700)C
it+(0.0213)Orn+(-0.1133)Trp; 0.850, 0.867, 0.793, 0.863, 0.866, 0.
833, 0.870, 0.859, (7.7024)+(-0.1161)Asn+(-0.0081)Gly+(0.0088)
Gln+(-0.0095)Pro+(0.0367)Tyr+(-0.1345)Trp; 0.850, 0.867, 0.839,
0.847, 0.838, 0.857, 0.820, 0.846,
(6.1803)+(0.0054)Gln+(0.0040)Thr+(-0.0723)Cit+(0.0490)Tyr+(-0.1736)Met+(--
0.1222)Trp; 0.85 0, 0.866, 0.845, 0.835, 0.819, 0.854, 0.802,
0.835, (7.3709)+(0.004
1)Ser+(-0.0769)Cit+(0.0486)Tyr+(-0.1440)Met+(0.0200)Orn+(-0.
1180)Trp; 0.850, 0.870, 0.843, 0.853, 0.846, 0.859, 0.833, 0.852,
(6. 8958)+(-0.1183)Asn+(0.0072)Gln+(-0.0760)Cit+(0.0370)Tyr+(0.
0173)Orn+(-0.1312)Trp; 0.850, 0.863, 0.814, 0.838, 0.828, 0.840, 0.
809, 0.835,
(8.4140)+(-0.0571)Cit+(-0.0057)Pro+(0.0539)Tyr+(-0.1193)Met+(-0.12-
14)Trp; 0.850, 0.870, 0.848, 0.846, 0.830, 0.849, 0.833, 0.845,
(7.6348)+(-0.0196)His+(-0.0494)Cit+(0.0488)Tyr+(-0.1613)Met+(0.0422)Phe+(-
-0.1223)Trp; 0.850, 0.864, 0.832, 0.8 38, 0.819, 0.838, 0.837,
0.839, (7.9697)+(-0.0022)Gly+(-0.0592)C
it+(0.0500)Tyr+(-0.1438)Met+(0.0145)Ile+(-0.1193)Trp; 0.850, 0.868,
0.875, 0.859, 0.853, 0.858, 0.859, 0.860,
(4.5131)+(0.0067)Gln+(-0.0464)His+(0.0415)Tyr+(-0.2036)Met+(0.0584)Phe+(--
0.1 196)Trp; 0.850, 0.863, 0.825, 0.844, 0.833, 0.850, 0.829,
0.844, (8.
3132)+(-0.0031)Ala+(-0.0590)Cit+(0.0534)Tyr+(-0.1191)Met+(-0.1139)Trp;
0.850, 0.867, 0.847, 0.848, 0.836, 0.855, 0.836, 0.849,
(5.6910)+(0.0057)Gln+(-0.0742)Cit+(0.0503)Tyr+(-0.1833)Met+(0.0155)Ile+(--
0.1225)Trp; 0.849, 0.865, 0.838, 0.833, 0.816, 0.84 9, 0.802,
0.833, (7.7061)+(-0.0762)Cit+(0.0483)Tyr+(-0.1365)Me
t+(0.0203)Orn+(-0.0004)Leu+(-0.1182)Trp; 0.849, 0.865, 0.817, 0.
864, 0.869, 0.846, 0.860, 0.860,
(7.8536)+(-0.1003)Asn+(-0.0078)Gly+(0.0098)Gln+(-0.0540)Cit+(-0.1119)Trp;
0.849, 0.867, 0.828, 0.855, 0.854, 0.853, 0.834, 0.852,
(7.1131)+(-0.1160)Asn+(0.007
8)Gln+(-0.0623)Cit+(0.0398)Tyr+(-0.0050)Ile+(-0.1306)Trp; 0. 849,
0.864, 0.834, 0.834, 0.821, 0.849, 0.795, 0.832, (7.7842)+(0.0
018)Ser+(0.0075)Thr+(-0.0632)Cit+(0.0510)Tyr+(-0.1594)Met+(-0.1200)Trp;
0.849, 0.865, 0.834, 0.843, 0.832, 0.858, 0.815, 0.84 3,
(8.2047)+(0.0082)Thr+(-0.0031)Ala+(-0.0623)Cit+(0.0528)Ty
r+(-0.1442)Met+(-0.1158)Trp; 0.849, 0.864, 0.816, 0.837, 0.825, 0.
839, 0.811, 0.835, (8.3035)+(-0.0577)Cit+(-0.0058)Pro+(0.0541)
Tyr+(-0.1240)Met+(0.0031)Leu+(-0.1235)Trp; 0.849, 0.866, 0.842,
0.846, 0.831, 0.859, 0.832, 0.847, (8.9582)+(-0.0769)Asn+(-0.003
8)Ala+(-0.0696)Cit+(0.0432)Tyr+(0.0230)Orn+(-0.1195)Trp; 0.8 49,
0.863, 0.835, 0.835, 0.816, 0.844, 0.824, 0.836, (7.6049)+(-0.0
626)Cit+(0.0526)Tyr+(-0.1533)Met+(0.0155)Ile+(-0.1195)Trp; 0. 849,
0.866, 0.820, 0.840, 0.825, 0.842, 0.825, 0.840, (9.1048)+(-0.
0593)Asn+(-0.0567)Cit+(0.0059)Arg+(0.0570)Tyr+(-0.1096)Met+(-0.1193)Trp;
0.849, 0.864, 0.832, 0.834, 0.821, 0.847, 0.795, 0.83 2,
(7.9340)+(0.0081)Thr+(-0.0629)Cit+(0.0510)Tyr+(-0.0002)Va
l+(-0.1580)Met+(-0.1199)Trp; 0.849, 0.868, 0.832, 0.856, 0.854, 0.
856, 0.839, 0.854,
(7.0675)+(-0.1170)Asn+(0.0077)Gln+(-0.0621)Cit+(0.0397)Tyr+(-0.0011)Val+(-
-0.1298)Trp; 0.849, 0.865, 0.837, 0.835, 0.819, 0.852, 0.804,
0.835, (7.7848)+(-0.0756)Cit+(0.048
7)Tyr+(-0.0014)Val+(-0.1369)Met+(0.0208)Orn+(-0.1163)Trp; 0. 849,
0.865, 0.830, 0.839, 0.823, 0.844, 0.825, 0.839, (7.9489)+(-0.
0602)Cit+(-0.0065)Pro+(0.0557)Tyr+(-0.1420)Met+(0.0190)Ile+(-0.1232)Trp;
0.849, 0.865, 0.830, 0.847, 0.840, 0.852, 0.825, 0.84 6,
(6.2111)+(-0.0027)Ser+(0.0061)Gln+(-0.0716)Cit+(0.0489)Ty
r+(-0.1605)Met+(-0.1218)Trp; 0.849, 0.869, 0.843, 0.852, 0.842, 0.
870, 0.833, 0.853, (6.3176)+(0.0071)Gln+(-0.0309)His+(-0.0651)
Cit+(0.0504)Tyr+(-0.1529)Met+(-0.1069)Trp; 0.849, 0.864, 0.832,
0.834, 0.821, 0.845, 0.795, 0.831, (7.9243)+(0.0083)Thr+(-0.062
4)Cit+(-0.0009)Arg+(0.0508)Tyr+(-0.1570)Met+(-0.1201)Trp; 0. 849,
0.864, 0.827, 0.844, 0.832, 0.850, 0.828, 0.843, (8.2323)+(-0.
0032)Ala+(-0.0600)Cit+(0.0531)Tyr+(0.0013)Val+(-0.1188)Met+(-0.1157)Trp;
0.849, 0.862, 0.823, 0.835, 0.822, 0.842, 0.811, 0.83 4,
(8.0322)+(-0.0597)Cit+(0.0515)Tyr+(-0.0001)Val+(-0.1332)M
et+(-0.1183)Trp; 0.849, 0.864, 0.833, 0.836, 0.820, 0.846, 0.811,
0. 835, (7.5334)+(0.0048)Ser+(-0.0612)Cit+(0.0519)Tyr+(-0.1460)
Met+(0.0030)Leu+(-0.1198)Trp; 0.849, 0.865, 0.845, 0.836, 0.820,
0.843, 0.814, 0.835, (8.4285)+(0.0042)Ser+(-0.0903)Asn+(-0.069
5)Cit+(0.0393)Tyr+(0.0222)Orn+(-0.1261)Trp; 0.849, 0.868, 0.84 4,
0.844, 0.831, 0.843, 0.830, 0.843, (7.1352)+(-0.0595)Cit+(0.00
58)Arg+(0.0478)Tyr+(-0.1841)Met+(0.0431)Phe+(-0.1337)Trp; 0. 849,
0.863, 0.830, 0.836, 0.822, 0.846, 0.807, 0.835, (7.6634)+(0.0
044)Ser+(-0.0608)Cit+(0.0516)Tyr+(0.0003)Val+(-0.1405)Met+(-0.1184)Trp;
0.848, 0.863, 0.846, 0.837, 0.816, 0.850, 0.826, 0.83 9,
(7.1469)+(0.0054)Ser+(-0.0638)Cit+(0.0530)Tyr+(-0.1638)Me
t+(0.0167)Ile+(-0.1191)Trp; 0.848, 0.863, 0.832, 0.845, 0.834, 0.
856, 0.827, 0.845, (8.0011)+(0.0039)Ser+(-0.0030)Ala+(-0.0597)
Cit+(0.0535)Tyr+(-0.1258)Met+(-0.1136)Trp; 0.848, 0.864, 0.818,
0.838, 0.824, 0.833, 0.825, 0.837, (8.4155)+(-0.0026)Gly+(-0.056
1)Cit+(0.0485)Tyr+(-0.1238)Met+(-0.1183)Trp
[0497] List (2) of Logistic Regression Equations Searched in
Example 6
[0498] The logistic regression equations searched in Example 6
above are listed below. Before each equation, "the value of ROC_AUC
for the pancreatic cancer group and the colorectal cancer group
with validation", "the value of ROC_AUC for the pancreatic cancer
group and the colorectal cancer group without validation", "the
value of ROC_AUC for the pancreatic cancer group and the healthy
group", "the value of ROC_AUC for the pancreatic cancer group and
the other cancers group", "the value of ROC_AUC for the pancreatic
cancer group and the lung cancer group", "the value of ROC_AUC for
the pancreatic cancer group and the prostatic cancer group", "the
value of ROC_AUC for the pancreatic cancer group and the breast
cancer group", and "the average value of the value of ROC_AUC for
the pancreatic cancer group and the lung cancer group, the value of
ROC_AUC for the pancreatic cancer group and the colorectal cancer
group, the value of ROC_AUC for the pancreatic cancer group and the
prostatic cancer group, and the value of ROC_AUC for the pancreatic
cancer group and the breast cancer group" obtained for the equation
are additionally listed. 0.822, 0.849, 0.870, 0.853, 0.863, 0.864,
0.828, 0.851, (4.045
7)+(0.0070)Gln+(-0.0515)His+(0.0059)Thr+(-0.1935)Met+(0.037
3)Phe+(-0.0815)Trp; 0.816, 0.846, 0.867, 0.852, 0.860, 0.857, 0.84
2, 0.851, (3.8120)+(0.0071)Gln+(-0.0493)His+(-0.1898)Met+(0.0
091)Ile+(0.0363)Phe+(-0.0794)Trp; 0.814, 0.843, 0.865, 0.845, 0.
845, 0.853, 0.843, 0.846, (3.9326)+(0.0076)Gln+(-0.0633)His+(-0.
1928)Met+(0.0151)Leu+(0.0318)Phe+(-0.0832)Trp; 0.815, 0.845, 0.
864, 0.849, 0.857, 0.852, 0.835, 0.847, (3.9733)+(0.0067)Gln+(-0.
0552)His+(-0.1915)Met+(0.0066)Lys+(0.0373)Phe+(-0.0839)Trp; 0.829,
0.856, 0.862, 0.862, 0.873, 0.865, 0.847, 0.860,
(4.3532)+(-0.0698)Asn+(0.0097)Gln+(-0.0451)His+(-0.1329)Met+(0.0325)Ph
e+(-0.0772)Trp; 0.792, 0.823, 0.861, 0.830, 0.825, 0.849, 0.841, 0.
835,
(4.3379)+(0.0035)Gln+(-0.0631)His+(-0.0027)Ala+(0.0100)Leu+(0.0235)Phe+(--
0.0977)Trp; 0.816, 0.844, 0.861, 0.844, 0.847, 0.850, 0.834, 0.844,
(4.0571)+(0.0071)Gln+(-0.0612)His+(0.006
5)Val+(-0.1772)Met+(0.0336)Phe+(-0.0857)Trp; 0.819, 0.846, 0.8 60,
0.852, 0.862, 0.857, 0.831, 0.849, (4.0114)+(0.0072)Gln+(-0.0
503)His+(0.0005)Ala+(-0.1800)Met+(0.0363)Phe+(-0.0804)Trp; 0. 807,
0.836, 0.860, 0.833, 0.833, 0.844, 0.817, 0.833, (5.8122)+(-0.
0364)His+(0.0086)Thr+(-0.1719)Met+(0.0137)Ile+(0.0317)Phe+(-0.0854)Trp;
0.814, 0.843, 0.860, 0.848, 0.851, 0.852, 0.850, 0.84 9,
(4.9199)+(-0.0928)Asn+(0.0076)Gln+(-0.0574)His+(0.0073)Le
u+(0.0163)Phe+(-0.0871)Trp; 0.822, 0.846, 0.859, 0.853, 0.864, 0.
860, 0.834, 0.851,
(4.0072)+(0.0073)Gln+(-0.0498)His+(-0.1774)Met+(0.0364)Phe+(-0.0796)Trp;
0.817, 0.844, 0.859, 0.851, 0.858, 0.853, 0.846, 0.850,
(4.9719)+(-0.0954)Asn+(0.0074)Gln+(-0.052
2)His+(0.0021)Lys+(0.0185)Phe+(-0.0856)Trp; 0.791, 0.823, 0.85 9,
0.823, 0.816, 0.837, 0.830, 0.826, (4.3739)+(0.0037)Gln+(-0.06
29)His+(-0.0049)Lys+(0.0114)Leu+(0.0215)Phe+(-0.1003)Trp; 0. 796,
0.827, 0.859, 0.828, 0.822, 0.845, 0.837, 0.833, (4.3455)+(0.0
034)Gln+(-0.0670)His+(-0.0028)Ala+(0.0077)Val+(0.0250)Phe+(-0.1011)Trp;
0.822, 0.846, 0.858, 0.853, 0.861, 0.855, 0.846, 0.85 2,
(4.9586)+(-0.0934)Asn+(0.0076)Gln+(-0.0505)His+(0.0188)Ph
e+(-0.0842)Trp; 0.818, 0.847, 0.858, 0.855, 0.863, 0.861, 0.848, 0.
855, (4.9370)+(-0.0916)Asn+(0.0076)Gln+(-0.0496)His+(-0.000
8)Ala+(0.0196)Phe+(-0.0830)Trp; 0.816, 0.845, 0.858, 0.845, 0.84 6,
0.846, 0.845, 0.845, (4.8767)+(-0.0938)Asn+(0.0075)Gln+(-0.0
609)His+(0.0063)Val+(0.0188)Phe+(-0.0922)Trp; 0.794, 0.827, 0. 858,
0.821, 0.812, 0.831, 0.822, 0.823, (4.3702)+(0.0035)Gln+(-0.
0660)His+(0.0077)Val+(-0.0042)Lys+(0.0236)Phe+(-0.1043)Trp; 0.797,
0.821, 0.858, 0.819, 0.813, 0.830, 0.826, 0.822, (4.3809)+(0.
0030)Gln+(-0.0646)His+(0.0086)Leu+(0.0219)Phe+(-0.1028)Trp; 0.796,
0.826, 0.857, 0.837, 0.842, 0.853, 0.832, 0.838, (4.3693)+(0.
0036)Gln+(-0.0529)His+(-0.0022)Ala+(-0.0016)Lys+(0.0258)Phe
+(-0.0919)Trp; 0.800, 0.826, 0.857, 0.835, 0.839, 0.850, 0.832, 0.8
36, (4.3693)+(0.0034)Gln+(-0.0543)His+(-0.0023)Ala+(0.0258)P
he+(-0.0931)Trp; 0.799, 0.828, 0.857, 0.828, 0.829, 0.837, 0.818,
0. 828,
(4.4040)+(0.0033)Gln+(-0.0549)His+(-0.0020)Lys+(0.0243)Phe+(-0.0964)Trp;
0.803, 0.826, 0.857, 0.826, 0.826, 0.834, 0.819, 0.826,
(4.4043)+(0.0030)Gln+(-0.0567)His+(0.0242)Phe+(-0.098 1)Trp; 0.799,
0.825, 0.856, 0.817, 0.806, 0.823, 0.823, 0.819, (4.36
13)+(0.0029)Gln+(-0.0684)His+(0.0069)Val+(0.0236)Phe+(-0.10 68)Trp;
0.811, 0.839, 0.856, 0.835, 0.842, 0.848, 0.800, 0.832, (6.0
297)+(0.0019)Ser+(-0.0368)His+(0.0082)Thr+(-0.1534)Met+(0.0
322)Phe+(-0.0850)Trp; 0.830, 0.859, 0.856, 0.856, 0.863, 0.866, 0.
825, 0.853,
(4.6037)+(0.0080)Gln+(-0.0384)His+(-0.0575)Cit+(-0.1601)Met+(0.031-
8)Phe+(-0.0822)Trp; 0.818, 0.847, 0.856, 0.854, 0.862, 0.856,
0.843, 0.852,
(4.9921)+(-0.0923)Asn+(0.0077)Gln+(-0.0506)His+(-0.0023)Ile+(0.019-
0)Phe+(-0.0838)Trp; 0.816, 0. 845, 0.855, 0.854, 0.862, 0.856,
0.848, 0.853, (5.0050)+(-0.0914)A
sn+(0.0078)Gln+(-0.0507)His+(-0.0043)Orn+(0.0193)Phe+(-0.08 43)Trp;
0.827, 0.856, 0.855, 0.857, 0.863, 0.865, 0.841, 0.856, (5.4
374)+(-0.0773)Asn+(0.0079)Gln+(-0.0403)His+(-0.0527)Cit+(0.
0160)Phe+(-0.0886)Trp; 0.795, 0.826, 0.855, 0.818, 0.808, 0.823, 0.
820, 0.819, (4.3684)+(0.0029)Gln+(-0.0676)His+(0.0089)Val+(-0.
0044)Leu+(0.0245)Phe+(-0.1068)Trp; 0.818, 0.848, 0.855, 0.857, 0.
871, 0.856, 0.839, 0.853, (4.1613)+(0.0081)Gln+(-0.0492)His+(-0.
1782)Met+(-0.0128)Orn+(0.0386)Phe+(-0.0807)Trp; 0.807, 0.835,
0.855, 0.825, 0.819, 0.837, 0.815, 0.826,
(6.2118)+(-0.0495)His+(0.0098)Thr+(-0.1688)Met+(0.0149)Leu+(0.0276)Phe+(--
0.0903)T rp; 0.829, 0.857, 0.854, 0.848, 0.848, 0.871, 0.814,
0.848, (5.8334)
+(-0.0856)Asn+(0.0070)Gln+(-0.0341)His+(-0.0759)Cit+(0.025
2)Orn+(-0.0832)Trp; 0.835, 0.858, 0.854, 0.846, 0.848, 0.856, 0.80
8, 0.842, (5.5348)+(-0.0893)Asn+(0.0051)Gln+(-0.0838)Cit+(0.0
263)Orn+(0.0084)Phe+(-0.1077)Trp; 0.800, 0.833, 0.854, 0.840, 0.
850, 0.860, 0.818, 0.840, (5.1355)+(0.0055)Gln+(-0.0488)His+(0.
0041)Thr+(-0.1734)Met+(0.0096)Ile+(-0.0642)Trp; 0.817, 0.846,
0.853, 0.852, 0.863, 0.853, 0.834, 0.849,
(4.2089)+(-0.0036)Ser+(0.0077)Gln+(-0.0497)His+(-0.1744)Met+(0.0355)Phe+(-
-0.0801)Trp; 0.809, 0.836, 0.853, 0.831, 0.835, 0.837, 0.808,
0.829, (5.966
7)+(-0.0448)His+(0.0070)Thr+(-0.1730)Met+(0.0092)Lys+(0.033
2)Phe+(-0.0909)Trp; 0.824, 0.848, 0.853, 0.832, 0.830, 0.839, 0.80
1, 0.829, (5.9620)+(0.0074)Thr+(-0.0656)Cit+(-0.1745)Met+(0.0
231)Ile+(0.0281)Phe+(-0.1031)Trp; 0.800, 0.835, 0.853, 0.833, 0.
829, 0.850, 0.826, 0.835, (5.0671)+(0.0062)Gln+(-0.0681)His+(0.
0057)Thr+(-0.1904)Met+(0.0201)Leu+(-0.0719)Trp; 0.814, 0.838,
0.853, 0.834, 0.840, 0.846, 0.801, 0.831,
(6.2023)+(-0.0364)His+(0.0085)Thr+(-0.1512)Met+(0.0316)Phe+(-0.0855)Trp;
0.811, 0.8 38, 0.853, 0.831, 0.836, 0.838, 0.797, 0.827,
(6.1897)+(-0.0376)Hi
s+(0.0087)Thr+(0.0010)Ala+(-0.1574)Met+(0.0315)Phe+(-0.087 2)Trp;
0.802, 0.832, 0.853, 0.831, 0.832, 0.840, 0.821, 0.831, (5.54
37)+(0.0039)Ser+(-0.0337)His+(-0.1517)Met+(0.0141)Ile+(0.03
12)Phe+(-0.0824)Trp; 0.831, 0.858, 0.852, 0.852, 0.845, 0.863, 0.8
46, 0.853, (4.3912)+(0.0064)Gln+(-0.0514)His+(0.0516)Tyr+(-0.
2316)Met+(0.0226)Phe+(-0.0955)Trp; 0.817, 0.845, 0.852, 0.854, 0.
862, 0.854, 0.849, 0.853, (4.8907)+(-0.0922)Asn+(0.0080)Gln+(-0.
0490)His+(-0.0038)Thr+(0.0196)Phe+(-0.0830)Trp; 0.799, 0.831,
0.852, 0.832, 0.827, 0.848, 0.839, 0.836,
(4.5889)+(0.0025)Gln+(-0.0565)His+(-0.0028)Ala+(0.0262)Tyr+(0.0187)Phe+(--
0.1029)Tr p; 0.820, 0.849, 0.852, 0.857, 0.870, 0.866, 0.836,
0.855,
(4.2012)+(0.0079)Gln+(-0.0482)His+(-0.0063)Pro+(-0.1598)Met+(0.0364)Phe+(-
-0.0837)Trp; 0.791, 0.823, 0.852, 0.823, 0.817, 0.829, 0.835,
0.826, (4.2681)+(0.0038)Gln+(-0.0624)His+(-0.0062)Thr+(0.008
8)Leu+(0.0231)Phe+(-0.1003)Trp; 0.787, 0.819, 0.852, 0.821, 0.81 8,
0.828, 0.828, 0.823, (4.5779)+(0.0037)Gln+(-0.0648)His+(-0.0
121)Orn+(0.0092)Leu+(0.0229)Phe+(-0.1034)Trp; 0.816, 0.842, 0. 851,
0.837, 0.842, 0.846, 0.807, 0.834, (6.6822)+(-0.0302)Asn+(-0.
0328)His+(0.0090)Thr+(-0.1260)Met+(0.0291)Phe+(-0.0845)Trp; 0.795,
0.827, 0.851, 0.838, 0.844, 0.849, 0.840, 0.840, (4.2848)+(0.
0041)Gln+(-0.0522)His+(-0.0055)Thr+(-0.0021)Ala+(0.0265)Phe
+(-0.0911)Trp; 0.817, 0.845, 0.851, 0.853, 0.861, 0.853, 0.847, 0.8
52,
(5.1736)+(-0.0042)Ser+(-0.0910)Asn+(0.0080)Gln+(-0.0507)His+(0.0180)Phe+(-
-0.0846)Trp; 0.809, 0.842, 0.851, 0.826, 0.820, 0.849, 0.792,
0.826, (5.1495)+(0.0033)Gln+(-0.0404)His+(-0.076
6)Cit+(0.0195)Orn+(0.0172)Phe+(-0.1043)Trp; 0.808, 0.836, 0.85 1,
0.824, 0.821, 0.831, 0.805, 0.823, (6.2140)+(-0.0491)His+(0.00
83)Thr+(0.0071)Val+(-0.1516)Met+(0.0289)Phe+(-0.0928)Trp; 0. 834,
0.857, 0.851, 0.850, 0.853, 0.869, 0.814, 0.848, (5.7897)+(-0.
0886)Asn+(0.0053)Gln+(-0.0015)Ala+(-0.0858)Cit+(0.0278)Orn+(-0.0973)Trp;
0.823, 0.851, 0.851, 0.851, 0.851, 0.863, 0.842, 0.85 2,
(5.7685)+(-0.0813)Asn+(0.0080)Gln+(-0.0472)His+(-0.0543)C
it+(0.0100)Leu+(-0.0856)Trp; 0.793, 0.826, 0.851, 0.813, 0.794, 0.
825, 0.829, 0.818, (4.5317)+(0.0021)Gln+(-0.0669)His+(0.0242)T
yr+(0.0088)Leu+(0.0158)Phe+(-0.1140)Trp; 0.826, 0.854, 0.851, 0.
855, 0.857, 0.868, 0.840, 0.855, (5.8304)+(-0.0850)Asn+(0.0077)G
ln+(-0.0377)His+(-0.0555)Cit+(0.0078)Ile+(-0.0813)Trp; 0.792,
0.825, 0.850, 0.837, 0.845, 0.847, 0.833, 0.837,
(4.5443)+(0.0041)Gln+(-0.0540)His+(-0.0022)Ala+(-0.0112)Orn+(0.0271)Phe+(-
-0. 0938)Trp; 0.797, 0.825, 0.850, 0.834, 0.843, 0.847, 0.821,
0.834, (4.
5421)+(0.0038)Gln+(-0.0550)His+(-0.0018)Ala+(-0.0085)Ile+(0.
0260)Phe+(-0.0924)Trp; 0.837, 0.858, 0.850, 0.848, 0.850, 0.866, 0.
807, 0.845, (5.8033)+(-0.0866)Asn+(0.0058)Gln+(-0.0883)Cit+(0.
0298)Orn+(-0.0049)Lys+(-0.0965)Trp; 0.805, 0.837, 0.850, 0.843,
0.846, 0.850, 0.841, 0.843,
(5.3970)+(-0.0980)Asn+(0.0075)Gln+(-0.0577)His+(0.0004)Lys+(0.0102)Leu+(--
0.0802)Trp; 0.811, 0.8 37, 0.850, 0.842, 0.845, 0.850, 0.841,
0.843, (5.3938)+(-0.0977)As
n+(0.0076)Gln+(-0.0576)His+(0.0103)Leu+(-0.0800)Trp; 0.792, 0. 823,
0.850, 0.819, 0.813, 0.821, 0.824, 0.820, (4.5738)+(0.0037)Gl
n+(-0.0693)His+(0.0078)Val+(-0.0139)Orn+(0.0252)Phe+(-0.108 5)Trp;
0.827, 0.854, 0.850, 0.846, 0.851, 0.845, 0.815, 0.841, (4.14
30)+(0.0054)Gln+(-0.0702)Cit+(-0.1900)Met+(0.0191)Ile+(0.03
16)Phe+(-0.1007)Trp; 0.817, 0.848, 0.850, 0.852, 0.867, 0.860, 0.8
18, 0.848, (4.1776)+(0.0086)Gln+(-0.0460)His+(-0.0196)Arg+(-0.
1497)Met+(0.0332)Phe+(-0.0773)Trp; 0.798, 0.825, 0.849, 0.829, 0.
832, 0.835, 0.827, 0.830, (4.3007)+(0.0038)Gln+(-0.0543)His+(-0.
0060)Thr+(0.0253)Phe+(-0.0955)Trp; 0.807, 0.837, 0.849, 0.843, 0.
846, 0.850, 0.844, 0.844, (5.3904)+(-0.0965)Asn+(0.0076)Gln+(-0.
0573)His+(-0.0006)Ala+(0.0108)Leu+(-0.0791)Trp; 0.799, 0.829,
0.849, 0.823, 0.816, 0.833, 0.824, 0.825,
(4.5722)+(0.0024)Gln+(-0.0569)His+(0.0239)Tyr+(-0.0022)Lys+(0.0180)Phe+(--
0.1069)Tr p; 0.794, 0.825, 0.849, 0.820, 0.811, 0.825, 0.831,
0.823,
(4.2729)+(0.0037)Gln+(-0.0658)His+(-0.0059)Thr+(0.0068)Val+(0.0244)P
he+(-0.1039)Trp; 0.796, 0.828, 0.849, 0.812, 0.793, 0.820, 0.823,
0. 816, (4.5205)+(0.0021)Gln+(-0.0693)His+(0.0224)Tyr+(0.0063)V
al(0.0176)Phe+(-0.1157)Trp; 0.794, 0.825, 0.849, 0.830, 0.833, 0.
836, 0.827, 0.830,
(4.3037)+(0.0038)Gln+(-0.0538)His+(-0.0059)Thr+(-0.0005)Lys+(0.0253)Phe+(-
-0.0951)Trp; 0.836, 0.856, 0.849, 0.844, 0.847, 0.859, 0.804,
0.841, (5.7897)+(-0.0922)Asn+(0.005
2)Gln+(-0.0857)Cit+(0.0278)Orn+(-0.1020)Trp; 0.801, 0.828, 0.8 49,
0.821, 0.812, 0.829, 0.823, 0.823, (4.5646)+(0.0021)Gln+(-0.0
589)His+(0.0239)Tyr+(0.0181)Phe+(-0.1088)Trp; 0.810, 0.842, 0. 849,
0.847, 0.848, 0.857, 0.844, 0.848, (5.2333)+(-0.0746)Asn+(0.
0091)Gln+(-0.0597)His+(-0.1225)Met+(0.0171)Leu+(-0.0685)Tr p;
0.811, 0.842, 0.849, 0.830, 0.840, 0.839, 0.776, 0.824,
(6.6704)+(-0.0318)His+(0.0119)Thr+(-0.0163)Arg+(-0.1329)Met+(0.0289)
Phe+(-0.0854)Trp; 0.803, 0.830, 0.849, 0.827, 0.827, 0.826, 0.823,
0.827, (5.7665)+(-0.0422)His+(-0.1658)Met+(0.0094)Lys+(0.009
8)Ile+(0.0318)Phe+(-0.0891)Trp; 0.834, 0.856, 0.849, 0.844, 0.84 7,
0.859, 0.804, 0.841, (5.7989)+(-0.0921)Asn+(0.0052)Gln+(-0.0
858)Cit+(0.0279)Orn+(-0.0006)Ile+(-0.1018)Trp; 0.806, 0.838, 0.
849, 0.827, 0.821, 0.842, 0.809, 0.827, (5.1326)+(0.0042)Gln+(-0.
0505)His+(-0.0593)Cit+(0.0075)Leu+(0.0181)Phe+(-0.1065)Trp; 0.832,
0.856, 0.849, 0.845, 0.847, 0.859, 0.804, 0.842,
(5.8035)+(-0.0922)Asn+(0.0052)Gln+(-0.0857)Cit+(0.0279)Orn+(-0.0007)Le
u+(-0.1011)Trp; 0.796, 0.832, 0.848, 0.839, 0.847, 0.854, 0.822, 0.
839,
(5.1013)+(0.0054)Gln+(-0.0516)His+(-0.1702)Met+(0.0048)Lys+(0.0079)Ile+(--
0.0660)Trp; 0.791, 0.823, 0.848, 0.829, 0.835, 0.834, 0.820, 0.828,
(4.5886)+(0.0039)Gln+(-0.0552)His+(-0.011
3)Orn+(-0.0014)Lys+(0.0255)Phe+(-0.0973)Trp; 0.811, 0.840, 0.8 48,
0.835, 0.842, 0.843, 0.801, 0.831, (6.4219)+(-0.0355)His+(0.0
092)Thr+(-0.1507)Met+(-0.0066)Orn+(0.0324)Phe+(-0.0865)Trp; 0.823,
0.854, 0.848, 0.849, 0.840, 0.854, 0.855, 0.851,
(5.1755)+(-0.1116)Asn+(0.0070)Gln+(-0.0522)His+(0.0366)Tyr+(0.0104)Phe
+(-0.0981)Trp; 0.790, 0.817, 0.848, 0.822, 0.816, 0.847, 0.829, 0.8
28, (4.9852)+(0.0031)Gln+(-0.0632)His+(-0.0023)Ala+(0.0132)L
eu+(-0.0876)Trp; 0.812, 0.843, 0.848, 0.843, 0.847, 0.862, 0.818,
0. 843, (5.1065)+(0.0045)Gln+(-0.0407)His+(-0.0023)Ala+(-0.059
5)Cit+(0.0227)Phe+(-0.0981)Trp; 0.794, 0.823, 0.848, 0.827, 0.83 3,
0.831, 0.819, 0.826, (4.5935)+(0.0037)Gln+(-0.0564)His+(-0.0
115)Orn+(0.0254)Phe+(-0.0985)Trp; 0.807, 0.838, 0.848, 0.844, 0.
858, 0.833, 0.827, 0.839, (3.3646)+(0.0045)Gln+(-0.0045)Val+(-0.
2143)Met+(0.0181)Ile+(0.0375)Phe+(-0.0948)Trp; 0.797, 0.827, 0.
848, 0.820, 0.814, 0.817, 0.826, 0.821, (4.7359)+(-0.0071)Ser+(0.
0039)Gln+(-0.0666)His+(0.0061)Val+(0.0229)Phe+(-0.1070)Trp; 0.828,
0.851, 0.848, 0.835, 0.833, 0.850, 0.795, 0.832,
(6.9364)+(-0.0552)Asn+(-0.0016)Ala+(-0.0835)Cit+(0.0294)Orn+(0.0112)Ph
e+(-0.1032)Trp; 0.806, 0.837, 0.848, 0.843, 0.846, 0.847, 0.844, 0.
843, (5.4499)+(-0.0957)Asn+(0.0078)Gln+(-0.0581)His+(-0.004
4)Orn+(0.0108)Leu+(-0.0803)Trp; 0.801, 0.830, 0.847, 0.824, 0.82 0,
0.835, 0.817, 0.825, (5.8651)+(0.0050)Ser+(-0.0458)His+(-0.1
451)Met+(0.0143)Leu+(0.0271)Phe+(-0.0868)Trp; 0.812, 0.837, 0. 847,
0.837, 0.844, 0.843, 0.813, 0.834, (6.3477)+(0.0051)Ser+(-0.
0331)Asn+(-0.0294)His+(-0.1029)Met+(0.0287)Phe+(-0.0814)Tr p;
0.827, 0.853, 0.847, 0.846, 0.843, 0.857, 0.832, 0.846,
(5.8232)+(-0.0817)Asn+(0.0079)Gln+(-0.0518)His+(-0.0593)Cit+(0.0090)Val+(-
-0.0901)Trp; 0.814, 0.844, 0.847, 0.854, 0.861, 0.865, 0.846,
0.854, (5.3017)+(-0.0842)Asn+(0.0086)Gln+(-0.0431)His+(-0.11
04)Met+(0.0125)Ile+(-0.0628)Trp; 0.805, 0.834, 0.847, 0.824, 0.8
21, 0.831, 0.808, 0.823, (5.8236)+(0.0053)Ser+(-0.0478)His+(0.0
077)Val+(-0.1340)Met+(0.0287)Phe+(-0.0904)Trp; 0.801, 0.833, 0.
847, 0.832, 0.834, 0.847, 0.809, 0.831, (5.2756)+(0.0057)Gln+(-0.
0645)His+(0.0040)Thr+(0.0085)Val+(-0.1633)Met+(-0.0737)Trp; 0.833,
0.856, 0.847, 0.842, 0.841, 0.854, 0.803, 0.839,
(5.7383)+(-0.0931)Asn+(0.0050)Gln+(-0.0875)Cit+(0.0028)Val+(0.0269)Orn
+(-0.1075)Trp; 0.800, 0.825, 0.847, 0.826, 0.835, 0.829, 0.803, 0.8
23, (4.6321)+(0.0036)Gln+(-0.0570)His+(-0.0115)Ile+(0.0249)P
he+(-0.0957)Trp; 0.800, 0.833, 0.847, 0.840, 0.850, 0.858, 0.812,
0. 838,
(5.3399)+(0.0053)Gln+(-0.0529)His+(0.0033)Thr+(-0.1680)Met+(0.0049)Lys+(--
0.0673)Trp; 0.794, 0.816, 0.847, 0.813, 0.806, 0.831, 0.814, 0.817,
(4.9732)+(0.0027)Gln+(-0.0645)His+(0.011 9)Leu+(-0.0927)Trp
[0499] List (2) of Linear Discriminants Searched in Example 6
[0500] The linear discriminants searched in Example 6 above are
listed below. Before each equation, "the value of ROC_AUC for the
pancreatic cancer group and the colorectal cancer group with
validation", "the value of ROC_AUC for the pancreatic cancer group
and the colorectal cancer group without validation", "the value of
ROC_AUC for the pancreatic cancer group and the healthy group",
"the value of ROC_AUC for the pancreatic cancer group and the other
cancers group", "the value of ROC_AUC for the pancreatic cancer
group and the lung cancer group", "the value of ROC_AUC for the
pancreatic cancer group and the prostatic cancer group", "the value
of ROC_AUC for the pancreatic cancer group and the breast cancer
group", and "the average value of the value of ROC_AUC for the
pancreatic cancer group and the lung cancer group, the value of
ROC_AUC for the pancreatic cancer group and the colorectal cancer
group, the value of ROC_AUC for the pancreatic cancer group and the
prostatic cancer group, and the value of ROC_AUC for the pancreatic
cancer group and the breast cancer group" obtained for the equation
are additionally listed.
[0501] 0.835, 0.856, 0.885, 0.856, 0.862, 0.858, 0.839, 0.853,
(4.775 0)+(0.0066)Gln+(-0.0466)His+(0.0084)Thr+(-0.1967)Met+(0.066
6)Phe+(-0.1057)Trp; 0.830, 0.847, 0.879, 0.841, 0.844, 0.850, 0.81
1, 0.838, (6.3287)+(0.0082)Ser+(-0.0354)His+(0.0106)Thr+(-0.1
818)Met+(0.0636)Phe+(-0.1048)Trp; 0.832, 0.854, 0.879, 0.857, 0.
864, 0.857, 0.845, 0.855, (4.5078)+(0.0044)Ser+(0.0068)Gln+(-0.
0446)His+(-0.1778)Met+(0.0652)Phe+(-0.1034)Trp; 0.850, 0.868,
0.875, 0.859, 0.853, 0.858, 0.859, 0.860,
(4.5131)+(0.0067)Gln+(-0.0464)His+(0.0415)Tyr+(-0.2036)Met+(0.0584)Phe+(--
0.1196)Tr p; 0.842, 0.861, 0.874, 0.847, 0.836, 0.858, 0.840,
0.849,
(5.8514)+(0.0112)Ser+(-0.0351)His+(0.0451)Tyr+(-0.1899)Met+(0.0558)P
he+(-0.1194)Trp; 0.843, 0.861, 0.874, 0.867, 0.877, 0.860, 0.857,
0. 864, (5.4146)+(-0.0732)Asn+(0.0098)Gln+(-0.0393)His+(-0.133
0)Met+(0.0569)Phe+(-0.1021)Trp; 0.833, 0.852, 0.873, 0.856, 0.86 4,
0.853, 0.846, 0.854, (4.7041)+(0.0072)Gln+(-0.0445)His+(-0.1
723)Met+(0.0010)Ile+(0.0629)Phe+(-0.1036)Trp; 0.832, 0.853, 0. 872,
0.856, 0.864, 0.853, 0.846, 0.854, (4.7480)+(0.0073)Gln+(-0.
0442)His+(-0.1698)Met+(-0.0005)Lys+(0.0629)Phe+(-0.1034)Tr p;
0.832, 0.853, 0.872, 0.856, 0.864, 0.853, 0.845, 0.854,
(4.7112)+(0.0073)Gln+(-0.0449)His+(-0.1718)Met+(0.0006)Leu+(0.0627)P
he+(-0.1037)Trp; 0.835, 0.853, 0.872, 0.857, 0.865, 0.854, 0.846,
0. 854, (4.7280)+(0.0073)Gln+(-0.0444)His+(-0.1713)Met+(0.0630)
Phe+(-0.1036)Trp; 0.832, 0.853, 0.872, 0.857, 0.866, 0.854, 0.846,
0.855, (4.7677)+(0.0072)Gln+(-0.0432)His+(-0.0008)Val+(-0.17
18)Met+(0.0634)Phe+(-0.1030)Trp; 0.834, 0.855, 0.871, 0.861, 0.8
71, 0.850, 0.852, 0.857, (4.7622)+(0.0081)Gln+(-0.0434)His+(-0.
1739)Met+(-0.0123)Orn+(0.0662)Phe+(-0.1044)Trp; 0.823, 0.842,
0.871, 0.839, 0.842, 0.846, 0.821, 0.838,
(6.1502)+(0.0114)Ser+(-0.0320)His+(-0.1569)Met+(0.0047)Ile+(0.0595)Phe+(--
0.1018)Tr p; 0.833, 0.852, 0.871, 0.861, 0.870, 0.863, 0.851,
0.859,
(4.8549)+(0.0073)Gln+(-0.0426)His+(-0.0016)Ala+(-0.1636)Met+(0.0627)Phe+(-
-0.1016)Trp; 0.835, 0.857, 0.870, 0.860, 0.870, 0.858, 0.840,
0.856, (4.6757)+(0.0083)Gln+(-0.0434)His+(-0.0124)Arg+(-0.15
13)Met+(0.0604)Phe+(-0.1006)Trp; 0.827, 0.846, 0.870, 0.838, 0.8
41, 0.840, 0.812, 0.835, (6.8948)+(-0.0343)His+(0.0126)Thr+(-0.
1757)Met+(0.0036)Ile+(0.0589)Phe+(-0.1054)Trp; 0.826, 0.847, 0.
870, 0.842, 0.848, 0.849, 0.814, 0.839, (7.1174)+(-0.0323)His+(0.
0125)Thr+(-0.0016)Ala+(-0.1639)Met+(0.0590)Phe+(-0.1035)Tr p;
0.844, 0.864, 0.869, 0.860, 0.866, 0.864, 0.833, 0.857,
(5.0647)+(0.0091)Gln+(-0.0334)His+(-0.0581)Cit+(-0.1734)Met+(0.0589)Phe+(-
-0.1056)Trp; 0.829, 0.848, 0.869, 0.838, 0.842, 0.840, 0.807,
0.834, (7.0009)+(-0.0338)His+(0.0125)Thr+(-0.1709)Met+(-0.00
04)Leu+(0.0595)Phe+(-0.1054)Trp; 0.826, 0.848, 0.869, 0.838, 0.8
42, 0.840, 0.807, 0.834, (7.0012)+(-0.0340)His+(0.0126)Thr+(-0.
1710)Met+(-0.0001)Lys+(0.0593)Phe+(-0.1054)Trp; 0.831, 0.847,
0.869, 0.838, 0.842, 0.840, 0.807, 0.834,
(6.9942)+(-0.0341)His+(0.0126)Thr+(-0.1713)Met+(0.0593)Phe+(-0.1054)Trp;
0.827, 0.8 47, 0.869, 0.839, 0.844, 0.842, 0.805, 0.835,
(7.0613)+(-0.0318)Hi
s+(0.0126)Thr+(-0.0016)Val+(-0.1729)Met+(0.0603)Phe+(-0.104 4)Trp;
0.829, 0.851, 0.869, 0.838, 0.843, 0.842, 0.796, 0.833, (7.19
12)+(-0.0326)His+(0.0151)Thr+(-0.0095)Arg+(-0.1597)Met+(0.0
574)Phe+(-0.1037)Trp; 0.824, 0.843, 0.868, 0.843, 0.851, 0.840, 0.
822, 0.839, (6.3042)+(0.0115)Thr+(-0.0104)Val+(-0.2152)Met+(0.
0227)Ile+(0.0629)Phe+(-0.1080)Trp; 0.823, 0.843, 0.868, 0.839, 0.
844, 0.846, 0.815, 0.837, (6.3043)+(0.0111)Ser+(-0.0316)His+(-0.
1509)Met+(-0.0002)Leu+(0.0599)Phe+(-0.1019)Trp; 0.822, 0.842,
0.868, 0.839, 0.844, 0.846, 0.816, 0.837,
(6.2737)+(0.0110)Ser+(-0.0321)His+(-0.1527)Met+(0.0006)Lys+(0.0599)Phe+(--
0.1022)Tr p; 0.824, 0.843, 0.868, 0.844, 0.849, 0.854, 0.823,
0.842,
(6.4322)+(0.0108)Ser+(-0.0301)His+(-0.0013)Ala+(-0.1441)Met+(0.0594)Phe+(-
-0.1003)Trp; 0.826, 0.843, 0.868, 0.839, 0.844, 0.847, 0.815,
0.837, (6.2988)+(0.0111)Ser+(-0.0317)His+(-0.1511)Met+(0.059
9)Phe+(-0.1019)Trp; 0.822, 0.842, 0.868, 0.839, 0.844, 0.847, 0.81
5, 0.837, (6.3189)+(0.0111)Ser+(-0.0312)His+(-0.0003)Val+(-0.
1512)Met+(0.0600)Phe+(-0.1017)Trp; 0.828, 0.849, 0.868, 0.840, 0.
845, 0.840, 0.808, 0.835, (7.1759)+(-0.0328)His+(0.0140)Thr+(-0.
1746)Met+(-0.0077)Orn+(0.0613)Phe+(-0.1062)Trp; 0.844, 0.863,
0.867, 0.842, 0.830, 0.848, 0.828, 0.842,
(6.5893)+(-0.0369)His+(0.0115)Thr+(0.0437)Tyr+(-0.2052)Met+(0.0547)Phe+(--
0.1221)I rp; 0.841, 0.861, 0.867, 0.842, 0.842, 0.849, 0.797,
0.837, (7.7857)
+(-0.0223)His+(0.0149)Thr+(-0.0491)Cit+(-0.1717)Met+(0.054
8)Phe+(-0.1074)Trp; 0.830, 0.848, 0.867, 0.846, 0.851, 0.854, 0.82
3, 0.844, (7.0759)+(0.0136)Ser+(-0.0459)Asn+(-0.0257)His+(-0.
1226)Met+(0.0554)Phe+(-0.1006)Trp; 0.834, 0.852, 0.866, 0.843, 0.
847, 0.842, 0.814, 0.839, (7.9229)+(-0.0447)Asn+(-0.0283)His+(0.
0142)Thr+(-0.1444)Met+(0.0542)Phe+(-0.1046)Trp; 0.824, 0.844,
0.866, 0.841, 0.845, 0.846, 0.819, 0.838,
(6.3750)+(0.0113)Ser+(-0.0310)His+(-0.1507)Met+(-0.0033)Orn+(0.0605)Phe+(-
-0.1021)T rp; 0.841, 0.857, 0.866, 0.840, 0.844, 0.848, 0.791,
0.835, (6.7740)
+(0.0068)Ser+(0.0115)Thr+(-0.0553)Cit+(-0.1877)Met+(0.0567)Phe+(-
-0.1179)Trp; 0.825, 0.845, 0.866, 0.840, 0.845, 0.849, 0.811,
0.837, (6.3684)+(0.0123)Ser+(-0.0303)His+(-0.0065)Arg+(-0.13
97)Met+(0.0585)Phe+(-0.1002)Trp; 0.833, 0.850, 0.865, 0.843, 0.8
50, 0.839, 0.811, 0.837, (6.7437)+(0.0097)Ser+(-0.0600)Asn+(0.0
098)Thr+(-0.1567)Met+(0.0563)Phe+(-0.1173)Trp; 0.826, 0.845, 0.
865, 0.854, 0.868, 0.842, 0.844, 0.850, (4.5855)+(0.0053)Gln+(-0.
0102)Val+(-0.2080)Met+(0.0200)Ile+(0.0644)Phe+(-0.1098)Trp; 0.820,
0.837, 0.865, 0.842, 0.851, 0.841, 0.828, 0.839, (5.7758)+(0.
0089)Ser+(-0.0087)Val+(-0.1895)Met+(0.0202)Ile+(0.0618)Phe+(-0.1060)Trp;
0.836, 0.852, 0.864, 0.840, 0.840, 0.845, 0.811, 0.83 7,
(6.4386)+(0.0108)Ser+(-0.0536)Cit+(-0.1663)Met+(0.0106)Il
e+(0.0523)Phe+(-0.1131)Trp; 0.833, 0.853, 0.863, 0.860, 0.872, 0.
859, 0.845, 0.857,
(4.9038)+(0.0081)Gln+(-0.0419)His+(-0.0071)Pro+(-0.1583)Met+(0.0642)Phe+(-
-0.1083)Trp; 0.842, 0.858, 0.863, 0.839, 0.838, 0.841, 0.798,
0.834, (7.1060)+(0.0135)Thr+(-0.057
2)Cit+(-0.1907)Met+(0.0101)Ile+(0.0521)Phe+(-0.1180)Trp; 0.8 29,
0.849, 0.863, 0.856, 0.865, 0.851, 0.850, 0.854, (6.3399)+(-0.1
007)Asn+(0.0081)Gln+(-0.0420)His+(-0.0000)Val+(0.0309)Phe+(-0.1053)Trp;
0.831, 0.849, 0.863, 0.856, 0.865, 0.851, 0.850, 0.85 4,
(6.3386)+(-0.1007)Asn+(0.0081)Gln+(-0.0420)His+(0.0308)Ph
e+(-0.1053)Trp; 0.828, 0.849, 0.863, 0.848, 0.847, 0.840, 0.853, 0.
847, (6.8868)+(0.0203)Ser+(-0.0083)Gly+(-0.0288)His+(-0.142
5)Met+(0.0575)Phe+(-0.1048)Trp; 0.833, 0.852, 0.863, 0.842, 0.84 5,
0.854, 0.806, 0.839, (7.0529)+(0.0115)Ser+(-0.0199)His+(-0.0
457)Cit+(-0.1445)Met+(0.0547)Phe+(-0.1032)Trp; 0.828, 0.849, 0.
862, 0.856, 0.865, 0.850, 0.851, 0.854, (6.3566)+(-0.0005)Ser+(-0.
1005)Asn+(0.0081)Gln+(-0.0420)His+(0.0307)Phe+(-0.1053)Trp; 0.821,
0.839, 0.862, 0.839, 0.849, 0.832, 0.816, 0.834, (5.5659)+(0.
0083)Ser+(-0.1741)Met+(0.0220)Ile+(-0.0162)Leu+(0.0645)Phe+(-0.1118)Trp;
0.829, 0.849, 0.862, 0.856, 0.865, 0.850, 0.852, 0.85 4,
(6.3041)+(-0.0997)Asn+(0.0082)Gln+(-0.0417)His+(-0.0012)T
hr+(0.0310)Phe+(-0.1049)Trp; 0.842, 0.861, 0.862, 0.864, 0.870, 0.
868, 0.849, 0.862,
(6.6307)+(-0.0962)Asn+(0.0095)Gln+(-0.0324)His+(-0.0535)Cit+(0.0266)Phe+(-
-0.1073)Trp; 0.845, 0.862, 0.862, 0.853, 0.864, 0.847, 0.809,
0.845,
(4.9646)+(0.0069)Gln+(0.0085)Thr+(-0.0668)Cit+(-0.2085)Met+(0.0592)Phe+(--
0.1238)Trp; 0.85 6, 0.870, 0.861, 0.849, 0.837, 0.854, 0.831,
0.848, (6.2989)+(0.010
2)Ser+(-0.0563)Cit+(0.0477)Tyr+(-0.1949)Met+(0.0483)Phe+(-0.
1330)Trp; 0.830, 0.850, 0.861, 0.858, 0.868, 0.856, 0.850, 0.856,
(6. 4072)+(-0.0961)Asn+(0.0084)Gln+(-0.0397)His+(-0.0046)Lys+(0.
0328)Phe+(-0.1032)Trp; 0.842, 0.859, 0.861, 0.836, 0.836, 0.844, 0.
780, 0.830, (7.2191)+(0.0113)Thr+(-0.0664)Cit+(-0.1726)Met+(0.
0139)Orn+(0.0485)Phe+(-0.1168)Trp; 0.833, 0.851, 0.861, 0.846, 0.
850, 0.825, 0.843, 0.842, (6.2953)+(0.0165)Ser+(-0.0095)Gly+(0.
0104)Thr+(-0.1883)Met+(0.0594)Phe+(-0.1251)Trp; 0.845, 0.861,
0.861, 0.844, 0.847, 0.848, 0.798, 0.839,
(8.2542)+(-0.0415)Asn+(0.0150)Thr+(-0.0507)Cit+(-0.1521)Met+(0.0491)Phe+(-
-0.1149)Trp; 0.838, 0.854, 0.861, 0.837, 0.837, 0.851, 0.791,
0.833, (6.584
5)+(0.0094)Ser+(-0.0666)Cit+(-0.1530)Met+(0.0177)Orn+(0.048
0)Phe+(-0.1126)Trp; 0.830, 0.850, 0.861, 0.858, 0.867, 0.852, 0.85
3, 0.856, (6.3558)+(-0.0996)Asn+(0.0084)Gln+(-0.0417)His+(-0.
0061)Orn+(0.0322)Phe+(-0.1058)Trp; 0.829, 0.849, 0.861, 0.858, 0.
870, 0.852, 0.847, 0.854, (6.4511)+(-0.1005)Asn+(0.0080)Gln+(-0.
0378)His+(-0.0054)Leu+(0.0344)Phe+(-0.1046)Trp; 0.840, 0.855,
0.861, 0.846, 0.852, 0.855, 0.808, 0.842,
(7.4662)+(0.0127)Ser+(-0.0419)Asn+(-0.0466)Cit+(-0.1258)Met+(0.0499)Phe+(-
-0.1095)T rp; 0.827, 0.849, 0.860, 0.862, 0.872, 0.867, 0.862,
0.862, (6.4302)
+(-0.0953)Asn+(0.0081)Gln+(-0.0393)His+(-0.0025)Ala+(0.032
6)Phe+(-0.1021)Trp; 0.807, 0.826, 0.860, 0.825, 0.827, 0.827, 0.81
9, 0.825, (5.6387)+(0.0034)Gln+(-0.0527)His+(0.0009)Val+(0.02
82)Phe+(-0.1097)Trp; 0.824, 0.844, 0.860, 0.841, 0.848, 0.850, 0.8
09, 0.838, (6.6200)+(0.0112)Ser+(-0.0287)His+(-0.0049)Pro+(-0.
1387)Met+(0.0598)Phe+(-0.1050)Trp; 0.821, 0.840, 0.860, 0.831, 0.
840, 0.820, 0.797, 0.824, (5.4732)+(0.0067)Ser+(0.0076)Thr+(-0.
1949)Met+(0.0028)Ile+(0.0608)Phe+(-0.1223)Trp; 0.811, 0.826, 0.
860, 0.826, 0.828, 0.828, 0.819, 0.826, (5.6897)+(0.0033)Gln+(-0.
0513)His+(0.0286)Phe+(-0.1090)Trp; 0.828, 0.847, 0.860, 0.832, 0.
843, 0.826, 0.778, 0.823, (5.7500)+(0.0081)Ser+(0.0108)Thr+(-0.
0127)Arg+(-0.1771)Met+(0.0594)Phe+(-0.1189)Trp; 0.817, 0.838,
0.859, 0.841, 0.846, 0.856, 0.821, 0.840,
(6.2129)+(0.0053)Gln+(-0.0482)His+(0.0045)Thr+(-0.1235)Met+(0.0088)Leu+(--
0.0845)Tr p; 0.837, 0.859, 0.859, 0.864, 0.870, 0.841, 0.876,
0.862,
(5.4692)+(-0.0070)Gly+(0.0085)Gln+(-0.0426)His+(-0.1550)Met+(0.0577)
Phe+(-0.1064)Trp; 0.809, 0.832, 0.859, 0.832, 0.836, 0.839, 0.818,
0.831, (5.7477)+(0.0046)Gln+(-0.0497)His+(0.0028)Val+(-0.009
7)Lys+(0.0316)Phe+(-0.1061)Trp; 0.842, 0.858, 0.859, 0.839, 0.84 3,
0.843, 0.785, 0.832, (7.5521)+(0.0141)Thr+(-0.0552)Cit+(-0.1
713)Met+(-0.0030)Lys+(0.0530)Phe+(-0.1161)Trp; 0.835, 0.854, 0.
859, 0.848, 0.842, 0.842, 0.854, 0.848, (6.1029)+(0.0480)Tyr+(-0.
0117)Val+(-0.2202)Met+(0.0273)Ile+(0.0526)Phe+(-0.1209)Trp; 0.860,
0.874, 0.859, 0.845, 0.831, 0.848, 0.818, 0.843, (6.9429)+(0.
0121)Thr+(-0.0594)Cit+(0.0463)Tyr+(-0.2151)Met+(0.0479)Phe+(-0.1367)Trp;
0.842, 0.857, 0.859, 0.845, 0.850, 0.852, 0.798, 0.83 9,
(7.5772)+(0.0133)Thr+(-0.0022)Ala+(-0.0545)Cit+(-0.1673)M
et+(0.0529)Phe+(-0.1141)Trp; 0.841, 0.858, 0.859, 0.840, 0.844, 0.
843, 0.787, 0.833, (7.4685)+(0.0135)Thr+(-0.0534)Cit+(-0.0019)
Val+(-0.1797)Met+(0.0547)Phe+(-0.1154)Trp; 0.804, 0.826, 0.859,
0.840, 0.846, 0.856, 0.843, 0.843, (5.7909)+(0.0039)Gln+(-0.048
9)His+(-0.0045)Ala+(0.0024)Val+(0.0309)Phe+(-0.1046)Trp; 0.8 25,
0.843, 0.858, 0.837, 0.852, 0.828, 0.794, 0.829, (6.0754)+(0.00
56)Ser+(0.0089)Thr+(-0.0053)Val+(-0.1927)Met+(0.0643)Phe+(-0.1147)Trp;
0.823, 0.841, 0.858, 0.832, 0.843, 0.823, 0.791, 0.824,
(5.7463)+(0.0071)Ser+(0.0085)Thr+(-0.1836)Met+(-0.0035)Lys+(0.0611)Phe+(--
0.1201)Trp; 0.841, 0.857, 0.858, 0.849, 0.849, 0.84 2, 0.838,
0.847, (7.1001)+(0.0175)Ser+(-0.0066)Gly+(-0.0442)Ci
t+(-0.1473)Met+(0.0522)Phe+(-0.1150)Trp; 0.844, 0.857, 0.858, 0.
838, 0.841, 0.840, 0.788, 0.831, (7.3543)+(0.0132)Thr+(-0.0552)C
it+(-0.1786)Met+(0.0532)Phe+(-0.1179)Trp; 0.840, 0.857, 0.858,
0.838, 0.841, 0.839, 0.788, 0.831, (7.3518)+(0.0132)Thr+(-0.055
3)Cit+(0.0002)Arg+(-0.1789)Met+(0.0532)Phe+(-0.1180)Trp; 0.8 08,
0.829, 0.858, 0.843, 0.850, 0.858, 0.841, 0.844, (5.9101)+(0.00
38)Gln+(-0.0456)His+(-0.0043)Ala+(0.0319)Phe+(-0.1032)Trp; 0. 829,
0.850, 0.857, 0.840, 0.846, 0.843, 0.801, 0.835, (7.3449)+(-0.
0311)His+(0.0137)Thr+(-0.0056)Pro+(-0.1609)Met+(0.0599)Phe+(-0.1093)Trp;
0.843, 0.859, 0.857, 0.839, 0.844, 0.841, 0.784, 0.83 2,
(7.4594)+(0.0130)Thr+(-0.0542)Cit+(-0.1740)Met+(-0.0037)L
eu+(0.0552)Phe+(-0.1163)Trp; 0.835, 0.853, 0.857, 0.839, 0.834, 0.
826, 0.832, 0.836, (4.9461)+(0.0090)Ser+(0.0425)Tyr+(-0.2123)M
et+(0.0050)Ile+(0.0541)Phe+(-0.1370)Trp; 0.823, 0.843, 0.857, 0.
839, 0.854, 0.819, 0.809, 0.831, (4.3521)+(0.0027)Ser+(0.0040)Gl
n+(0.0054)Thr+(-0.2041)Met+(0.0630)Phe+(-0.1262)Trp; 0.827, 0. 841,
0.857, 0.831, 0.840, 0.819, 0.794, 0.823, (5.5659)+(0.0066)Se
r+(0.0076)Thr+(-0.1913)Met+(0.0610)Phe+(-0.1223)Trp; 0.821, 0. 841,
0.857, 0.837, 0.847, 0.826, 0.807, 0.830, (6.0719)+(0.0090)Th
r+(-0.1880)Met+(0.0215)Ile+(-0.0165)Leu+(0.0640)Phe+(-0.115 0)Trp;
0.812, 0.833, 0.857, 0.834, 0.840, 0.840, 0.816, 0.832, (5.88
26)+(0.0045)Gln+(-0.0459)His+(-0.0090)Lys+(0.0325)Phe+(-0.1
046)Trp; 0.853, 0.869, 0.857, 0.868, 0.879, 0.860, 0.841, 0.863,
(5. 6045)+(-0.0728)Asn+(0.0103)Gln+(-0.0613)Cit+(-0.1429)Met+(0.
0505)Phe+(-0.1170)Trp; 0.836, 0.855, 0.857, 0.856, 0.870, 0.836, 0.
834, 0.849, (5.3166)+(-0.0835)Asn+(0.0074)Gln+(0.0075)Thr+(-0.
1613)Met+(0.0561)Phe+(-0.1225)Trp; 0.848, 0.863, 0.857, 0.850, 0.
842, 0.845, 0.845, 0.849, (6.4101)+(0.0131)Ser+(-0.0699)Asn+(0.
0499)Tyr+(-0.1645)Met+(0.0474)Phe+(-0.1332)Trp; 0.835, 0.854,
0.857, 0.859, 0.874, 0.843, 0.840, 0.853,
(4.9875)+(0.0058)Ser+(-0.0829)Asn+(0.0074)Gln+(-0.1472)Met+(0.0560)Phe+(--
0.1197)Tr p; 0.844, 0.861, 0.857, 0.851, 0.845, 0.823, 0.863,
0.848,
(5.7670)+(0.0170)Ser+(-0.0073)Gly+(0.0351)Tyr+(-0.1905)Met+(0.0532)P
he+(-0.1350)Trp; 0.828, 0.845, 0.857, 0.843, 0.851, 0.838, 0.821,
0. 839, (6.5849)+(0.0126)Ser+(-0.0559)Asn+(-0.1341)Met+(0.0038)
Ile+(0.0530)Phe+(-0.1133)Trp; 0.821, 0.846, 0.857, 0.833, 0.829,
0.851, 0.801, 0.832, (6.0414)+(0.0046)Gln+(-0.0396)His+(-0.067
3)Cit+(0.0130)Orn+(0.0205)Phe+(-0.1104)Trp; 0.808, 0.832, 0.85 7,
0.834, 0.842, 0.840, 0.815, 0.832, (5.9095)+(0.0044)Gln+(-0.04
48)His+(-0.0087)Lys+(-0.0016)Leu+(0.0334)Phe+(-0.1045)Trp; 0. 814,
0.836, 0.857, 0.842, 0.851, 0.860, 0.816, 0.841, (6.3887)+(0.0
050)Gln+(-0.0414)His+(0.0036)Thr+(-0.1159)Met+(0.0058)Ile+(-0.0823)Trp;
0.838, 0.859, 0.857, 0.855, 0.859, 0.876, 0.823, 0.85 4,
(7.2421)+(-0.0971)Asn+(0.0087)Gln+(-0.0275)His+(-0.0714)C
it+(0.0201)Orn+(-0.0961)Trp; 0.840, 0.859, 0.857, 0.853, 0.861, 0.
847, 0.823, 0.847, (4.7303)+(0.0076)Gln+(-0.0666)Cit+(-0.1912)
Met+(0.0082)Ile+(0.0548)Phe+(-0.1207)Trp
[0502] List (1) of Logistic Regression Equations Searched in
Example 7
[0503] The logistic regression equations searched in Example 7
above are listed below. Before each equation, "the value of ROC_AUC
for the pancreatic cancer group and the prostatic cancer group with
validation", "the value of ROC_AUC for the pancreatic cancer group
and the prostatic cancer group without validation", "the value of
ROC_AUC for the pancreatic cancer group and the healthy group",
"the value of ROC_AUC for the pancreatic cancer group and the other
cancers group", "the value of ROC_AUC for the pancreatic cancer
group and the lung cancer group", "the value of ROC_AUC for the
pancreatic cancer group and the colorectal cancer group", and "the
average value of the value of ROC_AUC for the pancreatic cancer
group and the lung cancer group, the value of ROC_AUC for the
pancreatic cancer group and the colorectal cancer group, and the
value of ROC_AUC for the pancreatic cancer group and the prostatic
cancer group" obtained for the equation are additionally
listed.
[0504] 0.877, 0.907, 0.895, 0.804, 0.799, 0.752, 0.819,
(3.0499)+(0.
0406)Ser+(-0.0121)Ala+(-0.0402)Val+(-0.1789)Met+(0.1361)Il e;
0.874, 0.914, 0.889, 0.824, 0.829, 0.766, 0.836, (1.8050)+(0.028
7)Ser+(0.0081)Gln+(-0.0133)Ala+(-0.0421)Val+(-0.2379)Met+(0.
1384)Ile; 0.873, 0.911, 0.872, 0.841, 0.854, 0.785, 0.850, (3.2506)
+(0.0146)Gln+(-0.0127)Ala+(-0.0711)Cit+(-0.0454)Val+(-0.217
7)Met+(0.1443)Ile; 0.872, 0.909, 0.906, 0.801, 0.796, 0.747, 0.817,
(3.3965)+(0.0311)Ser+(0.0246)Thr+(-0.0128)Ala+(-0.0466)Val+(-0.2635)Met+(-
0.1591)Ile; 0.872, 0.909, 0.898, 0.804, 0.798, 0.75 2, 0.820,
(1.9444)+(0.0409)Ser+(-0.0141)Ala+(-0.0498)Val+(-0.
2446)Met+(0.0197)Lys+(0.1613)Ile; 0.871, 0.906, 0.896, 0.810, 0.
813, 0.753, 0.824, (3.0424)+(0.0387)Ser+(0.0297)His+(-0.0131)A
la+(-0.0487)Val+(-0.2265)Met+(0.1561)Ile; 0.871, 0.910, 0.897,
0.808, 0.801, 0.761, 0.824,
(3.3274)+(0.0409)Ser+(-0.0117)Ala+(-0.0293)Cit+(-0.0398)Val+(-0.1603)Met+-
(0.1354)Ile; 0.871, 0. 910, 0.886, 0.795, 0.791, 0.736, 0.812,
(2.9136)+(0.0391)Ser+(-0.
0129)Ala+(-0.0439)Val+(-0.1895)Met+(0.1445)Ile+(0.0213)Trp; 0.871,
0.909, 0.904, 0.809, 0.804, 0.758, 0.824, (2.5705)+(0.0423)
Ser+(-0.0115)Ala+(-0.0427)Val+(-0.1878)Met+(0.1360)Ile+(0.0
134)Phe; 0.871, 0.907, 0.894, 0.803, 0.797, 0.753, 0.819,
(3.0263)+(0.0422)Ser+(-0.0117)Ala+(-0.0466)Val+(-0.1894)Met+(0.1237)
Ile+(0.0178)Leu; 0.870, 0.913, 0.906, 0.806, 0.790, 0.766, 0.823,
(2.4936)+(0.0432)Ser+(-0.0118)Ala+(0.0462)Tyr+(-0.0485)Val+(-0.2565)Met+(-
0.1511)Ile; 0.870, 0.906, 0.897, 0.803, 0.796, 0.75 4, 0.819,
(3.0382)+(0.0402)Ser+(-0.0120)Ala+(-0.0407)Val+(-0.
1802)Met+(0.0043)Orn+(0.1345)Ile; 0.869, 0.906, 0.893, 0.800, 0.
794, 0.747, 0.816,
(3.1053)+(0.0413)Ser+(-0.0187)Asn+(-0.0122)Ala+(-0.0403)Val+(-0.1520)Met+-
(0.1375)Ile; 0.869, 0.911, 0.844, 0.821, 0.852, 0.728, 0.830,
(3.6477)+(-0.1046)Asn+(0.0141)Gln+(-0.0129)Ala+(-0.0256)Pro+(-0.0496)Val+-
(0.1669)Ile; 0.868, 0. 906, 0.842, 0.816, 0.830, 0.745, 0.827,
(3.9145)+(-0.1050)Asn+(0.
0147)Gln+(-0.0158)Ala+(-0.0820)Cit+(-0.0437)Val+(0.1389)Il e;
0.867, 0.908, 0.854, 0.793, 0.801, 0.717, 0.808, (2.5456)+(0.025
9)Ser+(-0.1002)Asn+(0.0075)Gln+(-0.0164)Ala+(-0.0403)Val+(0.
1270)Ile; 0.865, 0.898, 0.867, 0.777, 0.776, 0.711, 0.795, (3.8433)
+(0.0389)Ser+(-0.0574)Asn+(-0.0145)Ala+(-0.0373)Cit+(-0.039
4)Val+(0.1275)Ile; 0.865, 0.912, 0.902, 0.802, 0.793, 0.753, 0.819,
(2.8640)+(0.0372)Ser+(-0.0135)Ala+(0.0205)Arg+(-0.0437)Val+(-0.2293)Met+(-
0.1532)Ile; 0.865, 0.914, 0.884, 0.822, 0.829, 0.76 1, 0.835,
(3.6660)+(0.0086)Gln+(0.0244)Thr+(-0.0136)Ala+(-0.0
488)Val+(-0.2914)Met+(0.1546)Ile; 0.865, 0.907, 0.891, 0.811, 0.
816, 0.749, 0.824, (3.7418)+(0.0379)Ser+(-0.0109)Ala+(-0.0113)
Pro+(-0.0427)Val+(-0.1565)Met+(0.1486)Ile; 0.864, 0.917, 0.864,
0.842, 0.867, 0.765, 0.850,
(3.2795)+(0.0145)Gln+(-0.0114)Ala+(-0.0234)Pro+(-0.0513)Val+(-0.2086)Met+-
(0.1692)Ile; 0.864, 0. 904, 0.880, 0.807, 0.804, 0.757, 0.822,
(6.4815)+(-0.0134)Ala+(-0.
0621)Cit+(0.0404)Arg+(-0.0464)Val+(-0.1757)Met+(0.1534)Ile; 0.864,
0.906, 0.896, 0.807, 0.799, 0.762, 0.822, (6.2885)+(0.0375)
Thr+(-0.0124)Ala+(-0.0376)Cit+(-0.0494)Val+(-0.2412)Met+(0.
1628)Ile; 0.864, 0.898, 0.861, 0.764, 0.762, 0.690, 0.783, (2.7856)
+(0.0404)Ser+(-0.0938)Asn+(-0.0176)Ala+(-0.0470)Val+(0.016
0)Lys+(0.1421)Ile; 0.863, 0.898, 0.864, 0.772, 0.771, 0.701, 0.790,
(3.4932)+(0.0376)Ser+(-0.0658)Asn+(-0.0152)Ala+(-0.0395)Val
+(0.1263)Ile; 0.863, 0.892, 0.848, 0.777, 0.779, 0.711, 0.794, (3.8
688)+(0.0304)Ser+(-0.0164)Ala+(-0.0455)Cit+(-0.0380)Val+(0.
1120)Ile; 0.862, 0.892, 0.838, 0.768, 0.773, 0.691, 0.785, (3.4307)
+(0.0273)Ser+(-0.0177)Ala+(-0.0373)Val+(0.1054)Ile; 0.862, 0. 905,
0.831, 0.818, 0.845, 0.732, 0.827, (3.7841)+(0.0113)Gln+(-0.
0162)Ala+(-0.0585)Cit+(-0.0201)Pro+(-0.0455)Val+(0.1396)Il e;
0.862, 0.892, 0.885, 0.830, 0.830, 0.794, 0.839, (1.4679)+(0.022
4)Ser+(0.0106)Gln+(-0.0645)Cit+(-0.0500)Val+(-0.3305)Met+(0.
1556)Ile; 0.861, 0.902, 0.862, 0.765, 0.761, 0.694, 0.786, (3.4150)
+(0.0353)Ser+(-0.0913)Asn+(-0.0170)Ala+(0.0192)Arg+(-0.041
9)Val+(0.1393)Ile; 0.861, 0.911, 0.870, 0.828, 0.842, 0.761, 0.838,
(3.2184)+(0.0111)Gln+(-0.0132)Ala+(-0.0439)Val+(-0.2077)Met
+(0.1344)Ile; 0.861, 0.894, 0.830, 0.801, 0.823, 0.720, 0.812, (3.7
223)+(-0.0870)Asn+(0.0100)Gln+(-0.0160)Ala+(-0.0424)Val+(0.
1267)Ile; 0.861, 0.898, 0.864, 0.772, 0.769, 0.706, 0.791, (3.4579)
+(0.0372)Ser+(-0.0704)Asn+(-0.0149)Ala+(-0.0403)Val+(0.008
5)Orn+(0.1246)Ile; 0.860, 0.903, 0.822, 0.820, 0.840, 0.745, 0.829,
(2.5839)+(0.0123)Gln+(-0.0180)Ala+(-0.0933)Cit+(-0.0160)Pro
+(0.1735)Ile+(-0.0857)Leu; 0.860, 0.907, 0.895, 0.804, 0.796, 0.7
56, 0.820, (3.2301)+(0.0443)Ser+(-0.0029)Gly+(-0.0119)Ala+(-0.
0403)Val+(-0.1807)Met+(0.1358)Ile; 0.859, 0.890, 0.905, 0.800, 0.
783, 0.774, 0.816, (2.8315)+(0.0312)Ser+(0.0223)Thr+(-0.0416)C
it+(-0.0522)Val+(-0.3341)Met+(0.1697)Ile; 0.859, 0.895, 0.843,
0.785, 0.798, 0.705, 0.799,
(4.0937)+(0.0273)Ser+(-0.0151)Ala+(-0.0154)Pro+(-0.0408)Val+(0.1272)Ile;
0.859, 0.895, 0.825, 0.8 07, 0.838, 0.715, 0.816,
(3.6909)+(0.0090)Gln+(-0.0160)Ala+(-0.
0233)Pro+(-0.0459)Val+(0.1389)Ile; 0.859, 0.895, 0.897, 0.795, 0.
765, 0.780, 0.814, (2.3171)+(0.0426)Ser+(-0.0369)Cit+(0.0544)T
yr+(-0.0577)Val+(-0.3487)Met+(0.1682)Ile; 0.859, 0.905, 0.866,
0.789, 0.796, 0.713, 0.805,
(4.1103)+(0.0358)Ser+(-0.0610)Asn+(-0.0129)Ala+(-0.0140)Pro+(-0.0425)Val+-
(0.1452)Ile; 0.859, 0. 900, 0.861, 0.766, 0.765, 0.693, 0.786,
(3.6380)+(0.0339)Ser+(-0.
0808)Asn+(0.0105)Thr+(-0.0161)Ala+(-0.0412)Val+(0.1322)Ile; 0.859,
0.894, 0.860, 0.768, 0.767, 0.700, 0.787, (3.4924)+(0.0388)
Ser+(-0.0697)Asn+(-0.0149)Ala+(-0.0454)Val+(0.1160)Ile+(0.0
159)Leu; 0.858, 0.901, 0.852, 0.829, 0.840, 0.772, 0.838,
(1.8392)+(0.0145)Gln+(-0.0164)Ala+(-0.0957)Cit+(-0.1504)Met+(0.1590)
Ile+(-0.0746)Leu; 0.858, 0.896, 0.846, 0.822, 0.848, 0.743, 0.829,
(3.2627)+(-0.1568)Asn+(0.0168)Gln+(-0.0623)Cit+(-0.0290)Pro
+(-0.0560)Val+(0.1759)Ile; 0.858, 0.900, 0.889, 0.804, 0.802, 0.7
52, 0.818, (5.9958)+(0.0352)Thr+(-0.0126)Ala+(-0.0500)Val+(-0.
2580)Met+(0.1616)Ile; 0.858, 0.885, 0.893, 0.798, 0.782, 0.771, 0.
813, (2.5428)+(0.0397)Ser+(-0.0359)Cit+(-0.0470)Val+(-0.258
0)Met+(0.1513)Ile; 0.858, 0.914, 0.874, 0.829, 0.838, 0.769, 0.840,
(3.0001)+(0.0109)Gln+(-0.0126)Ala+(0.0335)Tyr+(-0.0501)Val+(-0.2630)Met+(-
0.1449)Ile; 0.858, 0.898, 0.854, 0.775, 0.782, 0.69 6, 0.792,
(3.5574)+(0.0359)Ser+(-0.0834)Asn+(0.0225)His+(-0.0
163)Ala+(-0.0455)Val+(0.1400)Ile; 0.858, 0.894, 0.886, 0.826, 0.
828, 0.787, 0.836, (2.7972)+(0.0118)Gln+(0.0191)Thr+(-0.0733)C
it+(-0.0554)Val+(-0.3788)Met+(0.1690)Ile; 0.858, 0.894, 0.833,
0.770, 0.762, 0.712, 0.789,
(3.0835)+(0.0252)Ser+(-0.0192)Ala+(-0.0851)Cit+(0.0179)Arg+(0.1508)Ile+(--
0.0734)Leu; 0.857, 0.8 90, 0.836, 0.776, 0.773, 0.718, 0.793,
(3.0854)+(0.0294)Ser+(-0.0
175)Ala+(-0.0646)Cit+(0.1380)Ile+(-0.0672)Leu; 0.857, 0.900, 0.
890, 0.801, 0.797, 0.750, 0.815, (6.0223)+(0.0410)Thr+(-0.0122)A
la+(-0.0638)Val+(-0.2943)Met+(0.1436)Ile+(0.0347)Leu; 0.857, 0.910,
0.870, 0.830, 0.848, 0.760, 0.839,
(3.1052)+(0.0120)Gln+(-0.0135)Ala+(-0.0435)Val+(-0.2153)Met+(-0.0102)Orn+-
(0.1397)I le; 0.857, 0.897, 0.853, 0.791, 0.800, 0.717, 0.805,
(4.2897)+(0.03
03)Ser+(-0.0146)Ala+(-0.0342)Cit+(-0.0130)Pro+(-0.0403)Val+(0.1270)Ile;
0.857, 0.892, 0.867, 0.828, 0.832, 0.786, 0.837, (2.58
32)+(0.0139)Gln+(-0.0769)Cit+(-0.0528)Val+(-0.3151)Met+(0.1
570)Ile; 0.857, 0.895, 0.877, 0.827, 0.828, 0.789, 0.837,
(2.6930)+(0.0125)Gln+(-0.0905)Cit+(0.0196)Arg+(-0.0556)Val+(-0.3549)Met+(-
0.1713)Ile; 0.857, 0.895, 0.854, 0.765, 0.766, 0.691, 0.784,
(3.4388)+(0.0368)Ser+(-0.0683)Asn+(-0.0158)Ala+(-0.0419)Val
+(0.1308)Ile+(0.0135)Trp; 0.857, 0.906, 0.875, 0.827, 0.842, 0.76
3, 0.837, (2.9477)+(0.0100)Gln+(-0.0140)Ala+(-0.0502)Val+(-0.
2536)Met+(0.0138)Lys+(0.1490)Ile; 0.857, 0.900, 0.870, 0.846, 0.
864, 0.790, 0.851, (2.5434)+(0.0169)Gln+(-0.0594)Cit+(-0.0230)
Pro+(-0.0575)Val+(-0.2953)Met+(0.1812)Ile; 0.857, 0.889, 0.891,
0.799, 0.775, 0.780, 0.815,
(2.6896)+(0.0379)Ser+(-0.0547)Cit+(-0.0483)Val+(-0.2479)Met+(0.0250)Orn+(-
0.1398)Ile; 0.856, 0.8 93, 0.838, 0.768, 0.772, 0.691, 0.786,
(3.4271)+(0.0272)Ser+(-0.0
177)Ala+(-0.0373)Val+(0.0008)Orn+(0.1051)Ile; 0.856, 0.899, 0. 836,
0.788, 0.787, 0.726, 0.804, (3.3509)+(0.0284)Ser+(-0.0162)A
la+(-0.0601)Cit+(-0.0084)Pro+(0.1519)Ile+(-0.0706)Leu; 0.856,
0.898, 0.871, 0.828, 0.824, 0.795, 0.839,
(2.5863)+(0.0143)Gln+(-0.0787)Cit+(0.0496)Tyr+(-0.0626)Val+(-0.4003)Met+(-
0.1719)Il e; 0.856, 0.898, 0.872, 0.810, 0.818, 0.748, 0.821,
(5.9124)+(0.007
8)Gly+(-0.0121)Ala+(-0.0412)Cit+(-0.0420)Val+(-0.0905)Met+(0.1313)Ile;
0.855, 0.895, 0.843, 0.778, 0.768, 0.725, 0.796, (3.05
05)+(0.0335)Ser+(-0.0316)Asn+(-0.0166)Ala+(-0.0603)Cit+(0.1
406)Ile+(-0.0641)Leu; 0.855, 0.899, 0.849, 0.775, 0.774, 0.706, 0.
793, (3.8752)+(0.0268)Ser+(-0.0182)Ala+(-0.0618)Cit+(0.0162)
Arg+(-0.0393)Val+(0.1173)Ile; 0.855, 0.896, 0.852, 0.781, 0.781,
0.715, 0.797,
(3.9231)+(0.0304)Ser+(-0.0164)Ala+(-0.0504)Cit+(-0.0319)Val+(0.124-
0)Ile+(-0.0164)Leu; 0.855, 0.903, 0.887, 0.8 03, 0.793, 0.760,
0.819, (5.7717)+(0.0386)Thr+(-0.0122)Ala+(0.0
496)Tyr+(-0.0607)Val+(-0.3491)Met+(0.1793)Ile; 0.855, 0.900, 0.
832, 0.801, 0.826, 0.712, 0.812, (3.1275)+(0.0128)Ser+(0.0072)Gl
n+(-0.0164)Ala+(-0.0220)Pro+(-0.0443)Val+(0.1356)Ile; 0.855, 0.897,
0.824, 0.809, 0.841, 0.715, 0.817,
(3.7322)+(0.0096)Gln+(-0.0155)Ala+(-0.0241)Pro+(-0.0450)Val+(-0.0031)Lys+-
(0.1382)I le; 0.855, 0.904, 0.889, 0.812, 0.818, 0.752, 0.825,
(6.5665)+(0.03
43)Thr+(-0.0114)Ala+(-0.0117)Pro+(-0.0524)Val+(-0.2395)Met+(0.1748)Ile;
0.854, 0.907, 0.862, 0.827, 0.841, 0.762, 0.837, (3.27
24)+(-0.0426)Asn+(0.0120)Gln+(-0.0133)Ala+(-0.0438)Val+(-0.
1613)Met+(0.1368)Ile; 0.854, 0.891, 0.895, 0.793, 0.766, 0.775, 0.
811, (1.8590)+(0.0421)Ser+(0.0528)Tyr+(-0.0584)Val+(-0.3709)
Met+(0.1702)Ile; 0.854, 0.900, 0.888, 0.802, 0.799, 0.750, 0.816,
(6.0654)+(-0.0155)Asn+(0.0360)Thr+(-0.0127)Ala+(-0.0499)Val
+(-0.2400)Met+(0.1630)Ile; 0.854, 0.897, 0.869, 0.773, 0.773, 0.7
02, 0.791, (3.2158)+(0.0385)Ser+(-0.0678)Asn+(-0.0149)Ala+(-0.
0410)Val+(0.1264)Ile+(0.0079)Phe; 0.854, 0.900, 0.889, 0.803, 0.
802, 0.749, 0.817, (6.0284)+(0.0359)Thr+(-0.0127)Ala+(-0.0499)
Val+(-0.2595)Met+(-0.0029)Orn+(0.1631)Ile; 0.854, 0.898, 0.888,
0.806, 0.808, 0.751, 0.819,
(5.6950)+(0.0289)Thr+(-0.0136)Ala+(-0.0545)Val+(-0.2696)Met+(0.0117)Lys+(-
0.1676)Ile; 0.854, 0.8 94, 0.845, 0.768, 0.770, 0.694, 0.786,
(3.4259)+(0.0290)Ser+(-0.0
084)His+(-0.0170)Ala+(-0.0353)Val+(0.1023)Ile; 0.854, 0.893, 0.
837, 0.768, 0.773, 0.691, 0.785, (3.4296)+(0.0274)Ser+(-0.0177)A
la+(-0.0383)Val+(0.1035)Ile+(0.0028)Leu; 0.854, 0.901, 0.824, 0.
814, 0.824, 0.753, 0.826, (2.5302)+(-0.0860)Asn+(0.0153)Gln+(-0.
0185)Ala+(-0.1030)Cit+(0.1517)Ile+(-0.0712)Leu; 0.854, 0.899,
0.848, 0.804, 0.824, 0.722, 0.815, (5.9360)+(0.0082)Gly+(-0.013
4)Ala+(-0.0388)Cit+(-0.0144)Pro+(-0.0424)Val+(0.1336)Ile; 0. 854,
0.893, 0.830, 0.802, 0.824, 0.720, 0.812, (3.7050)+(-0.0869)A
sn+(0.0102)Gln+(-0.0161)Ala+(-0.0422)Val+(-0.0021)Orn+(0.12 73)Ile;
0.854, 0.891, 0.848, 0.777, 0.779, 0.711, 0.794,
(3.8714)+(0.0303)Ser+(0.0005)His+(-0.0164)Ala+(-0.0456)Cit+(-0.0381)
Val+(0.1122)Ile; 0.854, 0.894, 0.891, 0.808, 0.793, 0.780, 0.822,
(0.8790)+(0.0322)Ser+(0.0063)Gln+(0.0517)Tyr+(-0.0600)Val+(-0.4205)Met+(0-
.1715)Ile; 0.853, 0.895, 0.838, 0.796, 0.809, 0.72 2, 0.809,
(3.2537)+(0.0140)Ser+(0.0069)Gln+(-0.0181)Ala+(-0.0
663)Cit+(-0.0401)Val+(0.1149)Ile; 0.853, 0.892, 0.899, 0.796, 0.
780, 0.764, 0.812, (2.5496)+(0.0324)Ser+(0.0274)Thr+(-0.0707)V
al+(-0.4062)Met+(0.1451)Ile+(0.0461)Leu; 0.853, 0.910, 0.872, 0.
824, 0.835, 0.760, 0.835, (3.3387)+(0.0097)Gln+(-0.0140)Ala+(0.
0136)Arg+(-0.0454)Val+(-0.2275)Met+(0.1422)Ile; 0.853, 0.900,
0.884, 0.807, 0.813, 0.747, 0.820,
(5.8451)+(0.0314)His+(0.0340)Thr+(-0.0137)Ala+(-0.0592)Val+(-0.3052)Met+(-
0.1829)Ile; 0.85 3, 0.894, 0.855, 0.781, 0.775, 0.727, 0.798,
(3.9165)+(0.0302)Ser+(-0.0157)Ala+(-0.0654)Cit+(-0.0399)Val+(0.0235)Orn+(-
0.1034) Ile; 0.853, 0.892, 0.846, 0.777, 0.778, 0.710, 0.793,
(3.8648)+(0.0
302)Ser+(-0.0165)Ala+(-0.0456)Cit+(-0.0383)Val+(0.1125)Ile+(0.0023)Trp;
0.853, 0.894, 0.899, 0.799, 0.779, 0.773, 0.815, (2.50
79)+(0.0358)Ser+(-0.0597)Cit+(0.0250)Arg+(-0.0515)Val+(-0.3
189)Met+(0.1728)Ile; 0.853, 0.894, 0.829, 0.801, 0.809, 0.735, 0.8
13, (2.1340)+(0.0131)Ser+(0.0081)Gln+(-0.0194)Ala+(-0.0888)C
it+(0.1439)Ile+(-0.0743)Leu; 0.853, 0.902, 0.861, 0.769, 0.764, 0.
702, 0.789, (3.3789)+(0.0378)Ser+(-0.0746)Asn+(-0.0156)Ala+(0.
0166)Tyr+(-0.0425)Val+(0.1301)Ile; 0.853, 0.885, 0.891, 0.794, 0.
779, 0.762, 0.809,
(2.1611)+(0.0392)Ser+(-0.0480)Val+(-0.2807)Met+(0.1521)Ile; 0.852,
0.888, 0.897, 0.791, 0.766, 0.770, 0.808,
(2.2714)+(0.0316)Ser+(0.0231)Thr+(0.0575)Tyr+(-0.0649)Val+(-0.4616)Met+(0-
.1911)Ile; 0.852, 0.886, 0.889, 0.804, 0.793, 0.77 3, 0.817,
(2.5336)+(0.0383)Ser+(0.0215)His+(-0.0411)Cit+(-0.0
534)Val+(-0.2934)Met+(0.1659)Ile; 0.852, 0.878, 0.885, 0.795, 0.
787, 0.759, 0.808, (5.2691)+(0.0342)Thr+(-0.0406)Cit+(-0.0551)
Val+(-0.3347)Met+(0.1739)Ile; 0.852, 0.895, 0.844, 0.785, 0.799,
0.705, 0.800,
(4.0912)+(0.0270)Ser+(-0.0151)Ala+(-0.0157)Pro+(-0.0411)Val+(0.003-
4)Orn+(0.1262)Ile; 0.852, 0.892, 0.847, 0.77 7, 0.778, 0.711,
0.794, (3.9086)+(0.0303)Ser+(-0.0164)Ala+(-0.0
455)Cit+(-0.0377)Val+(0.1120)Ile+(-0.0011)Phe; 0.852, 0.889, 0.
816, 0.801, 0.813, 0.734, 0.812, (2.7806)+(0.0089)Gln+(-0.0202)A
la+(-0.1039)Cit+(0.0130)Arg+(0.1532)Ile+(-0.0795)Leu
[0505] List (1) of Linear Discriminants Searched in Example 7
[0506] The linear discriminants searched in Example 7 above are
listed below. Before each equation, "the value of ROC_AUC for the
pancreatic cancer group and the prostatic cancer group with
validation", "the value of ROC_AUC for the pancreatic cancer group
and the prostatic cancer group without validation", "the value of
ROC_AUC for the pancreatic cancer group and the healthy group",
"the value of ROC_AUC for the pancreatic cancer group and the other
cancers group", "the value of ROC_AUC for the pancreatic cancer
group and the lung cancer group", "the value of ROC_AUC for the
pancreatic cancer group and the colorectal cancer group", and "the
average value of the value of ROC_AUC for the pancreatic cancer
group and the lung cancer group, the value of ROC_AUC for the
pancreatic cancer group and the colorectal cancer group, and the
value of ROC_AUC for the pancreatic cancer group and the prostatic
cancer group" obtained for the equation are additionally
listed.
[0507] 0.889, 0.914, 0.864, 0.834, 0.844, 0.774, 0.844,
(5.0859)+(0.
0109)Gln+(-0.0171)Ala+(-0.0452)Cit+(-0.0389)Val+(-0.1548)Me
t+(0.1284)Ile; 0.888, 0.912, 0.883, 0.817, 0.820, 0.758, 0.830, (4.
2244)+(0.0244)Ser+(0.0058)Gln+(-0.0176)Ala+(-0.0382)Val+(-0.
1788)Met+(0.1319)Ile; 0.888, 0.907, 0.886, 0.803, 0.798, 0.751, 0.
818, (5.2330)+(0.0342)Ser+(-0.0170)Ala+(-0.0368)Val+(-0.150
9)Met+(0.1323)Ile; 0.888, 0.911, 0.905, 0.814, 0.811, 0.763, 0.828,
(3.9212)+(0.0380)Ser+(-0.0160)Ala+(-0.0426)Val+(-0.1846)Met
+(0.1388)Ile+(0.0358)Phe; 0.887, 0.909, 0.852, 0.820, 0.833, 0.75
2, 0.832, (5.2382)+(0.0091)Gln+(-0.0176)Ala+(-0.0397)Val+(-0.
1581)Met+(0.1265)Ile; 0.886, 0.907, 0.887, 0.805, 0.799, 0.756, 0.
821, (5.4168)+(0.0347)Ser+(-0.0165)Ala+(-0.0246)Cit+(-0.036
1)Val+(-0.1422)Met+(0.1331)Ile; 0.886, 0.911, 0.887, 0.801, 0.79 4,
0.747, 0.817, (5.4113)+(0.0284)Ser+(0.0124)Thr+(-0.0177)Ala
+(-0.0384)Val+(-0.1808)Met+(0.1375)Ile; 0.886, 0.910, 0.894, 0.
805, 0.791, 0.763, 0.822, (4.9603)+(0.0350)Ser+(-0.0175)Ala+(0.
0518)Tyr+(-0.0451)Val+(-0.2283)Met+(0.1452)Ile; 0.885, 0.909,
0.885, 0.804, 0.800, 0.750, 0.820, (5.1334)+(0.0336)Ser+(0.0076)
His+(-0.0172)Ala+(-0.0387)Val+(-0.1574)Met+(0.1365)Ile; 0.88 5,
0.909, 0.886, 0.800, 0.794, 0.747, 0.816,
(5.0407)+(0.0361)Ser+(-0.0168)Ala+(-0.0446)Val+(-0.1632)Met+(0.1200)Ile+(-
0.0226) Leu; 0.885, 0.909, 0.881, 0.799, 0.795, 0.741, 0.815,
(5.1188)+(0.0
337)Ser+(-0.0174)Ala+(-0.0385)Val+(-0.1546)Met+(0.1360)Ile+(0.0103)Trp;
0.885, 0.912, 0.859, 0.836, 0.858, 0.761, 0.844, (5.10
53)+(0.0114)Gln+(-0.0154)Ala+(-0.0193)Pro+(-0.0456)Val+(-0.
1536)Met+(0.1567)Ile; 0.885, 0.909, 0.839, 0.816, 0.831, 0.742, 0.
827, (5.6785)+(-0.0836)Asn+(0.0106)Gln+(-0.0184)Ala+(-0.044
5)Cit+(-0.0374)Val+(0.1214)Ile; 0.885, 0.904, 0.855, 0.779, 0.77 6,
0.712, 0.797, (5.8722)+(0.0304)Ser+(-0.0707)Asn+(-0.0184)Al
a+(-0.0355)Val+(0.1234)Ile; 0.884, 0.907, 0.841, 0.819, 0.846, 0.
732, 0.828,
(5.7402)+(-0.0940)Asn+(0.0119)Gln+(-0.0163)Ala+(-0.0211)Pro+(-0.04-
49)Val+(0.1544)Ile; 0.884, 0.908, 0.887, 0.803, 0.799, 0.749,
0.819, (4.8169)+(0.0329)Ser+(-0.0175)Ala+(-0.039
4)Val+(-0.1681)Met+(0.0072)Lys+(0.1378)Ile; 0.884, 0.908, 0.84 9,
0.797, 0.804, 0.725, 0.813, (5.0488)+(0.0206)Ser+(-0.0938)Asn
+(0.0061)Gln+(-0.0191)Ala+(-0.0368)Val+(0.1230)Ile; 0.884, 0. 906,
0.883, 0.801, 0.797, 0.747, 0.817, (5.4787)+(0.0353)Ser+(-0.
0245)Asn+(-0.0168)Ala+(-0.0367)Val+(-0.1284)Met+(0.1335)Il e;
0.883, 0.907, 0.887, 0.799, 0.793, 0.747, 0.816, (5.1392)+(0.030
5)Ser+(-0.0182)Ala+(0.0142)Arg+(-0.0382)Val+(-0.1711)Met+(0.
1393)Ile; 0.883, 0.906, 0.859, 0.793, 0.799, 0.720, 0.808, (6.2281)
+(0.0316)Ser+(-0.0654)Asn+(-0.0163)Ala+(-0.0145)Pro+(-0.039
7)Val+(0.1469)Ile; 0.883, 0.906, 0.832, 0.816, 0.839, 0.733, 0.826,
(5.0766)+(0.0094)Gln+(-0.0180)Ala+(-0.0436)Cit+(-0.0191)Pro
+(-0.0418)Val+(0.1394)Ile; 0.883, 0.905, 0.888, 0.801, 0.796, 0.7
48, 0.817, (5.2204)+(0.0337)Ser+(-0.0169)Ala+(-0.0373)Val+(-0.
1522)Met+(0.0065)Orn+(0.1298)Ile; 0.882, 0.907, 0.886, 0.802, 0.
796, 0.751, 0.818, (5.3105)+(0.0362)Ser+(-0.0016)Gly+(-0.0168)
Ala+(-0.0368)Val+(-0.1527)Met+(0.1323)Ile; 0.882, 0.910, 0.862,
0.822, 0.825, 0.767, 0.834,
(5.1908)+(0.0087)Gln+(-0.0179)Ala+(0.0430)Tyr+(-0.0465)Val+(-0.2179)Met+(-
0.1368)Ile; 0.881, 0.9 08, 0.852, 0.820, 0.833, 0.752, 0.831,
(5.2315)+(0.0091)Gln+(-0.0
176)Ala+(-0.0396)Val+(-0.1582)Met+(-0.0007)Orn+(0.1268)Ile; 0.881,
0.907, 0.884, 0.809, 0.814, 0.747, 0.822,
(5.5923)+(0.0347)Ser+(-0.0153)Ala+(-0.0130)Pro+(-0.0404)Val+(-0.1363)Met+-
(0. 1521)Ile; 0.880, 0.907, 0.847, 0.822, 0.837, 0.754, 0.833,
(5.5183)
+(-0.0448)Asn+(0.0101)Gln+(-0.0173)Ala+(-0.0398)Val+(-0.121
7)Met+(0.1286)Ile; 0.880, 0.913, 0.862, 0.830, 0.840, 0.769, 0.841,
(3.2318)+(0.0105)Gln+(-0.0278)Pro+(0.0580)Tyr+(-0.0620)Val+(-0.2907)Met+(-
0.1812)Ile; 0.880, 0.902, 0.861, 0.784, 0.781, 0.72 1, 0.801,
(5.9949)+(0.0308)Ser+(-0.0636)Asn+(-0.0180)Ala+(-0.
0257)Cit+(-0.0348)Val+(0.1242)Ile; 0.879, 0.908, 0.850, 0.819, 0.
832, 0.749, 0.830, (5.2157)+(0.0090)Gln+(-0.0177)Ala+(-0.0402)
Val+(-0.1589)Met+(0.1276)Ile+(0.0029)Trp; 0.879, 0.902, 0.857,
0.780, 0.776, 0.717, 0.798,
(5.8969)+(0.0298)Ser+(-0.0750)Asn+(-0.0183)Ala+(-0.0364)Val+(0.0106)Orn+(-
0.1198)Ile; 0.879, 0.9 08, 0.853, 0.820, 0.833, 0.753, 0.831,
(5.1537)+(0.0013)Gly+(0.00
87)Gln+(-0.0177)Ala+(-0.0395)Val+(-0.1569)Met+(0.1267)Ile; 0. 879,
0.908, 0.853, 0.822, 0.834, 0.756, 0.833, (5.2667)+(0.0096)Gl
n+(-0.0091)His+(-0.0174)Ala+(-0.0374)Val+(-0.1528)Met+(0.12 14)Ile;
0.879, 0.908, 0.869, 0.817, 0.826, 0.755, 0.830,
(5.4077)+(0.0074)Gln+(0.0149)Thr+(-0.0183)Ala+(-0.0410)Val+(-0.1935)
Met+(0.1340)Ile; 0.878, 0.907, 0.851, 0.820, 0.832, 0.754, 0.831,
(5.1231)+(0.0094)Gln+(-0.0174)Ala+(-0.0455)Val+(-0.1667)Met
+(0.1173)Ile+(0.0164)Leu; 0.878, 0.905, 0.865, 0.828, 0.843, 0.76
5, 0.838, (4.5753)+(0.0093)Gln+(-0.0170)Ala+(-0.0433)Val+(-0.
1757)Met+(0.1299)Ile+(0.0215)Phe; 0.878, 0.904, 0.854, 0.779, 0.
776, 0.711, 0.797,
(5.8641)+(0.0303)Ser+(-0.0708)Asn+(-0.0185)Ala+(-0.0356)Val+(0.1237)Ile+(-
0.0008)Trp; 0.878, 0.907, 0.857, 0.821, 0.834, 0.754, 0.832,
(4.9840)+(0.0086)Gln+(-0.0179)Ala+(-0.0415)Val+(-0.1693)Met+(0.0054)Lys+(-
0.1307)Ile; 0.878, 0.8 99, 0.830, 0.806, 0.825, 0.726, 0.817,
(5.8504)+(-0.0870)Asn+(0.0
089)Gln+(-0.0189)Ala+(-0.0382)Val+(0.1196)Ile; 0.878, 0.902, 0.
850, 0.777, 0.774, 0.711, 0.796, (5.7854)+(0.0316)Ser+(-0.0759)A
sn+(-0.0183)Ala+(-0.0410)Val+(0.1144)Ile+(0.0160)Leu; 0.878, 0.904,
0.853, 0.778, 0.776, 0.710, 0.797,
(5.6760)+(0.0294)Ser+(-0.0768)Asn+(-0.0188)Ala+(-0.0370)Val+(0.0044)Lys+(-
0.1263)Il e; 0.878, 0.903, 0.852, 0.778, 0.775, 0.712, 0.797,
(6.0289)+(0.027
4)Ser+(-0.0785)Asn+(0.0059)Thr+(-0.0189)Ala+(-0.0361)Val+(0.
1252)Ile; 0.877, 0.894, 0.832, 0.769, 0.771, 0.696, 0.787, (5.1118)
+(0.0222)Ser+(-0.0205)Ala+(-0.0349)Val+(0.1105)Ile; 0.877, 0. 904,
0.854, 0.780, 0.778, 0.713, 0.798, (5.8368)+(0.0295)Ser+(-0.
0708)Asn+(0.0008)Gly+(-0.0185)Ala+(-0.0355)Val+(0.1235)Ile; 0.877,
0.904, 0.866, 0.799, 0.795, 0.745, 0.814, (7.4944)+(-0.018
8)Ala+(-0.0579)Cit+(0.0387)Arg+(-0.0401)Val+(-0.1376)Met+(0.
1463)Ile; 0.877, 0.907, 0.853, 0.778, 0.771, 0.714, 0.797, (5.8649)
+(0.0297)Ser+(-0.0799)Asn+(-0.0189)Ala+(0.0165)Tyr+(-0.037
9)Val+(0.1256)Ile; 0.877, 0.903, 0.852, 0.776, 0.773, 0.709, 0.795,
(5.9419)+(0.0268)Ser+(-0.0879)Asn+(-0.0197)Ala+(0.0149)Arg+(-0.0369)Val+(-
0.1308)Ile; 0.877, 0.902, 0.851, 0.781, 0.781, 0.71 3, 0.798,
(5.8149)+(0.0297)Ser+(-0.0780)Asn+(0.0099)His+(-0.0
187)Ala+(-0.0380)Val+(0.1289)Ile; 0.876, 0.900, 0.866, 0.782, 0.
781, 0.718, 0.800,
(5.2550)+(0.0318)Ser+(-0.0782)Asn+(-0.0181)Ala+(-0.0383)Val+(0.1256)Ile+(-
0.0187)Phe; 0.876, 0.896, 0.843, 0.779, 0.780, 0.711, 0.796,
(5.3713)+(0.0238)Ser+(-0.0197)Ala+(-0.0335)Cit+(-0.0341)Val+(0.1133)Ile;
0.876, 0.907, 0.860, 0.8 17, 0.829, 0.751, 0.829,
(5.3043)+(0.0079)Gln+(-0.0184)Ala+(0.0
105)Arg+(-0.0404)Val+(-0.1690)Met+(0.1319)Ile; 0.876, 0.909, 0.
847, 0.812, 0.810, 0.759, 0.826, (8.3155)+(-0.0147)Ala+(-0.0159)
Pro+(0.0616)Tyr+(-0.0523)Val+(-0.1569)Met+(0.1622)Ile; 0.875,
0.902, 0.862, 0.836, 0.855, 0.771, 0.843,
(3.2313)+(0.0124)Gln+(-0.0465)Cit+(-0.0237)Pro+(-0.0505)Val+(-0.2054)Met+-
(0.1627)I le; 0.875, 0.902, 0.880, 0.843, 0.869, 0.773, 0.848,
(2.1201)+(0.01
12)Gln+(-0.0255)Pro+(-0.0590)Val+(-0.2410)Met+(0.1706)Ile+(0.0439)Phe;
0.874, 0.902, 0.874, 0.804, 0.800, 0.755, 0.819, (7.67
55)+(0.0283)Thr+(-0.0175)Ala+(-0.0339)Cit+(-0.0403)Val+(-0.
1661)Met+(0.1394)Ile; 0.874, 0.895, 0.832, 0.769, 0.771, 0.697, 0.
787,
(5.1032)+(0.0217)Ser+(-0.0205)Ala+(-0.0352)Val+(0.0041)Orn+(0.1088)Ile;
0.874, 0.900, 0.834, 0.809, 0.829, 0.731, 0.820,
(5.9023)+(-0.0868)Asn+(0.0091)Gln+(-0.0186)Ala+(-0.0371)Val
+(0.1172)Ile+(-0.0071)Trp; 0.874, 0.895, 0.843, 0.817, 0.842, 0.7
38, 0.825, (3.9047)+(-0.1206)Asn+(0.0126)Gln+(-0.0453)Cit+(-0.
0265)Pro+(-0.0500)Val+(0.1585)Ile; 0.873, 0.900, 0.847, 0.789, 0.
796, 0.716, 0.804, (5.7240)+(0.0252)Ser+(-0.0176)Ala+(-0.0265)
Cit+(-0.0142)Pro+(-0.0385)Val+(0.1368)Ile; 0.873, 0.897, 0.867,
0.799, 0.799, 0.745, 0.813,
(7.4475)+(0.0250)Thr+(-0.0179)Ala+(-0.0408)Val+(-0.1687)Met+(0.1367)Ile;
0.873, 0.901, 0.865, 0.8 07, 0.818, 0.739, 0.819,
(7.8313)+(0.0255)Thr+(-0.0162)Ala+(-0.
0128)Pro+(-0.0444)Val+(-0.1548)Met+(0.1565)Ile; 0.873, 0.894,
0.839, 0.769, 0.767, 0.700, 0.787, (5.3222)+(0.0245)Ser+(-0.015
2)His+(-0.0197)Ala+(-0.0311)Val+(0.1040)Ile; 0.873, 0.900, 0.8 51,
0.796, 0.814, 0.712, 0.809, (6.6258)+(0.0107)Gly+(-0.0172)Al
a+(-0.0355)Cit+(-0.0155)Pro+(-0.0396)Val+(0.1411)Ile; 0.873, 0.901,
0.834, 0.805, 0.825, 0.722, 0.816,
(5.6692)+(-0.0870)Asn+(0.0027)Gly+(0.0082)Gln+(-0.0191)Ala+(-0.0380)Val+(-
0.1205)I le; 0.873, 0.902, 0.868, 0.804, 0.798, 0.759, 0.819,
(6.2881)+(0.01
00)Gly+(-0.0183)Ala+(0.0616)Tyr+(-0.0473)Val+(-0.1885)Met+(0.1411)Ile;
0.873, 0.894, 0.842, 0.782, 0.793, 0.703, 0.797, (5.55
35)+(0.0241)Ser+(-0.0181)Ala+(-0.0154)Pro+(-0.0394)Val+(0.1
367)Ile; 0.872, 0.897, 0.842, 0.784, 0.794, 0.706, 0.799,
(5.7455)+(0.0253)Ser+(-0.0177)Ala+(-0.0157)Pro+(-0.0385)Val+(-0.003
1)Lys+(0.1358)Ile; 0.872, 0.898, 0.842, 0.785, 0.795, 0.707, 0.800,
(5.5167)+(0.0259)Ser+(-0.0027)Thr+(-0.0178)Ala+(-0.0153)Pro
+(-0.0391)Val+(0.1362)Ile; 0.872, 0.894, 0.832, 0.769, 0.771, 0.6
96, 0.787, (5.1178)+(0.0221)Ser+(-0.0205)Ala+(-0.0347)Val+(0.
1109)Ile+(-0.0007)Leu; 0.872, 0.894, 0.837, 0.772, 0.773, 0.702, 0.
790,
(5.1793)+(0.0226)Ser+(-0.0203)Ala+(-0.0339)Val+(0.1087)Ile+(-0.0059)Trp;
0.872, 0.902, 0.818, 0.819, 0.839, 0.744, 0.828,
(4.3698)+(0.0092)Gln+(-0.0190)Ala+(-0.0647)Cit+(-0.0133)Pro
+(0.1499)Ile+(-0.0727)Leu; 0.872, 0.895, 0.835, 0.769, 0.772, 0.6
95, 0.787, (4.9662)+(0.0223)Ser+(-0.0205)Ala+(-0.0355)Val+(0.
1107)Ile+(0.0039)Phe; 0.872, 0.898, 0.827, 0.803, 0.824, 0.721, 0.
814, (5.7877)+(-0.0918)Asn+(0.0092)Gln+(-0.0188)Ala+(-0.043
0)Val+(0.1119)Ile+(0.0135)Leu; 0.872, 0.900, 0.847, 0.778, 0.775,
0.714, 0.796,
(5.4824)+(0.0251)Ser+(-0.0091)His+(-0.0193)Ala+(-0.0317)Cit+(-0.03-
19)Val+(0.1092)Ile; 0.871, 0.899, 0.835, 0.8 07, 0.826, 0.728,
0.818, (5.5960)+(-0.0901)Asn+(0.0090)Gln+(-0.
0187)Ala+(-0.0396)Val+(0.1206)Ile+(0.0090)Phe; 0.871, 0.898, 0.
831, 0.800, 0.816, 0.722, 0.812, (6.0160)+(-0.0970)Asn+(0.0079)G
ln+(0.0082)Thr+(-0.0195)Ala+(-0.0388)Val+(0.1228)Ile; 0.871, 0.897,
0.830, 0.805, 0.824, 0.727, 0.816,
(5.8935)+(-0.0879)Asn+(0.0087)Gln+(-0.0188)Ala+(-0.0386)Val+(0.0043)Orn+(-
0.1182)I le; 0.871, 0.890, 0.849, 0.816, 0.845, 0.734, 0.823,
(3.2521)+(-0.1
343)Asn+(0.0113)Gln+(-0.0284)Pro+(-0.0560)Val+(0.1630)Ile+(0.0298)Phe;
0.871, 0.895, 0.833, 0.771, 0.772, 0.699, 0.789, (5.20
33)+(0.0227)Ser+(-0.0203)Ala+(-0.0344)Val+(-0.0015)Lys+(0.1
099)Ile; 0.871, 0.893, 0.829, 0.803, 0.829, 0.716, 0.813,
(5.2203)+(0.0076)Gln+(-0.0185)Ala+(-0.0199)Pro+(-0.0428)Val+(0.1384)Ile;
0.871, 0.894, 0.830, 0.769, 0.771, 0.695, 0.786, (5.0943)+(0.0
213)Ser+(-0.0208)Ala+(0.0023)Arg+(-0.0351)Val+(0.1112)Ile; 0. 871,
0.898, 0.847, 0.796, 0.815, 0.713, 0.809, (7.3141)+(-0.0436)A
sn+(0.0099)Gly+(-0.0163)Ala+(-0.0160)Pro+(-0.0412)Val+(0.14 69)Ile;
0.871, 0.897, 0.846, 0.782, 0.776, 0.724, 0.799,
(5.4563)+(0.0223)Ser+(-0.0192)Ala+(-0.0504)Cit+(-0.0356)Val+(0.0221)Orn+(-
0.1055)Ile; 0.871, 0.899, 0.836, 0.789, 0.800, 0.711, 0.803,
(8.3595)+(-0.0678)Asn+(0.0198)Thr+(-0.0170)Ala+(-0.0144)Pro
+(-0.0429)Val+(0.1487)Ile; 0.871, 0.895, 0.837, 0.771, 0.775, 0.6
97, 0.789, (5.0555)+(0.0252)Ser+(-0.0045)Thr+(-0.0200)Ala+(-0.
0344)Val+(0.1102)Ile; 0.871, 0.900, 0.835, 0.798, 0.813, 0.721, 0.
811,
(5.9904)+(-0.0972)Asn+(0.0078)Gln+(-0.0198)Ala+(0.0117)Arg+(-0.0390)Val+(-
0.1257)Ile; 0.871, 0.896, 0.839, 0.795, 0.816, 0.710, 0.807,
(4.6855)+(0.0132)Ser+(0.0055)Gln+(-0.0188)Ala+(-0.0190)Pro+(-0.0415)Val+(-
0.1386)Ile; 0.870, 0.893, 0.828, 0.7 75, 0.783, 0.696, 0.791,
(4.6677)+(0.0170)Ser+(0.0025)Gln+(-0.0
211)Ala+(-0.0354)Val+(0.1086)Ile; 0.870, 0.896, 0.845, 0.781, 0.
782, 0.714, 0.797,
(5.4134)+(0.0241)Ser+(-0.0195)Ala+(-0.0334)Cit+(-0.0335)Val+(0.1121)Ile+(-
-0.0038)Trp; 0.870, 0.899, 0.831, 0.806, 0.825, 0.728, 0.817,
(5.8480)+(-0.0845)Asn+(0.0091)Gln+(-0.0044)His+(-0.0188)Ala+(-0.0371)Val+-
(0.1171)Ile; 0.870, 0. 896, 0.846, 0.789, 0.798, 0.714, 0.803,
(5.6854)+(0.0250)Ser+(-0.
0176)Ala+(-0.0157)Pro+(-0.0377)Val+(0.1335)Ile+(-0.0111)Tr p;
0.870, 0.898, 0.827, 0.790, 0.790, 0.728, 0.805, (4.9798)+(0.024
5)Ser+(-0.0186)Ala+(-0.0457)Cit+(-0.0089)Pro+(0.1426)Ile+(-0.0641)Leu;
0.870, 0.900, 0.840, 0.826, 0.838, 0.770, 0.836, (4.313
8)+(0.0102)Gln+(-0.0184)Ala+(-0.0642)Cit+(-0.1069)Met+(0.13
71)Ile+(-0.0659)Leu; 0.870, 0.898, 0.818, 0.814, 0.824, 0.754, 0.8
25,
(4.7702)+(-0.0547)Asn+(0.0099)Gln+(-0.0193)Ala+(-0.0636)Cit+(0.1331)Ile+(-
-0.0653)Leu; 0.870, 0.897, 0.850, 0.791, 0.798, 0.721, 0.805,
(7.0384)+(-0.0404)Asn+(0.0099)Gly+(-0.0180)Ala+(-0.0363)Cit+(-0.0356)Val+-
(0.1222)Ile; 0.870, 0.901, 0.866, 0.8 04, 0.794, 0.762, 0.819,
(7.2269)+(0.0258)Thr+(-0.0184)Ala+(0.0
510)Tyr+(-0.0490)Val+(-0.2458)Met+(0.1496)Ile; 0.870, 0.896, 0.
842, 0.782, 0.793, 0.703, 0.797, (5.5448)+(0.0236)Ser+(-0.0181)A
la+(-0.0155)Pro+(-0.0399)Val+(0.0055)Orn+(0.1345)Ile; 0.870, 0.894,
0.846, 0.772, 0.772, 0.704, 0.790,
(5.3689)+(0.0186)Ser+(-0.0212)Ala+(-0.0488)Cit+(0.0156)Arg+(-0.0351)Val+(-
0.1190)Il e; 0.869, 0.895, 0.833, 0.770, 0.772, 0.696, 0.788,
(5.0899)+(0.021
6)Ser+(0.0005)Gly+(-0.0206)Ala+(-0.0349)Val+(0.1106)Ile; 0.8 69,
0.901, 0.851, 0.797, 0.788, 0.750, 0.813, (7.1204)+(-0.0191)Al
a+(0.0259)Arg+(0.0537)Tyr+(-0.0490)Val+(-0.2142)Met+(0.150
7)Ile
[0508] List (2) of Logistic Regression Equations Searched in
Example 7
[0509] The logistic regression equations searched in Example 7
above are listed below. Before each equation, "the value of ROC_AUC
for the pancreatic cancer group and the prostatic cancer group with
validation", "the value of ROC_AUC for the pancreatic cancer group
and the prostatic cancer group without validation", "the value of
ROC_AUC for the pancreatic cancer group and the healthy group",
"the value of ROC_AUC for the pancreatic cancer group and the other
cancers group", "the value of ROC_AUC for the pancreatic cancer
group and the lung cancer group", "the value of ROC_AUC for the
pancreatic cancer group and the colorectal cancer group", and "the
average value of the value of ROC_AUC for the pancreatic cancer
group and the lung cancer group, the value of ROC_AUC for the
pancreatic cancer group and the colorectal cancer group, and the
value of ROC_AUC for the pancreatic cancer group and the prostatic
cancer group" obtained for the equation are additionally
listed.
[0510] 0.787, 0.856, 0.911, 0.807, 0.794, 0.798, 0.816,
(-0.4061)+(0.
0399)Ser+(-0.2141)Met+(0.1298)Ile+(-0.0658)Leu+(0.0402)Phe+(-0.0539)Trp;
0.845, 0.887, 0.907, 0.802, 0.793, 0.768, 0.816, (1.4
919)+(0.0330)Ser+(0.0236)Thr+(-0.0587)Val+(-0.3796)Met+(0.1
721)Ile+(0.0320)Phe; 0.766, 0.842, 0.907, 0.810, 0.786, 0.825, 0.8
18, (2.7409)+(0.0412)Ser+(-0.0481)His+(0.0105)Thr+(-0.1506)M
et+(0.0196)Phe+(-0.0683)Trp; 0.872, 0.909, 0.906, 0.801, 0.796, 0.
747, 0.817, (3.3965)+(0.0311)Ser+(0.0246)Thr+(-0.0128)Ala+(-0.
0466)Val+(-0.2635)Met+(0.1591)Ile; 0.847, 0.888, 0.906, 0.802, 0.
791, 0.769, 0.816,
(1.4566)+(0.0427)Ser+(-0.0507)Val+(-0.2852)Met+(0.1486)Ile+(0.0258)Phe+(--
0.0079)Trp; 0.870, 0.913, 0.906, 0.806, 0.790, 0.766, 0.823,
(2.4936)+(0.0432)Ser+(-0.0118)Ala+(0.0462)Tyr+(-0.0485)Val+(-0.2565)Met+(-
0.1511)Ile; 0.840, 0.8 84, 0.906, 0.804, 0.794, 0.774, 0.817,
(0.1031)+(0.0419)Ser+(-0.0
611)Val+(-0.3616)Met+(0.0157)Lys+(0.1732)Ile+(0.0341)Phe; 0. 837,
0.890, 0.905, 0.800, 0.788, 0.766, 0.814, (1.1161)+(0.0402)Se
r+(0.0132)Arg+(-0.0550)Val+(-0.3329)Met+(0.1633)Ile+(0.028 0)Phe;
0.859, 0.890, 0.905, 0.800, 0.783, 0.774, 0.816, (2.8315)+(0.
0312)Ser+(0.0223)Thr+(-0.0416)Cit+(-0.0522)Val+(-0.3341)Met
+(0.1697)Ile; 0.840, 0.887, 0.904, 0.798, 0.786, 0.765, 0.813, (2.5
575)+(0.0314)Ser+(0.0204)Thr+(-0.0510)Val+(-0.3475)Met+(0.1
657)Ile+(-0.0106)Trp; 0.871, 0.909, 0.904, 0.809, 0.804, 0.758, 0.
824, (2.5705)+(0.0423)Ser+(-0.0115)Ala+(-0.0427)Val+(-0.187
8)Met+(0.1360)Ile+(0.0134)Phe; 0.769, 0.845, 0.904, 0.837, 0.833,
0.839, 0.839,
(3.9929)+(0.0400)Ser+(0.0086)Thr+(-0.0166)Val+(-0.1972)Met+(0.0304-
)Phe+(-0.0775)Trp; 0.757, 0.832, 0.903, 0.8 46, 0.848, 0.850,
0.843, (0.6788)+(0.0326)Ser+(0.0074)Gln+(-0.2
186)Met+(0.0155)Phe+(-0.1029)Trp; 0.768, 0.840, 0.903, 0.797, 0.
769, 0.813, 0.807, (0.1065)+(0.0395)Ser+(0.0074)Thr+(-0.2230)M
et+(0.0523)Ile+(0.0032)Phe+(-0.0885)Trp; 0.783, 0.851, 0.903, 0.
839, 0.834, 0.840, 0.842, (0.7685)+(0.0313)Ser+(0.0107)Gln+(-0.
0649)His+(-0.1807)Met+(0.0214)Phe+(-0.0676)Trp; 0.865, 0.912,
0.902, 0.802, 0.793, 0.753, 0.819, (2.8640)+(0.0372)Ser+(-0.013
5)Ala+(0.0205)Arg+(-0.0437)Val+(-0.2293)Met+(0.1532)Ile; 0.7 64,
0.844, 0.902, 0.797, 0.769, 0.809, 0.807, (0.2468)+(0.0393)Ser
+(0.0081)Thr+(-0.2243)Met+(-0.0048)Orn+(0.0562)Ile+(-0.087 5)Trp;
0.753, 0.826, 0.902, 0.826, 0.816, 0.838, 0.827, (2.3570)+(0.
0391)Ser+(0.0053)Thr+(-0.1808)Met+(0.0138)Phe+(-0.0941)Trp; 0.849,
0.893, 0.902, 0.798, 0.774, 0.778, 0.815,
(1.4618)+(0.0434)Ser+(0.0469)Tyr+(-0.0595)Val+(-0.3666)Met+(0.1679)Ile+(0-
.01 43)Phe; 0.845, 0.888, 0.902, 0.818, 0.821, 0.776, 0.828,
(0.1275)+(0.0321)Ser+(0.0069)Gln+(-0.0548)Val+(-0.3477)Met+(0.1541)I
le+(0.0292)Phe; 0.750, 0.829, 0.902, 0.829, 0.820, 0.841, 0.830,
(2. 7046)+(0.0394)Ser+(-0.0334)Asn+(0.0075)Thr+(-0.1510)Met+(0.
0156)Phe+(-0.0941)Trp; 0.849, 0.885, 0.901, 0.799, 0.788, 0.765, 0.
813,
(1.3699)+(0.0422)Ser+(-0.0521)Val+(-0.2912)Met+(0.1519)Ile+(0.0255)Phe;
0.845, 0.894, 0.901, 0.791, 0.772, 0.759, 0.808,
(3.2528)+(0.0397)Ser+(-0.0098)Gly+(0.0290)Thr+(-0.0550)Val+(-0.3919)Met+(-
0.1778)Ile; 0.845, 0.888, 0.901, 0.797, 0.785, 0.76 4, 0.812,
(1.4189)+(0.0428)Ser+(-0.0176)Asn+(-0.0520)Val+(-0.
2679)Met+(0.1528)Ile+(0.0258)Phe; 0.778, 0.846, 0.901, 0.784, 0.
746, 0.800, 0.797, (1.0109)+(0.0400)Ser+(-0.0431)His+(0.0099)I
hr+(-0.1847)Met+(0.0516)Ile+(-0.0627)Trp; 0.776, 0.840, 0.901,
0.796, 0.767, 0.810, 0.806,
(0.2150)+(0.0392)Ser+(0.0071)Thr+(-0.2212)Met+(0.0532)Ile+(-0.0873)Trp;
0.766, 0.844, 0.901, 0.813, 0.795, 0.819, 0.819,
(0.8719)+(0.0382)Ser+(0.0063)Thr+(-0.012
1)Pro+(-0.1778)Met+(0.0598)Ile+(-0.0914)Trp; 0.755, 0.841, 0.9 01,
0.796, 0.768, 0.809, 0.806, (0.2359)+(0.0392)Ser+(0.0070)Thr
+(-0.0015)Tyr+(-0.2193)Met+(0.0533)Ile+(-0.0869)Trp; 0.842, 0. 885,
0.900, 0.799, 0.788, 0.765, 0.813, (1.3987)+(0.0418)Ser+(-0.
0522)Val+(-0.2913)Met+(0.0033)Orn+(0.1505)Ile+(0.0246)Phe; 0. 840,
0.885, 0.900, 0.803, 0.791, 0.774, 0.817, (1.5211)+(0.0390)Se
r+(-0.0520)Val+(-0.3244)Met+(0.0134)Lys+(0.1634)Ile+(-0.014 6)Trp;
0.838, 0.888, 0.900, 0.799, 0.784, 0.768, 0.814, (1.7262)+(0.
0473)Ser+(-0.0041)Gly+(-0.0517)Val+(-0.2911)Met+(0.1510)Ile
+(0.0239)Phe; 0.765, 0.836, 0.900, 0.798, 0.773, 0.812, 0.807, (0.0
541)+(0.0418)Ser+(-0.2012)Met+(0.0007)Lys+(0.0512)Ile+(0.00
15)Phe+(-0.0851)Trp; 0.755, 0.836, 0.900, 0.798, 0.770, 0.814, 0.8
07, (-0.0500)+(0.0412)Ser+(0.0061)Arg+(-0.2132)Met+(0.0536)I
le+(0.0022)Phe+(-0.0885)Trp; 0.852, 0.887, 0.900, 0.803, 0.791, 0.
774, 0.817,
(1.7457)+(0.0427)Ser+(-0.0341)Cit+(-0.0509)Val+(-0.2679)Met+(0.150-
6)Ile+(0.0246)Phe; 0.768, 0.839, 0.900, 0.837, 0.836, 0.838, 0.837,
(3.7251)+(0.0418)Ser+(-0.0166)Val+(-0.176
2)Met+(0.0031)Lys+(0.0287)Phe+(-0.0760)Trp; 0.765, 0.841, 0.90 0,
0.796, 0.768, 0.809, 0.806,
(0.3181)+(0.0390)Ser+(0.0078)Thr+(-0.2195)Met+(-0.0013)Lys+(0.0529)Ile+(--
0.0861)Trp; 0.753, 0. 837, 0.900, 0.798, 0.773, 0.811, 0.807,
(0.1262)+(0.0418)Ser+(-0.
0031)Tyr+(-0.1953)Met+(0.0511)Ile+(0.0022)Phe+(-0.0836)Trp; 0.767,
0.849, 0.900, 0.815, 0.800, 0.817, 0.822,
(0.7019)+(0.0407)Ser+(-0.0123)Pro+(-0.1573)Met+(0.0573)Ile+(0.0038)Phe+(--
0.0 896)Trp; 0.783, 0.846, 0.899, 0.785, 0.748, 0.803, 0.799,
(0.7119)+(0.0440)Ser+(-0.0418)His+(-0.1561)Met+(0.0480)Ile+(0.0049)P
he+(-0.0595)Trp; 0.832, 0.891, 0.899, 0.796, 0.784, 0.759, 0.811,
(1.8597)+(0.0323)Ser+(0.0144)Thr+(-0.0557)Val+(-0.3670)Met+(0.0086)Lys+(0-
.1750)Ile; 0.853, 0.894, 0.899, 0.799, 0.779, 0.773, 0.815,
(2.5079)+(0.0358)Ser+(-0.0597)Cit+(0.0250)Arg+(-0.051
5)Val+(-0.3189)Met+(0.1728)Ile; 0.763, 0.836, 0.899, 0.808, 0.78 3,
0.828, 0.816, (2.3381)+(0.0437)Ser+(-0.0492)His+(-0.1301)Me
t+(0.0054)Lys+(0.0179)Phe+(-0.0679)Trp; 0.753, 0.838, 0.899, 0.
797, 0.770, 0.812, 0.807, (0.0362)+(0.0413)Ser+(0.0071)Arg+(-0.
2149)Met+(-0.0048)Orn+(0.0575)Ile+(-0.0880)Trp; 0.831, 0.888,
0.899, 0.793, 0.780, 0.757, 0.808,
(2.3644)+(0.0309)Ser+(0.0180)Thr+(0.0035)Arg+(-0.0531)Val+(-0.3565)Met+(0-
.1710)Ile; 0.853, 0.892, 0.899, 0.796, 0.780, 0.764, 0.812,
(2.5496)+(0.0324)Ser+(0.
0274)Thr+(-0.0707)Val+(-0.4062)Met+(0.1451)Ile+(0.0461)Leu; 0.851,
0.893, 0.899, 0.797, 0.770, 0.782, 0.815,
(1.9332)+(0.0425)Ser+(0.0529)Tyr+(-0.0570)Val+(-0.3650)Met+(0.1672)Ile+(--
0.0 077)Trp; 0.841, 0.887, 0.899, 0.798, 0.786, 0.764, 0.812,
(1.5611)+(0.0426)Ser+(-0.0554)Val+(-0.2950)Met+(0.1435)Ile+(0.0122)L
eu+(0.0198)Phe; 0.772, 0.836, 0.899, 0.797, 0.771, 0.811, 0.806,
(0. 1129)+(0.0416)Ser+(-0.2006)Met+(0.0006)Lys+(0.0516)Ile+(-0.
0846)Trp; 0.763, 0.837, 0.899, 0.797, 0.769, 0.812, 0.806, (0.0333)
+(0.0410)Ser+(0.0059)Arg+(-0.2123)Met+(0.0542)Ile+(-0.0877)Trp;
0.754, 0.839, 0.899, 0.798, 0.770, 0.813, 0.807, (0.0984)+(0.0
410)Ser+(0.0065)Arg+(-0.2105)Met+(-0.0010)Lys+(0.0542)Ile+(-0.0868)Trp;
0.792, 0.851, 0.899, 0.803, 0.767, 0.826, 0.814, (0.8
107)+(0.0383)Ser+(0.0108)Thr+(-0.0446)Cit+(-0.2057)Met+(0.0
551)Ile+(-0.0874)Trp; 0.833, 0.882, 0.899, 0.820, 0.798, 0.815, 0.
832,
(4.9562)+(0.0414)Ser+(0.0278)Thr+(-0.0638)Val+(-0.3446)Met+(0.0994)Leu+(--
0.0711)Trp; 0.825, 0.886, 0.899, 0.799, 0.785, 0.770, 0.814,
(2.1351)+(0.0379)Ser+(0.0123)Arg+(-0.0482)Val+(-0.3089)Met+(0.1579)Ile+(--
0.0124)Trp; 0.782, 0.857, 0.899, 0.7 95, 0.771, 0.795, 0.807,
(0.5033)+(0.0376)Ser+(0.0252)Tyr+(-0.2
367)Met+(0.1213)Ile+(-0.0531)Leu+(-0.0562)Trp; 0.766, 0.838, 0.
899, 0.800, 0.775, 0.812, 0.808, (0.1040)+(0.0421)Ser+(-0.1990)M
et+(-0.0026)Orn+(0.0523)Ile+(0.0020)Phe+(-0.0842)Trp; 0.842, 0.896,
0.899, 0.811, 0.813, 0.759, 0.823,
(2.2023)+(0.0398)Ser+(-0.0153)Pro+(-0.0542)Val+(-0.2462)Met+(0.1642)Ile+(-
0.0285)Ph e; 0.838, 0.886, 0.898, 0.793, 0.780, 0.758, 0.808,
(2.4345)+(0.030
7)Ser+(0.0196)Thr+(-0.0529)Val+(-0.3523)Met+(0.0013)Orn+(0.
1689)Ile; 0.779, 0.836, 0.898, 0.799, 0.773, 0.812, 0.807, (0.1169)
+(0.0418)Ser+(-0.1989)Met+(0.0510)Ile+(0.0013)Phe+(-0.0842)Trp;
0.760, 0.838, 0.898, 0.809, 0.786, 0.825, 0.817, (2.6855)+(0.0
431)Ser+(-0.0468)His+(0.0046)Arg+(-0.1275)Met+(0.0172)Phe+(-0.0652)Trp;
0.755, 0.836, 0.898, 0.797, 0.772, 0.810, 0.806, (0.1
422)+(0.0416)Ser+(-0.0019)Tyr+(-0.1981)Met+(0.0006)Lys+(0.0
518)Ile+(-0.0840)Trp; 0.847, 0.887, 0.898, 0.793, 0.781, 0.757, 0.
808,
(2.4351)+(0.0308)Ser+(0.0198)Thr+(-0.0529)Val+(-0.3530)Met+(0.1697)Ile;
0.839, 0.883, 0.898, 0.802, 0.795, 0.767, 0.815,
(1.3018)+(0.0415)Ser+(0.0135)His+(-0.0562)Val+(-0.3154)Met+(0.1609)Ile+(0-
.0259)Phe; 0.830, 0.886, 0.898, 0.795, 0.783, 0.761, 0.810,
(1.4446)+(0.0374)Ser+(0.0048)Arg+(-0.0545)Val+(-0.340
3)Met+(0.0111)Lys+(0.1701)Ile; 0.769, 0.837, 0.898, 0.798, 0.773,
0.810, 0.807,
(0.1887)+(0.0416)Ser+(-0.0020)Tyr+(-0.1962)Met+(0.0517)Ile+(-0.083-
2)Trp; 0.761, 0.826, 0.898, 0.826, 0.819, 0.83 5, 0.827,
(2.3360)+(0.0405)Ser+(-0.1633)Met+(0.0123)Phe+(-0.0 909)Trp; 0.753,
0.838, 0.898, 0.796, 0.768, 0.811, 0.805,
(0.1271)+(0.0394)Ser+(0.0055)Thr+(0.0036)Arg+(-0.2243)Met+(0.0544)Il
e+(-0.0889)Trp; 0.770, 0.845, 0.898, 0.783, 0.743, 0.804, 0.797,
(0. 7499)+(0.0421)Ser+(-0.0450)His+(0.0103)Arg+(-0.1751)Met+(0.
0545)Ile+(-0.0634)Trp; 0.872, 0.909, 0.898, 0.804, 0.798, 0.752, 0.
820, (1.9444)+(0.0409)Ser+(-0.0141)Ala+(-0.0498)Val+(-0.244
6)Met+(0.0197)Lys+(0.1613)Ile; 0.787, 0.851, 0.898, 0.803, 0.765,
0.830, 0.815,
(0.6431)+(0.0391)Ser+(-0.0590)Cit+(0.0211)Arg+(-0.2103)Met+(0.0617-
)Ile+(-0.0960)Trp; 0.783, 0.851, 0.898, 0.7 96, 0.779, 0.788,
0.806, (0.7806)+(0.0359)Ser+(0.0029)Thr+(-0.2
110)Met+(0.1124)Ile+(-0.0447)Leu+(-0.0553)Trp; 0.751, 0.826, 0.
898, 0.826, 0.820, 0.836, 0.827, (2.3934)+(0.0405)Ser+(-0.1612)M
et+(-0.0008)Lys+(0.0120)Phe+(-0.0899)Trp; 0.767, 0.837, 0.898,
0.793, 0.761, 0.813, 0.804,
(0.7266)+(0.0451)Ser+(-0.0064)Gly+(0.0122)Thr+(-0.2369)Met+(0.0535)Ile+(--
0.0895)Trp; 0.755, 0.8 50, 0.898, 0.814, 0.797, 0.816, 0.821,
(0.7671)+(0.0404)Ser+(-0.0
125)Pro+(0.0052)Tyr+(-0.1625)Met+(0.0579)Ile+(-0.0898)Trp; 0. 771,
0.843, 0.898, 0.838, 0.837, 0.835, 0.838, (4.0479)+(0.0425)Se
r+(-0.0215)Asn+(-0.0157)Val+(-0.1429)Met+(0.0277)Phe+(-0.07 15)Trp;
0.787, 0.838, 0.898, 0.798, 0.773, 0.811, 0.807,
(0.1611)+(0.0417)Ser+(-0.1986)Met+(0.0514)Ile+(-0.0838)Trp; 0.765,
0.8 40, 0.898, 0.819, 0.808, 0.822, 0.823,
(-1.3681)+(0.0342)Ser+(0.0
072)Gln+(-0.2506)Met+(0.0486)Ile+(0.0053)Phe+(-0.0963)Trp; 0. 762,
0.838, 0.898, 0.798, 0.773, 0.811, 0.807, (0.1189)+(0.0419)Se
r+(-0.2007)Met+(-0.0023)Orn+(0.0007)Lys+(0.0530)Ile+(-0.084 4)Trp;
0.762, 0.845, 0.898, 0.811, 0.794, 0.815, 0.818, (0.7179)+(0.
0391)Ser+(0.0082)Arg+(-0.0125)Pro+(-0.1741)Met+(0.0620)Ile+(-0.0939)Trp;
0.846, 0.894, 0.898, 0.794, 0.764, 0.778, 0.812, (0.8
674)+(0.0411)Ser+(0.0658)Tyr+(-0.0692)Val+(-0.4644)Met+(0.0
167)Lys+(0.1956)Ile; 0.772, 0.846, 0.898, 0.783, 0.741, 0.807, 0.7
98, (0.7633)+(0.0441)Ser+(-0.0443)His+(0.0124)Tyr+(-0.1685)M
et+(0.0480)Ile+(-0.0602)Trp; 0.774, 0.846, 0.898, 0.819, 0.810, 0.
816, 0.824,
(3.7367)+(0.0442)Ser+(-0.0356)His+(-0.0123)Val+(-0.1301)Met+(0.026-
8)Phe+(-0.0542)Trp; 0.751, 0.826, 0.897, 0.825, 0.818, 0.835,
0.826, (2.2889)+(0.0405)Ser+(-0.1639)Met+(0.001
1)Leu+(0.0113)Phe+(-0.0913)Trp; 0.766, 0.836, 0.897, 0.807, 0.78 6,
0.821, 0.814, (2.6417)+(0.0433)Ser+(0.0083)Asn+(-0.0464)His
+(-0.1277)Met+(0.0158)Phe+(-0.0625)Trp; 0.761, 0.826, 0.897, 0.
829, 0.823, 0.838, 0.829, (2.6077)+(0.0411)Ser+(-0.0261)Asn+(-0.
1345)Met+(0.0131)Phe+(-0.0898)Trp; 0.832, 0.892, 0.897, 0.801, 0.
797, 0.756, 0.815, (3.3038)+(0.0284)Ser+(0.0196)Thr+(-0.0147)P
ro+(-0.0547)Val+(-0.3097)Met+(0.1831)Ile; 0.782, 0.850, 0.897,
0.796, 0.779, 0.789, 0.806,
(0.5053)+(0.0367)Ser+(-0.2127)Met+(0.0039)Lys+(0.1158)Ile+(-0.0473)Leu+(--
0.0569)Trp; 0.776, 0.8 44, 0.897, 0.782, 0.744, 0.799, 0.796,
(0.8779)+(0.0432)Ser+(-0.0
419)His+(-0.1553)Met+(0.0024)Orn+(0.0482)Ile+(-0.0582)Trp; 0. 770,
0.837, 0.897, 0.809, 0.788, 0.823, 0.816, (2.7102)+(0.0435)Se
r+(-0.0451)His+(-0.1198)Met+(0.0160)Phe+(-0.0629)Trp; 0.852, 0.889,
0.897, 0.801, 0.786, 0.774, 0.816,
(1.7797)+(0.0393)Ser+(-0.0363)Cit+(-0.0537)Val+(-0.3102)Met+(0.0125)Lys+(-
0.1682)Il e; 0.766, 0.842, 0.897, 0.829, 0.809, 0.849, 0.833,
(2.8945)+(0.039
4)Ser+(0.0095)Thr+(-0.0428)Cit+(-0.1675)Met+(0.0161)Phe+(-0.
0970)Trp; 0.757, 0.838, 0.897, 0.798, 0.773, 0.810, 0.807, (0.1935)
+(0.0418)Ser+(-0.0016)Tyr+(-0.1966)Met+(-0.0021)Orn+(0.052
8)Ile+(-0.0832)Trp; 0.769, 0.842, 0.897, 0.796, 0.770, 0.806, 0.80
6, (0.5416)+(0.0393)Ser+(-0.0291)Asn+(0.0084)Thr+(-0.1912)Me
t+(0.0538)Ile+(-0.0869)Trp; 0.871, 0.910, 0.897, 0.808, 0.801, 0.
761, 0.824,
(3.3274)+(0.0409)Ser+(-0.0117)Ala+(-0.0293)Cit+(-0.0398)Val+(-0.16-
03)Met+(0.1354)Ile; 0.859, 0.895, 0.897, 0.795, 0.765, 0.780,
0.814, (2.3171)+(0.0426)Ser+(-0.0369)Cit+(0.054
4)Tyr+(-0.0577)Val+(-0.3487)Met+(0.1682)Ile; 0.767, 0.848, 0.8 97,
0.812, 0.798, 0.813, 0.819, (0.8303)+(0.0401)Ser+(-0.0123)Pr
o+(-0.1569)Met+(0.0005)Orn+(0.0582)Ile+(-0.0883)Trp; 0.852, 0. 888,
0.897, 0.791, 0.766, 0.770, 0.808, (2.2714)+(0.0316)Ser+(0.0
231)Thr+(0.0575)Tyr+(-0.0649)Val+(-0.4616)Met+(0.1911)Ile; 0. 848,
0.884, 0.897, 0.795, 0.783, 0.762, 0.810, (1.4167)+(0.0382)Se
r+(-0.0543)Val+(-0.3324)Met+(0.0125)Lys+(0.1682)Ile; 0.870, 0. 906,
0.897, 0.803, 0.796, 0.754, 0.819, (3.0382)+(0.0402)Ser+(-0.
0120)Ala+(-0.0407)Val+(-0.1802)Met+(0.0043)Orn+(0.1345)Ile; 0.775,
0.848, 0.897, 0.812, 0.797, 0.812, 0.819,
(0.8305)+(0.0402)Ser+(-0.0122)Pro+(-0.1568)Met+(0.0584)Ile+(-0.0883)Trp;
0.76 7, 0.849, 0.897, 0.813, 0.800, 0.810, 0.820,
(0.9285)+(0.0402)Ser+(-0.0123)Pro+(-0.1530)Met+(-0.0012)Lys+(0.0582)Ile+(-
-0.086 8)Trp
[0511] List (2) of Linear Discriminants Searched in Example 7
[0512] The linear discriminants searched in Example 7 above are
listed below. Before each equation, "the value of ROC_AUC for the
pancreatic cancer group and the prostatic cancer group with
validation", "the value of ROC_AUC for the pancreatic cancer group
and the prostatic cancer group without validation", "the value of
ROC_AUC for the pancreatic cancer group and the healthy group",
"the value of ROC_AUC for the pancreatic cancer group and the other
cancers group", "the value of ROC_AUC for the pancreatic cancer
group and the lung cancer group", "the value of ROC_AUC for the
pancreatic cancer group and the colorectal cancer group", and "the
average value of the value of ROC_AUC for the pancreatic cancer
group and the lung cancer group, the value of ROC_AUC for the
pancreatic cancer group and the colorectal cancer group, and the
value of ROC_AUC for the pancreatic cancer group and the prostatic
cancer group" obtained for the equation are additionally
listed.
[0513] 0.859, 0.885, 0.925, 0.819, 0.809, 0.795, 0.830,
(1.6394)+(0.
0387)Ser+(-0.0455)Val+(-0.2545)Met+(0.1283)Ile+(0.0546)Phe+(-0.0299)Trp;
0.819, 0.855, 0.925, 0.822, 0.810, 0.820, 0.829, (0.8
073)+(0.0364)Ser+(-0.2030)Met+(0.1178)Ile+(-0.0647)Leu+(0.0
578)Phe+(-0.0648)Trp; 0.861, 0.892, 0.917, 0.807, 0.788, 0.786, 0.
822,
(1.2830)+(0.0364)Ser+(0.0328)Tyr+(-0.0547)Val+(-0.3122)Met+(0.1451)Ile+(0-
.0444)Phe; 0.855, 0.884, 0.917, 0.805, 0.796, 0. 772, 0.817,
(1.1869)+(0.0330)Ser+(0.0086)Thr+(-0.0523)Val+(-0.
2940)Met+(0.1427)Ile+(0.0555)Phe; 0.847, 0.881, 0.916, 0.804, 0.
796, 0.772, 0.816, (1.1400)+(0.0359)Ser+(0.0037)Arg+(-0.0511)V
al+(-0.2757)Met+(0.1404)Ile+(0.0531)Phe; 0.852, 0.882, 0.915, 0.
816, 0.818, 0.776, 0.825, (0.5185)+(0.0298)Ser+(0.0040)Gln+(-0.
0515)Val+(-0.2886)Met+(0.1379)Ile+(0.0511)Phe; 0.855, 0.885, 0.
914, 0.801, 0.787, 0.774, 0.815, (1.4582)+(0.0381)Ser+(-0.0133)H
is+(-0.0470)Val+(-0.2554)Met+(0.1313)Ile+(0.0525)Phe; 0.781, 0.829,
0.914, 0.854, 0.857, 0.865, 0.850, (1.6910)+(0.0271)Ser+(0.
0058)Gln+(-0.1824)Met+(-0.0027)Leu+(0.0278)Phe+(-0.0977)Tr p;
0.863, 0.888, 0.913, 0.802, 0.792, 0.768, 0.816, (1.6900)+(0.038
8)Ser+(-0.0430)Asn+(-0.0504)Val+(-0.2279)Met+(0.1409)Ile+(0.
0530)Phe; 0.851, 0.882, 0.913, 0.805, 0.798, 0.772, 0.817, (0.8294)
+(0.0361)Ser+(-0.0528)Val+(-0.2835)Met+(0.0048)Lys+(0.1426)Ile+(0.0546)Ph-
e; 0.779, 0.823, 0.913, 0.835, 0.826, 0.854, 0.835,
(2.6420)+(0.0366)Ser+(0.0049)Tyr+(-0.1614)Met+(0.0250)Phe+(-0.0903)Trp;
0.856, 0.879, 0.913, 0.802, 0.794, 0.771, 0.815, (1.2
512)+(0.0368)Ser+(-0.0505)Val+(-0.2680)Met+(0.1384)Ile+(0.0
518)Phe; 0.776, 0.824, 0.913, 0.834, 0.827, 0.849, 0.833,
(2.6819)+(0.0357)Ser+(-0.1556)Met+(0.0061)Orn+(-0.0028)Leu+(0.0262)P
he+(-0.0876)Trp; 0.862, 0.887, 0.913, 0.806, 0.794, 0.777, 0.819,
(1.5875)+(0.0375)Ser+(-0.0335)Cit+(-0.0493)Val+(-0.2533)Met
+(0.1395)Ile+(0.0515)Phe; 0.793, 0.821, 0.912, 0.834, 0.828, 0.85
0, 0.833, (2.6509)+(0.0366)Ser+(-0.1555)Met+(0.0265)Phe+(-0.0
891)Trp; 0.782, 0.823, 0.912, 0.831, 0.825, 0.845, 0.831,
(2.5358)+(0.0361)Ser+(-0.1575)Met+(0.0056)Orn+(0.0244)Phe+(-0.0884)T
rp; 0.773, 0.822, 0.912, 0.837, 0.829, 0.855, 0.836, (2.7656)+(0.03
63)Ser+(0.0057)Tyr+(-0.1606)Met+(-0.0022)Leu+(0.0264)Phe+(-0.0899)Trp;
0.815, 0.853, 0.912, 0.846, 0.838, 0.854, 0.848, (1.874
2)+(0.0274)Ser+(0.0093)Gln+(-0.0669)His+(-0.1684)Met+(0.037
4)Phe+(-0.0669)Trp; 0.805, 0.845, 0.912, 0.820, 0.796, 0.837, 0.82
6, (3.4001)+(0.0382)Ser+(-0.0523)His+(0.0061)Thr+(-0.1457)Me
t+(0.0379)Phe+(-0.0630)Trp; 0.791, 0.829, 0.912, 0.852, 0.854, 0.
861, 0.848, (1.5432)+(0.0275)Ser+(0.0058)Gln+(-0.1842)Met+(0.
0258)Phe+(-0.0984)Trp; 0.818, 0.852, 0.912, 0.798, 0.759, 0.820, 0.
810,
(1.4300)+(0.0432)Ser+(-0.0477)His+(-0.1657)Met+(0.0415)Ile+(0.0293)Phe+(--
0.0605)Trp; 0.779, 0.829, 0.912, 0.853, 0.856, 0.863, 0.849,
(1.5550)+(0.0274)Ser+(0.0059)Gln+(-0.1843)Met+(-0.0018)Orn+(0.0265)Phe+(--
0.0988)Trp; 0.784, 0.823, 0.912, 0.8 36, 0.830, 0.851, 0.835,
(2.7434)+(0.0364)Ser+(-0.1543)Met+(-0.
0016)Leu+(0.0277)Phe+(-0.0886)Trp; 0.849, 0.879, 0.912, 0.802, 0.
793, 0.771, 0.814,
(1.2798)+(0.0363)Ser+(-0.0506)Val+(-0.2678)Met+(0.0040)Orn+(0.1367)Ile+(0-
.0509)Phe; 0.776, 0.829, 0.912, 0. 851, 0.853, 0.861, 0.848,
(1.5439)+(0.0275)Ser+(0.0058)Gln+(0.0
011)Tyr+(-0.1854)Met+(0.0255)Phe+(-0.0987)Trp; 0.796, 0.841, 0.
911, 0.864, 0.867, 0.873, 0.860, (1.9967)+(0.0277)Ser+(-0.0557)A
sn+(0.0072)Gln+(-0.1368)Met+(0.0276)Phe+(-0.1002)Trp; 0.792, 0.834,
0.911, 0.811, 0.789, 0.830, 0.818,
(0.6202)+(0.0402)Ser+(-0.1911)Met+(-0.0054)Orn+(0.0461)Ile+(0.0222)Phe+(--
0.0873)Tr p; 0.853, 0.882, 0.911, 0.802, 0.792, 0.771, 0.815,
(1.2814)+(0.037
1)Ser+(-0.0525)Val+(-0.2695)Met+(0.1342)Ile+(0.0070)Leu+(0.
0494)Phe; 0.770, 0.822, 0.911, 0.832, 0.824, 0.850, 0.832, (2.5316)
+(0.0361)Ser+(0.0043)Tyr+(-0.1624)Met+(0.0054)Orn+(0.0231)P
he+(-0.0895)Trp; 0.866, 0.893, 0.911, 0.815, 0.822, 0.760, 0.825,
(2.0101)+(0.0383)Ser+(-0.0194)Pro+(-0.0555)Val+(-0.2381)Met
+(0.1692)Ile+(0.0552)Phe; 0.771, 0.821, 0.911, 0.835, 0.827, 0.85
3, 0.834, (2.6482)+(0.0373)Ser+(-0.0017)Thr+(0.0052)Tyr+(-0.1
572)Met+(0.0243)Phe+(-0.0895)Trp; 0.803, 0.842, 0.911, 0.852, 0.
853, 0.857, 0.851,
(4.4894)+(0.0357)Ser+(-0.0265)Asn+(-0.0138)Val+(-0.1282)Met+(0.0413)Phe+(-
-0.0729)Trp; 0.776, 0.822, 0.910, 0.835, 0.830, 0.850, 0.834,
(2.7554)+(0.0371)Ser+(-0.0016)Thr+(-0.1500)Met+(-0.0017)Leu+(0.0272)Phe+(-
-0.0878)Trp; 0.797, 0. 840, 0.910, 0.827, 0.814, 0.836, 0.830,
(-0.1760)+(0.0313)Ser+(0.
0051)Gln+(-0.2131)Met+(0.0400)Ile+(0.0204)Phe+(-0.0952)Trp; 0.791,
0.838, 0.910, 0.848, 0.849, 0.852, 0.846,
(4.1952)+(0.0342)Ser+(0.0009)Thr+(-0.0142)Val+(-0.1563)Met+(0.0411)Phe+(--
0.0 730)Trp; 0.786, 0.831, 0.910, 0.809, 0.786, 0.829, 0.815,
(0.6370)+(0.0395)Ser+(0.0024)Tyr+(-0.1934)Met+(0.0432)Ile+(0.0198)Ph
e+(-0.0875)Trp; 0.855, 0.887, 0.910, 0.804, 0.789, 0.779, 0.818,
(1. 6257)+(0.0420)Ser+(-0.0043)Gly+(-0.0499)Val+(-0.2682)Met+(0.
1382)Ile+(0.0491)Phe; 0.802, 0.838, 0.909, 0.847, 0.849, 0.851, 0.
846,
(4.1917)+(0.0346)Ser+(-0.0142)Val+(-0.1540)Met+(0.0408)Phe+(-0.0727)Trp;
0.797, 0.845, 0.909, 0.851, 0.846, 0.862, 0.851,
(4.2901)+(0.0344)Ser+(0.0172)Tyr+(-0.0153)Val+(-0.1740)Met+(0.0367)Phe+(--
0.0756)Trp; 0.791, 0.832, 0.909, 0.810, 0.788, 0.82 7, 0.816,
(0.6399)+(0.0397)Ser+(-0.0004)Thr+(-0.1897)Met+(0.0
433)Ile+(0.0204)Phe+(-0.0867)Trp; 0.783, 0.821, 0.909, 0.833, 0.
828, 0.848, 0.832,
(2.6569)+(0.0373)Ser+(-0.0016)Thr+(-0.1515)Met+(0.0260)Phe+(-0.0883)Trp;
0.798, 0.832, 0.909, 0.810, 0.788, 0.827, 0.816,
(0.6369)+(0.0395)Ser+(-0.1907)Met+(0.0433)Ile+(0.0205)Phe+(-0.0869)Trp;
0.788, 0.830, 0.908, 0.810, 0.789, 0.82 7, 0.815,
(0.6970)+(0.0400)Ser+(-0.0021)Arg+(-0.1869)Met+(0.0
430)Ile+(0.0199)Phe+(-0.0857)Trp; 0.799, 0.841, 0.908, 0.814, 0.
787, 0.834, 0.821,
(3.1997)+(0.0398)Ser+(-0.0514)His+(-0.1338)Met+(0.0102)Orn+(0.0317)Phe+(--
0.0594)Trp; 0.793, 0.835, 0.908, 0.808, 0.787, 0.823, 0.815,
(1.1478)+(0.0401)Ser+(-0.1769)Met+(-0.0056)Lys+(0.0437)Ile+(0.0187)Phe+(--
0.0814)Trp; 0.788, 0.8 28, 0.908, 0.838, 0.831, 0.853, 0.837,
(3.0682)+(0.0378)Ser+(-0.0
326)Asn+(0.0005)Thr+(-0.1252)Met+(0.0278)Phe+(-0.0890)Trp; 0. 802,
0.845, 0.908, 0.830, 0.819, 0.835, 0.833, (4.3232)+(0.0385)Se
r+(-0.0413)His+(-0.0098)Val+(-0.1342)Met+(0.0437)Phe+(-0.05 49)Trp;
0.800, 0.844, 0.908, 0.819, 0.798, 0.835, 0.826,
(3.3748)+(0.0404)Ser+(-0.0495)His+(0.0004)Arg+(-0.1319)Met+(0.0355)P
he+(-0.0618)Trp; 0.781, 0.827, 0.908, 0.832, 0.827, 0.843, 0.832,
(3.1718)+(0.0365)Ser+(0.0015)Thr+(-0.1454)Met+(-0.0056)Lys+(0.0252)Phe+(--
0.0843)Trp; 0.785, 0.828, 0.908, 0.836, 0.828, 0.85 2, 0.836,
(3.0792)+(0.0383)Ser+(-0.0302)Asn+(-0.0020)Arg+(-0.
1229)Met+(0.0269)Phe+(-0.0877)Trp; 0.782, 0.829, 0.908, 0.837, 0.
829, 0.853, 0.837, (3.0578)+(0.0380)Ser+(-0.0324)Asn+(0.0054)T
yr+(-0.1303)Met+(0.0260)Phe+(-0.0901)Trp; 0.769, 0.819, 0.908,
0.830, 0.824, 0.843, 0.829,
(2.5234)+(0.0374)Ser+(-0.0033)Thr+(-0.1495)Met+(0.0068)Orn+(0.0228)Phe+(--
0.0867)Trp; 0.810, 0.8 44, 0.908, 0.819, 0.797, 0.836, 0.826,
(3.3810)+(0.0405)Ser+(-0.0
494)His+(-0.1313)Met+(0.0353)Phe+(-0.0617)Trp; 0.806, 0.844, 0.
908, 0.819, 0.797, 0.836, 0.826, (3.3834)+(0.0405)Ser+(-0.0002)A
sn+(-0.0494)His+(-0.1311)Met+(0.0353)Phe+(-0.0617)Trp; 0.842,
0.873, 0.908, 0.816, 0.816, 0.784, 0.824,
(4.1550)+(0.0238)Thr+(-0.0499)Val+(-0.2634)Met+(0.1320)Ile+(0.0496)Phe+(--
0.0243)Tr p; 0.795, 0.828, 0.908, 0.838, 0.831, 0.853, 0.837,
(3.0653)+(0.038
0)Ser+(-0.0322)Asn+(-0.1242)Met+(0.0276)Phe+(-0.0888)Trp; 0. 788,
0.827, 0.908, 0.838, 0.831, 0.853, 0.837, (3.0623)+(0.0380)Se
r+(-0.0322)Asn+(-0.1242)Met+(0.0001)Leu+(0.0276)Phe+(-0.088 8)Trp;
0.803, 0.849, 0.908, 0.818, 0.787, 0.843, 0.826, (3.3971)+(0.
0408)Ser+(-0.0528)His+(0.0189)Tyr+(-0.1518)Met+(0.0302)Phe+(-0.0645)Trp;
0.777, 0.823, 0.907, 0.834, 0.829, 0.849, 0.833, (2.8
679)+(0.0374)Ser+(-0.0049)Arg+(-0.1461)Met+(-0.0022)Leu+(0.
0265)Phe+(-0.0858)Trp; 0.775, 0.821, 0.907, 0.832, 0.826, 0.848, 0.
832,
(2.7471)+(0.0375)Ser+(0.0006)Thr+(-0.0050)Arg+(-0.1491)Met+(0.0251)Phe+(--
0.0867)Trp; 0.780, 0.821, 0.907, 0.832, 0.826, 0.846, 0.831,
(2.7438)+(0.0377)Ser+(-0.0047)Arg+(-0.1479)Met+(0.0250)Phe+(-0.0865)Trp;
0.800, 0.845, 0.907, 0.867, 0.878, 0.86 4, 0.862,
(3.0948)+(0.0245)Ser+(0.0063)Gln+(-0.0151)Val+(-0.1
849)Met+(0.0410)Phe+(-0.0817)Trp; 0.861, 0.888, 0.906, 0.808, 0.
795, 0.779, 0.821, (3.3913)+(0.0305)Ser+(0.0041)Thr+(-0.0388)V
al+(-0.2230)Met+(0.1218)Ile+(-0.0241)Trp; 0.790, 0.827, 0.906,
0.833, 0.827, 0.845, 0.833,
(3.1423)+(0.0371)Ser+(-0.1424)Met+(-0.0053)Lys+(0.0248)Phe+(-0.0839)Trp;
0.781, 0.827, 0.906, 0.8 33, 0.827, 0.845, 0.833,
(3.1421)+(0.0371)Ser+(-0.1424)Met+(-0.
0053)Lys+(0.0000)Leu+(0.0248)Phe+(-0.0839)Trp; 0.785, 0.831, 0.
906, 0.850, 0.856, 0.853, 0.847, (2.1609)+(0.0273)Ser+(0.0064)Gl
n+(-0.1677)Met+(-0.0079)Lys+(0.0233)Phe+(-0.0918)Trp; 0.781, 0.824,
0.906, 0.833, 0.826, 0.849, 0.833,
(2.9560)+(0.0374)Ser+(-0.0372)Asn+(-0.1222)Met+(0.0084)Orn+(0.0246)Phe+(--
0.0878)Tr p; 0.777, 0.828, 0.906, 0.833, 0.825, 0.847, 0.833,
(3.1277)+(0.037
1)Ser+(0.0038)Tyr+(-0.1471)Met+(-0.0052)Lys+(0.0237)Phe+(-0.
0850)Trp; 0.772, 0.823, 0.906, 0.832, 0.825, 0.848, 0.832, (2.7349)
+(0.0377)Ser+(-0.0047)Arg+(0.0049)Tyr+(-0.1538)Met+(0.0235)Phe+(-0.0878)T-
rp; 0.805, 0.845, 0.906, 0.819, 0.798, 0.835, 0.826,
(3.4430)+(0.0405)Ser+(-0.0489)His+(-0.1297)Met+(-0.0007)Lys
+(0.0350)Phe+(-0.0612)Trp; 0.804, 0.845, 0.906, 0.820, 0.808, 0.8
22, 0.825, (1.1919)+(0.0410)Ser+(-0.0151)Pro+(-0.1612)Met+(0.
0598)Ile+(0.0208)Phe+(-0.0943)Trp; 0.803, 0.843, 0.906, 0.814, 0.
789, 0.832, 0.822,
(3.1179)+(0.0413)Ser+(-0.0509)His+(-0.1343)Met+(0.0051)Leu+(0.0318)Phe+(--
0.0623)Trp; 0.770, 0.819, 0.906, 0.827, 0.821, 0.839, 0.827,
(2.6188)+(0.0374)Ser+(-0.0067)Arg+(-0.1474)Met+(0.0080)Orn+(0.0213)Phe+(--
0.0845)Trp; 0.794, 0.8 39, 0.906, 0.847, 0.848, 0.851, 0.846,
(4.3044)+(0.0348)Ser+(-0.0
138)Val+(-0.1499)Met+(-0.0017)Lys+(0.0398)Phe+(-0.0715)Trp; 0.800,
0.835, 0.906, 0.811, 0.788, 0.828, 0.817,
(1.0631)+(0.0415)Ser+(-0.0424)Asn+(-0.1515)Met+(0.0459)Ile+(0.0216)Phe+(--
0.0 864)Trp; 0.796, 0.841, 0.906, 0.842, 0.840, 0.845, 0.842,
(4.1524)+(0.0328)Ser+(-0.0168)Val+(-0.1591)Met+(0.0156)Orn+(0.0374)P
he+(-0.0679)Trp; 0.779, 0.828, 0.905, 0.833, 0.826, 0.844, 0.833,
(3.1338)+(0.0375)Ser+(-0.0019)Arg+(-0.1406)Met+(-0.0048)Lys
+(0.0244)Phe+(-0.0834)Trp; 0.778, 0.825, 0.905, 0.829, 0.823, 0.8
39, 0.829, (3.0497)+(0.0366)Ser+(-0.1434)Met+(0.0071)Orn+(-0.
0058)Lys+(0.0219)Phe+(-0.0826)Trp; 0.888, 0.911, 0.905, 0.814, 0.
811, 0.763, 0.828,
(3.9212)+(0.0380)Ser+(-0.0160)Ala+(-0.0426)Val+(-0.1846)Met+(0.1388)Ile+(-
0.0358)Phe; 0.866, 0.897, 0.905, 0.811, 0.787, 0.796, 0.827,
(3.1432)+(0.0334)Ser+(0.0477)Tyr+(-0.0449)Val+(-0.2823)Met+(0.1298)Ile+(--
0.0300)Trp; 0.784, 0.83 2, 0.904, 0.853, 0.859, 0.858, 0.850,
(1.4842)+(0.0295)Ser+(0.006
3)Gln+(-0.0064)Thr+(-0.1698)Met+(0.0236)Phe+(-0.0961)Trp; 0. 795,
0.838, 0.904, 0.845, 0.844, 0.851, 0.844, (4.4818)+(0.0350)Se
r+(-0.0281)Cit+(-0.0131)Val+(-0.1413)Met+(0.0402)Phe+(-0.07 15)Trp;
0.786, 0.826, 0.904, 0.836, 0.831, 0.848, 0.835,
(3.4140)+(0.0382)Ser+(-0.0284)Asn+(-0.1173)Met+(-0.0043)Lys+(0.0261)Phe+(-
-0.0847)Trp; 0.788, 0.836, 0.904, 0.845, 0.846, 0.849, 0.844,
(4.2580)+(0.0354)Ser+(-0.0039)Arg+(-0.0141)Val+(-0.1477)Met
+(0.0394)Phe+(-0.0707)Trp; 0.863, 0.888, 0.903, 0.810, 0.794, 0.7
87, 0.823, (3.6413)+(0.0330)Ser+(-0.0331)Cit+(-0.0376)Val+(-0.
1994)Met+(0.1223)Ile+(-0.0213)Trp; 0.769, 0.822, 0.903, 0.831, 0.
822, 0.849, 0.831, (3.0434)+(0.0416)Ser+(-0.0042)Gly+(0.0011)T
yr+(-0.1575)Met+(0.0237)Phe+(-0.0875)Trp; 0.858, 0.887, 0.903,
0.806, 0.793, 0.778, 0.819,
(3.3252)+(0.0317)Ser+(-0.0392)Val+(-0.2144)Met+(0.0077)Orn+(0.1179)Ile+(--
0.0221)Trp; 0.794, 0.8 35, 0.903, 0.806, 0.781, 0.824, 0.813,
(1.0512)+(0.0454)Ser+(-0.0
049)Gly+(-0.1923)Met+(0.0443)Ile+(0.0175)Phe+(-0.0847)Trp; 0. 791,
0.837, 0.903, 0.844, 0.841, 0.852, 0.843, (4.4934)+(0.0388)Se
r+(-0.0036)Gly+(-0.0138)Val+(-0.1546)Met+(0.0383)Phe+(-0.07 15)Trp;
0.786, 0.833, 0.903, 0.852, 0.857, 0.857, 0.849,
(1.5600)+(0.0284)Ser+(0.0071)Gln+(-0.0128)Arg+(-0.1697)Met+(0.0216)P
he+(-0.0935)Trp; 0.772, 0.823, 0.903, 0.830, 0.821, 0.848, 0.830,
(3.0737)+(0.0412)Ser+(-0.0046)Gly+(0.0019)Thr+(-0.1612)Met+(0.0244)Phe+(--
0.0880)Trp; 0.783, 0.822, 0.903, 0.831, 0.822, 0.84 9, 0.831,
(3.0498)+(0.0416)Ser+(-0.0043)Gly+(-0.1562)Met+(0.0
240)Phe+(-0.0873)Trp; 0.792, 0.836, 0.903, 0.836, 0.824, 0.854, 0.
838,
(3.0762)+(0.0358)Ser+(-0.0372)Cit+(0.0053)Arg+(-0.1472)Met+(0.0288)Phe+(--
0.0888)Trp; 0.777, 0.822, 0.903, 0.833, 0.825, 0.849, 0.832,
(3.1720)+(0.0414)Ser+(-0.0043)Gly+(-0.1547)Met+(-0.0021)Leu+(0.0255)Phe+(-
-0.0866)Trp; 0.771, 0.821, 0.903, 0.8 30, 0.821, 0.847, 0.830,
(3.0605)+(0.0417)Ser+(-0.0040)Gly+(-0.
0020)Arg+(-0.1530)Met+(0.0235)Phe+(-0.0863)Trp; 0.785, 0.836,
0.903, 0.853, 0.852, 0.863, 0.851, (1.9995)+(0.0342)Ser+(-0.007
2)Gly+(0.0070)Gln+(-0.1910)Met+(0.0214)Phe+(-0.0972)Trp; 0.7 80,
0.831, 0.903, 0.839, 0.837, 0.846, 0.838, (3.3346)+(0.0361)Ser
+(-0.0097)Pro+(-0.1308)Met+(0.0080)Orn+(0.0251)Phe+(-0.093 4)Trp;
0.819, 0.858, 0.902, 0.813, 0.790, 0.819, 0.822, (2.2718)+(0.
0320)Ser+(0.0294)Tyr+(-0.2078)Met+(0.1025)Ile+(-0.0485)Leu+(-0.0652)Trp;
0.855, 0.888, 0.902, 0.807, 0.795, 0.777, 0.820, (3.3
430)+(0.0323)Ser+(0.0006)Arg+(-0.0384)Val+(-0.2135)Met+(0.1
206)Ile+(-0.0235)Trp; 0.821, 0.851, 0.902, 0.810, 0.796, 0.805, 0.
817,
(2.3989)+(0.0319)Ser+(-0.1700)Met+(0.0944)Ile+(-0.0402)Leu+(-0.0594)Trp
[0514] List (1) of Logistic Regression Equations Searched in
Example 8
[0515] The logistic regression equations searched in Example 8
above are listed below. Before each equation, "the value of ROC_AUC
for the pancreatic cancer group and the breast cancer group with
validation", "the value of ROC_AUC for the pancreatic cancer group
and the breast cancer group without validation", "the value of
ROC_AUC for the pancreatic cancer group and the healthy group",
"the value of ROC_AUC for the pancreatic cancer group and the other
cancers group", "the value of ROC_AUC for the pancreatic cancer
group and the lung cancer group", "the value of ROC_AUC for the
pancreatic cancer group and the colorectal cancer group", and "the
average value of the value of ROC_AUC for the pancreatic cancer
group and the lung cancer group, the value of ROC_AUC for the
pancreatic cancer group and the colorectal cancer group, and the
value of ROC_AUC for the pancreatic cancer group and the breast
cancer group" obtained for the equation are additionally
listed.
[0516] 0.945, 0.965, 0.856, 0.937, 0.919, 0.922, 0.936,
(19.7721)+(-0.1860)Asn+(-0.0214)Gly+(-0.0294)Arg+(0.1519)Tyr+(-0.0325)V
al+(-0.1932)Trp; 0.943, 0.962, 0.845, 0.931, 0.915, 0.910, 0.929,
(18.2716)+(-0.1808)Asn+(-0.0209)Gly+(0.1319)Tyr+(-0.0291)Va
l+(-0.0849)Met+(-0.1671)Trp; 0.942, 0.961, 0.843, 0.928, 0.914, 0.
904, 0.926,
(18.6950)+(-0.2049)Asn+(-0.0227)Gly+(0.1247)Tyr+(-0.0313)Val+(-0.1-
689)Trp; 0.940, 0.964, 0.852, 0.931, 0.908, 0.9 14, 0.929,
(18.5628)+(-0.1809)Asn+(-0.0213)Gly+(0.1403)Tyr+(-0.0261)Val+(-0.0149)Lys-
+(-0.1804)Trp; 0.939, 0.967, 0.829, 0.92 5, 0.898, 0.903, 0.922,
(19.2936)+(-0.1920)Asn+(-0.0216)Gly+(0.
1768)Tyr+(-0.0310)Val+(-0.0428)Orn+(-0.2144)Trp; 0.939, 0.962,
0.843, 0.931, 0.916, 0.908, 0.929, (19.1391)+(-0.2047)Asn+(-0.02
27)Gly+(0.1279)Tyr+(-0.0303)Val+(-0.0160)Phe+(-0.1678)Trp; 0. 938,
0.963, 0.834, 0.929, 0.915, 0.904, 0.927,
(18.4477)+(-0.1783)Asn+(-0.0211)Gly+(-0.0102)Ala+(0.1495)Tyr+(-0.0246)Val-
+(-0. 1848)Trp; 0.938, 0.962, 0.838, 0.929, 0.914, 0.904, 0.926,
(18.518 7)+(-0.1989)Asn+(-0.0223)Gly+(-0.0039)Thr+(0.1257)Tyr+(-0.0
307)Val+(-0.1660)Trp; 0.938, 0.961, 0.844, 0.929, 0.913, 0.905, 0.
926, (18.6585)+(-0.2034)Asn+(-0.0223)Gly+(-0.0051)Cit+(0.125
0)Tyr+(-0.0309)Val+(-0.1696)Trp; 0.937, 0.960, 0.853, 0.921, 0.9
03, 0.893, 0.919,
(14.2988)+(-0.0198)Gly+(-0.0185)Ala+(0.1778)Tyr+(-0.0453)Lys+(0.0589)Ile+-
(-0.2460)Trp; 0.936, 0.961, 0.839, 0.926, 0.908, 0.902, 0.924,
(15.5250)+(-0.0179)Gly+(-0.0145)Ala
+(0.1906)Tyr+(-0.1690)Met+(-0.0266)Lys+(-0.2415)Trp; 0.936, 0. 952,
0.832, 0.919, 0.910, 0.886, 0.916,
(13.9656)+(-0.0178)Gly+(-0.0153)Ala+(0.1596)Tyr+(-0.2595)Met+(-0.2181)Trp-
; 0.936, 0.96 5, 0.867, 0.929, 0.914, 0.899, 0.926,
(16.5833)+(0.0280)Ser+(-0.2
436)Asn+(-0.0259)Gly+(0.1294)Tyr+(-0.0295)Val+(-0.1576)Trp; 0.935,
0.962, 0.870, 0.941, 0.920, 0.938, 0.940, (18.8523)+(-0.169
8)Asn+(-0.0207)Gly+(-0.0278)Arg+(0.1337)Tyr+(-0.0451)Leu+(-0.2089)Trp;
0.935, 0.954, 0.827, 0.921, 0.904, 0.898, 0.919, (15.51
36)+(-0.0218)Gly+(-0.0152)Ala+(0.1870)Tyr+(-0.0365)Lys+(-0.
2577)Trp; 0.935, 0.958, 0.826, 0.917, 0.902, 0.884, 0.914, (15.072
4)+(-0.0164)Gly+(-0.0156)Ala+(0.2082)Tyr+(-0.2478)Met+(-0.0
445)Orn+(-0.2598)Trp; 0.934, 0.964, 0.850, 0.929, 0.910, 0.907, 0.
927, (17.3759)+(-0.1143)Asn+(-0.0180)Gly+(-0.0144)Ala+(0.182
0)Tyr+(-0.0310)Lys+(-0.2361)Trp; 0.934, 0.960, 0.858, 0.926, 0.9
15, 0.897, 0.924,
(17.5160)+(-0.1971)Asn+(-0.0223)Gly+(0.1061)Tyr+(-0.0379)Val+(0.0390)Ile+-
(-0.1469)Trp; 0.933, 0.956, 0.826, 0.920, 0.911, 0.885, 0.917,
(14.7011)+(-0.0195)Gly+(-0.0128)Ala
+(0.1600)Tyr+(-0.0115)Val+(-0.2308)Met+(-0.2077)Trp; 0.933, 0. 956,
0.846, 0.923, 0.905, 0.899, 0.920,
(15.5936)+(-0.0203)Gly+(-0.0275)His+(-0.0142)Ala+(0.1768)Tyr+(-0.0313)Lys-
+(-0.2379)T rp; 0.933, 0.955, 0.836, 0.919, 0.901, 0.891, 0.916,
(16.2475)+(-0.
1293)Asn+(-0.0178)Gly+(-0.0149)Ala+(0.1739)Tyr+(-0.0420)Orn
+(-0.2480)Trp; 0.933, 0.962, 0.834, 0.925, 0.912, 0.892, 0.922,
(18. 4104)+(-0.2075)Asn+(-0.0230)Gly+(0.1248)Tyr+(-0.0486)Val+(0.
0337)Leu+(-0.1596)Trp; 0.933, 0.957, 0.841, 0.919, 0.910, 0.882, 0.
916, (12.7704)+(0.0158)Ser+(-0.0200)Gly+(-0.0151)Ala+(0.164
9)Tyr+(-0.2878)Met+(-0.2158)Trp; 0.933, 0.959, 0.861, 0.928, 0.9
09, 0.909, 0.926, (16.6886)+(-0.1353)Asn+(-0.0146)Gly+(-0.017
4)Ala+(-0.0709)Cit+(0.1542)Tyr+(-0.2304)Trp; 0.932, 0.956, 0.8 65,
0.933, 0.920, 0.919, 0.932,
(17.8934)+(-0.1885)Asn+(-0.0219)Gly+(0.1074)Tyr+(-0.0427)Leu+(-0.1860)Trp-
; 0.932, 0.961, 0.846, 0.930, 0.906, 0.919, 0.928,
(18.6123)+(-0.1766)Asn+(-0.0211)Gly
+(0.1599)Tyr+(-0.0436)Orn+(-0.0448)Leu+(-0.2264)Trp; 0.932, 0. 961,
0.892, 0.917, 0.891, 0.892, 0.914,
(12.7382)+(-0.0270)Ala+(-0.1091)Cit+(0.1739)Tyr+(-0.0494)Lys+(0.1149)Ile+-
(-0.2253)Tr p; 0.932, 0.958, 0.857, 0.929, 0.914, 0.909, 0.927,
(16.6371)+(-0.1
199)Asn+(-0.0175)Gly+(-0.0160)Ala+(-0.0322)Arg+(0.1667)Tyr+(-0.2438)Trp;
0.932, 0.953, 0.829, 0.920, 0.911, 0.889, 0.918, (14.
5685)+(-0.0183)Gly+(-0.0153)Ala+(0.1628)Tyr+(-0.2435)Met+(-0.0186)Phe+(-0-
.2174)Trp; 0.932, 0.957, 0.827, 0.924, 0.908, 0.901, 0.922,
(16.1441)+(-0.0220)Gly+(-0.0153)Ala+(0.1898)Tyr+(-0.0
347)Lys+(-0.0218)Phe+(-0.2544)Trp; 0.932, 0.955, 0.846, 0.922, 0.
909, 0.896, 0.920, (14.8528)+(-0.0153)Gly+(-0.0170)Ala+(-0.056
1)Cit+(0.1709)Tyr+(-0.2161)Met+(-0.2359)Trp; 0.932, 0.953, 0.8 30,
0.920, 0.912, 0.886, 0.917,
(14.3526)+(-0.0184)Gly+(-0.0144)Ala+(0.1591)Tyr+(-0.2409)Met+(-0.0090)Leu-
+(-0.2174)Trp; 0.93 1, 0.960, 0.859, 0.929, 0.903, 0.919, 0.927,
(17.4730)+(-0.1593)As
n+(-0.0189)Ala+(-0.0859)Cit+(0.1918)Tyr+(-0.0280)Lys+(-0.22 34)Trp;
0.931, 0.960, 0.864, 0.936, 0.914, 0.930, 0.935,
(17.7847)+(-0.1585)Asn+(-0.0208)Gly+(0.1310)Tyr+(-0.0193)Lys+(-0.029
8)Leu+(-0.2023)Trp; 0.931, 0.955, 0.828, 0.931, 0.917, 0.916, 0.92
9, (15.1833)+(-0.0229)Gly+(-0.0305)Arg+(0.1523)Tyr+(-0.0235)
Val+(-0.1789)Met+(-0.2015)Trp; 0.931, 0.951, 0.821, 0.920, 0.903,
0.898, 0.918, (15.2754)+(-0.0207)Gly+(-0.0103)Thr+(-0.0148)Al
a+(0.1882)Tyr+(-0.0341)Lys+(-0.2458)Trp; 0.931, 0.959, 0.841, 0.
924, 0.899, 0.907, 0.922,
(16.0715)+(-0.0188)Gly+(-0.0166)Ala+(-0.0509)Cit+(0.1942)Tyr+(-0.0317)Lys-
+(-0.2679)Trp; 0.931, 0. 957, 0.863, 0.935, 0.921, 0.923, 0.934,
(18.3571)+(-0.1881)Asn+(-0.0221)Gly+(0.1111)Tyr+(-0.0408)Leu+(-0.0171)Phe-
+(-0.1843)I rp; 0.931, 0.955, 0.822, 0.920, 0.905, 0.892, 0.917,
(15.8004)+(-0.
0227)Gly+(-0.0141)Ala+(0.1839)Tyr+(-0.0068)Val+(-0.0331)Lys
+(-0.2473)Trp; 0.931, 0.963, 0.819, 0.927, 0.914, 0.895, 0.924,
(19. 3362)+(-0.2361)Asn+(-0.0246)Gly+(0.0353)His+(0.1325)Tyr+(-0.
0382)Val+(-0.1807)Trp; 0.931, 0.957, 0.814, 0.916, 0.884, 0.897, 0.
913, (16.1310)+(-0.0213)Gly+(-0.0146)Ala+(0.2199)Tyr+(-0.036
7)Orn+(-0.0311)Lys+(-0.2948)Trp; 0.931, 0.953, 0.839, 0.926, 0.9
13, 0.906, 0.924, (14.9224)+(-0.0172)Gly+(-0.0158)Ala+(-0.026
9)Arg+(0.1821)Tyr+(-0.2001)Met+(-0.2469)Trp; 0.930, 0.953, 0.8 35,
0.918, 0.909, 0.884, 0.915,
(13.3776)+(-0.0169)Gly+(-0.0168)Ala+(0.1532)Tyr+(-0.2681)Met+(0.0193)Ile+-
(-0.2103)Trp; 0.930, 0.956, 0.843, 0.922, 0.911, 0.893, 0.920,
(15.5012)+(-0.0214)Gly+(-0.0162)Ala+(0.0056)Pro+(0.1831)Tyr+(-0.0401)Lys+-
(-0.2513)Trp; 0.930, 0.963, 0.833, 0.929, 0.910, 0.908, 0.927,
(18.6294)+(-0.
1987)Asn+(-0.0223)Gly+(-0.0058)Pro+(0.1346)Tyr+(-0.0299)Val
+(-0.1767)Trp; 0.930, 0.960, 0.848, 0.930, 0.918, 0.907, 0.928,
(17.
8737)+(-0.1634)Asn+(-0.0201)Gly+(-0.0124)Ala+(0.1429)Tyr+(-0.0304)Leu+(-0-
.2040)Trp; 0.930, 0.956, 0.824, 0.922, 0.908, 0.895, 0.919,
(14.1671)+(-0.0227)Gly+(0.0040)Gln+(-0.0153)Ala+(0.18
00)Tyr+(-0.0397)Lys+(-0.2508)Trp; 0.929, 0.956, 0.833, 0.901, 0.
874, 0.863, 0.898, (11.0189)+(-0.0238)Ala+(0.1862)Tyr+(-0.046
4)Orn+(-0.0480)Lys+(0.0979)Ile+(-0.2219)Trp; 0.929, 0.954, 0.8 28,
0.921, 0.904, 0.898, 0.919,
(15.4882)+(-0.0218)Gly+(-0.0153)Ala+(0.1873)Tyr+(-0.0368)Lys+(0.0009)Leu+-
(-0.2582)Trp; 0.929, 0.958, 0.834, 0.927, 0.904, 0.913, 0.925,
(16.5859)+(-0.0204)Gly+(-0.0162)Ala+(-0.0269)Arg+(0.2107)Tyr+(-0.0310)Lys-
+(-0.284 1)Trp; 0.929, 0.955, 0.830, 0.921, 0.905, 0.896, 0.919,
(14.8299)+(0.0085)Ser+(-0.0235)Gly+(-0.0150)Ala+(0.1904)Tyr+(-0.0376)Lys+-
(-0.2587)Trp; 0.929, 0.954, 0.828, 0.918, 0.909, 0.882, 0.915,
(13.7957)+(-0.0177)Gly+(-0.0065)Thr+(-0.0149)Ala+(0.1605)Ty
r+(-0.2347)Met+(-0.2138)Trp; 0.928, 0.956, 0.848, 0.922, 0.911, 0.
892, 0.920,
(15.5990)+(-0.1429)Asn+(-0.0194)Gly+(-0.0149)Ala+(0.1291)Tyr+(-0.2-
079)Trp; 0.928, 0.955, 0.859, 0.925, 0.906, 0.90 9, 0.923,
(15.7802)+(-0.1780)Asn+(-0.0196)Ala+(-0.1054)Cit+(0.
1536)Tyr+(-0.2061)Trp; 0.928, 0.957, 0.883, 0.932, 0.915, 0.919, 0.
930, (15.7143)+(0.0305)Ser+(-0.2338)Asn+(-0.0255)Gly+(0.114
1)Tyr+(-0.0410)Leu+(-0.1715)Trp; 0.928, 0.956, 0.848, 0.922, 0.9
11, 0.891, 0.919, (14.4104)+(-0.0167)Gly+(-0.0336)His+(-0.014
3)Ala+(0.1516)Tyr+(-0.2112)Met+(-0.2011)Trp; 0.928, 0.955, 0.8 18,
0.919, 0.888, 0.905, 0.916,
(16.1039)+(-0.0202)Gly+(-0.0171)Ala+(-0.0410)Arg+(0.2243)Tyr+(-0.0454)Orn-
+(-0.3189)Trp; 0.92 8, 0.955, 0.882, 0.934, 0.913, 0.929, 0.932,
(16.4372)+(-0.1106)As
n+(-0.0192)Gly+(-0.0364)His+(0.1264)Tyr+(-0.0285)Lys+(-0.19 35)Trp;
0.928, 0.952, 0.832, 0.919, 0.910, 0.886, 0.916,
(13.9641)+(-0.0178)Gly+(-0.0153)Ala+(0.0000)Pro+(0.1595)Tyr+(-0.2595)Met+-
(-0.2180)Trp; 0.927, 0.950, 0.812, 0.919, 0.907, 0.893, 0.917,
(13.8882)+(-0.0231)Gly+(0.1310)Tyr+(-0.0217)Val+(-0.2380)Me
t+(-0.1781)Trp; 0.927, 0.948, 0.796, 0.908, 0.893, 0.877, 0.906, (1
3.0373)+(-0.0176)Ala+(0.2102)Tyr+(-0.3645)Met+(-0.0525)Orn+(-0.2193)Trp;
0.927, 0.962, 0.836, 0.931, 0.919, 0.906, 0.929, (17.
0704)+(-0.2285)Asn+(-0.0240)Gly+(0.0056)Gln+(0.1137)Tyr+(-0.
0320)Val+(-0.1577)Trp; 0.927, 0.955, 0.866, 0.935, 0.920, 0.926, 0.
934, (17.4567)+(-0.1669)Asn+(-0.0206)Gly+(0.1134)Tyr+(-0.072
2)Met+(-0.0394)Leu+(-0.1828)Trp; 0.927, 0.953, 0.834, 0.903, 0.8
82, 0.862, 0.899,
(10.5201)+(-0.0204)Thr+(-0.0225)Ala+(0.1669)Tyr+(-0.0496)Lys+(0.0851)Ile+-
(-0.1799)Trp; 0.927, 0.952, 0.833, 0.921, 0.904, 0.900, 0.919,
(14.6656)+(-0.0213)Gly+(-0.0170)Ala
+(-0.0414)Arg+(0.1714)Tyr+(-0.2699)Trp; 0.927, 0.953, 0.868, 0.
936, 0.914, 0.938, 0.935,
(16.2015)+(-0.1073)Asn+(-0.0194)Gly+(0.1392)Tyr+(-0.0897)Met+(-0.0309)Lys-
+(-0.2105)Trp; 0.926, 0. 955, 0.832, 0.920, 0.912, 0.885, 0.917,
(13.2893)+(-0.0180)Gly+(0.
0017)Gln+(-0.0153)Ala+(0.1555)Tyr+(-0.2670)Met+(-0.2134)Tr p;
0.926, 0.951, 0.813, 0.913, 0.896, 0.885, 0.911, (14.0525)+(-0.0
170)Ala+(0.2217)Tyr+(-0.3129)Met+(-0.0447)Orn+(-0.0176)Lys+(-0.2287)Trp;
0.926, 0.943, 0.811, 0.902, 0.897, 0.858, 0.899, (12.
9309)+(-0.0255)Gly+(-0.0158)Ala+(0.1244)Tyr+(-0.2339)Trp; 0. 926,
0.952, 0.864, 0.934, 0.912, 0.934, 0.933,
(16.3460)+(-0.1262)Asn+(-0.0207)Gly+(0.1315)Tyr+(-0.0334)Lys+(-0.2145)Trp-
; 0.92 6, 0.956, 0.864, 0.933, 0.920, 0.919, 0.932,
(17.9000)+(-0.1886)As
n+(-0.0220)Gly+(0.1076)Tyr+(-0.0002)Ile+(-0.0427)Leu+(-0.18 61)Trp;
0.926, 0.953, 0.825, 0.925, 0.907, 0.909, 0.923,
(14.7538)+(-0.0224)Gly+(0.1545)Tyr+(-0.0166)Val+(-0.1813)Met+(-0.021
7)Lys+(-0.1983)Trp; 0.926, 0.950, 0.827, 0.925, 0.908, 0.912, 0.92
3, (15.6837)+(-0.0262)Gly+(-0.0290)Arg+(0.1608)Tyr+(-0.0204)
Val+(-0.0210)Lys+(-0.2305)Trp; 0.926, 0.954, 0.854, 0.918, 0.907,
0.886, 0.916, (14.2981)+(-0.0208)Gly+(-0.0676)His+(-0.0139)Al
a+(0.1262)Tyr+(-0.1988)Trp; 0.926, 0.946, 0.819, 0.921, 0.909, 0.
904, 0.920,
(15.3785)+(-0.0281)Gly+(-0.0419)Arg+(0.1444)Tyr+(-0.0269)Val+(-0.2-
218)Trp; 0.926, 0.959, 0.834, 0.914, 0.889, 0.8 86, 0.911,
(15.4621)+(-0.0195)Gly+(-0.0639)His+(-0.0141)Ala+(0.1778)Tyr+(-0.0458)Orn-
+(-0.2444)Trp; 0.926, 0.956, 0.851, 0.9 26, 0.917, 0.897, 0.923,
(15.5754)+(-0.0969)Asn+(-0.0165)Gly+(-0.0147)Ala+(0.1540)Tyr+(-0.1825)Met-
+(-0.2075)Trp; 0.926, 0.95 5, 0.866, 0.921, 0.911, 0.891, 0.919,
(14.1295)+(0.0273)Ser+(-0.1
871)Asn+(-0.0231)Gly+(-0.0145)Ala+(0.1350)Tyr+(-0.1992)Trp; 0.926,
0.955, 0.846, 0.926, 0.894, 0.924, 0.924, (16.4740)+(-0.117
9)Asn+(-0.0198)Gly+(0.1615)Tyr+(-0.0308)Orn+(-0.0315)Lys+(-0.2373)Trp;
0.926, 0.954, 0.815, 0.923, 0.908, 0.899, 0.920, (16.94
20)+(-0.0245)Gly+(-0.0139)Ala+(-0.0434)Arg+(0.1893)Tyr+(-0.
0195)Val+(-0.2614)Trp; 0.926, 0.953, 0.848, 0.914, 0.895, 0.885, 0.
911, (11.9904)+(-0.0221)Ala+(0.1867)Tyr+(-0.2787)Met+(-0.038
8)Lys+(0.0756)Ile+(-0.1870)Trp; 0.925, 0.959, 0.869, 0.937, 0.92 1,
0.927, 0.935, (17.8321)+(-0.1846)Asn+(-0.0209)Gly+(-0.0167)
Cit+(0.1097)Tyr+(-0.0418)Leu+(-0.1871)Trp; 0.925, 0.958, 0.859,
0.926, 0.907, 0.907, 0.924, (15.6209)+(-0.0183)Gly+(-0.0567)His
+(-0.0149)Ala+(-0.0360)Arg+(0.1653)Tyr+(-0.2352)Trp; 0.925, 0. 956,
0.864, 0.935, 0.924, 0.922, 0.934,
(16.7684)+(-0.2019)Asn+(-0.0229)Gly+(0.0037)Gln+(0.0987)Tyr+(-0.0427)Leu+-
(-0.1790)Tr p; 0.925, 0.956, 0.832, 0.920, 0.887, 0.910, 0.918,
(15.8037)+(-0.2
082)Asn+(0.1740)Tyr+(-0.0257)Val+(-0.1788)Met+(-0.0481)Orn+(-0.1578)Trp;
0.925, 0.955, 0.798, 0.915, 0.891, 0.891, 0.912, (14.
7090)+(-0.0226)Gly+(0.1806)Tyr+(-0.0223)Val+(-0.2174)Met+(-0.0426)Orn+(-0-
.2171)Trp; 0.925, 0.955, 0.873, 0.935, 0.910, 0.936, 0.934,
(16.2745)+(-0.1252)Asn+(-0.0195)Gly+(-0.0151)Cit+(0.1
319)Tyr+(-0.0326)Lys+(-0.2131)Trp; 0.925, 0.953, 0.843, 0.921, 0.
901, 0.904, 0.919, (14.6029)+(-0.0186)Ala+(-0.0729)Cit+(0.198
2)Tyr+(-0.2438)Met+(-0.0226)Lys+(-0.2219)Trp; 0.925, 0.951, 0. 813,
0.912, 0.891, 0.885, 0.909, (14.2251)+(-0.1875)Asn+(-0.016
6)Ala+(0.1617)Tyr+(-0.0542)Orn+(-0.1972)Trp; 0.925, 0.949, 0.8 98,
0.928, 0.912, 0.918, 0.927,
(13.7121)+(-0.0209)Gly+(-0.0815)His+(-0.0281)Arg+(0.0983)Tyr+(-0.1762)Trp-
; 0.925, 0.958, 0.807, 0.917, 0.897, 0.886, 0.914,
(16.4874)+(-0.2226)Asn+(-0.0129)Ala
+(0.1765)Tyr+(-0.0193)Val+(-0.0525)Orn+(-0.1802)Trp; 0.925, 0. 958,
0.859, 0.928, 0.906, 0.913, 0.926,
(15.6232)+(-0.1300)Asn+(-0.0187)Ala+(-0.0890)Cit+(0.1729)Tyr+(-0.1691)Met-
+(-0.2059)T rp; 0.925, 0.957, 0.859, 0.934, 0.922, 0.918, 0.932,
(17.6413)+(-0.
1786)Asn+(-0.0212)Gly+(-0.0075)Thr+(0.1100)Tyr+(-0.0417)Leu
+(-0.1801)Trp; 0.925, 0.955, 0.823, 0.919, 0.896, 0.897, 0.916,
(15.
6904)+(-0.1567)Asn+(-0.0176)Ala+(-0.0346)Arg+(0.1966)Tyr+(-0.0486)Orn+(-0-
.2395)Trp; 0.925, 0.954, 0.842, 0.917, 0.905, 0.885, 0.915,
(14.0720)+(-0.0193)Gly+(-0.0614)His+(-0.0139)Thr+(-0.
0134)Ala+(0.1326)Tyr+(-0.1877)Trp; 0.925, 0.948, 0.797, 0.907, 0.
893, 0.872, 0.904, (12.5917)+(-0.0175)Ala+(0.2088)Tyr+(-0.377
1)Met+(-0.0531)Orn+(0.0170)Phe+(-0.2220)Trp; 0.925, 0.947, 0.8 44,
0.934, 0.920, 0.934, 0.934,
(14.4805)+(-0.0223)Gly+(-0.0287)Arg+(0.1367)Tyr+(-0.1646)Met+(-0.0311)Leu-
+(-0.2103)Trp; 0.92 4, 0.954, 0.855, 0.923, 0.904, 0.905, 0.921,
(14.8267)+(-0.0185)Gl
y+(-0.0460)His+(-0.0161)Ala+(-0.0548)Cit+(0.1444)Tyr+(-0.22 56)Trp;
0.924, 0.952, 0.830, 0.917, 0.903, 0.890, 0.915,
(15.4019)+(-0.1670)Asn+(-0.0176)Ala+(0.1748)Tyr+(-0.0359)Lys+(-0.184
4)Trp; 0.924, 0.961, 0.873, 0.928, 0.915, 0.903, 0.926,
(16.1644)+(-0.1179)Asn+(-0.0173)Gly+(-0.0477)His+(-0.0138)Ala+(0.127
6)Tyr+(-0.1856)Trp
[0517] List (1) of Linear Discriminants Searched in Example 8
[0518] The linear discriminants searched in Example 8 above are
listed below. Before each equation, "the value of ROC_AUC for the
pancreatic cancer group and the breast cancer group with
validation", "the value of ROC_AUC for the pancreatic cancer group
and the breast cancer group without validation", "the value of
ROC_AUC for the pancreatic cancer group and the healthy group",
"the value of ROC_AUC for the pancreatic cancer group and the other
cancers group", "the value of ROC_AUC for the pancreatic cancer
group and the lung cancer group", "the value of ROC_AUC for the
pancreatic cancer group and the colorectal cancer group", and "the
average value of the value of ROC_AUC for the pancreatic cancer
group and the lung cancer group, the value of ROC_AUC for the
pancreatic cancer group and the colorectal cancer group, and the
value of ROC_AUC for the pancreatic cancer group and the breast
cancer group" obtained for the equation are additionally
listed.
[0519] 0.947, 0.963, 0.857, 0.932, 0.910, 0.917, 0.930,
(16.5080)+(-0.1847)Asn+(-0.0136)Gly+(0.1059)Tyr+(-0.0166)Val+(-0.0144)L
ys+(-0.1261)Trp; 0.947, 0.963, 0.887, 0.926, 0.917, 0.890, 0.923,
(15.4522)+(0.0407)Ser+(-0.2621)Asn+(-0.0204)Gly+(0.0901)Tyr
+(-0.0238)Val+(-0.1073)Trp; 0.946, 0.961, 0.856, 0.931, 0.916, 0.
911, 0.929,
(16.3693)+(-0.2032)Asn+(-0.0143)Gly+(0.0911)Tyr+(-0.0205)Val+(-0.1-
222)Trp; 0.946, 0.964, 0.867, 0.938, 0.921, 0.9 25, 0.937,
(16.6747)+(-0.1853)Asn+(-0.0142)Gly+(-0.0165)Arg+(0.1002)Tyr+(-0.0198)Val-
+(-0.1310)Trp; 0.945, 0.964, 0.851, 0.9 31, 0.907, 0.914, 0.928,
(16.3302)+(-0.1982)Asn+(-0.0137)Gly+(0.
1050)Tyr+(-0.0184)Val+(-0.0221)Orn+(-0.1288)Trp; 0.945, 0.962,
0.844, 0.930, 0.917, 0.902, 0.927, (16.0086)+(-0.1827)Asn+(-0.01
15)Gly+(-0.0089)Ala+(0.1042)Tyr+(-0.0142)Val+(-0.1271)Trp; 0. 945,
0.959, 0.858, 0.907, 0.881, 0.869, 0.903,
(11.1280)+(-0.0097)Gly+(-0.0205)Ala+(0.1331)Tyr+(-0.0405)Lys+(0.0966)Ile+-
(-0.1 673)Trp; 0.944, 0.960, 0.895, 0.910, 0.882, 0.877, 0.906,
(11.7959)
+(-0.0251)Ala+(-0.0900)Cit+(0.1411)Tyr+(-0.0407)Lys+(0.126
3)Ile+(-0.1856)Trp; 0.944, 0.962, 0.853, 0.934, 0.917, 0.918, 0.93
2, (17.5529)+(-0.2011)Asn+(-0.0145)Gly+(0.1006)Tyr+(-0.0198)
Val+(-0.0362)Phe+(-0.1205)Trp; 0.944, 0.961, 0.848, 0.931, 0.914,
0.912, 0.929, (16.2146)+(-0.1878)Asn+(-0.0134)Gly+(-0.0126)Th
r+(0.0973)Tyr+(-0.0189)Val+(-0.1200)Trp; 0.944, 0.960, 0.854, 0.
930, 0.911, 0.912, 0.928,
(15.2276)+(-0.1416)Asn+(-0.0098)Gly+(-0.0117)Ala+(0.1260)Tyr+(-0.0207)Lys-
+(-0.1443)Trp; 0.944, 0. 960, 0.858, 0.933, 0.914, 0.920, 0.931,
(16.1002)+(-0.1600)Asn+(-0.0131)Gly+(0.1159)Tyr+(-0.0179)Val+(-0.1568)Met-
+(-0.1278)T rp; 0.943, 0.962, 0.843, 0.931, 0.913, 0.912, 0.929,
(16.4600)+(-0.
2005)Asn+(-0.0145)Gly+(-0.0054)Pro+(0.0991)Tyr+(-0.0195)Val
+(-0.1249)Trp; 0.942, 0.960, 0.867, 0.933, 0.916, 0.918, 0.931,
(16.
5160)+(-0.1988)Asn+(-0.0140)Gly+(-0.0190)Cit+(0.0919)Tyr+(-0.0186)Val+(-0-
.1282)Trp; 0.941, 0.962, 0.854, 0.932, 0.916, 0.912, 0.930,
(14.9371)+(-0.2207)Asn+(-0.0147)Gly+(0.0048)Gln+(0.08
31)Tyr+(-0.0217)Val+(-0.1161)Trp; 0.941, 0.960, 0.871, 0.932, 0.
918, 0.914, 0.931, (16.5717)+(-0.1866)Asn+(-0.0139)Gly+(-0.024
0)His+(0.0870)Tyr+(-0.0167)Val+(-0.1176)Trp; 0.941, 0.954, 0.8 26,
0.918, 0.901, 0.889, 0.915,
(12.1179)+(-0.0106)Gly+(-0.0117)Ala+(0.1440)Tyr+(-0.2897)Met+(-0.1605)Trp-
; 0.940, 0.956, 0.830, 0.924, 0.906, 0.902, 0.921,
(12.7376)+(-0.0103)Gly+(-0.0115)Ala
+(0.1511)Tyr+(-0.2252)Met+(-0.0157)Lys+(-0.1579)Trp; 0.940, 0. 955,
0.817, 0.919, 0.906, 0.889, 0.917,
(12.0399)+(-0.0119)Gly+(-0.0131)Ala+(0.1263)Tyr+(-0.0268)Lys+(-0.1583)Trp-
; 0.940, 0.95 7, 0.868, 0.930, 0.912, 0.916, 0.928,
(15.4763)+(-0.1546)Asn+(-0.
0097)Gly+(-0.0124)Ala+(-0.0541)Cit+(0.1083)Tyr+(-0.1552)Tr p;
0.940, 0.959, 0.855, 0.931, 0.906, 0.922, 0.929, (15.6243)+(-0.1
898)Asn+(-0.0134)Gly+(0.1050)Tyr+(-0.0275)Orn+(-0.0239)Leu+(-0.1400)Trp;
0.940, 0.955, 0.816, 0.918, 0.902, 0.888, 0.915, (12.
3851)+(-0.0099)Gly+(-0.0114)Ala+(0.1608)Tyr+(-0.2771)Met+(-0.0286)Orn+(-0-
.1649)Trp; 0.940, 0.958, 0.854, 0.928, 0.914, 0.905, 0.926,
(14.7420)+(-0.1429)Asn+(-0.0107)Gly+(-0.0122)Ala+(-0.
0172)Arg+(0.1125)Tyr+(-0.1549)Trp; 0.939, 0.959, 0.843, 0.925, 0.
903, 0.907, 0.923, (12.8941)+(-0.0112)Gly+(-0.0131)Ala+(-0.045
3)Cit+(0.1270)Tyr+(-0.0236)Lys+(-0.1657)Trp; 0.939, 0.959, 0.8 11,
0.924, 0.910, 0.896, 0.922,
(13.1099)+(-0.0121)Gly+(-0.0133)Ala+(0.1333)Tyr+(-0.0249)Lys+(-0.0329)Phe-
+(-0.1560)Trp; 0.93 9, 0.955, 0.837, 0.921, 0.902, 0.898, 0.919,
(14.6581)+(-0.1573)As
n+(-0.0099)Gly+(-0.0122)Ala+(0.1240)Tyr+(-0.0316)Orn+(-0.15 17)Trp;
0.939, 0.955, 0.845, 0.914, 0.907, 0.872, 0.911,
(10.6239)+(0.0293)Ser+(-0.0148)Gly+(-0.0125)Ala+(0.1523)Tyr+(-0.3524)Met+-
(-0.1562)Trp; 0.939, 0.955, 0.825, 0.919, 0.905, 0.889, 0.916,
(12.5337)+(-0.0111)Gly+(-0.0104)Ala+(0.1436)Tyr+(-0.0056)Va
l+(-0.2875)Met+(-0.1538)Trp; 0.939, 0.959, 0.854, 0.925, 0.906, 0.
904, 0.923,
(14.3597)+(-0.1172)Asn+(-0.0097)Gly+(-0.0114)Ala+(0.1303)Tyr+(-0.1-
746)Met+(-0.1492)Trp; 0.939, 0.959, 0.881, 0.9 37, 0.916, 0.934,
0.936,
(15.9776)+(-0.1880)Asn+(-0.0136)Gly+(-0.0357)Cit+(0.0894)Tyr+(-0.0223)Leu-
+(-0.1425)Trp; 0.938, 0.95 7, 0.871, 0.939, 0.922, 0.935, 0.938,
(15.9323)+(-0.1756)Asn+(-0.
0140)Gly+(-0.0180)Arg+(0.0973)Tyr+(-0.0263)Leu+(-0.1424)Tr p;
0.938, 0.955, 0.866, 0.919, 0.914, 0.879, 0.916, (13.1790)+(0.03
71)Ser+(-0.2085)Asn+(-0.0159)Gly+(-0.0138)Ala+(0.1030)Tyr+(-0.1369)Trp;
0.938, 0.960, 0.848, 0.926, 0.911, 0.898, 0.923, (16.
3220)+(-0.2038)Asn+(-0.0147)Gly+(0.0915)Tyr+(-0.0362)Val+(0.
0305)Leu+(-0.1208)Trp; 0.938, 0.957, 0.869, 0.935, 0.914, 0.931, 0.
934, (15.2147)+(-0.1496)Asn+(-0.0130)Gly+(0.1127)Tyr+(-0.162
5)Met+(-0.0211)Leu+(-0.1395)Trp; 0.938, 0.957, 0.857, 0.930, 0.9
08, 0.917, 0.928, (15.5841)+(-0.1546)Asn+(-0.0144)Ala+(-0.049
6)Cit+(0.1320)Tyr+(-0.0194)Lys+(-0.1521)Trp; 0.938, 0.952, 0.8 44,
0.920, 0.907, 0.894, 0.918,
(14.3471)+(-0.1601)Asn+(-0.0107)Gly+(-0.0126)Ala+(0.1033)Tyr+(-0.1466)Trp-
; 0.938, 0.958, 0.876, 0.927, 0.913, 0.905, 0.925,
(15.6470)+(-0.1385)Asn+(-0.0102)Gly
+(-0.0477)His+(-0.0111)Ala+(0.0965)Tyr+(-0.1270)Trp; 0.938, 0. 957,
0.870, 0.898, 0.899, 0.826, 0.894,
(14.4031)+(-0.1984)Asn+(-0.0182)Ala+(0.0946)Tyr+(-0.0405)Val+(0.1414)Ile+-
(-0.1133)Tr p; 0.938, 0.955, 0.829, 0.893, 0.863, 0.846, 0.888,
(10.1586)+(-0.0
245)Ala+(0.1579)Tyr+(-0.0387)Orn+(-0.0396)Lys+(0.1157)Ile+(-0.1772)Trp;
0.938, 0.955, 0.826, 0.922, 0.896, 0.910, 0.920, (12.
5518)+(-0.0137)Gly+(0.1473)Tyr+(-0.0099)Val+(-0.3155)Met+(-0.0247)Orn+(-0-
.1580)Trp; 0.938, 0.957, 0.860, 0.924, 0.911, 0.896, 0.921,
(13.3437)+(-0.0116)Gly+(-0.0466)His+(-0.0118)Ala+(0.1
118)Tyr+(-0.0191)Lys+(-0.1384)Trp; 0.938, 0.954, 0.800, 0.914, 0.
895, 0.883, 0.911, (12.3842)+(-0.0102)Gly+(-0.0213)Thr+(-0.012
9)Ala+(0.1337)Tyr+(-0.0221)Lys+(-0.1492)Trp; 0.937, 0.955, 0.8 97,
0.926, 0.913, 0.905, 0.924, (14.7173)+(0.0403)Ser+(-0.2536)A
sn+(-0.0201)Gly+(0.0863)Tyr+(-0.0344)Leu+(-0.1182)Trp; 0.937,
0.957, 0.875, 0.930, 0.917, 0.910, 0.928,
(13.9507)+(-0.0120)Gly+(-0.0592)His+(-0.0114)Ala+(-0.0282)Arg+(0.1050)Tyr-
+(-0.147 1)Trp; 0.937, 0.953, 0.829, 0.895, 0.870, 0.849, 0.891,
(10.7321)+(-0.0256)Thr+(-0.0233)Ala+(0.1469)Tyr+(-0.0383)Lys+(0.1041)Ile+-
(-0.1579)Trp; 0.937, 0.954, 0.831, 0.918, 0.902, 0.890, 0.915,
(12.0889)+(-0.0104)Gly+(-0.0121)Ala+(0.0017)Pro+(0.1426)Tyr
+(-0.2931)Met+(-0.1599)Trp; 0.937, 0.954, 0.846, 0.922, 0.907, 0.
899, 0.920,
(12.9961)+(-0.0100)Gly+(-0.0118)Ala+(-0.0441)Cit+(0.1441)Tyr+(-0.2-
649)Met+(-0.1673)Trp; 0.937, 0.953, 0.882, 0.9 09, 0.904, 0.858,
0.905, (16.0905)+(-0.2100)Asn+(-0.0159)Gly+(0.
0744)Tyr+(-0.0462)Val+(0.1138)Ile+(-0.1069)Trp; 0.937, 0.958,
0.824, 0.926, 0.909, 0.904, 0.924, (12.5889)+(-0.0119)Gly+(-0.01
28)Ala+(-0.0188)Arg+(0.1309)Tyr+(-0.0213)Lys+(-0.1665)Trp; 0. 937,
0.949, 0.834, 0.920, 0.900, 0.905, 0.918,
(12.4904)+(-0.0144)Gly+(0.1329)Tyr+(-0.0120)Val+(-0.3245)Met+(-0.1515)Trp-
; 0.93 7, 0.954, 0.869, 0.933, 0.916, 0.924, 0.932,
(15.5873)+(-0.1951)As
n+(-0.0141)Gly+(0.0873)Tyr+(-0.0276)Leu+(-0.1330)Trp; 0.937, 0.953,
0.854, 0.909, 0.893, 0.870, 0.905,
(11.0454)+(-0.0094)Gly+(-0.0170)Ala+(0.1417)Tyr+(-0.3112)Met+(0.0646)Ile+-
(-0.1681)Trp; 0.937, 0.954, 0.854, 0.922, 0.907, 0.899, 0.920,
(13.3413)+(-0.
0105)Gly+(-0.0412)His+(-0.0108)Ala+(0.1291)Tyr+(-0.2305)Met
+(-0.1422)Trp; 0.936, 0.957, 0.852, 0.916, 0.900, 0.884, 0.913,
(12.
9722)+(-0.0118)Gly+(-0.0613)His+(-0.0119)Ala+(0.1048)Tyr+(-0.0249)Orn+(-0-
.1395)Trp; 0.936, 0.956, 0.816, 0.920, 0.906, 0.889, 0.917,
(12.0468)+(-0.0119)Gly+(-0.0131)Ala+(0.1262)Tyr+(-0.0
001)Val+(-0.0267)Lys+(-0.1582)Trp; 0.936, 0.953, 0.864, 0.917, 0.
908, 0.881, 0.914, (12.9335)+(-0.0123)Gly+(-0.0681)His+(-0.012
1)Ala+(0.0875)Tyr+(-0.1326)Trp; 0.936, 0.955, 0.901, 0.925, 0.90 1,
0.912, 0.923, (13.6542)+(0.0419)Ser+(-0.2060)Asn+(-0.0196)G
ly+(0.1123)Tyr+(-0.0301)Lys+(-0.1388)Trp; 0.936, 0.953, 0.842,
0.927, 0.913, 0.909, 0.925, (12.8082)+(-0.0106)Gly+(-0.0115)Ala
+(-0.0194)Arg+(0.1488)Tyr+(-0.2507)Met+(-0.1681)Trp; 0.936, 0. 956,
0.870, 0.934, 0.913, 0.928, 0.932,
(15.6590)+(-0.1730)Asn+(-0.0135)Gly+(0.1043)Tyr+(-0.0168)Lys+(-0.0177)Leu-
+(-0.1380)I rp; 0.936, 0.953, 0.824, 0.919, 0.904, 0.892, 0.916,
(12.4561)+(-0.
0107)Gly+(-0.0119)Ala+(0.1455)Tyr+(-0.2805)Met+(-0.0109)Phe
+(-0.1597)Trp; 0.936, 0.953, 0.919, 0.927, 0.911, 0.911, 0.925,
(14. 4885)+(0.0371)Ser+(-0.1934)Asn+(-0.0192)Gly+(-0.0699)His+(0.
0714)Tyr+(-0.1141)Trp; 0.936, 0.954, 0.856, 0.925, 0.909, 0.905, 0.
923, (14.9924)+(-0.1717)Asn+(-0.0154)Ala+(-0.0627)Cit+(0.112
2)Tyr+(-0.1563)Trp; 0.936, 0.957, 0.812, 0.921, 0.907, 0.890, 0.91
8, (11.1096)+(-0.0121)Gly+(0.0026)Gln+(-0.0134)Ala+(0.1238)T
yr+(-0.0287)Lys+(-0.1563)Trp; 0.936, 0.958, 0.839, 0.923, 0.905,
0.896, 0.920, (14.8034)+(-0.1502)Asn+(-0.0120)Ala+(0.1354)Tyr
+(-0.0098)Val+(-0.1821)Met+(-0.1355)Trp; 0.936, 0.954, 0.808, 0.
916, 0.895, 0.889, 0.913,
(12.0702)+(-0.0116)Gly+(-0.0130)Ala+(0.1357)Tyr+(-0.0198)Orn+(-0.0236)Lys-
+(-0.1620)Trp; 0.936, 0. 956, 0.838, 0.925, 0.914, 0.898, 0.923,
(16.1477)+(-0.1582)Asn+(-0.0109)Gly+(-0.0127)Ala+(0.1174)Tyr+(-0.0509)Phe-
+(-0.1427)T rp; 0.936, 0.957, 0.863, 0.928, 0.906, 0.914, 0.926,
(14.8516)+(-0.
1293)Asn+(-0.0140)Ala+(-0.0527)Cit+(0.1374)Tyr+(-0.1708)Met
+(-0.1572)Trp; 0.936, 0.957, 0.867, 0.922, 0.905, 0.898, 0.920,
(14.
7218)+(-0.1226)Asn+(-0.0374)His+(-0.0134)Ala+(0.1252)Tyr+(-0.1562)Met+(-0-
.1332)Trp; 0.936, 0.956, 0.834, 0.920, 0.908, 0.887, 0.917,
(12.0287)+(-0.0114)Gly+(-0.0139)Ala+(0.0044)Pro+(0.12
31)Tyr+(-0.0287)Lys+(-0.1566)Trp; 0.936, 0.952, 0.843, 0.932, 0.
913, 0.929, 0.931, (13.3270)+(-0.0143)Gly+(-0.0226)Arg+(0.138
9)Tyr+(-0.0121)Val+(-0.2773)Met+(-0.1600)Trp; 0.936, 0.956, 0. 857,
0.928, 0.897, 0.926, 0.926, (14.8306)+(-0.1568)Asn+(-0.013
1)Gly+(0.1191)Tyr+(-0.0233)Orn+(-0.0198)Lys+(-0.1540)Trp; 0. 935,
0.956, 0.844, 0.928, 0.917, 0.904, 0.926,
(15.3753)+(-0.1731)Asn+(-0.0109)Gly+(-0.0106)Ala+(0.1040)Tyr+(-0.0165)Leu-
+(-0. 1356)Trp; 0.935, 0.955, 0.888, 0.932, 0.917, 0.920, 0.931,
(16.050 7)+(-0.1678)Asn+(-0.0136)Gly+(-0.0415)His+(0.0809)Tyr+(-0.0
169)Leu+(-0.1231)Trp; 0.935, 0.955, 0.854, 0.932, 0.912, 0.924, 0.
931, (15.5051)+(-0.1765)Asn+(-0.0130)Gly+(-0.0162)Thr+(0.095
8)Tyr+(-0.0254)Leu+(-0.1287)Trp; 0.935, 0.949, 0.872, 0.924, 0.9
02, 0.917, 0.923,
(13.0474)+(-0.0137)Gly+(-0.0518)His+(0.1132)Tyr+(-0.2621)Met+(-0.1438)Trp-
; 0.935, 0.951, 0.840, 0.919, 0.907, 0.892, 0.917,
(11.1397)+(0.0267)Ser+(-0.0184)Gly+(0.1398)Tyr+(-0.0125)Val+(-0.3839)Met+-
(-0.1473)Trp; 0.935, 0.955, 0.817, 0. 920, 0.902, 0.897, 0.918,
(12.0468)+(-0.0123)Gly+(-0.0132)Ala+(-0.0301)Arg+(0.1297)Tyr+(-0.0248)Orn-
+(-0.1789)Trp; 0.935, 0. 956, 0.849, 0.927, 0.896, 0.922, 0.925,
(14.9546)+(-0.1717)Asn+(0.
1391)Tyr+(-0.0155)Val+(-0.2103)Met+(-0.0281)Orn+(-0.1382)Tr p;
0.935, 0.955, 0.864, 0.922, 0.911, 0.893, 0.920, (14.3376)+(0.01
76)Ser+(-0.1990)Asn+(-0.0167)Ala+(-0.0661)Cit+(0.1131)Tyr+(-0.1522)Trp;
0.935, 0.955, 0.801, 0.916, 0.900, 0.883, 0.913, (14.
0874)+(-0.1543)Asn+(-0.0185)Thr+(-0.0148)Ala+(0.1343)Tyr+(-0.0276)Orn+(-0-
.1442)Trp; 0.935, 0.952, 0.840, 0.914, 0.900, 0.880, 0.911,
(10.8203)+(0.0236)Ser+(-0.0155)Gly+(-0.0140)Ala+(0.12
98)Tyr+(-0.0314)Lys+(-0.1545)Trp; 0.935, 0.950, 0.811, 0.914, 0.
900, 0.886, 0.912, (12.2540)+(-0.0097)Gly+(-0.0151)Thr+(-0.011
9)Ala+(0.1445)Tyr+(-0.2381)Met+(-0.1539)Trp; 0.935, 0.955, 0.8 23,
0.919, 0.900, 0.896, 0.917,
(14.7476)+(-0.1586)Asn+(-0.0144)Ala+(0.1432)Tyr+(-0.0249)Orn+(-0.0188)Lys-
+(-0.1482)Trp; 0.93 5, 0.957, 0.822, 0.920, 0.900, 0.897, 0.918,
(14.0739)+(-0.1276)As
n+(-0.0136)Ala+(0.1568)Tyr+(-0.1877)Met+(-0.0328)Orn+(-0.15 44)Trp;
0.935, 0.956, 0.866, 0.923, 0.907, 0.897, 0.920,
(13.1599)+(-0.0120)Gly+(-0.0565)His+(-0.0124)Ala+(-0.0288)Cit+(0.091
7)Tyr+(-0.1422)Trp; 0.935, 0.954, 0.848, 0.919, 0.912, 0.883, 0.91
6, (14.7472)+(-0.0125)Gly+(-0.0667)His+(-0.0122)Ala+(0.1020)
Tyr+(-0.0514)Phe+(-0.1290)Trp; 0.934, 0.956, 0.817, 0.920, 0.903,
0.892, 0.917, (15.0014)+(-0.1917)Asn+(-0.0131)Ala+(0.1274)Tyr
+(-0.0092)Val+(-0.0307)Orn+(-0.1386)Trp; 0.934, 0.954, 0.826, 0.
918, 0.901, 0.889, 0.915,
(12.1119)+(-0.0106)Gly+(-0.0118)Ala+(0.1440)Tyr+(-0.2899)Met+(0.0002)Leu+-
(-0.1606)Trp; 0.934, 0.9 53, 0.821, 0.916, 0.904, 0.882, 0.913,
(10.9010)+(-0.0107)Gly+(0.
0033)Gln+(-0.0120)Ala+(0.1417)Tyr+(-0.3117)Met+(-0.1582)Tr p;
0.934, 0.954, 0.862, 0.895, 0.872, 0.845, 0.891, (10.1814)+(-0.0
252)Ala+(0.0068)Pro+(0.1339)Tyr+(-0.0472)Lys+(0.1043)Ile+(-0.1663)Trp;
0.934, 0.955, 0.840, 0.923, 0.904, 0.905, 0.921, (14.86
58)+(-0.1515)Asn+(-0.0183)Thr+(-0.0150)Ala+(-0.0497)Cit+(0.
1206)Tyr+(-0.1477)Trp; 0.934, 0.953, 0.851, 0.928, 0.897, 0.929, 0.
926, (14.1169)+(-0.1226)Asn+(-0.0124)Gly+(0.1356)Tyr+(-0.204
6)Met+(-0.0316)Orn+(-0.1602)Trp; 0.934, 0.955, 0.818, 0.921, 0.9
05, 0.897, 0.919, (14.6476)+(-0.1394)Asn+(-0.0183)Thr+(-0.014
3)Ala+(0.1373)Tyr+(-0.0194)Lys+(-0.1376)Trp; 0.934, 0.952, 0.8 99,
0.925, 0.909, 0.910, 0.924, (12.5242)+(0.0388)Ser+(-0.1621)A
sn+(-0.0187)Gly+(0.1221)Tyr+(-0.2685)Met+(-0.1466)Trp; 0.934,
0.949, 0.845, 0.891, 0.865, 0.846, 0.887,
(10.1038)+(-0.0243)Ala+(0.1393)Tyr+(-0.0448)Lys+(0.1060)Ile+(-0.1693)Trp;
0.934, 0.9 48, 0.834, 0.921, 0.893, 0.918, 0.920,
(11.7488)+(-0.0134)Gly+(0.
1493)Tyr+(-0.3266)Met+(-0.0313)Orn+(-0.1722)Trp; 0.934, 0.953,
0.828, 0.920, 0.908, 0.891, 0.917, (14.4137)+(-0.1406)Asn+(-0.00
93)Gly+(-0.0184)Thr+(-0.0125)Ala+(0.1134)Tyr+(-0.1400)Trp; 0. 934,
0.951, 0.861, 0.925, 0.901, 0.918, 0.923,
(13.0882)+(-0.0131)Gly+(-0.0449)His+(0.1309)Tyr+(-0.2602)Met+(-0.0256)Orn-
+(-0. 1508)Trp; 0.934, 0.952, 0.831, 0.920, 0.908, 0.893, 0.918,
(14.650 3)+(-0.1578)Asn+(-0.0147)Ala+(0.1316)Tyr+(-0.0230)Lys+(-0.1
437)Trp; 0.934, 0.953, 0.830, 0.923, 0.904, 0.907, 0.921, (11.4657)
+(-0.0146)Gly+(0.0028)Gln+(0.1308)Tyr+(-0.0122)Val+(-0.343
7)Met+(-0.1493)Trp
[0520] List (2) of Logistic Regression Equations Searched in
Example 8
[0521] The logistic regression equations searched in Example 8
above are listed below. Before each equation, "the value of ROC_AUC
for the pancreatic cancer group and the breast cancer group with
validation", "the value of ROC_AUC for the pancreatic cancer group
and the breast cancer group without validation", "the value of
ROC_AUC for the pancreatic cancer group and the healthy group",
"the value of ROC_AUC for the pancreatic cancer group and the other
cancers group", "the value of ROC_AUC for the pancreatic cancer
group and the lung cancer group", "the value of ROC_AUC for the
pancreatic cancer group and the colorectal cancer group", and "the
average value of the value of ROC_AUC for the pancreatic cancer
group and the lung cancer group, the value of ROC_AUC for the
pancreatic cancer group and the colorectal cancer group, and the
value of ROC_AUC for the pancreatic cancer group and the breast
cancer group" obtained for the equation are additionally
listed.
[0522] 0.878, 0.923, 0.927, 0.909, 0.900, 0.901, 0.908,
(9.6001)+(0.
0010)Gln+(-0.1052)His+(-0.0386)Arg+(0.0762)Tyr+(0.0049)Ile+(-0.1257)Trp;
0.856, 0.914, 0.927, 0.906, 0.919, 0.882, 0.905, (8.8
698)+(0.0050)Gln+(-0.1070)His+(-0.0297)Cit+(-0.0255)Arg+(0.
0249)Ile+(-0.0876)Trp; 0.878, 0.925, 0.926, 0.915, 0.905, 0.913, 0.
914, (9.4249)+(0.0020)Gln+(-0.0976)His+(-0.0257)Cit+(-0.035
1)Arg+(0.0781)Tyr+(-0.1311)Trp; 0.856, 0.909, 0.926, 0.899, 0.91 5,
0.871, 0.898, (8.5944)+(0.0042)Gln+(-0.1176)His+(-0.0314)Ar
g+(0.0224)Ile+(0.0210)Phe+(-0.0870)Trp; 0.883, 0.923, 0.925, 0.
912, 0.899, 0.912, 0.911,
(9.9732)+(-0.0965)His+(-0.0219)Cit+(-0.0338)Arg+(0.0784)Tyr+(0.0045)Ile+(-
-0.1313)Trp; 0.852, 0.905, 0.925, 0.890, 0.905, 0.857, 0.889,
(9.7626)+(-0.0840)His+(-0.035
1)Arg+(0.0775)Ile+(-0.0405)Leu+(0.0236)Phe+(-0.0852)Trp; 0.8 59,
0.911, 0.924, 0.898, 0.906, 0.872, 0.896, (8.8638)+(0.0075)Gln
+(-0.1049)His+(-0.0193)Arg+(-0.0250)Lys+(0.0456)Ile+(-0.080 9)Trp;
0.877, 0.922, 0.924, 0.908, 0.907, 0.891, 0.907,
(9.8083)+(-0.0784)His+(-0.0460)Arg+(0.0750)Tyr+(0.0530)Ile+(-0.0358)Le
u+(-0.1225)Trp; 0.879, 0.923, 0.923, 0.908, 0.898, 0.901, 0.907,
(9. 8751)+(-0.1039)His+(-0.0376)Arg+(0.0774)Tyr+(0.0043)Ile+(0.
0030)Phe+(-0.1276)Trp; 0.852, 0.909, 0.923, 0.898, 0.912, 0.869, 0.
897,
(9.6098)+(0.0024)Gln+(-0.0889)His+(-0.0357)Arg+(0.0729)Ile+(-0.0357)Leu+(-
-0.0792)Trp; 0.888, 0.924, 0.923, 0.909, 0.900, 0.901, 0.908,
(9.9446)+(-0.1035)His+(-0.0375)Arg+(0.0780)Tyr+(0.0046)Ile+(-0.1272)Trp;
0.839, 0.905, 0.922, 0.894, 0.910, 0.86 4, 0.893,
(10.3931)+(-0.0806)His+(-0.0101)Cit+(-0.0305)Arg+(0.
0755)Ile+(-0.0371)Leu+(-0.0825)Trp; 0.883, 0.924, 0.922, 0.911,
0.901, 0.905, 0.910, (9.7155)+(0.0010)Gln+(-0.1041)His+(-0.038
4)Arg+(0.0793)Tyr+(-0.1277)Trp; 0.879, 0.923, 0.922, 0.913, 0.90 0,
0.914, 0.912,
(10.0421)+(-0.0958)His+(-0.0218)Cit+(-0.0337)Arg+(0.0809)Tyr+(0.0010)Phe+-
(-0.1332)Trp; 0.875, 0.923, 0.922, 0.910, 0.901, 0.904, 0.909,
(9.5308)+(0.0011)Gln+(-0.1051)His+(-0.0387)Arg+(0.0778)Tyr+(0.0054)Phe+(--
0.1280)Trp; 0.886, 0.9 23, 0.921, 0.913, 0.900, 0.914, 0.912,
(10.0671)+(-0.0956)His+(-0.
0220)Cit+(-0.0337)Arg+(0.0812)Tyr+(-0.1331)Trp; 0.867, 0.907,
0.921, 0.900, 0.917, 0.873, 0.899, (9.2775)+(0.0038)Gln+(-0.115
0)His+(-0.0292)Arg+(0.0247)Ile+(-0.0826)Trp; 0.893, 0.924, 0.9 21,
0.910, 0.898, 0.905, 0.909,
(10.0339)+(-0.1026)His+(-0.0374)Arg+(0.0809)Tyr+(-0.1290)Trp;
0.883, 0.924, 0.920, 0.909, 0.898, 0.903, 0.908,
(9.9431)+(-0.1031)His+(-0.0375)Arg+(0.0799)Tyr+(0.0037)Phe+(-0.1294)Trp;
0.856, 0.907, 0.920, 0.895, 0.908, 0.86 5, 0.893,
(10.4038)+(-0.0830)His+(-0.0327)Arg+(0.0770)Ile+(-0.
0383)Leu+(-0.0808)Trp; 0.857, 0.912, 0.920, 0.898, 0.905, 0.872, 0.
897, (8.3365)+(0.0077)Gln+(-0.0942)His+(-0.0392)Cit+(-0.028
5)Lys+(0.0450)Ile+(-0.0831)Trp; 0.854, 0.902, 0.918, 0.895, 0.91 3,
0.867, 0.894, (10.1863)+(-0.1042)His+(-0.0185)Cit+(-0.0211)
Arg+(0.0244)Ile+(0.0154)Phe+(-0.0922)Trp; 0.845, 0.897, 0.918,
0.883, 0.897, 0.851, 0.882,
(9.0563)+(-0.0936)His+(-0.0351)Cit+(0.0462)Ile+(-0.0209)Leu+(0.0101)Phe+(-
-0.0839)Trp; 0.873, 0.9 03, 0.918, 0.896, 0.913, 0.870, 0.895,
(10.6087)+(-0.1088)His+(-0. 0235)Arg+(0.0256)Ile+(-0.0853)Trp;
0.859, 0.910, 0.918, 0.890, 0. 896, 0.858, 0.888,
(8.0345)+(0.0061)Gln+(-0.1078)His+(-0.0304)
Lys+(0.0433)Ile+(0.0228)Phe+(-0.0800)Trp; 0.864, 0.903, 0.917,
0.894, 0.910, 0.866, 0.893, (10.1783)+(-0.1106)His+(-0.0248)Arg
+(0.0239)Ile+(0.0167)Phe+(-0.0888)Trp; 0.845, 0.912, 0.916, 0.8 93,
0.901, 0.863, 0.892,
(10.8910)+(-0.0765)His+(-0.0203)Arg+(-0.0162)Lys+(0.0819)Ile+(-0.0320)Leu-
+(-0.0813)Trp; 0.862, 0.90 6, 0.916, 0.892, 0.904, 0.861, 0.890,
(10.5355)+(-0.0976)His+(-0.
0126)Arg+(-0.0200)Lys+(0.0412)Ile+(0.0220)Phe+(-0.0891)Trp; 0.885,
0.921, 0.916, 0.909, 0.900, 0.905, 0.909, (10.2678)+(-0.092
5)His+(-0.0396)Arg+(0.0892)Tyr+(-0.0102)Leu+(-0.1337)Trp; 0. 851,
0.895, 0.915, 0.885, 0.899, 0.857, 0.884, (9.3770)+(-0.0927)H
is+(-0.0351)Cit+(0.0470)Ile+(-0.0205)Leu+(-0.0821)Trp; 0.886,
0.936, 0.915, 0.926, 0.917, 0.923, 0.925,
(11.1011)+(-0.1844)Asn+(0.0062)Gln+(-0.0780)His+(-0.0271)Arg+(0.0716)Tyr+-
(-0.1071)Trp; 0.876, 0.920, 0.915, 0.909, 0.901, 0.903, 0.908,
(10.0831)+(-0.
0930)His+(-0.0400)Arg+(0.0877)Tyr+(-0.0108)Leu+(0.0084)Phe+(-0.1348)Trp;
0.874, 0.921, 0.915, 0.910, 0.901, 0.905, 0.909, (10.
1698)+(0.0003)Gln+(-0.0931)His+(-0.0398)Arg+(0.0886)Tyr+(-0.
0100)Leu+(-0.1333)Trp; 0.851, 0.905, 0.915, 0.890, 0.899, 0.862, 0.
889, (10.2816)+(-0.0898)His+(-0.0242)Cit+(-0.0225)Lys+(0.041
5)Ile+(0.0199)Phe+(-0.0906)Trp; 0.860, 0.902, 0.915, 0.897, 0.91 5,
0.872, 0.896, (10.5947)+(-0.1021)His+(-0.0201)Cit+(-0.0197)
Arg+(0.0261)Ile+(-0.0894)Trp; 0.848, 0.898, 0.914, 0.879, 0.894,
0.841, 0.877,
(8.7586)+(-0.1076)His+(0.0447)Ile+(-0.0216)Leu+(0.0086)Phe+(-0.073-
9)Trp; 0.880, 0.923, 0.914, 0.912, 0.900, 0.91 1, 0.911,
(10.3061)+(-0.0863)His+(-0.0210)Cit+(-0.0361)Arg+(0.
0895)Tyr+(-0.0100)Leu+(-0.1375)Trp; 0.860, 0.914, 0.914, 0.902,
0.919, 0.868, 0.900, (8.7347)+(0.0074)Gln+(-0.1182)His+(-0.027
1)Arg+(-0.0340)Orn+(0.0347)Ile+(-0.0829)Trp; 0.840, 0.896, 0.9 13,
0.886, 0.899, 0.859, 0.885, (8.9963)+(0.0011)Gln+(-0.0949)Hi
s+(-0.0380)Cit+(0.0440)Ile+(-0.0187)Leu+(-0.0821)Trp; 0.889, 0.938,
0.913, 0.927, 0.909, 0.931, 0.926,
(12.9372)+(-0.1672)Asn+(-0.0593)His+(-0.0312)Cit+(-0.0174)Arg+(0.0835)Tyr-
+(-0.127 9)Trp; 0.873, 0.924, 0.913, 0.911, 0.918, 0.887, 0.910,
(14.1381)+(-0.1398)Asn+(-0.0613)His+(-0.0223)Cit+(-0.0137)Lys+(0.021
9)Ile+(-0.0808)Trp; 0.850, 0.908, 0.913, 0.888, 0.894, 0.858, 0.88
6, (8.9650)+(0.0048)Gln+(-0.0968)His+(-0.0279)Lys+(0.0630)Il
e+(-0.0151)Leu+(-0.0723)Trp; 0.829, 0.893, 0.913, 0.880, 0.893, 0.
848, 0.878,
(6.9815)+(0.0070)Gln+(-0.1203)His+(-0.0170)Arg+(-0.0236)Lys+(0.080-
3)Ile+(-0.0295)Leu; 0.865, 0.906, 0.913, 0.890, 0.897, 0.861,
0.888, (8.8005)+(0.0058)Gln+(-0.1058)His+(-0.029
0)Lys+(0.0444)Ile+(-0.0755)Trp; 0.844, 0.903, 0.913, 0.900, 0.91 7,
0.880, 0.900, (8.4103)+(0.0059)Gln+(-0.1058)His+(-0.0297)Ci
t+(-0.0249)Arg+(0.0261)Phe+(-0.0931)Trp; 0.853, 0.897, 0.912, 0.
885, 0.895, 0.860, 0.884, (9.5213)+(-0.1040)His+(-0.0362)Cit+(0.
0198)Ile+(0.0084)Phe+(-0.0902)Trp; 0.864, 0.906, 0.912, 0.884, 0.
882, 0.860, 0.883, (8.2547)+(-0.1087)His+(0.0439)Tyr+(0.0252)I
le+(-0.0164)Leu+(-0.0941)Trp; 0.857, 0.902, 0.912, 0.898, 0.916,
0.875, 0.898,
(8.8568)+(0.0046)Gln+(-0.1133)His+(-0.0288)Arg+(0.0260)Phe+(-0.088-
4)Trp; 0.850, 0.902, 0.912, 0.898, 0.916, 0.87 5, 0.898,
(8.8496)+(0.0046)Gln+(-0.1137)His+(-0.0288)Arg+(0.0
004)Leu+(0.0258)Phe+(-0.0884)Trp; 0.854, 0.905, 0.911, 0.893, 0.
904, 0.865, 0.892, (11.0651)+(-0.0894)His+(-0.0185)Cit+(-0.007
6)Arg+(-0.0192)Lys+(0.0423)Ile+(-0.0880)Trp; 0.858, 0.895, 0.9 11,
0.886, 0.898, 0.862, 0.885, (9.7757)+(-0.1031)His+(-0.0363)C
it+(0.0209)Ile+(-0.0885)Trp; 0.843, 0.903, 0.911, 0.888, 0.896, 0.
860, 0.886,
(10.5209)+(-0.0775)His+(-0.0227)Cit+(-0.0215)Lys+(0.0694)Ile+(-0.0-
216)Leu+(-0.0811)Trp; 0.874, 0.924, 0.911, 0.9 06, 0.912, 0.880,
0.905,
(13.6158)+(-0.1402)Asn+(-0.0713)His+(-0.0156)Lys+(0.0215)Ile+(0.0135)Phe+-
(-0.0766)Trp; 0.845, 0.906, 0.911, 0.905, 0.922, 0.886, 0.905,
(9.1990)+(0.0055)Gln+(-0.105
1)His+(-0.0314)Cit+(-0.0217)Arg+(0.0038)Leu+(-0.0884)Trp; 0. 860,
0.907, 0.910, 0.885, 0.882, 0.862, 0.884, (8.3024)+(-0.1085)H
is+(0.0443)Tyr+(0.0252)Ile+(-0.0163)Leu+(-0.0019)Phe+(-0.09 39)Trp;
0.855, 0.898, 0.910, 0.880, 0.893, 0.843, 0.878,
(9.0287)+(-0.1068)His+(0.0455)Ile+(-0.0213)Leu+(-0.0722)Trp; 0.838,
0. 897, 0.910, 0.877, 0.890, 0.840, 0.875,
(9.1904)+(-0.0011)Gln+(-0.
1042)His+(0.0479)Ile+(-0.0234)Leu+(0.0083)Phe+(-0.0747)Trp; 0.854,
0.907, 0.910, 0.885, 0.890, 0.851, 0.883, (10.4124)+(-0.085
6)His+(-0.0229)Lys+(0.0703)Ile+(-0.0224)Leu+(-0.0752)Trp; 0. 848,
0.906, 0.910, 0.883, 0.889, 0.849, 0.881, (9.7873)+(-0.0866)H
is+(-0.0241)Lys+(0.0707)Ile+(-0.0233)Leu+(0.0210)Phe+(-0.07 88)Trp;
0.917, 0.952, 0.910, 0.908, 0.888, 0.874, 0.905,
(12.0134)+(-0.0750)His+(-0.0226)Ala+(0.1357)Tyr+(-0.0433)Lys+(0.0960)Ile+-
(-0.1473)Trp; 0.864, 0.922, 0.910, 0.906, 0.914, 0.878, 0.905,
(13.9693)+(-0.1394)Asn+(-0.0710)His+(-0.0005)Pro+(-0.0147)L
ys+(0.0231)Ile+(-0.0734)Trp; 0.861, 0.910, 0.910, 0.891, 0.881, 0.
877, 0.889, (8.6416)+(-0.0913)His+(-0.0449)Cit+(0.0518)Tyr+(0.
0246)Ile+(-0.0160)Leu+(-0.1099)Trp; 0.846, 0.907, 0.910, 0.891,
0.904, 0.857, 0.890, (10.8127)+(-0.0790)His+(-0.0271)Arg+(-0.0
252)Orn+(0.0869)Ile+(-0.0403)Leu+(-0.0825)Trp; 0.868, 0.906, 0.
909, 0.893, 0.906, 0.862, 0.891, (11.0959)+(-0.0955)His+(-0.011
3)Arg+(-0.0192)Lys+(0.0422)Ile+(-0.0847)Trp; 0.857, 0.902, 0.9 09,
0.891, 0.901, 0.867, 0.890,
(10.8521)+(-0.0882)His+(-0.0242)Cit+(-0.0213)Lys+(0.0424)Ile+(-0.0870)Trp-
; 0.847, 0.897, 0.909, 0.880, 0.893, 0.844, 0.878,
(9.4678)+(-0.0011)Gln+(-0.1032)His+(0.0488)Ile+(-0.0232)Leu+(-0.0731)Trp;
0.898, 0.934, 0.909, 0.9 21, 0.905, 0.922, 0.921,
(9.9364)+(-0.0678)His+(-0.0228)Arg+(0.
1032)Tyr+(-0.2902)Met+(0.0304)Phe+(-0.1309)Trp; 0.882, 0.922,
0.909, 0.907, 0.915, 0.879, 0.905, (13.9887)+(-0.1405)Asn+(-0.07
04)His+(-0.0149)Lys+(0.0224)Ile+(-0.0735)Trp; 0.867, 0.921, 0. 909,
0.906, 0.915, 0.879, 0.905, (13.9854)+(-0.1386)Asn+(-0.070
1)His+(-0.0064)Met+(-0.0147)Lys+(0.0224)Ile+(-0.0733)Trp; 0. 869,
0.922, 0.909, 0.906, 0.915, 0.879, 0.905, (13.9674)+(-0.1414)
Asn+(-0.0703)His+(0.0010)Arg+(-0.0152)Lys+(0.0223)Ile+(-0.0
730)Trp; 0.848, 0.898, 0.908, 0.888, 0.901, 0.862, 0.887,
(8.7919)+(0.0025)Gln+(-0.1058)His+(-0.0429)Cit+(0.0193)Ile+(-0.0876)Trp;
0.902, 0.940, 0.908, 0.926, 0.901, 0.934, 0.925, (12.4034)+(-0.
1371)Asn+(-0.0424)His+(-0.0386)Cit+(0.0954)Tyr+(-0.1758)Met
+(-0.1255)Trp; 0.882, 0.936, 0.908, 0.923, 0.911, 0.919, 0.922,
(12. 7284)+(0.0009)Ser+(-0.1668)Asn+(-0.0699)His+(-0.0230)Arg+(0.
0823)Tyr+(-0.1190)Trp; 0.870, 0.926, 0.908, 0.913, 0.917, 0.894, 0.
912, (13.5663)+(-0.1599)Asn+(-0.0658)His+(-0.0299)Cit+(0.003
2)Ile+(0.0120)Phe+(-0.0827)Trp; 0.843, 0.897, 0.908, 0.887, 0.89 8,
0.863, 0.886, (8.4470)+(0.0027)Gln+(-0.1069)His+(-0.0432)Ci
t+(0.0178)Ile+(0.0099)Phe+(-0.0896)Trp; 0.838, 0.890, 0.908, 0.
877, 0.890, 0.846, 0.876, (6.1643)+(0.0088)Gln+(-0.1408)His+(-0.
0124)Arg+(-0.0275)Lys+(0.0435)Ile+(0.0104)Phe; 0.895, 0.936, 0.
908, 0.924, 0.909, 0.926, 0.924, (9.5592)+(0.0028)Gln+(-0.0715)H
is+(-0.0243)Arg+(0.1018)Tyr+(-0.2678)Met+(-0.1206)Trp; 0.893,
0.936, 0.908, 0.923, 0.911, 0.919, 0.922,
(12.7996)+(-0.1646)Asn+(-0.0701)His+(-0.0229)Arg+(0.0820)Tyr+(-0.1195)Trp-
; 0.887, 0. 936, 0.908, 0.924, 0.912, 0.923, 0.924,
(12.9743)+(-0.1657)Asn+(-0.0693)His+(-0.0222)Arg+(0.0833)Tyr+(-0.0068)Phe-
+(-0.1184)T rp; 0.872, 0.926, 0.908, 0.917, 0.926, 0.897, 0.916,
(10.7486)+(-0.
1900)Asn+(0.0100)Gln+(-0.0896)His+(-0.0197)Arg+(0.0165)Phe+(-0.0661)Trp;
0.868, 0.921, 0.908, 0.906, 0.912, 0.882, 0.905, (14.
1516)+(-0.0023)Ser+(-0.1355)Asn+(-0.0708)His+(-0.0148)Lys+(0.0225)Ile+(-0-
.0756)Trp; 0.858, 0.902, 0.908, 0.900, 0.918, 0.87 7, 0.899,
(9.6592)+(0.0042)Gln+(-0.1120)His+(-0.0255)Arg+(0.0
026)Leu+(-0.0828)Trp; 0.844, 0.896, 0.907, 0.873, 0.878, 0.839, 0.
871,
(7.1016)+(0.0059)Gln+(-0.1236)His+(-0.0282)Lys+(0.0739)Ile+(-0.0244)Leu;
0.833, 0.904, 0.907, 0.894, 0.909, 0.865, 0.893,
(9.3694)+(0.0046)Gln+(-0.1205)His+(-0.0238)Arg+(-0.0096)Pro
+(0.0380)Ile+(-0.0832)Trp; 0.915, 0.952, 0.907, 0.929, 0.911, 0.9
19, 0.927,
(13.1055)+(0.0246)Ser+(-0.1652)Asn+(-0.0220)Gly+(-0.0550)His+(0.07-
98)Tyr+(-0.1402)Trp; 0.871, 0.924, 0.907, 0.914, 0.918, 0.898,
0.913, (13.8954)+(-0.1569)Asn+(-0.0662)His+(-0.0
271)Cit+(-0.0013)Arg+(0.0056)Ile+(-0.0798)Trp; 0.869, 0.926, 0.
907, 0.913, 0.917, 0.894, 0.912, (13.7453)+(-0.1599)Asn+(-0.064
8)His+(-0.0283)Cit+(-0.0018)Arg+(0.0136)Phe+(-0.0841)Trp; 0. 865,
0.917, 0.907, 0.889, 0.895, 0.850, 0.887, (9.5610)+(-0.0680)H
is+(-0.0515)Arg+(0.0712)Tyr+(-0.0348)Val+(0.0951)Ile+(-0.10 19)Trp;
0.854, 0.900, 0.907, 0.897, 0.917, 0.873, 0.897,
(8.9866)+(0.0046)Gln+(-0.1077)His+(-0.0288)Arg+(-0.0035)Val+(0.0284)Phe+(-
-0.0874)Trp; 0.850, 0.906, 0.907, 0.905, 0.922, 0.886, 0.905,
(9.3514)+(0.0054)Gln+(-0.1016)His+(-0.0302)Cit+(-0.0217)Arg
+(-0.0878)Trp; 0.869, 0.907, 0.907, 0.885, 0.879, 0.864, 0.884, (8.
4769)+(-0.1175)His+(0.0479)Tyr+(0.0032)Ile+(-0.1006)Trp; 0.8 54,
0.910, 0.907, 0.898, 0.906, 0.876, 0.897, (12.5091)+(-0.0195)S
er+(-0.0783)His+(-0.0273)Arg+(0.0748)Ile+(-0.0375)Leu+(-0.0
924)Trp; 0.840, 0.897, 0.907, 0.871, 0.875, 0.836, 0.869,
(6.6755)+(0.0060)Gln+(-0.1246)His+(-0.0289)Lys+(0.0743)Ile+(-0.0251)Leu+(-
0.0113)Phe; 0.829, 0.894, 0.907, 0.876, 0.884, 0.846, 0.875,
(6.7089)+(0.0072)Gln+(-0.1209)His+(-0.0213)Cit+(-0.0284)Lys
+(0.0722)Ile+(-0.0224)Leu; 0.879, 0.923, 0.907, 0.909, 0.900, 0.9
02, 0.908,
(10.4669)+(-0.0816)His+(-0.0193)Cit+(-0.0374)Arg+(0.0952)Tyr+(-0.0-
094)Val+(-0.1365)Trp; 0.876, 0.925, 0.907, 0.9 13, 0.917, 0.894,
0.912,
(13.7038)+(-0.1617)Asn+(-0.0645)His+(-0.0298)Cit+(0.0129)Phe+(-0.0835)Trp-
; 0.870, 0.923, 0.907, 0.909, 0.915, 0.887, 0.908,
(13.5547)+(-0.1521)Asn+(-0.0781)His+(-0.0
086)Arg+(0.0055)Ile+(0.0110)Phe+(-0.0764)Trp; 0.860, 0.901, 0. 906,
0.883, 0.892, 0.851, 0.881, (10.1853)+(-0.0988)His+(-0.023
8)Lys+(0.0415)Ile+(0.0191)Phe+(-0.0843)Trp; 0.845, 0.907, 0.90 6,
0.876, 0.886, 0.828, 0.874, (10.8001)+(-0.0636)His+(-0.0267)A
rg+(-0.0353)Val+(-0.0186)Lys+(0.1318)Ile+(-0.0615)Trp; 0.840,
0.901, 0.906, 0.874, 0.870, 0.844, 0.872,
(6.7544)+(0.0049)Gln+(-0.1223)His+(0.0298)Tyr+(-0.0317)Lys+(0.0706)Ile+(--
0.0256)Le u
[0523] List (2) of Linear Discriminants Searched in Example 8
[0524] The linear discriminants searched in Example 8 above are
listed below. Before each equation, "the value of ROC_AUC for the
pancreatic cancer group and the breast cancer group with
validation", "the value of ROC_AUC for the pancreatic cancer group
and the breast cancer group without validation", "the value of
ROC_AUC for the pancreatic cancer group and the healthy group",
"the value of ROC_AUC for the pancreatic cancer group and the other
cancers group", "the value of ROC_AUC for the pancreatic cancer
group and the lung cancer group", "the value of ROC_AUC for the
pancreatic cancer group and the colorectal cancer group", and "the
average value of the value of ROC_AUC for the pancreatic cancer
group and the lung cancer group, the value of ROC_AUC for the
pancreatic cancer group and the colorectal cancer group, and the
value of ROC_AUC for the pancreatic cancer group and the breast
cancer group" obtained for the equation are additionally
listed.
[0525] 0.896, 0.924, 0.943, 0.907, 0.901, 0.893, 0.906,
(10.5615)+(0.
0037)Gln+(-0.1087)His+(-0.0445)Arg+(0.0653)Tyr+(0.0380)Ile+(-0.1489)Trp;
0.895, 0.921, 0.943, 0.902, 0.897, 0.885, 0.901, (11.
7120)+(-0.0796)His+(-0.0490)Arg+(0.0724)Tyr+(0.0897)Ile+(-0.
0380)Leu+(-0.1510)Trp; 0.882, 0.917, 0.943, 0.902, 0.912, 0.873, 0.
901, (10.4832)+(0.0072)Gln+(-0.1152)His+(-0.0273)Cit+(-0.033
4)Arg+(0.0505)Ile+(-0.1141)Trp; 0.883, 0.913, 0.942, 0.900, 0.91 1,
0.872, 0.899, (10.5912)+(0.0066)Gln+(-0.1228)His+(-0.0359)A
rg+(0.0473)Ile+(-0.1069)Trp; 0.878, 0.910, 0.942, 0.899, 0.911, 0.
874, 0.898,
(10.3696)+(0.0067)Gln+(-0.1228)His+(-0.0366)Arg+(0.0469)Ile+(0.005-
3)Phe+(-0.1082)Trp; 0.876, 0.911, 0.941, 0.89 3, 0.901, 0.863,
0.892, (11.1623)+(0.0049)Gln+(-0.1018)His+(-0.
0405)Arg+(0.0916)Ile+(-0.0320)Leu+(-0.1048)Trp; 0.895, 0.921,
0.940, 0.908, 0.898, 0.902, 0.907, (11.7459)+(-0.0948)His+(-0.02
13)Cit+(-0.0381)Arg+(0.0714)Tyr+(0.0400)Ile+(-0.1586)Trp; 0. 882,
0.916, 0.939, 0.900, 0.909, 0.870, 0.899, (10.2523)+(0.0079)G
ln+(-0.1137)His+(-0.0243)Arg+(-0.0173)Lys+(0.0587)Ile+(-0.0
985)Trp; 0.876, 0.913, 0.938, 0.900, 0.911, 0.871, 0.898, (10.5605)
+(0.0067)Gln+(-0.1234)His+(-0.0349)Arg+(-0.0018)Pro+(0.049
1)Ile+(-0.1059)Trp; 0.900, 0.927, 0.937, 0.909, 0.898, 0.898, 0.90
8, (12.6498)+(-0.1023)His+(-0.0383)Arg+(0.0775)Tyr+(0.0388)I
le+(-0.0307)Phe+(-0.1495)Trp; 0.884, 0.914, 0.936, 0.900, 0.914,
0.868, 0.899,
(9.9586)+(0.0086)Gln+(-0.1245)His+(-0.0316)Arg+(-0.0252)Orn+(0.055-
9)Ile+(-0.1032)Trp; 0.914, 0.939, 0.935, 0.9 20, 0.927, 0.890,
0.919, (11.6880)+(-0.0161)Gly+(0.0087)Gln+(-0.
1109)His+(-0.0326)Arg+(0.0504)Ile+(-0.1027)Trp; 0.902, 0.923,
0.934, 0.908, 0.898, 0.901, 0.907, (11.6884)+(-0.1016)His+(-0.04
05)Arg+(0.0710)Tyr+(0.0375)Ile+(-0.1527)Trp; 0.926, 0.945, 0.9 33,
0.925, 0.913, 0.912, 0.923, (13.3589)+(-0.0158)Gly+(-0.0857)
His+(-0.0354)Arg+(0.0757)Tyr+(0.0401)Ile+(-0.1518)Trp; 0.885,
0.917, 0.933, 0.902, 0.908, 0.878, 0.901,
(10.9845)+(-0.0122)Ser+(0.0075)Gln+(-0.1190)His+(-0.0335)Arg+(0.0494)Ile+-
(-0.1086) Trp; 0.913, 0.936, 0.931, 0.915, 0.923, 0.881, 0.913,
(13.5929)+(0.
0203)Ser+(-0.0187)Gly+(-0.1029)His+(-0.0261)Arg+(0.0483)Ile
+(-0.0997)Trp; 0.893, 0.923, 0.931, 0.905, 0.891, 0.898, 0.904,
(11. 6722)+(-0.1017)His+(-0.0382)Arg+(-0.0052)Pro+(0.0766)Tyr+(0.
0418)Ile+(-0.1536)Trp; 0.886, 0.920, 0.931, 0.897, 0.900, 0.867, 0.
896, (9.8279)+(0.0079)Gln+(-0.0960)His+(-0.0483)Cit+(-0.025
4)Lys+(0.0659)Ile+(-0.1057)Trp; 0.878, 0.907, 0.931, 0.891, 0.90 0,
0.860, 0.889, (12.7518)+(-0.0908)His+(-0.0349)Arg+(0.0984)I
le+(-0.0366)Leu+(-0.1047)Trp; 0.874, 0.908, 0.931, 0.890, 0.900,
0.857, 0.888, (12.3164)+(-0.0891)His+(-0.0367)Arg+(0.0998)Ile
+(-0.0383)Leu+(0.0127)Phe+(-0.1077)Trp; 0.874, 0.910, 0.931, 0.
892, 0.901, 0.860, 0.891,
(12.7898)+(-0.0872)His+(-0.0130)Cit+(-0.0332)Arg+(0.0989)Ile+(-0.0358)Leu-
+(-0.1082)Trp; 0.907, 0. 932, 0.930, 0.913, 0.923, 0.878, 0.911,
(14.5433)+(-0.0162)Gly+(-0.0706)His+(-0.0305)Arg+(0.1130)Ile+(-0.0447)Leu-
+(-0.1001)I rp; 0.892, 0.924, 0.929, 0.895, 0.894, 0.861, 0.893,
(11.7007)+(-0.
0696)His+(-0.0523)Arg+(0.0755)Tyr+(-0.0280)Val+(0.1034)Ile+(-0.1467)Trp;
0.865, 0.907, 0.929, 0.891, 0.900, 0.862, 0.889, (12.
7663)+(-0.0909)His+(-0.0341)Arg+(-0.0012)Pro+(0.0997)Ile+(-0.0367)Leu+(-0-
.1041)Trp; 0.876, 0.911, 0.928, 0.892, 0.901, 0.860, 0.891,
(12.8033)+(-0.0866)His+(-0.0266)Arg+(-0.0096)Lys+(0.0
996)Ile+(-0.0328)Leu+(-0.1003)Trp; 0.872, 0.910, 0.928, 0.893, 0.
901, 0.865, 0.892, (12.7713)+(-0.1058)His+(-0.0190)Cit+(-0.024
5)Arg+(-0.0005)Pro+(0.0507)Ile+(-0.1120)Trp; 0.885, 0.910, 0.9 28,
0.894, 0.903, 0.865, 0.893, (12.7657)+(-0.1057)His+(-0.0191)
Cit+(-0.0248)Arg+(0.0503)Ile+(-0.1123)Trp; 0.877, 0.910, 0.928,
0.895, 0.904, 0.866, 0.893, (12.9164)+(-0.1059)His+(-0.0192)Cit
+(-0.0242)Arg+(0.0506)Ile+(-0.0044)Phe+(-0.1113)Trp; 0.900, 0. 927,
0.927, 0.902, 0.886, 0.887, 0.900,
(11.5713)+(-0.0828)His+(-0.0250)Arg+(0.0890)Tyr+(-0.0244)Lys+(0.0511)Ile+-
(-0.1525)Tr p; 0.902, 0.930, 0.927, 0.912, 0.911, 0.889, 0.910,
(15.7882)+(-0.1
398)Asn+(-0.0689)His+(-0.0330)Cit+(-0.0112)Lys+(0.0428)Ile+(-0.0927)Trp;
0.879, 0.912, 0.927, 0.888, 0.890, 0.855, 0.886, (9.5
328)+(0.0064)Gln+(-0.1093)His+(-0.0254)Lys+(0.0581)Ile+(0.0
109)Phe+(-0.0950)Trp; 0.878, 0.911, 0.927, 0.895, 0.901, 0.868, 0.
893, (12.8747)+(-0.0935)His+(-0.0262)Cit+(-0.0122)Arg+(-0.01
50)Lys+(0.0611)Ile+(-0.1069)Trp; 0.914, 0.939, 0.926, 0.914, 0.9
16, 0.882, 0.912,
(11.1729)+(-0.0158)Gly+(0.0080)Gln+(-0.1004)His+(-0.0203)Lys+(0.0589)Ile+-
(-0.0909)Trp; 0.905, 0.936, 0.926, 0.918, 0.914, 0.900, 0.917,
(12.6371)+(-0.1861)Asn+(0.0103)Gln+(-0.0831)His+(-0.0526)Cit+(0.0262)Ile+-
(-0.0947)Trp; 0.899, 0. 928, 0.926, 0.911, 0.914, 0.889, 0.910,
(15.4137)+(0.0066)Ser+(-0.
1637)Asn+(-0.0771)His+(-0.0330)Cit+(0.0287)Ile+(-0.0930)Tr p;
0.897, 0.924, 0.926, 0.909, 0.894, 0.906, 0.908, (12.1993)+(-0.0
089)Ser+(-0.0975)His+(-0.0379)Arg+(0.0712)Tyr+(0.0391)Ile+(-0.1542)Trp;
0.876, 0.914, 0.926, 0.890, 0.899, 0.851, 0.888, (11.
0445)+(0.0054)Gln+(-0.0933)His+(-0.0438)Arg+(-0.0246)Val+(0.
1058)Ile+(-0.0992)Trp; 0.872, 0.908, 0.926, 0.889, 0.892, 0.862, 0.
887, (12.4787)+(-0.0894)His+(-0.0345)Cit+(0.0014)Pro+(-0.020
0)Lys+(0.0613)Ile+(-0.1063)Trp; 0.870, 0.907, 0.926, 0.892, 0.90 4,
0.859, 0.890, (12.8262)+(-0.1120)His+(-0.0263)Arg+(-0.0006)
Pro+(0.0488)Ile+(-0.0032)Phe+(-0.1062)Trp; 0.876, 0.907, 0.925,
0.889, 0.892, 0.861, 0.887, (12.3896)+(-0.0900)His+(-0.0337)Cit
+(-0.0195)Lys+(0.0621)Ile+(0.0031)Phe+(-0.1064)Trp; 0.890, 0. 922,
0.925, 0.913, 0.905, 0.909, 0.912, (10.9127)+(0.0037)Gln+(-0.
0988)His+(-0.0410)Arg+(0.0730)Tyr+(0.0021)Leu+(-0.1470)Trp; 0.888,
0.907, 0.925, 0.893, 0.905, 0.862, 0.892, (12.7085)+(-0.111
7)His+(-0.0270)Arg+(0.0480)Ile+(-0.1073)Trp; 0.885, 0.915, 0.9 25,
0.901, 0.908, 0.876, 0.900, (10.3213)+(0.0091)Gln+(-0.1112)H
is+(-0.0241)Arg+(-0.1761)Met+(0.0520)Ile+(-0.0913)Trp; 0.881,
0.910, 0.925, 0.892, 0.899, 0.862, 0.890,
(12.7530)+(-0.1081)His+(-0.0083)Cit+(-0.0224)Arg+(-0.0131)Orn+(0.0535)Ile-
+(-0.107 6)Trp; 0.875, 0.907, 0.925, 0.892, 0.905, 0.861, 0.891,
(12.7166)+(-0.1118)His+(-0.0266)Arg+(-0.0007)Pro+(0.0487)Ile+(-0.106
9)Trp; 0.874, 0.909, 0.925, 0.891, 0.900, 0.861, 0.890,
(12.7260)+(-0.1105)His+(-0.0231)Arg+(0.0004)Pro+(-0.0152)Orn+(0.0529)
Ile+(-0.1053)Trp; 0.882, 0.913, 0.925, 0.894, 0.900, 0.863, 0.892,
(13.3747)+(-0.0108)Ser+(-0.0849)His+(-0.0320)Arg+(0.1028)Il
e+(-0.0384)Leu+(-0.1061)Trp; 0.881, 0.908, 0.925, 0.889, 0.892, 0.
862, 0.887,
(12.5014)+(-0.0904)His+(-0.0336)Cit+(-0.0192)Lys+(0.0622)Ile+(-0.1-
058)Trp; 0.881, 0.907, 0.925, 0.892, 0.905, 0.86 1, 0.891,
(12.8361)+(-0.1119)His+(-0.0266)Arg+(0.0483)Ile+(-0.
0037)Phe+(-0.1064)Trp; 0.901, 0.928, 0.924, 0.907, 0.909, 0.878, 0.
905, (16.0042)+(-0.1870)Asn+(-0.0435)His+(-0.0319)Cit+(0.093
2)Ile+(-0.0495)Leu+(-0.0864)Trp; 0.895, 0.926, 0.924, 0.912, 0.9
20, 0.888, 0.911, (12.6275)+(-0.1644)Asn+(0.0099)Gln+(-0.1006)
His+(-0.0174)Arg+(0.0256)Ile+(-0.0849)Trp; 0.893, 0.923, 0.924,
0.915, 0.906, 0.914, 0.914,
(10.9400)+(0.0039)Gln+(-0.0916)His+(-0.0155)Cit+(-0.0395)Arg+(0.0741)Tyr+-
(-0.1507)Trp; 0.884, 0. 909, 0.924, 0.891, 0.899, 0.861, 0.890,
(12.7311)+(-0.1106)His+(-0.0229)Arg+(-0.0149)Orn+(0.0532)Ile+(-0.1051)Trp-
; 0.880, 0.91 0, 0.924, 0.888, 0.893, 0.855, 0.886,
(10.0166)+(0.0061)Gln+(-0.1
101)His+(-0.0242)Lys+(0.0583)Ile+(-0.0930)Trp; 0.877, 0.909, 0.
924, 0.891, 0.899, 0.861, 0.890, (12.7606)+(-0.1107)His+(-0.022
8)Arg+(-0.0149)Orn+(0.0533)Ile+(-0.0009)Phe+(-0.1049)Trp; 0. 914,
0.940, 0.924, 0.917, 0.921, 0.884, 0.915, (14.4226)+(-0.0151)
Gly+(-0.0910)His+(-0.0140)Arg+(-0.0094)Lys+(0.0574)Ile+(-0.
0989)Trp; 0.878, 0.912, 0.924, 0.892, 0.901, 0.857, 0.890, (12.777
4)+(-0.0892)His+(-0.0305)Arg+(-0.0163)Orn+(0.1051)Ile+(-0.0
373)Leu+(-0.1023)Trp; 0.873, 0.910, 0.924, 0.892, 0.902, 0.861, 0.
891, (12.7745)+(-0.1020)His+(-0.0168)Arg+(0.0014)Pro+(-0.014
3)Lys+(0.0562)Ile+(-0.1011)Trp; 0.875, 0.904, 0.923, 0.881, 0.88 7,
0.847, 0.880, (11.3813)+(-0.0947)His+(-0.0339)Cit+(0.0750)I
le+(-0.0231)Leu+(-0.1108)Trp; 0.897, 0.923, 0.923, 0.913, 0.906,
0.908, 0.912, (10.9813)+(0.0035)Gln+(-0.0964)His+(-0.0411)Arg
+(0.0739)Tyr+(-0.1469)Trp; 0.883, 0.910, 0.923, 0.892, 0.901, 0.8
61, 0.891,
(12.7883)+(-0.1027)His+(-0.0164)Arg+(-0.0137)Lys+(0.0571)Ile+(-0.1-
007)Trp; 0.909, 0.934, 0.923, 0.916, 0.920, 0.88 9, 0.914,
(14.4257)+(-0.0153)Gly+(-0.0935)His+(-0.0109)Cit+(-0.0199)Arg+(0.0524)Ile-
+(-0.1063)Trp; 0.873, 0.908, 0.923, 0.886, 0.890, 0.855, 0.884,
(12.2612)+(-0.0795)His+(-0.0331)Cit+(-0.0
188)Lys+(0.0904)Ile+(-0.0219)Leu+(-0.1036)Trp; 0.912, 0.934, 0.
923, 0.918, 0.898, 0.921, 0.918, (11.9502)+(-0.0675)His+(-0.023
6)Arg+(0.1184)Tyr+(-0.3005)Met+(0.0390)Ile+(-0.1568)Trp; 0.9 10,
0.936, 0.923, 0.905, 0.887, 0.887, 0.903, (11.4866)+(-0.0966)H
is+(-0.0344)Arg+(0.0886)Tyr+(-0.0339)Orn+(0.0467)Ile+(-0.15 91)Trp;
0.897, 0.924, 0.923, 0.896, 0.876, 0.884, 0.895,
(11.1211)+(-0.0665)His+(-0.0458)Cit+(0.0869)Tyr+(-0.0325)Lys+(0.0581)
Ile+(-0.1576)Trp; 0.893, 0.926, 0.923, 0.913, 0.908, 0.903, 0.912,
(15.1663)+(-0.1644)Asn+(-0.0654)Cit+(0.0044)Pro+(-0.0184)Ly
s+(0.0337)Ile+(-0.1159)Trp; 0.878, 0.910, 0.923, 0.892, 0.902, 0.
860, 0.891,
(12.5796)+(-0.1020)His+(-0.0167)Arg+(-0.0141)Lys+(0.0570)Ile+(0.00-
61)Phe+(-0.1020)Trp; 0.872, 0.910, 0.923, 0.88 4, 0.884, 0.850,
0.881, (10.2978)+(0.0049)Gln+(-0.1007)His+(-0.
0230)Lys+(0.0778)Ile+(-0.0152)Leu+(-0.0923)Trp; 0.911, 0.935,
0.922, 0.911, 0.911, 0.881, 0.909, (14.1119)+(-0.0150)Gly+(-0.08
26)His+(-0.0229)Cit+(-0.0142)Lys+(0.0608)Ile+(-0.1017)Trp; 0. 881,
0.913, 0.922, 0.895, 0.900, 0.868, 0.894, (13.1702)+(-0.0067)
Ser+(-0.1002)His+(-0.0150)Arg+(-0.0128)Lys+(0.0577)Ile+(-0.
1020)Trp; 0.879, 0.912, 0.922, 0.895, 0.907, 0.861, 0.893, (13.174
4)+(-0.0786)His+(-0.0232)Arg+(-0.1345)Met+(0.1020)Ile+(-0.0
365)Leu+(-0.0929)Trp; 0.869, 0.909, 0.922, 0.888, 0.893, 0.856, 0.
886, (10.0135)+(0.0062)Gln+(-0.1104)His+(-0.0005)Pro+(-0.024
0)Lys+(0.0587)Ile+(-0.0929)Trp; 0.930, 0.950, 0.922, 0.918, 0.90 2,
0.893, 0.915, (12.5111)+(-0.0154)Gly+(-0.0709)His+(0.0841)T
yr+(-0.0271)Lys+(0.0516)Ile+(-0.1420)Trp; 0.912, 0.936, 0.922,
0.907, 0.912, 0.867, 0.905,
(13.0273)+(0.0198)Ser+(-0.0184)Gly+(-0.0948)His+(-0.0171)Lys+(0.0557)Ile+-
(-0.0899)Trp; 0.897, 0. 925, 0.922, 0.906, 0.913, 0.877, 0.905,
(15.2500)+(0.0073)Ser+(-0.
1563)Asn+(-0.0885)His+(-0.0074)Arg+(0.0264)Ile+(-0.0855)Tr p;
0.886, 0.918, 0.922, 0.895, 0.905, 0.858, 0.894, (12.4065)+(-0.0
962)His+(-0.0161)Arg+(-0.1564)Met+(0.0507)Ile+(0.0231)Phe+(-0.0992)Trp;
0.878, 0.910, 0.922, 0.891, 0.900, 0.859, 0.890, (12.
7961)+(-0.1028)His+(-0.0145)Arg+(-0.0107)Orn+(-0.0122)Lys+(0.0599)Ile+(-0-
.0998)Trp; 0.928, 0.948, 0.922, 0.914, 0.914, 0.87 4, 0.912,
(15.5554)+(0.0353)Ser+(-0.2340)Asn+(-0.0199)Gly+(0.
0981)Ile+(-0.0695)Leu+(-0.0719)Trp; 0.875, 0.909, 0.922, 0.886,
0.872, 0.873, 0.885, (10.2052)+(0.0008)Gln+(-0.1006)His+(-0.04
31)Cit+(0.0477)Tyr+(0.0357)Ile+(-0.1449)Trp; 0.917, 0.936, 0.9 21,
0.915, 0.919, 0.886, 0.914, (14.4010)+(-0.0154)Gly+(-0.0969)
His+(-0.0212)Arg+(0.0512)Ile+(-0.1034)Trp; 0.883, 0.910, 0.921,
0.895, 0.902, 0.869, 0.894, (13.2008)+(-0.0085)Ser+(-0.1078)His
+(-0.0244)Arg+(0.0495)Ile+(-0.1085)Trp; 0.869, 0.907, 0.921, 0.
883, 0.888, 0.849, 0.881,
(10.6236)+(0.0021)Gln+(-0.0990)His+(-0.0380)Cit+(0.0707)Ile+(-0.0202)Leu+-
(-0.1118)Trp; 0.897, 0.92 9, 0.921, 0.912, 0.914, 0.890, 0.911,
(15.6380)+(-0.1496)Asn+(-0.
0762)His+(-0.0320)Cit+(-0.0023)Arg+(0.0323)Ile+(-0.0959)Tr p;
0.895, 0.925, 0.921, 0.903, 0.907, 0.872, 0.901, (15.2549)+(0.00
91)Ser+(-0.1546)Asn+(-0.0811)His+(-0.0123)Lys+(0.0350)Ile+(-0.0797)Trp;
0.912, 0.936, 0.921, 0.909, 0.912, 0.873, 0.907, (13.
6749)+(-0.0160)Gly+(-0.0733)His+(-0.0134)Lys+(0.0991)Ile+(-0.0322)Leu+(-0-
.0922)Trp; 0.911, 0.935, 0.921, 0.915, 0.918, 0.886, 0.913,
(14.3947)+(-0.0152)Gly+(-0.0965)His+(-0.0191)Arg+(-0.
0077)Orn+(0.0538)Ile+(-0.1023)Trp; 0.880, 0.912, 0.921, 0.885, 0.
872, 0.865, 0.883, (10.3226)+(-0.0890)His+(-0.0409)Cit+(0.047
3)Tyr+(0.0628)Ile+(-0.0206)Leu+(-0.1422)Trp; 0.896, 0.926, 0.9 21,
0.904, 0.906, 0.874, 0.902, (15.5396)+(-0.1387)Asn+(-0.0806)
His+(-0.0107)Orn+(-0.0093)Lys+(0.0407)Ile+(-0.0832)Trp; 0.89 6,
0.924, 0.921, 0.914, 0.906, 0.909, 0.913, (11.8572)+(0.0028)Gln
+(-0.0953)His+(-0.0387)Arg+(0.0796)Tyr+(-0.0208)Phe+(-0.145 3)Trp;
0.875, 0.910, 0.920, 0.894, 0.903, 0.866, 0.893,
(13.2183)+(-0.0086)Ser+(-0.1080)His+(-0.0238)Arg+(-0.0009)Pro+(0.050
5)Ile+(-0.1080)Trp; 0.874, 0.906, 0.920, 0.886, 0.892, 0.857, 0.88
5, (10.2651)+(0.0036)Gln+(-0.1114)His+(-0.0413)Cit+(0.0439)I
le+(-0.1143)Trp; 0.873, 0.907, 0.920, 0.879, 0.880, 0.844, 0.877,
(11.6730)+(-0.0896)His+(-0.0196)Lys+(0.0863)Ile+(-0.0227)Le
u+(0.0078)Phe+(-0.0957)Trp; 0.928, 0.947, 0.920, 0.930, 0.918, 0.
919, 0.928,
(12.7898)+(0.0225)Ser+(-0.0193)Gly+(-0.0809)His+(-0.0379)Arg+(0.08-
40)Tyr+(-0.1457)Trp; 0.909, 0.935, 0.920, 0.9 20, 0.907, 0.916,
0.919,
(14.4930)+(-0.1522)Asn+(-0.0750)His+(-0.0203)Arg+(0.0765)Tyr+(0.0169)Ile+-
(-0.1361)Trp; 0.908, 0.936, 0.920, 0.926, 0.917, 0.922, 0.925,
(12.8808)+(-0.1740)Asn+(0.007
2)Gln+(-0.0802)His+(-0.0237)Arg+(0.0696)Tyr+(-0.1255)Trp; 0. 905,
0.929, 0.920, 0.912, 0.913, 0.890, 0.911,
(15.6038)+(-0.1524)Asn+(-0.0758)His+(-0.0334)Cit+(0.0315)Ile+(-0.0956)Trp-
; 0.91 0, 0.935, 0.920, 0.916, 0.921, 0.888, 0.915,
(14.7806)+(-0.0155)Gl
y+(-0.0974)His+(-0.0200)Arg+(0.0520)Ile+(-0.0109)Phe+(-0.10 07)Trp;
0.879, 0.912, 0.920, 0.896, 0.903, 0.868, 0.894,
(13.3032)+(-0.0092)Ser+(-0.1008)His+(-0.0215)Cit+(-0.0217)Arg+(0.052
2)Ile+(-0.1142)Trp; 0.877, 0.909, 0.920, 0.888, 0.890, 0.860, 0.88
6, (12.4932)+(-0.0923)His+(-0.0283)Cit+(-0.0057)Orn+(-0.018
1)Lys+(0.0628)Ile+(-0.1041)Trp
[0526] List of Logistic Regression Equations Searched in Example 2
(ROC_AUC value: 0.500 or greater)
[0527] The logistic regression equations searched in Example 2
above are listed below. Before each equation, "the value of ROC_AUC
for the pancreatic cancer group and the healthy group with
validation", "the value of ROC_AUC for the pancreatic cancer group
and the healthy group without validation", "the value of ROC_AUC
for the pancreatic cancer group and the other cancers group", "the
value of ROC_AUC for the pancreatic cancer group and the lung
cancer group", "the value of ROC_AUC for the pancreatic cancer
group and the colorectal cancer group", "the value of ROC_AUC for
the pancreatic cancer group and the prostatic cancer group", "the
value of ROC_AUC for the pancreatic cancer group and the breast
cancer group", and "the average value of the value of ROC_AUC for
the pancreatic cancer group and the lung cancer group, the value of
ROC_AUC for the pancreatic cancer group and the colorectal cancer
group, the value of ROC_AUC for the pancreatic cancer group and the
prostatic cancer group, and the value of ROC_AUC for the pancreatic
cancer group and the breast cancer group" obtained for the equation
are additionally listed.
[0528] 0.826, 0.840, 0.800, 0.804, 0.811, 0.753, 0.801, 0.792,
(3.264 6)+(0.0697)Phe+(-0.1735)Trp; 0.817, 0.828, 0.774, 0.782,
0.778, 0. 801, 0.727, 0.772, (3.1922)+(0.0271)Ser+(-0.1525)Trp;
0.812, 0.8 22, 0.774, 0.762, 0.777, 0.766, 0.804, 0.777,
(4.2601)+(0.0495)Ile +(-0.1715)Trp; 0.812, 0.825, 0.809, 0.812,
0.810, 0.827, 0.789, 0.8 09, (8.8631)+(-0.0763)His+(-0.0949)Trp;
0.804, 0.815, 0.736, 0.7 17, 0.737, 0.829, 0.719, 0.750,
(4.1731)+(0.0357)Ser+(-0.1324)Hi s; 0.802, 0.817, 0.816, 0.822,
0.831, 0.822, 0.765, 0.810, (7.5229)+(-0.0626)Cit+(-0.1412)Trp;
0.802, 0.815, 0.793, 0.803, 0.802, 0.7 83, 0.754, 0.786,
(5.1431)+(0.0173)Orn+(-0.1504)Trp; 0.801, 0.81 4, 0.795, 0.806,
0.800, 0.781, 0.766, 0.788, (5.4341)+(0.0049)Pro+(-0.1498)Trp;
0.801, 0.813, 0.781, 0.775, 0.769, 0.829, 0.787, 0.79 0,
(4.1211)+(0.0092)Gln+(-0.1498)His; 0.799, 0.812, 0.792, 0.804,
0.802, 0.788, 0.745, 0.785, (5.3459)+(0.0083)Thr+(-0.1543)Trp; 0.
798, 0.812, 0.808, 0.824, 0.807, 0.794, 0.775, 0.800, (4.4293)+(0.0
032)Gln+(-0.1532)Trp; 0.797, 0.811, 0.747, 0.721, 0.745, 0.783, 0.
795, 0.761, (4.6715)+(-0.1432)His+(0.0732)Phe; 0.796, 0.806, 0.7
41, 0.704, 0.738, 0.798, 0.804, 0.761, (5.5422)+(-0.1341)His+(0.0
453)Ile; 0.795, 0.807, 0.819, 0.832, 0.822, 0.807, 0.783, 0.811,
(7. 2003)+(-0.0494)Asn+(-0.1313)Trp; 0.794, 0.808, 0.803, 0.819,
0.8 06, 0.792, 0.765, 0.796, (5.8643)+(-0.0006)Val+(-0.1435)Trp;
0.7 94, 0.808, 0.794, 0.802, 0.802, 0.777, 0.770, 0.788,
(5.3577)+(0.00 86)Leu+(-0.1545)Trp; 0.793, 0.805, 0.816, 0.832,
0.812, 0.816, 0.7 84, 0.811, (6.3477)+(-0.0032)Ala+(-0.1356)Trp;
0.793, 0.807, 0.8 02, 0.819, 0.804, 0.789, 0.762, 0.793,
(5.9803)+(-0.0056)Tyr+(-0. 1416)Trp; 0.792, 0.807, 0.802, 0.816,
0.806, 0.788, 0.767, 0.794, (5. 7122)+(0.0009)Lys+(-0.1463)Trp;
0.791, 0.806, 0.817, 0.834, 0.82 0, 0.811, 0.769, 0.809,
(6.9335)+(-0.0867)Met+(-0.1276)Trp; 0.79 1, 0.807, 0.805, 0.818,
0.809, 0.790, 0.773, 0.798, (5.9630)+(-0.00 09)Gly+(-0.1445)Trp;
0.787, 0.801, 0.748, 0.720, 0.759, 0.808, 0.7 56, 0.761,
(6.1253)+(-0.1299)His+(0.0330)Orn; 0.784, 0.796, 0.74 5, 0.727,
0.750, 0.804, 0.741, 0.756, (6.4709)+(-0.1329)His+(0.01 49)Thr;
0.784, 0.802, 0.805, 0.822, 0.812, 0.795, 0.752, 0.795, (6.3
448)+(-0.0090)Arg+(-0.1399)Trp; 0.778, 0.788, 0.751, 0.725, 0.75 5,
0.801, 0.779, 0.765, (6.5324)+(-0.1304)His+(0.0128)Leu; 0.775,
0.786, 0.763, 0.748, 0.762, 0.810, 0.770, 0.772, (6.9613)+(-0.120
8)His+(0.0015)Val; 0.775, 0.788, 0.756, 0.747, 0.754, 0.813, 0.742,
0.764, (6.6776)+(0.0028)Gly+(-0.1206)His; 0.775, 0.786, 0.775, 0.
766, 0.765, 0.822, 0.784, 0.784,
(7.3273)+(-0.1124)His+(-0.0021)Ala; 0.773, 0.785, 0.752, 0.734,
0.753, 0.797, 0.764, 0.762, (6.633 1)+(-0.1215)His+(0.0052)Pro;
0.772, 0.785, 0.769, 0.758, 0.766, 0. 811, 0.776, 0.778,
(7.3401)+(-0.0143)Asn+(-0.1136)His; 0.772, 0. 783, 0.758, 0.744,
0.757, 0.803, 0.766, 0.768, (6.7145)+(-0.1239)H is+(0.0042)Lys;
0.770, 0.785, 0.766, 0.757, 0.761, 0.809, 0.768, 0. 774,
(7.2279)+(-0.1150)His+(-0.0062)Tyr; 0.767, 0.785, 0.775, 0. 768,
0.771, 0.817, 0.773, 0.782, (7.4695)+(-0.1078)His+(-0.0493)Met;
0.766, 0.784, 0.766, 0.753, 0.764, 0.812, 0.768, 0.774, (7.240
8)+(-0.1161)His+(-0.0036)Arg; 0.761, 0.778, 0.764, 0.750, 0.768,
0.810, 0.758, 0.771, (7.3735)+(-0.1115)His+(-0.0257)Cit; 0.760,
0.771, 0.696, 0.684, 0.626, 0.781, 0.814, 0.726, (0.9619)+(-0.055
9)Val+(0.1493)Ile; 0.755, 0.773, 0.737, 0.764, 0.736, 0.813, 0.613,
0.731, (0.2571)+(0.0364)Ser+(-0.2519)Met; 0.738, 0.754, 0.739, 0.
730, 0.737, 0.757, 0.755, 0.745, (1.8923)+(-0.2844)Met+(0.0530)I
le; 0.737, 0.752, 0.758, 0.772, 0.765, 0.712, 0.734, 0.746,
(0.4707) +(-0.3046)Met+(0.0871)Phe; 0.729, 0.744, 0.681, 0.679,
0.631, 0.7 46, 0.746, 0.701, (-0.1029)+(0.1443)Ile+(-0.0904)Leu;
0.724, 0.7 43, 0.707, 0.720, 0.698, 0.771, 0.648, 0.709,
(0.7877)+(0.0397)Ser +(-0.1603)Asn; 0.712, 0.731, 0.738, 0.769,
0.748, 0.764, 0.620, 0.7 25, (2.6702)+(0.0178)Thr+(-0.2686)Met;
0.707, 0.725, 0.742, 0.76 1, 0.740, 0.745, 0.693, 0.735,
(2.9233)+(0.0080)Pro+(-0.2391)Me t; 0.704, 0.721, 0.742, 0.762,
0.744, 0.767, 0.671, 0.736, (2.4989)+(-0.2277)Met+(0.0223)Orn;
0.704, 0.723, 0.732, 0.729, 0.642, 0.81 9, 0.864, 0.764,
(0.0800)+(-0.0136)Ala+(0.0441)Ile; 0.703, 0.722, 0.778, 0.814,
0.761, 0.782, 0.713, 0.768, (1.4382)+(0.0045)Gln+(-0.2387)Met;
0.703, 0.719, 0.775, 0.798, 0.775, 0.768, 0.721, 0.765,
(3.9824)+(-0.0433)Asn+(-0.1605)Met; 0.703, 0.723, 0.789, 0.817,
0.767, 0.811, 0.743, 0.785, (3.5534)+(-0.0040)Ala+(-0.1658)Met;
0.699, 0.720, 0.765, 0.781, 0.785, 0.773, 0.676, 0.754,
(4.3007)+(-0.0614)Cit+(-0.1733)Met; 0.695, 0.716, 0.776, 0.813,
0.764, 0.787, 0.697, 0.765, (3.8103)+(-0.0065)Val+(-0.1747)Met;
0.695, 0.713, 0.760, 0.788, 0.758, 0.764, 0.685, 0.749,
(3.0856)+(0.0006)Gly+(-0.2055)Met; 0.694, 0.712, 0.766, 0.794,
0.763, 0.770, 0.694, 0.755, (3.3474)+(-0.1943)Met+(-0.0022)Lys;
0.693, 0.712, 0.759, 0.784, 0.758, 0.758, 0.697, 0.749,
(3.0295)+(-0.2128)Met+(0.0031)Leu; 0. 692, 0.714, 0.766, 0.796,
0.767, 0.768, 0.684, 0.754, (3.5146)+(-0. 0079)Arg+(-0.1897)Met;
0.688, 0.708, 0.774, 0.787, 0.761, 0.821, 0. 736, 0.776,
(3.4870)+(-0.0086)Ala+(-0.0780)Cit; 0.688, 0.710, 0. 759, 0.791,
0.753, 0.756, 0.687, 0.747, (3.3052)+(-0.0074)Tyr+(-0. 1906)Met;
0.687, 0.707, 0.800, 0.821, 0.762, 0.827, 0.801, 0.803, (4.
0397)+(-0.0851)Asn+(-0.0064)Ala; 0.685, 0.709, 0.757, 0.766, 0.7
70, 0.754, 0.707, 0.749, (4.3414)+(-0.0921)Asn+(-0.0679)Cit; 0.6
79, 0.702, 0.751, 0.796, 0.724, 0.739, 0.696, 0.739, (4.2548)+(-0.0
854)Asn+(-0.0363)Tyr; 0.679, 0.698, 0.787, 0.822, 0.763, 0.795, 0.
737, 0.779, (4.9678)+(-0.0972)Asn+(-0.0120)Val; 0.675, 0.701, 0.
715, 0.755, 0.715, 0.732, 0.596, 0.699, (3.3013)+(-0.0711)Cit+(-0.
0448)Tyr; 0.672, 0.699, 0.623, 0.683, 0.584, 0.706, 0.486, 0.615,
(-0.4769)+(0.0218)Ser+(-0.0572)Tyr; 0.669, 0.694, 0.704, 0.733, 0.
618, 0.847, 0.702, 0.725, (-0.8615)+(0.0218)Ser+(-0.0099)Ala; 0.
668, 0.689, 0.736, 0.756, 0.660, 0.815, 0.789, 0.755, (1.0885)+(-0.
0125)Ala+(0.0096)Pro; 0.667, 0.689, 0.677, 0.647, 0.668, 0.732, 0.
736, 0.696, (1.0698)+(-0.0265)Lys+(0.0364)Ile; 0.667, 0.687, 0.6
27, 0.668, 0.570, 0.645, 0.625, 0.627, (0.7224)+(-0.0702)Tyr+(0.0
336)Ile; 0.666, 0.689, 0.720, 0.713, 0.712, 0.706, 0.762, 0.723,
(2. 1733)+(-0.1195)Asn+(0.0213)Ile; 0.665, 0.690, 0.754, 0.775,
0.68 1, 0.814, 0.806, 0.769, (0.0534)+(-0.0112)Ala+(0.0327)Phe;
0.662, 0.686, 0.728, 0.735, 0.729, 0.725, 0.713, 0.725,
(2.5997)+(-0.121 4)Asn+(0.0169)Orn; 0.662, 0.685, 0.734, 0.740,
0.734, 0.693, 0.745, 0.728, (1.9869)+(-0.1259)Asn+(0.0297)Phe;
0.661, 0.691, 0.639, 0. 647, 0.638, 0.762, 0.535, 0.645,
(-0.6030)+(0.0285)Ser+(-0.0227)Lys; 0.660, 0.680, 0.644, 0.717,
0.589, 0.609, 0.589, 0.626, (0.163 5)+(-0.0781)Tyr+(0.0525)Phe;
0.660, 0.685, 0.758, 0.816, 0.687, 0. 821, 0.708, 0.758,
(2.6325)+(-0.0068)Ala+(-0.0337)Tyr; 0.659, 0. 684, 0.788, 0.823,
0.742, 0.845, 0.749, 0.790, (2.4815)+(-0.0080)A la+(-0.0175)Arg;
0.659, 0.684, 0.768, 0.792, 0.751, 0.740, 0.760, 0. 761,
(1.6188)+(-0.1401)Asn+(0.0047)Gln; 0.656, 0.686, 0.789, 0.8 21,
0.735, 0.858, 0.766, 0.795, (2.7346)+(-0.0074)Ala+(-0.0108)L ys;
0.655, 0.686, 0.729, 0.802, 0.681, 0.760, 0.611, 0.714, (2.8329)
+(-0.0389)Tyr+(-0.0100)Val; 0.655, 0.678, 0.765, 0.796, 0.754, 0.
753, 0.718, 0.755, (3.8161)+(-0.1017)Asn+(-0.0101)Leu; 0.654, 0.
681, 0.744, 0.765, 0.673, 0.835, 0.770, 0.761, (0.8298)+(-0.0104)A
la+(0.0158)Orn; 0.653, 0.676, 0.735, 0.758, 0.729, 0.722, 0.695, 0.
726, (2.8947)+(-0.1145)Asn+(0.0017)Gly; 0.653, 0.684, 0.629, 0.6
48, 0.653, 0.741, 0.450, 0.623, (-1.5623)+(0.0264)Ser+(-0.0341)A
rg; 0.653, 0.681, 0.759, 0.776, 0.753, 0.757, 0.730, 0.754,
(3.7433) +(-0.0898)Asn+(-0.0085)Lys; 0.652, 0.678, 0.787, 0.837,
0.715, 0. 867, 0.743, 0.791, (2.4040)+(-0.0069)Ala+(-0.0089)Val;
0.651, 0. 674, 0.610, 0.597, 0.649, 0.696, 0.505, 0.612,
(-1.3060)+(0.0227)S er+(-0.0930)Cit; 0.648, 0.673, 0.736, 0.752,
0.730, 0.709, 0.724, 0. 729, (2.9528)+(-0.1135)Asn+(0.0018)Pro;
0.646, 0.676, 0.754, 0.7 77, 0.756, 0.739, 0.702, 0.743,
(3.4803)+(-0.0950)Asn+(-0.0123)A rg; 0.646, 0.674, 0.733, 0.748,
0.731, 0.712, 0.709, 0.725, (2.9573) +(-0.1231)Asn+(0.0056)Thr;
0.645, 0.670, 0.771, 0.805, 0.692, 0.8 55, 0.783, 0.784,
(1.1266)+(0.0006)Gln+(-0.0096)Ala; 0.645, 0.67 4, 0.717, 0.771,
0.689, 0.750, 0.606, 0.704, (2.9686)+(-0.0405)Tyr +(-0.0113)Lys;
0.644, 0.670, 0.636, 0.601, 0.699, 0.702, 0.553, 0.6 39,
(0.0045)+(-0.1113)Cit+(0.0318)Orn; 0.643, 0.676, 0.709, 0.77 4,
0.691, 0.729, 0.564, 0.689, (2.8079)+(-0.0184)Arg+(-0.0455)Ty r;
0.642, 0.671, 0.727, 0.731, 0.754, 0.773, 0.625, 0.721,
(3.2166)+(-0.0736)Cit+(-0.0142)Lys; 0.642, 0.668, 0.777, 0.806,
0.706, 0.8 51, 0.797, 0.790, (1.6342)+(-0.0013)Gly+(-0.0093)Ala;
0.642, 0.6 71, 0.776, 0.815, 0.703, 0.855, 0.765, 0.785,
(1.6244)+(-0.0088)Al a+(-0.0039)Leu; 0.641, 0.665, 0.641, 0.708,
0.600, 0.670, 0.525, 0. 626, (1.2368)+(-0.0616)Tyr+(0.0176)Orn;
0.641, 0.669, 0.777, 0.8 10, 0.701, 0.854, 0.794, 0.790,
(1.5960)+(-0.0029)Thr+(-0.0090)A la; 0.640, 0.661, 0.627, 0.594,
0.664, 0.663, 0.611, 0.633, (-0.087 3)+(-0.0926)Cit+(0.0212)Ile;
0.639, 0.663, 0.700, 0.735, 0.637, 0. 754, 0.697, 0.706,
(1.2645)+(-0.0316)Val+(0.0321)Leu; 0.637, 0.6 60, 0.720, 0.746,
0.727, 0.755, 0.612, 0.710, (2.7084)+(-0.0684)Ci t+(-0.0110)Val;
0.637, 0.663, 0.642, 0.714, 0.592, 0.658, 0.546, 0. 628,
(1.5667)+(0.0048)Pro+(-0.0616)Tyr; 0.635, 0.659, 0.704, 0.7 21,
0.729, 0.737, 0.581, 0.692, (1.9881)+(-0.0784)Cit+(-0.0111)L eu;
0.634, 0.668, 0.696, 0.775, 0.656, 0.712, 0.562, 0.676, (2.1802)
+(-0.0486)Tyr+(-0.0070)Leu; 0.632, 0.661, 0.690, 0.696, 0.729, 0.
716, 0.574, 0.679, (1.7181)+(-0.0714)Cit+(-0.0136)Arg; 0.631, 0.
658, 0.670, 0.753, 0.618, 0.680, 0.554, 0.651, (1.4409)+(0.0007)Gl
n+(-0.0560)Tyr; 0.631, 0.656, 0.726, 0.753, 0.730, 0.751, 0.626, 0.
715, (2.3484)+(-0.0162)Arg+(-0.0139)Lys; 0.630, 0.659, 0.690, 0.
692, 0.715, 0.705, 0.627, 0.684, (1.4777)+(-0.0058)Thr+(-0.0810)
Cit; 0.626, 0.657, 0.696, 0.767, 0.645, 0.679, 0.627, 0.679, (2.346
2)+(-0.0027)Gly+(-0.0552)Tyr; 0.626, 0.648, 0.652, 0.651, 0.689,
0.689, 0.551, 0.645, (0.7903)+(0.0012)Gly+(-0.0878)Cit; 0.626, 0.
657, 0.671, 0.750, 0.622, 0.681, 0.554, 0.652, (1.8014)+(-0.0007)T
hr+(-0.0540)Tyr; 0.625, 0.646, 0.664, 0.662, 0.697, 0.690, 0.582,
0. 657, (1.0033)+(-0.0855)Cit+(-0.0003)Pro; 0.625, 0.651, 0.636, 0.
684, 0.596, 0.738, 0.520, 0.635, (-0.5966)+(0.0186)Ser+(-0.0150)
Val; 0.624, 0.657, 0.689, 0.737, 0.653, 0.756, 0.591, 0.684, (0.826
3)+(-0.0178)Val+(0.0220)Orn; 0.623, 0.654, 0.685, 0.689, 0.693, 0.
738, 0.620, 0.685, (1.3552)+(0.0218)Orn+(-0.0227)Lys; 0.622, 0.6
47, 0.662, 0.660, 0.692, 0.689, 0.583, 0.656, (0.5838)+(0.0008)Gln
+(-0.0880)Cit; 0.621, 0.653, 0.748, 0.807, 0.728, 0.790, 0.603, 0.7
32, (2.8091)+(-0.0205)Arg+(-0.0129)Val; 0.620, 0.651, 0.689, 0.7
40, 0.641, 0.693, 0.652, 0.682, (0.0155)+(-0.0192)Val+(0.0395)Ph e;
0.620, 0.651, 0.744, 0.790, 0.716, 0.802, 0.640, 0.737,
(2.5515)+(-0.0106)Val+(-0.0108)Lys; 0.617, 0.647, 0.696, 0.701,
0.695, 0.7 06, 0.676, 0.695, (0.8491)+(-0.0220)Lys+(0.0271)Phe;
0.615, 0.63 9, 0.644, 0.636, 0.681, 0.658, 0.577, 0.638,
(0.3037)+(-0.0884)Cit +(0.0129)Phe; 0.611, 0.638, 0.724, 0.742,
0.719, 0.746, 0.673, 0.72 0, (1.9680)+(-0.0011)Gly+(-0.0183)Lys;
0.611, 0.647, 0.722, 0.74 7, 0.709, 0.757, 0.656, 0.718,
(1.2350)+(0.0014)Gln+(-0.0199)Ly s; 0.611, 0.641, 0.708, 0.726,
0.702, 0.744, 0.649, 0.705, (1.6959)+(0.0014)Pro+(-0.0191)Lys;
0.610, 0.635, 0.646, 0.645, 0.666, 0.66 5, 0.591, 0.642,
(-0.0841)+(-0.0308)Arg+(0.0193)Ile; 0.609, 0.63 8, 0.720, 0.742,
0.712, 0.752, 0.657, 0.716, (1.8217)+(-0.0012)Thr +(-0.0180)Lys;
0.607, 0.636, 0.688, 0.743, 0.641, 0.730, 0.608, 0.6 81,
(1.2424)+(0.0047)Pro+(-0.0170)Val; 0.605, 0.638, 0.723, 0.75 7,
0.713, 0.762, 0.626, 0.715, (1.9476)+(-0.0162)Lys+(-0.0053)Le u;
0.605, 0.635, 0.742, 0.794, 0.692, 0.768, 0.691, 0.736,
(1.9032)+(-0.0023)Gly+(-0.0149)Val; 0.603, 0.644, 0.599, 0.600,
0.567, 0.6 93, 0.597, 0.614, (-2.5189)+(0.0324)Ser+(-0.0236)Thr;
0.599, 0.6 33, 0.716, 0.777, 0.669, 0.764, 0.619, 0.707,
(1.5073)+(-0.0001)Gl n+(-0.0149)Val; 0.596, 0.634, 0.736, 0.792,
0.688, 0.771, 0.661, 0. 728, (1.7582)+(-0.0046)Thr+(-0.0140)Val;
0.596, 0.627, 0.665, 0. 685, 0.698, 0.695, 0.525, 0.651,
(0.3433)+(-0.0306)Arg+(0.0128)O rn; 0.595, 0.629, 0.728, 0.786,
0.733, 0.753, 0.548, 0.705, (1.9642) +(-0.0239)Arg+(-0.0135)Leu;
0.592, 0.622, 0.687, 0.720, 0.705, 0. 691, 0.562, 0.670,
(0.2892)+(0.0012)Gln+(-0.0295)Arg; 0.591, 0.6 23, 0.701, 0.732,
0.713, 0.701, 0.594, 0.685, (0.9755)+(-0.0037)Th r+(-0.0249)Arg;
0.590, 0.620, 0.683, 0.713, 0.705, 0.690, 0.555, 0. 666,
(0.7635)+(-0.0276)Arg+(0.0001)Pro; 0.590, 0.621, 0.688, 0.7 16,
0.709, 0.689, 0.567, 0.671, (0.8327)+(-0.0004)Gly+(-0.0273)A rg;
0.589, 0.623, 0.531, 0.479, 0.520, 0.596, 0.644, 0.560, (-3.257
5)+(0.0302)Ser+(-0.0083)Gly; 0.583, 0.619, 0.672, 0.697, 0.695, 0.
670, 0.556, 0.655, (0.2642)+(-0.0289)Arg+(0.0109)Phe; 0.579, 0.6
24, 0.454, 0.413, 0.483, 0.602, 0.395, 0.473, (-1.8253)+(0.0271)Se
r+(-0.0049)Gln; 0.574, 0.613, 0.577, 0.622, 0.564, 0.677, 0.415, 0.
570, (-1.8132)+(0.0190)Ser+(-0.0170)Leu; 0.572, 0.618, 0.639, 0.
620, 0.603, 0.638, 0.767, 0.657,
(-0.8939)+(-0.0159)Thr+(0.0180)Ile; 0.569, 0.605, 0.394, 0.342,
0.393, 0.534, 0.430, 0.425, (-4.499 1)+(0.0200)Ser+(0.0115)Ile;
0.552, 0.621, 0.683, 0.686, 0.656, 0. 698, 0.718, 0.690,
(-0.4947)+(-0.0157)Thr+(0.0121)Orn; 0.550, 0. 599, 0.467, 0.456,
0.465, 0.593, 0.407, 0.480, (-3.4533)+(0.0200)S er+(-0.0027)Pro;
0.544, 0.591, 0.705, 0.725, 0.674, 0.674, 0.738, 0. 703,
(-0.0754)+(-0.0006)Gly+(-0.0126)Thr; 0.542, 0.586, 0.732, 0. 788,
0.700, 0.739, 0.646, 0.718, (0.9960)+(-0.0087)Thr+(-0.0146) Leu;
0.538, 0.593, 0.661, 0.721, 0.652, 0.707, 0.486, 0.642, (-0.098
9)+(0.0130)Orn+(-0.0199)Leu; 0.538, 0.592, 0.700, 0.722, 0.669, 0.
677, 0.723, 0.698, (-0.1305)+(-0.0001)Gln+(-0.0128)Thr; 0.536, 0.
584, 0.656, 0.721, 0.640, 0.626, 0.540, 0.632, (-0.7104)+(-0.0235)
Leu+(0.0296)Phe; 0.534, 0.581, 0.428, 0.406, 0.430, 0.559, 0.387,
0. 445, (-3.6022)+(0.0197)Ser+(-0.0032)Phe; 0.533, 0.576, 0.725, 0.
785, 0.698, 0.718, 0.625, 0.707, (0.7956)+(-0.0023)Gly+(-0.0173)
Leu; 0.532, 0.593, 0.690, 0.708, 0.658, 0.665, 0.725, 0.689,
(-0.410 3)+(-0.0135)Thr+(0.0056)Phe; 0.530, 0.592, 0.700, 0.723,
0.668, 0. 678, 0.723, 0.698, (-0.1545)+(-0.0129)Thr+(0.0000)Pro;
0.524, 0. 572, 0.669, 0.742, 0.645, 0.692, 0.510, 0.647,
(0.2198)+(0.0018)Pr o+(-0.0186)Leu; 0.521, 0.571, 0.437, 0.424,
0.432, 0.546, 0.405, 0. 452, (-3.5449)+(0.0206)Ser+(-0.0062)Orn;
0.521, 0.573, 0.687, 0. 758, 0.671, 0.713, 0.515, 0.664,
(0.5502)+(-0.0005)Gln+(-0.0169) Leu
[0529] 0.847, 0.863, 0.807, 0.794, 0.809, 0.813, 0.833, 0.813,
(6.120 3)+(-0.1057)His+(0.1038)Phe+(-0.1160)Trp; 0.843, 0.861,
0.766, 0.764, 0.770, 0.765, 0.763, 0.766,
(0.3860)+(0.0285)Ser+(0.0708) Phe+(-0.1800)Trp; 0.841, 0.852,
0.788, 0.762, 0.789, 0.818, 0.835, 0.801,
(7.5109)+(-0.0925)His+(0.0651)Ile+(-0.1199)Trp; 0.837, 0.851,
0.786, 0.780, 0.786, 0.849, 0.754, 0.793,
(5.9269)+(0.0370)Ser+(-0.0914)His+(-0.0960)Trp; 0.835, 0.847,
0.775, 0.766, 0.739, 0.813, 0.848, 0.791,
(5.0718)+(-0.0408)Val+(0.1480)Ile+(-0.138 1)Trp; 0.833, 0.848,
0.787, 0.782, 0.771, 0.804, 0.820, 0.795, (4.81
74)+(0.1394)Ile+(-0.0646)Leu+(-0.1464)Trp; 0.832, 0.846, 0.821,
0.826, 0.811, 0.845, 0.810, 0.823, (5.8821)+(0.0098)Gln+(-0.108
8)His+(-0.1000)Trp; 0.830, 0.845, 0.796, 0.793, 0.801, 0.835, 0.76
5, 0.798, (8.3046)+(-0.0932)His+(0.0211)Thr+(-0.1065)Trp; 0.82 8,
0.847, 0.811, 0.820, 0.813, 0.770, 0.809, 0.803, (3.4267)+(-0.00
70)Val+(0.0829)Phe+(-0.1635)Trp; 0.828, 0.843, 0.803, 0.815, 0.8
00, 0.838, 0.753, 0.801, (4.9322)+(0.0381)Ser+(-0.0943)Asn+(-0.
1322)Trp; 0.828, 0.842, 0.803, 0.816, 0.803, 0.844, 0.739, 0.800,
(4. 3243)+(0.0350)Ser+(-0.1297)Met+(-0.1329)Trp; 0.827, 0.841, 0.7
44, 0.727, 0.745, 0.776, 0.766, 0.753, (1.4558)+(0.0279)Ser+(0.05
12)Ile+(-0.1787)Trp; 0.826, 0.839, 0.793, 0.776, 0.804, 0.807, 0.8
07, 0.798, (6.0150)+(-0.0807)Cit+(0.0621)Ile+(-0.1723)Trp; 0.8 26,
0.843, 0.797, 0.787, 0.806, 0.827, 0.783, 0.801, (8.0435)+(-0.0
898)His+(0.0369)Orn+(-0.0989)Trp; 0.825, 0.845, 0.824, 0.830, 0.
832, 0.776, 0.826, 0.816, (4.7154)+(-0.0675)Asn+(0.0782)Phe+(-0.
1556)Trp; 0.825, 0.837, 0.709, 0.671, 0.711, 0.796, 0.744, 0.731,
(0. 7000)+(0.0434)Ser+(-0.1690)His+(0.0910)Phe; 0.824, 0.845, 0.80
3, 0.810, 0.809, 0.756, 0.806, 0.795, (2.4095)+(0.0022)Gln+(0.067
0)Phe+(-0.1787)Trp; 0.824, 0.841, 0.795, 0.796, 0.810, 0.837, 0.72
7, 0.793, (4.8137)+(0.0312)Ser+(-0.0712)Cit+(-0.1507)Trp; 0.82 4,
0.837, 0.705, 0.655, 0.706, 0.816, 0.756, 0.733, (2.1410)+(0.039
5)Ser+(-0.1546)His+(0.0546)Ile; 0.823, 0.844, 0.826, 0.834, 0.83 6,
0.786, 0.816, 0.818, (3.9066)+(-0.1992)Met+(0.1112)Phe+(-0.1
427)Trp; 0.822, 0.839, 0.811, 0.810, 0.829, 0.788, 0.797, 0.806,
(4. 6574)+(-0.0877)Cit+(0.0903)Phe+(-0.1721)Trp; 0.822, 0.842, 0.7
92, 0.794, 0.807, 0.751, 0.787, 0.785, (3.0429)+(0.0058)Thr+(0.06
71)Phe+(-0.1790)Trp; 0.822, 0.839, 0.774, 0.762, 0.781, 0.744, 0.8
13, 0.775, (2.9066)+(0.0405)Ile+(0.0456)Phe+(-0.1860)Trp; 0.82 2,
0.841, 0.797, 0.801, 0.807, 0.750, 0.800, 0.789, (3.1910)+(0.002
2)Pro+(0.0675)Phe+(-0.1750)Trp; 0.821, 0.843, 0.821, 0.828, 0.81 4,
0.798, 0.834, 0.819, (3.6992)+(-0.0060)Ala+(0.0835)Phe+(-0.1
607)Trp; 0.821, 0.837, 0.798, 0.794, 0.801, 0.814, 0.790, 0.800,
(8. 4039)+(-0.0805)His+(0.0085)Pro+(-0.1012)Trp; 0.821, 0.835, 0.8
01, 0.794, 0.831, 0.824, 0.740, 0.797, (6.8352)+(-0.1114)Cit+(0.0
546)Orn+(-0.1576)Trp; 0.821, 0.842, 0.802, 0.808, 0.812, 0.755, 0.
801, 0.794, (3.2872)+(-0.0019)Leu+(0.0716)Phe+(-0.1719)Trp; 0. 821,
0.841, 0.798, 0.801, 0.809, 0.754, 0.796, 0.790, (3.1971)+(0.0
053)Orn+(0.0661)Phe+(-0.1736)Trp; 0.821, 0.839, 0.784, 0.772, 0.
740, 0.850, 0.859, 0.805, (4.6883)+(-0.0544)Val+(-0.2751)Met+(0.
1901)Ile; 0.821, 0.840, 0.801, 0.805, 0.812, 0.753, 0.803, 0.793,
(3. 3119)+(-0.0002)Gly+(0.0696)Phe+(-0.1733)Trp; 0.820, 0.845, 0.8
08, 0.813, 0.818, 0.767, 0.806, 0.801, (3.5616)+(-0.0050)Lys+(0.0
755)Phe+(-0.1678)Trp; 0.818, 0.838, 0.794, 0.811, 0.793, 0.747, 0.
786, 0.784, (3.5386)+(-0.0340)Tyr+(0.0898)Phe+(-0.1607)Trp; 0. 817,
0.831, 0.794, 0.776, 0.803, 0.814, 0.811, 0.801, (8.3524)+(-0.
0941)His+(0.0241)Leu+(-0.1113)Trp; 0.816, 0.833, 0.802, 0.819, 0.
816, 0.815, 0.718, 0.792, (6.6981)+(0.0249)Thr+(-0.1682)Met+(-0.
1414)Trp; 0.816, 0.830, 0.767, 0.748, 0.754, 0.807, 0.813, 0.780,
(2. 0184)+(0.0088)Gln+(-0.1733)His+(0.0702)Phe; 0.815, 0.832, 0.79
7, 0.787, 0.777, 0.817, 0.852, 0.808, (5.0478)+(-0.0082)Ala+(0.06
72)Ile+(-0.1566)Trp; 0.815, 0.830, 0.793, 0.802, 0.785, 0.835, 0.7
56, 0.795, (3.7617)+(0.0278)Ser+(-0.0037)Ala+(-0.1426)Trp; 0.8 14,
0.832, 0.765, 0.768, 0.772, 0.788, 0.725, 0.763, (2.8485)+(0.02
70)Ser+(0.0046)Pro+(-0.1571)Trp; 0.814, 0.837, 0.809, 0.815, 0.8
24, 0.761, 0.793, 0.798, (3.9358)+(-0.0169)Arg+(0.0791)Phe+(-0.
1682)Trp; 0.814, 0.828, 0.801, 0.799, 0.804, 0.813, 0.791, 0.802,
(8. 1974)+(-0.0879)His+(0.0110)Lys+(-0.1046)Trp; 0.813, 0.830, 0.7
90, 0.789, 0.790, 0.803, 0.786, 0.792, (3.6198)+(0.0383)Ser+(-0.0
082)Gly+(-0.1524)Trp; 0.813, 0.830, 0.803, 0.808, 0.804, 0.832, 0.
769, 0.803, (8.5172)+(0.0028)Gly+(-0.0799)His+(-0.0940)Trp; 0. 813,
0.826, 0.744, 0.719, 0.708, 0.814, 0.834, 0.768, (5.3459)+(-0.
0998)His+(-0.0349)Val+(0.1274)Ile; 0.813, 0.826, 0.752, 0.741, 0.
741, 0.835, 0.742, 0.765, (2.9114)+(0.0285)Ser+(0.0059)Gln+(-0.
1503)His; 0.813, 0.826, 0.757, 0.727, 0.747, 0.817, 0.816, 0.776,
(3. 0138)+(0.0083)Gln+(-0.1623)His+(0.0428)Ile; 0.812, 0.830, 0.77
1, 0.777, 0.777, 0.799, 0.723, 0.769, (2.9095)+(0.0258)Ser+(0.010
8)Orn+(-0.1557)Trp; 0.812, 0.828, 0.802, 0.795, 0.811, 0.819, 0.79
3, 0.804, (8.6020)+(-0.0875)His+(0.0079)Val+(-0.1054)Trp; 0.81 1,
0.828, 0.779, 0.787, 0.782, 0.812, 0.726, 0.777, (3.5040)+(0.029
1)Ser+(-0.0048)Lys+(-0.1458)Trp; 0.810, 0.827, 0.777, 0.788, 0.7
77, 0.808, 0.724, 0.774, (3.4604)+(0.0273)Ser+(-0.0085)Tyr+(-0.
1480)Trp; 0.810, 0.828, 0.763, 0.762, 0.771, 0.788, 0.732, 0.763,
(2. 5854)+(0.0277)Ser+(0.0099)Leu+(-0.1631)Trp; 0.810, 0.827, 0.77
8, 0.770, 0.777, 0.769, 0.807, 0.780, (3.5132)+(0.0019)Gln+(0.048
1)Ile+(-0.1761)Trp; 0.810, 0.827, 0.795, 0.786, 0.796, 0.799, 0.81
6, 0.799, (5.6954)+(-0.1645)Met+(0.0656)Ile+(-0.1435)Trp; 0.81 0,
0.826, 0.777, 0.785, 0.780, 0.805, 0.732, 0.776, (3.1987)+(0.028
4)Ser+(-0.0023)Thr+(-0.1503)Trp; 0.810, 0.822, 0.713, 0.674, 0.7
23, 0.814, 0.725, 0.734, (3.1069)+(0.0389)Ser+(-0.1528)His+(0.0
197)Leu; 0.809, 0.828, 0.774, 0.782, 0.778, 0.801, 0.727, 0.772,
(3. 1956)+(0.0271)Ser+(-0.0000)Val+(-0.1525)Trp; 0.809, 0.826, 0.8
04, 0.807, 0.827, 0.824, 0.734, 0.798, (6.9782)+(0.0146)Thr+(-0.0
722)Cit+(-0.1572)Trp; 0.809, 0.825, 0.810, 0.812, 0.810, 0.827, 0.
789, 0.810, (8.8689)+(-0.0762)His+(-0.0001)Ala+(-0.0948)Trp; 0.
809, 0.828, 0.774, 0.782, 0.778, 0.801, 0.726, 0.772, (3.2050)+(0.0
272)Ser+(-0.0000)Gln+(-0.1524)Trp; 0.808, 0.827, 0.726, 0.697, 0.
735, 0.826, 0.714, 0.743, (3.7633)+(0.0330)Ser+(-0.1411)His+(0.
0244)Orn; 0.808, 0.826, 0.793, 0.784, 0.792, 0.791, 0.821, 0.797,
(5. 7175)+(-0.0548)Asn+(0.0503)Ile+(-0.1556)Trp; 0.808, 0.827, 0.8
27, 0.836, 0.837, 0.829, 0.778, 0.820, (5.3892)+(0.0055)Gln+(-0.0
743)Cit+(-0.1543)Trp; 0.808, 0.822, 0.773, 0.761, 0.776, 0.766, 0.
803, 0.776, (4.2285)+(0.0012)Orn+(0.0490)Ile+(-0.1716)Trp; 0.8 08,
0.822, 0.750, 0.723, 0.734, 0.813, 0.813, 0.771, (5.3562)+(-0.1
130)His+(0.1080)Ile+(-0.0454)Leu; 0.808, 0.825, 0.811, 0.814, 0.
810, 0.827, 0.789, 0.810,
(8.9680)+(-0.0058)Asn+(-0.0747)His+(-0.0944)Trp; 0.807, 0.827,
0.809, 0.803, 0.814, 0.829, 0.799, 0.811,
(8.5780)+(-0.0825)His+(0.0182)Tyr+(-0.1025)Trp; 0.807, 0.820,
0.769, 0.738, 0.748, 0.836, 0.847, 0.792,
(5.9932)+(-0.1222)His+(-0.0065)Ala+(0.0581)Ile; 0.807, 0.826,
0.782, 0.794, 0.790, 0.81 6, 0.706, 0.777,
(3.8894)+(0.0312)Ser+(-0.0178)Arg+(-0.1448)Tr p; 0.806, 0.819,
0.722, 0.695, 0.726, 0.819, 0.713, 0.738,
(3.6702)+(0.0365)Ser+(-0.1381)His+(0.0064)Pro; 0.806, 0.819, 0.747,
0.72 4, 0.744, 0.831, 0.754, 0.763,
(4.3049)+(0.0422)Ser+(-0.0047)Gly +(-0.1309)His; 0.806, 0.825,
0.769, 0.758, 0.773, 0.764, 0.796, 0.7 73,
(4.0910)+(0.0035)Thr+(0.0484)Ile+(-0.1746)Trp; 0.805, 0.82 2,
0.775, 0.763, 0.779, 0.767, 0.808, 0.779, (4.3381)+(-0.0004)Gly
+(0.0493)Ile+(-0.1712)Trp; 0.805, 0.823, 0.771, 0.769, 0.765, 0.7
66, 0.795, 0.774, (4.8101)+(-0.0217)Tyr+(0.0537)Ile+(-0.1610)T rp;
0.805, 0.823, 0.804, 0.802, 0.823, 0.808, 0.766, 0.800, (7.1369)
+(-0.0711)Cit+(0.0084)Pro+(-0.1501)Trp; 0.804, 0.826, 0.809, 0.
811, 0.810, 0.827, 0.789, 0.809, (8.8109)+(-0.0768)His+(0.0012)A
rg+(-0.0952)Trp; 0.804, 0.821, 0.753, 0.740, 0.751, 0.839, 0.727,
0. 764, (4.8557)+(0.0410)Ser+(-0.0580)Asn+(-0.1163)His; 0.804, 0.
825, 0.811, 0.814, 0.811, 0.827, 0.788, 0.810, (8.9122)+(-0.0749)H
is+(-0.0084)Met+(-0.0941)Trp; 0.804, 0.820, 0.807, 0.818, 0.794,
0.815, 0.798, 0.806, (6.0813)+(-0.0065)Ala+(0.0108)Pro+(-0.137
6)Trp; 0.804, 0.823, 0.806, 0.819, 0.815, 0.807, 0.753, 0.798,
(7.09 40)+(-0.0817)Asn+(0.0180)Thr+(-0.1425)Trp; 0.803, 0.824,
0.837, 0.854, 0.832, 0.827, 0.813, 0.831,
(5.2819)+(-0.0842)Asn+(0.006 6)Gln+(-0.1385)Trp; 0.803, 0.818,
0.746, 0.731, 0.738, 0.841, 0.73 0, 0.760,
(4.3899)+(0.0357)Ser+(-0.1271)His+(-0.0019)Ala; 0.80 3, 0.819,
0.805, 0.802, 0.791, 0.846, 0.811, 0.813, (4.5718)+(-0.05
90)Asn+(0.0113)Gln+(-0.1379)His; 0.803, 0.820, 0.806, 0.808, 0.7
90, 0.849, 0.798, 0.811, (4.3417)+(0.0108)Gln+(-0.1346)His+(-0.
0961)Met; 0.803, 0.818, 0.726, 0.699, 0.733, 0.821, 0.717, 0.742,
(3. 7074)+(0.0371)Ser+(-0.1426)His+(0.0051)Val; 0.803, 0.821, 0.77
5, 0.764, 0.777, 0.769, 0.807, 0.779, (4.3262)+(-0.0019)Pro+(0.05
18)Ile+(-0.1706)Trp; 0.803, 0.825, 0.760, 0.752, 0.759, 0.850, 0.7
16, 0.769, (4.6315)+(0.0395)Ser+(-0.1137)His+(-0.0967)Met; 0.8 03,
0.821, 0.803, 0.798, 0.824, 0.798, 0.777, 0.799, (6.9309)+(-0.0
715)Cit+(0.0162)Leu+(-0.1593)Trp; 0.803, 0.822, 0.779, 0.765, 0.
781, 0.779, 0.808, 0.783, (4.8509)+(-0.0077)Lys+(0.0554)Ile+(-0.
1621)Trp; 0.802, 0.817, 0.735, 0.695, 0.733, 0.785, 0.810, 0.756,
(4. 2572)+(-0.1461)His+(0.0325)Ile+(0.0507)Phe; 0.802, 0.818, 0.82
6, 0.833, 0.838, 0.832, 0.777, 0.820, (8.3805)+(-0.0347)Asn+(-0.0
578)Cit+(-0.1321)Trp; 0.802, 0.813, 0.768, 0.748, 0.762, 0.819, 0.
798, 0.782, (3.5916)+(0.0092)Gln+(-0.1620)His+(0.0129)Leu; 0.8 02,
0.817, 0.768, 0.752, 0.765, 0.823, 0.777, 0.779, (3.9165)+(0.00
81)Gln+(-0.1538)His+(0.0212)Orn; 0.801, 0.823, 0.813, 0.815, 0.8
19, 0.833, 0.779, 0.812, (9.2144)+(-0.0654)His+(-0.0311)Cit+(-0.
0986)Trp; 0.801, 0.819, 0.801, 0.815, 0.799, 0.788, 0.773, 0.794,
(4. 3239)+(0.0027)Gln+(0.0039)Pro+(-0.1561)Trp; 0.801, 0.816, 0.73
2, 0.712, 0.733, 0.827, 0.711, 0.746, (4.1517)+(0.0343)Ser+(-0.13
54)His+(0.0035)Thr; 0.801, 0.814, 0.729, 0.687, 0.729, 0.796, 0.78
8, 0.750, (5.1464)+(-0.1456)His+(0.0119)Thr+(0.0436)Ile; 0.801,
0.818, 0.824, 0.832, 0.834, 0.834, 0.778, 0.819, (7.7964)+(-0.002
1)Ala+(-0.0603)Cit+(-0.1349)Trp; 0.801, 0.815, 0.793, 0.793, 0.7
74, 0.843, 0.798, 0.802, (4.3649)+(0.0093)Gln+(-0.1435)His+(-0.
0024)Ala; 0.801, 0.817, 0.811, 0.814, 0.831, 0.812, 0.765, 0.805,
(7. 2700)+(-0.0686)Cit+(0.0045)Val+(-0.1507)Trp; 0.801, 0.821, 0.7
83, 0.765, 0.789, 0.798, 0.809, 0.790, (4.7615)+(-0.1213)His+(-0.
1757)Met+(0.1150)Phe; 0.801, 0.820, 0.796, 0.798, 0.790, 0.792, 0.
805, 0.796, (5.6507)+(-0.0234)Val+(0.0470)Leu+(-0.1506)Trp; 0. 800,
0.816, 0.738, 0.719, 0.737, 0.831, 0.720, 0.752, (4.2496)+(0.0
359)Ser+(-0.1311)His+(-0.0011)Lys; 0.800, 0.822, 0.831, 0.852, 0.
824, 0.828, 0.791, 0.824, (4.8052)+(0.0061)Gln+(-0.1296)Met+(-0.
1348)Trp; 0.800, 0.813, 0.770, 0.762, 0.760, 0.820, 0.775, 0.779,
(4. 1381)+(0.0083)Gln+(-0.1538)His+(0.0072)Thr; 0.800, 0.820, 0.81
0, 0.819, 0.815, 0.799, 0.784, 0.804, (6.8969)+(-0.0563)Asn+(0.00
63)Pro+(-0.1355)Trp; 0.800, 0.815, 0.729, 0.706, 0.728, 0.783, 0.7
56, 0.743, (3.8156)+(0.0049)Gly+(-0.1500)His+(0.0793)Phe; 0.79 9,
0.817, 0.728, 0.697, 0.732, 0.773, 0.770, 0.743, (4.1977)+(-0.15
68)His+(0.0141)Thr+(0.0711)Phe; 0.799, 0.818, 0.810, 0.819, 0.81 9,
0.805, 0.774, 0.804, (6.6221)+(-0.0626)Asn+(0.0241)Orn+(-0.1
347)Trp; 0.799, 0.819, 0.788, 0.797, 0.797, 0.778, 0.755, 0.782,
(4. 9954)+(0.0033)Pro+(0.0146)Orn+(-0.1529)Trp; 0.799, 0.818, 0.81
0, 0.818, 0.826, 0.824, 0.745, 0.804, (7.2294)+(0.0021)Gly+(-0.06
62)Cit+(-0.1419)Trp; 0.799, 0.818, 0.788, 0.798, 0.795, 0.781, 0.7
49, 0.781, (5.1587)+(0.0066)Thr+(0.0037)Pro+(-0.1561)Trp; 0.79 9,
0.812, 0.777, 0.766, 0.768, 0.824, 0.790, 0.787, (3.9080)+(0.009
3)Gln+(-0.1550)His+(0.0027)Val; 0.798, 0.817, 0.743, 0.729, 0.74 8,
0.833, 0.705, 0.754, (4.6112)+(0.0384)Ser+(-0.1262)His+(-0.0
138)Arg; 0.798, 0.813, 0.781, 0.775, 0.769, 0.829, 0.788, 0.790,
(4. 1316)+(-0.0002)Gly+(0.0093)Gln+(-0.1498)His; 0.798, 0.813, 0.7
82, 0.777, 0.770, 0.830, 0.788, 0.791, (4.1650)+(0.0093)Gln+(-0.1
490)His+(-0.0008)Lys; 0.798, 0.812, 0.755, 0.749, 0.670, 0.843, 0.
881, 0.786, (2.4334)+(-0.0107)Ala+(-0.0528)Val+(0.1714)Ile; 0. 798,
0.819, 0.805, 0.816, 0.810, 0.799, 0.771, 0.799, (6.6861)+(0.0
096)Pro+(-0.1264)Met+(-0.1290)Trp; 0.798, 0.815, 0.737, 0.720, 0.
736, 0.828, 0.717, 0.750, (4.2895)+(0.0356)Ser+(-0.1300)His+(-0.
0046)Tyr; 0.798, 0.816, 0.813, 0.819, 0.829, 0.814, 0.762, 0.806,
(7. 2107)+(-0.0638)Cit+(0.0033)Lys+(-0.1461)Trp; 0.797, 0.811, 0.7
71, 0.761, 0.761, 0.820, 0.786, 0.782, (3.9323)+(0.0090)Gln+(-0.1
519)His+(0.0037)Pro; 0.797, 0.817, 0.796, 0.808, 0.802, 0.794, 0.7
52, 0.789, (5.3565)+(-0.0037)Val+(0.0209)Orn+(-0.1438)Trp; 0.7 97,
0.816, 0.823, 0.831, 0.835, 0.828, 0.770, 0.816, (7.9208)+(-0.0
559)Cit+(-0.0474)Met+(-0.1314)Trp; 0.797, 0.815, 0.771, 0.752, 0.
756, 0.816, 0.818, 0.786, (4.9478)+(-0.1345)His+(-0.0044)Ala+(0.
0817)Phe; 0.797, 0.813, 0.738, 0.720, 0.743, 0.830, 0.706, 0.750,
(4. 4233)+(0.0368)Ser+(-0.1250)His+(-0.0296)Cit; 0.797, 0.816, 0.7
97, 0.809, 0.800, 0.787, 0.765, 0.791, (5.6255)+(0.0058)Pro+(-0.0
028)Val+(-0.1449)Trp; 0.797, 0.817, 0.817, 0.819, 0.834, 0.822, 0.
771, 0.811, (7.3477)+(-0.0649)Cit+(0.0076)Tyr+(-0.1456)Trp; 0. 797,
0.815, 0.755, 0.749, 0.740, 0.778, 0.787, 0.764, (4.9925)+(-0.
1332)His+(-0.0409)Tyr+(0.0989)Phe; 0.797, 0.817, 0.739, 0.704, 0.
742, 0.790, 0.785, 0.755, (4.2734)+(-0.1473)His+(0.0224)Orn+(0.
0642)Phe; 0.796, 0.817, 0.799, 0.811, 0.805, 0.789, 0.763, 0.792,
(4. 2821)+(0.0023)Gln+(0.0135)Orn+(-0.1554)Trp; 0.796, 0.810, 0.76
5, 0.758, 0.705, 0.832, 0.859, 0.788, (5.2744)+(-0.1234)Asn+(-0.0
559)Val+(0.1648)Ile; 0.796, 0.816, 0.799, 0.814, 0.802, 0.790, 0.7
59, 0.791, (4.4453)+(0.0024)Gln+(0.0055)Thr+(-0.1576)Trp; 0.79 6,
0.817, 0.816, 0.820, 0.830, 0.823, 0.767, 0.810, (7.3786)+(-0.06
55)Cit+(0.0035)Arg+(-0.1428)Trp; 0.796, 0.815, 0.788, 0.797, 0.7
98, 0.785, 0.742, 0.781, (4.9842)+(0.0053)Thr+(0.0138)Orn+(-0.1
553)Trp; 0.796, 0.818, 0.779, 0.770, 0.785, 0.773, 0.793, 0.780,
(5. 0473)+(-0.0151)Arg+(0.0524)Ile+(-0.1642)Trp; 0.796, 0.813, 0.7
33, 0.688, 0.738, 0.802, 0.793, 0.755, (5.1743)+(-0.1399)His+(0.0
207)Orn+(0.0397)Ile; 0.796, 0.814, 0.794, 0.807, 0.801, 0.794, 0.7
43, 0.786, (5.5010)+(0.0089)Thr+(-0.0019)Val+(-0.1510)Trp; 0.7 96,
0.815, 0.791, 0.799, 0.797, 0.774, 0.773, 0.786, (5.1953)+(0.00
39)Pro+(0.0061)Leu+(-0.1559)Trp; 0.795, 0.809, 0.726, 0.689, 0.7
25, 0.798, 0.774, 0.747, (4.8966)+(0.0041)Gly+(-0.1388)His+(0.0
479)Ile; 0.795, 0.813, 0.755, 0.735, 0.748, 0.789, 0.797, 0.767,
(4. 7788)+(-0.1369)His+(-0.0061)Val+(0.0850)Phe; 0.795, 0.816, 0.7
98, 0.808, 0.803, 0.780, 0.773, 0.791, (5.6160)+(-0.0010)Gly+(0.0
049)Pro+(-0.1495)Trp; 0.795, 0.814, 0.794, 0.794, 0.783, 0.842, 0.
780, 0.800, (4.2855)+(0.0113)Gln+(-0.1468)His+(-0.0180)Arg; 0. 795,
0.813, 0.805, 0.820, 0.800, 0.821, 0.763, 0.801, (5.9142)+(0.0
119)Thr+(-0.0044)Ala+(-0.1462)Trp; 0.795, 0.813, 0.807, 0.818, 0.
804, 0.814, 0.778, 0.804, (5.7061)+(-0.0046)Ala+(0.0233)Orn+(-0.
1394)Trp; 0.794, 0.813, 0.797, 0.806, 0.804, 0.782, 0.768, 0.790,
(5. 3946)+(-0.0015)Gly+(0.0182)Orn+(-0.1500)Trp; 0.794, 0.807, 0.7
44, 0.709, 0.741, 0.801, 0.804, 0.764, (5.6225)+(-0.1339)His+(-0.
0017)Pro+(0.0476)Ile; 0.794, 0.811, 0.748, 0.722, 0.746, 0.785, 0.
793, 0.761, (4.6778)+(-0.1427)His+(-0.0011)Leu+(0.0746)Phe; 0. 794,
0.815, 0.789, 0.795, 0.798, 0.776, 0.761, 0.783, (4.9700)+(0.0
150)Orn+(0.0051)Leu+(-0.1554)Trp; 0.794, 0.814, 0.792, 0.808, 0.
793, 0.783, 0.756, 0.785, (5.7771)+(0.0063)Pro+(-0.0142)Tyr+(-0.
1432)Trp; 0.794, 0.814, 0.805, 0.816, 0.812, 0.811, 0.756, 0.799,
(6. 2480)+(-0.1144)Met+(0.0265)Orn+(-0.1300)Trp; 0.794, 0.811, 0.8
16, 0.831, 0.817, 0.796, 0.788, 0.808, (6.8947)+(-0.0617)Asn+(0.0
064)Lys+(-0.1383)Trp; 0.794, 0.814, 0.792, 0.806, 0.801, 0.793, 0.
740, 0.785, (5.5662)+(0.0100)Thr+(-0.0030)Lys+(-0.1515)Trp; 0. 794,
0.811, 0.783, 0.782, 0.767, 0.827, 0.785, 0.790, (4.2965)+(0.0
093)Gln+(-0.1450)His+(-0.0093)Tyr; 0.794, 0.813, 0.797, 0.807, 0.
808, 0.783, 0.761, 0.790, (5.6920)+(-0.0024)Gly+(0.0101)Thr+(-0.
1556)Trp; 0.793, 0.811, 0.744, 0.716, 0.743, 0.780, 0.794, 0.758,
(4. 6082)+(-0.1435)His+(0.0014)Pro+(0.0715)Phe; 0.793, 0.816, 0.79
4, 0.805, 0.804, 0.786, 0.752, 0.787, (5.3204)+(0.0192)Orn+(-0.00
25)Lys+(-0.1469)Trp; 0.793, 0.815, 0.795, 0.807, 0.800, 0.783, 0.7
65,
0.789, (5.4706)+(0.0049)Pro+(-0.0004)Lys+(-0.1493)Trp; 0.7 93,
0.814, 0.765, 0.735, 0.765, 0.808, 0.814, 0.781, (6.2924)+(-0.1
115)His+(-0.1437)Met+(0.0614)Ile; 0.793, 0.811, 0.809, 0.828, 0.
807, 0.797, 0.776, 0.802, (4.5282)+(0.0032)Gln+(-0.0014)Val+(-0.
1505)Trp; 0.793, 0.807, 0.747, 0.712, 0.746, 0.801, 0.806, 0.766,
(5. 8441)+(-0.0156)Asn+(-0.1291)His+(0.0452)Ile; 0.793, 0.813, 0.8
25, 0.844, 0.811, 0.828, 0.802, 0.821, (4.7615)+(0.0040)Gln+(-0.0
042)Ala+(-0.1437)Trp; 0.793, 0.815, 0.800, 0.812, 0.801, 0.785, 0.
779, 0.794, (4.1968)+(0.0029)Gln+(0.0070)Leu+(-0.1604)Trp; 0.7 92,
0.810, 0.758, 0.736, 0.756, 0.789, 0.801, 0.770, (5.1249)+(-0.0
297)Asn+(-0.1346)His+(0.0762)Phe; 0.792, 0.813, 0.788, 0.807, 0.
793, 0.786, 0.731, 0.779, (5.6817)+(0.0106)Thr+(-0.0143)Tyr+(-0.
1488)Trp; 0.792, 0.813, 0.807, 0.829, 0.801, 0.797, 0.769, 0.799,
(4. 6193)+(0.0036)Gln+(-0.0114)Tyr+(-0.1477)Trp; 0.792, 0.814, 0.7
85, 0.792, 0.796, 0.774, 0.750, 0.778, (5.0110)+(0.0075)Thr+(0.00
72)Leu+(-0.1615)Trp; 0.792, 0.811, 0.791, 0.805, 0.795, 0.790, 0.7
45, 0.784, (5.4696)+(-0.0144)Tyr+(0.0208)Orn+(-0.1432)Trp; 0.7 92,
0.806, 0.825, 0.841, 0.821, 0.824, 0.793, 0.820, (7.3985)+(-0.0
434)Asn+(-0.0021)Ala+(-0.1270)Trp; 0.792, 0.813, 0.810, 0.828, 0.
809, 0.798, 0.775, 0.802, (4.5134)+(0.0034)Gln+(-0.0019)Lys+(-0.
1508)Trp; 0.792, 0.810, 0.745, 0.721, 0.734, 0.792, 0.795, 0.761,
(6. 1180)+(-0.1249)His+(-0.0267)Tyr+(0.0521)Ile; 0.791, 0.812, 0.8
15, 0.830, 0.814, 0.792, 0.793, 0.807, (4.6372)+(-0.0022)Gly+(0.0
036)Gln+(-0.1532)Trp; 0.791, 0.814, 0.767, 0.764, 0.774, 0.827, 0.
717, 0.770, (7.1487)+(-0.1158)His+(0.0279)Thr+(-0.1455)Met; 0. 791,
0.810, 0.749, 0.723, 0.747, 0.787, 0.795, 0.763, (4.8024)+(-0.
1410)His+(-0.0023)Lys+(0.0755)Phe; 0.791, 0.810, 0.786, 0.779, 0.
777, 0.835, 0.785, 0.794, (4.2753)+(0.0099)Gln+(-0.1424)His+(-0.
0345)Cit; 0.790, 0.808, 0.819, 0.834, 0.822, 0.808, 0.784, 0.812,
(7. 2274)+(-0.0493)Asn+(-0.0003)Val+(-0.1307)Trp; 0.790, 0.811, 0.
797, 0.810, 0.806, 0.789, 0.750, 0.789, (6.0790)+(-0.0122)Arg+(0.
0062)Pro+(-0.1447)Trp; 0.790, 0.807, 0.744, 0.707, 0.742, 0.801, 0.
804, 0.763, (5.7493)+(-0.1302)His+(-0.0034)Lys+(0.0477)Ile; 0. 790,
0.808, 0.822, 0.837, 0.825, 0.816, 0.780, 0.815, (7.4464)+(-0.
0291)Asn+(-0.0612)Met+(-0.1251)Trp; 0.790, 0.811, 0.725, 0.737,
0.728, 0.755, 0.665, 0.721,
(-3.8956)+(0.0461)Ser+(-0.3860)Met+(0.1074)Phe; 0.790, 0.808,
0.813, 0.828, 0.816, 0.801, 0.771, 0.804,
(6.4637)+(-0.1161)Met+(0.0086)Lys+(-0.1362)Trp; 0.790, 0.810,
0.817, 0.832, 0.820, 0.809, 0.779, 0.810,
(7.1177)+(-0.0507)Asn+(0.0006)Gly+(-0.1311)Trp; 0.790, 0.808,
0.764, 0.741, 0.764, 0.82 8, 0.780, 0.778,
(6.4775)+(-0.1222)His+(-0.0034)Ala+(0.0360)Or n; 0.789, 0.808,
0.810, 0.818, 0.815, 0.792, 0.790, 0.804,
(6.7362)+(-0.0523)Asn+(0.0099)Leu+(-0.1411)Trp; 0.788, 0.812,
0.817, 0.8 38, 0.817, 0.809, 0.764, 0.807,
(4.7182)+(0.0047)Gln+(-0.0162)Ar g+(-0.1483)Trp; 0.788, 0.808,
0.820, 0.833, 0.823, 0.807, 0.786, 0. 812,
(7.1489)+(-0.0506)Asn+(0.0027)Tyr+(-0.1325)Trp; 0.788, 0. 808,
0.711, 0.692, 0.713, 0.786, 0.704, 0.724, (-2.2756)+(0.0463)S
er+(-0.3598)Met+(0.0667)Ile; 0.787, 0.807, 0.751, 0.726, 0.752, 0.
785, 0.788, 0.763, (4.9596)+(-0.1397)His+(-0.0076)Arg+(0.0755) Phe;
0.787, 0.805, 0.742, 0.708, 0.742, 0.797, 0.796, 0.761, (5.786
0)+(-0.1311)His+(-0.0055)Arg+(0.0456)Ile; 0.787, 0.810, 0.790,
0.807, 0.807, 0.793, 0.708, 0.779, (6.1198)+(0.0151)Thr+(-0.019
0)Arg+(-0.1520)Trp; 0.787, 0.808, 0.802, 0.817, 0.806, 0.791, 0.76
5, 0.794, (5.7631)+(-0.0011)Val+(0.0014)Lys+(-0.1448)Trp; 0.78 7,
0.807, 0.821, 0.838, 0.823, 0.819, 0.777, 0.814, (7.0144)+(-0.00
12)Ala+(-0.0771)Met+(-0.1262)Trp; 0.786, 0.807, 0.807, 0.813, 0.
800, 0.806, 0.804, 0.806, (5.8190)+(-0.0048)Ala+(0.0147)Leu+(-0.
1472)Trp; 0.786, 0.808, 0.735, 0.708, 0.746, 0.805, 0.735, 0.749,
(5. 8708)+(-0.1387)His+(0.0106)Thr+(0.0275)Orn; 0.786, 0.809, 0.82
3, 0.833, 0.831, 0.815, 0.786, 0.816, (6.7016)+(0.0220)Tyr+(-0.12
28)Met+(-0.1333)Trp; 0.786, 0.807, 0.797, 0.804, 0.804, 0.777, 0.7
80, 0.791, (5.5030)+(-0.0008)Gly+(0.0085)Leu+(-0.1541)Trp; 0.7 86,
0.804, 0.817, 0.832, 0.813, 0.816, 0.787, 0.812, (6.4245)+(-0.0
005)Gly+(-0.0032)Ala+(-0.1355)Trp; 0.786, 0.805, 0.819, 0.834, 0.
822, 0.808, 0.780, 0.811,
(7.2801)+(-0.0464)Asn+(-0.0027)Arg+(-0.1306)Trp; 0.786, 0.807,
0.802, 0.819, 0.803, 0.790, 0.762, 0.794,
(5.9934)+(-0.0053)Tyr+(-0.0002)Val+(-0.1413)Trp; 0.786, 0.808,
0.794, 0.806, 0.808, 0.796, 0.735, 0.786,
(5.8391)+(-0.0158)Arg+(0.0243)Orn+(-0.1443)Trp; 0.786, 0.804,
0.814, 0.829, 0.810, 0.81 5, 0.786, 0.810,
(6.2303)+(-0.0036)Ala+(0.0019)Val+(-0.1384)Tr p; 0.786, 0.805,
0.814, 0.829, 0.808, 0.813, 0.786, 0.809,
(6.0922)+(-0.0036)Ala+(0.0030)Lys+(-0.1395)Trp; 0.785, 0.806,
0.800, 0.8 17, 0.801, 0.785, 0.762, 0.791,
(5.8544)+(-0.0071)Tyr+(0.0017)Ly s+(-0.1435)Trp; 0.785, 0.806,
0.816, 0.834, 0.820, 0.811, 0.766, 0. 808,
(6.8851)+(0.0003)Gly+(-0.0874)Met+(-0.1276)Trp; 0.785, 0. 809,
0.795, 0.802, 0.803, 0.777, 0.772, 0.788, (5.4835)+(-0.0018)L
ys+(0.0097)Leu+(-0.1528)Trp; 0.785, 0.807, 0.805, 0.819, 0.808, 0.
790, 0.774, 0.798, (6.0235)+(-0.0009)Gly+(-0.0006)Val+(-0.143
2)Trp; 0.785, 0.801, 0.761, 0.751, 0.755, 0.824, 0.756, 0.772,
(6.78 03)+(-0.1262)His+(0.0162)Thr+(-0.0030)Ala; 0.785, 0.808,
0.792, 0.804, 0.795, 0.776, 0.767, 0.786,
(5.6121)+(-0.0103)Tyr+(0.010 0)Leu+(-0.1501)Trp; 0.785, 0.806,
0.817, 0.831, 0.812, 0.820, 0.78 8, 0.813,
(6.2724)+(-0.0034)Ala+(0.0036)Tyr+(-0.1371)Trp; 0.78 5, 0.806,
0.804, 0.821, 0.806, 0.786, 0.770, 0.796, (6.1519)+(-0.00
09)Gly+(-0.0057)Tyr+(-0.1412)Trp; 0.785, 0.797, 0.756, 0.731, 0.
749, 0.809, 0.798, 0.772, (6.6774)+(-0.1230)His+(-0.0200)Val+(0.
0435)Leu; 0.784, 0.800, 0.741, 0.703, 0.746, 0.798, 0.792, 0.760,
(5. 8176)+(-0.1253)His+(-0.0340)Cit+(0.0475)Ile; 0.784, 0.804, 0.8
18, 0.835, 0.815, 0.818, 0.776, 0.811, (6.6717)+(-0.0028)Ala+(-0.
0065)Arg+(-0.1332)Trp; 0.784, 0.804, 0.740, 0.714, 0.751, 0.809, 0.
735, 0.752, (5.8436)+(0.0022)Gly+(-0.1317)His+(0.0321)Orn; 0.7 84,
0.802, 0.740, 0.706, 0.751, 0.804, 0.760, 0.755, (5.8858)+(-0.1
364)His+(0.0294)Orn+(0.0081)Leu; 0.784, 0.806, 0.804, 0.817, 0.8
09, 0.787, 0.773, 0.797, (5.8656)+(-0.0009)Gly+(0.0011)Lys+(-0.
1462)Trp; 0.783, 0.802, 0.757, 0.744, 0.761, 0.810, 0.745, 0.765,
(7. 1127)+(-0.0416)Asn+(-0.1237)His+(0.0189)Thr; 0.783, 0.800, 0.7
31, 0.703, 0.737, 0.793, 0.749, 0.745, (5.9361)+(-0.1454)His+(0.0
149)Thr+(0.0130)Leu; 0.783, 0.806, 0.814, 0.830, 0.820, 0.805, 0.7
69, 0.806, (6.7969)+(0.0022)Val+(-0.0927)Met+(-0.1308)Trp; 0.7 83,
0.806, 0.817, 0.835, 0.820, 0.810, 0.767, 0.808, (6.9855)+(-0.0
014)Arg+(-0.0843)Met+(-0.1273)Trp; 0.783, 0.801, 0.748, 0.721, 0.
752, 0.783, 0.787, 0.761, (4.9427)+(-0.1364)His+(-0.0316)Cit+(0.
0770)Phe; 0.783, 0.802, 0.751, 0.725, 0.760, 0.810, 0.759, 0.764,
(6. 2198)+(-0.1266)His+(-0.0021)Val+(0.0348)Orn; 0.783, 0.805, 0.8
05, 0.811, 0.813, 0.792, 0.780, 0.799, (6.3971)+(-0.1169)Met+(0.0
160)Leu+(-0.1379)Trp; 0.782, 0.802, 0.741, 0.711, 0.751, 0.805, 0.
754, 0.755, (5.9329)+(-0.1309)His+(0.0030)Pro+(0.0306)Orn; 0.7 82,
0.803, 0.756, 0.730, 0.767, 0.814, 0.761, 0.768, (6.5383)+(-0.0
242)Asn+(-0.1227)His+(0.0345)Orn; 0.782, 0.799, 0.746, 0.738, 0.
746, 0.803, 0.725, 0.753, (6.8094)+(-0.1265)His+(0.0175)Thr+(-0.
0178)Tyr; 0.781, 0.805, 0.751, 0.731, 0.757, 0.809, 0.749, 0.762,
(6. 5160)+(-0.1228)His+(-0.0191)Tyr+(0.0379)Orn; 0.781, 0.796, 0.7
44, 0.726, 0.749, 0.803, 0.740, 0.754, (6.4251)+(-0.1340)His+(0.0
148)Thr+(0.0007)Val; 0.781, 0.807, 0.766, 0.744, 0.777, 0.824, 0.7
58, 0.776, (6.6441)+(-0.1159)His+(-0.0764)Met+(0.0375)Orn; 0.7 81,
0.797, 0.738, 0.718, 0.744, 0.795, 0.738, 0.749, (6.2349)+(-0.1
338)His+(0.0135)Thr+(0.0035)Pro; 0.781, 0.796, 0.740, 0.725, 0.7
44, 0.803, 0.728, 0.750, (6.3053)+(0.0014)Gly+(-0.1332)His+(0.0
140)Thr; 0.781, 0.797, 0.746, 0.729, 0.751, 0.805, 0.741, 0.756,
(6. 5100)+(-0.1324)His+(0.0151)Thr+(-0.0006)Lys; 0.780, 0.801, 0.7
48, 0.720, 0.759, 0.807, 0.756, 0.760, (6.1382)+(-0.1297)His+(0.0
331)Orn+(-0.0002)Lys; 0.779, 0.795, 0.767, 0.746, 0.760, 0.817, 0.
800, 0.781, (6.8557)+(-0.1243)His+(-0.0038)Ala+(0.0168)Leu; 0. 779,
0.802, 0.764, 0.760, 0.734, 0.817, 0.800, 0.778, (3.1078)+(-0.
2396)Met+(0.1675)Ile+(-0.0812)Leu; 0.778, 0.802, 0.805, 0.822, 0.
812, 0.795, 0.753, 0.795,
(6.3459)+(-0.0090)Arg+(-0.0000)Val+(-0.1399)Trp; 0.778, 0.797,
0.768, 0.770, 0.693, 0.843, 0.864, 0.793,
(1.7786)+(-0.0118)Ala+(0.1676)Ile+(-0.0861)Leu; 0.778, 0.798,
0.748, 0.736, 0.758, 0.808, 0.716, 0.754,
(6.9726)+(-0.1297)His+(0.0192)Thr+(-0.0139)Arg; 0.778, 0.804,
0.796, 0.806, 0.806, 0.77 9, 0.760, 0.788,
(5.9216)+(-0.0104)Arg+(0.0097)Leu+(-0.1501)Tr p; 0.778, 0.793,
0.738, 0.714, 0.743, 0.801, 0.747, 0.751,
(5.9686)+(0.0036)Gly+(-0.1351)His+(0.0144)Leu; 0.777, 0.800, 0.800,
0.81 7, 0.809, 0.787, 0.746, 0.790,
(6.0966)+(-0.0127)Arg+(0.0047)Lys +(-0.1455)Trp; 0.777, 0.802,
0.806, 0.822, 0.814, 0.795, 0.757, 0.7 97,
(6.4087)+(-0.0004)Gly+(-0.0088)Arg+(-0.1399)Trp; 0.777, 0. 790,
0.731, 0.724, 0.676, 0.807, 0.809, 0.754, (2.9430)+(-0.0292)A
rg+(-0.0568)Val+(0.1623)Ile; 0.777, 0.793, 0.768, 0.756, 0.752, 0.
824, 0.792, 0.781, (6.9352)+(-0.1113)His+(-0.0052)Ala+(0.0098) Pro;
0.776, 0.799, 0.750, 0.724, 0.764, 0.811, 0.744, 0.761, (6.486
0)+(-0.1257)His+(-0.0094)Arg+(0.0359)Orn; 0.776, 0.803, 0.805,
0.822, 0.811, 0.795, 0.753, 0.795, (6.3683)+(-0.0088)Arg+(-0.001
1)Tyr+(-0.1393)Trp; 0.775, 0.796, 0.745, 0.709, 0.771, 0.818, 0.73
0, 0.757, (6.3753)+(-0.1195)His+(-0.0645)Cit+(0.0505)Orn; 0.77 3,
0.789, 0.746, 0.719, 0.750, 0.794, 0.775, 0.759, (6.3352)+(-0.13
04)His+(0.0033)Pro+(0.0107)Leu; 0.773, 0.791, 0.746, 0.729, 0.75 6,
0.810, 0.725, 0.755, (6.7791)+(-0.1261)His+(0.0164)Thr+(-0.0
315)Cit; 0.773, 0.789, 0.751, 0.739, 0.751, 0.808, 0.741, 0.760,
(6. 4815)+(0.0030)Gly+(-0.1251)His+(0.0023)Val; 0.773, 0.789, 0.77
3, 0.760, 0.766, 0.821, 0.789, 0.784, (7.1829)+(-0.1170)His+(-0.0
028)Ala+(0.0033)Val; 0.773, 0.788, 0.757, 0.733, 0.759, 0.801, 0.7
84, 0.769, (6.8054)+(-0.0139)Asn+(-0.1260)His+(0.0128)Leu; 0.7 73,
0.790, 0.767, 0.762, 0.757, 0.823, 0.759, 0.775, (6.9417)+(0.00
27)Gly+(-0.1151)His+(-0.0021)Ala; 0.772, 0.787, 0.751, 0.725, 0.
754, 0.801, 0.778, 0.764, (6.4821)+(-0.1311)His+(0.0008)Lys+(0.
0124)Leu; 0.771, 0.788, 0.741, 0.726, 0.743, 0.798, 0.736, 0.751,
(6. 1975)+(0.0030)Gly+(-0.1244)His+(0.0054)Pro; 0.771, 0.787, 0.77
0, 0.760, 0.759, 0.818, 0.786, 0.781, (6.9282)+(-0.1189)His+(-0.0
026)Ala+(0.0057)Lys; 0.771, 0.788, 0.751, 0.733, 0.748, 0.794, 0.7
72, 0.762, (6.8495)+(-0.1257)His+(-0.0142)Tyr+(0.0148)Leu; 0.7 71,
0.785, 0.753, 0.736, 0.753, 0.798, 0.765, 0.763, (6.6606)+(-0.1
205)His+(0.0054)Pro+(-0.0006)Val; 0.770, 0.791, 0.720, 0.705, 0.
658, 0.804, 0.831, 0.749, (2.6163)+(-0.0523)Val+(-0.0156)Lys+(0.
1573)Ile; 0.770, 0.785, 0.719, 0.702, 0.667, 0.799, 0.814, 0.746,
(2. 1097)+(-0.0648)Cit+(-0.0522)Val+(0.1505)Ile; 0.770, 0.787, 0.7
78, 0.770, 0.768, 0.820, 0.790, 0.787, (7.5427)+(-0.0118)Asn+(-0.
1091)His+(-0.0020)Ala; 0.770, 0.786, 0.767, 0.754, 0.765, 0.811, 0.
775, 0.776, (7.2389)+(-0.0133)Asn+(-0.1160)His+(0.0012)Val; 0. 770,
0.788, 0.713, 0.718, 0.641, 0.784, 0.799, 0.736, (2.5533)+(-0.
0453)Tyr+(-0.0510)Val+(0.1527)Ile; 0.770, 0.788, 0.761, 0.754, 0.
758, 0.814, 0.745, 0.768, (7.0163)+(-0.0207)Asn+(0.0033)Gly+(-0.
1146)His; 0.769, 0.785, 0.748, 0.730, 0.748, 0.795, 0.764, 0.759,
(6. 4125)+(-0.1253)His+(0.0048)Pro+(0.0030)Lys; 0.769, 0.788, 0.75
9, 0.742, 0.759, 0.800, 0.772, 0.768, (6.9636)+(-0.0185)Asn+(-0.1
158)His+(0.0055)Pro; 0.769, 0.786, 0.775, 0.767, 0.766, 0.822, 0.7
84, 0.785, (7.3567)+(-0.1119)His+(-0.0020)Ala+(-0.0016)Tyr; 0. 769,
0.785, 0.749, 0.738, 0.748, 0.804, 0.743, 0.758, (6.3294)+(0.0
028)Gly+(-0.1262)His+(0.0042)Lys; 0.769, 0.787, 0.752, 0.743, 0.
747, 0.794, 0.755, 0.760, (6.9241)+(-0.1148)His+(0.0068)Pro+(-0.
0162)Tyr; 0.769, 0.784, 0.758, 0.743, 0.757, 0.803, 0.767, 0.768,
(6. 6973)+(-0.1245)His+(0.0005)Val+(0.0040)Lys; 0.769, 0.788, 0.75
3, 0.729, 0.756, 0.800, 0.774, 0.765, (6.6793)+(-0.1286)His+(-0.0
030)Arg+(0.0127)Leu; 0.768, 0.793, 0.765, 0.755, 0.763, 0.805, 0.7
64, 0.772, (7.1084)+(-0.1057)His+(0.0082)Pro+(-0.0867)Met; 0.7 68,
0.790, 0.765, 0.745, 0.769, 0.800, 0.783, 0.774, (7.0516)+(-0.1
178)His+(-0.0865)Met+(0.0181)Leu; 0.768, 0.787, 0.757, 0.751, 0.
754, 0.811, 0.740, 0.764, (6.7995)+(0.0027)Gly+(-0.1186)His+(-0.
0040)Tyr; 0.768, 0.790, 0.764, 0.787, 0.762, 0.818, 0.668, 0.759,
(1. 4313)+(0.0426)Ser+(-0.0855)Asn+(-0.1762)Met; 0.768, 0.783, 0.7
64, 0.750, 0.762, 0.801, 0.776, 0.772, (7.0329)+(-0.0227)Asn+(-0.
1189)His+(0.0057)Lys; 0.767, 0.786, 0.763, 0.752, 0.760, 0.806, 0.
768, 0.772, (7.1377)+(-0.1181)His+(-0.0089)Tyr+(0.0023)Val; 0. 767,
0.791, 0.768, 0.765, 0.763, 0.822, 0.744, 0.774, (7.0860)+(0.0
032)Gly+(-0.1098)His+(-0.0546)Met; 0.767, 0.786, 0.756, 0.750, 0.
755, 0.812, 0.736, 0.763, (6.8908)+(0.0031)Gly+(-0.1181)His+(-0.
0051)Arg; 0.767, 0.787, 0.779, 0.773, 0.771, 0.822, 0.782, 0.787,
(7. 5575)+(-0.1062)His+(-0.0013)Ala+(-0.0403)Met; 0.766, 0.787, 0.
775, 0.766, 0.766, 0.822, 0.784, 0.784, (7.4498)+(-0.1112)His+(-0.
0020)Ala+(-0.0027)Arg; 0.765, 0.784, 0.770, 0.762, 0.764, 0.810, 0.
773, 0.777, (7.4515)+(-0.0130)Asn+(-0.1115)His+(-0.0052)Tyr; 0.
765, 0.782, 0.759, 0.751, 0.752, 0.801, 0.765, 0.767, (6.8983)+(-0.
1206)His+(-0.0119)Tyr+(0.0059)Lys; 0.765, 0.781, 0.754, 0.746, 0.
759, 0.815, 0.722, 0.761, (6.9164)+(0.0038)Gly+(-0.1134)His+(-0.
0312)Cit; 0.764, 0.787, 0.772, 0.761, 0.770, 0.812, 0.773, 0.779,
(7. 3339)+(-0.1117)His+(0.0029)Val+(-0.0571)Met; 0.764, 0.785, 0.7
54, 0.737, 0.756, 0.800, 0.758, 0.763, (6.8590)+(-0.1188)His+(-0.
0052)Arg+(0.0055)Pro; 0.764, 0.785, 0.764, 0.749, 0.764, 0.810, 0.
768, 0.773, (7.1366)+(-0.1188)His+(-0.0036)Arg+(0.0015)Val; 0. 763,
0.780, 0.751, 0.725, 0.761, 0.797, 0.768, 0.763, (6.8232)+(-0.
1237)His+(-0.0274)Cit+(0.0134)Leu; 0.763, 0.785, 0.775, 0.768, 0.
771, 0.817, 0.774, 0.782,
(7.4745)+(-0.0004)Asn+(-0.1078)His+(-0.0490)Met; 0.763, 0.780,
0.714, 0.734, 0.660, 0.765, 0.738, 0.724,
(2.1382)+(-0.0567)Tyr+(0.1557)Ile+(-0.0852)Leu; 0.763, 0.776,
0.670, 0.653, 0.601, 0.781, 0.779, 0.704,
(-0.7855)+(0.0165)Ser+(-0.0556)Val+(0.1474)Ile; 0.763, 0.784,
0.769, 0.758, 0.766, 0.81 1, 0.775, 0.777,
(7.4187)+(-0.0123)Asn+(-0.1129)His+(-0.0024)A rg; 0.762, 0.786,
0.771, 0.762, 0.769, 0.808, 0.771, 0.777, (6.9998)
+(-0.1142)His+(-0.0846)Met+(0.0096)Lys; 0.762, 0.780, 0.752, 0.
732, 0.759, 0.801, 0.755, 0.762, (6.9361)+(-0.1148)His+(-0.0268)
Cit+(0.0054)Pro; 0.761, 0.775, 0.709, 0.696, 0.638, 0.785, 0.839,
0. 740, (1.5523)+(-0.0030)Gly+(-0.0562)Val+(0.1505)Ile; 0.761, 0.
779, 0.776, 0.767, 0.773, 0.825, 0.772, 0.784, (7.6847)+(-0.1047)H
is+(-0.0024)Ala+(-0.0275)Cit; 0.761, 0.774, 0.697, 0.679, 0.636,
0.779, 0.815, 0.727, (2.5091)+(-0.0032)Gln+(-0.0562)Val+(0.155
0)Ile; 0.760, 0.783, 0.767, 0.758, 0.762, 0.810, 0.768, 0.774,
(7.36 00)+(-0.1138)His+(-0.0031)Arg+(-0.0055)Tyr; 0.760, 0.773,
0.69 8, 0.692, 0.627, 0.783, 0.800, 0.726,
(1.1194)+(-0.0448)Val+(0.17 70)Ile+(-0.0364)Leu; 0.760, 0.775,
0.708, 0.699, 0.636, 0.790, 0.8 20, 0.736,
(1.2005)+(-0.0053)Pro+(-0.0558)Val+(0.1564)Ile; 0.7 60, 0.785,
0.775, 0.767, 0.770, 0.816, 0.773, 0.782, (7.4896)+(-0.1
077)His+(-0.0005)Arg+(-0.0486)Met; 0.759, 0.785, 0.775, 0.765, 0.
772, 0.817, 0.776, 0.783, (7.4082)+(-0.1085)His+(0.0049)Tyr+(-0.
0574)Met; 0.759, 0.778, 0.761, 0.744, 0.767, 0.805, 0.758, 0.769,
(7. 2302)+(-0.1151)His+(-0.0269)Cit+(0.0022)Val; 0.759, 0.780, 0.7
58, 0.744, 0.760, 0.800, 0.761, 0.766, (6.9309)+(-0.1226)His+(-0.
0077)Arg+(0.0062)Lys; 0.758, 0.778, 0.769, 0.757, 0.773, 0.812, 0.
764, 0.777, (7.6368)+(-0.0137)Asn+(-0.1072)His+(-0.0256)Cit; 0.
758, 0.775, 0.758, 0.743, 0.763, 0.801, 0.757, 0.766, (7.0221)+(-0.
1172)His+(-0.0256)Cit+(0.0042)Lys; 0.758, 0.774, 0.693, 0.680, 0.
620, 0.777, 0.819, 0.724, (0.3392)+(-0.0570)Val+(0.1469)Ile+(0.
0168)Phe; 0.757, 0.778, 0.766, 0.757, 0.768, 0.808, 0.758, 0.773,
(7. 5009)+(-0.1091)His+(-0.0253)Cit+(-0.0051)Tyr; 0.757, 0.781, 0.
775, 0.767, 0.779, 0.817, 0.761, 0.781, (7.7415)+(-0.1023)His+(-0.
0246)Cit+(-0.0459)Met; 0.757, 0.772, 0.707, 0.696, 0.636, 0.788, 0.
823, 0.736, (1.4159)+(-0.0063)Thr+(-0.0547)Val+(0.1495)Ile; 0. 755,
0.775, 0.752, 0.752, 0.709, 0.799, 0.805, 0.767, (3.2170)+(-0.
0959)Asn+(0.1425)Ile+(-0.0828)Leu; 0.755, 0.778, 0.760, 0.774, 0.
745,
0.814, 0.718, 0.763, (0.5617)+(0.0467)Ser+(-0.0073)Gly+(-0.
2492)Met; 0.755, 0.778, 0.764, 0.750, 0.768, 0.810, 0.758, 0.771,
(7. 3593)+(-0.1116)His+(-0.0260)Cit+(0.0004)Arg; 0.754, 0.779, 0.7
49, 0.762, 0.770, 0.821, 0.619, 0.743, (1.6186)+(0.0369)Ser+(-0.0
672)Cit+(-0.2258)Met; 0.754, 0.778, 0.773, 0.765, 0.744, 0.811, 0.
827, 0.787, (2.3927)+(-0.0080)Ala+(-0.2302)Met+(0.0660)Ile; 0. 754,
0.777, 0.759, 0.786, 0.742, 0.844, 0.661, 0.758, (0.6519)+(0.0
352)Ser+(-0.0029)Ala+(-0.2233)Met; 0.754, 0.780, 0.733, 0.760, 0.
740, 0.816, 0.586, 0.726, (0.2631)+(0.0340)Ser+(0.0084)Thr+(-0.
2814)Met; 0.752, 0.772, 0.690, 0.675, 0.624, 0.781, 0.805, 0.721,
(0. 7114)+(-0.0565)Val+(0.0086)Orn+(0.1475)Ile; 0.752, 0.775, 0.74
7, 0.737, 0.755, 0.734, 0.768, 0.749, (0.0520)+(-0.3443)Met+(0.04
21)Ile+(0.0671)Phe; 0.751, 0.775, 0.708, 0.724, 0.707, 0.784, 0.61
2, 0.707, (-0.2763)+(0.0394)Ser+(0.0104)Pro+(-0.3014)Met; 0.75 0,
0.776, 0.723, 0.740, 0.727, 0.791, 0.620, 0.720, (-0.4704)+(0.03
91)Ser+(-0.2831)Met+(0.0104)Leu; 0.750, 0.769, 0.783, 0.805, 0.7
79, 0.749, 0.758, 0.773, (1.1531)+(-0.0138)Val+(-0.2755)Met+(0.
1120)Phe; 0.747, 0.769, 0.762, 0.783, 0.724, 0.845, 0.724, 0.769,
(1. 7482)+(0.0379)Ser+(-0.1364)Asn+(-0.0056)Ala; 0.746, 0.776, 0.7
27, 0.748, 0.729, 0.810, 0.610, 0.724, (-0.1296)+(0.0353)Ser+(-0.
2683)Met+(0.0164)Orn; 0.746, 0.774, 0.740, 0.769, 0.736, 0.814, 0.
619, 0.735, (-0.0743)+(0.0352)Ser+(0.0011)Gln+(-0.2585)Met; 0. 746,
0.773, 0.738, 0.763, 0.738, 0.815, 0.615, 0.733, (0.1400)+(0.0
368)Ser+(0.0045)Tyr+(-0.2607)Met; 0.746, 0.770, 0.731, 0.741, 0.
741, 0.797, 0.638, 0.729, (2.1540)+(0.0396)Ser+(-0.1421)Asn+(-0.
0700)Cit; 0.746, 0.771, 0.738, 0.765, 0.738, 0.820, 0.608, 0.732,
(0. 4582)+(0.0365)Ser+(-0.2389)Met+(-0.0028)Lys; 0.745, 0.773, 0.7
41, 0.771, 0.748, 0.816, 0.597, 0.733, (0.7127)+(0.0374)Ser+(-0.0
122)Arg+(-0.2308)Met; 0.745, 0.774, 0.746, 0.776, 0.741, 0.830, 0.
621, 0.742, (0.7664)+(0.0349)Ser+(-0.0036)Val+(-0.2345)Met; 0. 744,
0.763, 0.725, 0.741, 0.743, 0.697, 0.663, 0.711, (-0.4451)+(0.
0224)Thr+(-0.3883)Met+(0.0934)Phe; 0.744, 0.762, 0.781, 0.796, 0.
772, 0.761, 0.777, 0.777, (0.8574)+(-0.0052)Ala+(-0.2608)Met+(0.
0912)Phe; 0.744, 0.765, 0.752, 0.739, 0.748, 0.779, 0.772, 0.760,
(2. 6270)+(-0.2513)Met+(-0.0101)Lys+(0.0585)Ile; 0.742, 0.766, 0.7
53, 0.735, 0.770, 0.774, 0.748, 0.757, (3.0275)+(-0.0670)Cit+(-0.
2520)Met+(0.0553)Ile; 0.742, 0.764, 0.716, 0.706, 0.691, 0.800, 0.
738, 0.733, (1.6755)+(-0.0852)Cit+(0.1568)Ile+(-0.0897)Leu; 0. 741,
0.761, 0.771, 0.794, 0.767, 0.729, 0.747, 0.759, (-1.3017)+(0.
0045)Gln+(-0.3394)Met+(0.0874)Phe; 0.740, 0.764, 0.748, 0.759, 0.
757, 0.709, 0.730, 0.739, (0.3020)+(0.0070)Pro+(-0.3324)Met+(0.
0853)Phe; 0.740, 0.760, 0.761, 0.742, 0.729, 0.830, 0.832, 0.783,
(2. 1633)+(-0.0140)Ala+(-0.0933)Cit+(0.0592)Ile; 0.740, 0.760, 0.7
69, 0.780, 0.778, 0.736, 0.746, 0.760, (0.9836)+(-0.2817)Met+(-0.
0070)Lys+(0.0910)Phe; 0.740, 0.763, 0.691, 0.690, 0.687, 0.732, 0.
672, 0.695, (-1.2217)+(0.0446)Ser+(-0.1933)Asn+(0.0490)Phe; 0. 738,
0.760, 0.750, 0.749, 0.739, 0.768, 0.763, 0.755, (0.3569)+(0.0
040)Gln+(-0.3138)Met+(0.0524)Ile; 0.738, 0.756, 0.717, 0.709, 0.
723, 0.744, 0.706, 0.721, (1.3103)+(0.0177)Thr+(-0.3453)Met+(0.
0533)Ile; 0.737, 0.756, 0.747, 0.737, 0.746, 0.760, 0.766, 0.752,
(2. 3078)+(-0.0199)Asn+(-0.2612)Met+(0.0511)Ile; 0.737, 0.757, 0.7
50, 0.767, 0.761, 0.718, 0.703, 0.737, (0.0077)+(0.0025)Gly+(-0.3
154)Met+(0.0905)Phe; 0.737, 0.763, 0.713, 0.703, 0.673, 0.777, 0.7
73, 0.732, (1.5790)+(-0.0149)Lys+(0.1433)Ile+(-0.0805)Leu; 0.7 37,
0.754, 0.768, 0.782, 0.777, 0.721, 0.747, 0.757, (1.2362)+(-0.0
369)Asn+(-0.2652)Met+(0.0849)Phe; 0.736, 0.757, 0.738, 0.728, 0.
737, 0.752, 0.757, 0.743, (1.8799)+(0.0023)Pro+(-0.2903)Met+(0.
0503)Ile; 0.736, 0.757, 0.752, 0.764, 0.761, 0.720, 0.724, 0.742,
(0. 2273)+(-0.3116)Met+(0.0129)Orn+(0.0820)Phe; 0.735, 0.762, 0.75
3, 0.782, 0.729, 0.825, 0.677, 0.753, (2.6428)+(0.0370)Ser+(-0.14
53)Asn+(-0.0107)Val; 0.734, 0.754, 0.735, 0.725, 0.734, 0.757, 0.7
50, 0.741, (1.7322)+(-0.2876)Met+(0.0071)Orn+(0.0504)Ile; 0.73 4,
0.757, 0.729, 0.721, 0.728, 0.755, 0.732, 0.734, (1.5227)+(0.002
2)Gly+(-0.2920)Met+(0.0545)Ile; 0.734, 0.759, 0.725, 0.759, 0.70 5,
0.784, 0.637, 0.721, (1.8544)+(0.0382)Ser+(-0.1364)Asn+(-0.0
309)Tyr; 0.732, 0.756, 0.674, 0.657, 0.664, 0.754, 0.685, 0.690,
(-0. 6580)+(0.0427)Ser+(-0.1756)Asn+(0.0295)Ile; 0.732, 0.754, 0.74
6, 0.738, 0.747, 0.760, 0.754, 0.750, (2.2765)+(-0.0085)Arg+(-0.2
689)Met+(0.0528)Ile; 0.731, 0.753, 0.725, 0.730, 0.697, 0.783, 0.7
25, 0.734, (2.2252)+(-0.0321)Arg+(0.1596)Ile+(-0.0944)Leu; 0.7 30,
0.751, 0.754, 0.742, 0.760, 0.826, 0.725, 0.763, (2.8460)+(-0.0
116)Ala+(-0.1225)Cit+(0.0535)Orn; 0.729, 0.754, 0.764, 0.782, 0.
774, 0.723, 0.727, 0.751, (0.8766)+(-0.0094)Arg+(-0.2888)Met+(0.
0877)Phe; 0.729, 0.751, 0.764, 0.784, 0.771, 0.720, 0.728, 0.751,
(0. 6223)+(-0.2897)Met+(-0.0090)Leu+(0.0957)Phe; 0.729, 0.752, 0.7
01, 0.700, 0.649, 0.763, 0.768, 0.720, (0.2540)+(-0.0070)Pro+(0.1
559)Ile+(-0.0916)Leu; 0.728, 0.749, 0.778, 0.774, 0.725, 0.835, 0.
861, 0.799, (2.7575)+(-0.0883)Asn+(-0.0105)Ala+(0.0457)Ile; 0. 727,
0.749, 0.717, 0.716, 0.666, 0.767, 0.792, 0.735, (1.1557)+(-0.
0150)Thr+(0.1545)Ile+(-0.0920)Leu; 0.727, 0.751, 0.760, 0.751, 0.
699, 0.833, 0.858, 0.785, (2.0924)+(-0.0111)Ala+(-0.0196)Lys+(0.
0576)Ile; 0.727, 0.751, 0.749, 0.776, 0.746, 0.704, 0.719, 0.736,
(0. 7541)+(-0.0268)Tyr+(-0.2652)Met+(0.0949)Phe; 0.726, 0.752, 0.7
58, 0.763, 0.784, 0.735, 0.710, 0.748, (1.4416)+(-0.0644)Cit+(-0.
2735)Met+(0.0916)Phe; 0.726, 0.751, 0.733, 0.731, 0.723, 0.746, 0.
749, 0.737, (2.1541)+(-0.0156)Tyr+(-0.2573)Met+(0.0542)Ile; 0. 725,
0.754, 0.782, 0.791, 0.756, 0.816, 0.787, 0.787, (4.0489)+(-0.
0363)Val+(-0.2236)Met+(0.0626)Leu; 0.725, 0.752, 0.722, 0.745, 0.
721, 0.783, 0.623, 0.718, (1.2211)+(0.0406)Ser+(-0.1411)Asn+(-0.
0154)Arg; 0.725, 0.751, 0.747, 0.764, 0.779, 0.783, 0.606, 0.733,
(3. 9391)+(0.0228)Thr+(-0.0713)Cit+(-0.2554)Met; 0.724, 0.753, 0.7
51, 0.744, 0.789, 0.795, 0.656, 0.746, (3.5164)+(-0.0968)Cit+(-0.
2017)Met+(0.0460)Orn; 0.724, 0.749, 0.745, 0.729, 0.780, 0.787, 0.
688, 0.746, (3.7326)+(-0.1110)Asn+(-0.1028)Cit+(0.0450)Orn; 0. 723,
0.747, 0.681, 0.674, 0.635, 0.748, 0.747, 0.701, (0.5731)+(-0.
0014)Gln+(0.1452)Ile+(-0.0899)Leu; 0.723, 0.748, 0.772, 0.785, 0.
744, 0.806, 0.767, 0.776, (3.5498)+(-0.0079)Ala+(0.0140)Pro+(-0.
1927)Met; 0.723, 0.746, 0.671, 0.666, 0.620, 0.730, 0.751, 0.692,
(-1.1447)+(0.1442)Ile+(-0.0959)Leu+(0.0285)Phe; 0.723, 0.747, 0.
641, 0.632, 0.592, 0.741, 0.691, 0.664, (-1.9553)+(0.0163)Ser+(0.
1425)Ile+(-0.0887)Leu; 0.723, 0.750, 0.720, 0.735, 0.711, 0.798, 0.
644, 0.722, (1.3728)+(0.0403)Ser+(-0.1361)Asn+(-0.0091)Lys; 0. 720,
0.746, 0.715, 0.728, 0.703, 0.777, 0.661, 0.717, (0.7730)+(0.0
412)Ser+(-0.1516)Asn+(-0.0046)Thr; 0.720, 0.747, 0.700, 0.706, 0.
695, 0.769, 0.642, 0.703, (0.4568)+(0.0394)Ser+(-0.1693)Asn+(0.
0136)Orn; 0.720, 0.744, 0.724, 0.721, 0.710, 0.772, 0.725, 0.732,
(1. 0301)+(0.0475)Ser+(-0.1581)Asn+(-0.0059)Gly; 0.719, 0.743, 0.7
56, 0.781, 0.768, 0.765, 0.654, 0.742, (3.6825)+(-0.0587)Asn+(0.0
207)Thr+(-0.2199)Met; 0.719, 0.744, 0.696, 0.690, 0.644, 0.748, 0.
780, 0.715, (0.4305)+(-0.0026)Gly+(0.1447)Ile+(-0.0907)Leu; 0. 718,
0.744, 0.682, 0.680, 0.630, 0.746, 0.748, 0.701, (-0.0598)+(-0.
0014)Orn+(0.1448)Ile+(-0.0903)Leu; 0.718, 0.747, 0.724, 0.744, 0.
710, 0.792, 0.651, 0.724, (1.2781)+(0.0386)Ser+(-0.1542)Asn+(-0.
0057)Leu; 0.716, 0.739, 0.692, 0.699, 0.684, 0.757, 0.641, 0.695,
(0. 5591)+(0.0400)Ser+(-0.1649)Asn+(0.0029)Pro; 0.715, 0.737, 0.75
9, 0.787, 0.749, 0.803, 0.676, 0.754, (3.2559)+(-0.0103)Val+(-0.1
926)Met+(0.0321)Orn; 0.714, 0.736, 0.802, 0.831, 0.789, 0.794, 0.7
56, 0.792, (2.0338)+(-0.0691)Asn+(0.0063)Gln+(-0.1839)Met; 0.7 14,
0.740, 0.716, 0.733, 0.702, 0.775, 0.661, 0.718, (0.2302)+(0.03
82)Ser+(-0.1720)Asn+(0.0021)Gln; 0.714, 0.736, 0.724, 0.747, 0.7
33, 0.750, 0.626, 0.714, (2.4827)+(0.0158)Thr+(0.0071)Pro+(-0.2
907)Met; 0.713, 0.742, 0.766, 0.799, 0.756, 0.811, 0.669, 0.759,
(3. 0994)+(0.0185)Thr+(-0.0043)Ala+(-0.2318)Met; 0.713, 0.739, 0.7
85, 0.809, 0.764, 0.755, 0.784, 0.778, (3.3010)+(-0.1273)Asn+(-0.
0191)Val+(0.0755)Phe; 0.712, 0.742, 0.759, 0.799, 0.760, 0.807, 0.
614, 0.745, (3.4295)+(0.0193)Thr+(-0.0077)Val+(-0.2413)Met; 0. 711,
0.737, 0.679, 0.668, 0.585, 0.815, 0.811, 0.720, (-2.4641)+(0.
0235)Ser+(-0.0143)Ala+(0.0473)Ile; 0.710, 0.734, 0.734, 0.745, 0.
719, 0.830, 0.668, 0.740, (1.1144)+(0.0249)Ser+(-0.0091)Ala+(-0.
0852)Cit; 0.710, 0.732, 0.730, 0.744, 0.729, 0.758, 0.676, 0.727,
(2. 4003)+(0.0067)Pro+(-0.2523)Met+(0.0184)Orn; 0.709, 0.734, 0.76
8, 0.789, 0.746, 0.810, 0.727, 0.768, (2.8987)+(-0.0050)Ala+(-0.1
855)Met+(0.0261)Orn; 0.709, 0.734, 0.697, 0.714, 0.715, 0.757, 0.5
71, 0.689, (2.6812)+(-0.1070)Cit+(-0.0592)Tyr+(0.0475)Orn; 0.7 09,
0.732, 0.756, 0.771, 0.757, 0.751, 0.719, 0.749, (3.6758)+(-0.0
395)Asn+(0.0076)Pro+(-0.1974)Met; 0.709, 0.733, 0.758, 0.771, 0.
762, 0.773, 0.706, 0.753, (3.3754)+(-0.0499)Asn+(-0.1796)Met+(0.
0244)Orn; 0.709, 0.732, 0.753, 0.754, 0.696, 0.815, 0.827, 0.773,
(1. 2719)+(-0.0122)Ala+(-0.0207)Arg+(0.0470)Ile; 0.709, 0.734, 0.7
70, 0.794, 0.754, 0.802, 0.716, 0.767, (4.6800)+(-0.1161)Asn+(-0.
0166)Val+(0.0369)Orn; 0.709, 0.735, 0.790, 0.801, 0.755, 0.804, 0.
825, 0.796, (2.4449)+(-0.1032)Asn+(-0.0085)Ala+(0.0518)Phe; 0. 709,
0.734, 0.752, 0.790, 0.749, 0.772, 0.640, 0.738, (1.3967)+(0.0
035)Gln+(0.0152)Thr+(-0.2857)Met; 0.709, 0.735, 0.752, 0.761, 0.
771, 0.766, 0.680, 0.745, (4.0694)+(-0.0632)Cit+(0.0086)Pro+(-0.
2096)Met; 0.707, 0.731, 0.729, 0.754, 0.740, 0.765, 0.615, 0.719,
(2. 2980)+(0.0140)Thr+(-0.2706)Met+(0.0156)Orn; 0.706, 0.736, 0.67
7, 0.708, 0.681, 0.756, 0.530, 0.669, (0.9989)+(0.0246)Ser+(-0.07
85)Cit+(-0.0478)Tyr; 0.705, 0.732, 0.801, 0.813, 0.789, 0.829, 0.7
72, 0.801, (5.3131)+(-0.0674)Asn+(-0.0063)Ala+(-0.0676)Cit; 0. 705,
0.732, 0.782, 0.807, 0.787, 0.792, 0.696, 0.770, (2.1230)+(0.0
061)Gln+(-0.0732)Cit+(-0.2136)Met; 0.705, 0.730, 0.741, 0.771, 0.
750, 0.762, 0.630, 0.728, (2.7756)+(-0.0008)Gly+(0.0183)Thr+(-0.
2684)Met; 0.705, 0.730, 0.801, 0.837, 0.764, 0.827, 0.761, 0.797,
(1. 8230)+(0.0045)Gln+(-0.0041)Ala+(-0.2001)Met; 0.705, 0.727, 0.7
48, 0.765, 0.751, 0.782, 0.673, 0.743, (2.9347)+(-0.2023)Met+(0.0
268)Orn+(-0.0070)Lys; 0.705, 0.732, 0.596, 0.620, 0.546, 0.685, 0.
573, 0.606, (-1.7471)+(0.0230)Ser+(-0.0738)Tyr+(0.0362)Ile; 0. 704,
0.729, 0.753, 0.779, 0.739, 0.758, 0.707, 0.746, (1.3604)+(0.0
041)Gln+(0.0074)Pro+(-0.2675)Met; 0.704, 0.732, 0.736, 0.772, 0.
755, 0.765, 0.579, 0.718, (3.2808)+(0.0223)Thr+(-0.0164)Arg+(-0.
2560)Met; 0.704, 0.729, 0.736, 0.781, 0.708, 0.684, 0.716, 0.722,
(2. 5464)+(-0.1004)Asn+(-0.0629)Tyr+(0.0685)Phe; 0.704, 0.733, 0.7
41, 0.776, 0.699, 0.849, 0.660, 0.746, (0.1779)+(0.0266)Ser+(-0.0
082)Ala+(-0.0243)Arg; 0.704, 0.729, 0.755, 0.784, 0.740, 0.773, 0.
695, 0.748, (3.8632)+(0.0111)Pro+(-0.0102)Val+(-0.2081)Met; 0. 704,
0.727, 0.746, 0.765, 0.745, 0.751, 0.696, 0.739, (3.1772)+(0.0
082)Pro+(-0.2263)Met+(-0.0031)Lys; 0.703, 0.730, 0.738, 0.770, 0.
748, 0.772, 0.611, 0.725, (3.0415)+(0.0190)Thr+(-0.2511)Met+(-0.
0051)Lys; 0.703, 0.733, 0.612, 0.568, 0.614, 0.739, 0.631, 0.638,
(-1.9031)+(0.0330)Ser+(-0.0328)Lys+(0.0445)Ile; 0.703, 0.730, 0.
733, 0.760, 0.744, 0.753, 0.623, 0.720, (2.4849)+(0.0180)Thr+(-0.
2794)Met+(0.0037)Leu; 0.703, 0.728, 0.773, 0.787, 0.730, 0.793, 0.
810, 0.780, (5.3423)+(-0.1196)Asn+(-0.0393)Val+(0.0550)Leu; 0. 703,
0.732, 0.737, 0.719, 0.750, 0.748, 0.747, 0.741, (3.2433)+(-0.
1014)Asn+(-0.0751)Cit+(0.0287)Ile; 0.702, 0.732, 0.718, 0.689, 0.
777, 0.813, 0.601, 0.720, (2.9594)+(-0.1128)Cit+(0.0544)Orn+(-0.
0225)Lys; 0.702, 0.726, 0.738, 0.759, 0.739, 0.745, 0.678, 0.730,
(2. 7991)+(0.0008)Gly+(0.0081)Pro+(-0.2412)Met; 0.702, 0.731, 0.73
4, 0.773, 0.739, 0.759, 0.602, 0.718, (2.8884)+(0.0185)Thr+(-0.01
21)Tyr+(-0.2498)Met; 0.702, 0.735, 0.796, 0.812, 0.797, 0.819, 0.7
33, 0.790, (4.8035)+(-0.0046)Ala+(-0.0642)Cit+(-0.1280)Met; 0. 702,
0.728, 0.720, 0.716, 0.630, 0.805, 0.856, 0.752, (0.0336)+(-0.
0148)Ala+(0.0055)Pro+(0.0392)Ile; 0.702, 0.726, 0.720, 0.742, 0.
633, 0.786, 0.796, 0.739, (1.5289)+(-0.0105)Ala+(-0.0464)Tyr+(0.
0519)Ile; 0.702, 0.729, 0.747, 0.765, 0.759, 0.776, 0.657, 0.739,
(2. 9766)+(-0.0132)Arg+(-0.2080)Met+(0.0262)Orn; 0.701, 0.726, 0.7
58, 0.787, 0.746, 0.782, 0.690, 0.751, (1.3109)+(0.0034)Gln+(-0.2
490)Met+(0.0176)Orn; 0.701, 0.724, 0.760, 0.760, 0.741, 0.818, 0.7
56, 0.769, (3.2929)+(-0.0124)Ala+(-0.0844)Cit+(0.0123)Pro; 0.7 01,
0.724, 0.777, 0.787, 0.736, 0.820, 0.807, 0.787, (3.8514)+(-0.0
890)Asn+(-0.0097)Ala+(0.0106)Pro; 0.701, 0.727, 0.719, 0.787, 0.
665, 0.699, 0.666, 0.704, (0.9960)+(-0.0670)Tyr+(-0.0154)Val+(0.
0803)Phe; 0.700, 0.727, 0.775, 0.790, 0.793, 0.775, 0.698, 0.764,
(4. 9949)+(-0.0392)Asn+(-0.0594)Cit+(-0.1347)Met; 0.700, 0.727, 0.
763, 0.769, 0.740, 0.804, 0.766, 0.770, (1.6184)+(-0.0109)Ala+(-0.
0852)Cit+(0.0489)Phe; 0.700, 0.722, 0.771, 0.797, 0.770, 0.771, 0.
703, 0.760, (3.8178)+(-0.0463)Asn+(0.0014)Gly+(-0.1606)Met; 0. 700,
0.725, 0.798, 0.822, 0.780, 0.809, 0.762, 0.793, (4.3442)+(-0.
0428)Asn+(-0.0039)Ala+(-0.1241)Met; 0.699, 0.728, 0.737, 0.764,
0.728, 0.740, 0.680, 0.728,
(3.1978)+(0.0089)Pro+(-0.0158)Tyr+(-0.2140)Met; 0.699, 0.728,
0.748, 0.769, 0.751, 0.753, 0.685, 0.73 9,
(3.3247)+(-0.0092)Arg+(0.0083)Pro+(-0.2236)Met; 0.699, 0.72 9,
0.793, 0.837, 0.769, 0.810, 0.714, 0.783,
(2.0695)+(0.0046)Gln+(-0.0069)Val+(-0.2098)Met; 0.699, 0.726,
0.756, 0.777, 0.779, 0.7 80, 0.637, 0.743,
(3.9881)+(0.0026)Gly+(-0.0659)Cit+(-0.1770)M et; 0.698, 0.720,
0.743, 0.762, 0.744, 0.767, 0.674, 0.737, (2.5228)
+(-0.0002)Gly+(-0.2274)Met+(0.0224)Orn; 0.698, 0.724, 0.743, 0.
762, 0.741, 0.746, 0.692, 0.735, (2.9703)+(0.0082)Pro+(-0.2366)M
et+(-0.0011)Leu; 0.697, 0.724, 0.745, 0.741, 0.663, 0.817, 0.873,
0. 773, (0.5464)+(-0.0075)Thr+(-0.0128)Ala+(0.0466)Ile; 0.697, 0.
722, 0.783, 0.817, 0.767, 0.795, 0.715, 0.773, (1.6816)+(0.0048)Gl
n+(-0.2216)Met+(-0.0045)Lys; 0.697, 0.730, 0.678, 0.693, 0.665, 0.
709, 0.644, 0.678, (2.1992)+(-0.0781)Cit+(-0.0618)Tyr+(0.0398)Ile;
0.697, 0.722, 0.743, 0.763, 0.744, 0.768, 0.671, 0.736, (2.540
2)+(-0.2249)Met+(0.0228)Orn+(-0.0012)Leu; 0.697, 0.722, 0.732,
0.727, 0.644, 0.817, 0.864, 0.763, (0.3244)+(-0.0005)Gln+(-0.013
4)Ala+(0.0445)Ile; 0.696, 0.725, 0.732, 0.729, 0.643, 0.818, 0.864,
0.763, (-0.2114)+(-0.0139)Ala+(0.0420)Ile+(0.0088)Phe; 0.696,
0.718, 0.775, 0.799, 0.775, 0.769, 0.719, 0.766, (4.0295)+(-0.042
7)Asn+(-0.1579)Met+(-0.0007)Lys; 0.696, 0.721, 0.782, 0.794, 0.7
49, 0.827, 0.786, 0.789, (3.5468)+(-0.0971)Asn+(-0.0075)Ala+(0.
0246)Orn; 0.696, 0.722, 0.783, 0.823, 0.771, 0.791, 0.694, 0.770,
(1. 6766)+(0.0054)Gln+(-0.0142)Arg+(-0.2204)Met; 0.696, 0.723, 0.7
87, 0.816, 0.765, 0.812, 0.737, 0.783, (3.4744)+(0.0005)Gly+(-0.0
040)Ala+(-0.1671)Met; 0.696, 0.722, 0.791, 0.818, 0.769, 0.816, 0.
744, 0.787, (3.6265)+(-0.0040)Ala+(-0.1620)Met+(-0.0010)Lys; 0.
695, 0.723, 0.795, 0.830, 0.770, 0.824, 0.735, 0.790, (3.9431)+(-0.
0031)Ala+(-0.0048)Val+(-0.1526)Met; 0.695, 0.721, 0.782, 0.817,
0.764, 0.783, 0.724, 0.772,
(1.4961)+(-0.0009)Gly+(0.0046)Gln+(-0.2380)Met; 0.695, 0.721,
0.816, 0.843, 0.770, 0.843, 0.820, 0.81 9,
(2.5124)+(-0.1142)Asn+(0.0050)Gln+(-0.0067)Ala; 0.695, 0.72 1,
0.685, 0.682, 0.714, 0.795, 0.556, 0.687,
(1.0121)+(0.0298)Ser+(-0.0794)Cit+(-0.0192)Lys; 0.695, 0.720,
0.760, 0.772, 0.780, 0.7 67, 0.678, 0.750,
(4.0944)+(-0.0627)Cit+(-0.1866)Met+(0.0050)L eu; 0.695, 0.721,
0.730, 0.727, 0.640, 0.817, 0.862, 0.762, (0.0306)
+(-0.0136)Ala+(0.0020)Orn+(0.0433)Ile; 0.695, 0.727, 0.750, 0.7 49,
0.769, 0.724, 0.730, 0.743, (2.8641)+(-0.1101)Asn+(-0.0727)C
it+(0.0411)Phe; 0.695, 0.719, 0.774, 0.795, 0.774, 0.766, 0.722, 0.
764, (3.9071)+(-0.0426)Asn+(-0.1649)Met+(0.0013)Leu; 0.694, 0. 724,
0.814, 0.854, 0.777, 0.826, 0.777, 0.809, (3.3276)+(-0.1300)A
sn+(0.0057)Gln+(-0.0132)Val; 0.694, 0.722, 0.735, 0.731, 0.648, 0.
817, 0.867, 0.766, (0.1922)+(-0.0006)Gly+(-0.0135)Ala+(0.0439)Ile;
0.694, 0.720, 0.712, 0.740, 0.668, 0.708, 0.729, 0.711, (3.224
6)+(-0.0883)Asn+(-0.0521)Tyr+(0.0357)Ile; 0.693, 0.723, 0.784,
0.803, 0.780, 0.780, 0.746, 0.777, (2.3580)+(-0.1318)Asn+(0.007
1)Gln+(-0.0812)Cit; 0.693, 0.725, 0.604, 0.659, 0.557, 0.641, 0.52
6, 0.596, (-2.3653)+(0.0237)Ser+(-0.0836)Tyr+(0.0567)Phe; 0.69 3,
0.721, 0.735, 0.763, 0.729, 0.759, 0.656, 0.726,
(2.7186)+(-0.01
46)Tyr+(-0.2029)Met+(0.0242)Orn; 0.693, 0.718, 0.776, 0.800, 0.7
79, 0.770, 0.713, 0.766, (4.1345)+(-0.0399)Asn+(-0.0050)Arg+(-0.
1545)Met; 0.693, 0.721, 0.774, 0.809, 0.757, 0.776, 0.712, 0.764,
(1. 3401)+(0.0044)Gln+(-0.2452)Met+(0.0024)Leu; 0.693, 0.719, 0.79
3, 0.825, 0.779, 0.802, 0.729, 0.784, (4.9530)+(-0.0537)Asn+(-0.0
078)Val+(-0.1146)Met; 0.693, 0.724, 0.784, 0.806, 0.764, 0.806, 0.
755, 0.783, (3.2879)+(-0.0046)Ala+(-0.1795)Met+(0.0070)Leu; 0. 693,
0.720, 0.766, 0.782, 0.785, 0.776, 0.676, 0.755, (4.3747)+(-0.
0612)Cit+(-0.1690)Met+(-0.0010)Lys; 0.692, 0.724, 0.767, 0.796,
0.767, 0.766, 0.694, 0.756,
(5.2257)+(-0.0737)Asn+(-0.0616)Cit+(-0.0299)Tyr; 0.692, 0.718,
0.772, 0.801, 0.767, 0.762, 0.712, 0.76 0,
(4.2145)+(-0.0452)Asn+(-0.0107)Tyr+(-0.1389)Met; 0.691, 0.7 28,
0.732, 0.758, 0.679, 0.859, 0.680, 0.744, (0.4512)+(0.0274)Ser
+(-0.0071)Ala+(-0.0153)Lys; 0.691, 0.717, 0.734, 0.787, 0.658, 0.
753, 0.738, 0.734, (0.8325)+(-0.0083)Ala+(-0.0578)Tyr+(0.0647)Phe;
0.691, 0.723, 0.776, 0.797, 0.789, 0.792, 0.682, 0.765, (4.671
5)+(-0.0572)Cit+(-0.0044)Val+(-0.1559)Met; 0.691, 0.720, 0.774,
0.817, 0.752, 0.778, 0.705, 0.763, (1.5803)+(0.0045)Gln+(-0.007
7)Tyr+(-0.2246)Met; 0.691, 0.720, 0.741, 0.761, 0.755, 0.759, 0.64
3, 0.730, (4.0158)+(-0.0997)Asn+(0.0041)Gly+(-0.0739)Cit; 0.69 1,
0.720, 0.794, 0.824, 0.777, 0.815, 0.733, 0.787, (3.8364)+(-0.00
39)Ala+(-0.0068)Arg+(-0.1543)Met; 0.690, 0.721, 0.686, 0.720, 0.
637, 0.733, 0.668, 0.689, (0.3358)+(0.0362)Ser+(-0.0104)Gly+(-0.
0620)Tyr; 0.690, 0.715, 0.709, 0.711, 0.732, 0.790, 0.601, 0.708,
(1. 9860)+(-0.1027)Cit+(-0.0155)Val+(0.0491)Orn; 0.690, 0.721, 0.7
64, 0.779, 0.783, 0.770, 0.678, 0.753, (4.2287)+(-0.0635)Cit+(0.0
025)Arg+(-0.1767)Met; 0.690, 0.719, 0.777, 0.804, 0.759, 0.818, 0.
713, 0.774, (4.1831)+(-0.0068)Ala+(-0.0720)Cit+(-0.0230)Tyr; 0.
690, 0.725, 0.672, 0.728, 0.664, 0.767, 0.476, 0.659, (0.4665)+(0.0
269)Ser+(-0.0255)Arg+(-0.0457)Tyr; 0.689, 0.722, 0.788, 0.817, 0.
765, 0.810, 0.741, 0.783,
(3.5905)+(-0.0040)Ala+(-0.0023)Tyr+(-0.1621)Met; 0.688, 0.718,
0.705, 0.751, 0.673, 0.698, 0.657, 0.695,
(1.4875)+(-0.0652)Tyr+(-0.0158)Lys+(0.0658)Phe; 0.688, 0.714,
0.763, 0.792, 0.762, 0.770, 0.687, 0.753,
(3.2655)+(0.0005)Gly+(-0.1956)Met+(-0.0022)Lys; 0.688, 0.720,
0.765, 0.783, 0.783, 0.773, 0.672, 0.753,
(4.3828)+(-0.0611)Cit+(-0.0047)Tyr+(-0.1648)Me t; 0.688, 0.715,
0.810, 0.842, 0.774, 0.844, 0.778, 0.809,
(5.0618)+(-0.0850)Asn+(-0.0039)Ala+(-0.0089)Val; 0.688, 0.717,
0.776, 0. 813, 0.764, 0.789, 0.694, 0.765,
(3.7789)+(0.0002)Gly+(-0.0065)V al+(-0.1753)Met; 0.687, 0.714,
0.756, 0.781, 0.755, 0.759, 0.687, 0. 746,
(2.9155)+(0.0007)Gly+(-0.2150)Met+(0.0033)Leu; 0.687, 0.7 11,
0.779, 0.797, 0.756, 0.825, 0.748, 0.781, (2.1936)+(0.0031)Gln
+(-0.0093)Ala+(-0.0855)Cit; 0.686, 0.715, 0.762, 0.784, 0.761, 0.
767, 0.699, 0.753, (3.2479)+(-0.2017)Met+(-0.0038)Lys+(0.0050)Leu;
0.686, 0.715, 0.726, 0.763, 0.705, 0.729, 0.667, 0.716, (3.823
7)+(-0.0965)Asn+(-0.0456)Tyr+(0.0270)Orn; 0.686, 0.717, 0.787,
0.809, 0.753, 0.827, 0.772, 0.790, (3.9179)+(-0.1048)Asn+(0.010
2)Thr+(-0.0071)Ala; 0.686, 0.715, 0.790, 0.828, 0.746, 0.812, 0.76
4, 0.787, (4.6033)+(-0.0747)Asn+(-0.0050)Ala+(-0.0236)Tyr; 0.6 86,
0.712, 0.763, 0.793, 0.764, 0.769, 0.673, 0.750, (3.4071)+(0.00
08)Gly+(-0.0081)Arg+(-0.1909)Met; 0.685, 0.710, 0.766, 0.784, 0.
754, 0.822, 0.707, 0.767, (3.2394)+(0.0017)Gly+(-0.0086)Ala+(-0.
0810)Cit; 0.685, 0.713, 0.767, 0.796, 0.768, 0.771, 0.684, 0.755,
(3. 5609)+(-0.0075)Arg+(-0.1869)Met+(-0.0008)Lys; 0.685, 0.716, 0.
775, 0.813, 0.762, 0.786, 0.696, 0.764, (3.7237)+(-0.0069)Val+(-0.
1803)Met+(0.0017)Lys; 0.685, 0.713, 0.780, 0.806, 0.776, 0.794, 0.
713, 0.772, (5.6126)+(-0.0859)Asn+(-0.0552)Cit+(-0.0093)Val; 0.
684, 0.715, 0.763, 0.789, 0.766, 0.762, 0.687, 0.751, (3.3782)+(-0.
0078)Arg+(-0.1982)Met+(0.0030)Leu; 0.683, 0.717, 0.776, 0.815, 0.
763, 0.788, 0.695, 0.765,
(3.8382)+(-0.0020)Tyr+(-0.0064)Val+(-0.1715)Met; 0.683, 0.713,
0.774, 0.826, 0.737, 0.759, 0.727, 0.762,
(2.6567)+(-0.1160)Asn+(0.0055)Gln+(-0.0404)Tyr; 0.683, 0.713,
0.770, 0.806, 0.754, 0.790, 0.697, 0.762,
(4.9807)+(-0.1229)Asn+(0.0129)Thr+(-0.0140)Val; 0.683, 0.711,
0.784, 0.829, 0.753, 0.79 9, 0.721, 0.775,
(5.2932)+(-0.0855)Asn+(-0.0208)Tyr+(-0.0097)V al; 0.683, 0.714,
0.788, 0.802, 0.779, 0.839, 0.734, 0.789, (4.2447)
+(-0.0074)Ala+(-0.0738)Cit+(-0.0069)Lys; 0.683, 0.708, 0.766, 0.
780, 0.754, 0.817, 0.719, 0.768, (3.2644)+(0.0044)Thr+(-0.0091)A
la+(-0.0812)Cit; 0.683, 0.711, 0.748, 0.752, 0.762, 0.748, 0.706,
0. 742, (4.1503)+(-0.0959)Asn+(-0.0691)Cit+(0.0029)Pro; 0.683, 0.
717, 0.711, 0.762, 0.636, 0.836, 0.647, 0.720, (0.3637)+(0.0223)Se
r+(-0.0070)Ala+(-0.0355)Tyr; 0.682, 0.712, 0.758, 0.791, 0.752, 0.
758, 0.681, 0.746, (3.2465)+(0.0003)Gly+(-0.0070)Tyr+(-0.1921)Met;
0.682, 0.715, 0.741, 0.749, 0.762, 0.748, 0.670, 0.732, (4.207
8)+(-0.1131)Asn+(0.0102)Thr+(-0.0722)Cit; 0.682, 0.708, 0.771,
0.780, 0.756, 0.816, 0.741, 0.773, (3.3435)+(-0.0090)Ala+(-0.079
5)Cit+(0.0030)Leu; 0.682, 0.713, 0.683, 0.700, 0.646, 0.721, 0.691,
0.689, (2.3941)+(-0.0530)Tyr+(-0.0191)Lys+(0.0466)Ile; 0.682,
0.711, 0.762, 0.794, 0.757, 0.766, 0.688, 0.751, (3.4544)+(-0.006
8)Tyr+(-0.1828)Met+(-0.0020)Lys; 0.682, 0.710, 0.797, 0.822, 0.7
59, 0.828, 0.785, 0.799, (3.8919)+(-0.0879)Asn+(0.0012)Gly+(-0.
0064)Ala; 0.682, 0.711, 0.735, 0.720, 0.726, 0.756, 0.778, 0.745,
(2. 9314)+(-0.0856)Asn+(-0.0161)Lys+(0.0340)Ile; 0.682, 0.714, 0.6
94, 0.712, 0.608, 0.811, 0.741, 0.718, (-2.3006)+(0.0224)Ser+(-0.
0118)Ala+(0.0340)Phe; 0.681, 0.708, 0.778, 0.791, 0.766, 0.823, 0.
733, 0.778, (3.5964)+(-0.0084)Ala+(-0.0752)Cit+(-0.0030)Arg; 0.
681, 0.707, 0.694, 0.659, 0.717, 0.761, 0.692, 0.707, (2.4775)+(-0.
0814)Cit+(-0.0233)Lys+(0.0444)Ile; 0.680, 0.711, 0.697, 0.773, 0.
653, 0.660, 0.617, 0.676, (0.5611)+(-0.0730)Tyr+(-0.0189)Leu+(0.
0764)Phe; 0.680, 0.711, 0.698, 0.734, 0.695, 0.718, 0.592, 0.685,
(3. 1112)+(-0.0727)Cit+(0.0059)Pro+(-0.0535)Tyr; 0.680, 0.713, 0.7
64, 0.797, 0.762, 0.764, 0.677, 0.750, (3.6363)+(-0.0078)Arg+(-0.
0069)Tyr+(-0.1771)Met; 0.680, 0.706, 0.780, 0.799, 0.763, 0.827, 0.
729, 0.780, (3.7935)+(-0.0075)Ala+(-0.0727)Cit+(-0.0040)Val; 0.
680, 0.712, 0.709, 0.770, 0.670, 0.766, 0.585, 0.698, (2.3261)+(-0.
0462)Tyr+(-0.0132)Val+(0.0294)Orn; 0.680, 0.712, 0.687, 0.730, 0.
675, 0.675, 0.607, 0.671, (1.4091)+(-0.0758)Cit+(-0.0711)Tyr+(0.
0632)Phe; 0.680, 0.707, 0.765, 0.796, 0.739, 0.776, 0.730, 0.760,
(4. 9611)+(-0.1058)Asn+(0.0081)Pro+(-0.0155)Val; 0.680, 0.710, 0.7
55, 0.785, 0.751, 0.751, 0.687, 0.743, (3.1642)+(-0.0082)Tyr+(-0.
1987)Met+(0.0034)Leu; 0.679, 0.708, 0.707, 0.752, 0.696, 0.815, 0.
531, 0.699, (0.6244)+(0.0249)Ser+(-0.0278)Arg+(-0.0126)Val; 0. 679,
0.714, 0.779, 0.819, 0.771, 0.790, 0.685, 0.766, (4.1123)+(-0.
0072)Arg+(-0.0064)Val+(-0.1618)Met; 0.679, 0.710, 0.729, 0.769,
0.701, 0.716, 0.690, 0.719,
(4.1127)+(-0.0887)Asn+(0.0061)Pro+(-0.0449)Tyr; 0.678, 0.712,
0.686, 0.678, 0.668, 0.762, 0.690, 0.69 9,
(-0.0670)+(0.0404)Ser+(-0.0088)Gly+(-0.0230)Lys; 0.678, 0.7 09,
0.804, 0.826, 0.770, 0.837, 0.795, 0.807, (4.2986)+(-0.0769)As
n+(-0.0060)Ala+(-0.0041)Lys; 0.677, 0.707, 0.766, 0.782, 0.777, 0.
769, 0.700, 0.757, (4.7394)+(-0.0877)Asn+(-0.0650)Cit+(-0.006
0)Leu; 0.677, 0.710, 0.766, 0.776, 0.780, 0.775, 0.704, 0.759,
(4.81 55)+(-0.0775)Asn+(-0.0656)Cit+(-0.0063)Lys; 0.677, 0.704,
0.72 7, 0.772, 0.650, 0.788, 0.722, 0.733,
(2.5799)+(-0.0100)Ala+(0.01 24)Pro+(-0.0425)Tyr; 0.677, 0.708,
0.727, 0.734, 0.653, 0.833, 0.7 86, 0.752,
(-0.4582)+(0.0313)Ser+(-0.0074)Gly+(-0.0098)Ala; 0. 676, 0.711,
0.729, 0.777, 0.711, 0.725, 0.641, 0.714, (4.2199)+(-0.
1080)Asn+(0.0132)Thr+(-0.0445)Tyr; 0.676, 0.703, 0.722, 0.770, 0.
711, 0.739, 0.606, 0.707, (2.1176)+(0.0030)Gln+(-0.0782)Cit+(-0.
0497)Tyr; 0.676, 0.711, 0.805, 0.830, 0.773, 0.826, 0.788, 0.804,
(4. 2511)+(-0.0760)Asn+(-0.0061)Ala+(-0.0079)Arg; 0.676, 0.707, 0.
802, 0.825, 0.765, 0.830, 0.797, 0.804, (4.1313)+(-0.0846)Asn+(-0.
0062)Ala+(-0.0017)Leu; 0.676, 0.710, 0.776, 0.790, 0.734, 0.820, 0.
795, 0.785, (1.3332)+(-0.0091)Ala+(-0.0150)Lys+(0.0464)Phe; 0. 675,
0.712, 0.729, 0.755, 0.647, 0.850, 0.745, 0.749, (-0.6360)+(0.
0289)Ser+(-0.0137)Thr+(-0.0082)Ala; 0.675, 0.699, 0.667, 0.664,
0.680, 0.740, 0.595, 0.670,
(-0.6502)+(0.0316)Ser+(-0.0176)Thr+(-0.0815)Cit; 0.675, 0.709,
0.757, 0.766, 0.770, 0.754, 0.707, 0.74 9,
(4.3427)+(-0.0921)Asn+(-0.0678)Cit+(-0.0001)Arg; 0.674, 0.7 15,
0.667, 0.713, 0.646, 0.770, 0.516, 0.661, (0.6099)+(0.0268)Ser
+(-0.0375)Tyr+(-0.0156)Lys; 0.674, 0.707, 0.758, 0.773, 0.721, 0.
829, 0.745, 0.767, (2.3528)+(-0.0082)Ala+(0.0271)Orn+(-0.0155)Lys;
0.674, 0.711, 0.675, 0.696, 0.685, 0.785, 0.521, 0.672, (-0.012
5)+(0.0307)Ser+(-0.0212)Arg+(-0.0172)Lys; 0.673, 0.703, 0.749,
0.796, 0.722, 0.741, 0.686, 0.736, (4.1822)+(-0.0869)Asn+(0.000
5)Gly+(-0.0359)Tyr; 0.673, 0.702, 0.783, 0.821, 0.758, 0.796, 0.72
2, 0.774, (4.8438)+(-0.0993)Asn+(0.0010)Gly+(-0.0120)Val; 0.67 3,
0.706, 0.762, 0.809, 0.734, 0.757, 0.698, 0.749, (4.4799)+(-0.08
38)Asn+(-0.0330)Tyr+(-0.0045)Leu; 0.672, 0.703, 0.759, 0.781, 0.
727, 0.823, 0.725, 0.764, (1.9774)+(-0.0092)Ala+(-0.0226)Arg+(0.
0240)Orn; 0.672, 0.706, 0.679, 0.692, 0.595, 0.814, 0.726, 0.707,
(-1.1331)+(0.0214)Ser+(-0.0129)Ala+(0.0096)Pro; 0.672, 0.705, 0.
756, 0.759, 0.756, 0.739, 0.760, 0.753, (2.5668)+(-0.1010)Asn+(-0.
0124)Lys+(0.0408)Phe; 0.671, 0.701, 0.755, 0.773, 0.702, 0.821, 0.
771, 0.767, (2.6204)+(-0.0106)Ala+(0.0106)Pro+(-0.0123)Lys; 0. 671,
0.703, 0.762, 0.786, 0.759, 0.707, 0.742, 0.748, (2.4528)+(-0.
1206)Asn+(-0.0205)Leu+(0.0570)Phe; 0.671, 0.704, 0.673, 0.738, 0.
628, 0.765, 0.526, 0.664, (0.6891)+(0.0202)Ser+(-0.0421)Tyr+(-0.
0094)Val; 0.671, 0.698, 0.701, 0.745, 0.703, 0.725, 0.560, 0.683,
(3. 1206)+(0.0047)Thr+(-0.0736)Cit+(-0.0492)Tyr; 0.670, 0.700, 0.7
22, 0.764, 0.722, 0.744, 0.594, 0.706, (3.4706)+(-0.0698)Cit+(-0.
0422)Tyr+(-0.0033)Leu; 0.670, 0.703, 0.672, 0.668, 0.677, 0.734, 0.
626, 0.676, (-1.1998)+(0.0359)Ser+(-0.0073)Gly+(-0.0333)Arg; 0.
670, 0.702, 0.757, 0.798, 0.734, 0.753, 0.697, 0.746, (4.4701)+(-0.
0780)Asn+(-0.0329)Tyr+(-0.0040)Lys; 0.670, 0.700, 0.765, 0.804,
0.695, 0.801, 0.782, 0.771,
(0.6504)+(-0.0085)Ala+(-0.0136)Val+(0.0552)Phe; 0.670, 0.701,
0.773, 0.796, 0.733, 0.806, 0.772, 0.776,
(0.9830)+(-0.0100)Ala+(-0.0207)Arg+(0.0413)Phe; 0.670, 0.704,
0.758, 0.803, 0.738, 0.748, 0.690, 0.745,
(4.4809)+(-0.0762)Asn+(-0.0086)Arg+(-0.0342)Tyr; 0.669, 0.700,
0.749, 0.770, 0.748, 0.7 63, 0.688, 0.742,
(3.4810)+(-0.1136)Asn+(0.0253)Orn+(-0.0150)L eu; 0.669, 0.697,
0.757, 0.780, 0.706, 0.818, 0.754, 0.765, (2.2570)
+(-0.0113)Ala+(-0.0190)Arg+(0.0105)Pro; 0.668, 0.698, 0.732, 0.
773, 0.653, 0.869, 0.687, 0.746, (0.2214)+(0.0209)Ser+(-0.0075)A
la+(-0.0085)Val; 0.668, 0.701, 0.714, 0.755, 0.714, 0.732, 0.593,
0. 698, (3.2818)+(0.0001)Gly+(-0.0713)Cit+(-0.0447)Tyr; 0.668, 0.
703, 0.694, 0.710, 0.628, 0.846, 0.678, 0.716, (-0.0649)+(0.0255)S
er+(-0.0025)Gln+(-0.0093)Ala; 0.668, 0.701, 0.739, 0.784, 0.731,
0.767, 0.616, 0.724, (3.9012)+(-0.0636)Cit+(-0.0350)Tyr+(-0.00
70)Val; 0.667, 0.704, 0.657, 0.707, 0.615, 0.733, 0.558, 0.653,
(-0. 4991)+(0.0281)Ser+(-0.0121)Thr+(-0.0460)Tyr; 0.667, 0.702, 0.6
15, 0.661, 0.594, 0.703, 0.475, 0.608, (0.2513)+(0.0257)Ser+(-0.0
025)Gln+(-0.0533)Tyr; 0.667, 0.698, 0.788, 0.826, 0.767, 0.800, 0.
722, 0.779, (5.1565)+(-0.0882)Asn+(-0.0076)Arg+(-0.0116)Val; 0.
667, 0.699, 0.787, 0.823, 0.761, 0.795, 0.738, 0.779, (4.9413)+(-0.
0995)Asn+(-0.0124)Val+(0.0011)Lys; 0.667, 0.703, 0.622, 0.613, 0.
623, 0.728, 0.566, 0.633, (-2.0771)+(0.0314)Ser+(-0.0282)Lys+(0.
0370)Phe; 0.667, 0.699, 0.728, 0.742, 0.651, 0.797, 0.803, 0.748,
(0. 0729)+(-0.0134)Ala+(0.0085)Pro+(0.0255)Phe; 0.666, 0.700, 0.76
0, 0.784, 0.675, 0.847, 0.811, 0.779, (2.2684)+(-0.0078)Ala+(-0.0
291)Val+(0.0409)Leu; 0.666, 0.698, 0.742, 0.743, 0.750, 0.764, 0.7
06, 0.741, (3.3712)+(-0.0951)Asn+(0.0256)Orn+(-0.0128)Lys; 0.6 65,
0.700, 0.593, 0.649, 0.554, 0.672, 0.468, 0.586, (-0.6777)+(0.0
217)Ser+(0.0049)Pro+(-0.0642)Tyr; 0.665, 0.699, 0.717, 0.770, 0.
653, 0.759, 0.677, 0.715, (2.6975)+(-0.0414)Tyr+(-0.0275)Val+(0.
0346)Leu; 0.665, 0.696, 0.692, 0.677, 0.694, 0.733, 0.700, 0.701,
(1. 6389)+(-0.0168)Arg+(-0.0217)Lys+(0.0367)Ile; 0.664, 0.690, 0.6
62, 0.697, 0.631, 0.683, 0.618, 0.657, (1.8322)+(-0.0214)Arg+(-0.
0607)Tyr+(0.0365)Ile; 0.664, 0.696, 0.728, 0.777, 0.664, 0.800, 0.
680, 0.730, (2.0851)+(-0.0076)Ala+(-0.0411)Tyr+(0.0233)Orn; 0. 664,
0.701, 0.739, 0.772, 0.745, 0.771, 0.617, 0.726, (4.1175)+(-0.
0671)Cit+(-0.0342)Tyr+(-0.0086)Lys; 0.664, 0.694, 0.690, 0.682,
0.739, 0.762, 0.556, 0.685,
(1.3113)+(-0.1091)Cit+(0.0421)Orn+(-0.0173)Leu; 0.664, 0.699,
0.724, 0.765, 0.728, 0.741, 0.596, 0.70 7,
(3.5317)+(-0.0650)Cit+(-0.0065)Arg+(-0.0423)Tyr; 0.664, 0.6 97,
0.648, 0.648, 0.689, 0.738, 0.497, 0.643, (-0.5081)+(0.0262)Se
r+(-0.0723)Cit+(-0.0209)Arg; 0.663, 0.699, 0.745, 0.747, 0.731, 0.
729, 0.783, 0.748, (0.9948)+(-0.1452)Asn+(0.0042)Gln+(0.0190)I le;
0.663, 0.692, 0.750, 0.785, 0.677, 0.827, 0.752, 0.760, (2.3233)
+(-0.0100)Ala+(0.0120)Pro+(-0.0114)Val; 0.663, 0.701, 0.611, 0.
669, 0.573, 0.694, 0.474, 0.603,
(-0.6651)+(0.0203)Ser+(-0.0614)Tyr+(0.0110)Orn; 0.663, 0.702,
0.684, 0.713, 0.665, 0.810, 0.552, 0. 685,
(0.3394)+(0.0258)Ser+(-0.0086)Val+(-0.0166)Lys; 0.662, 0. 698,
0.756, 0.792, 0.694, 0.843, 0.726, 0.764, (1.8353)+(-0.0076)A
la+(-0.0121)Val+(0.0269)Orn; 0.662, 0.700, 0.755, 0.772, 0.741, 0.
710, 0.772, 0.749, (0.7250)+(-0.1522)Asn+(0.0045)Gln+(0.0268)P he;
0.661, 0.694, 0.791, 0.827, 0.768, 0.781, 0.750, 0.782, (2.3138)
+(-0.1314)Asn+(0.0051)Gln+(-0.0117)Leu; 0.661, 0.693, 0.722, 0.
735, 0.723, 0.695, 0.705, 0.714, (1.6206)+(-0.1332)Asn+(0.0025)G
ly+(0.0324)Phe; 0.661, 0.696, 0.774, 0.835, 0.711, 0.842, 0.699, 0.
771, (3.1741)+(-0.0054)Ala+(-0.0274)Tyr+(-0.0067)Val; 0.661, 0.
697, 0.685, 0.751, 0.654, 0.661, 0.595, 0.665, (1.1401)+(-0.0212)A
rg+(-0.0698)Tyr+(0.0586)Phe; 0.661, 0.697, 0.723, 0.714, 0.723, 0.
699, 0.767, 0.726, (1.7288)+(-0.1267)Asn+(0.0164)Ile+(0.0178)P he;
0.661, 0.697, 0.726, 0.727, 0.731, 0.700, 0.733, 0.723, (1.8171)
+(-0.1311)Asn+(0.0129)Orn+(0.0242)Phe; 0.661, 0.696, 0.784, 0.8 10,
0.763, 0.780, 0.760, 0.778, (2.2172)+(-0.1171)Asn+(0.0053)Gl
n+(-0.0105)Lys; 0.661, 0.700, 0.695, 0.718, 0.616, 0.836, 0.700, 0.
718, (-1.0863)+(0.0206)Ser+(-0.0105)Ala+(0.0099)Orn; 0.660, 0. 696,
0.733, 0.733, 0.731, 0.727, 0.741, 0.733, (2.5602)+(-0.1007)A
sn+(-0.0152)Arg+(0.0236)Ile; 0.660, 0.694, 0.717, 0.709, 0.714, 0.
713, 0.746, 0.721, (2.0377)+(-0.1242)Asn+(0.0102)Orn+(0.0175)I le;
0.660, 0.687, 0.617, 0.665, 0.558, 0.611, 0.616, 0.612, (-0.133
1)+(-0.0822)Tyr+(0.0257)Ile+(0.0356)Phe; 0.660, 0.699, 0.774, 0.
827, 0.726, 0.826, 0.698, 0.769,
(3.3584)+(-0.0060)Ala+(-0.0144)Arg+(-0.0289)Tyr; 0.660, 0.685,
0.647, 0.685, 0.587, 0.648, 0.670, 0.648,
(1.2520)+(-0.0023)Gly+(-0.0705)Tyr+(0.0331)Ile; 0.659, 0.687,
0.626, 0.666, 0.569, 0.643, 0.624, 0.625,
(0.7200)+(0.0002)Pro+(-0.0704)Tyr+(0.0334)Ile; 0.659, 0.699, 0.638,
0.705, 0.599, 0.720, 0.480, 0.626,
(-0.1000)+(0.0213)Ser+(-0.0523)Tyr+(-0.00 56)Leu; 0.659, 0.695,
0.722, 0.735, 0.648, 0.812, 0.778, 0.743, (0.7
227)+(-0.0128)Ala+(0.0088)Pro+(0.0109)Orn; 0.659, 0.688, 0.690,
0.667, 0.675, 0.745, 0.742, 0.707, (1.2211)+(-0.0044)Pro+(-0.026
2)Lys+(0.0427)Ile; 0.658, 0.692, 0.704, 0.703, 0.698, 0.707, 0.717,
0.707, (1.8408)+(-0.1259)Asn+(0.0025)Gly+(0.0229)Ile; 0.658, 0.
693, 0.691, 0.731, 0.678, 0.741, 0.579, 0.682, (2.6442)+(-0.0469)T
yr+(0.0291)Orn+(-0.0161)Lys; 0.658, 0.690, 0.696, 0.764, 0.645, 0.
722, 0.603, 0.683, (2.7831)+(0.0084)Pro+(-0.0475)Tyr+(-0.0126) Val;
0.658, 0.698, 0.741, 0.756, 0.672, 0.809, 0.797, 0.759, (-0.164
0)+(-0.0116)Ala+(0.0115)Orn+(0.0280)Phe; 0.658, 0.686, 0.625, 0.
664, 0.570, 0.643, 0.626, 0.626,
(0.8474)+(-0.0003)Gln+(-0.0698)Tyr+(0.0339)Ile; 0.658, 0.689,
0.678, 0.647, 0.669, 0.733, 0.739, 0. 697,
(1.0995)+(-0.0002)Gly+(-0.0265)Lys+(0.0363)Ile; 0.658, 0. 692,
0.680, 0.653, 0.668, 0.731, 0.741, 0.698, (0.7503)+(0.0008)Gl
n+(-0.0273)Lys+(0.0361)Ile; 0.657, 0.689, 0.743, 0.759, 0.669, 0.
816,
0.801, 0.761, (1.3334)+(-0.0013)Gly+(-0.0124)Ala+(0.0097)Pro;
0.657, 0.696, 0.710, 0.742, 0.627, 0.856, 0.694, 0.730, (-0.663
6)+(0.0216)Ser+(-0.0094)Ala+(-0.0029)Leu; 0.657, 0.692, 0.754,
0.769, 0.746, 0.742, 0.743, 0.750, (1.4785)+(-0.1437)Asn+(0.004
1)Gln+(0.0121)Orn; 0.657, 0.689, 0.686, 0.657, 0.674, 0.735, 0.751,
0.704, (1.1759)+(-0.0033)Thr+(-0.0252)Lys+(0.0370)Ile; 0.657,
0.685, 0.618, 0.657, 0.564, 0.645, 0.606, 0.618, (0.5682)+(-0.071
8)Tyr+(0.0074)Orn+(0.0311)Ile; 0.657, 0.689, 0.746, 0.764, 0.672,
0.815, 0.802, 0.763, (1.5255)+(-0.0063)Thr+(-0.0119)Ala+(0.010
4)Pro; 0.657, 0.693, 0.600, 0.562, 0.659, 0.712, 0.494, 0.607,
(-1.8 027)+(0.0200)Ser+(-0.1129)Cit+(0.0254)Orn; 0.657, 0.690,
0.736, 0.754, 0.660, 0.815, 0.788, 0.754,
(1.1851)+(-0.0002)Gln+(-0.012 4)Ala+(0.0097)Pro; 0.657, 0.694,
0.674, 0.650, 0.743, 0.737, 0.552, 0.670,
(0.8893)+(-0.0969)Cit+(-0.0171)Arg+(0.0349)Orn; 0.656, 0.694,
0.774, 0.824, 0.719, 0.840, 0.710, 0.773, (3.3375)+(-0.005
9)Ala+(-0.0269)Tyr+(-0.0077)Lys; 0.656, 0.684, 0.637, 0.675, 0.5
81, 0.649, 0.645, 0.637, (0.8708)+(-0.0031)Thr+(-0.0675)Tyr+(0.
0342)Ile; 0.656, 0.686, 0.720, 0.732, 0.721, 0.725, 0.682, 0.715,
(2. 4533)+(-0.1245)Asn+(0.0014)Gly+(0.0166)Orn; 0.656, 0.685, 0.68
1, 0.735, 0.672, 0.721, 0.528, 0.664, (2.3664)+(-0.0236)Arg+(-0.0
538)Tyr+(0.0257)Orn; 0.656, 0.695, 0.681, 0.723, 0.693, 0.786, 0.4
69, 0.668, (-0.3477)+(0.0254)Ser+(-0.0309)Arg+(-0.0124)Leu; 0. 656,
0.694, 0.746, 0.760, 0.753, 0.709, 0.722, 0.736, (2.3290)+(-0.
1089)Asn+(-0.0146)Arg+(0.0332)Phe; 0.655, 0.700, 0.628, 0.626, 0.
638, 0.754, 0.521, 0.635, (-0.8227)+(0.0273)Ser+(0.0163)Orn+(-0.
0256)Lys; 0.655, 0.691, 0.665, 0.630, 0.664, 0.726, 0.712, 0.683,
(0. 8771)+(0.0133)Orn+(-0.0283)Lys+(0.0330)Ile; 0.655, 0.690, 0.67
5, 0.644, 0.666, 0.729, 0.736, 0.694, (0.8061)+(-0.0273)Lys+(0.03
44)Ile+(0.0090)Phe; 0.655, 0.689, 0.716, 0.709, 0.711, 0.703, 0.75
1, 0.719, (2.1464)+(-0.1254)Asn+(0.0029)Thr+(0.0204)Ile; 0.654,
0.688, 0.764, 0.798, 0.695, 0.807, 0.785, 0.771, (0.2354)+(-0.009
9)Ala+(-0.0119)Leu+(0.0455)Phe; 0.654, 0.688, 0.744, 0.771, 0.67 3,
0.820, 0.766, 0.758, (1.5477)+(-0.0115)Ala+(0.0106)Pro+(-0.0
079)Leu; 0.654, 0.694, 0.739, 0.750, 0.755, 0.744, 0.675, 0.731,
(3. 0146)+(-0.1030)Asn+(-0.0164)Arg+(0.0212)Orn; 0.654, 0.690, 0.7
92, 0.833, 0.741, 0.838, 0.756, 0.792, (1.5232)+(0.0025)Gln+(-0.0
085)Ala+(-0.0213)Arg; 0.654, 0.689, 0.759, 0.778, 0.687, 0.815, 0.
816, 0.774, (0.2429)+(-0.0009)Gly+(-0.0111)Ala+(0.0322)Phe; 0. 653,
0.688, 0.726, 0.763, 0.722, 0.800, 0.584, 0.717, (2.3817)+(-0.
0266)Arg+(-0.0168)Val+(0.0320)Orn; 0.653, 0.684, 0.629, 0.697, 0.
581, 0.609, 0.561, 0.612, (-0.0701)+(-0.0807)Tyr+(0.0119)Orn+(0.
0481)Phe; 0.653, 0.685, 0.628, 0.697, 0.574, 0.602, 0.578, 0.613,
(0. 1053)+(0.0032)Pro+(-0.0814)Tyr+(0.0497)Phe; 0.653, 0.690, 0.75
4, 0.774, 0.682, 0.814, 0.807, 0.769, (0.1270)+(-0.0002)Gln+(-0.0
112)Ala+(0.0330)Phe; 0.653, 0.689, 0.761, 0.783, 0.689, 0.811, 0.8
19, 0.776, (0.3087)+(-0.0049)Thr+(-0.0107)Ala+(0.0348)Phe; 0.6 53,
0.697, 0.659, 0.681, 0.656, 0.759, 0.536, 0.658, (-1.3617)+(0.0
325)Ser+(-0.0144)Thr+(-0.0254)Arg; 0.653, 0.682, 0.667, 0.682, 0.
676, 0.756, 0.541, 0.664, (0.4470)+(0.0218)Ser+(-0.0760)Cit+(-0.
0106)Val; 0.652, 0.686, 0.727, 0.733, 0.727, 0.722, 0.712, 0.723,
(2. 5793)+(-0.1218)Asn+(0.0004)Pro+(0.0166)Orn; 0.652, 0.690, 0.58
8, 0.573, 0.609, 0.703, 0.498, 0.596, (-2.7706)+(0.0280)Ser+(-0.0
386)Arg+(0.0237)Ile; 0.652, 0.687, 0.760, 0.824, 0.679, 0.823, 0.7
13, 0.760, (1.9241)+(0.0017)Gln+(-0.0071)Ala+(-0.0363)Tyr; 0.6 52,
0.687, 0.777, 0.812, 0.764, 0.760, 0.726, 0.766, (1.8410)+(-0.1
232)Asn+(0.0058)Gln+(-0.0181)Arg; 0.652, 0.688, 0.723, 0.718, 0.
713, 0.714, 0.765, 0.728, (2.1977)+(-0.1179)Asn+(-0.0018)Pro+(0.
0237)Ile; 0.652, 0.685, 0.764, 0.791, 0.746, 0.741, 0.745, 0.756,
(1. 5790)+(-0.1410)Asn+(0.0007)Gly+(0.0046)Gln; 0.651, 0.693, 0.68
4, 0.653, 0.732, 0.739, 0.624, 0.687, (0.8315)+(-0.0118)Thr+(-0.1
077)Cit+(0.0391)Orn; 0.651, 0.693, 0.629, 0.630, 0.631, 0.752, 0.5
30, 0.636, (-0.7616)+(0.0289)Ser+(0.0024)Pro+(-0.0238)Lys; 0.6 51,
0.679, 0.633, 0.610, 0.661, 0.696, 0.591, 0.639, (-1.1438)+(0.0
291)Ser+(-0.0052)Gly+(-0.0870)Cit; 0.651, 0.690, 0.793, 0.828, 0.
752, 0.851, 0.744, 0.794,
(3.1003)+(-0.0070)Ala+(-0.0125)Arg+(-0.0076)Lys; 0.650, 0.681,
0.695, 0.710, 0.650, 0.759, 0.702, 0.705,
(-0.0269)+(0.0302)Ser+(-0.0090)Gly+(-0.0151)Val; 0.650, 0.694,
0.632, 0.635, 0.638, 0.757, 0.523, 0.638,
(-0.1023)+(0.0307)Ser+(-0.0017)Gln+(-0.0214)Lys; 0.650, 0.686,
0.725, 0.732, 0.727, 0.6 86, 0.733, 0.719,
(1.9238)+(-0.1357)Asn+(0.0047)Thr+(0.0287)Ph e; 0.650, 0.686,
0.732, 0.739, 0.733, 0.691, 0.744, 0.727,
(1.9784)+(-0.1262)Asn+(0.0003)Pro+(0.0293)Phe; 0.649, 0.688, 0.793,
0.83 2, 0.730, 0.860, 0.773, 0.799,
(1.9157)+(0.0022)Gln+(-0.0077)Ala +(-0.0128)Lys; 0.649, 0.684,
0.764, 0.787, 0.746, 0.736, 0.758, 0.7 57,
(1.5901)+(-0.1407)Asn+(0.0047)Gln+(0.0007)Pro; 0.649, 0.69 6,
0.657, 0.667, 0.643, 0.771, 0.581, 0.665, (-0.6144)+(0.0325)Ser
+(-0.0110)Thr+(-0.0182)Lys; 0.649, 0.681, 0.760, 0.794, 0.749, 0.
754, 0.700, 0.749, (3.6586)+(-0.1046)Asn+(0.0012)Gly+(-0.0098)Leu;
0.649, 0.681, 0.643, 0.716, 0.589, 0.609, 0.588, 0.626, (0.178
7)+(-0.0000)Gln+(-0.0781)Tyr+(0.0525)Phe; 0.649, 0.686, 0.725,
0.732, 0.727, 0.722, 0.706, 0.722, (2.5807)+(-0.1257)Asn+(0.002
3)Thr+(0.0157)Orn; 0.649, 0.677, 0.646, 0.651, 0.676, 0.730, 0.511,
0.642, (-0.3162)+(0.0223)Ser+(-0.0859)Cit+(-0.0104)Leu; 0.649,
0.685, 0.761, 0.783, 0.748, 0.736, 0.746, 0.754, (1.6120)+(-0.146
3)Asn+(0.0045)Gln+(0.0033)Thr; 0.649, 0.684, 0.789, 0.823, 0.744,
0.841, 0.757, 0.791, (2.5406)+(-0.0004)Gly+(-0.0080)Ala+(-0.01
73)Arg; 0.649, 0.684, 0.750, 0.762, 0.745, 0.751, 0.728, 0.747,
(3.6 181)+(-0.0921)Asn+(0.0030)Pro+(-0.0094)Lys; 0.649, 0.682, 0.76
8, 0.822, 0.701, 0.812, 0.733, 0.767, (3.0178)+(-0.0019)Gly+(-0.0
066)Ala+(-0.0346)Tyr; 0.649, 0.681, 0.666, 0.733, 0.611, 0.612, 0.
641, 0.649, (0.7056)+(-0.0025)Gly+(-0.0786)Tyr+(0.0525)Phe; 0. 648,
0.688, 0.786, 0.814, 0.734, 0.854, 0.772, 0.794, (2.6655)+(-0.
0077)Ala+(-0.0118)Lys+(0.0030)Leu; 0.648, 0.685, 0.755, 0.785, 0.
751, 0.751, 0.690, 0.744, (3.7436)+(-0.1170)Asn+(0.0075)Thr+(-0.
0113)Leu; 0.648, 0.686, 0.780, 0.818, 0.737, 0.842, 0.728, 0.781,
(2. 3527)+(0.0036)Thr+(-0.0084)Ala+(-0.0196)Arg; 0.648, 0.684, 0.7
98, 0.848, 0.751, 0.857, 0.717, 0.793, (3.3069)+(-0.0059)Ala+(-0.
0157)Arg+(-0.0081)Val; 0.648, 0.680, 0.750, 0.778, 0.739, 0.738, 0.
706, 0.740, (3.7264)+(-0.1055)Asn+(0.0044)Pro+(-0.0131)Leu; 0. 647,
0.691, 0.641, 0.649, 0.638, 0.763, 0.535, 0.646, (-0.5867)+(0.
0285)Ser+(-0.0225)Lys+(-0.0003)Leu; 0.647, 0.681, 0.571, 0.527,
0.613, 0.675, 0.525, 0.585,
(-2.4726)+(0.0230)Ser+(-0.1000)Cit+(0.0226)Ile; 0.647, 0.686,
0.731, 0.746, 0.687, 0.798, 0.734, 0.741,
(2.6236)+(-0.0298)Val+(-0.0142)Lys+(0.0398)Leu; 0.647, 0.686,
0.748, 0.809, 0.677, 0.817, 0.685, 0.747,
(2.5029)+(0.0031)Thr+(-0.0070)Ala+(-0.0362)Tyr; 0.647, 0.689,
0.613, 0.624, 0.638, 0.711, 0.464, 0.609,
(-2.4918)+(0.0275)Ser+(-0.0369)Arg+(0.0181)Phe; 0.647, 0.681,
0.647, 0.719, 0.592, 0.610, 0.596, 0.629,
(0.2123)+(-0.0010)Thr+(-0.0772)Tyr+(0.0525)Phe; 0.647, 0.683,
0.676, 0.745, 0.644, 0.719, 0.530, 0.660,
(1.7456)+(-0.0545)Tyr+(0.0227)Orn+(-0.0110)Leu; 0.647, 0.684,
0.731, 0.806, 0.680, 0.761, 0.614, 0.71 5,
(2.2816)+(0.0013)Gln+(-0.0412)Tyr+(-0.0103)Val; 0.646, 0.68 2,
0.681, 0.742, 0.659, 0.697, 0.556, 0.663, (2.6606)+(-0.0199)Arg
+(0.0059)Pro+(-0.0535)Tyr; 0.646, 0.685, 0.793, 0.822, 0.740, 0.8
53, 0.780, 0.799, (2.8889)+(-0.0009)Gly+(-0.0074)Ala+(-0.0107)Lys;
0.646, 0.683, 0.750, 0.817, 0.700, 0.758, 0.670, 0.736, (3.404
5)+(-0.0027)Gly+(-0.0396)Tyr+(-0.0099)Val; 0.646, 0.685, 0.764,
0.785, 0.761, 0.765, 0.713, 0.756, (3.9062)+(-0.0829)Asn+(-0.008
7)Arg+(-0.0068)Lys; 0.645, 0.684, 0.792, 0.831, 0.747, 0.848, 0.73
9, 0.791, (2.6329)+(-0.0076)Ala+(-0.0173)Arg+(-0.0027)Leu; 0.6 45,
0.685, 0.750, 0.817, 0.722, 0.793, 0.598, 0.732, (3.6600)+(-0.0
161)Arg+(-0.0321)Tyr+(-0.0092)Val; 0.645, 0.687, 0.795, 0.839, 0.
739, 0.871, 0.740, 0.797,
(3.0632)+(-0.0062)Ala+(-0.0066)Val+(-0.0074)Lys; 0.645, 0.685,
0.758, 0.816, 0.686, 0.821, 0.708, 0.758,
(2.6269)+(-0.0068)Ala+(-0.0338)Tyr+(0.0001)Leu; 0.645, 0.683,
0.752, 0.773, 0.746, 0.760, 0.704, 0.746,
(3.5770)+(-0.0931)Asn+(0.0013)Gly+(-0.0083)Lys; 0.645, 0.684,
0.623, 0.640, 0.649, 0.73 5, 0.447, 0.618,
(-1.6470)+(0.0265)Ser+(-0.0346)Arg+(0.0009)Pr o; 0.645, 0.685,
0.782, 0.816, 0.728, 0.855, 0.749, 0.787,
(2.6443)+(0.0036)Thr+(-0.0076)Ala+(-0.0121)Lys; 0.645, 0.682,
0.755, 0.7 72, 0.691, 0.827, 0.793, 0.771,
(1.2016)+(-0.0075)Thr+(-0.0097)A la+(0.0206)Orn; 0.644, 0.677,
0.753, 0.768, 0.687, 0.832, 0.793, 0. 770,
(1.1321)+(-0.0018)Gly+(-0.0103)Ala+(0.0166)Orn; 0.644, 0. 686,
0.618, 0.628, 0.649, 0.731, 0.447, 0.614, (-0.9345)+(0.0290)S
er+(-0.0020)Gln+(-0.0315)Arg; 0.644, 0.677, 0.724, 0.745, 0.717,
0.710, 0.691, 0.716, (2.7479)+(-0.1177)Asn+(0.0018)Gly+(0.002
0)Pro; 0.644, 0.677, 0.603, 0.583, 0.647, 0.699, 0.493, 0.605,
(-0.5 312)+(0.0259)Ser+(-0.0023)Gln+(-0.0876)Cit; 0.644, 0.687,
0.72 2, 0.797, 0.676, 0.756, 0.596, 0.706,
(2.7471)+(0.0021)Thr+(-0.04 07)Tyr+(-0.0102)Val; 0.644, 0.682,
0.746, 0.775, 0.748, 0.745, 0.6 64, 0.733,
(3.2769)+(-0.0985)Asn+(0.0019)Gly+(-0.0127)Arg; 0.6 43, 0.687,
0.719, 0.746, 0.706, 0.796, 0.620, 0.717, (2.1246)+(-0.0
131)Val+(0.0301)Orn+(-0.0147)Lys; 0.643, 0.679, 0.790, 0.844, 0.
712, 0.870, 0.750, 0.794, (1.9236)+(0.0011)Gln+(-0.0071)Ala+(-0.
0091)Val; 0.643, 0.676, 0.633, 0.651, 0.580, 0.748, 0.610, 0.647,
(-0.7525)+(0.0187)Ser+(-0.0322)Val+(0.0328)Leu; 0.643, 0.678, 0.
726, 0.748, 0.722, 0.715, 0.681, 0.716, (2.8137)+(-0.1251)Asn+(0.
0014)Gly+(0.0051)Thr; 0.643, 0.680, 0.693, 0.743, 0.664, 0.720, 0.
601, 0.682, (2.8587)+(0.0057)Pro+(-0.0480)Tyr+(-0.0123)Lys; 0. 642,
0.679, 0.766, 0.792, 0.757, 0.759, 0.719, 0.757, (4.0030)+(-0.
0908)Asn+(-0.0056)Lys+(-0.0066)Leu; 0.642, 0.675, 0.795, 0.842,
0.726, 0.858, 0.769, 0.799,
(2.6892)+(-0.0015)Gly+(-0.0068)Ala+(-0.0089)Val; 0.642, 0.681,
0.743, 0.762, 0.675, 0.834, 0.767, 0.75 9,
(0.9937)+(-0.0004)Gln+(-0.0103)Ala+(0.0164)Orn; 0.642, 0.67 6,
0.677, 0.701, 0.623, 0.758, 0.669, 0.688, (0.6592)+(-0.0344)Val
+(0.0218)Orn+(0.0318)Leu; 0.642, 0.682, 0.727, 0.783, 0.710, 0.74
8, 0.598, 0.710, (3.3389)+(-0.0133)Arg+(-0.0381)Tyr+(-0.0078)L ys;
0.641, 0.686, 0.625, 0.638, 0.655, 0.741, 0.445, 0.620, (-1.725
0)+(0.0257)Ser+(-0.0355)Arg+(0.0065)Orn; 0.641, 0.674, 0.617, 0.
568, 0.676, 0.688, 0.572, 0.626, (-0.5498)+(-0.1116)Cit+(0.0266)
Orn+(0.0142)Ile; 0.641, 0.672, 0.593, 0.573, 0.632, 0.667, 0.513,
0. 596, (-2.2208)+(0.0233)Ser+(-0.0974)Cit+(0.0168)Phe; 0.641, 0.
680, 0.746, 0.766, 0.748, 0.731, 0.698, 0.736, (3.3356)+(-0.0975)A
sn+(-0.0131)Arg+(0.0025)Pro; 0.641, 0.673, 0.612, 0.599, 0.649, 0.
696, 0.505, 0.612, (-1.2775)+(0.0227)Ser+(-0.0928)Cit+(-0.000
3)Pro; 0.641, 0.676, 0.653, 0.625, 0.713, 0.719, 0.557, 0.653,
(0.29 02)+(-0.1121)Cit+(-0.0033)Pro+(0.0350)Orn; 0.640, 0.672,
0.701, 0.712, 0.722, 0.751, 0.594, 0.695,
(1.9962)+(-0.0195)Arg+(0.025 5)Orn+(-0.0181)Lys; 0.640, 0.667,
0.704, 0.715, 0.694, 0.754, 0.65 9, 0.705,
(2.4618)+(-0.0642)Cit+(-0.0261)Val+(0.0287)Leu; 0.64 0, 0.678,
0.741, 0.758, 0.739, 0.753, 0.693, 0.736, (3.6877)+(-0.10
41)Asn+(0.0093)Thr+(-0.0106)Lys; 0.639, 0.678, 0.770, 0.803, 0.7
68, 0.761, 0.693, 0.756, (4.1198)+(-0.0885)Asn+(-0.0110)Arg+(-0.
0092)Leu; 0.639, 0.679, 0.751, 0.782, 0.686, 0.836, 0.739, 0.761,
(1. 1714)+(-0.0094)Ala+(0.0192)Orn+(-0.0076)Leu; 0.639, 0.678, 0.7
16, 0.789, 0.687, 0.736, 0.569, 0.695, (1.7627)+(0.0029)Gln+(-0.0
230)Arg+(-0.0490)Tyr; 0.638, 0.675, 0.736, 0.747, 0.753, 0.790, 0.
636, 0.731, (1.9404)+(0.0036)Gln+(-0.0815)Cit+(-0.0173)Lys; 0. 638,
0.678, 0.725, 0.786, 0.688, 0.760, 0.616, 0.713, (2.1046)+(0.0
025)Gln+(-0.0429)Tyr+(-0.0134)Lys; 0.638, 0.671, 0.654, 0.630, 0.
696, 0.689, 0.606, 0.655, (0.6815)+(-0.0762)Cit+(-0.0162)Arg+(0.
0238)Ile; 0.638, 0.670, 0.630, 0.598, 0.694, 0.698, 0.534, 0.631,
(-0.1067)+(0.0008)Gly+(-0.1123)Cit+(0.0316)Orn; 0.638, 0.676, 0.
716, 0.724, 0.746, 0.777, 0.586, 0.708, (2.9874)+(0.0017)Gly+(-0.
0766)Cit+(-0.0144)Lys; 0.637, 0.676, 0.743, 0.762, 0.754, 0.790, 0.
634, 0.735, (3.6206)+(-0.0661)Cit+(-0.0073)Val+(-0.0094)Lys; 0.
637, 0.670, 0.664, 0.636, 0.685, 0.688, 0.676, 0.671, (0.5203)+(-0.
0087)Thr+(-0.0861)Cit+(0.0243)Ile; 0.637, 0.675, 0.706, 0.698, 0.
737, 0.739, 0.640, 0.704, (1.8805)+(-0.0786)Cit+(-0.0192)Lys+(0.
0413)Phe; 0.637, 0.679, 0.786, 0.837, 0.714, 0.868, 0.742, 0.790,
(2. 3947)+(0.0002)Thr+(-0.0069)Ala+(-0.0089)Val; 0.637, 0.679, 0.7
40, 0.802, 0.705, 0.785, 0.618, 0.728, (3.3349)+(-0.0334)Tyr+(-0.
0079)Val+(-0.0069)Lys; 0.637, 0.674, 0.718, 0.717, 0.747, 0.765, 0.
624, 0.713, (3.0730)+(-0.0746)Cit+(0.0026)Pro+(-0.0151)Lys; 0. 637,
0.675, 0.729, 0.743, 0.729, 0.708, 0.711, 0.723, (2.8856)+(-0.
1236)Asn+(0.0051)Thr+(0.0012)Pro; 0.637, 0.677, 0.673, 0.748, 0.
629, 0.696, 0.552, 0.656, (2.1275)+(0.0066)Pro+(-0.0554)Tyr+(-0.
0106)Leu; 0.636, 0.673, 0.734, 0.783, 0.714, 0.739, 0.643, 0.720,
(1. 2547)+(-0.0239)Arg+(-0.0179)Val+(0.0494)Phe; 0.636, 0.668, 0.7
23, 0.746, 0.751, 0.755, 0.582, 0.709, (2.5804)+(-0.0664)Cit+(-0.
0121)Arg+(-0.0102)Leu; 0.635, 0.679, 0.687, 0.755, 0.677, 0.720, 0.
502, 0.663, (2.6760)+(0.0075)Thr+(-0.0228)Arg+(-0.0510)Tyr; 0. 635,
0.675, 0.681, 0.717, 0.635, 0.785, 0.603, 0.685, (-0.4725)+(0.
0269)Ser+(-0.0153)Thr+(-0.0117)Val; 0.635, 0.674, 0.638, 0.600,
0.705, 0.706, 0.550, 0.640,
(0.4236)+(-0.0010)Gln+(-0.1102)Cit+(0.0336)Orn; 0.635, 0.671,
0.727, 0.760, 0.696, 0.748, 0.690, 0.724,
(1.1048)+(-0.0147)Val+(-0.0140)Lys+(0.0489)Phe; 0.635, 0.672,
0.620, 0.654, 0.581, 0.693, 0.562, 0.622,
(-2.1273)+(0.0193)Ser+(-0.0196)Val+(0.0411)Phe; 0.635, 0.676,
0.565, 0.522, 0.534, 0.66 6, 0.668, 0.598,
(-3.9146)+(0.0361)Ser+(-0.0293)Thr+(0.0273)Il e; 0.634, 0.670,
0.623, 0.691, 0.576, 0.657, 0.518, 0.610,
(1.1391)+(0.0037)Pro+(-0.0659)Tyr+(0.0154)Orn; 0.634, 0.670, 0.673,
0.73 8, 0.617, 0.662, 0.623, 0.660,
(2.1797)+(-0.0029)Gly+(0.0050)Pro +(-0.0625)Tyr; 0.634, 0.667,
0.699, 0.717, 0.702, 0.719, 0.632, 0.6 92,
(1.0527)+(-0.0712)Cit+(-0.0157)Val+(0.0466)Phe; 0.634, 0.6 71,
0.730, 0.736, 0.757, 0.775, 0.624, 0.723, (3.2572)+(-0.0732)Ci
t+(-0.0136)Lys+(-0.0014)Leu; 0.634, 0.675, 0.736, 0.761, 0.746, 0.
724, 0.655, 0.721, (3.3851)+(-0.1100)Asn+(0.0094)Thr+(-0.0161)Arg;
0.634, 0.669, 0.734, 0.764, 0.743, 0.770, 0.612, 0.722, (3.237
2)+(-0.0576)Cit+(-0.0109)Arg+(-0.0106)Val; 0.634, 0.674, 0.699,
0.759, 0.675, 0.743, 0.559, 0.684, (2.8790)+(0.0061)Thr+(-0.044
2)Tyr+(-0.0133)Lys; 0.634, 0.672, 0.738, 0.769, 0.734, 0.766, 0.64
1, 0.728, (1.4062)+(0.0027)Gln+(-0.0196)Arg+(-0.0156)Lys; 0.63 4,
0.670, 0.726, 0.732, 0.754, 0.771, 0.622, 0.720, (3.2458)+(-0.07
20)Cit+(-0.0018)Arg+(-0.0138)Lys; 0.633, 0.669, 0.633, 0.597, 0.
696, 0.696, 0.552, 0.635, (-0.1111)+(-0.1114)Cit+(0.0313)Orn+(0.
0025)Phe; 0.633, 0.660, 0.609, 0.578, 0.650, 0.664, 0.567, 0.615,
(-0.4475)+(0.0020)Gly+(-0.0965)Cit+(0.0224)Ile; 0.633, 0.669, 0.
674, 0.730, 0.629, 0.678, 0.613, 0.663, (1.9469)+(-0.0037)Gly+(-0.
0636)Tyr+(0.0205)Orn; 0.633, 0.680, 0.725, 0.793, 0.707, 0.754, 0.
561, 0.704, (3.1195)+(-0.0178)Arg+(-0.0410)Tyr+(-0.0058)Leu; 0.
632, 0.671, 0.729, 0.779, 0.697, 0.745, 0.649, 0.718, (3.3215)+(-0.
0019)Gly+(-0.0415)Tyr+(-0.0107)Lys; 0.632, 0.671, 0.780, 0.810,
0.704, 0.851, 0.808, 0.793,
(1.2611)+(-0.0017)Gly+(0.0009)Gln+(-0.0096)Ala; 0.632, 0.661,
0.629, 0.596, 0.666, 0.669, 0.613, 0.63 6,
(0.0296)+(-0.0922)Cit+(0.0221)Ile+(-0.0031)Phe; 0.632, 0.66 6,
0.685, 0.717, 0.628, 0.707, 0.703, 0.689, (0.2354)+(-0.0313)Val
+(0.0254)Leu+(0.0294)Phe; 0.632, 0.666, 0.723, 0.753, 0.658, 0.75
6, 0.758, 0.731, (1.7106)+(-0.0023)Gly+(-0.0315)Val+(0.0320)Le u;
0.631, 0.673, 0.717, 0.721, 0.749, 0.775, 0.600, 0.711,
(3.1124)+(0.0045)Thr+(-0.0761)Cit+(-0.0160)Lys; 0.631, 0.661,
0.641, 0.6 13, 0.672, 0.680, 0.621, 0.646,
(0.1161)+(-0.0915)Cit+(-0.0047)P ro+(0.0278)Ile; 0.631, 0.673,
0.718, 0.772, 0.690, 0.751, 0.605, 0. 705,
(2.9800)+(-0.0403)Tyr+(-0.0111)Lys+(-0.0005)Leu; 0.631, 0. 661,
0.718, 0.744, 0.725, 0.757, 0.605, 0.708, (2.6635)+(0.0003)Gl
y+(-0.0689)Cit+(-0.0110)Val; 0.631, 0.668, 0.780, 0.809, 0.708, 0.
854,
0.802, 0.793, (1.7446)+(-0.0010)Gly+(-0.0023)Thr+(-0.009 1)Ala;
0.631, 0.660, 0.702, 0.724, 0.705, 0.747, 0.608, 0.696, (2.50
68)+(-0.0687)Cit+(0.0049)Pro+(-0.0131)Val; 0.631, 0.661, 0.723,
0.748, 0.728, 0.757, 0.620, 0.713, (2.7662)+(-0.0009)Thr+(-0.067
9)Cit+(-0.0108)Val; 0.631, 0.674, 0.721, 0.782, 0.699, 0.722, 0.60
4, 0.702, (3.0951)+(-0.0016)Gly+(-0.0175)Arg+(-0.0464)Tyr; 0.6 31,
0.666, 0.660, 0.721, 0.619, 0.688, 0.566, 0.648, (1.4204)+(-0.0
049)Thr+(-0.0581)Tyr+(0.0204)Orn; 0.631, 0.671, 0.780, 0.815, 0.
700, 0.852, 0.803, 0.793, (1.1791)+(0.0011)Gln+(-0.0042)Thr+(-0.
0092)Ala; 0.630, 0.662, 0.717, 0.735, 0.737, 0.743, 0.611, 0.707,
(2. 2249)+(-0.0035)Thr+(-0.0761)Cit+(-0.0102)Leu; 0.630, 0.660, 0.
696, 0.713, 0.719, 0.730, 0.580, 0.685, (1.8697)+(-0.0791)Cit+(0.
0027)Pro+(-0.0130)Leu; 0.630, 0.672, 0.645, 0.629, 0.608, 0.695, 0.
727, 0.665, (-2.1524)+(0.0417)Ser+(-0.0072)Gly+(-0.0229)Thr; 0.
630, 0.672, 0.738, 0.774, 0.703, 0.787, 0.679, 0.736, (2.5885)+(-0.
0203)Arg+(-0.0301)Val+(0.0333)Leu; 0.630, 0.661, 0.711, 0.725, 0.
719, 0.728, 0.646, 0.704, (1.3493)+(-0.0174)Arg+(-0.0174)Lys+(0.
0299)Phe; 0.630, 0.661, 0.627, 0.594, 0.664, 0.664, 0.611, 0.633,
(-0.0980)+(0.0000)Gln+(-0.0927)Cit+(0.0212)Ile; 0.630, 0.662, 0.
723, 0.752, 0.720, 0.766, 0.621, 0.715, (1.9553)+(0.0017)Gln+(-0.
0725)Cit+(-0.0114)Val; 0.630, 0.664, 0.699, 0.729, 0.643, 0.752, 0.
701, 0.706, (1.7076)+(-0.0009)Gln+(-0.0318)Val+(0.0332)Leu; 0. 630,
0.671, 0.777, 0.820, 0.699, 0.856, 0.767, 0.786, (1.2964)+(0.0
007)Gln+(-0.0089)Ala+(-0.0043)Leu; 0.629, 0.664, 0.640, 0.706, 0.
603, 0.667, 0.522, 0.625, (1.3865)+(-0.0004)Gln+(-0.0611)Tyr+(0.
0182)Orn; 0.629, 0.658, 0.683, 0.714, 0.622, 0.735, 0.688, 0.690,
(1. 1178)+(0.0035)Pro+(-0.0321)Val+(0.0301)Leu; 0.629, 0.662, 0.68
8, 0.703, 0.711, 0.695, 0.592, 0.675, (0.6462)+(-0.0820)Cit+(-0.0
192)Leu+(0.0407)Phe; 0.629, 0.659, 0.699, 0.718, 0.726, 0.740, 0.5
65, 0.687, (1.8733)+(0.0007)Gly+(-0.0796)Cit+(-0.0109)Leu; 0.6 28,
0.667, 0.783, 0.817, 0.714, 0.854, 0.785, 0.793, (1.8980)+(-0.0
014)Gly+(-0.0087)Ala+(-0.0041)Leu; 0.628, 0.661, 0.680, 0.685, 0.
708, 0.711, 0.587, 0.673, (1.2728)+(0.0019)Gly+(-0.0067)Thr+(-0.
0836)Cit; 0.627, 0.665, 0.643, 0.717, 0.590, 0.657, 0.547, 0.628,
(1. 4184)+(0.0003)Gln+(0.0047)Pro+(-0.0621)Tyr; 0.627, 0.662, 0.70
3, 0.707, 0.720, 0.714, 0.651, 0.698, (0.7401)+(0.0020)Gln+(-0.00
81)Thr+(-0.0848)Cit; 0.627, 0.664, 0.678, 0.687, 0.720, 0.717, 0.5
38, 0.665, (1.5037)+(0.0015)Gly+(-0.0736)Cit+(-0.0139)Arg; 0.6 26,
0.671, 0.780, 0.819, 0.706, 0.856, 0.777, 0.790, (1.7696)+(-0.0
024)Thr+(-0.0085)Ala+(-0.0034)Leu; 0.625, 0.660, 0.708, 0.731, 0.
724, 0.742, 0.588, 0.696, (1.3034)+(0.0016)Gln+(-0.0822)Cit+(-0.
0120)Leu; 0.625, 0.669, 0.698, 0.782, 0.649, 0.715, 0.566, 0.678,
(1. 7190)+(0.0011)Gln+(-0.0502)Tyr+(-0.0077)Leu; 0.625, 0.659, 0.6
86, 0.690, 0.726, 0.712, 0.573, 0.675, (1.6569)+(-0.0715)Cit+(-0.
0139)Arg+(0.0007)Pro; 0.624, 0.664, 0.715, 0.748, 0.651, 0.757, 0.
727, 0.721, (1.5590)+(-0.0043)Thr+(-0.0307)Val+(0.0320)Leu; 0. 624,
0.668, 0.675, 0.715, 0.637, 0.701, 0.629, 0.671, (-0.3879)+(-0.
0213)Val+(0.0192)Orn+(0.0358)Phe; 0.623, 0.658, 0.717, 0.741, 0.
724, 0.742, 0.622, 0.708, (2.2409)+(-0.0168)Arg+(0.0021)Pro+(-0.
0146)Lys; 0.623, 0.663, 0.705, 0.779, 0.644, 0.684, 0.651, 0.690,
(1. 7768)+(-0.0035)Gly+(0.0016)Gln+(-0.0585)Tyr; 0.623, 0.659, 0.6
88, 0.686, 0.713, 0.705, 0.629, 0.683, (1.4265)+(-0.0061)Thr+(-0.
0812)Cit+(0.0008)Pro; 0.622, 0.654, 0.728, 0.754, 0.733, 0.749, 0.
633, 0.718, (2.4127)+(-0.0004)Gly+(-0.0160)Arg+(-0.0139)Lys; 0.
622, 0.666, 0.723, 0.795, 0.680, 0.712, 0.631, 0.705, (2.7777)+(-0.
0027)Gly+(-0.0491)Tyr+(-0.0071)Leu; 0.621, 0.664, 0.652, 0.722,
0.601, 0.661, 0.569, 0.638,
(1.6786)+(-0.0022)Thr+(0.0050)Pro+(-0.0598)Tyr; 0.621, 0.657,
0.716, 0.743, 0.727, 0.748, 0.602, 0.70 5,
(2.2883)+(0.0033)Thr+(-0.0178)Arg+(-0.0149)Lys; 0.621, 0.66 0,
0.624, 0.651, 0.606, 0.748, 0.504, 0.627,
(0.3633)+(0.0233)Ser+(-0.0030)Gln+(-0.0139)Val; 0.620, 0.664,
0.760, 0.822, 0.733, 0.8 02, 0.620, 0.744,
(1.9317)+(0.0023)Gln+(-0.0241)Arg+(-0.0135)V al; 0.620, 0.661,
0.678, 0.671, 0.688, 0.712, 0.649, 0.680, (0.6381)
+(0.0193)Orn+(-0.0251)Lys+(0.0224)Phe; 0.620, 0.662, 0.720, 0.7 56,
0.680, 0.761, 0.678, 0.719, (1.4259)+(-0.0034)Gly+(-0.0180)V
al(0.0244)Orn; 0.619, 0.658, 0.693, 0.706, 0.724, 0.715, 0.580, 0.
681, (0.8227)+(0.0022)Gln+(-0.0743)Cit+(-0.0169)Arg; 0.618, 0. 648,
0.653, 0.653, 0.690, 0.691, 0.552, 0.646, (0.8148)+(0.0012)Gl
y+(-0.0876)Cit+(-0.0002)Pro; 0.618, 0.663, 0.702, 0.705, 0.707, 0.
747, 0.647, 0.702, (1.4906)+(-0.0051)Thr+(0.0241)Orn+(-0.0210)Lys;
0.618, 0.662, 0.697, 0.704, 0.731, 0.719, 0.590, 0.686, (1.819
2)+(-0.0020)Thr+(-0.0710)Cit+(-0.0123)Arg; 0.618, 0.656, 0.724,
0.775, 0.703, 0.767, 0.600, 0.711, (2.6680)+(-0.0222)Arg+(0.006
1)Pro+(-0.0155)Val; 0.617, 0.666, 0.720, 0.757, 0.683, 0.776, 0.66
1, 0.719, (1.3333)+(-0.0095)Thr+(-0.0166)Val+(0.0278)Orn; 0.61 7,
0.668, 0.696, 0.774, 0.656, 0.712, 0.561, 0.676, (2.1779)+(0.000
0)Thr+(-0.0487)Tyr+(-0.0070)Leu; 0.617, 0.663, 0.634, 0.675, 0.5
98, 0.752, 0.512, 0.634, (-0.7619)+(0.0162)Ser+(-0.0169)Val+(0.
0149)Orn; 0.615, 0.656, 0.752, 0.803, 0.736, 0.797, 0.620, 0.739,
(3. 1437)+(-0.0166)Arg+(-0.0109)Val+(-0.0059)Lys; 0.615, 0.648, 0.
655, 0.655, 0.688, 0.691, 0.558, 0.648, (0.5282)+(0.0010)Gly+(0.0
006)Gln+(-0.0891)Cit; 0.615, 0.648, 0.733, 0.771, 0.735, 0.760, 0.
609, 0.719, (2.5834)+(-0.0169)Arg+(-0.0110)Lys+(-0.0064)Leu; 0.
615, 0.648, 0.666, 0.666, 0.696, 0.692, 0.583, 0.659, (0.6154)+(0.0
009)Gln+(-0.0878)Cit+(-0.0006)Pro; 0.614, 0.659, 0.685, 0.724, 0.
660, 0.760, 0.580, 0.681, (1.5065)+(-0.0016)Gln+(-0.0176)Val+(0.
0249)Orn; 0.614, 0.658, 0.690, 0.761, 0.640, 0.678, 0.618, 0.674,
(2. 3071)+(-0.0030)Gly+(0.0019)Thr+(-0.0571)Tyr; 0.614, 0.658, 0.6
78, 0.760, 0.622, 0.686, 0.574, 0.661, (1.4409)+(0.0009)Gln+(-0.0
018)Thr+(-0.0547)Tyr; 0.614, 0.654, 0.709, 0.750, 0.730, 0.759, 0.
519, 0.689, (1.5995)+(-0.0286)Arg+(0.0234)Orn+(-0.0180)Leu; 0. 614,
0.653, 0.617, 0.659, 0.577, 0.718, 0.515, 0.617, (-0.7319)+(0.
0181)Ser+(0.0042)Pro+(-0.0168)Val; 0.613, 0.659, 0.751, 0.801, 0.
714, 0.810, 0.653, 0.745, (1.9753)+(0.0015)Gln+(-0.0107)Val+(-0.
0123)Lys; 0.613, 0.655, 0.668, 0.668, 0.710, 0.682, 0.572, 0.658,
(0. 8739)+(-0.0733)Cit+(-0.0151)Arg+(0.0179)Phe; 0.613, 0.655, 0.6
74, 0.668, 0.697, 0.679, 0.634, 0.670, (0.7006)+(-0.0071)Thr+(-0.
0833)Cit+(0.0173)Phe; 0.612, 0.640, 0.631, 0.624, 0.671, 0.665, 0.
544, 0.626, (-0.0117)+(0.0016)Gly+(-0.0915)Cit+(0.0143)Phe; 0. 612,
0.651, 0.656, 0.662, 0.626, 0.717, 0.655, 0.665, (-1.2187)+(0.
0302)Ser+(-0.0087)Gly+(-0.0174)Leu; 0.611, 0.653, 0.698, 0.698,
0.705, 0.737, 0.660, 0.700,
(1.6400)+(-0.0018)Gly+(0.0228)Orn+(-0.0225)Lys; 0.611, 0.655,
0.720, 0.759, 0.691, 0.779, 0.635, 0.71 6,
(2.4074)+(0.0053)Pro+(-0.0128)Val+(-0.0115)Lys; 0.611, 0.65 4,
0.685, 0.689, 0.693, 0.738, 0.620, 0.685,
(1.3546)+(0.0000)Pro+(0.0218)Orn+(-0.0227)Lys; 0.611, 0.650, 0.756,
0.812, 0.735, 0.78 7, 0.633, 0.742,
(2.9984)+(-0.0011)Gly+(-0.0199)Arg+(-0.0130)V al; 0.610, 0.653,
0.698, 0.716, 0.704, 0.754, 0.597, 0.693, (1.5613)
+(0.0238)Orn+(-0.0196)Lys+(-0.0078)Leu; 0.609, 0.655, 0.672, 0.
716, 0.632, 0.742, 0.590, 0.670, (0.7196)+(0.0034)Pro+(-0.0189)V
al(0.0201)Orn; 0.609, 0.655, 0.742, 0.800, 0.727, 0.793, 0.579, 0.
725, (2.7162)+(0.0035)Thr+(-0.0226)Arg+(-0.0135)Val; 0.608, 0. 650,
0.710, 0.754, 0.663, 0.692, 0.705, 0.704, (0.4073)+(-0.0019)G
ly+(-0.0190)Val+(0.0387)Phe; 0.608, 0.648, 0.669, 0.670, 0.675, 0.
678, 0.648, 0.668, (0.1708)+(-0.0062)Thr+(-0.0268)Arg+(0.0210)Ile;
0.608, 0.650, 0.758, 0.799, 0.727, 0.797, 0.683, 0.752, (2.827
1)+(-0.0016)Gly+(-0.0108)Val+(-0.0104)Lys; 0.608, 0.653, 0.688,
0.694, 0.692, 0.740, 0.625, 0.688,
(1.1885)+(0.0005)Gln+(0.0212)Orn+(-0.0230)Lys; 0.607, 0.652, 0.742,
0.788, 0.714, 0.803, 0.634, 0.735,
(2.5172)+(0.0013)Thr+(-0.0107)Val+(-0.0114)Lys; 0.607, 0.645,
0.701, 0.704, 0.701, 0.704, 0.692, 0.700, (0.9834)+(-0.000
7)Gly+(-0.0219)Lys+(0.0268)Phe; 0.606, 0.654, 0.716, 0.764, 0.66 3,
0.706, 0.708, 0.710, (0.3654)+(-0.0061)Thr+(-0.0181)Val+(0.0
415)Phe; 0.606, 0.644, 0.660, 0.661, 0.675, 0.680, 0.609, 0.656,
(0. 0297)+(-0.0300)Arg+(-0.0036)Pro+(0.0240)Ile; 0.606, 0.639, 0.6
45, 0.638, 0.680, 0.661, 0.578, 0.639, (0.1051)+(0.0005)Gln+(-0.0
896)Cit+(0.0121)Phe; 0.605, 0.647, 0.710, 0.735, 0.702, 0.716, 0.6
53, 0.701, (0.8139)+(-0.0182)Lys+(-0.0124)Leu+(0.0393)Phe; 0.6 05,
0.648, 0.673, 0.723, 0.622, 0.682, 0.643, 0.667, (-0.0138)+(0.0
031)Pro+(-0.0201)Val+(0.0363)Phe; 0.605, 0.649, 0.696, 0.700, 0.
695, 0.706, 0.676, 0.694, (0.8463)+(0.0001)Pro+(-0.0221)Lys+(0.
0270)Phe; 0.605, 0.649, 0.702, 0.708, 0.699, 0.710, 0.687, 0.701,
(0. 9024)+(-0.0020)Thr+(-0.0212)Lys+(0.0275)Phe; 0.604, 0.654, 0.5
85, 0.575, 0.573, 0.687, 0.561, 0.599, (-1.6078)+(0.0349)Ser+(-0.
0026)Gln+(-0.0209)Thr; 0.604, 0.646, 0.719, 0.771, 0.728, 0.704, 0.
572, 0.694, (0.7574)+(-0.0269)Arg+(-0.0217)Leu+(0.0410)Phe; 0. 604,
0.649, 0.701, 0.708, 0.695, 0.714, 0.685, 0.700, (0.5105)+(0.0
010)Gln+(-0.0228)Lys+(0.0260)Phe; 0.604, 0.649, 0.688, 0.734, 0.
648, 0.690, 0.650, 0.680, (0.4529)+(-0.0011)Gln+(-0.0190)Val+(0.
0416)Phe; 0.603, 0.637, 0.647, 0.641, 0.683, 0.661, 0.576, 0.640,
(0. 3469)+(-0.0879)Cit+(-0.0013)Pro+(0.0149)Phe; 0.602, 0.646, 0.7
36, 0.756, 0.722, 0.755, 0.697, 0.732, (1.3798)+(-0.0018)Gly+(0.0
018)Gln+(-0.0199)Lys; 0.601, 0.640, 0.717, 0.732, 0.710, 0.742, 0.
672, 0.714, (1.8809)+(-0.0011)Gly+(0.0014)Pro+(-0.0189)Lys; 0. 601,
0.655, 0.647, 0.676, 0.611, 0.749, 0.575, 0.653, (-1.4968)+(0.
0299)Ser+(-0.0198)Thr+(-0.0105)Leu; 0.600, 0.648, 0.734, 0.759,
0.717, 0.762, 0.681, 0.730,
(1.2324)+(0.0016)Gln+(-0.0028)Thr+(-0.0189)Lys; 0.600, 0.646,
0.715, 0.738, 0.703, 0.750, 0.655, 0.71 1,
(1.2098)+(0.0013)Gln+(0.0011)Pro+(-0.0202)Lys; 0.600, 0.636, 0.641,
0.642, 0.663, 0.665, 0.577, 0.637,
(-0.1569)+(0.0004)Gly+(-0.0311)Arg+(0.0196)Ile; 0.600, 0.654,
0.586, 0.580, 0.553, 0.66 7, 0.612, 0.603,
(-3.3757)+(0.0338)Ser+(-0.0259)Thr+(0.0165)Ph e; 0.599, 0.638,
0.726, 0.744, 0.720, 0.748, 0.678, 0.722,
(1.9796)+(-0.0011)Gly+(-0.0006)Thr+(-0.0180)Lys; 0.599, 0.639,
0.641, 0. 637, 0.669, 0.670, 0.571, 0.637,
(-0.2096)+(-0.0320)Arg+(0.0066)Orn+(0.0171)Ile; 0.598, 0.637,
0.714, 0.762, 0.660, 0.737, 0.682, 0. 710,
(1.7211)+(-0.0024)Gly+(0.0048)Pro+(-0.0170)Val; 0.598, 0. 635,
0.649, 0.651, 0.668, 0.670, 0.590, 0.645, (-0.3177)+(0.0006)G
ln+(-0.0318)Arg+(0.0189)Ile; 0.597, 0.643, 0.713, 0.731, 0.704, 0.
745, 0.662, 0.711, (1.7506)+(-0.0020)Thr+(0.0017)Pro+(-0.0183)Lys;
0.597, 0.645, 0.696, 0.711, 0.718, 0.724, 0.593, 0.686, (0.608
5)+(-0.0073)Thr+(-0.0267)Arg+(0.0168)Orn; 0.595, 0.635, 0.734,
0.763, 0.724, 0.757, 0.660, 0.726, (2.1797)+(-0.0013)Gly+(-0.015
8)Lys+(-0.0056)Leu; 0.594, 0.644, 0.408, 0.325, 0.446, 0.563, 0.44
0, 0.443, (-2.6256)+(0.0293)Ser+(-0.0060)Gln+(0.0198)Ile; 0.59 3,
0.641, 0.527, 0.472, 0.537, 0.609, 0.593, 0.553, (-1.6391)+(0.03
54)Ser+(-0.0072)Gly+(-0.0043)Gln; 0.593, 0.638, 0.711, 0.743, 0.
702, 0.751, 0.620, 0.704, (1.8560)+(0.0026)Pro+(-0.0165)Lys+(-0.
0071)Leu; 0.593, 0.637, 0.746, 0.800, 0.692, 0.766, 0.698, 0.739,
(1. 7261)+(-0.0025)Gly+(0.0004)Gln+(-0.0151)Val; 0.593, 0.635, 0.6
85, 0.738, 0.641, 0.728, 0.606, 0.678, (1.5239)+(-0.0006)Gln+(0.0
049)Pro+(-0.0168)Val; 0.592, 0.652, 0.592, 0.581, 0.565, 0.697, 0.
601, 0.611, (-2.8016)+(0.0323)Ser+(-0.0261)Thr+(0.0104)Orn; 0. 592,
0.645, 0.730, 0.769, 0.713, 0.767, 0.637, 0.721, (1.3757)+(0.0
015)Gln+(-0.0175)Lys+(-0.0056)Leu; 0.591, 0.636, 0.647, 0.644, 0.
667, 0.668, 0.594, 0.643, (0.0425)+(-0.0305)Arg+(0.0204)Ile+(-0.
0037)Phe; 0.591, 0.635, 0.735, 0.796, 0.735, 0.761, 0.556, 0.712,
(1. 1864)+(0.0021)Gln+(-0.0272)Arg+(-0.0146)Leu; 0.591, 0.644, 0.5
83, 0.576, 0.555, 0.675, 0.595, 0.600, (-2.7073)+(0.0330)Ser+(-0.
0251)Thr+(0.0022)Pro; 0.590, 0.638, 0.726, 0.759, 0.716, 0.762, 0.
632, 0.717, (1.9844)+(-0.0011)Thr+(-0.0157)Lys+(-0.0053)Leu; 0.
590, 0.631, 0.673, 0.694, 0.705, 0.705, 0.529, 0.658, (0.4140)+(-0.
0303)Arg+(-0.0011)Pro+(0.0137)Orn; 0.589, 0.627, 0.672, 0.688, 0.
703, 0.698, 0.548, 0.659, (0.4351)+(-0.0006)Gly+(-0.0303)Arg+(0.
0130)Orn; 0.588, 0.633, 0.502, 0.429, 0.492, 0.580, 0.658, 0.540,
(-3.8716)+(0.0301)Ser+(-0.0081)Gly+(0.0098)Ile; 0.587, 0.635, 0.
707, 0.758, 0.657, 0.736, 0.658, 0.702, (1.6617)+(-0.0065)Thr+(0.
0055)Pro+(-0.0160)Val; 0.587, 0.629, 0.566, 0.530, 0.549, 0.628, 0.
652, 0.590, (-2.9399)+(0.0304)Ser+(-0.0082)Gly+(-0.0026)Pro; 0.
585, 0.634, 0.750, 0.802, 0.699, 0.767, 0.705, 0.743, (2.0426)+(-0.
0018)Gly+(-0.0034)Thr+(-0.0142)Val; 0.585, 0.627, 0.667, 0.688,
0.697, 0.695, 0.530, 0.652,
(0.1680)+(0.0005)Gln+(-0.0312)Arg+(0.0121)Orn; 0.585, 0.627, 0.736,
0.789, 0.740, 0.750, 0.577, 0.714,
(2.1260)+(-0.0009)Gly+(-0.0234)Arg+(-0.0136)Leu; 0.584, 0.623,
0.689, 0.722, 0.706, 0.694, 0.562, 0.671,
(0.2990)+(0.0012)Gln+(-0.0295)Arg+(-0.0002)Pro; 0.584, 0.627,
0.712, 0.748, 0.715, 0.711, 0.614, 0.697,
(0.3627)+(0.0017)Gln+(-0.0053)Thr+(-0.0268)Arg; 0.583, 0.636,
0.740, 0.799, 0.689, 0.773, 0.667, 0.732, (1.5339)+(0.
0006)Gln+(-0.0053)Thr+(-0.0140)Val; 0.583, 0.622, 0.694, 0.726,
0.708, 0.689, 0.586, 0.677,
(0.3474)+(-0.0008)Gly+(0.0013)Gln+(-0.0294)Arg; 0.583, 0.627,
0.709, 0.763, 0.716, 0.734, 0.535, 0.68 7,
(1.8698)+(-0.0251)Arg+(0.0037)Pro+(-0.0161)Leu; 0.582, 0.62 2,
0.702, 0.733, 0.713, 0.700, 0.597, 0.686, (0.9886)+(-0.0001)Gly
+(-0.0037)Thr+(-0.0249)Arg; 0.582, 0.629, 0.729, 0.786, 0.735, 0.
753, 0.551, 0.706, (1.9831)+(-0.0006)Thr+(-0.0235)Arg+(-0.013
3)Leu; 0.581, 0.621, 0.687, 0.716, 0.708, 0.689, 0.566, 0.670,
(0.82 14)+(-0.0004)Gly+(-0.0274)Arg+(0.0001)Pro; 0.579, 0.622,
0.697, 0.727, 0.709, 0.697, 0.593, 0.681,
(0.9313)+(-0.0041)Thr+(-0.025 0)Arg+(0.0007)Pro; 0.579, 0.626,
0.662, 0.680, 0.695, 0.685, 0.531, 0.648,
(0.0884)+(-0.0311)Arg+(0.0117)Orn+(0.0062)Phe; 0.579, 0. 635,
0.565, 0.580, 0.576, 0.699, 0.404, 0.565, (-0.7368)+(0.0244)S
er+(-0.0035)Gln+(-0.0142)Leu; 0.576, 0.625, 0.562, 0.600, 0.548,
0.628, 0.441, 0.554, (-2.8622)+(0.0193)Ser+(-0.0236)Leu+(0.030
1)Phe; 0.575, 0.619, 0.673, 0.698, 0.695, 0.670, 0.559, 0.656,
(0.28 53)+(-0.0001)Gly+(-0.0288)Arg+(0.0108)Phe; 0.575, 0.624,
0.693, 0.719, 0.704, 0.682, 0.606, 0.678,
(0.4214)+(-0.0046)Thr+(-0.026 0)Arg+(0.0128)Phe; 0.574, 0.621,
0.676, 0.704, 0.696, 0.675, 0.560, 0.659,
(-0.0683)+(0.0009)Gln+(-0.0304)Arg+(0.0096)Phe; 0.573, 0.623,
0.544, 0.498, 0.532, 0.616, 0.641, 0.572, (-2.8896)+(0.030
3)Ser+(-0.0084)Gly+(-0.0061)Phe; 0.573, 0.620, 0.675, 0.703, 0.6
97, 0.673, 0.556, 0.657, (0.2802)+(-0.0287)Arg+(-0.0006)Pro+(0.
0117)Phe; 0.570, 0.625, 0.713, 0.749, 0.693, 0.746, 0.637, 0.706,
(0. 6602)+(-0.0129)Thr+(0.0215)Orn+(-0.0178)Leu; 0.569, 0.623, 0.4
56, 0.415, 0.443, 0.597, 0.489, 0.486, (-4.2643)+(0.0205)Ser+(-0.
0060)Pro+(0.0197)Ile; 0.566, 0.627, 0.465, 0.428, 0.491, 0.612, 0.
399, 0.483, (-1.7722)+(0.0270)Ser+(-0.0048)Gln+(-0.0008)Pro; 0.
565, 0.624, 0.435, 0.388, 0.468, 0.572, 0.395, 0.456, (-2.1461)+(0.
0276)Ser+(-0.0052)Gln+(0.0074)Phe; 0.561, 0.616, 0.541, 0.497, 0.
526, 0.597, 0.646, 0.566,
(-3.0559)+(0.0308)Ser+(-0.0082)Gly+(-0.0051)Orn; 0.556, 0.618,
0.637, 0.618, 0.600, 0.638, 0.764, 0.655,
(-0.9160)+(0.0001)Gly+(-0.0160)Thr+(0.0181)Ile; 0.555, 0.618,
0.634, 0.609, 0.605, 0.633, 0.761, 0.652,
(-0.6774)+(-0.0006)Gln+(-0.0152)Thr+(0.0184)Ile; 0.555, 0.617,
0.650, 0.634, 0.612, 0.65 9, 0.766, 0.668,
(-0.8340)+(-0.0148)Thr+(-0.0033)Pro+(0.0223)I le; 0.555, 0.628,
0.449, 0.405, 0.481, 0.599, 0.390, 0.469, (-1.854
2)+(0.0270)Ser+(-0.0050)Gln+(0.0018)Orn; 0.555, 0.618, 0.574, 0.
618, 0.565, 0.680, 0.402, 0.566, (-1.8983)+(0.0182)Ser+(0.0055)O
rn+(-0.0181)Leu; 0.554, 0.608, 0.565, 0.607, 0.552, 0.663, 0.407,
0. 558, (-1.8728)+(0.0189)Ser+(0.0014)Pro+(-0.0180)Leu; 0.553, 0.
606, 0.714, 0.763, 0.684, 0.671, 0.676, 0.698, (-0.0661)+(-0.0103)
Thr+(-0.0212)Leu+(0.0341)Phe; 0.550, 0.626, 0.635, 0.607, 0.606,
0.648, 0.756, 0.654, (-1.0019)+(-0.0170)Thr+(0.0065)Orn+(0.016
1)Ile; 0.549, 0.615, 0.643, 0.624, 0.608, 0.653, 0.764, 0.662,
(-0.5 794)+(-0.0153)Thr+(0.0207)Ile+(-0.0092)Phe; 0.547, 0.601,
0.41 0, 0.361,
0.403, 0.575, 0.439, 0.444, (-3.9086)+(0.0198)Ser+(0.01
64)Ile+(-0.0150)Phe; 0.538, 0.621, 0.688, 0.688, 0.664, 0.693, 0.7
34, 0.695, (-0.4056)+(-0.0007)Gly+(-0.0154)Thr+(0.0122)Orn; 0. 533,
0.621, 0.674, 0.672, 0.656, 0.690, 0.706, 0.681, (-0.2638)+(-0.
0006)Gln+(-0.0151)Thr+(0.0128)Orn; 0.530, 0.584, 0.742, 0.794, 0.
711, 0.728, 0.679, 0.728,
(1.1970)+(-0.0013)Gly+(-0.0079)Thr+(-0.0148)Leu; 0.530, 0.594,
0.701, 0.747, 0.685, 0.716, 0.603, 0.688,
(0.4425)+(-0.0030)Gly+(0.0151)Orn+(-0.0204)Leu; 0.528, 0.582,
0.708, 0.759, 0.674, 0.715, 0.641, 0.697,
(0.9378)+(-0.0101)Thr+(0.0034)Pro+(-0.0167)Leu; 0.528, 0.622,
0.686, 0.692, 0.661, 0.70 0, 0.715, 0.692,
(-0.4550)+(-0.0154)Thr+(-0.0008)Pro+(0.0126)O rn; 0.528, 0.599,
0.466, 0.456, 0.465, 0.591, 0.408, 0.480, (-3.475
5)+(0.0200)Ser+(-0.0027)Pro+(0.0004)Phe; 0.527, 0.589, 0.737, 0.
797, 0.696, 0.742, 0.659, 0.724, (0.7102)+(0.0007)Gln+(-0.0096)I
hr+(-0.0149)Leu; 0.526, 0.621, 0.681, 0.683, 0.655, 0.695, 0.719,
0. 688, (-0.5559)+(-0.0158)Thr+(0.0118)Orn+(0.0015)Phe; 0.526, 0.
590, 0.414, 0.372, 0.404, 0.520, 0.467, 0.441, (-4.2575)+(0.0216)S
er+(-0.0122)Orn+(0.0157)Ile; 0.525, 0.591, 0.706, 0.726, 0.675, 0.
675, 0.739, 0.704, (-0.0943)+(-0.0006)Gly+(0.0001)Gln+(-0.012
6)Thr; 0.524, 0.590, 0.691, 0.745, 0.671, 0.638, 0.631, 0.671,
(-0.2 627)+(-0.0021)Gly+(-0.0233)Leu+(0.0289)Phe; 0.522, 0.596,
0.63 8, 0.694, 0.630, 0.632, 0.512, 0.617,
(-0.9720)+(0.0108)Orn+(-0.0 252)Leu+(0.0272)Phe; 0.519, 0.597,
0.655, 0.701, 0.662, 0.705, 0.4 80, 0.637,
(0.4763)+(-0.0013)Gln+(0.0154)Orn+(-0.0194)Leu; 0.5 18, 0.592,
0.695, 0.711, 0.666, 0.661, 0.739, 0.694, (-0.3335)+(-0.
0004)Gly+(-0.0132)Thr+(0.0052)Phe; 0.516, 0.590, 0.705, 0.726, 0.
674, 0.674, 0.737, 0.703,
(-0.0734)+(-0.0006)Gly+(-0.0126)Thr+(-0.0000)Pro; 0.516, 0.592,
0.469, 0.462, 0.463, 0.587, 0.413, 0.48 1,
(-3.3459)+(0.0204)Ser+(-0.0023)Pro+(-0.0039)Orn; 0.515, 0.5 94,
0.688, 0.705, 0.659, 0.664, 0.722, 0.688, (-0.3432)+(-0.0002)G
ln+(-0.0133)Thr+(0.0059)Phe; 0.514, 0.581, 0.647, 0.712, 0.630, 0.
616, 0.532, 0.622, (-0.7417)+(0.0011)Pro+(-0.0241)Leu+(0.0289)Phe;
0.513, 0.592, 0.700, 0.722, 0.669, 0.678, 0.723, 0.698, (-0.132
4)+(-0.0001)Gln+(-0.0129)Thr+(0.0000)Pro; 0.511, 0.573, 0.707,
0.767, 0.678, 0.696, 0.614, 0.689, (0.7028)+(-0.0024)Gly+(0.001
9)Pro+(-0.0187)Leu; 0.511, 0.590, 0.651, 0.711, 0.641, 0.696, 0.48
0, 0.632, (-0.1366)+(0.0010)Pro+(0.0124)Orn+(-0.0205)Leu; 0.51 0,
0.585, 0.652, 0.706, 0.646, 0.627, 0.542, 0.630, (-0.2737)+(-0.0
010)Gln+(-0.0231)Leu+(0.0313)Phe; 0.509, 0.576, 0.725, 0.786, 0.
698, 0.718, 0.627, 0.707, (0.7731)+(-0.0024)Gly+(0.0001)Gln+(-0.
0173)Leu; 0.505, 0.594, 0.692, 0.710, 0.661, 0.668, 0.725, 0.691,
(-0.4065)+(-0.0134)Thr+(-0.0003)Pro+(0.0060)Phe; 0.501, 0.572, 0.
438, 0.425, 0.434, 0.547, 0.404, 0.452, (-3.5143)+(0.0206)Ser+(-0.
0060)Orn+(-0.0006)Phe 0.868, 0.887, 0.812, 0.814, 0.816, 0.826,
0.787, 0.811, (-0.69
36)+(0.0495)Ser+(-0.2897)Met+(0.1345)Phe+(-0.1458)Trp; 0.867,
0.887, 0.767, 0.742, 0.767, 0.829, 0.787, 0.781,
(1.8981)+(0.0482)Ser+(-0.1330)His+(0.1211)Phe+(-0.1189)Trp; 0.859,
0.880, 0.788, 0.765, 0.799, 0.810, 0.807, 0.795,
(5.5872)+(-0.1248)His+(0.022 7)Thr+(0.1034)Phe+(-0.1281)Trp; 0.859,
0.879, 0.818, 0.810, 0.81 2, 0.831, 0.842, 0.824,
(3.3687)+(0.0094)Gln+(-0.1373)His+(0.10 16)Phe+(-0.1198)Trp; 0.858,
0.873, 0.755, 0.719, 0.757, 0.828, 0.7 95, 0.775,
(3.8688)+(0.0418)Ser+(-0.1122)His+(0.0756)Ile+(-0. 1226)Trp; 0.858,
0.878, 0.802, 0.806, 0.796, 0.815, 0.796, 0.803, (1.
4379)+(0.0468)Ser+(-0.1406)Asn+(0.0925)Phe+(-0.1494)Trp; 0.8 57,
0.876, 0.767, 0.742, 0.776, 0.835, 0.770, 0.781, (-0.3631)+(0.0
601)Ser+(-0.1472)His+(-0.2802)Met+(0.1624)Phe; 0.852, 0.871, 0.
791, 0.760, 0.793, 0.812, 0.852, 0.804, (5.7984)+(-0.1096)His+(0.
0488)Ile+(0.0764)Phe+(-0.1294)Trp; 0.852, 0.870, 0.796, 0.784, 0.
752, 0.839, 0.888, 0.816, (1.7025)+(-0.0640)Val+(-0.3892)Met+(0.
2012)Ile+(0.1197)Phe; 0.852, 0.872, 0.808, 0.798, 0.778, 0.844, 0.
873, 0.823,
(6.6666)+(-0.0432)Val+(-0.1839)Met+(0.1753)Ile+(-0.1070)Trp; 0.852,
0.870, 0.782, 0.766, 0.781, 0.831, 0.788, 0.792,
(1.7250)+(0.0453)Ser+(-0.2355)Met+(0.0785)Ile+(-0.1464)Trp; 0.851,
0.868, 0.777, 0.768, 0.743, 0.797, 0.861, 0.792,
(3.1638)+(-0.0441)Val+(0.1421)Ile+(0.0684)Phe+(-0.1578)Trp; 0.850,
0.867, 0.771, 0.744, 0.784, 0.822, 0.777, 0.782,
(2.8932)+(0.0351)Ser+(-0.0931)Cit+(0.0687)Ile+(-0.1868)Trp; 0.850,
0.866, 0.799, 0.780, 0.793, 0.829, 0.842, 0.811,
(4.9396)+(0.0088)Gln+(-0.1221)His+(0.0645)Ile+(-0.1245)Trp; 0.849,
0.864, 0.776, 0.748, 0.778, 0.82 0, 0.816, 0.791,
(7.0898)+(-0.1081)His+(0.0181)Thr+(0.0644)Ile +(-0.1288)Trp; 0.848,
0.868, 0.770, 0.751, 0.729, 0.872, 0.831, 0.7 96,
(1.0778)+(0.0407)Ser+(-0.0537)Val+(-0.3400)Met+(0.1986)I le; 0.847,
0.868, 0.801, 0.781, 0.810, 0.815, 0.825, 0.808, (5.9199)
+(-0.1114)His+(0.0225)Orn+(0.0932)Phe+(-0.1159)Trp; 0.847, 0. 868,
0.809, 0.812, 0.833, 0.786, 0.764, 0.799, (2.8552)+(0.0368)Th
r+(-0.3410)Met+(0.1295)Phe+(-0.1602)Trp; 0.847, 0.862, 0.797, 0.
791, 0.746, 0.844, 0.886, 0.817,
(5.8480)+(-0.0079)Ala+(-0.0409)Val+(0.1684)Ile+(-0.1273)Trp; 0.847,
0.867, 0.796, 0.784, 0.797, 0.820, 0.809, 0.803,
(5.3440)+(0.0046)Gly+(-0.1128)His+(0.108 8)Phe+(-0.1149)Trp; 0.846,
0.862, 0.782, 0.765, 0.756, 0.825, 0.85 3, 0.800,
(7.1512)+(-0.0690)His+(-0.0299)Val+(0.1370)Ile+(-0. 1095)Trp;
0.846, 0.872, 0.778, 0.777, 0.780, 0.783, 0.771, 0.778, (0.
6197)+(0.0338)Ser+(-0.0124)Lys+(0.0844)Phe+(-0.1674)Trp; 0.8 46,
0.864, 0.788, 0.783, 0.771, 0.792, 0.832, 0.794, (2.9278)+(0.13
67)Ile+(-0.0728)Leu+(0.0636)Phe+(-0.1605)Trp; 0.845, 0.867, 0. 802,
0.786, 0.806, 0.808, 0.832, 0.808, (5.9787)+(-0.1062)His+(0.
0042)Pro+(0.0998)Phe+(-0.1185)Trp; 0.845, 0.864, 0.781, 0.768, 0.
740, 0.868, 0.837, 0.803, (3.9962)+(0.0311)Thr+(-0.0608)Val+(-0.
3891)Met+(0.2090)Ile; 0.845, 0.867, 0.776, 0.782, 0.770, 0.777, 0.
773, 0.776, (0.5852)+(0.0287)Ser+(-0.0073)Val+(0.0843)Phe+(-0.
1708)Trp; 0.845, 0.863, 0.807, 0.793, 0.809, 0.812, 0.833, 0.812,
(6. 1244)+(-0.1061)His+(0.0006)Val+(0.1029)Phe+(-0.1166)Trp; 0.8
45, 0.861, 0.795, 0.776, 0.784, 0.827, 0.844, 0.808, (7.2040)+(-0.0
764)His+(0.1160)Ile+(-0.0374)Leu+(-0.1146)Trp; 0.844, 0.861, 0.
769, 0.754, 0.773, 0.835, 0.754, 0.779, (5.3551)+(0.0386)Ser+(-0.
0976)His+(0.0099)Pro+(-0.1040)Trp; 0.844, 0.862, 0.791, 0.776, 0.
764, 0.835, 0.855, 0.807, (6.2375)+(-0.0640)Cit+(-0.0362)Val+(0.
1489)Ile+(-0.1415)Trp; 0.843, 0.865, 0.812, 0.801, 0.814, 0.818, 0.
835, 0.817,
(6.3125)+(-0.0124)Asn+(-0.1023)His+(0.1040)Phe+(-0.1146)Trp; 0.843,
0.864, 0.818, 0.808, 0.814, 0.830, 0.843, 0.824,
(6.2917)+(-0.1021)His+(-0.0028)Ala+(0.1090)Phe+(-0.1131)Tr p;
0.843, 0.863, 0.803, 0.783, 0.809, 0.810, 0.836, 0.809,
(6.1579)+(-0.1100)His+(0.0102)Leu+(0.0940)Phe+(-0.1216)Trp; 0.843,
0.8 60, 0.777, 0.768, 0.793, 0.797, 0.754, 0.778,
(1.1802)+(0.0372)Ser +(-0.1027)Cit+(0.0987)Phe+(-0.1854)Trp; 0.843,
0.859, 0.809, 0. 805, 0.775, 0.843, 0.867, 0.822,
(5.7424)+(-0.0082)Ala+(0.1610)I le+(-0.0664)Leu+(-0.1350)Trp;
0.842, 0.859, 0.798, 0.791, 0.758, 0.840, 0.870, 0.815,
(6.8143)+(-0.0695)Asn+(-0.0424)Val+(0.154 6)Ile+(-0.1154)Trp;
0.842, 0.866, 0.827, 0.817, 0.834, 0.827, 0.83 8, 0.829,
(6.1768)+(-0.0922)His+(-0.1319)Met+(0.1301)Phe+(-0. 1062)Trp;
0.842, 0.862, 0.780, 0.766, 0.788, 0.847, 0.750, 0.788, (5.
5527)+(0.0338)Ser+(-0.1006)His+(0.0284)Orn+(-0.0991)Trp; 0.8 41,
0.859, 0.783, 0.752, 0.791, 0.822, 0.823, 0.797, (7.2352)+(-0.1
007)His+(0.0228)Orn+(0.0594)Ile+(-0.1205)Trp; 0.841, 0.861, 0. 756,
0.742, 0.720, 0.817, 0.821, 0.775, (2.7061)+(0.0256)Ser+(-0.
0402)Val+(0.1469)Ile+(-0.1474)Trp; 0.841, 0.857, 0.801, 0.779, 0.
791, 0.838, 0.855, 0.816, (7.8145)+(-0.0856)His+(-0.0049)Ala+(0.
0743)Ile+(-0.1162)Trp; 0.840, 0.862, 0.803, 0.788, 0.805, 0.810, 0.
830, 0.808, (5.9127)+(-0.1100)His+(0.0052)Lys+(0.1000)Phe+(-0.
1200)Trp; 0.840, 0.863, 0.781, 0.785, 0.792, 0.786, 0.746, 0.777,
(0. 8091)+(0.0353)Ser+(-0.0284)Arg+(0.0879)Phe+(-0.1742)Trp; 0.8
40, 0.856, 0.799, 0.800, 0.792, 0.852, 0.776, 0.805, (4.6131)+(0.02
88)Ser+(0.0066)Gln+(-0.1102)His+(-0.0990)Trp; 0.840, 0.857, 0. 773,
0.753, 0.784, 0.834, 0.758, 0.782, (5.1823)+(0.0402)Ser+(-0.
1098)His+(0.0120)Val+(-0.1100)Trp; 0.839, 0.857, 0.760, 0.729, 0.
772, 0.825, 0.768, 0.774, (4.7218)+(0.0420)Ser+(-0.1164)His+(0.
0313)Leu+(-0.1150)Trp; 0.839, 0.857, 0.776, 0.763, 0.768, 0.823, 0.
792, 0.787, (2.8672)+(0.0433)Ser+(-0.1153)Asn+(0.0572)Ile+(-0.
1517)Trp; 0.839, 0.862, 0.744, 0.704, 0.745, 0.841, 0.776, 0.767,
(2. 1986)+(0.0514)Ser+(-0.1264)His+(-0.2196)Met+(0.0830)Ile; 0.8
39, 0.861, 0.793, 0.795, 0.778, 0.811, 0.806, 0.798, (0.7514)+(0.03
01)Ser+(-0.0068)Ala+(0.0855)Phe+(-0.1659)Trp; 0.839, 0.857, 0. 769,
0.745, 0.789, 0.808, 0.760, 0.775, (3.7383)+(-0.1490)His+(0.
0429)Thr+(-0.3207)Met+(0.1423)Phe; 0.839, 0.856, 0.798, 0.797, 0.
796, 0.859, 0.764, 0.804, (6.4883)+(0.0411)Ser+(-0.0461)Asn+(-0.
0805)His+(-0.0932)Trp; 0.838, 0.859, 0.763, 0.753, 0.746, 0.814, 0.
791, 0.776, (2.2558)+(0.0259)Ser+(0.1387)Ile+(-0.0624)Leu+(-0.
1558)Trp; 0.838, 0.861, 0.763, 0.761, 0.766, 0.761, 0.763, 0.763,
(0. 3487)+(0.0284)Ser+(0.0015)Pro+(0.0693)Phe+(-0.1812)Trp; 0.83 8,
0.861, 0.767, 0.768, 0.770, 0.766, 0.762, 0.766, (0.4098)+(0.028
5)Ser+(-0.0019)Leu+(0.0727)Phe+(-0.1786)Trp; 0.838, 0.862, 0.8 10,
0.798, 0.812, 0.817, 0.831, 0.815, (6.2982)+(-0.1037)His+(-0.
0050)Arg+(0.1052)Phe+(-0.1153)Trp; 0.838, 0.854, 0.778, 0.753, 0.
777, 0.821, 0.814, 0.791, (6.9014)+(0.0041)Gly+(-0.0990)His+(0.
0678)Ile+(-0.1183)Trp; 0.838, 0.861, 0.774, 0.774, 0.773, 0.775, 0.
776, 0.774, (0.2426)+(0.0325)Ser+(-0.0071)Thr+(0.0745)Phe+(-0.
1744)Trp; 0.838, 0.863, 0.808, 0.801, 0.806, 0.814, 0.830, 0.813,
(6. 1545)+(-0.1031)His+(-0.0154)Tyr+(0.1119)Phe+(-0.1109)Trp; 0.
838, 0.855, 0.804, 0.799, 0.786, 0.826, 0.841, 0.813, (6.0808)+(-0.
0486)Asn+(0.1377)Ile+(-0.0625)Leu+(-0.1335)Trp; 0.837, 0.858,
0.779, 0.771, 0.783, 0.848, 0.740, 0.785,
(6.0131)+(0.0326)Ser+(-0.0989)His+(0.0111)Thr+(-0.1019)Trp; 0.837,
0.857, 0.790, 0.782, 0.820, 0.841, 0.713, 0.789,
(4.6027)+(0.0276)Ser+(-0.1146)Cit+(0.0484)Orn+(-0.1654)Trp; 0.837,
0.859, 0.766, 0.776, 0.760, 0.76 4, 0.753, 0.763,
(0.5464)+(0.0307)Ser+(-0.0422)Tyr+(0.0961)Phe +(-0.1664)Trp; 0.837,
0.854, 0.809, 0.798, 0.807, 0.831, 0.824, 0.8 15,
(5.3566)+(0.0099)Gln+(-0.1282)His+(0.0250)Leu+(-0.1168)I rp; 0.837,
0.855, 0.786, 0.791, 0.787, 0.828, 0.738, 0.786, (3.6885)
+(0.0399)Ser+(0.0129)Pro+(-0.1933)Met+(-0.1350)Trp; 0.836, 0. 853,
0.789, 0.762, 0.789, 0.817, 0.836, 0.801, (7.4907)+(-0.0926)H
is+(0.0006)Pro+(0.0644)Ile+(-0.1201)Trp; 0.836, 0.852, 0.788, 0.
762, 0.788, 0.818, 0.835, 0.801, (7.4632)+(0.0027)Asn+(-0.0934)H
is+(0.0653)Ile+(-0.1202)Trp; 0.836, 0.862, 0.761, 0.756, 0.767, 0.
766, 0.756, 0.761, (0.7507)+(0.0312)Ser+(-0.0017)Gln+(0.0730)P
he+(-0.1768)Trp; 0.836, 0.856, 0.796, 0.795, 0.795, 0.860, 0.757,
0. 802, (6.1565)+(0.0388)Ser+(-0.0829)His+(-0.0539)Met+(-0.092
2)Trp; 0.836, 0.851, 0.736, 0.697, 0.715, 0.844, 0.803, 0.765,
(2.42 33)+(0.0412)Ser+(-0.1423)His+(-0.0074)Ala+(0.0706)Ile; 0.836,
0.855, 0.800, 0.787, 0.789, 0.836, 0.828, 0.810, (6.1927)+(-0.073
2)Cit+(0.1445)Ile+(-0.0583)Leu+(-0.1486)Trp; 0.836, 0.853, 0.7 87,
0.760, 0.788, 0.816, 0.836, 0.800, (7.3754)+(-0.0953)His+(0.0
030)Lys+(0.0633)Ile+(-0.1220)Trp; 0.836, 0.856, 0.806, 0.799, 0.
790, 0.832, 0.838, 0.815, (6.1190)+(-0.1498)Met+(0.1521)Ile+(-0.
0618)Leu+(-0.1243)Trp; 0.836, 0.857, 0.743, 0.725, 0.748, 0.752, 0.
778, 0.750, (0.0321)+(0.0282)Ser+(0.0410)Ile+(0.0467)Phe+(-0.
1924)Trp; 0.835, 0.860, 0.781, 0.770, 0.785, 0.764, 0.812, 0.783,
(0. 8860)+(0.0394)Ser+(-0.0080)Gly+(0.0665)Phe+(-0.1768)Trp; 0.8
35, 0.852, 0.835, 0.842, 0.825, 0.856, 0.823, 0.836, (6.2303)+(-0.0
477)Asn+(0.0114)Gln+(-0.1009)His+(-0.0967)Trp; 0.835, 0.861, 0.
768, 0.767, 0.771, 0.764, 0.766, 0.767, (0.3827)+(0.0289)Ser+(-0.
0037)Orn+(0.0733)Phe+(-0.1799)Trp; 0.835, 0.853, 0.774, 0.758, 0.
750, 0.828, 0.827, 0.791, (2.0142)+(0.0307)Ser+(-0.0093)Ala+(0.
0731)Ile+(-0.1641)Trp; 0.835, 0.854, 0.783, 0.770, 0.788, 0.847, 0.
763, 0.792, (5.6027)+(0.0377)Ser+(-0.0990)His+(0.0199)Tyr+(-0.
1043)Trp; 0.835, 0.854, 0.793, 0.765, 0.798, 0.825, 0.832, 0.805,
(7. 7949)+(-0.0751)His+(-0.0448)Cit+(0.0687)Ile+(-0.1275)Trp; 0.
834, 0.851, 0.785, 0.780, 0.786, 0.848, 0.753, 0.792, (5.9101)+(0.0
370)Ser+(-0.0917)His+(0.0002)Ala+(-0.0962)Trp; 0.834, 0.852, 0.
782, 0.774, 0.783, 0.844, 0.754, 0.789, (5.6352)+(0.0358)Ser+(-0.
0975)His+(0.0063)Lys+(-0.1016)Trp; 0.834, 0.851, 0.810, 0.813, 0.
803, 0.842, 0.791, 0.812, (6.0421)+(0.0082)Gln+(-0.1143)His+(0.
0137)Thr+(-0.1073)Trp; 0.834, 0.855, 0.808, 0.812, 0.815, 0.847, 0.
755, 0.807,
(8.8275)+(-0.0828)His+(0.0309)Thr+(-0.1132)Met+(-0.1022)Trp; 0.834,
0.853, 0.816, 0.812, 0.814, 0.836, 0.818, 0.820,
(5.4534)+(0.0102)Gln+(-0.1239)His+(0.0097)Val+(-0.1123)Trp; 0.834,
0.854, 0.814, 0.819, 0.823, 0.859, 0.750, 0.813, (6.0473)+(0.
0405)Ser+(-0.0809)Asn+(-0.0633)Cit+(-0.1326)Trp; 0.834, 0.854,
0.788, 0.777, 0.800, 0.831, 0.761, 0.792,
(7.8145)+(-0.1004)His+(0.0165)Thr+(0.0288)Orn+(-0.1072)Trp; 0.834,
0.850, 0.738, 0.70 9, 0.738, 0.810, 0.762, 0.755,
(1.2617)+(0.0555)Ser+(-0.1047)Asn +(-0.1496)His+(0.1097)Phe; 0.833,
0.852, 0.810, 0.808, 0.810, 0.8 38, 0.797, 0.813,
(5.7609)+(0.0085)Gln+(-0.1139)His+(0.0253)Or n+(-0.1025)Trp; 0.833,
0.852, 0.788, 0.762, 0.789, 0.818, 0.835, 0. 801,
(7.5060)+(-0.0927)His+(0.0004)Tyr+(0.0650)Ile+(-0.1200)Trp; 0.833,
0.859, 0.812, 0.797, 0.821, 0.819, 0.825, 0.815, (6.415
8)+(-0.0901)His+(-0.0521)Cit+(0.1152)Phe+(-0.1253)Trp; 0.833,
0.852, 0.773, 0.763, 0.739, 0.812, 0.842, 0.789, (4.8036)+(-0.041
7)Val+(0.0115)Orn+(0.1461)Ile+(-0.1393)Trp; 0.833, 0.851, 0.81 1,
0.812, 0.805, 0.835, 0.805, 0.814, (5.7123)+(0.0094)Gln+(-0.11
20)His+(0.0071)Pro+(-0.1050)Trp; 0.833, 0.847, 0.789, 0.784, 0.7
93, 0.822, 0.768, 0.792, (8.0392)+(-0.0941)His+(0.0187)Thr+(0.0
059)Pro+(-0.1095)Trp; 0.833, 0.851, 0.789, 0.764, 0.790, 0.820, 0.
834, 0.802,
(7.5890)+(-0.0916)His+(-0.0019)Arg+(0.0652)Ile+(-0.1195)Trp; 0.832,
0.849, 0.793, 0.785, 0.791, 0.845, 0.783, 0.801,
(6.0170)+(0.0442)Ser+(-0.0053)Gly+(-0.0883)His+(-0.0968)Tr p;
0.832, 0.853, 0.791, 0.785, 0.798, 0.856, 0.747, 0.797,
(6.2172)+(0.0386)Ser+(-0.0802)His+(-0.0357)Cit+(-0.0996)Trp; 0.832,
0. 848, 0.801, 0.788, 0.830, 0.803, 0.771, 0.798,
(4.5988)+(-0.1254)C it+(0.0457)Orn+(0.0749)Phe+(-0.1801)Trp; 0.832,
0.848, 0.776, 0. 768, 0.739, 0.811, 0.847, 0.791,
(4.7921)+(0.0007)Gln+(-0.0405)V al(0.1467)Ile+(-0.1401)Trp; 0.832,
0.858, 0.813, 0.801, 0.807, 0. 833, 0.839, 0.820,
(0.8683)+(0.0127)Gln+(-0.1563)His+(-0.2363)Met+(0.1260)Phe; 0.832,
0.849, 0.777, 0.757, 0.790, 0.811, 0.778, 0. 784,
(7.7615)+(-0.1131)His+(0.0218)Thr+(0.0251)Leu+(-0.1231)Trp; 0.832,
0.850, 0.770, 0.761, 0.736, 0.811, 0.838, 0.786, (4.807
5)+(0.0056)Thr+(-0.0413)Val+(0.1476)Ile+(-0.1427)Trp; 0.831, 0.847,
0.777, 0.768, 0.739, 0.812, 0.852, 0.793, (5.1738)+(-0.000
6)Gly+(-0.0408)Val+(0.1480)Ile+(-0.1376)Trp; 0.831, 0.849, 0.8 04,
0.803, 0.809, 0.839, 0.769, 0.805, (8.9090)+(-0.0386)Asn+(-0.
0857)His+(0.0248)Thr+(-0.1052)Trp; 0.831, 0.849, 0.804, 0.787, 0.
813, 0.816, 0.820, 0.809, (4.2918)+(0.0047)Gln+(-0.0911)Cit+(0.
0618)Ile+(-0.1841)Trp; 0.831, 0.850, 0.780, 0.774, 0.800, 0.824, 0.
722, 0.780, (4.3970)+(0.0326)Ser+(-0.0821)Cit+(0.0095)Pro+(-0.
1628)Trp; 0.831, 0.849, 0.789, 0.788, 0.769, 0.805, 0.820, 0.796,
(3. 9802)+(0.0021)Gln+(0.1386)Ile+(-0.0651)Leu+(-0.1514)Trp; 0.8
31, 0.847, 0.823, 0.829, 0.812, 0.847, 0.812, 0.825, (5.9272)+(0.00
99)Gln+(-0.1077)His+(-0.0006)Ala+(-0.0993)Trp; 0.831, 0.848, 0.
776, 0.769, 0.737, 0.816, 0.845, 0.792, (5.0725)+(-0.0343)Val+(0.
1637)Ile+(-0.0217)Leu+(-0.1350)Trp; 0.831, 0.847, 0.813, 0.797,
0.805, 0.839, 0.853, 0.824,
(6.6077)+(-0.0078)Ala+(-0.0782)Cit+(0.0801)Ile+(-0.1575)Trp; 0.830,
0.846, 0.699, 0.649, 0.698, 0.80 1, 0.761, 0.727,
(0.2117)+(0.0436)Ser+(-0.1732)His+(0.0360)Ile +(0.0678)Phe; 0.830,
0.848, 0.777, 0.767, 0.740, 0.818, 0.850, 0.79 4,
(5.3363)+(-0.0402)Val+(-0.0038)Lys+(0.1498)Ile+(-0.1338)T rp;
0.830, 0.848, 0.775, 0.769, 0.737, 0.810, 0.844, 0.790,
(5.3708)
+(-0.0126)Tyr+(-0.0400)Val+(0.1488)Ile+(-0.1327)Trp; 0.830, 0. 851,
0.831, 0.838, 0.819, 0.856, 0.816, 0.833, (5.9044)+(0.0108)Gl
n+(-0.1018)His+(-0.0566)Met+(-0.0952)Trp; 0.830, 0.849, 0.787,
0.781, 0.770, 0.805, 0.820, 0.794,
(4.7452)+(0.0028)Orn+(0.1385)Ile+(-0.0647)Leu+(-0.1466)Trp; 0.830,
0.855, 0.840, 0.851, 0.842, 0.798, 0.834, 0.831,
(1.6077)+(0.0063)Gln+(-0.2432)Met+(0.112 4)Phe+(-0.1488)Trp; 0.830,
0.848, 0.789, 0.796, 0.788, 0.826, 0.75 0, 0.790,
(4.4666)+(0.0401)Ser+(-0.1088)Asn+(0.0079)Pro+(-0.1 356)Trp; 0.830,
0.855, 0.841, 0.851, 0.841, 0.802, 0.844, 0.835, (3.
1099)+(-0.0982)Asn+(0.0059)Gln+(0.0746)Phe+(-0.1606)Trp; 0.8 29,
0.845, 0.789, 0.765, 0.814, 0.815, 0.784, 0.794, (5.7602)+(-0.1
121)Cit+(0.0395)Orn+(0.0510)Ile+(-0.1782)Trp; 0.829, 0.854, 0. 799,
0.776, 0.800, 0.828, 0.837, 0.810, (7.7863)+(-0.0798)His+(-0.
0851)Met+(0.0715)Ile+(-0.1120)Trp; 0.829, 0.848, 0.793, 0.773, 0.
807, 0.786, 0.822, 0.797, (4.1507)+(-0.0952)Cit+(0.0503)Ile+(0.
0657)Phe+(-0.1880)Trp; 0.829, 0.847, 0.821, 0.826, 0.811, 0.845, 0.
809, 0.823, (5.8736)+(0.0001)Gly+(0.0098)Gln+(-0.1089)His+(-0.
1000)Trp; 0.829, 0.846, 0.791, 0.780, 0.803, 0.823, 0.773, 0.795,
(8. 0622)+(-0.1033)His+(0.0205)Thr+(0.0074)Val+(-0.1153)Trp; 0.8
29, 0.850, 0.811, 0.816, 0.824, 0.858, 0.738, 0.809, (5.3014)+(0.03
62)Ser+(-0.0595)Cit+(-0.1015)Met+(-0.1322)Trp; 0.829, 0.850, 0.
788, 0.784, 0.790, 0.851, 0.749, 0.793, (6.1599)+(0.0387)Ser+(-0.
0885)His+(-0.0087)Arg+(-0.0935)Trp; 0.829, 0.846, 0.731, 0.701,
0.720, 0.823, 0.770, 0.753,
(0.9324)+(0.0445)Ser+(-0.1600)His+(-0.0048)Ala+(0.0994)Phe; 0.829,
0.848, 0.783, 0.776, 0.747, 0.82 2, 0.845, 0.798,
(6.0528)+(-0.0187)Arg+(-0.0425)Val+(0.1569)Il e+(-0.1281)Trp;
0.829, 0.852, 0.802, 0.811, 0.802, 0.763, 0.807, 0. 796,
(3.3228)+(0.0042)Pro+(-0.0082)Val+(0.0808)Phe+(-0.1647)Trp; 0.829,
0.846, 0.787, 0.766, 0.804, 0.809, 0.790, 0.792, (5.603
6)+(0.0109)Thr+(-0.0876)Cit+(0.0608)Ile+(-0.1828)Trp; 0.829, 0.846,
0.715, 0.674, 0.703, 0.823, 0.768, 0.742,
(2.2744)+(0.0369)Ser+(-0.1381)His+(0.1008)Ile+(-0.0337)Leu; 0.828,
0.848, 0.787, 0.783, 0.770, 0.805, 0.820, 0.794,
(4.7835)+(0.0007)Thr+(0.1389)Ile+(-0.0644)Leu+(-0.1470)Trp; 0.828,
0.846, 0.776, 0.768, 0.739, 0.813, 0.849, 0.792,
(5.1250)+(-0.0016)Pro+(-0.0407)Val+(0.150 0)Ile+(-0.1376)Trp;
0.828, 0.849, 0.788, 0.783, 0.772, 0.804, 0.82 4, 0.796,
(4.9098)+(-0.0005)Gly+(0.1392)Ile+(-0.0645)Leu+(-0. 1461)Trp;
0.828, 0.847, 0.816, 0.819, 0.808, 0.838, 0.809, 0.818, (5.
6906)+(0.0092)Gln+(-0.1127)His+(0.0057)Lys+(-0.1046)Trp; 0.8 28,
0.848, 0.820, 0.821, 0.813, 0.845, 0.815, 0.824, (5.7459)+(0.00
97)Gln+(-0.1148)His+(0.0152)Tyr+(-0.1061)Trp; 0.828, 0.848, 0. 828,
0.828, 0.841, 0.808, 0.817, 0.823, (5.6837)+(-0.0504)Asn+(-0.
0816)Cit+(0.0953)Phe+(-0.1596)Trp; 0.828, 0.846, 0.726, 0.683, 0.
724, 0.827, 0.772, 0.752, (2.8591)+(0.0473)Ser+(-0.0729)Asn+(-0.
1376)His+(0.0587)Ile; 0.828, 0.843, 0.724, 0.689, 0.726, 0.812, 0.
747, 0.744, (1.1550)+(0.0475)Ser+(-0.1605)His+(-0.0124)Lys+(0.
1035)Phe; 0.828, 0.847, 0.812, 0.828, 0.808, 0.849, 0.754, 0.810,
(5. 1227)+(0.0391)Ser+(-0.0638)Asn+(-0.0785)Met+(-0.1277)Trp; 0.
828, 0.849, 0.791, 0.777, 0.804, 0.820, 0.783, 0.796, (7.8247)+(-0.
0917)His+(0.0061)Pro+(0.0327)Orn+(-0.1030)Trp; 0.827, 0.849, 0.
799, 0.811, 0.807, 0.845, 0.716, 0.795, (4.6547)+(0.0294)Ser+(0.0
152)Thr+(-0.1745)Met+(-0.1408)Trp; 0.827, 0.845, 0.809, 0.822, 0.
802, 0.847, 0.761, 0.808, (5.0939)+(0.0377)Ser+(-0.0893)Asn+(-0.
0015)Ala+(-0.1295)Trp; 0.827, 0.852, 0.801, 0.802, 0.794, 0.769, 0.
836, 0.800, (3.4551)+(-0.0264)Val+(0.0414)Leu+(0.0783)Phe+(-0.
1718)Trp; 0.827, 0.847, 0.818, 0.834, 0.811, 0.847, 0.772, 0.816,
(4. 0201)+(0.0346)Ser+(-0.1139)Asn+(0.0041)Gln+(-0.1359)Trp; 0.8
27, 0.850, 0.786, 0.776, 0.793, 0.806, 0.784, 0.790, (5.1661)+(0.02
48)Thr+(-0.2423)Met+(0.0661)Ile+(-0.1533)Trp; 0.827, 0.848, 0. 799,
0.808, 0.799, 0.837, 0.747, 0.798, (4.5281)+(0.0374)Ser+(-0.
1072)Asn+(0.0208)Orn+(-0.1346)Trp; 0.827, 0.844, 0.714, 0.665, 0.
717, 0.824, 0.759, 0.741, (2.5591)+(0.0437)Ser+(-0.1436)His+(-0.
0125)Lys+(0.0645)Ile; 0.827, 0.845, 0.793, 0.787, 0.800, 0.826, 0.
768, 0.795, (8.0144)+(-0.0971)His+(0.0190)Thr+(0.0053)Lys+(-0.
1096)Trp; 0.827, 0.847, 0.787, 0.782, 0.771, 0.805, 0.820, 0.795,
(4. 9183)+(-0.0014)Lys+(0.1392)Ile+(-0.0637)Leu+(-0.1450)Trp; 0.
827, 0.846, 0.785, 0.785, 0.764, 0.804, 0.813, 0.791, (5.3062)+(-0.
0195)Tyr+(0.1428)Ile+(-0.0641)Leu+(-0.1374)Trp; 0.827, 0.846,
0.799, 0.800, 0.800, 0.841, 0.769, 0.802,
(8.4236)+(-0.0912)His+(0.0218)Thr+(-0.0013)Ala+(-0.1053)Trp; 0.827,
0.851, 0.833, 0.8 32, 0.850, 0.810, 0.815, 0.827,
(4.9049)+(-0.0733)Cit+(-0.1545)M et+(0.1213)Phe+(-0.1501)Trp;
0.827, 0.847, 0.829, 0.834, 0.822, 0. 856, 0.811, 0.831,
(6.0384)+(0.0103)Gln+(-0.0971)His+(-0.0361)Cit+(-0.1033)Trp; 0.827,
0.844, 0.721, 0.703, 0.711, 0.796, 0.737, 0.737,
(0.9223)+(0.0443)Ser+(-0.1561)His+(-0.0445)Tyr+(0.116 7)Phe; 0.827,
0.852, 0.834, 0.843, 0.836, 0.792, 0.833, 0.826, (4.91
95)+(-0.0704)Asn+(-0.0076)Val+(0.0926)Phe+(-0.1432)Trp; 0.82 7,
0.849, 0.799, 0.809, 0.805, 0.762, 0.789, 0.791, (3.1688)+(0.007
7)Thr+(-0.0081)Val+(0.0811)Phe+(-0.1696)Trp; 0.827, 0.850, 0.8 08,
0.799, 0.815, 0.787, 0.835, 0.809, (3.5338)+(-0.2354)Met+(0.0
529)Ile+(0.0869)Phe+(-0.1526)Trp; 0.827, 0.845, 0.826, 0.834, 0.
817, 0.849, 0.806, 0.827, (6.0110)+(0.0113)Gln+(-0.1081)His+(-0.
0133)Arg+(-0.0973)Trp; 0.826, 0.848, 0.800, 0.798, 0.811, 0.841, 0.
754, 0.801,
(8.6973)+(-0.0816)His+(0.0235)Thr+(-0.0402)Cit+(-0.1118)Trp; 0.826,
0.846, 0.789, 0.786, 0.771, 0.812, 0.821, 0.797,
(4.9708)+(-0.0039)Pro+(0.1460)Ile+(-0.0657)Leu+(-0.1450)Tr p;
0.826, 0.849, 0.806, 0.816, 0.809, 0.770, 0.797, 0.798,
(3.3064)+(-0.0084)Val+(0.0116)Orn+(0.0776)Phe+(-0.1620)Trp; 0.826,
0.8 42, 0.716, 0.678, 0.690, 0.828, 0.790, 0.747,
(2.4994)+(0.0345)Ser +(-0.1225)His+(-0.0289)Val+(0.1190)Ile; 0.826,
0.845, 0.795, 0. 793, 0.800, 0.835, 0.762, 0.797,
(8.2697)+(0.0003)Gly+(-0.0934)H is+(0.0209)Thr+(-0.1063)Trp; 0.826,
0.851, 0.813, 0.827, 0.811, 0. 771, 0.810, 0.805,
(2.5428)+(0.0024)Gln+(-0.0073)Val+(0.0802)P he+(-0.1689)Trp; 0.826,
0.844, 0.724, 0.693, 0.719, 0.804, 0.760, 0. 744,
(-0.0269)+(0.0379)Ser+(0.0042)Gln+(-0.1801)His+(0.0873)Phe; 0.826,
0.846, 0.796, 0.786, 0.742, 0.867, 0.884, 0.820, (4.891
0)+(-0.0055)Ala+(-0.0528)Val+(-0.2382)Met+(0.1962)Ile; 0.826,
0.847, 0.785, 0.764, 0.754, 0.849, 0.858, 0.806, (6.4465)+(-0.062
3)His+(-0.0425)Val+(-0.2014)Met+(0.1680)Ile; 0.826, 0.847, 0.7 51,
0.730, 0.749, 0.797, 0.774, 0.762, (1.9569)+(0.0345)Ser+(-0.0
151)Lys+(0.0633)Ile+(-0.1628)Trp; 0.826, 0.845, 0.759, 0.734, 0.
761, 0.778, 0.808, 0.770, (1.8343)+(0.0391)Ser+(-0.0078)Gly+(0.
0503)Ile+(-0.1780)Trp; 0.826, 0.852, 0.813, 0.816, 0.826, 0.783, 0.
799, 0.806, (4.7103)+(-0.1025)Asn+(0.0179)Thr+(0.0754)Phe+(-0.
1634)Trp; 0.826, 0.841, 0.721, 0.678, 0.716, 0.823, 0.771, 0.747,
(1. 3899)+(0.0338)Ser+(0.0043)Gln+(-0.1663)His+(0.0516)Ile; 0.82 6,
0.846, 0.782, 0.771, 0.805, 0.819, 0.738, 0.783, (3.9934)+(0.032
7)Ser+(-0.0816)Cit+(0.0184)Leu+(-0.1713)Trp; 0.826, 0.847, 0.7 88,
0.762, 0.804, 0.818, 0.798, 0.796, (7.8351)+(-0.1031)His+(0.0
312)Orn+(0.0199)Leu+(-0.1126)Trp; 0.825, 0.845, 0.796, 0.786, 0.
825, 0.790, 0.765, 0.792, (4.2249)+(0.0140)Thr+(-0.0971)Cit+(0.
0876)Phe+(-0.1863)Trp; 0.825, 0.839, 0.716, 0.677, 0.717, 0.799, 0.
760, 0.738, (0.8595)+(0.0474)Ser+(-0.0029)Gly+(-0.1674)His+(0.
0891)Phe; 0.825, 0.849, 0.796, 0.807, 0.800, 0.838, 0.731, 0.794,
(3. 8520)+(0.0340)Ser+(-0.1511)Met+(0.0222)Orn+(-0.1358)Trp; 0.8
25, 0.839, 0.768, 0.750, 0.719, 0.839, 0.869, 0.794, (5.6712)+(-0.0
866)His+(-0.0066)Ala+(-0.0356)Val+(0.1435)Ile; 0.825, 0.850, 0.
816, 0.819, 0.826, 0.777, 0.811, 0.808, (3.7488)+(0.0077)Pro+(-0.
2244)Met+(0.1082)Phe+(-0.1441)Trp; 0.825, 0.847, 0.786, 0.786, 0.
793, 0.820, 0.749, 0.787, (2.9723)+(0.0407)Ser+(-0.1830)Met+(0.
0237)Leu+(-0.1459)Trp; 0.825, 0.844, 0.779, 0.764, 0.740, 0.851, 0.
850, 0.801, (4.2474)+(-0.0569)Val+(-0.2918)Met+(0.0254)Orn+(0.
1891)Ile; 0.825, 0.848, 0.801, 0.792, 0.781, 0.809, 0.863, 0.811,
(3. 4695)+(-0.0094)Ala+(0.0570)Ile+(0.0568)Phe+(-0.1709)Trp; 0.8
25, 0.848, 0.832, 0.843, 0.838, 0.792, 0.821, 0.823, (4.0106)+(-0.0
055)Val+(-0.1937)Met+(0.1205)Phe+(-0.1359)Trp; 0.825, 0.846, 0.
796, 0.792, 0.803, 0.833, 0.768, 0.799, (8.2465)+(-0.0944)His+(0.
0205)Thr+(0.0050)Tyr+(-0.1083)Trp; 0.825, 0.845, 0.799, 0.809, 0.
799, 0.840, 0.742, 0.798, (5.0944)+(0.0351)Ser+(-0.1065)Asn+(0.
0084)Thr+(-0.1374)Trp; 0.825, 0.839, 0.715, 0.663, 0.715, 0.816, 0.
778, 0.743, (2.2774)+(0.0451)Ser+(-0.0039)Gly+(-0.1532)His+(0.
0536)Ile; 0.824, 0.842, 0.804, 0.817, 0.803, 0.846, 0.741, 0.802,
(4. 3447)+(0.0349)Ser+(-0.0002)Ala+(-0.1279)Met+(-0.1326)Trp; 0.
824, 0.845, 0.814, 0.821, 0.810, 0.839, 0.787, 0.814, (4.6255)+(0.0
454)Ser+(-0.0076)Gly+(-0.1269)Met+(-0.1326)Trp; 0.824, 0.842,
0.813, 0.805, 0.840, 0.835, 0.762, 0.811,
(7.9934)+(-0.0506)Asn+(-0.1077)Cit+(0.0583)Orn+(-0.1443)Trp; 0.824,
0.844, 0.829, 0.8 37, 0.838, 0.791, 0.820, 0.821,
(4.2708)+(-0.0186)Asn+(-0.1817)M et+(0.1099)Phe+(-0.1408)Trp;
0.824, 0.843, 0.802, 0.815, 0.804, 0. 837, 0.740, 0.799,
(4.1442)+(0.0340)Ser+(-0.1451)Met+(0.0047)L ys+(-0.1372)Trp; 0.824,
0.843, 0.802, 0.814, 0.799, 0.834, 0.755, 0. 800,
(4.8290)+(0.0376)Ser+(-0.1001)Asn+(0.0030)Lys+(-0.1352)Trp; 0.824,
0.843, 0.793, 0.783, 0.804, 0.828, 0.769, 0.796, (7.798
6)+(0.0020)Gly+(-0.0922)His+(0.0361)Orn+(-0.0980)Trp; 0.824, 0.845,
0.795, 0.781, 0.807, 0.823, 0.784, 0.799, (7.9900)+(-0.095
6)His+(0.0047)Val+(0.0337)Orn+(-0.1050)Trp; 0.824, 0.842, 0.74 4,
0.714, 0.709, 0.805, 0.848, 0.769, (3.8311)+(-0.1147)His+(-0.0
364)Val+(0.1156)Ile+(0.0627)Phe; 0.824, 0.846, 0.794, 0.773, 0.7
82, 0.847, 0.838, 0.810, (3.0854)+(0.0111)Gln+(-0.1404)His+(-0.
1937)Met+(0.0647)Ile; 0.824, 0.847, 0.812, 0.828, 0.809, 0.847, 0.
752, 0.809, (3.5073)+(0.0315)Ser+(0.0032)Gln+(-0.1476)Met+(-0.
1366)Trp; 0.823, 0.840, 0.749, 0.733, 0.692, 0.855, 0.830, 0.778,
(2. 6416)+(0.0435)Ser+(-0.1848)Asn+(-0.0564)Val+(0.1742)Ile; 0.8
23, 0.842, 0.751, 0.733, 0.748, 0.785, 0.783, 0.762, (1.3069)+(0.03
39)Ser+(-0.0098)Thr+(0.0550)Ile+(-0.1714)Trp; 0.823, 0.844, 0. 796,
0.798, 0.805, 0.835, 0.748, 0.796, (8.7711)+(-0.0909)His+(0.
0252)Thr+(-0.0126)Arg+(-0.1062)Trp; 0.823, 0.847, 0.811, 0.820,
0.813, 0.770, 0.810, 0.803,
(3.4357)+(-0.0000)Gly+(-0.0070)Val+(0.0829)Phe+(-0.1635)Trp; 0.823,
0.848, 0.758, 0.725, 0.766, 0.82 6, 0.780, 0.774,
(5.8041)+(-0.1283)His+(0.0327)Thr+(-0.2487)Me t+(0.0694)Ile; 0.823,
0.848, 0.809, 0.817, 0.793, 0.788, 0.838, 0.8 09,
(3.6329)+(-0.0084)Ala+(0.0088)Pro+(0.0794)Phe+(-0.1620)T rp; 0.823,
0.849, 0.799, 0.800, 0.815, 0.768, 0.785, 0.792, (3.4271)
+(0.0104)Thr+(-0.0090)Lys+(0.0753)Phe+(-0.1737)Trp; 0.823, 0. 843,
0.793, 0.795, 0.811, 0.835, 0.719, 0.790, (4.8416)+(0.0291)Se
r+(0.0048)Thr+(-0.0742)Cit+(-0.1554)Trp; 0.823, 0.845, 0.836, 0.
843, 0.830, 0.813, 0.846, 0.833,
(4.8475)+(-0.0576)Asn+(-0.0048)Ala+(0.0879)Phe+(-0.1481)Trp; 0.823,
0.843, 0.814, 0.817, 0.809, 0.836, 0.799, 0.815,
(5.2563)+(0.0481)Ser+(-0.0913)Asn+(-0.007 3)Gly+(-0.1336)Trp;
0.823, 0.842, 0.803, 0.809, 0.811, 0.850, 0.74 1, 0.803,
(5.0720)+(0.0313)Ser+(-0.0023)Ala+(-0.0684)Cit+(-0. 1435)Trp;
0.823, 0.847, 0.810, 0.816, 0.805, 0.795, 0.815, 0.808, (3.
3924)+(0.0108)Thr+(-0.0071)Ala+(0.0812)Phe+(-0.1693)Trp; 0.8 23,
0.843, 0.816, 0.824, 0.840, 0.842, 0.725, 0.808, (7.7700)+(0.02
80)Thr+(-0.0628)Cit+(-0.1480)Met+(-0.1411)Trp; 0.823, 0.840, 0.
781, 0.764, 0.794, 0.808, 0.779, 0.786, (5.3945)+(0.0040)Gly+(-0.
0885)Cit+(0.0647)Ile+(-0.1744)Trp; 0.823, 0.846, 0.811, 0.815, 0.
817, 0.854, 0.756, 0.810, (3.7672)+(0.0377)Ser+(0.0329)Tyr+(-0.
1848)Met+(-0.1427)Trp; 0.822, 0.841, 0.781, 0.786, 0.762, 0.834, 0.
769, 0.788, (3.4525)+(0.0283)Ser+(-0.0071)Ala+(0.0112)Pro+(-0.
1448)Trp; 0.822, 0.836, 0.713, 0.680, 0.711, 0.799, 0.742, 0.733,
(0. 7961)+(0.0431)Ser+(-0.1648)His+(-0.0035)Val+(0.0969)Phe; 0.8
22, 0.841, 0.746, 0.719, 0.725, 0.795, 0.827, 0.767, (3.5737)+(-0.1
257)His+(0.1043)Ile+(-0.0558)Leu+(0.0707)Phe; 0.822, 0.844, 0. 802,
0.793, 0.807, 0.832, 0.790, 0.806, (8.1624)+(-0.0874)His+(-0.
0014)Ala+(0.0381)Orn+(-0.0971)Trp; 0.822, 0.839, 0.797, 0.787, 0.
826, 0.822, 0.742, 0.794, (6.6466)+(-0.1136)Cit+(0.0053)Pro+(0.
0516)Orn+(-0.1628)Trp; 0.822, 0.840, 0.793, 0.775, 0.804, 0.806, 0.
808, 0.798, (5.9868)+(-0.0815)Cit+(0.0013)Pro+(0.0607)Ile+(-0.
1730)Trp; 0.822, 0.847, 0.819, 0.827, 0.827, 0.778, 0.812, 0.811,
(4. 4054)+(-0.0721)Asn+(0.0019)Gly+(0.0801)Phe+(-0.1554)Trp; 0.8
22, 0.842, 0.804, 0.789, 0.812, 0.817, 0.818, 0.809, (6.8072)+(-0.0
327)Asn+(-0.0753)Cit+(0.0612)Ile+(-0.1629)Trp; 0.822, 0.847, 0.
822, 0.831, 0.832, 0.787, 0.801, 0.813, (3.4599)+(0.0022)Gly+(-0.
2067)Met+(0.1140)Phe+(-0.1427)Trp; 0.822, 0.838, 0.811, 0.804, 0.
832, 0.841, 0.760, 0.809, (7.3871)+(-0.0047)Ala+(-0.1128)Cit+(0.
0607)Orn+(-0.1448)Trp; 0.822, 0.843, 0.794, 0.781, 0.804, 0.824, 0.
782, 0.798, (7.7222)+(-0.0961)His+(0.0329)Orn+(0.0072)Lys+(-0.
1051)Trp; 0.822, 0.845, 0.802, 0.793, 0.810, 0.830, 0.786, 0.805,
(8. 2801)+(-0.0150)Asn+(-0.0858)His+(0.0377)Orn+(-0.0977)Trp; 0.
822, 0.840, 0.746, 0.728, 0.746, 0.776, 0.771, 0.755, (1.5426)+(0.0
288)Ser+(-0.0073)Orn+(0.0543)Ile+(-0.1783)Trp; 0.822, 0.845, 0.
753, 0.740, 0.757, 0.799, 0.746, 0.761, (2.0871)+(0.0350)Ser+(-0.
0260)Arg+(0.0585)Ile+(-0.1705)Trp; 0.822, 0.841, 0.789, 0.785, 0.
812, 0.826, 0.726, 0.787, (4.3822)+(0.0320)Ser+(-0.0794)Cit+(0.
0060)Val+(-0.1629)Trp; 0.822, 0.840, 0.795, 0.783, 0.783, 0.822, 0.
835, 0.805, (2.3417)+(-0.0780)Asn+(0.0116)Gln+(-0.1598)His+(0.
0775)Phe; 0.821, 0.844, 0.804, 0.813, 0.802, 0.840, 0.759, 0.803,
(4. 7828)+(0.0384)Ser+(-0.0983)Asn+(0.0068)Tyr+(-0.1350)Trp; 0.8
21, 0.848, 0.813, 0.822, 0.816, 0.774, 0.811, 0.806, (3.5653)+(-0.0
064)Val+(-0.0026)Lys+(0.0847)Phe+(-0.1614)Trp; 0.821, 0.838, 0.
798, 0.791, 0.830, 0.828, 0.732, 0.795, (6.6189)+(0.0070)Thr+(-0.
1126)Cit+(0.0506)Orn+(-0.1639)Trp; 0.821, 0.845, 0.792, 0.791, 0.
777, 0.812, 0.812, 0.798, (5.8598)+(-0.0193)Arg+(0.1507)Ile+(-0.
0691)Leu+(-0.1367)Trp; 0.821, 0.843, 0.801, 0.812, 0.799, 0.836, 0.
753, 0.800, (4.7908)+(0.0383)Ser+(-0.0950)Asn+(0.0013)Val+(-0.
1345)Trp; 0.821, 0.843, 0.817, 0.815, 0.834, 0.801, 0.802, 0.813,
(4. 9214)+(-0.0877)Cit+(-0.0042)Lys+(0.0951)Phe+(-0.1677)Trp; 0.
821, 0.841, 0.707, 0.666, 0.711, 0.799, 0.740, 0.729, (0.6425)+(0.0
422)Ser+(-0.1707)His+(0.0097)Orn+(0.0874)Phe; 0.821, 0.839, 0. 782,
0.758, 0.755, 0.850, 0.854, 0.804, (3.4009)+(0.0083)Gln+(-0.
1498)His+(-0.0065)Ala+(0.0558)Ile; 0.821, 0.837, 0.707, 0.668, 0.
709, 0.794, 0.742, 0.728, (0.6625)+(0.0434)Ser+(-0.1693)His+(0.
0012)Pro+(0.0895)Phe; 0.821, 0.840, 0.792, 0.785, 0.745, 0.860, 0.
861, 0.812, (3.2291)+(0.0039)Gln+(-0.0540)Val+(-0.3077)Met+(0.
1887)Ile; 0.821, 0.838, 0.707, 0.668, 0.709, 0.796, 0.745, 0.729,
(0. 6638)+(0.0436)Ser+(-0.1704)His+(0.0029)Leu+(0.0876)Phe; 0.82 1,
0.847, 0.824, 0.834, 0.813, 0.798, 0.841, 0.822, (2.5743)+(0.003
2)Gln+(-0.0066)Ala+(0.0806)Phe+(-0.1673)Trp; 0.821, 0.850, 0.8 15,
0.823, 0.820, 0.773, 0.816, 0.808, (2.5403)+(0.0031)Gln+(-0.0
073)Lys+(0.0744)Phe+(-0.1724)Trp; 0.821, 0.844, 0.800, 0.793, 0.
801, 0.773, 0.838, 0.801, (4.3282)+(-0.0658)Asn+(0.0395)Ile+(0.
0549)Phe+(-0.1688)Trp; 0.821, 0.843, 0.786, 0.776, 0.742, 0.849, 0.
859, 0.807, (4.3158)+(-0.0570)Val+(-0.3044)Met+(0.0078)Lys+(0.
1925)Ile; 0.821, 0.840, 0.803, 0.801, 0.798, 0.826, 0.803, 0.807,
(8. 6130)+(-0.0758)His+(-0.0035)Ala+(0.0116)Pro+(-0.0986)Trp; 0.
821, 0.845, 0.817, 0.818, 0.830, 0.796, 0.804, 0.812, (3.0066)+(0.0
045)Gln+(-0.0964)Cit+(0.0862)Phe+(-0.1806)Trp; 0.821, 0.839, 0.
798, 0.780, 0.808, 0.814, 0.816, 0.804, (6.4963)+(-0.0800)Cit+(-0.
0063)Lys+(0.0668)Ile+(-0.1650)Trp; 0.821, 0.844, 0.799, 0.784, 0.
824, 0.837, 0.760, 0.801, (8.4227)+(-0.0693)His+(-0.0798)Cit+(0.
0587)Orn+(-0.1115)Trp; 0.821, 0.841, 0.804, 0.817, 0.804, 0.843, 0.
744, 0.802,
(5.0975)+(0.0394)Ser+(-0.0859)Asn+(-0.0090)Arg+(-0.1298)Trp; 0.821,
0.846, 0.826, 0.832, 0.833, 0.781, 0.825, 0.818,
(4.7404)+(-0.0676)Asn+(-0.0021)Leu+(0.0802)Phe+(-0.1539)Tr p;
0.821, 0.837, 0.708, 0.659, 0.708, 0.815, 0.759, 0.735,
(2.1978)+(0.0395)Ser+(-0.1543)His+(-0.0018)Pro+(0.0571)Ile; 0.821,
0.8 49, 0.818, 0.821, 0.827, 0.773, 0.824, 0.811,
(4.6563)+(-0.0699)As n+(0.0034)Pro+(0.0750)Phe+(-0.1574)Trp; 0.821,
0.843, 0.826, 0. 828, 0.829, 0.817, 0.824, 0.825,
(4.9871)+(-0.0055)Ala+(-0.0855)Cit+(0.1039)Phe+(-0.1612)Trp; 0.821,
0.839, 0.808, 0.803, 0.833, 0.830, 0.751, 0.804,
(5.5816)+(0.0035)Gln+(-0.1140)Cit+(0.049 8)Orn+(-0.1651)Trp; 0.821,
0.842, 0.803, 0.816, 0.806, 0.844, 0.73 2, 0.800,
(4.5256)+(0.0364)Ser+(-0.0086)Arg+(-0.1186)Met+(-0. 1304)Trp;
0.821, 0.837, 0.711, 0.673, 0.712, 0.798, 0.745, 0.732, (0.
6824)+(0.0442)Ser+(-0.1678)His+(-0.0016)Thr+(0.0916)Phe; 0.8 21,
0.840, 0.791, 0.789, 0.793, 0.818, 0.770, 0.793, (8.0410)+(0.00
28)Gly+(-0.0842)His+(0.0085)Pro+(-0.0999)Trp; 0.821, 0.838, 0. 803,
0.795, 0.835, 0.830, 0.740, 0.800, (7.2015)+(-0.1128)Cit+(0.
0582)Orn+(-0.0045)Lys+(-0.1516)Trp; 0.821, 0.843, 0.797, 0.786,
0.806, 0.827, 0.785, 0.801,
(7.9860)+(-0.0911)His+(0.0054)Tyr+(0.0356)Orn+(-0.1010)Trp; 0.820,
0.841, 0.739, 0.717, 0.743, 0.77 7, 0.762, 0.750,
(1.8760)+(0.0309)Ser+(-0.0018)Gln+(0.0529)Ile +(-0.1751)Trp; 0.820,
0.844, 0.822, 0.828, 0.832, 0.788, 0.807, 0.8 14,
(3.7571)+(-0.2062)Met+(0.0121)Orn+(0.1044)Phe+(-0.1418)T rp; 0.820,
0.843, 0.787, 0.789, 0.788, 0.818, 0.759, 0.789, (4.0203)
+(0.0409)Ser+(-0.1056)Asn+(0.0150)Leu+(-0.1436)Trp; 0.820, 0. 846,
0.819, 0.824, 0.827, 0.780, 0.815, 0.812, (4.6656)+(-0.0728)A
sn+(0.0119)Orn+(0.0709)Phe+(-0.1547)Trp; 0.820, 0.845, 0.833, 0.
841, 0.836, 0.801, 0.829, 0.827,
(4.0312)+(-0.0024)Ala+(-0.1819)Met+(0.1131)Phe+(-0.1403)Trp; 0.820,
0.841, 0.803, 0.795, 0.822, 0.782, 0.797, 0.799,
(4.5507)+(-0.0914)Cit+(0.0052)Pro+(0.085 5)Phe+(-0.1756)Trp; 0.820,
0.840, 0.792, 0.784, 0.798, 0.809, 0.79 3, 0.796,
(7.8709)+(-0.0898)His+(0.0076)Pro+(0.0095)Lys+(-0.1 092)Trp; 0.820,
0.841, 0.796, 0.799, 0.811, 0.839, 0.726, 0.794, (4.
9275)+(0.0317)Ser+(-0.0703)Cit+(-0.0017)Lys+(-0.1483)Trp; 0. 820,
0.838, 0.720, 0.688, 0.730, 0.802, 0.727, 0.737, (0.9230)+(0.0
488)Ser+(-0.1613)His+(-0.0224)Arg+(0.1010)Phe; 0.820, 0.837, 0.
708, 0.659, 0.708, 0.814, 0.760, 0.735, (2.1004)+(0.0413)Ser+(-0.
1519)His+(-0.0037)Thr+(0.0557)Ile; 0.820, 0.842, 0.802, 0.806, 0.
815, 0.840, 0.735, 0.799, (4.1992)+(0.0279)Ser+(0.0024)Gln+(-0.
0755)Cit+(-0.1555)Trp; 0.820, 0.838, 0.790, 0.771, 0.799, 0.810, 0.
810, 0.797, (8.1128)+(-0.0944)His+(0.0055)Pro+(0.0210)Leu+(-0.
1135)Trp; 0.820, 0.844, 0.826, 0.835, 0.818, 0.800, 0.835, 0.822,
(3. 7508)+(-0.0053)Ala+(-0.0041)Val+(0.0896)Phe+(-0.1563)Trp; 0.
820, 0.835, 0.796, 0.791, 0.826, 0.826, 0.727, 0.792, (6.5880)+(0.0
017)Gly+(-0.1135)Cit+(0.0543)Orn+(-0.1581)Trp; 0.820, 0.842, 0.
746, 0.738, 0.740, 0.778, 0.758, 0.754, (2.0254)+(0.0284)Ser+(-0.
0242)Tyr+(0.0558)Ile+(-0.1671)Trp; 0.820, 0.839, 0.793, 0.775, 0.
804, 0.806, 0.808, 0.798, (5.9893)+(-0.0812)Cit+(0.0007)Arg+(0.
0620)Ile+(-0.1726)Trp; 0.819, 0.840, 0.814, 0.814, 0.829, 0.791, 0.
800, 0.809,
(4.6843)+(-0.0860)Cit+(-0.0021)Val+(0.0935)Phe+(-0.1689)Trp; 0.819,
0.840, 0.747, 0.731, 0.747, 0.782, 0.766, 0.757,
(1.5135)+(0.0281)Ser+(-0.0027)Pro+(0.0546)Ile+(-0.1775)Trp; 0.819,
0.842, 0.795, 0.805, 0.800, 0.833, 0.734, 0.793, (3.8344)+(0.
0366)Ser+(0.0051)Val+(-0.1446)Met+(-0.1402)Trp; 0.819, 0.842,
0.808, 0.792, 0.818, 0.821, 0.821, 0.813,
(6.6752)+(-0.0659)Cit+(-0.1095)Met+(0.0690)Ile+(-0.1520)Trp; 0.819,
0.836, 0.784, 0.7 60, 0.770, 0.836, 0.837, 0.801,
(3.4714)+(-0.0644)Asn+(0.0107)Gl n+(-0.1505)His+(0.0434)Ile; 0.819,
0.841, 0.780, 0.768, 0.737, 0. 849, 0.850, 0.801,
(4.3739)+(0.0021)Gly+(-0.0544)Val+(-0.2823)Met+(0.1909)Ile; 0.819,
0.837, 0.781, 0.763, 0.744, 0.845, 0.856, 0. 802,
(5.8218)+(-0.0986)His+(-0.0072)Ala+(0.1275)Ile+(-0.049 0)Leu;
0.819, 0.845, 0.797, 0.801, 0.807, 0.753, 0.795, 0.789, (2.44
13)+(0.0018)Gln+(0.0038)Thr+(0.0659)Phe+(-0.1813)Trp; 0.819, 0.840,
0.795, 0.807, 0.806, 0.810, 0.726, 0.787,
(6.4477)+(0.0236)Thr+(0.0085)Pro+(-0.1986)Met+(-0.1414)Trp; 0.819,
0.835, 0.801, 0.794, 0.831, 0.824, 0.740, 0.797,
(6.8299)+(-0.1115)Cit+(0.000 1)Val+(0.0545)Orn+(-0.1579)Trp; 0.819,
0.837, 0.712, 0.669, 0.71 9, 0.819, 0.738, 0.736,
(2.4734)+(0.0444)Ser+(-0.1468)His+(-0.0 188)Arg+(0.0578)Ile; 0.819,
0.845, 0.790, 0.777, 0.751, 0.855, 0.8 61, 0.811,
(5.1987)+(-0.0400)Cit+(-0.0526)Val+(-0.2529)Met+(0. 1872)Ile;
0.819, 0.835, 0.783, 0.768, 0.792, 0.817, 0.781, 0.789, (7.
7903)+(0.0040)Gly+(-0.1008)His+(0.0259)Leu+(-0.1106)Trp; 0.8 19,
0.837, 0.797, 0.787, 0.804, 0.812, 0.795, 0.800, (8.2935)+(-0.0
874)His+(0.0069)Pro+(0.0056)Val+(-0.1076)Trp; 0.819, 0.846, 0. 806,
0.814, 0.811, 0.759, 0.806, 0.798, (2.4211)+(0.0023)Gln+(-0.
0027)Leu+(0.0696)Phe+(-0.1766)Trp; 0.819, 0.844, 0.807, 0.814, 0.
813, 0.757, 0.814, 0.799, (2.5496)+(-0.0011)Gly+(0.0024)Gln+(0.
0660)Phe+(-0.1783)Trp; 0.819, 0.838, 0.710, 0.674, 0.703, 0.807, 0.
752, 0.734, (2.6390)+(0.0390)Ser+(-0.1448)His+(-0.0245)Tyr+(0.
0606)Ile; 0.819, 0.837, 0.808, 0.801, 0.837, 0.834, 0.749, 0.805,
(7. 3107)+(-0.1036)Cit+(-0.0665)Met+(0.0563)Orn+(-0.1431)Trp; 0.
819, 0.842, 0.778, 0.768, 0.783, 0.745, 0.815, 0.778, (2.3450)+(0.0
015)Gln+(0.0396)Ile+(0.0442)Phe+(-0.1894)Trp; 0.819, 0.840, 0. 802,
0.800, 0.813, 0.831, 0.765, 0.802, (4.9203)+(0.0384)Ser+(-0.
0055)Gly+(-0.0648)Cit+(-0.1503)Trp; 0.819, 0.841, 0.789, 0.778,
0.743, 0.854, 0.866, 0.810,
(5.4149)+(-0.0352)Asn+(-0.0549)Val+(-0.2354)Met+(0.1889)Ile; 0.818,
0.841, 0.787, 0.771, 0.747, 0.85 1, 0.864, 0.808,
(4.4779)+(0.0172)Tyr+(-0.0562)Val+(-0.3039)Me t+(0.1932)Ile; 0.818,
0.837, 0.784, 0.773, 0.740, 0.852, 0.853, 0.8 05,
(4.7133)+(-0.0495)Val+(-0.2688)Met+(0.2025)Ile+(-0.0173)Leu; 0.818,
0.846, 0.800, 0.808, 0.804, 0.752, 0.805, 0.792, (2.411
0)+(0.0021)Gln+(0.0014)Pro+(0.0657)Phe+(-0.1794)Trp; 0.818, 0. 843,
0.816, 0.821, 0.811, 0.795, 0.828, 0.814, (3.6151)+(-0.0064)A
la+(0.0105)Orn+(0.0767)Phe+(-0.1602)Trp; 0.818, 0.844, 0.821, 0.
828, 0.814, 0.797, 0.832, 0.818, (3.6279)+(0.0004)Gly+(-0.0060)A
la+(0.0838)Phe+(-0.1610)Trp; 0.818, 0.844, 0.786, 0.771, 0.790, 0.
766, 0.831, 0.789, (3.4864)+(-0.0111)Lys+(0.0475)Ile+(0.0550)P
he+(-0.1761)Trp; 0.818, 0.842, 0.777, 0.794, 0.779, 0.742, 0.755,
0. 767, (3.1694)+(0.0120)Thr+(-0.0445)Tyr+(0.0907)Phe+(-0.1687)Trp;
0.818, 0.842, 0.795, 0.796, 0.812, 0.836, 0.727, 0.793, (4.706
1)+(0.0312)Ser+(-0.0726)Cit+(0.0049)Tyr+(-0.1536)Trp; 0.818, 0.840,
0.796, 0.799, 0.812, 0.839, 0.725, 0.794, (4.9229)+(0.0319)
Ser+(-0.0672)Cit+(-0.0046)Arg+(-0.1489)Trp; 0.818, 0.835, 0.75 5,
0.726, 0.742, 0.808, 0.824, 0.775, (1.8011)+(0.0083)Gln+(-0.17
42)His+(0.0298)Ile+(0.0498)Phe; 0.818, 0.836, 0.796, 0.784, 0.82 7,
0.815, 0.749, 0.794, (6.5469)+(-0.1141)Cit+(0.0515)Orn+(0.00
98)Leu+(-0.1682)Trp; 0.818, 0.843, 0.792, 0.797, 0.819, 0.760, 0.7
49, 0.781, (3.7422)+(0.0153)Thr+(-0.0270)Arg+(0.0783)Phe+(-0.
1803)Trp; 0.818, 0.845, 0.802, 0.794, 0.811, 0.833, 0.782, 0.805,
(8. 1896)+(-0.0845)His+(-0.0339)Met+(0.0384)Orn+(-0.0957)Trp; 0.
818, 0.838, 0.704, 0.653, 0.707, 0.816, 0.754, 0.732, (2.1105)+(0.0
385)Ser+(-0.1565)His+(0.0077)Orn+(0.0522)Ile; 0.818, 0.838, 0. 801,
0.797, 0.803, 0.816, 0.795, 0.803, (8.5784)+(-0.0102)Asn+(-0.
0777)His+(0.0086)Pro+(-0.1004)Trp; 0.817, 0.839, 0.798, 0.799, 0.
819, 0.787, 0.762, 0.792, (4.0024)+(0.0037)Gly+(-0.0942)Cit+(0.
0934)Phe+(-0.1738)Trp; 0.817, 0.843, 0.798, 0.818, 0.791, 0.752, 0.
792, 0.788, (2.4214)+(0.0031)Gln+(-0.0376)Tyr+(0.0880)Phe+(-0.
1667)Trp; 0.817, 0.837, 0.792, 0.776, 0.800, 0.809, 0.805, 0.798,
(6. 1603)+(-0.0786)Cit+(-0.0073)Tyr+(0.0630)Ile+(-0.1686)Trp; 0.
817, 0.842, 0.798, 0.802, 0.808, 0.750, 0.803, 0.791, (3.2524)+(-0.
0003)Gly+(0.0022)Pro+(0.0673)Phe+(-0.1748)Trp; 0.817, 0.844, 0.
826, 0.833, 0.837, 0.780, 0.815, 0.816, (4.8783)+(-0.0571)Asn+(-0.
0093)Arg+(0.0818)Phe+(-0.1554)Trp; 0.817, 0.842, 0.790, 0.792, 0.
805, 0.747, 0.786, 0.783, (3.0209)+(0.0052)Thr+(0.0012)Pro+(0.0
661)Phe+(-0.1793)Trp; 0.817, 0.839, 0.812, 0.810, 0.829, 0.787, 0.
797, 0.806,
(4.6997)+(-0.0867)Cit+(-0.0013)Arg+(0.0906)Phe+(-0.1716)Trp; 0.817,
0.837, 0.818, 0.824, 0.839, 0.837, 0.745, 0.811,
(8.3908)+(-0.0711)Asn+(0.0226)Thr+(-0.0679)Cit+(-0.1462)Tr p;
0.817, 0.842, 0.795, 0.795, 0.810, 0.750, 0.794, 0.787,
(3.2765)+(-0.0014)Gly+(0.0069)Thr+(0.0658)Phe+(-0.1792)Trp; 0.817,
0.8 41, 0.782, 0.771, 0.739, 0.847, 0.856, 0.803,
(4.6877)+(0.0034)Pro +(-0.0546)Val+(-0.2834)Met+(0.1866)Ile; 0.817,
0.844, 0.799, 0. 804, 0.807, 0.752, 0.800, 0.791,
(3.2164)+(0.0025)Pro+(-0.0031)L eu+(0.0702)Phe+(-0.1726)Trp; 0.817,
0.839, 0.816, 0.834, 0.821, 0. 833, 0.743, 0.808,
(5.1219)+(0.0047)Gln+(0.0218)Thr+(-0.1900)M et+(-0.1459)Trp; 0.817,
0.844, 0.794, 0.798, 0.807, 0.753, 0.785, 0. 786,
(3.0698)+(0.0060)Thr+(-0.0028)Leu+(0.0697)Phe+(-0.1769)Trp; 0.817,
0.838, 0.809, 0.805, 0.803, 0.815, 0.828, 0.813, (3.750
3)+(0.0055)Gln+(-0.2027)Met+(0.0651)Ile+(-0.1494)Trp; 0.817, 0.843,
0.825, 0.831, 0.834, 0.784, 0.817, 0.816, (3.8804)+(-0.201
4)Met+(0.0028)Leu+(0.1088)Phe+(-0.1444)Trp; 0.817, 0.839, 0.77 4,
0.762, 0.781, 0.743, 0.814, 0.775, (2.9276)+(-0.0001)Gly+(0.04
05)Ile+(0.0455)Phe+(-0.1859)Trp; 0.817, 0.839, 0.809, 0.804, 0.8
27, 0.786, 0.799, 0.804, (4.6225)+(-0.0886)Cit+(0.0037)Leu+(0.0
868)Phe+(-0.1750)Trp; 0.817, 0.837, 0.787, 0.776, 0.763, 0.831, 0.
837, 0.802, (2.2663)+(0.0089)Gln+(-0.1642)His+(-0.0045)Ala+(0.
0782)Phe; 0.817, 0.846, 0.803, 0.806, 0.814, 0.763, 0.804, 0.797,
(3. 5025)+(0.0027)Pro+(-0.0056)Lys+(0.0734)Phe+(-0.1691)Trp; 0.8
17, 0.842, 0.796, 0.799, 0.806, 0.750, 0.798, 0.788, (3.1515)+(0.00
18)Pro+(0.0040)Orn+(0.0651)Phe+(-0.1748)Trp; 0.817, 0.844, 0.8 22,
0.828, 0.830, 0.773, 0.825, 0.814, (4.6894)+(-0.0697)Asn+(0.0
012)Lys+(0.0772)Phe+(-0.1565)Trp; 0.817, 0.843, 0.821, 0.830, 0.
831, 0.776, 0.811, 0.812, (3.6313)+(-0.2158)Met+(0.0056)Lys+(0.
1086)Phe+(-0.1471)Trp; 0.817, 0.843, 0.827, 0.835, 0.836, 0.787, 0.
813, 0.818,
(4.0199)+(-0.0030)Arg+(-0.1938)Met+(0.1115)Phe+(-0.1425)Trp; 0.817,
0.833, 0.709, 0.660, 0.715, 0.816, 0.746, 0.734,
(2.3089)+(0.0414)Ser+(-0.1445)His+(-0.0406)Cit+(0.0570)Ile; 0.817,
0.835, 0.811, 0.825, 0.825, 0.825, 0.735, 0.802,
(7.4658)+(-0.0458)Asn+(0.0267)Thr+(-0.1335)Met+(-0.1382)Trp; 0.816,
0.84 2, 0.804, 0.824, 0.798, 0.761, 0.794, 0.794,
(3.6487)+(-0.0319)Tyr +(-0.0061)Val+(0.1000)Phe+(-0.1528)Trp;
0.816, 0.842, 0.784, 0. 800, 0.779, 0.738, 0.781, 0.775,
(3.4300)+(0.0048)Pro+(-0.0388)T yr+(0.0875)Phe+(-0.1622)Trp; 0.816,
0.833, 0.767, 0.750, 0.756, 0. 839, 0.787, 0.783,
(2.9524)+(0.0361)Ser+(-0.0059)Gly+(0.0065)G ln+(-0.1506)His; 0.816,
0.845, 0.802, 0.809, 0.809, 0.757, 0.805, 0. 795,
(2.4243)+(0.0021)Gln+(0.0019)Orn+(0.0658)Phe+(-0.1785)T rp; 0.816,
0.842, 0.792, 0.794, 0.805, 0.751, 0.788, 0.784, (3.0333)
+(0.0054)Thr+(0.0017)Orn+(0.0660)Phe+(-0.1787)Trp; 0.816, 0.8 37,
0.774, 0.772, 0.752, 0.803, 0.804, 0.783, (2.1541)+(0.0090)Gln
+(-0.1616)His+(-0.0425)Tyr+(0.0965)Phe; 0.816, 0.836, 0.795, 0.
785, 0.774, 0.817, 0.852, 0.807, (5.0005)+(-0.0095)Ala+(0.0053)P
ro+(0.0631)Ile+(-0.1567)Trp; 0.816, 0.845, 0.805, 0.809, 0.815, 0.
767, 0.799, 0.797, (3.5182)+(0.0091)Orn+(-0.0064)Lys+(0.0708)P
he+(-0.1665)Trp; 0.816, 0.834, 0.776, 0.759, 0.764, 0.814, 0.819,
0. 789, (2.2648)+(0.0094)Gln+(-0.1690)His+(-0.0069)Lys+(0.0763)Phe;
0.816, 0.836, 0.801, 0.794, 0.832, 0.826, 0.738, 0.798, (6.976
6)+(-0.1092)Cit+(-0.0036)Arg+(0.0554)Orn+(-0.1563)Trp; 0.816,
0.840, 0.799, 0.803, 0.810, 0.753, 0.799, 0.791, (3.2922)+(-0.000
5)Gly+(0.0056)Orn+(0.0655)Phe+(-0.1733)Trp; 0.816, 0.841, 0.79 7,
0.788, 0.809, 0.828, 0.775, 0.800, (8.2720)+(-0.0875)His+(-0.0
064)Arg+(0.0391)Orn+(-0.0980)Trp; 0.816, 0.844, 0.818, 0.829, 0.
827, 0.774, 0.799, 0.807, (2.5685)+(0.0042)Gln+(-0.0228)Arg+(0.
0772)Phe+(-0.1758)Trp; 0.816, 0.840, 0.772, 0.759, 0.781, 0.742, 0.
809, 0.773, (2.8028)+(0.0026)Thr+(0.0397)Ile+(0.0449)Phe+(-0.
1881)Trp; 0.816, 0.840, 0.771, 0.773, 0.763, 0.744, 0.805, 0.771,
(3. 2319)+(-0.0388)Tyr+(0.0434)Ile+(0.0670)Phe+(-0.1733)Trp; 0.8
16, 0.838, 0.776, 0.763, 0.783, 0.745, 0.821, 0.778, (2.9617)+(-0.0
060)Orn+(0.0424)Ile+(0.0488)Phe+(-0.1866)Trp; 0.816, 0.832, 0. 760,
0.737, 0.737, 0.824, 0.820, 0.780, (3.1450)+(0.0073)Gln+(-0.
1412)His+(0.0960)Ile+(-0.0379)Leu; 0.816, 0.835, 0.799, 0.793, 0.
804, 0.816, 0.794, 0.802, (8.3239)+(-0.0827)His+(0.0077)Pro+(0.
0077)Tyr+(-0.1038)Trp; 0.816, 0.837, 0.814, 0.812, 0.806, 0.809, 0.
840, 0.817, (4.2955)+(-0.0872)Asn+(0.0055)Gln+(0.0477)Ile+(-0.
1600)Trp; 0.816, 0.835, 0.785, 0.781, 0.772, 0.858, 0.769, 0.795,
(3. 3460)+(0.0340)Ser+(-0.0879)Asn+(0.0084)Gln+(-0.1328)His; 0.8
16, 0.842, 0.800, 0.805, 0.809, 0.757, 0.795, 0.792, (3.2198)+(0.00
62)Orn+(-0.0030)Leu+(0.0684)Phe+(-0.1712)Trp; 0.816, 0.842, 0. 803,
0.808, 0.814, 0.755, 0.803, 0.795, (3.3373)+(-0.0002)Gly+(-0.
0019)Leu+(0.0715)Phe+(-0.1717)Trp; 0.815, 0.845, 0.808, 0.813, 0.
818, 0.766, 0.806, 0.801, (3.5543)+(0.0000)Gly+(-0.0050)Lys+(0.
0755)Phe+(-0.1678)Trp; 0.815, 0.842, 0.818, 0.822, 0.811, 0.798, 0.
836, 0.817, (3.6653)+(-0.0064)Ala+(0.0046)Leu+(0.0799)Phe+(-0.
1637)Trp; 0.815, 0.839, 0.808, 0.815, 0.819, 0.787, 0.786, 0.802,
(4. 7872)+(-0.0837)Cit+(-0.0245)Tyr+(0.1037)Phe+(-0.1626)Trp; 0.
815, 0.836, 0.778, 0.772, 0.779, 0.791, 0.784, 0.782, (3.2510)+(0.0
387)Ser+(-0.0084)Gly+(0.0052)Pro+(-0.1578)Trp; 0.815, 0.842, 0.
824, 0.831, 0.817, 0.801, 0.836, 0.822, (3.8272)+(-0.0058)Ala+(-0.
0023)Lys+(0.0855)Phe+(-0.1585)Trp; 0.815, 0.829, 0.732, 0.700, 0.
731, 0.822, 0.751, 0.751, (2.0457)+(0.0320)Ser+(0.0054)Gln+(-0.
1677)His+(0.0183)Leu; 0.815, 0.836, 0.802, 0.796, 0.775, 0.824, 0.
856, 0.813, (3.8876)+(0.0031)Gln+(-0.0089)Ala+(0.0663)Ile+(-0.
1635)Trp; 0.815, 0.844, 0.828, 0.834, 0.839, 0.790, 0.819, 0.820,
(3. 8949)+(0.0043)Tyr+(-0.2057)Met+(0.1101)Phe+(-0.1435)Trp; 0.8
15, 0.836, 0.790, 0.779, 0.770, 0.819, 0.839, 0.802, (4.7362)+(0.00
87)Thr+(-0.0090)Ala+(0.0661)Ile+(-0.1638)Trp; 0.815, 0.837, 0. 766,
0.760, 0.761, 0.805, 0.765, 0.773, (3.0161)+(0.0274)Ser+(-0.
0229)Val+(0.0464)Leu+(-0.1591)Trp; 0.815, 0.834, 0.769, 0.740, 0.
743, 0.835, 0.853, 0.793, (4.6064)+(-0.1341)His+(-0.0072)Ala+(0.
0453)Ile+(0.0556)Phe; 0.815, 0.835, 0.771, 0.756, 0.780, 0.811, 0.
762, 0.777, (3.6828)+(0.0072)Gly+(-0.1310)His+(-0.1994)Met+(0.
1297)Phe; 0.815, 0.831, 0.764, 0.745, 0.723, 0.832, 0.849, 0.787,
(6. 4118)+(-0.0589)Asn+(-0.0765)His+(-0.0398)Val+(0.1396)Ile; 0.
814, 0.838, 0.747, 0.729, 0.753, 0.843, 0.714, 0.760, (3.9919)+(0.0
440)Ser+(-0.1143)His+(0.0126)Pro+(-0.1592)Met; 0.814, 0.837, 0.
777, 0.744, 0.784, 0.810, 0.829, 0.792, (4.2846)+(-0.1217)His+(-0.
2243)Met+(0.0477)Ile+(0.0942)Phe; 0.814, 0.834, 0.799, 0.794, 0.
827, 0.826, 0.735, 0.796, (6.9713)+(-0.1105)Cit+(-0.0070)Tyr+(0.
0559)Orn+(-0.1538)Trp; 0.814, 0.845, 0.808, 0.812, 0.818, 0.766, 0.
806, 0.800, (3.5631)+(-0.0052)Lys+(0.0008)Leu+(0.0749)Phe+(-0.
1683)Trp; 0.814, 0.838, 0.783, 0.773, 0.739, 0.849, 0.857, 0.804,
(4. 7993)+(-0.0029)Arg+(-0.0544)Val+(-0.2685)Met+(0.1899)Ile; 0.
814, 0.840, 0.815, 0.830, 0.813, 0.771, 0.810, 0.806, (4.7289)+(-0.
0585)Asn+(-0.0268)Tyr+(0.0925)Phe+(-0.1473)Trp; 0.814, 0.844,
0.819, 0.830, 0.826, 0.780, 0.802, 0.810,
(4.0493)+(-0.0160)Arg+(-0.0065)Val+(0.0907)Phe+(-0.1591)Trp; 0.814,
0.838, 0.850, 0.8 62, 0.851, 0.855, 0.816, 0.846,
(6.0237)+(-0.0754)Asn+(0.0086)Gl n+(-0.0705)Cit+(-0.1410)Trp;
0.814, 0.830, 0.770, 0.756, 0.755, 0. 809, 0.812, 0.783,
(2.1781)+(0.0086)Gln+(-0.1681)His+(-0.0044)Val+(0.0785)Phe; 0.814,
0.832, 0.793, 0.787, 0.802, 0.822, 0.768, 0. 795,
(8.1194)+(0.0035)Gly+(-0.0936)His+(0.0088)Val+(-0.1049)Trp; 0.814,
0.839, 0.812, 0.827, 0.800, 0.782, 0.818, 0.807, (3.795
6)+(-0.0049)Ala+(-0.0235)Tyr+(0.0945)Phe+(-0.1539)Trp; 0.814,
0.838, 0.786, 0.786, 0.773, 0.862, 0.756, 0.794,
(3.0692)+(0.0317)Ser+(0.0076)Gln+(-0.1310)His+(-0.1234)Met; 0.814,
0.832, 0.791, 0.773, 0.800, 0.805, 0.807, 0.797,
(8.0392)+(-0.0985)His+(0.006 2)Lys+(0.0213)Leu+(-0.1151)Trp; 0.814,
0.836, 0.798, 0.795, 0.80 1, 0.814, 0.787, 0.800,
(8.4970)+(-0.0796)His+(-0.0022)Arg+(0.0
086)Pro+(-0.1009)Trp; 0.814, 0.832, 0.754, 0.733, 0.715, 0.825, 0.
838, 0.778, (3.6783)+(0.0055)Gln+(-0.1227)His+(-0.0298)Val+(0.
1135)Ile; 0.814, 0.839, 0.804, 0.800, 0.808, 0.819, 0.793, 0.805,
(8. 5953)+(-0.0732)His+(0.0099)Pro+(-0.0468)Met+(-0.0979)Trp; 0.
813, 0.830, 0.774, 0.761, 0.708, 0.860, 0.885, 0.803, (3.6750)+(-0.
0113)Ala+(-0.0708)Cit+(-0.0492)Val+(0.1781)Ile; 0.813, 0.833,
0.795, 0.795, 0.798, 0.818, 0.772, 0.796,
(7.8532)+(0.0026)Gly+(-0.0911)His+(0.0109)Lys+(-0.1036)Trp; 0.813,
0.831, 0.767, 0.739, 0.756, 0.827, 0.822, 0.786,
(3.3314)+(0.0090)Gln+(-0.1557)His+(-0.0081)Lys+(0.0483)Ile; 0.813,
0.835, 0.808, 0.799, 0.795, 0.82 4, 0.847, 0.816,
(5.9042)+(-0.0054)Ala+(-0.1299)Met+(0.0744)Il e+(-0.1398)Trp;
0.813, 0.840, 0.755, 0.737, 0.764, 0.848, 0.715, 0. 766,
(4.2088)+(0.0378)Ser+(-0.1210)His+(-0.1223)Met+(0.0316) Orn; 0.813,
0.837, 0.790, 0.780, 0.791, 0.796, 0.805, 0.793, (5.704
4)+(-0.0810)Asn+(0.0138)Thr+(0.0470)Ile+(-0.1606)Trp; 0.813, 0.832,
0.711, 0.674, 0.718, 0.798, 0.732, 0.730, (0.8705)+(0.0447)
Ser+(-0.1603)His+(-0.0351)Cit+(0.0938)Phe; 0.813, 0.836, 0.777,
0.765, 0.784, 0.748, 0.816, 0.778, (2.9742)+(-0.0025)Pro+(0.043
2)Ile+(0.0463)Phe+(-0.1850)Trp; 0.813, 0.834, 0.804, 0.798, 0.81 2,
0.829, 0.788, 0.807, (8.7544)+(-0.0673)His+(-0.0366)Cit+(0.0
095)Pro+(-0.1075)Trp; 0.813, 0.832, 0.799, 0.782, 0.803, 0.822, 0.
818, 0.807,
(8.4947)+(-0.0914)His+(-0.0020)Ala+(0.0259)Leu+(-0.1094)Trp; 0.813,
0.838, 0.795, 0.812, 0.793, 0.748, 0.787, 0.785,
(3.5466)+(-0.0339)Tyr+(-0.0009)Leu+(0.0906)Phe+(-0.1600)Tr p;
0.813, 0.830, 0.767, 0.748, 0.755, 0.808, 0.813, 0.781,
(2.0217)+(0.0088)Gln+(-0.1733)His+(-0.0004)Pro+(0.0707)Phe; 0.813,
0.8 28, 0.744, 0.723, 0.740, 0.831, 0.743, 0.759,
(2.4500)+(0.0299)Ser +(0.0059)Gln+(-0.1606)His+(0.0051)Val; 0.812,
0.833, 0.808, 0.7 99, 0.789, 0.826, 0.856, 0.818,
(5.9288)+(-0.0368)Asn+(-0.0072)A la+(0.0657)Ile+(-0.1481)Trp;
0.812, 0.830, 0.767, 0.748, 0.755, 0. 808, 0.813, 0.781,
(2.0207)+(0.0088)Gln+(-0.1732)His+(-0.0003)Leu+(0.0705)Phe; 0.812,
0.831, 0.794, 0.775, 0.803, 0.815, 0.810, 0. 801,
(8.3222)+(0.0017)Asn+(-0.0946)His+(0.0241)Leu+(-0.1115)Trp; 0.812,
0.833, 0.737, 0.706, 0.710, 0.813, 0.823, 0.763, (4.927
9)+(-0.1071)His+(-0.0356)Val+(0.0258)Orn+(0.1225)Ile; 0.812, 0.827,
0.735, 0.708, 0.701, 0.812, 0.821, 0.760, (5.0451)+(-0.108
9)His+(0.0091)Thr+(-0.0341)Val+(0.1239)Ile; 0.812, 0.832, 0.80 2,
0.819, 0.815, 0.812, 0.723, 0.792, (6.4831)+(0.0235)Thr+(-0.17
75)Met+(0.0040)Lys+(-0.1444)Trp; 0.812, 0.833, 0.781, 0.768, 0.7
73, 0.819, 0.804, 0.791, (1.9858)+(0.0116)Gln+(-0.1727)His+(-0.
0231)Arg+(0.0777)Phe; 0.812, 0.832, 0.757, 0.736, 0.746, 0.800, 0.
802, 0.771, (2.0544)+(0.0079)Gln+(-0.1767)His+(0.0067)Thr+(0.
0696)Phe; 0.812, 0.838, 0.795, 0.812, 0.793, 0.746, 0.790, 0.785,
(3. 6285)+(-0.0004)Gly+(-0.0341)Tyr+(0.0896)Phe+(-0.1603)Trp; 0.
812, 0.833, 0.795, 0.773, 0.806, 0.817, 0.815, 0.803, (8.2111)+(-0.
0968)His+(0.0103)Tyr+(0.0231)Leu+(-0.1151)Trp; 0.812, 0.831, 0.
798, 0.788, 0.807, 0.809, 0.796, 0.800, (8.1159)+(-0.0945)His+(0.
0062)Val+(0.0090)Lys+(-0.1112)Trp; 0.812, 0.828, 0.758, 0.728, 0.
735, 0.835, 0.830, 0.782, (5.5845)+(-0.1345)His+(0.0136)Thr+(-0.
0070)Ala+(0.0568)Ile; 0.812, 0.826, 0.738, 0.719, 0.723, 0.844, 0.
746, 0.758, (3.9273)+(0.0374)Ser+(-0.1280)His+(-0.0056)Ala+(0.
0115)Pro; 0.812, 0.831, 0.743, 0.722, 0.742, 0.833, 0.736, 0.758,
(2. 8050)+(0.0276)Ser+(0.0050)Gln+(-0.1543)His+(0.0188)Orn; 0.81 2,
0.827, 0.761, 0.732, 0.749, 0.819, 0.819, 0.780, (3.0899)+(0.008
4)Gln+(-0.1622)His+(-0.0030)Pro+(0.0468)Ile; 0.812, 0.833, 0.7 64,
0.772, 0.763, 0.795, 0.718, 0.762, (3.2489)+(0.0273)Ser+(0.00
63)Pro+(-0.0169)Tyr+(-0.1497)Trp; 0.812, 0.829, 0.785, 0.781, 0.
714, 0.862, 0.891, 0.812,
(5.4739)+(-0.1006)Asn+(-0.0074)Ala+(-0.0541)Val+(0.1787)Ile; 0.812,
0.833, 0.767, 0.771, 0.768, 0.796, 0.735, 0.768,
(2.7816)+(0.0302)Ser+(-0.0057)Thr+(0.0057)Pro+(-0.1527)Trp; 0.812,
0.832, 0.796, 0.787, 0.775, 0.818, 0.850, 0.80 8,
(4.9433)+(0.0006)Gly+(-0.0083)Ala+(0.0675)Ile+(-0.1568)Tr p; 0.811,
0.829, 0.758, 0.740, 0.746, 0.805, 0.797, 0.772,
(1.8310)+(0.0020)Gly+(0.0083)Gln+(-0.1741)His+(0.0728)Phe; 0.811,
0.84 2, 0.803, 0.808, 0.817, 0.758, 0.790, 0.793,
(3.8711)+(-0.0184)Arg +(0.0037)Pro+(0.0761)Phe+(-0.1703)Trp; 0.811,
0.833, 0.807, 0.8 25, 0.815, 0.826, 0.728, 0.799,
(6.8213)+(0.0251)Thr+(-0.0015)Al a+(-0.1577)Met+(-0.1396)Trp;
0.811, 0.839, 0.825, 0.834, 0.822, 0. 799, 0.824, 0.820,
(4.1970)+(-0.0054)Ala+(-0.0140)Arg+(0.0902)Phe+(-0.1577)Trp; 0.811,
0.831, 0.808, 0.823, 0.821, 0.812, 0.736, 0.798,
(7.0422)+(-0.0024)Gly+(0.0268)Thr+(-0.1690)Met+(-0.14 24)Trp;
0.811, 0.828, 0.731, 0.695, 0.726, 0.835, 0.762, 0.755, (3.3
756)+(0.0398)Ser+(-0.1462)His+(-0.0044)Ala+(0.0244)Leu; 0.81 1,
0.834, 0.807, 0.818, 0.825, 0.822, 0.731, 0.799, (6.5035)+(0.024
4)Thr+(0.0176)Tyr+(-0.1936)Met+(-0.1464)Trp; 0.811, 0.829, 0.7 65,
0.758, 0.748, 0.848, 0.759, 0.778, (3.1230)+(0.0283)Ser+(0.00
61)Gln+(-0.1446)His+(-0.0022)Ala; 0.811, 0.837, 0.789, 0.805, 0.
788, 0.744, 0.777, 0.779, (3.4379)+(-0.0363)Tyr+(0.0096)Orn+(0.
0843)Phe+(-0.1600)Trp; 0.811, 0.834, 0.770, 0.778, 0.777, 0.808, 0.
705, 0.767, (3.5483)+(0.0320)Ser+(-0.0216)Arg+(0.0070)Pro+(-0.
1506)Trp; 0.811, 0.836, 0.740, 0.708, 0.752, 0.829, 0.735, 0.756,
(3. 3118)+(0.0473)Ser+(-0.1330)His+(-0.1623)Met+(0.0304)Leu; 0.8
11, 0.832, 0.803, 0.804, 0.794, 0.827, 0.801, 0.806, (4.0489)+(0.03
80)Ser+(-0.0076)Gly+(-0.0031)Ala+(-0.1436)Trp; 0.811, 0.832, 0.
790, 0.772, 0.791, 0.815, 0.818, 0.799, (8.3663)+(-0.0902)His+(-0.
0165)Val+(0.0504)Leu+(-0.1084)Trp; 0.811, 0.834, 0.818, 0.819, 0.
823, 0.834, 0.795, 0.818, (7.7200)+(-0.0062)Ala+(-0.0702)Cit+(0.
0142)Pro+(-0.1382)Trp; 0.811, 0.832, 0.761, 0.738, 0.752, 0.809, 0.
805, 0.776, (2.0033)+(0.0083)Gln+(-0.1735)His+(0.0107)Orn+(0.
0661)Phe; 0.811, 0.833, 0.795, 0.785, 0.777, 0.815, 0.847, 0.806,
(4. 9222)+(-0.0084)Ala+(0.0064)Orn+(0.0649)Ile+(-0.1571)Trp; 0.8
11, 0.833, 0.767, 0.770, 0.772, 0.800, 0.723, 0.766, (3.1908)+(0.02
97)Ser+(0.0056)Pro+(-0.0064)Lys+(-0.1489)Trp; 0.811, 0.838, 0. 798,
0.814, 0.796, 0.752, 0.790, 0.788, (3.6783)+(-0.0324)Tyr+(-0.
0026)Lys+(0.0918)Phe+(-0.1582)Trp; 0.811, 0.830, 0.804, 0.803, 0.
804, 0.819, 0.795, 0.805, (8.2595)+(-0.0867)His+(-0.0008)Ala+(0.
0113)Lys+(-0.1036)Trp; 0.810, 0.837, 0.803, 0.809, 0.819, 0.765, 0.
778, 0.793, (3.8918)+(-0.0199)Arg+(0.0130)Orn+(0.0718)Phe+(-0.
1678)Trp; 0.810, 0.828, 0.770, 0.748, 0.761, 0.828, 0.807, 0.786,
(3. 1225)+(0.0109)Gln+(-0.1602)His+(-0.0209)Arg+(0.0449)Ile; 0.8
10, 0.825, 0.752, 0.720, 0.743, 0.816, 0.808, 0.772, (3.0409)+(0.00
78)Gln+(-0.1646)His+(0.0044)Thr+(0.0422)Ile; 0.810, 0.831, 0.8 16,
0.824, 0.833, 0.826, 0.755, 0.810, (5.5175)+(0.0042)Gln+(0.01
00)Thr+(-0.0780)Cit+(-0.1625)Trp; 0.810, 0.835, 0.842, 0.856, 0.
845, 0.850, 0.793, 0.836, (5.4438)+(0.0073)Gln+(-0.0645)Cit+(-0.
0924)Met+(-0.1392)Trp; 0.810, 0.834, 0.786, 0.783, 0.789, 0.796, 0.
780, 0.787, (3.3162)+(0.0370)Ser+(-0.0084)Gly+(0.0122)Orn+(-0.
1560)Trp; 0.810, 0.834, 0.779, 0.758, 0.763, 0.833, 0.830, 0.796,
(6. 1820)+(-0.0886)His+(-0.1511)Met+(0.1324)Ile+(-0.0501)Leu; 0.
810, 0.836, 0.783, 0.776, 0.793, 0.753, 0.805, 0.782, (3.6270)+(-0.
0194)Arg+(0.0424)Ile+(0.0553)Phe+(-0.1799)Trp; 0.810, 0.834, 0.
776, 0.770, 0.752, 0.800, 0.826, 0.787, (0.2209)+(-0.3247)Met+(0.
1744)Ile+(-0.0961)Leu+(0.1055)Phe; 0.810, 0.831, 0.743, 0.720, 0.
742, 0.843, 0.734, 0.760, (4.0623)+(0.0328)Ser+(-0.1341)His+(-0.
0031)Ala+(0.0278)Orn; 0.810, 0.829, 0.771, 0.766, 0.767, 0.851, 0.
735, 0.780, (3.0439)+(0.0309)Ser+(0.0082)Gln+(-0.1468)His+(-0.
0224)Arg; 0.810, 0.834, 0.797, 0.811, 0.810, 0.816, 0.720, 0.789,
(6. 2620)+(0.0216)Thr+(-0.1736)Met+(0.0173)Orn+(-0.1415)Trp; 0.8
10, 0.826, 0.740, 0.720, 0.736, 0.828, 0.738, 0.756, (2.6042)+(0.02
98)Ser+(0.0055)Gln+(-0.1538)His+(0.0053)Pro; 0.810, 0.825, 0.7 38,
0.713, 0.703, 0.815, 0.821, 0.763, (5.0639)+(0.0019)Gly+(-0.1
025)His+(-0.0340)Val+(0.1261)Ile; 0.810, 0.831, 0.772, 0.762, 0.
715, 0.823, 0.881, 0.795, (3.8224)+(-0.1505)Asn+(-0.0607)Val+(0.
1632)Ile+(0.0631)Phe; 0.810, 0.829, 0.759, 0.749, 0.748, 0.843, 0.
746, 0.771, (3.0972)+(0.0291)Ser+(0.0062)Gln+(-0.1468)His+(-0.
0038)Lys; 0.810, 0.830, 0.739, 0.705, 0.744, 0.830, 0.751, 0.758,
(3. 9002)+(0.0395)Ser+(-0.0047)Gly+(-0.1396)His+(0.0244)Orn; 0.8
10, 0.829, 0.807, 0.806, 0.809, 0.815, 0.799, 0.808, (8.5292)+(-0.0
228)Asn+(-0.0833)His+(0.0125)Lys+(-0.1041)Trp; 0.810, 0.826, 0.
753, 0.742, 0.742, 0.836, 0.744, 0.766, (2.9040)+(0.0286)Ser+(0.0
060)Gln+(-0.1501)His+(-0.0005)Thr; 0.810, 0.832, 0.763, 0.767, 0.
771, 0.786, 0.722, 0.761, (2.7135)+(0.0261)Ser+(0.0038)Pro+(0.0
076)Orn+(-0.1585)Trp; 0.810, 0.830, 0.804, 0.808, 0.804, 0.833, 0.
770, 0.804,
(8.5238)+(0.0028)Gly+(-0.0797)His+(-0.0001)Ala+(-0.0940)Trp; 0.810,
0.833, 0.794, 0.776, 0.802, 0.812, 0.812, 0.801,
(8.2462)+(-0.0954)His+(0.0024)Arg+(0.0242)Leu+(-0.1119)Trp; 0.810,
0.827, 0.806, 0.800, 0.810, 0.825, 0.801, 0.809,
(8.7168)+(-0.0860)His+(-0.0014)Ala+(0.0087)Val+(-0.1042)Trp; 0.810,
0.83 7, 0.806, 0.813, 0.822, 0.762, 0.785, 0.796,
(3.7751)+(0.0009)Gly+(-0.0174)Arg+(0.0801)Phe+(-0.1687)Trp; 0.810,
0.830, 0.791, 0.7 99, 0.782, 0.834, 0.755, 0.793,
(3.4755)+(0.0260)Ser+(-0.0048)Al a+(0.0174)Orn+(-0.1451)Trp; 0.810,
0.830, 0.768, 0.773, 0.773, 0. 795, 0.725, 0.766,
(3.0252)+(0.0269)Ser+(0.0053)Pro+(-0.0021)V al+(-0.1536)Trp; 0.809,
0.825, 0.752, 0.722, 0.742, 0.816, 0.807, 0. 772,
(2.9319)+(0.0012)Gly+(0.0080)Gln+(-0.1625)His+(0.0435)I le; 0.809,
0.825, 0.744, 0.720, 0.708, 0.814, 0.832, 0.769, (5.3081)
+(-0.0979)His+(-0.0325)Val+(0.1336)Ile+(-0.0085)Leu; 0.809, 0. 830,
0.792, 0.801, 0.785, 0.835, 0.753, 0.794, (3.7787)+(0.0271)Se
r+(0.0014)Thr+(-0.0038)Ala+(-0.1437)Trp; 0.809, 0.831, 0.732, 0.
704, 0.743, 0.830, 0.711, 0.747, (4.0471)+(0.0341)Ser+(-0.1364)H
is+(0.0276)Orn+(-0.0051)Lys; 0.809, 0.830, 0.797, 0.795, 0.820, 0.
812, 0.742, 0.792, (6.7657)+(0.0118)Thr+(-0.0771)Cit+(0.0068)P
ro+(-0.1612)Trp; 0.809, 0.829, 0.806, 0.812, 0.806, 0.834, 0.771,
0. 806, (8.6863)+(-0.0109)Asn+(0.0030)Gly+(-0.0772)His+(-0.093
1)Trp; 0.809, 0.830, 0.796, 0.788, 0.775, 0.815, 0.849, 0.807,
(5.15 10)+(-0.0079)Ala+(-0.0053)Tyr+(0.0676)Ile+(-0.1546)Trp; 0.80
9, 0.839, 0.810, 0.817, 0.825, 0.763, 0.794, 0.799, (3.9502)+(-0.01
69)Arg+(-0.0013)Leu+(0.0804)Phe+(-0.1672)Trp; 0.809, 0.833, 0. 801,
0.817, 0.816, 0.813, 0.717, 0.791, (6.6421)+(0.0247)Thr+(0.0
008)Val+(-0.1696)Met+(-0.1424)Trp; 0.809, 0.831, 0.804, 0.792, 0.
814, 0.819, 0.801, 0.807, (8.4259)+(-0.0904)His+(0.0126)Tyr+(0.
0071)Val+(-0.1097)Trp; 0.809, 0.832, 0.775, 0.782, 0.781, 0.810, 0.
721, 0.774, (3.2415)+(0.0283)Ser+(0.0157)Orn+(-0.0073)Lys+(-0.
1466)Trp; 0.809, 0.832, 0.762, 0.764, 0.770, 0.790, 0.723, 0.761,
(3. 0270)+(0.0281)Ser+(-0.0007)Gln+(0.0049)Pro+(-0.1559)Trp; 0.8
09, 0.832, 0.810, 0.810, 0.814, 0.822, 0.795, 0.810, (8.3905)+(-0.0
822)His+(-0.0596)Met+(0.0146)Lys+(-0.1023)Trp; 0.809, 0.829, 0.
731, 0.695, 0.741, 0.822, 0.739, 0.749, (3.8159)+(0.0451)Ser+(-0.
0632)Asn+(-0.1372)His+(0.0209)Leu; 0.809, 0.827, 0.761, 0.743, 0.
741, 0.813, 0.810, 0.777, (3.4909)+(0.0084)Gln+(-0.1515)His+(-0.
0270)Tyr+(0.0495)Ile; 0.809, 0.831, 0.815, 0.813, 0.830, 0.816, 0.
788, 0.812, (5.0136)+(0.0051)Gln+(-0.0817)Cit+(0.0146)Leu+(-0.
1696)Trp; 0.809, 0.829, 0.744, 0.725, 0.725, 0.780, 0.806, 0.759,
(4. 6402)+(-0.1371)His+(-0.0491)Tyr+(0.0390)Ile+(0.0786)Phe; 0.8
08, 0.830, 0.732, 0.724, 0.724, 0.764, 0.744, 0.739, (4.3880)+(-0.1
500)His+(0.0218)Thr+(-0.0566)Tyr+(0.1046)Phe; 0.808, 0.831, 0. 802,
0.819, 0.820, 0.820, 0.704, 0.791, (7.1418)+(0.0288)Thr+(-0.
0132)Arg+(-0.1612)Met+(-0.1394)Trp; 0.808, 0.830, 0.790, 0.789,
0.790, 0.803, 0.787, 0.792,
(3.6192)+(0.0384)Ser+(-0.0082)Gly+(-0.0002)Thr+(-0.1522)Trp; 0.808,
0.830, 0.781, 0.779, 0.771, 0.8 22, 0.775, 0.787,
(2.9611)+(0.0292)Ser+(-0.0056)Ala+(0.0171)Le u+(-0.1552)Trp; 0.808,
0.831, 0.746, 0.722, 0.755, 0.839, 0.723, 0. 760,
(4.4635)+(0.0392)Ser+(-0.0690)Asn+(-0.1235)His+(0.0287)Orn; 0.808,
0.825, 0.724, 0.682, 0.730, 0.815, 0.757, 0.746, (3.266
7)+(0.0444)Ser+(-0.0040)Gly+(-0.1508)His+(0.0189)Leu; 0.808, 0.823,
0.717, 0.680, 0.717, 0.815, 0.746, 0.740,
(3.3138)+(0.0383)Ser+(-0.1448)His+(-0.0176)Val+(0.0456)Leu; 0.808,
0.828, 0.802, 0.794, 0.811, 0.818, 0.793, 0.804,
(8.5804)+(0.0012)Asn+(-0.087 8)His+(0.0080)Val+(-0.1055)Trp; 0.808,
0.826, 0.720, 0.679, 0.73 1, 0.821, 0.730, 0.740,
(3.4087)+(0.0421)Ser+(-0.1472)His+(-0.0 090)Lys+(0.0248)Leu; 0.808,
0.831, 0.794, 0.803, 0.787, 0.839, 0.7 53, 0.796,
(3.8930)+(0.0288)Ser+(-0.0034)Ala+(-0.0026)Lys+(-0. 1398)Trp;
0.808, 0.827, 0.815, 0.815, 0.829, 0.818, 0.783, 0.811, (8.
0818)+(-0.0400)Asn+(-0.0653)Cit+(0.0090)Pro+(-0.1401)Trp; 0. 808,
0.831, 0.794, 0.784, 0.795, 0.796, 0.815, 0.797, (5.6821)+(0.0
029)Pro+(-0.1724)Met+(0.0626)Ile+(-0.1434)Trp; 0.808, 0.833, 0.
778, 0.768, 0.782, 0.788, 0.789, 0.782, (3.0340)+(0.0387)Ser+(-0.
0081)Gly+(0.0093)Leu+(-0.1623)Trp; 0.808, 0.830, 0.793, 0.785, 0.
822, 0.804, 0.749, 0.790, (6.4457)+(0.0135)Thr+(-0.0795)Cit+(0.
0150)Leu+(-0.1727)Trp; 0.808, 0.830, 0.802, 0.796, 0.808, 0.836, 0.
780, 0.805, (8.1309)+(0.0032)Gly+(-0.0876)His+(0.0203)Tyr+(-0.
1020)Trp; 0.808, 0.829, 0.795, 0.809, 0.793, 0.837, 0.732, 0.793,
(4. 2202)+(0.0312)Ser+(-0.0028)Ala+(-0.0153)Arg+(-0.1382)Trp; 0.
808, 0.827, 0.747, 0.723, 0.711, 0.817, 0.836, 0.772, (5.4084)+(-0.
0995)His+(-0.0018)Pro+(-0.0348)Val+(0.1296)Ile; 0.808, 0.827,
0.710, 0.666, 0.721, 0.818, 0.724, 0.732,
(2.9965)+(0.0366)Ser+(-0.1553)His+(0.0164)Orn+(0.0166)Leu; 0.808,
0.827, 0.754, 0.722, 0.747, 0.815, 0.812, 0.774,
(3.0101)+(0.0079)Gln+(-0.1632)His+(0.0081)Orn+(0.0404)Ile; 0.808,
0.828, 0.837, 0.849, 0.840, 0.846, 0.794, 0.832,
(5.5839)+(0.0060)Gln+(-0.0030)Ala+(-0.0710)Cit+(-0.1465)Trp; 0.808,
0.825, 0.756, 0.728, 0.734, 0.836, 0.818, 0.77 9,
(5.3494)+(0.0041)Gly+(-0.1269)His+(-0.0066)Ala+(0.0608)Il e; 0.808,
0.828, 0.792, 0.782, 0.796, 0.798, 0.809, 0.796,
(5.4986)+(-0.1707)Met+(0.0099)Orn+(0.0623)Ile+(-0.1436)Trp; 0.808,
0.8 31, 0.825, 0.841, 0.825, 0.824, 0.784, 0.819,
(5.5542)+(-0.1088)As n+(0.0056)Gln+(0.0151)Thr+(-0.1462)Trp; 0.808,
0.831, 0.796, 0. 806, 0.786, 0.836, 0.759, 0.797,
(3.5343)+(0.0265)Ser+(0.0009)Gl n+(-0.0039)Ala+(-0.1440)Trp; 0.808,
0.830, 0.793, 0.794, 0.792, 0. 814, 0.781, 0.795,
(3.9816)+(0.0406)Ser+(-0.0084)Gly+(-0.0052)Lys+(-0.1450)Trp; 0.808,
0.824, 0.742, 0.711, 0.728, 0.810, 0.801, 0.763,
(5.1458)+(-0.1220)His+(0.0072)Thr+(0.1016)Ile+(-0.041 5)Leu; 0.808,
0.832, 0.794, 0.797, 0.787, 0.849, 0.762, 0.799, (4.59
95)+(0.0092)Gln+(-0.1364)His+(0.0221)Thr+(-0.1690)Met; 0.808,
0.831, 0.801, 0.791, 0.780, 0.823, 0.853, 0.812, (5.4072)+(-0.007
9)Ala+(-0.0051)Lys+(0.0704)Ile+(-0.1512)Trp; 0.807, 0.835, 0.7 56,
0.749, 0.762, 0.850, 0.694, 0.764, (4.8062)+(0.0348)Ser+(-0.1
177)His+(0.0181)Thr+(-0.1569)Met; 0.807, 0.832, 0.764, 0.762, 0.
769, 0.797, 0.734, 0.766, (2.8281)+(0.0322)Ser+(-0.0098)Lys+(0.
0160)Leu+(-0.1558)Trp; 0.807, 0.829, 0.797, 0.788, 0.799, 0.799, 0.
817, 0.801,
(5.8591)+(-0.0084)Asn+(-0.1562)Met+(0.0649)Ile+(-0.1427)Trp; 0.807,
0.831, 0.815, 0.821, 0.831, 0.843, 0.747, 0.811,
(7.3461)+(0.0173)Thr+(-0.0036)Ala+(-0.0701)Cit+(-0.1494)Tr p;
0.807, 0.828, 0.771, 0.751, 0.763, 0.816, 0.807, 0.784,
(2.0475)+(0.0097)Gln+(-0.1673)His+(-0.0421)Cit+(0.0760)Phe; 0.807,
0.8 26, 0.746, 0.721, 0.709, 0.815, 0.835, 0.770,
(5.4947)+(-0.0969)Hi s+(-0.0349)Val+(-0.0026)Lys+(0.1294)Ile;
0.807, 0.824, 0.757, 0. 746, 0.751, 0.842, 0.736, 0.769,
(3.0133)+(0.0294)Ser+(0.0066)Gl n+(-0.1431)His+(-0.0360)Cit; 0.807,
0.830, 0.814, 0.818, 0.826, 0. 816, 0.776, 0.809,
(5.2929)+(0.0050)Gln+(-0.0816)Cit+(0.0074)P ro+(-0.1613)Trp; 0.807,
0.825, 0.747, 0.729, 0.707, 0.815, 0.829, 0. 770,
(5.7567)+(-0.0932)His+(-0.0208)Tyr+(-0.0340)Val+(0.131 0)Ile;
0.807, 0.830, 0.790, 0.788, 0.790, 0.802, 0.786, 0.792, (3.60
27)+(0.0383)Ser+(-0.0082)Gly+(0.0002)Val+(-0.1527)Trp; 0.807,
0.829, 0.790, 0.782, 0.791, 0.799, 0.803, 0.794,
(5.3784)+(0.0018)
Gly+(-0.1712)Met+(0.0667)Ile+(-0.1429)Trp; 0.807, 0.826, 0.755,
0.740, 0.731, 0.809, 0.807, 0.772, (5.8998)+(-0.1026)His+(-0.027
8)Tyr+(0.1161)Ile+(-0.0460)Leu; 0.807, 0.829, 0.772, 0.782, 0.77 4,
0.806, 0.714, 0.769, (3.2676)+(0.0258)Ser+(-0.0144)Tyr+(0.01
42)Orn+(-0.1491)Trp; 0.807, 0.829, 0.776, 0.781, 0.779, 0.806, 0.7
36, 0.775, (2.8373)+(0.0286)Ser+(-0.0055)Thr+(0.0138)Orn+(-0.
1513)Trp; 0.807, 0.831, 0.806, 0.810, 0.813, 0.840, 0.753, 0.804,
(8. 7794)+(0.0040)Gly+(-0.0687)His+(-0.0364)Cit+(-0.0982)Trp; 0.
807, 0.831, 0.759, 0.757, 0.767, 0.783, 0.731, 0.759, (2.4883)+(0.0
274)Ser+(0.0033)Pro+(0.0077)Leu+(-0.1642)Trp; 0.807, 0.829, 0. 743,
0.709, 0.733, 0.816, 0.804, 0.766, (5.0254)+(-0.1197)His+(0.
0212)Orn+(0.1025)Ile+(-0.0454)Leu; 0.807, 0.831, 0.775, 0.782, 0.
781, 0.802, 0.724, 0.772, (3.0725)+(0.0254)Ser+(-0.0019)Val+(0.
0126)Orn+(-0.1525)Trp; 0.807, 0.823, 0.760, 0.729, 0.755, 0.818, 0.
812, 0.778, (3.0007)+(0.0094)Gln+(-0.1544)His+(-0.0459)Cit+(0.
0473)Ile; 0.807, 0.827, 0.736, 0.712, 0.752, 0.833, 0.696, 0.748,
(4. 2235)+(0.0363)Ser+(-0.1345)His+(-0.0183)Arg+(0.0296)Orn; 0.8
07, 0.828, 0.739, 0.718, 0.744, 0.829, 0.724, 0.754, (4.3549)+(0.04
27)Ser+(-0.0662)Asn+(-0.1212)His+(0.0078)Pro; 0.807, 0.833, 0. 779,
0.788, 0.791, 0.817, 0.700, 0.774, (3.5973)+(0.0299)Ser+(-0.
0224)Arg+(0.0192)Orn+(-0.1488)Trp; 0.806, 0.831, 0.792, 0.791, 0.
791, 0.804, 0.788, 0.794, (3.4870)+(0.0377)Ser+(-0.0083)Gly+(0.
0005)Gln+(-0.1533)Trp; 0.806, 0.827, 0.762, 0.725, 0.747, 0.836, 0.
836, 0.786, (5.6514)+(-0.1284)His+(-0.0068)Ala+(0.0226)Orn+(0.
0522)Ile; 0.806, 0.831, 0.799, 0.782, 0.808, 0.817, 0.812, 0.805,
(8. 5247)+(-0.0884)His+(-0.0400)Met+(0.0255)Leu+(-0.1078)Trp; 0.
806, 0.828, 0.718, 0.684, 0.728, 0.822, 0.712, 0.737, (3.4414)+(0.0
340)Ser+(-0.1439)His+(0.0048)Pro+(0.0207)Orn; 0.806, 0.830, 0. 802,
0.796, 0.807, 0.817, 0.798, 0.805, (8.0929)+(-0.0900)His+(0.
0105)Tyr+(0.0098)Lys+(-0.1081)Trp; 0.806, 0.827, 0.779, 0.787, 0.
782, 0.813, 0.725, 0.777, (3.5121)+(0.0289)Ser+(0.0004)Thr+(-0.
0049)Lys+(-0.1460)Trp; 0.806, 0.825, 0.755, 0.748, 0.743, 0.837, 0.
743, 0.768, (3.0494)+(0.0282)Ser+(0.0060)Gln+(-0.1469)His+(-0.
0065)Tyr; 0.806, 0.823, 0.709, 0.666, 0.719, 0.813, 0.726, 0.731,
(2. 9629)+(0.0389)Ser+(-0.1532)His+(0.0033)Pro+(0.0174)Leu; 0.80 6,
0.830, 0.791, 0.794, 0.788, 0.807, 0.779, 0.792, (3.9719)+(0.038
9)Ser+(-0.0084)Gly+(-0.0115)Tyr+(-0.1460)Trp; 0.806, 0.826, 0. 804,
0.807, 0.827, 0.825, 0.733, 0.798, (6.9470)+(0.0003)Gly+(0.0
144)Thr+(-0.0725)Cit+(-0.1571)Trp; 0.806, 0.823, 0.733, 0.702, 0.
735, 0.822, 0.749, 0.752, (3.8136)+(0.0430)Ser+(-0.0047)Gly+(-0.
1366)His+(0.0063)Pro; 0.806, 0.823, 0.746, 0.720, 0.715, 0.820, 0.
827, 0.770,
(5.6289)+(-0.0914)His+(-0.0344)Cit+(-0.0350)Val+(0.1308)Ile; 0.806,
0.827, 0.778, 0.771, 0.777, 0.768, 0.809, 0.781,
(3.5241)+(0.0020)Gln+(-0.0020)Orn+(0.0489)Ile+(-0.1762)Trp; 0.806,
0.827, 0.797, 0.779, 0.813, 0.817, 0.800, 0.802,
(8.6915)+(-0.0810)His+(-0.0365)Cit+(0.0254)Leu+(-0.1175)Trp; 0.806,
0.83 8, 0.809, 0.815, 0.825, 0.762, 0.794, 0.799,
(3.9508)+(-0.0166)Arg +(-0.0005)Lys+(0.0795)Phe+(-0.1678)Trp;
0.806, 0.828, 0.777, 0. 779, 0.766, 0.773, 0.798, 0.779,
(3.9166)+(0.0024)Gln+(-0.0244)T yr+(0.0522)Ile+(-0.1656)Trp; 0.806,
0.831, 0.769, 0.772, 0.777, 0. 801, 0.720, 0.767,
(3.0920)+(0.0268)Ser+(-0.0007)Gln+(0.0117)O rn+(-0.1544)Trp; 0.806,
0.835, 0.801, 0.816, 0.804, 0.760, 0.780, 0. 790,
(4.0243)+(-0.0135)Arg+(-0.0287)Tyr+(0.0939)Phe+(-0.158 0)Trp;
0.806, 0.830, 0.794, 0.802, 0.786, 0.835, 0.757, 0.795, (3.72
98)+(0.0278)Ser+(-0.0038)Ala+(0.0015)Tyr+(-0.1432)Trp; 0.806,
0.829, 0.802, 0.793, 0.811, 0.818, 0.796, 0.805, (8.5338)+(-0.088
2)His+(0.0015)Arg+(0.0080)Val+(-0.1058)Trp; 0.806, 0.834, 0.74 2,
0.733, 0.714, 0.839, 0.754, 0.760, (-0.5532)+(0.0402)Ser+(-0.3
095)Met+(0.1705)Ile+(-0.0749)Leu; 0.806, 0.828, 0.792, 0.782, 0.
793, 0.793, 0.815, 0.796, (5.6139)+(-0.0593)Asn+(0.0086)Orn+(0.
0471)Ile+(-0.1553)Trp; 0.806, 0.828, 0.723, 0.690, 0.734, 0.822, 0.
715, 0.740, (3.5910)+(0.0339)Ser+(-0.1449)His+(0.0023)Val+(0.
0222)Orn; 0.806, 0.821, 0.738, 0.708, 0.741, 0.824, 0.750, 0.756,
(3. 8853)+(0.0430)Ser+(-0.0044)Gly+(-0.1400)His+(0.0045)Val; 0.8
06, 0.827, 0.777, 0.788, 0.778, 0.810, 0.725, 0.775, (3.4438)+(0.02
77)Ser+(-0.0008)Thr+(-0.0079)Tyr+(-0.1476)Trp; 0.805, 0.828, 0.
806, 0.810, 0.829, 0.830, 0.733, 0.800, (7.1581)+(0.0157)Thr+(-0.
0719)Cit+(-0.0023)Lys+(-0.1552)Trp; 0.805, 0.829, 0.800, 0.794,
0.784, 0.817, 0.842, 0.809,
(5.5251)+(-0.0077)Ala+(-0.0104)Arg+(0.0683)Ile+(-0.1526)Trp; 0.805,
0.828, 0.813, 0.814, 0.829, 0.81 8, 0.773, 0.809,
(7.7121)+(-0.0607)Cit+(0.0108)Pro+(-0.0833)Me t+(-0.1355)Trp;
0.805, 0.829, 0.789, 0.796, 0.782, 0.831, 0.756, 0. 791,
(3.5070)+(0.0282)Ser+(-0.0043)Ala+(0.0031)Val+(-0.1469) Trp; 0.805,
0.828, 0.794, 0.785, 0.795, 0.798, 0.814, 0.798, (5.613
1)+(-0.1691)Met+(0.0017)Lys+(0.0647)Ile+(-0.1449)Trp; 0.805, 0.829,
0.788, 0.788, 0.784, 0.793, 0.790, 0.789, (5.1604)+(-0.027
0)Val+(0.0218)Orn+(0.0479)Leu+(-0.1519)Trp; 0.805, 0.825, 0.81 1,
0.814, 0.811, 0.827, 0.789, 0.810, (8.9674)+(-0.0058)Asn+(-0.0
747)His+(0.0000)Ala+(-0.0944)Trp; 0.805, 0.827, 0.828, 0.838, 0.
839, 0.831, 0.779, 0.822, (5.4327)+(0.0057)Gln+(-0.0742)Cit+(-0.
0010)Lys+(-0.1532)Trp; 0.805, 0.826, 0.801, 0.801, 0.828, 0.816, 0.
734, 0.795, (6.8094)+(0.0138)Thr+(-0.0759)Cit+(0.0033)Val+(-0.
1631)Trp; 0.805, 0.828, 0.776, 0.783, 0.780, 0.810, 0.725, 0.774,
(3. 3635)+(0.0296)Ser+(0.0018)Val+(-0.0057)Lys+(-0.1480)Trp; 0.8
05, 0.826, 0.798, 0.789, 0.819, 0.797, 0.779, 0.796, (6.7541)+(-0.0
761)Cit+(0.0066)Pro+(0.0126)Leu+(-0.1622)Trp; 0.805, 0.828, 0. 781,
0.790, 0.783, 0.815, 0.729, 0.779, (3.3702)+(0.0284)Ser+(0.0
005)Gln+(-0.0051)Lys+(-0.1464)Trp; 0.805, 0.829, 0.766, 0.766, 0.
771, 0.790, 0.741, 0.767, (2.5362)+(0.0301)Ser+(-0.0043)Thr+(0.
0108)Leu+(-0.1599)Trp; 0.805, 0.830, 0.844, 0.863, 0.837, 0.842, 0.
812, 0.838,
(5.2885)+(-0.0564)Asn+(0.0076)Gln+(-0.0913)Met+(-0.1317)Trp; 0.805,
0.830, 0.803, 0.808, 0.804, 0.832, 0.770, 0.803,
(8.5141)+(0.0027)Gly+(-0.0799)His+(0.0001)Arg+(-0.0941)Trp; 0.805,
0.826, 0.826, 0.835, 0.836, 0.830, 0.775, 0.819, (5.3574)+(0.
0004)Gly+(0.0055)Gln+(-0.0749)Cit+(-0.1543)Trp; 0.805, 0.829,
0.778, 0.755, 0.788, 0.807, 0.801, 0.788,
(4.3758)+(-0.1254)His+(-0.1794)Met+(0.0247)Orn+(0.1050)Phe; 0.805,
0.828, 0.728, 0.69 8, 0.737, 0.828, 0.717, 0.745,
(3.7556)+(0.0336)Ser+(-0.1402)His +(-0.0014)Thr+(0.0251)Orn; 0.805,
0.823, 0.712, 0.673, 0.722, 0.8 13, 0.724, 0.733,
(3.1098)+(0.0383)Ser+(-0.1539)His+(0.0014)Th r+(0.0196)Leu; 0.805,
0.822, 0.793, 0.778, 0.786, 0.835, 0.820, 0.8 05,
(4.0394)+(-0.0611)Asn+(0.0114)Gln+(-0.1504)His+(0.0132)L eu; 0.804,
0.824, 0.759, 0.732, 0.745, 0.817, 0.821, 0.779, (5.7670)
+(-0.0218)Asn+(-0.1057)His+(0.1096)Ile+(-0.0464)Leu; 0.804, 0. 828,
0.782, 0.775, 0.781, 0.768, 0.813, 0.784, (3.6405)+(-0.0012)G
ly+(0.0021)Gln+(0.0476)Ile+(-0.1760)Trp; 0.804, 0.827, 0.778, 0.
790, 0.790, 0.813, 0.696, 0.772, (3.9836)+(0.0292)Ser+(0.0049)Th
r+(-0.0204)Arg+(-0.1485)Trp; 0.804, 0.825, 0.737, 0.709, 0.742, 0.
780, 0.769, 0.750,
(4.6210)+(-0.1532)His+(0.0179)Thr+(-0.0086)Lys+(0.0790)Phe; 0.804,
0.825, 0.806, 0.797, 0.823, 0.818, 0.789, 0. 807,
(8.9569)+(-0.0754)His+(-0.0377)Cit+(0.0092)Val+(-0.112 2)Trp;
0.804, 0.821, 0.739, 0.711, 0.723, 0.814, 0.790, 0.760, (4.88
48)+(0.0031)Gly+(-0.1178)His+(0.1065)Ile+(-0.0430)Leu; 0.804,
0.828, 0.775, 0.767, 0.775, 0.767, 0.803, 0.778,
(3.5135)+(0.0017)Gln+(0.0016)Thr+(0.0477)Ile+(-0.1771)Trp; 0.804,
0.831, 0.806, 0.811, 0.807, 0.834, 0.770, 0.806,
(8.5901)+(0.0029)Gly+(-0.077 6)His+(-0.0143)Met+(-0.0927)Trp;
0.804, 0.826, 0.813, 0.807, 0.8 15, 0.836, 0.805, 0.816,
(8.6540)+(-0.0811)His+(-0.0012)Ala+(0. 0209)Tyr+(-0.1020)Trp;
0.804, 0.822, 0.740, 0.717, 0.738, 0.838, 0. 738, 0.758,
(3.8950)+(0.0378)Ser+(-0.1383)His+(-0.0034)Ala+(0. 0075)Val; 0.804,
0.830, 0.800, 0.786, 0.805, 0.804, 0.823, 0.805, (5.
5396)+(0.0151)Tyr+(-0.1889)Met+(0.0648)Ile+(-0.1468)Trp; 0.8 04,
0.830, 0.763, 0.762, 0.772, 0.789, 0.729, 0.763, (2.5017)+(0.02
68)Ser+(0.0069)Orn+(0.0083)Leu+(-0.1635)Trp; 0.804, 0.827, 0.7 64,
0.763, 0.757, 0.767, 0.777, 0.766, (4.5967)+(0.0074)Thr+(-0.0
274)Tyr+(0.0525)Ile+(-0.1651)Trp; 0.804, 0.819, 0.718, 0.687, 0.
725, 0.816, 0.715, 0.736, (3.4756)+(0.0371)Ser+(-0.1430)His+(0.
0055)Pro+(0.0029)Val; 0.804, 0.822, 0.793, 0.790, 0.782, 0.842, 0.
793, 0.801, (4.7632)+(-0.0783)Asn+(0.0102)Gln+(-0.1415)His+(0.
0133)Thr; 0.804, 0.828, 0.797, 0.784, 0.790, 0.841, 0.814, 0.807,
(3. 6372)+(0.0114)Gln+(-0.1481)His+(-0.1400)Met+(0.0212)Leu; 0.8
04, 0.825, 0.746, 0.731, 0.748, 0.838, 0.715, 0.758, (4.9208)+(0.03
85)Ser+(-0.0688)Asn+(-0.1209)His+(0.0090)Thr; 0.804, 0.828, 0. 778,
0.790, 0.777, 0.807, 0.725, 0.775, (3.3878)+(0.0269)Ser+(0.0
003)Gln+(-0.0089)Tyr+(-0.1484)Trp; 0.804, 0.826, 0.803, 0.808, 0.
825, 0.823, 0.729, 0.796, (7.0519)+(0.0152)Thr+(-0.0713)Cit+(-0.
0043)Tyr+(-0.1554)Trp; 0.804, 0.826, 0.820, 0.825, 0.835, 0.822, 0.
775, 0.814, (5.1891)+(0.0054)Gln+(-0.0796)Cit+(0.0041)Val+(-0.
1625)Trp; 0.804, 0.825, 0.802, 0.813, 0.810, 0.803, 0.757, 0.796,
(6. 8961)+(-0.0843)Asn+(0.0163)Thr+(0.0043)Pro+(-0.1438)Trp; 0.8
04, 0.820, 0.736, 0.729, 0.646, 0.849, 0.860, 0.771, (0.3125)+(0.02
08)Ser+(-0.0116)Ala+(-0.0520)Val+(0.1708)Ile; 0.804, 0.828, 0. 779,
0.789, 0.781, 0.815, 0.721, 0.777, (3.6205)+(0.0289)Ser+(-0.
0050)Tyr+(-0.0041)Lys+(-0.1440)Trp; 0.804, 0.827, 0.790, 0.781,
0.788, 0.792, 0.812, 0.793,
(5.5169)+(-0.0584)Asn+(0.0014)Gly+(0.0508)Ile+(-0.1551)Trp; 0.804,
0.826, 0.753, 0.763, 0.754, 0.78 2, 0.707, 0.751,
(-2.7237)+(0.0542)Ser+(-0.0949)Asn+(-0.3071)M et+(0.1089)Phe;
0.803, 0.821, 0.767, 0.735, 0.745, 0.833, 0.848, 0. 790,
(5.8863)+(-0.1211)His+(-0.0075)Ala+(0.0039)Pro+(0.0547)Ile; 0.803,
0.819, 0.722, 0.695, 0.726, 0.820, 0.713, 0.738, (3.666
8)+(0.0367)Ser+(-0.1378)His+(-0.0005)Thr+(0.0065)Pro; 0.803, 0.827,
0.775, 0.786, 0.775, 0.805, 0.723, 0.772,
(3.3948)+(0.0274)Ser+(-0.0093)Tyr+(0.0008)Val+(-0.1492)Trp; 0.803,
0.827, 0.778, 0.786, 0.779, 0.805, 0.733, 0.776,
(3.1455)+(0.0282)Ser+(0.0002)Gln+(-0.0025)Thr+(-0.1505)Trp; 0.803,
0.821, 0.718, 0.678, 0.719, 0.787, 0.774, 0.740,
(3.3468)+(0.0050)Gly+(-0.1532)His+(0.033 7)Ile+(0.0562)Phe; 0.803,
0.821, 0.731, 0.703, 0.739, 0.828, 0.717, 0.747,
(3.8861)+(0.0385)Ser+(-0.1400)His+(0.0063)Val+(-0.004 3)Lys; 0.803,
0.824, 0.792, 0.781, 0.784, 0.841, 0.800, 0.802, (4.38
29)+(-0.0626)Asn+(0.0102)Gln+(-0.1414)His+(0.0227)Orn; 0.803,
0.821, 0.745, 0.724, 0.750, 0.832, 0.727, 0.758,
(4.4239)+(0.0422)Ser+(-0.0562)Asn+(-0.1259)His+(0.0045)Val; 0.803,
0.827, 0.811, 0.805, 0.815, 0.830, 0.801, 0.813,
(8.7447)+(-0.0101)Asn+(-0.079 9)His+(0.0191)Tyr+(-0.1021)Trp;
0.803, 0.821, 0.721, 0.686, 0.73 4, 0.818, 0.715, 0.738,
(3.5066)+(0.0420)Ser+(-0.1462)His+(-0.0 141)Arg+(0.0198)Leu; 0.803,
0.824, 0.756, 0.730, 0.737, 0.819, 0.8 19, 0.776,
(5.4911)+(-0.1122)His+(-0.0033)Pro+(0.1143)Ile+(-0. 0465)Leu;
0.803, 0.821, 0.757, 0.739, 0.747, 0.843, 0.764, 0.773, (4.
5186)+(0.0422)Ser+(-0.0047)Gly+(-0.1256)His+(-0.0019)Ala; 0. 803,
0.825, 0.793, 0.784, 0.792, 0.792, 0.820, 0.797, (5.7215)+(-0.
0545)Asn+(-0.0004)Pro+(0.0508)Ile+(-0.1555)Trp; 0.803, 0.822,
0.748, 0.727, 0.715, 0.817, 0.825, 0.771,
(5.9235)+(-0.0906)His+(-0.0137)Arg+(-0.0375)Val+(0.1359)Ile; 0.803,
0.828, 0.817, 0.8 34, 0.812, 0.812, 0.787, 0.811,
(4.7049)+(0.0058)Gln+(0.0089)Pro +(-0.1649)Met+(-0.1355)Trp; 0.803,
0.826, 0.788, 0.794, 0.808, 0. 796, 0.729, 0.782,
(5.9811)+(0.0259)Thr+(-0.2020)Met+(0.0171)L eu+(-0.1511)Trp; 0.803,
0.827, 0.777, 0.784, 0.779, 0.804, 0.732, 0. 775,
(3.1557)+(0.0285)Ser+(-0.0025)Thr+(0.0004)Val+(-0.1509)Trp; 0.803,
0.827, 0.806, 0.799, 0.813, 0.821, 0.796, 0.807, (8.719
6)+(-0.0843)His+(0.0083)Val+(-0.0221)Met+(-0.1036)Trp; 0.803,
0.821, 0.743, 0.719, 0.741, 0.828, 0.750, 0.759,
(4.2903)+(0.0407)Ser+(-0.0049)Gly+(-0.1344)His+(0.0042)Thr; 0.803,
0.827, 0.806, 0.804, 0.815, 0.823, 0.782, 0.806,
(8.5235)+(-0.0772)His+(-0.029 7)Cit+(0.0107)Lys+(-0.1074)Trp;
0.803, 0.822, 0.759, 0.747, 0.75 5, 0.845, 0.735, 0.770,
(4.9822)+(0.0408)Ser+(-0.0558)Asn+(-0.1 136)His+(-0.0013)Ala;
0.803, 0.829, 0.829, 0.842, 0.828, 0.825, 0. 802, 0.824,
(5.1398)+(-0.0902)Asn+(0.0057)Gln+(0.0178)Orn+(-0. 1401)Trp; 0.803,
0.825, 0.727, 0.692, 0.753, 0.833, 0.691, 0.742, (3.
9437)+(0.0338)Ser+(-0.1318)His+(-0.0643)Cit+(0.0430)Orn; 0.8 03,
0.824, 0.796, 0.795, 0.816, 0.811, 0.743, 0.791, (6.7942)+(0.00
25)Gly+(-0.0756)Cit+(0.0086)Pro+(-0.1510)Trp; 0.803, 0.828, 0. 788,
0.803, 0.794, 0.818, 0.712, 0.782, (3.4831)+(0.0292)Ser+(0.0
017)Gln+(-0.0197)Arg+(-0.1474)Trp; 0.803, 0.825, 0.801, 0.801, 0.
806, 0.810, 0.784, 0.800, (8.4039)+(-0.0867)His+(-0.0069)Arg+(0.
0126)Lys+(-0.1045)Trp; 0.803, 0.824, 0.761, 0.744, 0.758, 0.838, 0.
758, 0.774,
(4.9336)+(0.0467)Ser+(-0.0558)Asn+(-0.0042)Gly+(-0.1154)His; 0.803,
0.822, 0.726, 0.700, 0.730, 0.823, 0.715, 0.742,
(3.8546)+(0.0374)Ser+(-0.1345)His+(0.0068)Pro+(-0.0033)Lys; 0.803,
0.827, 0.829, 0.843, 0.824, 0.819, 0.809, 0.824,
(5.1932)+(-0.0885)Asn+(0.0062)Gln+(0.0050)Pro+(-0.1413)Trp; 0.803,
0.829, 0.730, 0.709, 0.737, 0.826, 0.706, 0.744,
(4.0882)+(0.0323)Ser+(-0.1352)His+(-0.0147)Tyr+(0.0285)Orn; 0.803,
0.830, 0.746, 0.733, 0.737, 0.785, 0.773, 0.757,
(4.5795)+(-0.1375)His+(-0.0471)Tyr+(0.0290)Orn+(0.0905)Phe; 0.803,
0.829, 0.796, 0.800, 0.799, 0.815, 0.765, 0.795,
(4.3066)+(0.0418)Ser+(-0.0080)Gly+(-0.0169)Arg+(-0.1455)Trp; 0.803,
0.826, 0.811, 0.814, 0.811, 0.827, 0.792, 0.81 1,
(8.9100)+(-0.0074)Asn+(-0.0751)His+(0.0019)Arg+(-0.0948)T rp;
0.803, 0.824, 0.745, 0.716, 0.753, 0.780, 0.779, 0.757, (4.9500)
+(-0.0613)Asn+(-0.1456)His+(0.0202)Thr+(0.0768)Phe; 0.803, 0. 820,
0.727, 0.702, 0.718, 0.788, 0.769, 0.744, (5.7341)+(-0.1368)H
is+(0.0165)Thr+(-0.0366)Tyr+(0.0524)Ile; 0.802, 0.824, 0.815, 0.
811, 0.825, 0.817, 0.802, 0.814,
(7.2581)+(-0.0042)Ala+(-0.0693)Cit+(0.0214)Leu+(-0.1523)Trp; 0.802,
0.820, 0.750, 0.729, 0.746, 0.834, 0.755, 0.766,
(4.4427)+(0.0428)Ser+(-0.0049)Gly+(-0.128 3)His+(-0.0020)Lys;
0.802, 0.829, 0.748, 0.729, 0.757, 0.836, 0.71 6, 0.760,
(3.9412)+(0.0435)Ser+(-0.1262)His+(0.0089)Val+(-0.1 253)Met; 0.802,
0.827, 0.790, 0.791, 0.784, 0.786, 0.804, 0.791, (5.
4591)+(0.0052)Pro+(-0.0246)Val+(0.0457)Leu+(-0.1523)Trp; 0.8 02,
0.825, 0.780, 0.791, 0.789, 0.813, 0.705, 0.775, (3.7700)+(0.03
14)Ser+(-0.0181)Arg+(0.0012)Val+(-0.1470)Trp; 0.802, 0.824, 0. 809,
0.824, 0.817, 0.815, 0.749, 0.801, (7.3471)+(-0.0828)Asn+(0.
0189)Thr+(-0.0027)Val+(-0.1379)Trp; 0.802, 0.823, 0.803, 0.800,
0.823, 0.805, 0.766, 0.799,
(7.0482)+(-0.0731)Cit+(0.0079)Pro+(0.0020)Val+(-0.1536)Trp; 0.802,
0.820, 0.820, 0.824, 0.832, 0.82 5, 0.783, 0.816,
(7.5701)+(-0.0033)Ala+(-0.0679)Cit+(0.0067)Va l+(-0.1453)Trp;
0.802, 0.829, 0.789, 0.783, 0.785, 0.786, 0.813, 0. 792,
(3.8693)+(0.0029)Gln+(-0.0101)Lys+(0.0551)Ile+(-0.1666)Trp; 0.802,
0.827, 0.793, 0.786, 0.786, 0.844, 0.789, 0.801, (4.183
1)+(0.0096)Gln+(-0.1379)His+(-0.1094)Met+(0.0258)Orn; 0.802, 0.829,
0.760, 0.758, 0.768, 0.787, 0.730, 0.761,
(2.7470)+(0.0287)Ser+(-0.0007)Gln+(0.0103)Leu+(-0.1621)Trp; 0.802,
0.826, 0.772, 0.760, 0.776, 0.766, 0.802, 0.776,
(4.2587)+(-0.0011)Gly+(0.004 4)Thr+(0.0478)Ile+(-0.1749)Trp; 0.802,
0.825, 0.810, 0.813, 0.81 2, 0.826, 0.787, 0.810,
(8.9054)+(-0.0749)His+(0.0001)Ala+(-0.0 091)Met+(-0.0942)Trp;
0.802, 0.823, 0.816, 0.830, 0.816, 0.830, 0. 767, 0.811,
(7.4091)+(-0.0752)Asn+(0.0199)Thr+(-0.0033)Ala+(-0.1380)Trp; 0.802,
0.822, 0.782, 0.772, 0.768, 0.840, 0.796, 0.794,
(4.2396)+(0.0081)Gln+(-0.1461)His+(-0.0034)Ala+(0.0246)Orn; 0.802,
0.819, 0.743, 0.728, 0.736, 0.842, 0.724, 0.757, (4.3920)+(0.
0337)Ser+(-0.1305)His+(0.0049)Thr+(-0.0022)Ala; 0.802, 0.827,
0.795, 0.786, 0.797, 0.800, 0.813, 0.799,
(5.7694)+(-0.0019)Arg+(-0.1610)Met+(0.0656)Ile+(-0.1431)Trp; 0.802,
0.826, 0.764, 0.7 56, 0.764, 0.852, 0.722, 0.773,
(4.9352)+(0.0419)Ser+(-0.0371)As n+(-0.1085)His+(-0.0702)Met;
0.802, 0.825, 0.770, 0.758, 0.773, 0. 765, 0.797, 0.773,
(4.1099)+(0.0037)Thr+(-0.0011)Orn+(0.0487)I le+(-0.1747)Trp; 0.802,
0.823, 0.818, 0.829, 0.831, 0.837, 0.751, 0. 812,
(8.0816)+(-0.0409)Asn+(0.0034)Gly+(-0.0628)Cit+(-0.131 5)Trp;
0.802, 0.826, 0.810, 0.812, 0.810, 0.827, 0.789, 0.810, (8.81
85)+(-0.0766)His+(-0.0001)Ala+(0.0012)Arg+(-0.0950)Trp; 0.80 2,
0.823, 0.769, 0.766, 0.764, 0.767, 0.790, 0.772, (4.7063)+(-0.02
35)Tyr+(0.0060)Orn+(0.0517)Ile+(-0.1608)Trp; 0.802, 0.826, 0.7 83,
0.784, 0.779, 0.791, 0.779, 0.783, (5.2381)+(0.0101)Thr+(-0.0
254)Val+(0.0483)Leu+(-0.1597)Trp; 0.802, 0.828, 0.770, 0.773, 0.
783, 0.799, 0.712, 0.767, (3.2251)+(0.0323)Ser+(-0.0195)Arg+(0.
0120)Leu+(-0.1570)Trp; 0.802, 0.829, 0.763, 0.739, 0.753, 0.818, 0.
808, 0.780, (4.5620)+(-0.1380)His+(-0.0050)Ala+(0.0252)Orn+(0.
0724)Phe; 0.802, 0.826, 0.805, 0.815, 0.815, 0.806, 0.754, 0.798,
(6. 7049)+(-0.0856)Asn+(0.0148)Thr+(0.0168)Orn+(-0.1426)Trp; 0.8
02, 0.822, 0.722, 0.676, 0.726, 0.779, 0.793, 0.743, (3.8819)+(-0.1
579)His+(0.0122)Thr+(0.0301)Ile+(0.0507)Phe; 0.802, 0.821, 0.7 71,
0.739, 0.751, 0.837, 0.848, 0.794, (6.1476)+(-0.0081)Asn+(-0.
1200)His+(-0.0064)Ala+(0.0579)Ile; 0.802, 0.822, 0.800, 0.810, 0.
787, 0.815, 0.792, 0.801, (5.6100)+(-0.0071)Ala+(0.0093)Pro+(0.
0187)Orn+(-0.1406)Trp; 0.802, 0.820, 0.811, 0.812, 0.792, 0.854, 0.
820, 0.819,
(4.7431)+(-0.0558)Asn+(0.0112)Gln+(-0.1340)His+(-0.0018)Ala; 0.802,
0.829, 0.763, 0.766, 0.768, 0.786, 0.728, 0.762,
(2.8994)+(0.0282)Ser+(-0.0145)Tyr+(0.0120)Leu+(-0.1575)Trp; 0.802,
0.822, 0.775, 0.762, 0.778, 0.766, 0.807, 0.778,
(4.3096)+(-0.0005)Gly+(0.0016)Orn+(0.0487)Ile+(-0.1714)Trp; 0.802,
0.821, 0.715, 0.681, 0.721, 0.809, 0.723, 0.733,
(3.4061)+(0.0390)Ser+(-0.1472)His+(-0.0156)Tyr+(0.0220)Leu; 0.802,
0.827, 0.780, 0.774, 0.778, 0.771, 0.809, 0.783,
(3.5339)+(0.0020)Gln+(-0.0025)Pro+(0.0511)Ile+(-0.1754)Trp; 0.801,
0.827, 0.827, 0.836, 0.837, 0.83 0, 0.778, 0.820,
(5.3899)+(0.0055)Gln+(-0.0743)Cit+(-0.0001)Ty r+(-0.1543)Trp;
0.801, 0.827, 0.793, 0.783, 0.792, 0.794, 0.821, 0. 798,
(5.7796)+(-0.0505)Asn+(-0.0023)Lys+(0.0519)Ile+(-0.154 0)Trp;
0.801, 0.825, 0.789, 0.785, 0.783, 0.789, 0.813, 0.793, (5.91
06)+(-0.0486)Asn+(-0.0142)Tyr+(0.0530)Ile+(-0.1505)Trp; 0.80 1,
0.827, 0.828, 0.838, 0.839, 0.830, 0.775, 0.820, (5.4297)+(0.005
9)Gln+(-0.0715)Cit+(-0.0043)Arg+(-0.1532)Trp; 0.801, 0.826, 0. 782,
0.794, 0.790, 0.816, 0.706, 0.777, (3.8862)+(0.0312)Ser+(-0.
0178)Arg+(0.0001)Lys+(-0.1449)Trp; 0.801, 0.820, 0.801, 0.797, 0.
789, 0.842, 0.809, 0.809, (4.4220)+(-0.0579)Asn+(0.0113)Gln+(-0.
1416)His+(0.0018)Val; 0.801, 0.828, 0.774, 0.782, 0.778, 0.801, 0.
726, 0.772,
(3.2066)+(0.0272)Ser+(-0.0000)Gln+(-0.0000)Val+(-0.1524)Trp; 0.801,
0.820, 0.786, 0.770, 0.769, 0.840, 0.823, 0.801,
(3.8574)+(0.0094)Gln+(-0.1553)His+(-0.0041)Ala+(0.0170)Leu; 0.801,
0.826, 0.805, 0.809, 0.829, 0.826, 0.727, 0.798, (7.1633)+(0.
0164)Thr+(-0.0679)Cit+(-0.0064)Arg+(-0.1564)Trp; 0.801, 0.821,
0.807, 0.811, 0.790, 0.851, 0.801, 0.813,
(4.3833)+(0.0108)Gln+(-0.1339)His+(-0.0005)Ala+(-0.0924)Met; 0.801,
0.829, 0.710, 0.69 0, 0.711, 0.769, 0.716, 0.722,
(-5.2379)+(0.0523)Ser+(-0.4475)Me t+(0.0549)Ile+(0.0871)Phe; 0.801,
0.821, 0.770, 0.739, 0.748, 0.8 38, 0.846, 0.793,
(6.0890)+(-0.1204)His+(-0.0065)Ala+(-0.0017)Lys+(0.0592)Ile; 0.801,
0.825, 0.811, 0.815, 0.811, 0.828, 0.789, 0. 811,
(8.9760)+(-0.0046)Asn+(-0.0741)His+(-0.0051)Met+(-0.094 0)Trp;
0.801, 0.818, 0.765, 0.762, 0.694, 0.839, 0.868, 0.791, (3.73
46)+(-0.0093)Ala+(-0.0220)Arg+(-0.0546)Val+(0.1810)Ile; 0.80 1,
0.821, 0.732, 0.692, 0.733, 0.803, 0.788, 0.754, (5.5649)+(-0.14
03)His+(0.0148)Thr+(-0.0077)Lys+(0.0482)Ile; 0.801, 0.819, 0.7 22,
0.704, 0.721, 0.818, 0.704, 0.737, (3.9411)+(0.0364)Ser+(-0.1
312)His+(0.0082)Pro+(-0.0163)Tyr; 0.801, 0.824, 0.846, 0.863, 0.
832, 0.848, 0.826, 0.842, (5.4530)+(-0.0767)Asn+(0.0068)Gln+(-0.
0027)Ala+(-0.1339)Trp; 0.801, 0.829, 0.772, 0.758, 0.775, 0.781, 0.
794, 0.777, (4.6947)+(0.0083)Thr+(-0.0107)Lys+(0.0549)Ile+(-0.
1663)Trp; 0.801, 0.825, 0.804, 0.798, 0.814, 0.807, 0.798, 0.804,
(6. 9437)+(-0.0646)Cit+(-0.0165)Val+(0.0426)Leu+(-0.1550)Trp; 0.
801, 0.822, 0.750, 0.723, 0.734, 0.813, 0.813, 0.771, (5.3817)+(-0.
1127)His+(-0.0004)Lys+(0.1081)Ile+(-0.0452)Leu; 0.801, 0.826,
0.782, 0.795, 0.790, 0.816, 0.705, 0.777,
(3.9043)+(0.0312)Ser+(-0.0177)Arg+(-0.0006)Tyr+(-0.1445)Trp; 0.801,
0.826, 0.759, 0.75 2, 0.759, 0.849, 0.716, 0.769,
(4.6196)+(0.0395)Ser+(-0.1138)His +(0.0001)Ala+(-0.0979)Met; 0.801,
0.820, 0.754, 0.740, 0.737, 0.8 17, 0.783, 0.769,
(4.1104)+(0.0049)Gly+(-0.1412)His+(-0.0044)A la+(0.0875)Phe; 0.801,
0.823, 0.803, 0.801, 0.822, 0.807, 0.765, 0. 799,
(6.9920)+(-0.0715)Cit+(0.0083)Pro+(0.0016)Lys+(-0.1523)Trp; 0.801,
0.819, 0.768, 0.743, 0.744, 0.830, 0.838, 0.789, (6.294
8)+(-0.1179)His+(-0.0058)Ala+(-0.0165)Tyr+(0.0607)Ile; 0.801,
0.819, 0.725, 0.698, 0.732, 0.822, 0.714, 0.741,
(3.7173)+(0.0363)Ser+(-0.1437)His+(0.0018)Thr+(0.0049)Val; 0.800,
0.825, 0.806, 0.812, 0.814, 0.799, 0.777, 0.800,
(6.4936)+(-0.0657)Asn+(0.004 4)Pro+(0.0208)Orn+(-0.1371)Trp; 0.800,
0.823, 0.794, 0.790, 0.81 7, 0.800, 0.753, 0.790,
(6.4992)+(0.0029)Gly+(-0.0769)Cit+(0.01 71)Leu+(-0.1611)Trp; 0.800,
0.820, 0.737, 0.713, 0.734, 0.784, 0.7 72, 0.751,
(4.2970)+(-0.1503)His+(0.0150)Thr+(-0.0069)Val+(0. 0842)Phe; 0.800,
0.817, 0.732, 0.693, 0.731, 0.801, 0.790, 0.753, (5.
2730)+(-0.1464)His+(0.0129)Thr+(-0.0033)Pro+(0.0479)Ile; 0.8 00,
0.818, 0.774, 0.755, 0.767, 0.826, 0.802, 0.788, (3.7650)+(0.00
97)Gln+(-0.1592)His+(-0.0050)Lys+(0.0153)Leu; 0.800, 0.819, 0. 772,
0.757, 0.769, 0.827, 0.780, 0.783, (4.0868)+(0.0083)Gln+(-0.
1509)His+(0.0232)Orn+(-0.0035)Lys; 0.800, 0.817, 0.715, 0.676, 0.
731, 0.812, 0.716, 0.734, (3.3301)+(0.0402)Ser+(-0.1449)His+(-0.
0325)Cit+(0.0202)Leu; 0.800, 0.817, 0.803, 0.801, 0.788, 0.847, 0.
807, 0.811, (4.5374)+(-0.0599)Asn+(0.0007)Gly+(0.0111)Gln+(-0.
1377)His; 0.800, 0.822, 0.809, 0.820, 0.819, 0.805, 0.761, 0.801,
(7. 2315)+(-0.0803)Asn+(-0.0011)Gly+(0.0186)Thr+(-0.1434)Trp; 0.
800, 0.827, 0.790, 0.788, 0.790, 0.785, 0.796, 0.790, (3.7945)+(0.0
039)Gln+(-0.0212)Arg+(0.0512)Ile+(-0.1710)Trp; 0.800, 0.820, 0.
804, 0.808, 0.790, 0.849, 0.794, 0.810, (4.3284)+(0.0003)Gly+(0.0
108)Gln+(-0.1346)His+(-0.0964)Met; 0.800, 0.825, 0.783, 0.762, 0.
789, 0.796, 0.814, 0.790, (4.4203)+(-0.1277)His+(-0.1970)Met+(0.
0074)Lys+(0.1142)Phe; 0.800, 0.819, 0.737, 0.699, 0.737, 0.800, 0.
793, 0.757, (5.7928)+(-0.0411)Asn+(-0.1372)His+(0.0163)Thr+(0.
0433)Ile; 0.800, 0.823, 0.813, 0.815, 0.799, 0.852, 0.808, 0.819,
(4. 5541)+(-0.0365)Asn+(0.0117)Gln+(-0.1310)His+(-0.0710)Met; 0.
800, 0.822, 0.795, 0.792, 0.783, 0.839, 0.794, 0.802, (4.0639)+(0.0
109)Gln+(-0.1343)His+(0.0083)Pro+(-0.1328)Met; 0.800, 0.823, 0.
768, 0.755, 0.763, 0.849, 0.754, 0.780, (4.7071)+(0.0455)Ser+(-0.
0045)Gly+(-0.1119)His+(-0.0945)Met; 0.800, 0.822, 0.801, 0.806,
0.788, 0.808, 0.811, 0.803,
(5.7028)+(-0.0073)Ala+(0.0096)Pro+(0.0114)Leu+(-0.1467)Trp; 0.800,
0.821, 0.818, 0.828, 0.808, 0.82 2, 0.807, 0.816,
(7.1980)+(-0.0466)Asn+(-0.0054)Ala+(0.0110)Pr o+(-0.1281)Trp;
0.800, 0.825, 0.741, 0.725, 0.715, 0.828, 0.777, 0. 761,
(-1.7307)+(0.0453)Ser+(-0.0075)Ala+(-0.3100)Met+(0.079 8)Ile;
0.800, 0.823, 0.752, 0.723, 0.753, 0.814, 0.780, 0.768, (5.56
59)+(0.0057)Gly+(-0.1171)His+(-0.1599)Met+(0.0673)Ile; 0.800,
0.825, 0.840, 0.857, 0.833, 0.833, 0.813, 0.834, (5.3972)+(-0.084
4)Asn+(0.0067)Gln+(-0.0016)Val+(-0.1355)Trp; 0.800, 0.825, 0.7 77,
0.755, 0.785, 0.791, 0.807, 0.785, (4.5021)+(-0.1195)His+(0.0
062)Pro+(-0.1985)Met+(0.1122)Phe; 0.800, 0.822, 0.781, 0.754, 0.
767, 0.833, 0.843, 0.799,
(6.5161)+(-0.1062)His+(-0.0050)Ala+(-0.1211)Met+(0.0688)Ile; 0.800,
0.825, 0.801, 0.808, 0.791, 0.799, 0.808, 0.802,
(4.6487)+(0.0026)Gln+(-0.0227)Val+(0.0443)Leu+(-0.1564)Trp; 0.800,
0.825, 0.816, 0.809, 0.823, 0.840, 0.804, 0.81 9,
(8.7198)+(-0.0769)His+(0.0277)Tyr+(-0.0504)Met+(-0.1018)I rp;
0.800, 0.824, 0.804, 0.802, 0.823, 0.808, 0.766, 0.800, (7.1151)
+(-0.0715)Cit+(0.0006)Arg+(0.0084)Pro+(-0.1503)Trp; 0.800, 0. 823,
0.816, 0.828, 0.821, 0.817, 0.776, 0.810, (6.9239)+(-0.0647)A
sn+(-0.0045)Val+(0.0289)Orn+(-0.1262)Trp 0.902, 0.923, 0.809,
0.790, 0.778, 0.870, 0.878, 0.829, (-1.32 17)+(0
0.0545)Ser+(-0.0544)Val+(-0.3973)Met+(0.1922)Ile+(0.15
06)Phe+(-0.1179)Trp; 0.900, 0.919, 0.800, 0.780, 0.815, 0.860, 0.7
77, 0.808, (1.1114)+(0.0530)Ser+(-0.1384)His+(0.0420)Thr+(-0.
3641)Met+(0.1993)Phe+(-0.1237)Trp; 0.899, 0.917, 0.812, 0.798, 0.
789, 0.854, 0.864, 0.826, (2.2454)+(0.0452)Thr+(-0.0612)Val+(-0.
4741)Met+(0.2021)Ile+(0.1569)Phe+(-0.1267)Trp; 0.894, 0.918, 0.
783, 0.749, 0.760, 0.870, 0.859, 0.810, (-1.8219)+(0.0622)Ser+(-0.
1003)His+(-0.0447)Val+(-0.4105)Met+(0.1701)Ile+(0.1621)Phe; 0.891,
0.913, 0.825, 0.813, 0.822, 0.870, 0.830, 0.834,
(-0.7646)+(0.0539)Ser+(0.0080)Gln+(-0.1367)His+(-0.2716)Met+(0.1766)P
he+(-0.1028)Trp; 0.891, 0.910, 0.793, 0.765, 0.776, 0.856, 0.858,
0. 814, (2.3264)+(-0.0966)His+(0.0489)Thr+(-0.0552)Val+(-0.489
6)Met+(0.1897)Ile+(0.1580)Phe; 0.890, 0.916, 0.807, 0.794, 0.791,
0.854, 0.841, 0.820, (-1.8334)+(0.0536)Ser+(-0.3463)Met+(0.173
5)Ile+(-0.0820)Leu+(0.1380)Phe+(-0.1330)Trp; 0.890, 0.912, 0.7 85,
0.765, 0.749, 0.870, 0.849, 0.808, (-3.2110)+(0.0409)Ser+(0.0
284)Thr+(-0.0697)Val+(-0.5814)Met+(0.2181)Ile+(0.1512)Phe; 0. 890,
0.914, 0.791, 0.754, 0.794, 0.854, 0.836, 0.810, (-0.4856)+(0.
0659)Ser+(-0.1214)His+(-0.2902)Met+(0.0720)Ile+(0.1503)Phe+(-0.1121)Trp;
0.889, 0.910, 0.831, 0.819, 0.840, 0.854, 0.829, 0.83 5,
(2.1791)+(0.0103)Gln+(-0.1446)His+(0.0467)Thr+(-0.3603)Me
t+(0.1795)Phe+(-0.1251)Trp; 0.888, 0.909, 0.797, 0.783, 0.752, 0.
872, 0.876, 0.821, (-2.0528)+(0.0623)Ser+(-0.1191)Asn+(-0.067
1)Val+(-0.3897)Met+(0.2086)Ile+(0.1559)Phe; 0.887, 0.911, 0.79 4,
0.768, 0.802, 0.853, 0.801, 0.806, (0.2218)+(0.0663)Ser+(-0.11
76)His+(0.0128)Pro+(-0.2882)Met+(0.1713)Phe+(-0.1063)Trp; 0. 885,
0.906, 0.770, 0.736, 0.762, 0.850, 0.821, 0.792, (-2.1269)+(0.
0641)Ser+(-0.1326)His+(-0.3520)Met+(0.1518)Ile+(-0.0632)Leu
+(0.1622)Phe; 0.885, 0.908, 0.812, 0.789, 0.821, 0.865, 0.815, 0.82
2, (0.6585)+(0.0637)Ser+(-0.1191)His+(0.0234)Tyr+(-0.2771)Me
t+(0.1715)Phe+(-0.1085)Trp; 0.884, 0.906, 0.805, 0.777, 0.785, 0.
883, 0.862, 0.827, (2.1234)+(0.0509)Ser+(0.0590)Tyr+(-0.0488)V
al+(-0.3619)Met+(0.1995)Ile+(-0.1244)Trp; 0.884, 0.905, 0.810,
0.795, 0.815, 0.858, 0.807, 0.819, (1.0354)+(0.0642)Ser+(-0.029
8)Asn+(-0.1127)His+(-0.2223)Met+(0.1737)Phe+(-0.1009)Trp; 0. 884,
0.909, 0.795, 0.777, 0.745, 0.877, 0.887, 0.821, (-3.0328)+(0.
0510)Ser+(-0.0050)Ala+(-0.0625)Val+(-0.4487)Met+(0.2107)Ile
+(0.1401)Phe; 0.883, 0.907, 0.791, 0.769, 0.747, 0.865, 0.888, 0.81
7, (-3.0576)+(0.0592)Ser+(-0.0056)Gly+(-0.0640)
Val+(-0.4783)Met+(0.2055)Ile+(0.1405)Phe; 0.882, 0.903, 0.805,
0.787, 0.810, 0. 855, 0.804, 0.814,
(0.7088)+(0.0622)Ser+(-0.1177)His+(0.0009)A
la+(-0.2474)Met+(0.1748)Phe+(-0.1026)Trp; 0.882, 0.906, 0.804,
0.785, 0.812, 0.858, 0.803, 0.814, (0.7718)+(0.0609)Ser+(-0.119
5)His+(-0.2422)Met+(0.0111)Orn+(0.1700)Phe+(-0.1017)Trp; 0.8 82,
0.905, 0.799, 0.771, 0.809, 0.852, 0.813, 0.811, (0.5016)+(0.06
36)Ser+(-0.1239)His+(-0.2582)Met+(0.0196)Leu+(0.1610)Phe+(-0.1091)Trp;
0.881, 0.904, 0.802, 0.772, 0.819, 0.829, 0.825, 0.811,
(4.6013)+(-0.1241)His+(0.0491)Thr+(-0.3361)Met+(0.0575)Ile+(0.1484)Phe+(--
0.1339)Trp; 0.881, 0.904, 0.805, 0.787, 0.811, 0.85 2, 0.806,
0.814, (0.5622)+(0.0605)Ser+(-0.1208)His+(-0.2627)Me
t+(0.0083)Lys+(0.1749)Phe+(-0.1088)Trp; 0.881, 0.906, 0.790, 0.
769, 0.755, 0.871, 0.860, 0.814,
(-2.7772)+(0.0534)Ser+(-0.0583)Cit+(-0.0611)Val+(-0.4725)Met+(0.2025)Ile+-
(0.1483)Phe; 0.881, 0.903, 0.805, 0.784, 0.812, 0.856, 0.807,
0.815,
(0.7259)+(0.0625)Ser+(-0.1217)His+(0.0048)Val+(-0.2448)Met+(0.1692)Phe+(--
0.1 064)Trp; 0.881, 0.902, 0.798, 0.784, 0.760, 0.859, 0.869,
0.818, (1.
4747)+(-0.0872)Asn+(0.0451)Thr+(-0.0745)Val+(-0.4746)Met+(0.
2248)Ile+(0.1468)Phe; 0.880, 0.904, 0.810, 0.792, 0.812, 0.857, 0.
817, 0.819,
(0.8210)+(0.0648)Ser+(-0.0022)Gly+(-0.1140)His+(-0.2398)Met+(0.173-
8)Phe+(-0.1039)Trp; 0.880, 0.905, 0.809, 0.792, 0.817, 0.858,
0.800, 0.817,
(0.8548)+(0.0627)Ser+(-0.1030)His+(-0.0434)Cit+(-0.2268)Met+(0.181-
0)Phe+(-0.1120)Trp; 0.880, 0. 902, 0.804, 0.783, 0.783, 0.880,
0.849, 0.824, (3.5594)+(0.0437)Se
r+(-0.0504)Cit+(-0.0373)Val+(-0.2208)Met+(0.1758)Ile+(-0.11 70)Trp;
0.880, 0.901, 0.798, 0.783, 0.774, 0.878, 0.833, 0.817, (3.5
083)+(0.0341)Ser+(0.0217)Thr+(-0.0447)Val+(-0.3282)Met+(0.1
883)Ile+(-0.1110)Trp; 0.880, 0.900, 0.831, 0.825, 0.800, 0.853, 0.
898, 0.844, (1.6131)+(0.0057)Gln+(-0.0525)Val+(-0.3431)Met+(0.
1808)Ile+(0.1304)Phe+(-0.1173)Trp; 0.880, 0.904, 0.789, 0.773, 0.
750, 0.855, 0.866, 0.811, (1.3300)+(0.0530)Ser+(-0.1787)Asn+(-0.
0502)Val+(0.1586)Ile+(0.1013)Phe+(-0.1205)Trp; 0.879, 0.903, 0.
784, 0.768, 0.742, 0.863, 0.861, 0.808, (-3.3275)+(0.0510)Ser+(-0.
0566)Val+(-0.4745)Met+(0.2287)Ile+(-0.0295)Leu+(0.1461)Phe; 0.879,
0.906, 0.789, 0.765, 0.751, 0.871, 0.874, 0.815,
(-3.4771)+(0.0531)Ser+(0.0228)Tyr+(-0.0672)Val+(-0.5232)Met+(0.2117)I
le+(0.1378)Phe; 0.878, 0.903, 0.801, 0.777, 0.813, 0.835, 0.817, 0.
811, (-1.3020)+(0.0581)Ser+(-0.0917)Cit+(-0.3118)Met+(0.070
8)Ile+(0.1355)Phe+(-0.1702)Trp; 0.878, 0.905, 0.782, 0.763, 0.74 1,
0.862, 0.860, 0.807, (-3.2369)+(0.0521)Ser+(0.0053)Pro+(-0.0
643)Val+(-0.4981)Met+(0.1980)Ile+(0.1419)Phe; 0.878, 0.904, 0. 807,
0.792, 0.812, 0.857, 0.802, 0.816, (0.8772)+(0.0632)Ser+(-0.
1150)His+(-0.0075)Arg+(-0.2326)Met+(0.1756)Phe+(-0.1014)Tr p;
0.878, 0.898, 0.758, 0.725, 0.747, 0.823, 0.821, 0.779,
(1.1231)+(0.0472)Ser+(-0.1274)His+(0.1065)Ile+(-0.0390)Leu+(0.1044)P
he+(-0.1281)Trp; 0.877, 0.903, 0.807, 0.797, 0.795, 0.855, 0.824,
0. 818,
(1.0488)+(0.0524)Ser+(-0.1170)Asn+(0.0077)Gln+(-0.1332)His+(0.1277)Phe+(--
0.1078)Trp; 0.877, 0.900, 0.754, 0.707, 0.768, 0.840, 0.783, 0.775,
(-1.3972)+(0.0567)Ser+(-0.1699)His+(0.029
5)Thr+(-0.4330)Met+(0.0672)Ile+(0.1506)Phe; 0.877, 0.904, 0.78 2,
0.761, 0.740, 0.865, 0.866, 0.808, (-2.9436)+(0.0528)Ser+(-0.0
012)Gln+(-0.0642)Val+(-0.4767)Met+(0.2056)Ile+(0.1425)Phe; 0. 877,
0.900, 0.812, 0.798, 0.791, 0.876, 0.848, 0.828, (6.5712)+(0.0
336)Thr+(-0.0519)Cit+(-0.0438)Val+(-0.2732)Met+(0.1832)Ile+(-0.1144)Trp;
0.877, 0.903, 0.819, 0.801, 0.795, 0.849, 0.894, 0.83 5,
(4.9139)+(-0.0543)His+(-0.0452)Val+(-0.2526)Met+(0.1687)I
le+(0.1312)Phe+(-0.0958)Trp; 0.877, 0.900, 0.797, 0.784, 0.755, 0.
863, 0.875, 0.819,
(0.3843)+(0.0393)Thr+(-0.0042)Ala+(-0.0697)Val+(-0.5055)Met+(0.2222)Ile+(-
0.1346)Phe; 0.877, 0.899, 0.803, 0.787, 0.768, 0.879, 0.865, 0.824,
(3.2446)+(0.0417)Ser+(-0.004
6)Ala+(-0.0407)Val+(-0.2260)Met+(0.1885)Ile+(-0.1079)Trp; 0. 877,
0.896, 0.806, 0.783, 0.828, 0.827, 0.804, 0.811, (5.1385)+(-0.
1262)His+(0.0512)Thr+(-0.3199)Met+(0.0154)Leu+(0.1582)Phe+(-0.1315)Trp;
0.877, 0.895, 0.811, 0.802, 0.778, 0.873, 0.862, 0.82 8,
(6.3171)+(0.0318)Thr+(-0.0048)Ala+(-0.0466)Val+(-0.2706)M
et+(0.1948)Ile+(-0.1108)Trp; 0.877, 0.901, 0.770, 0.737, 0.753, 0.
844, 0.841, 0.794,
(1.5645)+(0.0502)Ser+(-0.1331)His+(-0.0071)Ala+(0.0682)Ile+(0.1022)Phe+(--
0.1303)Trp; 0.877, 0.904, 0.787, 0.767, 0.744, 0.867, 0.870, 0.812,
(-3.2265)+(0.0513)Ser+(-0.064
0)Val+(-0.4840)Met+(-0.0021)Orn+(0.2050)Ile+(0.1430)Phe; 0.8 76,
0.899, 0.796, 0.776, 0.772, 0.871, 0.847, 0.817, (3.1391)+(0.04
31)Ser+(0.0063)Pro+(-0.0420)Val+(-0.2707)Met+(0.1750)Ile+(-0.1119)Trp;
0.876, 0.896, 0.800, 0.782, 0.782, 0.859, 0.843, 0.817,
(7.1237)+(-0.0566)His+(0.0346)Thr+(-0.0375)Val+(-0.2613)Met
+(0.1722)Ile+(-0.0947)Trp; 0.876, 0.900, 0.789, 0.772, 0.802, 0.8
20, 0.788, 0.796, (-1.7780)+(0.0469)Ser+(0.0220)Thr+(-0.4185)M
et+(0.0601)Ile+(0.1200)Phe+(-0.1623)Trp; 0.876, 0.900, 0.814, 0.
814,
0.828, 0.840, 0.768, 0.812, (0.3731)+(0.0463)Ser+(-0.0799)A
sn+(0.0272)Thr+(-0.3209)Met+(0.1461)Phe+(-0.1531)Trp; 0.876, 0.898,
0.813, 0.799, 0.830, 0.833, 0.801, 0.816, (5.1380)+(-0.116
4)His+(0.0508)Thr+(-0.0016)Val+(-0.3109)Met+(0.1713)Phe+(-0.
1240)Trp; 0.876, 0.898, 0.781, 0.748, 0.787, 0.859, 0.796, 0.798,
(4. 0210)+(0.0445)Ser+(-0.1021)His+(0.0220)Thr+(-0.2402)Met+(0.
0941)Ile+(-0.1075)Trp; 0.876, 0.898, 0.804, 0.786, 0.774, 0.882, 0.
856, 0.824,
(3.7945)+(0.0469)Ser+(-0.0611)Asn+(-0.0421)Val+(-0.2051)Met+(0.180-
6)Ile+(-0.1024)Trp; 0.876, 0.899, 0.803, 0.783, 0.772, 0.871,
0.868, 0.824,
(3.1847)+(0.0513)Ser+(-0.0059)Gly+(-0.0407)Val+(-0.2496)Met+(0.179-
5)Ile+(-0.1110)Trp; 0.876, 0. 898, 0.815, 0.806, 0.785, 0.847,
0.882, 0.830, (3.0411)+(0.0040)Gl
y+(-0.0542)Val+(-0.3097)Met+(0.1869)Ile+(0.1305)Phe+(-0.112 3)Trp;
0.876, 0.899, 0.777, 0.739, 0.777, 0.852, 0.825, 0.798, (-3.0
222)+(0.0578)Ser+(0.0068)Gln+(-0.1683)His+(-0.3616)Met+(0.0
626)Ile+(0.1415)Phe; 0.876, 0.900, 0.792, 0.772, 0.765, 0.863, 0.8
51, 0.813, (0.6553)+(0.0436)Thr+(-0.0620)Cit+(-0.0694)Val+(-0.
5305)Met+(0.2201)Ile+(0.1426)Phe; 0.875, 0.898, 0.808, 0.802, 0.
833, 0.838, 0.750, 0.806, (0.0690)+(0.0437)Ser+(0.0320)Thr+(-0.
0895)Cit+(-0.3650)Met+(0.1686)Phe+(-0.1704)Trp; 0.875, 0.898,
0.810, 0.795, 0.828, 0.831, 0.799, 0.813,
(5.0416)+(0.0077)Asn+(-0.1194)His+(0.0503)Thr+(-0.3161)Met+(0.1699)Phe+(--
0.1255)Tr p; 0.875, 0.899, 0.825, 0.817, 0.787, 0.854, 0.906,
0.841,
(3.9291)+(-0.0044)Ala+(-0.0534)Val+(-0.2665)Met+(0.1920)Ile+(0.1248)Phe+(-
-0.1088)Trp; 0.875, 0.897, 0.794, 0.778, 0.763, 0.875, 0.845,
0.815, (4.6063)+(0.0465)Ser+(-0.1092)Asn+(-0.0635)Cit+(-0.03
74)Val+(0.1596)Ile+(-0.1266)Trp; 0.875, 0.899, 0.781, 0.761, 0.7
83, 0.844, 0.786, 0.793, (2.7059)+(0.0543)Ser+(-0.1114)Asn+(-0.
1258)His+(0.0185)Thr+(0.1304)Phe+(-0.1179)Trp; 0.875, 0.903, 0.
785, 0.768, 0.746, 0.863, 0.855, 0.808, (-3.1220)+(0.0548)Ser+(-0.
0162)Arg+(-0.0640)Val+(-0.4578)Met+(0.2053)Ile+(0.1464)Phe; 0.875,
0.898, 0.806, 0.793, 0.824, 0.832, 0.786, 0.809, (4.7360)+(0.
0034)Gly+(-0.1236)His+(0.0487)Thr+(-0.3151)Met+(0.1724)Phe+(-0.1208)Trp;
0.875, 0.904, 0.786, 0.767, 0.743, 0.868, 0.870, 0.81 2,
(-3.2133)+(0.0512)Ser+(-0.0641)Val+(-0.4828)Met+(-0.0003)Lys+(0.2046)Ile+-
(0.1423)Phe; 0.875, 0.895, 0.792, 0.776, 0.753, 0. 867, 0.864,
0.815,
(3.8125)+(0.0350)Ser+(-0.0086)Ala+(-0.0759)Cit+(-0.0342)Val+(0.1732)Ile+(-
-0.1444)Trp; 0.875, 0.898, 0.808, 0.792, 0.825, 0.827, 0.799,
0.811, (5.0167)+(-0.1163)His+(0.049
3)Thr+(0.0042)Pro+(-0.3173)Met+(0.1656)Phe+(-0.1257)Trp; 0.8 74,
0.892, 0.811, 0.795, 0.789, 0.870, 0.856, 0.827, (5.8798)+(0.03
06)Thr+(0.0275)Tyr+(-0.0494)Val+(-0.3312)Met+(0.1907)Ile+(-0.1191)Trp;
0.874, 0.898, 0.811, 0.797, 0.829, 0.831, 0.799, 0.814,
(5.1472)+(-0.1179)His+(0.0507)Thr+(-0.0017)Tyr+(-0.3085)Met
+(0.1695)Phe+(-0.1249)Trp; 0.874, 0.898, 0.788, 0.761, 0.770, 0.8
65, 0.842, 0.810, (3.8623)+(0.0473)Ser+(-0.0629)His+(-0.0301)V
al+(-0.2091)Met+(0.1648)Ile+(-0.0919)Trp; 0.874, 0.898, 0.792,
0.790, 0.806, 0.814, 0.751, 0.790, (-1.0344)+(0.0456)Ser+(0.023
0)Thr+(0.0098)Pro+(-0.4138)Met+(0.1413)Phe+(-0.1577)Trp; 0.8 74,
0.895, 0.788, 0.774, 0.751, 0.854, 0.859, 0.809, (0.0531)+(0.00
05)Gly+(0.0394)Thr+(-0.0716)Val+(-0.5394)Met+(0.2193)Ile+(0.
1383)Phe; 0.874, 0.897, 0.812, 0.798, 0.830, 0.831, 0.801, 0.815,
(5. 1552)+(-0.1177)His+(0.0509)Thr+(-0.3113)Met+(-0.0016)Orn+(0.
1700)Phe+(-0.1256)Trp; 0.874, 0.896, 0.754, 0.722, 0.735, 0.823, 0.
828, 0.777, (1.3999)+(0.0456)Ser+(-0.1187)His+(-0.0254)Val+(0.
1124)Ile+(0.1002)Phe+(-0.1271)Trp; 0.874, 0.895, 0.768, 0.727, 0.
765, 0.852, 0.820, 0.791,
(-1.5196)+(0.0660)Ser+(-0.1481)His+(-0.0042)Ala+(-0.3256)Met+(0.0732)Ile+-
(0.1382)Phe; 0.873, 0.897, 0.812, 0.814, 0.827, 0.835, 0.756,
0.808,
(-0.1619)+(0.0395)Ser+(0.0286)Thr+(-0.0081)Val+(-0.3801)Met+(0.1583)Phe+(-
-0.1520)Trp; 0.873, 0.895, 0.802, 0.787, 0.773, 0.876, 0.850,
0.821, (3.615
4)+(0.0371)Ser+(-0.0090)Ala+(-0.0871)Cit+(0.1770)Ile+(-0.05
99)Leu+(-0.1475)Trp; 0.873, 0.897, 0.812, 0.798, 0.829, 0.832, 0.8
00, 0.815, (5.1575)+(-0.1177)His+(0.0505)Thr+(-0.0002)Ala+(-0.
3093)Met+(0.1691)Phe+(-0.1253)Trp; 0.873, 0.896, 0.799, 0.783, 0.
771, 0.872, 0.851, 0.819, (3.0224)+(0.0410)Ser+(-0.0428)Val+(-0.
2747)Met+(0.0061)Lys+(0.1815)Ile+(-0.1138)Trp; 0.873, 0.897, 0.
810, 0.795, 0.829, 0.825, 0.801, 0.812, (4.9661)+(-0.1202)His+(0.
0488)Thr+(-0.3182)Met+(0.0049)Lys+(0.1679)Phe+(-0.1273)Trp; 0.873,
0.896, 0.821, 0.812, 0.790, 0.844, 0.896, 0.836,
(3.8662)+(-0.0081)Asn+(-0.0538)Val+(-0.2881)Met+(0.1849)Ile+(0.1257)Ph
e+(-0.1096)Trp; 0.873, 0.897, 0.811, 0.799, 0.833, 0.830, 0.787, 0.
812, (5.5816)+(-0.1144)His+(0.0550)Thr+(-0.0157)Arg+(-0.301
9)Met+(0.1705)Phe+(-0.1270)Trp; 0.873, 0.896, 0.801, 0.784, 0.77 3,
0.874, 0.851, 0.821, (2.9282)+(0.0409)Ser+(0.0009)Gln+(-0.04
10)Val+(-0.2589)Met+(0.1794)Ile+(-0.1121)Trp; 0.873, 0.898, 0. 818,
0.808, 0.788, 0.842, 0.891, 0.832, (3.7193)+(0.0050)Pro+(-0.
0540)Val+(-0.3080)Met+(0.1806)Ile+(0.1269)Phe+(-0.1125)Trp; 0.873,
0.900, 0.837, 0.818, 0.833, 0.859, 0.882, 0.848, (2.0349)+(0.
0121)Gln+(-0.1284)His+(-0.2378)Met+(0.0584)Ile+(0.1200)Phe+(-0.1165)Trp;
0.873, 0.894, 0.796, 0.777, 0.771, 0.871, 0.843, 0.81 6,
(3.1019)+(0.0405)Ser+(-0.0430)Val+(-0.2624)Met+(0.0147)Or
n+(0.1798)Ile+(-0.1110)Trp; 0.873, 0.898, 0.769, 0.735, 0.765, 0.
837, 0.822, 0.790,
(1.7038)+(0.0588)Ser+(-0.0844)Asn+(-0.1247)His+(0.0537)Ile+(0.1038)Phe+(--
0.1227)Trp; 0.872, 0.895, 0.789, 0.774, 0.751, 0.853, 0.860, 0.809,
(0.1187)+(0.0392)Thr+(-0.070
2)Val+(-0.5356)Met+(0.2227)Ile+(-0.0048)Leu+(0.1384)Phe; 0.8 72,
0.897, 0.808, 0.807, 0.808, 0.826, 0.795, 0.809, (-0.3872)+(0.0
586)Ser+(-0.0695)Asn+(0.0110)Pro+(-0.2845)Met+(0.1316)Phe+(-0.1409)Trp;
0.872, 0.897, 0.818, 0.807, 0.789, 0.844, 0.891, 0.83 3,
(3.6639)+(-0.0543)Val+(-0.2976)Met+(0.0093)Orn+(0.1841)Il
e+(0.1213)Phe+(-0.1100)Trp; 0.872, 0.892, 0.805, 0.794, 0.778, 0.
865, 0.849, 0.821,
(6.2184)+(-0.0009)Gly+(0.0321)Thr+(-0.0472)Val+(-0.2963)Met+(0.1870)Ile+(-
-0.1125)Trp; 0.872, 0.896, 0.789, 0.773, 0.751, 0.854, 0.860,
0.810,
(0.1211)+(0.0396)Thr+(0.0010)Pro+(-0.0716)Val+(-0.5408)Met+(0.2183)Ile+(0-
.1378)Phe; 0.872, 0.898, 0.791, 0.775, 0.753, 0.853, 0.864, 0.811,
(0.1174)+(0.0429)Thr+(-0.0717)Val+(-0.5487)Met+(-0.0139)Orn+(0.2238)Ile+(-
0.1 444)Phe; 0.872, 0.895, 0.804, 0.803, 0.823, 0.830, 0.751,
0.802, (-0.
3855)+(0.0418)Ser+(0.0273)Thr+(-0.3721)Met+(-0.0047)Lys+(0.
1470)Phe+(-0.1560)Trp; 0.872, 0.896, 0.792, 0.778, 0.754, 0.855, 0.
861, 0.812,
(-0.4936)+(0.0017)Gln+(0.0386)Thr+(-0.0713)Val+(-0.5505)Met+(0.218-
1)Ile+(0.1387)Phe; 0.872, 0.892, 0.810, 0.801, 0.783, 0.867, 0.850,
0.825,
(5.1257)+(0.0031)Gln+(0.0295)Thr+(-0.0462)Val+(-0.3115)Met+(0.1835)Ile+(--
0.1169)Trp; 0.872, 0.89 7, 0.784, 0.770, 0.755, 0.853, 0.836,
0.803,
(0.6618)+(0.0508)Thr+(-0.0287)Arg+(-0.0751)Val+(-0.5262)Met+(0.2298)Ile+(-
0.1475)Phe; 0.872, 0.893, 0.823, 0.823, 0.831, 0.842, 0.795, 0.823,
(0.773 5)+(0.0580)Ser+(-0.0672)Asn+(-0.0788)Cit+(-0.2115)Met+(0.15
22)Phe+(-0.1461)Trp; 0.872, 0.895, 0.804, 0.805, 0.831, 0.829, 0.7
26, 0.798, (-0.0447)+(0.0437)Ser+(0.0341)Thr+(-0.0257)Arg+(-0.
3805)Met+(0.1530)Phe+(-0.1579)Trp; 0.871, 0.893, 0.767, 0.741, 0.
747, 0.824, 0.833, 0.787, (0.6532)+(0.0399)Ser+(-0.1010)Cit+(-0.
0387)Val+(0.1447)Ile+(0.0903)Phe+(-0.1830)Trp; 0.871, 0.895, 0.
801, 0.789, 0.816, 0.826, 0.782, 0.803, (-0.4540)+(0.0581)Ser+(-0.
0898)Cit+(0.0143)Pro+(-0.3145)Met+(0.1525)Phe+(-0.1610)Trp; 0.871,
0.894, 0.798, 0.781, 0.770, 0.870, 0.848, 0.817, (3.1438)+(0.
0420)Ser+(-0.0384)Val+(-0.2517)Met+(0.1878)Ile+(-0.0099)Leu
+(-0.1101)Trp; 0.871, 0.895, 0.820, 0.810, 0.790, 0.843, 0.890, 0.8
33,
(3.6738)+(-0.0474)Val+(-0.2911)Met+(0.1986)Ile+(-0.0204)Leu+(0.1266)Phe+(-
-0.1089)Trp; 0.871, 0.897, 0.818, 0.811, 0.786, 0.839, 0.890,
0.832, (3.2462)+(-0.0581)Val+(-0.3358)Met+(0.012
5)Lys+(0.1891)Ile+(0.1268)Phe+(-0.1163)Trp; 0.871, 0.895, 0.76 2,
0.726, 0.756, 0.827, 0.820, 0.782, (0.8269)+(0.0429)Ser+(0.003
9)Gln+(-0.1493)His+(0.0532)Ile+(0.0925)Phe+(-0.1345)Trp; 0.8 71,
0.897, 0.801, 0.802, 0.797, 0.825, 0.786, 0.803, (-0.8865)+(0.0
535)Ser+(0.0137)Pro+(-0.0091)Val+(-0.3360)Met+(0.1445)Phe+(-0.1393)Trp;
0.871, 0.892, 0.810, 0.800, 0.783, 0.867, 0.851, 0.82 5,
(6.8120)+(-0.0424)Asn+(0.0335)Thr+(-0.0480)Val+(-0.2646)M
et+(0.1872)Ile+(-0.1073)Trp; 0.871, 0.895, 0.795, 0.779, 0.786, 0.
855, 0.811, 0.808,
(2.4257)+(0.0586)Ser+(-0.0850)Asn+(-0.1155)His+(-0.0026)Ala+(0.1346)Phe+(-
-0.1062)Trp; 0.871, 0.888, 0.811, 0.791, 0.810, 0.856, 0.834,
0.823, (5.0596)+(0.0087)Gln+(-0.113
4)His+(0.0284)Thr+(-0.2241)Met+(0.0791)Ile+(-0.1159)Trp; 0.8 71,
0.897, 0.815, 0.798, 0.841, 0.833, 0.792, 0.816, (5.2824)+(-0.1
036)His+(0.0517)Thr+(-0.0508)Cit+(-0.2946)Met+(0.1765)Phe+(-0.1356)Trp;
0.871, 0.895, 0.756, 0.716, 0.752, 0.827, 0.816, 0.77 8,
(1.5449)+(0.0511)Ser+(-0.1339)His+(-0.0108)Lys+(0.0614)Il
e+(0.1007)Phe+(-0.1260)Trp; 0.871, 0.897, 0.797, 0.789, 0.772, 0.
840, 0.837, 0.810, (0.8635)+(0.0485)Ser+(-0.1466)Asn+(0.1404)I
le+(-0.0731)Leu+(0.0917)Phe+(-0.1395)Trp; 0.871, 0.900, 0.825,
0.810, 0.799, 0.852, 0.900, 0.840, (3.6620)+(0.0189)Tyr+(-0.054
7)Val+(-0.3223)Met+(0.1869)Ile+(0.1221)Phe+(-0.1142)Trp; 0.8 71,
0.898, 0.802, 0.787, 0.804, 0.828, 0.819, 0.810, (-1.1859)+(0.0
587)Ser+(-0.0576)Asn+(-0.2971)Met+(0.0598)Ile+(0.1109)Phe+(-0.1476)Trp;
0.871, 0.896, 0.787, 0.774, 0.749, 0.851, 0.858, 0.80 8,
(0.1420)+(0.0403)Thr+(-0.0082)Tyr+(-0.0709)Val+(-0.5292)M
et+(0.2182)Ile+(0.1402)Phe; 0.870, 0.895, 0.784, 0.741, 0.795, 0.
857, 0.820, 0.803, (2.8514)+(0.0578)Ser+(-0.0991)His+(0.0424)T
yr+(-0.2438)Met+(0.0940)Ile+(-0.1184)Trp; 0.870, 0.894, 0.804,
0.802, 0.796, 0.833, 0.806, 0.809, (-0.9039)+(0.0533)Ser+(-0.004
8)Ala+(0.0145)Pro+(-0.3144)Met+(0.1326)Phe+(-0.1433)Trp; 0.8 70,
0.894, 0.786, 0.758, 0.779, 0.860, 0.821, 0.805, (3.6476)+(0.04
95)Ser+(-0.0805)His+(-0.1772)Met+(0.1341)Ile+(-0.0304)Leu+(-0.1014)Trp;
0.870, 0.890, 0.805, 0.795, 0.779, 0.864, 0.844, 0.82 1,
(5.9503)+(0.0300)Thr+(-0.0479)Val+(-0.3079)Met+(0.0045)Ly
s+(0.1867)Ile+(-0.1141)Trp; 0.870, 0.896, 0.756, 0.713, 0.762, 0.
830, 0.803, 0.777,
(0.9717)+(0.0559)Ser+(-0.1185)His+(-0.0763)Cit+(0.0654)Ile+(0.1134)Phe+(--
0.1581)Trp; 0.870, 0.897, 0.813, 0.806, 0.811, 0.826, 0.828, 0.818,
(2.2784)+(0.0315)Thr+(-0.358
6)Met+(0.1475)Ile+(-0.0720)Leu+(0.1298)Phe+(-0.1440)Trp; 0.8 70,
0.892, 0.804, 0.793, 0.779, 0.863, 0.847, 0.820, (6.0995)+(0.03
25)Thr+(-0.0501)Val+(-0.3037)Met+(0.1815)Ile+(0.0092)Leu+(-0.1132)Trp;
0.870, 0.895, 0.816, 0.810, 0.829, 0.822, 0.798, 0.815,
(-0.0766)+(0.0525)Ser+(-0.0089)Gly+(0.0286)Thr+(-0.3786)Met
+(0.1447)Phe+(-0.1642)Trp; 0.870, 0.895, 0.772, 0.751, 0.758, 0.8
41, 0.807, 0.789, (1.9594)+(0.0504)Ser+(-0.1286)His+(-0.0061)A
la+(0.0101)Pro+(0.1227)Phe+(-0.1212)Trp; 0.870, 0.894, 0.797, 0.
771, 0.790, 0.864, 0.830, 0.814, (2.4540)+(0.0435)Ser+(0.0062)Gl
n+(-0.1068)His+(-0.1908)Met+(0.0901)Ile+(-0.1059)Trp; 0.870, 0.891,
0.803, 0.793, 0.777, 0.863, 0.843, 0.819,
(6.1040)+(0.0310)Thr+(0.0023)Pro+(-0.0473)Val+(-0.3002)Met+(0.1846)Ile+(--
0.1 123)Trp; 0.870, 0.896, 0.802, 0.784, 0.795, 0.839, 0.834,
0.813, (-1.
5943)+(0.0537)Ser+(-0.0051)Ala+(-0.3108)Met+(0.0703)Ile+(0.
1090)Phe+(-0.1489)Trp; 0.869, 0.897, 0.803, 0.784, 0.797, 0.875, 0.
813, 0.817, (3.1790)+(0.0447)Ser+(-0.0674)Cit+(-0.1848)Met+(0.
1607)Ile+(-0.0544)Leu+(-0.1324)Trp; 0.869, 0.893, 0.826, 0.817,
0.824, 0.840, 0.846, 0.832,
(4.0806)+(-0.0912)Asn+(0.0098)Gln+(-0.1333)His+(0.0236)Thr+(0.1047)Phe+(--
0.1234)Trp; 0.869, 0.8 94, 0.829, 0.834, 0.826, 0.850, 0.808,
0.830, (0.3755)+(0.0547)Ser
+(-0.0756)Asn+(-0.0061)Val+(-0.2286)Met+(0.1454)Phe+(-0.131 8)Trp;
0.869, 0.893, 0.790, 0.777, 0.776, 0.846, 0.816, 0.804, (1.24
61)+(0.0423)Ser+(0.0050)Gln+(-0.1418)His+(-0.0035)Ala+(0.12
39)Phe+(-0.1183)Trp; 0.869, 0.895, 0.780, 0.759, 0.780, 0.836, 0.7
96, 0.793, (2.1699)+(0.0590)Ser+(-0.0907)Asn+(-0.1184)His+(0.
0057)Pro+(0.1246)Phe+(-0.1119)Trp; 0.869, 0.896, 0.821, 0.811, 0.
790, 0.844, 0.894, 0.835,
(3.8316)+(-0.0033)Arg+(-0.0537)Val+(-0.2892)Met+(0.1854)Ile+(0.1263)Phe+(-
-0.1106)Trp; 0.869, 0.896, 0.788, 0.772, 0.751, 0.855, 0.859,
0.809,
(0.2904)+(0.0414)Thr+(-0.0711)Val+(-0.5313)Met+(-0.0041)Lys+(0.2202)Ile+(-
0.1389)Ph e; 0.869, 0.892, 0.750, 0.709, 0.750, 0.818, 0.807,
0.771,
(1.4934)+(0.0466)Ser+(-0.1422)His+(0.0045)Thr+(0.0540)Ile+(0.0946)Ph
e+(-0.1361)Trp; 0.869, 0.893, 0.800, 0.783, 0.789, 0.871, 0.815, 0.
815,
(4.1082)+(0.0451)Ser+(-0.0842)Asn+(-0.0783)Cit+(0.1465)Ile+(-0.0537)Leu+(-
-0.1444)Trp; 0.869, 0.890, 0.770, 0.742, 0.747, 0.875, 0.816,
0.795, (3.1785)+(0.0381)Ser+(-0.0850)His+(0.024
8)Thr+(-0.0407)Val+(-0.3478)Met+(0.1847)Ile; 0.869, 0.894, 0.8 05,
0.805, 0.823, 0.824, 0.753, 0.801, (-0.7569)+(0.0403)Ser+(0.0
008)Gln+(0.0252)Thr+(-0.3816)Met+(0.1444)Phe+(-0.1594)Trp; 0. 869,
0.894, 0.780, 0.761, 0.787, 0.844, 0.769, 0.790, (-1.5917)+(0.
0454)Ser+(0.0066)Gln+(-0.1764)His+(0.0279)Thr+(-0.3912)Met+(0.1740)Phe;
0.869, 0.895, 0.809, 0.809, 0.822, 0.835, 0.763, 0.808,
(-0.3426)+(0.0405)Ser+(0.0264)Thr+(-0.0022)Ala+(-0.3665)Met
+(0.1466)Phe+(-0.1574)Trp; 0.869, 0.894, 0.805, 0.804, 0.823, 0.8
23, 0.754, 0.801, (-0.4795)+(0.0413)Ser+(0.0282)Thr+(-0.3834)M
et+(-0.0111)Orn+(0.1519)Phe+(-0.1603)Trp; 0.869, 0.895, 0.787,
0.769, 0.786, 0.842, 0.800, 0.799, (2.3090)+(0.0582)Ser+(-0.087
0)Asn+(-0.1185)His+(0.0006)Val+(0.1287)Phe+(-0.1090)Trp; 0.8 69,
0.893, 0.817, 0.800, 0.786, 0.865, 0.892, 0.836, (0.5258)+(0.01
00)Gln+(-0.0985)His+(-0.0458)Val+(-0.3722)Met+(0.1631)Ile+(0.1351)Phe;
0.869, 0.890, 0.824, 0.829, 0.825, 0.843, 0.795, 0.823,
(0.2250)+(0.0564)Ser+(-0.0653)Asn+(-0.0101)Arg+(-0.2300)Met
+(0.1366)Phe+(-0.1375)Trp; 0.869, 0.901, 0.824, 0.809, 0.797, 0.8
54, 0.898, 0.840, (4.1844)+(-0.0609)Cit+(-0.0510)Val+(-0.2579)
Met+(0.1827)Ile+(0.1353)Phe+(-0.1182)Trp; 0.868, 0.895, 0.788,
0.771, 0.791, 0.812, 0.809, 0.796, (-1.9994)+(0.0558)Ser+(0.005
7)Pro+(-0.3633)Met+(0.0566)Ile+(0.1109)Phe+(-0.1533)Trp; 0.8 68,
0.892, 0.754, 0.707, 0.765, 0.838, 0.798, 0.777, (-1.9080)+(0.0
670)Ser+(-0.1511)His+(0.0053)Pro+(-0.3599)Met+(0.0585)Ile+(0.1410)Phe;
0.868, 0.895, 0.796, 0.780, 0.770, 0.872, 0.842, 0.816,
(3.3463)+(0.0444)Ser+(-0.0119)Arg+(-0.0417)Val+(-0.2311)Met
+(0.1832)Ile+(-0.1109)Trp; 0.868, 0.891, 0.829, 0.827, 0.827, 0.8
37, 0.833, 0.831, (0.3991)+(0.0648)Ser+(-0.0667)Asn+(-0.0068)G
ly+(-0.2386)Met+(0.1341)Phe+(-0.1412)Trp; 0.868, 0.896, 0.801,
0.781, 0.802, 0.817, 0.839, 0.810, (-1.5767)+(0.0643)Ser+(-0.006
7)Gly+(-0.3335)Met+(0.0613)Ile+(0.1087)Phe+(-0.1557)Trp; 0.8 68,
0.894, 0.811, 0.799, 0.833, 0.844, 0.772, 0.812, (0.0980)+(0.05
04)Ser+(-0.1092)Cit+(-0.2618)Met+(0.0359)Orn+(0.1442)Phe+(-0.1602)Trp;
0.868, 0.889, 0.789, 0.764, 0.779, 0.848, 0.835, 0.806,
(3.2684)+(0.0388)Ser+(-0.0118)Ala+(-0.1003)Cit+(0.0118)Pro+(0.0864)Ile+(--
0.1745)Trp; 0.868, 0.896, 0.785, 0.765, 0.784, 0.84 5, 0.800,
0.798, (2.3402)+(0.0569)Ser+(-0.0913)Asn+(-0.1196)Hi
s+(0.0126)Orn+(0.1246)Phe+(-0.1080)Trp; 0.868, 0.891, 0.801, 0.
792, 0.776, 0.865, 0.833, 0.817, (6.7713)+(0.0382)Thr+(-0.0212)A
rg+(-0.0496)Val+(-0.2765)Met+(0.1948)Ile+(-0.1122)Trp; 0.868,
0.891, 0.826, 0.830, 0.822, 0.846, 0.808, 0.826, (0.2060)+(0.0545)
Ser+(-0.0705)Asn+(-0.0012)Ala+(-0.2287)Met+(0.1360)Phe+(-0.
1381)Trp; 0.868, 0.892, 0.782, 0.772, 0.729, 0.838, 0.877, 0.804,
(0. 9936)+(0.0306)Ser+(-0.0102)Ala+(-0.0445)Val+(0.1636)Ile+(0.
0800)Phe+(-0.1555)Trp; 0.868, 0.892, 0.777, 0.753, 0.782, 0.842, 0.
783, 0.790, (-2.4869)+(0.0571)Ser+(0.0073)Gln+(-0.1658)His+(0.
0106)Pro+(-0.3511)Met+(0.1619)Phe; 0.868, 0.890, 0.802, 0.791, 0.
778, 0.860, 0.842, 0.818, (5.9836)+(0.0294)Thr+(-0.0480)Val+(-0.
2963)Met+(0.0107)Orn+(0.1855)Ile+(-0.1124)Trp; 0.868, 0.895, 0.
805, 0.799, 0.804, 0.815, 0.815, 0.808, (-0.8311)+(0.0652)Ser+(-0.
0078)Gly+(0.0120)Pro+(-0.3325)Met+(0.1286)Phe+(-0.1503)Trp; 0.868,
0.891, 0.779, 0.744, 0.782, 0.851, 0.813, 0.797, (3.4931)+(0.
0524)Ser+(-0.0928)His+(0.0053)Pro+(-0.1883)Met+(0.0860)Ile+(-0.1064)Trp;
0.868, 0.895, 0.832, 0.839, 0.828, 0.844, 0.815, 0.83 1,
(-0.6892)+(0.0513)Ser+(-0.0838)Asn+(0.0039)Gln+(-0.2447)M
et+(0.1330)Phe+(-0.1425)Trp; 0.868, 0.890, 0.796, 0.783, 0.745, 0.
879, 0.874, 0.820,
(4.2472)+(0.0428)Ser+(-0.1132)Asn+(-0.0063)Ala+(-0.0417)Val+(0.1750)Ile+(-
-0.1087)Trp; 0.868, 0.891, 0.761, 0.716, 0.775, 0.842, 0.796,
0.782, (-1.6262)+(0.0675)Ser+(-0.141
2)His+(-0.0439)Cit+(-0.3459)Met+(0.0672)Ile+(0.1438)Phe; 0.8 68,
0.892, 0.767, 0.744, 0.769, 0.829, 0.778, 0.780, (2.2937)+(0.04
51)Ser+(-0.1366)His+(0.0115)Thr+(-0.0066)Lys+(0.1247)Phe+(-0.1208)Trp;
0.868, 0.894, 0.774, 0.754, 0.767, 0.840, 0.795, 0.789,
(2.2525)+(0.0447)Ser+(-0.1350)His+(0.0112)Thr+(-0.0038)Ala+(0.1265)Phe+(--
0.1230)Trp; 0.867, 0.891, 0.757, 0.715, 0.756, 0.81 9, 0.825,
0.779, (1.5060)+(0.0542)Ser+(-0.0038)Gly+(-0.1366)Hi
s+(0.0553)Ile+(0.0939)Phe+(-0.1360)Trp; 0.867, 0.893, 0.780, 0.
755, 0.782, 0.838, 0.802, 0.794, (2.2478)+(0.0581)Ser+(-0.0838)A
sn+(-0.1233)His+(0.0115)Leu+(0.1186)Phe+(-0.1141)Trp; 0.867, 0.889,
0.777, 0.753, 0.774, 0.841, 0.804, 0.793, (2.0388)+(0.0493)
Ser+(-0.1334)His+(-0.0039)Ala+(0.0052)Val+(0.1209)Phe+(-0.1
200)Trp; 0.867, 0.891, 0.753, 0.722, 0.772, 0.831, 0.741, 0.767,
(-0. 8189)+(0.0563)Ser+(-0.1611)His+(0.0269)Thr+(0.0098)Pro+(-0.
4047)Met+(0.1707)Phe; 0.867, 0.895, 0.803, 0.802, 0.823, 0.824, 0.
751, 0.800, (-0.5658)+(0.0414)Ser+(0.0253)Thr+(0.0018)Tyr+(-0.
3805)Met+(0.1444)Phe+(-0.1591)Trp; 0.867, 0.895, 0.792, 0.772, 0.
789, 0.843, 0.814, 0.804, (2.4275)+(0.0621)Ser+(-0.0859)Asn+(-0.
0031)Gly+(-0.1151)His+(0.1283)Phe+(-0.1105)Trp; 0.867, 0.891,
0.752, 0.712, 0.751, 0.820, 0.811, 0.774,
(1.4074)+(0.0485)Ser+(-0.1393)His+(-0.0010)Pro+(0.0563)Ile+(0.0949)Phe+(--
0.1333)Tr p; 0.867, 0.893, 0.794, 0.778, 0.794, 0.817, 0.820,
0.802, (-1.9288)
+(0.0564)Ser+(-0.3435)Met+(-0.0160)Orn+(0.0684)Ile+(0.1169)
Phe+(-0.1541)Trp; 0.867, 0.896, 0.793, 0.775, 0.794, 0.850, 0.794,
0.803, (2.3480)+(0.0613)Ser+(-0.0851)Asn+(-0.1000)His+(-0.05
62)Cit+(0.1417)Phe+(-0.1226)Trp; 0.867, 0.891, 0.770, 0.749, 0.7
60, 0.826, 0.805, 0.785, (-0.0684)+(0.0424)Ser+(-0.1171)Cit+(0.
1614)Ile+(-0.0751)Leu+(0.1005)Phe+(-0.1877)Trp; 0.867, 0.890,
0.821, 0.824, 0.821, 0.837, 0.803, 0.821,
(0.0351)+(0.0542)Ser+(-0.0729)Asn+(-0.2437)Met+(0.0031)Lys+(0.1343)Phe+(--
0.1420)Tr p; 0.867, 0.891, 0.758, 0.713, 0.766, 0.840, 0.801,
0.780, (-1.6511)
+(0.0665)Ser+(-0.0078)Asn+(-0.1508)His+(-0.3388)Met+(0.064
9)Ile+(0.1399)Phe; 0.867, 0.888, 0.790, 0.757, 0.799, 0.838, 0.824,
0.804, (0.1367)+(0.0102)Gln+(-0.1786)His+(0.0394)Thr+(-0.413
6)Met+(0.0524)Ile+(0.1319)Phe; 0.867, 0.892, 0.801, 0.786, 0.785,
0.856, 0.836, 0.816, (2.6511)+(0.0525)Ser+(-0.0066)Gly+(-0.216
0)Met+(0.1593)Ile+(-0.0571)Leu+(-0.1317)Trp; 0.867, 0.892, 0.7 74,
0.753, 0.772, 0.828, 0.794, 0.787, (1.3292)+(0.0396)Ser+(0.00
43)Gln+(-0.1484)His+(0.0066)Thr+(0.1172)Phe+(-0.1250)Trp; 0. 867,
0.893, 0.800, 0.798, 0.806, 0.823, 0.774, 0.800, (-0.8880)+(0.
0556)Ser+(-0.0141)Arg+(0.0115)Pro+(-0.3189)Met+(0.1333)Phe+(-0.1456)Trp;
0.867, 0.891, 0.758, 0.711, 0.766, 0.840, 0.804, 0.78 0,
(-1.7131)+(0.0671)Ser+(-0.0009)Gly+(-0.1512)His+(-0.3443)Met+(0.0654)Ile+-
(0.1392)Phe; 0.866, 0.893, 0.787, 0.769, 0.784, 0. 842, 0.800,
0.799,
(2.2796)+(0.0581)Ser+(-0.0901)Asn+(-0.1183)His+(0.0017)Lys+(0.1287)Phe+(--
0.1095)Trp; 0.866, 0.889, 0.761, 0.734, 0.766, 0.822, 0.778, 0.775,
(2.0257)+(0.0449)Ser+(-0.140
6)His+(0.0087)Thr+(0.0023)Val+(0.1167)Phe+(-0.1265)Trp; 0.86 6,
0.893, 0.758, 0.714, 0.766, 0.840, 0.800, 0.780, (-1.6271)+(0.06
78)Ser+(-0.1484)His+(-0.3320)Met+(-0.0062)Lys+(0.0684)Ile+(0.1411)Phe;
0.866, 0.890, 0.787, 0.757, 0.780, 0.862, 0.828, 0.807,
(3.6922)+(0.0512)Ser+(-0.0915)His+(-0.0033)Ala+(-0.1574)Met
+(0.0972)Ile+(-0.1026)Trp; 0.866, 0.891, 0.795, 0.792, 0.797, 0.8
15, 0.784, 0.797, (-1.2230)+(0.0532)Ser+(0.0113)Pro+(-0.3405)M
et+(0.0012)Lys+(0.1306)Phe+(-0.1485)Trp; 0.866, 0.892, 0.777, 0.
753, 0.772, 0.841, 0.806, 0.793, (2.0937)+(0.0472)Ser+(-0.1310)H
is+(-0.0036)Ala+(0.0119)Orn+(0.1224)Phe+(-0.1156)Trp; 0.866, 0.894,
0.840, 0.838, 0.836, 0.858, 0.841, 0.843,
(2.0299)+(0.0044)Gly+(0.0119)Gln+(-0.1319)His+(-0.2072)Met+(0.1476)Phe+(--
0.1 045)Trp; 0.866, 0.892, 0.784, 0.767, 0.776, 0.836, 0.805,
0.796, (1.
2252)+(0.0426)Ser+(0.0051)Gln+(-0.1436)His+(-0.0054)Lys+(0.
1216)Phe+(-0.1167)Trp; 0.866, 0.890, 0.785, 0.751, 0.791, 0.860, 0.
806, 0.802,
(3.7885)+(0.0526)Ser+(-0.0815)His+(-0.0435)Cit+(-0.1576)Met+(0.093-
5)Ile+(-0.1113)Trp; 0.866, 0.892, 0.791, 0.775, 0.793, 0.844,
0.791, 0.801,
(2.4370)+(0.0597)Ser+(-0.0754)Asn+(-0.1162)His+(-0.0134)Arg+(0.133-
4)Phe+(-0.1076)Trp; 0.866, 0. 888, 0.801, 0.785, 0.785, 0.825,
0.862, 0.814, (3.1208)+(0.0076)Gl
n+(-0.1219)His+(0.0989)Ile+(-0.0386)Leu+(0.0840)Phe+(-0.126 5)Trp;
0.866, 0.894, 0.793, 0.776, 0.795, 0.823, 0.813, 0.802, (-1.7
476)+(0.0555)Ser+(-0.3303)Met+(-0.0055)Lys+(0.0653)Ile+(0.1
103)Phe+(-0.1483)Trp; 0.866, 0.895, 0.757, 0.721, 0.760, 0.828, 0.
798, 0.777, (1.4925)+(0.0554)Ser+(-0.1343)His+(-0.0241)Arg+(0.
0596)Ile+(0.1037)Phe+(-0.1320)Trp; 0.866, 0.891, 0.795, 0.773, 0.
814, 0.856, 0.771, 0.803, (3.0257)+(0.0414)Ser+(0.0176)Thr+(-0.
0784)Cit+(-0.2548)Met+(0.0840)Ile+(-0.1531)Trp; 0.866, 0.890,
0.776, 0.753, 0.775, 0.830, 0.802, 0.790, (1.0534)+(0.0417)Ser+(0.
0049)Gln+(-0.1499)His+(0.0040)Val+(0.1119)Phe+(-0.1245)Trp; 0.866,
0.889, 0.817, 0.800, 0.799, 0.851, 0.876, 0.832, (3.5835)+(0.
0088)Gln+(-0.1319)His+(-0.0062)Ala+(0.0581)Ile+(0.0803)Phe+(-0.1303)Trp;
0.866, 0.889, 0.771, 0.744, 0.770, 0.828, 0.806, 0.78 7,
(1.0660)+(0.0421)Ser+(0.0048)Gln+(-0.1523)His+(0.0147)Leu
+(0.1045)Phe+(-0.1284)Trp; 0.866, 0.890, 0.825, 0.825, 0.832, 0.8
41, 0.795, 0.823, (-0.8342)+(0.0482)Ser+(0.0037)Gln+(-0.0860)C
it+(-0.2778)Met+(0.1531)Phe+(-0.1566)Trp; 0.866, 0.895, 0.843,
0.838, 0.841, 0.846, 0.859, 0.846, (2.3031)+(0.0124)Gln+(-0.126
4)His+(0.0070)Pro+(-0.2170)Met+(0.1381)Phe+(-0.1083)Trp; 0.8 66,
0.889, 0.804, 0.792, 0.779, 0.871, 0.839, 0.821, (2.8020)+(0.04
16)Ser+(-0.0058)Ala+(-0.1867)Met+(0.1731)Ile+(-0.0597)Leu+(-0.1252)Trp;
0.865, 0.888, 0.784, 0.750, 0.784, 0.855, 0.826, 0.80 4,
(3.5909)+(0.0564)Ser+(-0.0033)Gly+(-0.0910)His+(-0.1714)M
et+(0.0910)Ile+(-0.1063)Trp; 0.865, 0.893, 0.794, 0.779, 0.798, 0.
821, 0.808, 0.802, (-1.6680)+(0.0575)Ser+(-0.0151)Arg+(-0.325
3)Met+(0.0635)Ile+(0.1129)Phe+(-0.1509)Trp; 0.865, 0.889, 0.78 1,
0.747, 0.782, 0.854, 0.815, 0.800, (3.5323)+(0.0511)Ser+(-0.09
58)His+(-0.1835)Met+(0.0037)Lys+(0.0906)Ile+(-0.1071)Trp; 0. 865,
0.892, 0.798, 0.797, 0.799, 0.816, 0.787, 0.800, (-1.4158)+(0.
0521)Ser+(0.0010)Gln+(0.0110)Pro+(-0.3405)Met+(0.1305)Phe+(-0.1484)Trp;
0.865, 0.895, 0.769, 0.749, 0.778, 0.834, 0.754, 0.77 9,
(2.5338)+(0.0471)Ser+(-0.1358)His+(0.0176)Thr+(-0.0274)Ar
g+(0.1296)Phe+(-0.1266)Trp; 0.865, 0.891, 0.804, 0.790, 0.766, 0.
843, 0.894, 0.823, (5.5204)+(-0.0756)His+(-0.0068)Ala+(-0.034
1)Val+(0.1401)Ile+(0.0910)Phe+(-0.1166)Trp; 0.865, 0.891, 0.75 7,
0.713, 0.765, 0.840, 0.801, 0.779, (-1.7494)+(0.0664)Ser+(-0.1
512)His+(-0.3463)Met+(-0.0033)Orn+(0.0665)Ile+(0.1411)Phe; 0. 865,
0.890, 0.773, 0.745, 0.768, 0.840, 0.810, 0.791, (2.0372)+(0.0
496)Ser+(-0.1359)His+(-0.0044)Ala+(0.0178)Leu+(0.1135)Phe+(-0.1237)Trp;
0.865, 0.895, 0.795, 0.773, 0.801, 0.823, 0.819, 0.80 4,
(-2.0581)+(0.0556)Ser+(0.0151)Tyr+(-0.3670)Met+(0.0633)Il
e+(0.1059)Phe+(-0.1563)Trp; 0.865, 0.890, 0.758, 0.731, 0.762, 0.
823, 0.776, 0.773, (1.9326)+(0.0456)Ser+(-0.1383)His+(0.0072)T
hr+(0.0036)Pro+(0.1169)Phe+(-0.1262)Trp; 0.865, 0.889, 0.791, 0.
769, 0.797, 0.826, 0.809, 0.800, (1.3487)+(0.0550)Ser+(-0.1235)A
sn+(-0.1030)Cit+(0.0544)Ile+(0.0926)Phe+(-0.1805)Trp; 0.865, 0.890,
0.771, 0.750, 0.766, 0.827, 0.797, 0.785,
(1.0884)+(0.0423)Ser+(0.0045)Gln+(-0.1457)His+(0.0039)Pro+(0.1143)Phe+(-0-
.12 38)Trp; 0.865, 0.889, 0.809, 0.788, 0.838, 0.817, 0.799, 0.811,
(2.9 169)+(0.0417)Thr+(-0.0943)Cit+(-0.3517)Met+(0.0567)Ile+(0.1
356)Phe+(-0.1834)Trp; 0.865, 0.888, 0.796, 0.781, 0.791, 0.853, 0.
804, 0.807,
(-1.7952)+(0.0557)Ser+(-0.0577)Asn+(0.0089)Gln+(-0.1605)His+(-0.26-
76)Met+(0.1623)Phe; 0.865, 0.892, 0.786, 0.774, 0.779, 0.837,
0.793, 0.796,
(2.2847)+(0.0586)Ser+(-0.0854)Asn+(-0.1150)His+(-0.0190)Tyr+(0.139-
3)Phe+(-0.1025)Trp; 0.865, 0. 890, 0.780, 0.759, 0.773, 0.846,
0.801, 0.795, (2.1048)+(0.0494)Se
r+(-0.1277)His+(-0.0031)Ala+(-0.0024)Lys+(0.1286)Phe+(-0.11 41)Trp;
0.865, 0.889, 0.769, 0.742, 0.772, 0.821, 0.799, 0.783, (2.2
494)+(0.0499)Ser+(-0.0043)Gly+(-0.1359)His+(0.0106)Thr+(0.1
185)Phe+(-0.1282)Trp; 0.865, 0.888, 0.805, 0.784, 0.803, 0.866, 0.
823, 0.819,
(2.9717)+(0.0465)Ser+(-0.0060)Ala+(-0.0755)Cit+(-0.1622)Met+(0.096-
0)Ile+(-0.1444)Trp; 0.865, 0.892, 0.852, 0.849, 0.848, 0.857,
0.864, 0.854,
(2.5117)+(-0.0105)Asn+(0.0128)Gln+(-0.1258)His+(-0.1885)Met+(0.139-
1)Phe+(-0.1051)Trp; 0.865, 0. 893, 0.799, 0.796, 0.819, 0.820,
0.753, 0.797, (-0.7088)+(0.0421)S
er+(0.0252)Thr+(-0.3842)Met+(0.0058)Leu+(0.1397)Phe+(-0.160 8)Trp;
0.865, 0.890, 0.751, 0.711, 0.748, 0.819, 0.812, 0.772, (1.35
71)+(0.0491)Ser+(-0.1387)His+(-0.0035)Orn+(0.0561)Ile+(0.09
58)Phe+(-0.1340)Trp; 0.865, 0.893, 0.845, 0.835, 0.844, 0.857, 0.8
67, 0.851, (2.3748)+(0.0127)Gln+(-0.1335)His+(-0.2057)Met+(0.
0145)Leu+(0.1299)Phe+(-0.1120)Trp; 0.865, 0.891, 0.757, 0.714, 0.
767, 0.837, 0.791, 0.777,
(-1.6794)+(0.0690)Ser+(-0.1484)His+(-0.0117)Arg+(-0.3335)Met+(0.0656)Ile+-
(0.1416)Phe; 0.865, 0.894, 0.794, 0.782, 0.792, 0.842, 0.796,
0.803, (0.9549)+(0.0446)Ser+(0.
0073)Gln+(-0.1453)His+(-0.0274)Arg+(0.1274)Phe+(-0.1172)Tr p;
0.865, 0.889, 0.821, 0.817, 0.829, 0.835, 0.806, 0.821,
(0.1829)+(0.0577)Ser+(-0.0039)Gly+(-0.0750)Cit+(-0.2586)Met+(0.1518)Phe+(-
-0.1545)Trp; 0.865, 0.891, 0.821, 0.824, 0.823, 0.839, 0.799,
0.821, (0.0942)+(0.0544)Ser+(-0.0720)Asn+(-0.2377)Met+(0.005
1)Orn+(0.1323)Phe+(-0.1393)Trp; 0.865, 0.890, 0.786, 0.766, 0.78 1,
0.828, 0.823, 0.799, (1.2183)+(0.0475)Ser+(-0.0045)Gly+(0.00
52)Gln+(-0.1433)His+(0.1159)Phe+(-0.1227)Trp; 0.865, 0.888, 0. 781,
0.751, 0.782, 0.830, 0.823, 0.796, (2.7991)+(-0.1308)His+(0.
0387)Thr+(-0.3675)Met+(0.1279)Ile+(-0.0562)Leu+(0.1397)Phe; 0.864,
0.889, 0.804, 0.791, 0.823, 0.839, 0.772, 0.806, (2.3497)+(0.
0518)Ser+(-0.1359)Asn+(-0.1254)Cit+(0.0433)Orn+(0.1044)Phe+(-0.1673)Trp;
0.864, 0.890, 0.779, 0.745, 0.783, 0.851, 0.810, 0.79 7,
(3.5422)+(0.0504)Ser+(-0.0975)His+(-0.1768)Met+(0.0137)Or
n+(0.0882)Ile+(-0.1053)Trp; 0.864, 0.892, 0.797, 0.793, 0.802, 0.
817, 0.786, 0.799, (-1.2270)+(0.0537)Ser+(0.0110)Pro+(0.0054)T
yr+(-0.3440)Met+(0.1298)Phe+(-0.1487)Trp; 0.864, 0.888, 0.782,
0.749, 0.774, 0.863, 0.827, 0.803, (4.2658)+(0.0461)Ser+(-0.085
4)His+(-0.0063)Ala+(-0.0595)Cit+(0.0951)Ile+(-0.1256)Trp; 0. 864,
0.891, 0.751, 0.719, 0.744, 0.816, 0.806, 0.771, (1.3876)+(0.0
483)Ser+(-0.1346)His+(-0.0247)Tyr+(0.0557)Ile+(0.1074)Phe+(-0.1254)Trp;
0.864, 0.887, 0.791, 0.766, 0.788, 0.822, 0.842, 0.80 4,
(3.4080)+(0.0072)Gln+(-0.1453)His+(0.0132)Thr+(0.0462)Ile
+(0.0770)Phe+(-0.1387)Trp; 0.864, 0.888, 0.815, 0.812, 0.826, 0.8
38, 0.783, 0.815, (0.0448)+(0.0526)Ser+(-0.0812)Cit+(-0.2603)M
et+(-0.0002)Lys+(0.1539)Phe+(-0.1533)Trp; 0.864, 0.884, 0.775,
0.750, 0.743, 0.856, 0.847, 0.799, (4.2402)+(0.0376)Ser+(-0.080
2)His+(-0.0058)Ala+(-0.0245)Val+(0.1442)Ile+(-0.1113)Trp; 0. 864,
0.889, 0.782, 0.750, 0.782, 0.854, 0.815, 0.800, (3.6743)+(0.0
522)Ser+(-0.0094)Asn+(-0.0924)His+(-0.1661)Met+(0.0914)Ile+(-0.1051)Trp;
0.864, 0.888, 0.820, 0.803, 0.812, 0.838, 0.866, 0.83 0,
(5.0566)+(-0.0729)His+(-0.1924)Met+(0.1327)Ile+(-0.0570)L
eu+(0.1232)Phe+(-0.1063)Trp; 0.864, 0.893, 0.793, 0.777, 0.794, 0.
818, 0.815, 0.801,
(-2.0466)+(0.0535)Ser+(0.0008)Gln+(-0.3468)Met+(0.0622)Ile+(0.1090)Phe+(--
0.1534)Trp; 0.864, 0.889, 0.825, 0.825, 0.823, 0.829, 0.826, 0.826,
(-0.1857)+(0.0596)Ser+(-0.007
2)Gly+(-0.0043)Val+(-0.2817)Met+(0.1400)Phe+(-0.1423)Trp; 0. 864,
0.886, 0.767, 0.739, 0.769, 0.847, 0.778, 0.784, (-0.8531)+(0.
0651)Ser+(-0.1440)His+(-0.0039)Ala+(0.0146)Pro+(-0.3181)Met
+(0.1608)Phe; 0.864, 0.886, 0.759, 0.730, 0.762, 0.822, 0.782, 0.77
4, (1.7703)+(0.0486)Ser+(-0.1357)His+(0.0044)Pro+(0.0018)Val
+(0.1145)Phe+(-0.1240)Trp; 0.864, 0.889, 0.770, 0.736, 0.767, 0.8
51, 0.803, 0.790, (4.0197)+(0.0434)Ser+(-0.0798)His+(-0.0580)C
it+(0.1226)Ile+(-0.0301)Leu+(-0.1288)Trp; 0.864, 0.889, 0.817,
0.815, 0.826, 0.840, 0.788, 0.817, (0.1084)+(0.0522)Ser+(-0.000
8)Ala+(-0.0807)Cit+(-0.2550)Met+(0.1540)Phe+(-0.1526)Trp; 0. 864,
0.892, 0.824, 0.826, 0.825, 0.842, 0.805, 0.825, (0.0360)+(0.0
550)Ser+(-0.0689)Asn+(0.0075)Tyr+(-0.2492)Met+(0.1334)Phe+(-0.1414)Trp;
0.864, 0.892, 0.849, 0.846, 0.846, 0.856, 0.861, 0.85 2,
(2.4120)+(0.0126)Gln+(-0.1277)His+(0.0002)Ala+(-0.1968)Me
t+(0.1405)Phe+(-0.1055)Trp; 0.864, 0.890, 0.764, 0.737, 0.783, 0.
837, 0.741, 0.775, (0.0799)+(0.0530)Ser+(-0.1604)His+(0.0323)I
hr+(-0.3660)Met+(-0.0063)Lys+(0.1763)Phe; 0.864, 0.889, 0.797,
0.776, 0.791, 0.861, 0.822, 0.812,
(1.8167)+(0.0463)Ser+(0.0346)Tyr+(-0.2758)Met+(0.1638)Ile+(-0.0597)Leu+(--
0.1427)Trp; 0.86 4, 0.888, 0.810, 0.801, 0.823, 0.832, 0.789,
0.811, (-0.1720)+(0.05
35)Ser+(-0.0842)Cit+(-0.2714)Met+(0.0110)Leu+(0.1461)Phe+(-0.1599)Trp;
0.864, 0.891, 0.795, 0.792, 0.798, 0.815, 0.785, 0.797,
(-1.1994)+(0.0534)Ser+(0.0111)Pro+(-0.3373)Met+(0.0010)Leu+(0.1301)Phe+(--
0.1479)Trp; 0.864, 0.888, 0.754, 0.718, 0.762, 0.82 0, 0.782,
0.771, (2.0064)+(0.0451)Ser+(-0.1450)His+(0.0090)Thr
+(0.0141)Leu+(0.1073)Phe+(-0.1317)Trp; 0.864, 0.887, 0.794, 0.7 69,
0.784, 0.857, 0.832, 0.811, (3.2807)+(0.0414)Ser+(-0.0853)As
n+(0.0072)Gln+(-0.1132)His+(0.0727)Ile+(-0.1148)Trp; 0.864, 0. 889,
0.820, 0.803, 0.810, 0.841, 0.872, 0.831, (3.5412)+(-0.0498)A
sn+(0.0104)Gln+(-0.1311)His+(0.0461)Ile+(0.0770)Phe+(-0.127 0)Trp;
0.864, 0.888, 0.815, 0.812, 0.826, 0.837, 0.784, 0.815, (0.02
55)+(0.0526)Ser+(-0.0815)Cit+(0.0003)Val+(-0.2612)Met+(0.15
34)Phe+(-0.1539)Trp; 0.864, 0.887, 0.774, 0.750, 0.746, 0.858, 0.8
38, 0.798, (4.6036)+(0.0464)Ser+(-0.0829)Asn+(-0.0690)His+(-0.
0291)Val+(0.1429)Ile+(-0.1011)Trp; 0.864, 0.883, 0.785, 0.761, 0.
768, 0.854, 0.836, 0.805, (3.3127)+(0.0353)Ser+(0.0049)Gln+(-0.
1169)His+(-0.0056)Ala+(0.0838)Ile+(-0.1203)Trp; 0.864, 0.892,
0.844, 0.840, 0.841, 0.848, 0.860, 0.847,
(2.0904)+(0.0121)Gln+(-0.1342)His+(-0.2275)Met+(0.0111)Lys+(0.1425)Phe+(--
0.1118)Tr p; 0.863, 0.886, 0.784, 0.757, 0.779, 0.815, 0.841,
0.798,
(4.9673)+(-0.1107)His+(0.0156)Thr+(0.0966)Ile+(-0.0378)Leu+(0.0869)P
he+(-0.1312)Trp; 0.863, 0.885, 0.792, 0.775, 0.767, 0.827, 0.866,
0. 809,
(3.5146)+(0.0063)Gln+(-0.1107)His+(-0.0256)Val+(0.1070)Ile+(0.0825)Phe+(--
0.1245)Trp; 0.863, 0.891, 0.757, 0.712, 0.764, 0.839, 0.801, 0.779,
(-1.6709)+(0.0656)Ser+(-0.1514)His+(-0.00
41)Tyr+(-0.3390)Met+(0.0655)Ile+(0.1408)Phe; 0.863, 0.892, 0.8 49,
0.844, 0.846, 0.853, 0.863, 0.851, (2.4047)+(0.0126)Gln+(-0.1
304)His+(0.0029)Val+(-0.1969)Met+(0.1366)Phe+(-0.1080)Trp; 0. 863,
0.887, 0.774, 0.747, 0.757, 0.817, 0.850, 0.793, (4.8935)+(-0.
1028)His+(0.0174)Thr+(-0.0298)Val+(0.1160)Ile+(0.0854)Phe+(-0.1281)Trp;
0.863, 0.885, 0.780, 0.755, 0.759, 0.856, 0.837, 0.80 2,
(4.1227)+(0.0399)Ser+(-0.0899)His+(-0.0061)Ala+(0.1284)Il
e+(-0.0302)Leu+(-0.1135)Trp; 0.863, 0.884, 0.765, 0.734, 0.751, 0.
845, 0.817, 0.787,
(4.2121)+(0.0410)Ser+(-0.0738)His+(-0.0527)Cit+(-0.0233)Val+(0.1356)Ile+(-
-0.1258)Trp; 0.863, 0.885, 0.780, 0.748, 0.781, 0.850, 0.814,
0.798,
(3.0084)+(0.0371)Ser+(0.0059)Gln+(-0.1080)His+(-0.0611)Cit+(0.0802)Ile+(--
0.1360)Trp; 0.86 3, 0.882, 0.803, 0.790, 0.765, 0.863, 0.875,
0.823, (6.3790)+(0.016
2)Thr+(-0.0087)Ala+(-0.0729)Cit+(-0.0371)Val+(0.1714)Ile+(-0.1424)Trp;
0.863, 0.885, 0.783, 0.768, 0.732, 0.889, 0.849, 0.810,
(1.5650)+(0.0333)Ser+(0.0217)Thr+(-0.0059)Ala+(-0.0563)Val+(-0.3799)Met+(-
0.2184)Ile; 0.863, 0.887, 0.792, 0.775, 0.751, 0.86 7, 0.868,
0.815, (4.3520)+(0.0524)Ser+(-0.1265)Asn+(-0.0061)Gl
y+(-0.0420)Val+(0.1596)Ile+(-0.1160)Trp; 0.863, 0.889, 0.762, 0.
736, 0.763, 0.826, 0.784, 0.777, (1.8943)+(0.0496)Ser+(-0.1317)H
is+(0.0052)Pro+(-0.0045)Lys+(0.1201)Phe+(-0.1193)Trp; 0.863, 0.888,
0.783, 0.760, 0.776, 0.840, 0.817, 0.798,
(2.1571)+(0.0537)Ser+(-0.0036)Gly+(-0.1260)His+(-0.0031)Ala+(0.1256)Phe+(-
-0. 1177)Trp; 0.863, 0.888, 0.800, 0.789, 0.766, 0.839, 0.874,
0.817, (4.
9568)+(-0.1417)Asn+(0.0221)Thr+(-0.0505)Val+(0.1538)Ile+(0.
0842)Phe+(-0.1306)Trp; 0.863, 0.885, 0.774, 0.749, 0.760, 0.852, 0.
812, 0.793, (3.4650)+(0.0302)Ser+(-0.1034)Cit+(-0.0349)Val+(0.
0353)Orn+(0.1427)Ile+(-0.1640)Trp; 0.863, 0.895, 0.811, 0.805, 0.
802, 0.845, 0.820, 0.818,
(-0.5507)+(0.0517)Ser+(-0.0339)Val+(-0.3204)Met+(0.0609)Leu+(0.1370)Phe+(-
-0.1400)Trp; 0.863, 0.890, 0.768, 0.743, 0.769, 0.831, 0.788,
0.783,
(2.0556)+(0.0477)Ser+(-0.1327)His+(0.0113)Orn+(-0.0050)Lys+(0.1201)Phe+(--
0.1146)Tr p; 0.863, 0.890, 0.818, 0.824, 0.818, 0.835, 0.792,
0.817, (-0.4446)
+(0.0488)Ser+(-0.0006)Ala+(-0.0046)Val+(-0.2805)Met+(0.142
2)Phe+(-0.1403)Trp; 0.863, 0.889, 0.813, 0.800, 0.787, 0.841, 0.87
9, 0.827, (5.5709)+(-0.0835)His+(-0.0070)Ala+(0.1302)Ile+(-0.
0527)Leu+(0.0937)Phe+(-0.1185)Trp; 0.863, 0.888, 0.815, 0.812, 0.
826, 0.838, 0.784, 0.815, (0.0233)+(0.0525)Ser+(-0.0816)Cit+(0.
0007)Arg+(-0.2617)Met+(0.1538)Phe+(-0.1536)Trp; 0.863, 0.884,
0.771, 0.738, 0.757, 0.850, 0.829, 0.794,
(4.0266)+(0.0428)Ser+(-0.1045)His+(-0.0070)Ala+(0.0064)Pro+(0.0814)Ile+(--
0.1189)Tr p; 0.863, 0.889, 0.754, 0.719, 0.774, 0.833, 0.745,
0.768, (-0.4550)
+(0.0535)Ser+(-0.1693)His+(0.0310)Thr+(-0.3949)Met+(0.0155)Leu+-
(0.1606)Phe; 0.863, 0.887, 0.792, 0.780, 0.780, 0.852, 0.806, 0.
805, (2.6565)+(0.0384)Ser+(0.0084)Thr+(-0.2437)Met+(0.1554)I
le+(-0.0546)Leu+(-0.1348)Trp; 0.863, 0.889, 0.794, 0.766, 0.784,
0.839, 0.853, 0.811, (5.7173)+(-0.1214)His+(0.0225)Thr+(-0.007
0)Ala+(0.0585)Ile+(0.0849)Phe+(-0.1386)Trp; 0.863, 0.888, 0.81 6,
0.821, 0.818, 0.829, 0.789, 0.814, (-0.5584)+(0.0482)Ser+(-0.0
058)Val+(-0.2932)Met+(0.0033)Lys+(0.1427)Phe+(-0.1425)Trp; 0. 863,
0.891, 0.818, 0.818, 0.819, 0.834, 0.803, 0.818, (-0.0585)+(0.
0554)Ser+(-0.0692)Asn+(-0.2448)Met+(0.0061)Leu+(0.1296)Phe+(-0.1422)Trp;
0.863, 0.889, 0.801, 0.785, 0.773, 0.833, 0.879, 0.81 8,
(5.7446)+(-0.0428)Asn+(-0.0718)His+(-0.0356)Val+(0.1300)I
le+(0.0895)Phe+(-0.1126)Trp; 0.863, 0.889, 0.768, 0.740, 0.773, 0.
829, 0.786, 0.782, (2.0007)+(0.0496)Ser+(-0.1342)His+(0.0043)V
al+(-0.0052)Lys+(0.1190)Phe+(-0.1184)Trp; 0.863, 0.891, 0.820,
0.814, 0.834, 0.843, 0.791, 0.821, (-0.0691)+(0.0532)Ser+(-0.081
4)Cit+(0.0147)Tyr+(-0.2826)Met+(0.1505)Phe+(-0.1569)Trp; 0.8 63,
0.890, 0.777, 0.758, 0.771, 0.830, 0.800, 0.790, (1.1804)+(0.04
12)Ser+(0.0046)Gln+(-0.1460)His+(0.0048)Orn+(0.1157)Phe+(-0.
1208)Trp; 0.863, 0.889, 0.767, 0.737, 0.767, 0.823, 0.801, 0.782,
(1. 9300)+(0.0545)Ser+(-0.0042)Gly+(-0.1310)His+(0.0055)Pro+(0.
1147)Phe+(-0.1255)Trp; 0.862, 0.890, 0.815, 0.807, 0.827, 0.820, 0.
808, 0.815, (3.0045)+(0.0478)Thr+(-0.0476)Val+(-0.4018)Met+(0.
0773)Leu+(0.1444)Phe+(-0.1555)Trp; 0.862, 0.890, 0.762, 0.737, 0.
765, 0.826, 0.778, 0.777, (2.0560)+(0.0441)Ser+(-0.1392)His+(0.
0082)Thr+(0.0052)Orn+(0.1178)Phe+(-0.1241)Trp; 0.862, 0.883, 0.
811, 0.795, 0.793, 0.852, 0.864, 0.826, (0.0062)+(0.0116)Gln+(-0.
1305)His+(-0.3134)Met+(0.1368)Ile+(-0.0627)Leu+(0.1303)Phe; 0.862,
0.886, 0.805, 0.785, 0.794, 0.865, 0.835, 0.820, (3.9584)+(0.
0461)Ser+(-0.0734)Asn+(-0.0072)Ala+(-0.0832)Cit+(0.0874)Ile
+(-0.1536)Trp; 0.862, 0.888, 0.783, 0.757, 0.787, 0.846, 0.800, 0.7
97,
(-2.2507)+(0.0539)Ser+(0.0077)Gln+(-0.1716)His+(-0.3210)Met+(0.0132)Leu+(-
0.1530)Phe; 0.862, 0.890, 0.764, 0.741, 0.789, 0. 840, 0.719,
0.772, (0.1342)+(0.0545)Ser+(-0.1584)His+(0.0363)I
hr+(-0.0227)Arg+(-0.3686)Met+(0.1778)Phe; 0.862, 0.888, 0.830,
0.827, 0.820, 0.848, 0.843, 0.835, (3.3589)+(-0.0610)Asn+(0.003
4)Gly+(0.0107)Gln+(-0.1298)His+(0.1065)Phe+(-0.1130)Trp; 0.8 62,
0.888, 0.818, 0.812, 0.768, 0.854, 0.911, 0.836, (5.0118)+(-0.0
713)Asn+(-0.0075)Ala+(-0.0478)Val+(0.1664)Ile+(0.0865)Phe+(-0.1230)Trp;
0.862, 0.892, 0.796, 0.793, 0.800, 0.813, 0.786, 0.79 8,
(-1.1707)+(0.0540)Ser+(0.0117)Pro+(-0.3362)Met+(-0.0057)O
rn+(0.1339)Phe+(-0.1477)Trp; 0.862, 0.886, 0.807, 0.793, 0.808, 0.
826, 0.829, 0.814, (3.7059)+(0.0079)Gln+(-0.1425)His+(0.0180)I
hr+(-0.0058)Lys+(0.1061)Phe+(-0.1258)Trp; 0.862, 0.886, 0.780,
0.762, 0.750, 0.889, 0.810, 0.803,
(2.0491)+(0.0334)Ser+(0.0249)Thr+(-0.0577)Cit+(-0.0553)Val+(-0.4016)Met+(-
0.2076)Ile; 0.86 2, 0.885, 0.806, 0.784, 0.798, 0.831, 0.861,
0.819, (3.3636)+(0.009
1)Gln+(-0.1363)His+(-0.0053)Lys+(0.0507)Ile+(0.0776)Phe+(-0.
1297)Trp; 0.862, 0.894, 0.855, 0.850, 0.855, 0.863, 0.864, 0.858,
(2. 2508)+(0.0135)Gln+(-0.1156)His+(-0.0544)Cit+(-0.1821)Met+(0.
1518)Phe+(-0.1151)Trp; 0.862, 0.891, 0.821, 0.823, 0.824, 0.837, 0.
797, 0.820,
(-0.5815)+(0.0496)Ser+(0.0134)Tyr+(-0.0052)Val+(-0.3040)Met+(0.139-
9)Phe+(-0.1435)Trp; 0.862, 0.888, 0.759, 0.742, 0.756, 0.819,
0.766, 0.771,
(2.0936)+(0.0434)Ser+(-0.1355)His+(0.0137)Thr+(-0.0302)Tyr+(0.1349-
)Phe+(-0.1183)Trp; 0.862, 0.8 88, 0.793, 0.771, 0.806, 0.843,
0.788, 0.802, (2.7887)+(0.0484)Ser
+(-0.0749)Cit+(0.0067)Pro+(-0.2175)Met+(0.0776)Ile+(-0.153 1)Trp;
0.862, 0.891, 0.767, 0.740, 0.779, 0.836, 0.761, 0.779, (2.16
49)+(0.0468)Ser+(-0.1226)His+(0.0155)Thr+(-0.0671)Cit+(0.13
59)Phe+(-0.1458)Trp; 0.862, 0.886, 0.788, 0.770, 0.790, 0.845, 0.7
92, 0.799, (-2.0421)+(0.0523)Ser+(0.0078)Gln+(-0.1671)His+(0.
0005)Ala+(-0.3088)Met+(0.1634)Phe; 0.862, 0.890, 0.801, 0.769, 0.
822, 0.853, 0.805, 0.812, (2.0511)+(0.0517)Ser+(-0.0769)Cit+(0.
0386)Tyr+(-0.2669)Met+(0.0863)Ile+(-0.1620)Trp; 0.862, 0.887,
0.789, 0.772, 0.790, 0.846, 0.794, 0.800,
(-1.9995)+(0.0523)Ser+(0.0078)Gln+(-0.1667)His+(0.0002)Val+(-0.3055)Met+(-
0.1631)P he; 0.862, 0.883, 0.796, 0.774, 0.786, 0.859, 0.831,
0.813, (3.7707)
+(0.0409)Ser+(-0.0083)Ala+(-0.0902)Cit+(-0.0127)Lys+(0.100
6)Ile+(-0.1581)Trp; 0.862, 0.887, 0.815, 0.817, 0.817, 0.830, 0.79
4, 0.815, (-0.6094)+(0.0489)Ser+(-0.0013)Ala+(-0.2831)Met+(0.
0010)Lys+(0.1348)Phe+(-0.1453)Trp; 0.862, 0.892, 0.846, 0.841, 0.
843, 0.853, 0.858, 0.849, (2.4961)+(0.0121)Gln+(-0.1282)His+(-0.
1947)Met+(0.0089)Orn+(0.1359)Phe+(-0.1050)Trp; 0.862, 0.890, 0.
788, 0.769, 0.787, 0.844, 0.801, 0.800, (0.8908)+(0.0444)Ser+(0.0
059)Gln+(-0.1300)His+(-0.0634)Cit+(0.1329)Phe+(-0.1355)Trp; 0.862,
0.888, 0.825, 0.825, 0.824, 0.823, 0.829, 0.825,
(-0.8441)+(0.0579)Ser+(-0.0075)Gly+(0.0021)Gln+(-0.2941)Met+(0.1310)P
he+(-0.1491)Trp; 0.862, 0.883, 0.790, 0.770, 0.758, 0.870, 0.852,
0. 813, (5.9999)+(-0.0698)His+(0.0356)Thr+(-0.0035)Ala+(-0.044
9)Val+(-0.3132)Met+(0.1885)Ile; 0.862, 0.887, 0.799, 0.785, 0.78 4,
0.859, 0.819, 0.812, (3.0000)+(0.0447)Ser+(-0.0404)Asn+(-0.1
829)Met+(0.1554)Ile+(-0.0555)Leu+(-0.1287)Trp; 0.862, 0.886, 0.
776, 0.745, 0.788, 0.818, 0.801, 0.788, (0.9605)+(0.0456)Ser+(-0.
1169)Cit+(-0.0220)Lys+(0.0716)Ile+(0.0939)Phe+(-0.1893)Trp; 0.862,
0.884, 0.800, 0.780, 0.799, 0.849, 0.822, 0.812,
(7.2924)+(-0.0813)His+(0.0306)Thr+(-0.1943)Met+(0.1154)Ile+(-0.0277)Le
u+(-0.1092)Trp; 0.862, 0.886, 0.759, 0.733, 0.776, 0.830, 0.741, 0.
770,
(-0.2427)+(0.0522)Ser+(-0.1627)His+(0.0303)Thr+(0.0004)Ala+(-0.3769)Met+(-
0.1726)Phe; 0.862, 0.889, 0.819, 0.825, 0.821, 0.839, 0.782, 0.817,
(-0.2673)+(0.0512)Ser+(-0.0124)Arg+(-0.00
45)Val+(-0.2696)Met+(0.1437)Phe+(-0.1386)Trp; 0.862, 0.886, 0. 766,
0.753, 0.735, 0.815, 0.828, 0.783, (0.7726)+(0.0391)Ser+(-0.
0385)Arg+(-0.0478)Val+(0.1588)Ile+(0.0886)Phe+(-0.1566)Trp; 0.862,
0.887, 0.764, 0.738, 0.781, 0.835, 0.745, 0.775, (0.0802)+(0.
0548)Ser+(-0.0357)Asn+(-0.1569)His+(0.0307)Thr+(-0.3490)Met
+(0.1712)Phe; 0.862, 0.884, 0.803, 0.786, 0.804, 0.822, 0.828, 0.81
0, (3.5153)+(0.0077)Gln+(-0.1456)His+(0.0155)Thr+(0.0015)Val
+(0.0996)Phe+(-0.1295)Trp; 0.862, 0.887, 0.823, 0.822, 0.825, 0.8
27, 0.816, 0.822, (-0.1067)+(0.0621)Ser+(-0.0071)Gly+(-0.0122)
Arg+(-0.2722)Met+(0.1352)Phe+(-0.1448)Trp; 0.862, 0.885, 0.836,
0.831, 0.828, 0.845, 0.858, 0.841, (3.6527)+(-0.0537)Asn+(0.011
2)Gln+(-0.1292)His+(0.0009)Val+(0.1007)Phe+(-0.1149)Trp; 0.8 61,
0.887, 0.831, 0.830, 0.814, 0.835, 0.867, 0.837, (1.0670)+(0.00
65)Gln+(-0.2951)Met+(0.1623)Ile+(-0.0802)Leu+(0.1153)Phe+(-0.1345)Trp;
0.861, 0.888, 0.763, 0.739, 0.778, 0.834, 0.743, 0.773,
(-0.1525)+(0.0517)Ser+(-0.1593)His+(0.0310)Thr+(-0.0027)Val
+(-0.3728)Met+(0.1768)Phe; 0.861, 0.885, 0.755, 0.720, 0.761, 0.8
19, 0.788, 0.772, (1.7702)+(0.0487)Ser+(-0.1391)His+(0.0033)Pr
o+(0.0126)Leu+(0.1067)Phe+(-0.1278)Trp; 0.861, 0.888, 0.794, 0.
790, 0.750, 0.844, 0.861, 0.811, (0.5930)+(0.0316)Ser+(-0.0111)A
la+(0.1686)Ile+(-0.0786)Leu+(0.0776)Phe+(-0.1552)Trp; 0.861, 0.888,
0.759, 0.732, 0.761, 0.823, 0.781, 0.774,
(1.8109)+(0.0475)Ser+(-0.1354)His+(0.0044)Pro+(0.0067)Orn+(0.1142)Phe+(-0-
.12 23)Trp; 0.861, 0.883, 0.803, 0.793, 0.769, 0.875, 0.851, 0.822,
(3.7 243)+(0.0406)Ser+(-0.0863)Asn+(-0.0075)Ala+(0.1609)Ile+(-0.
0610)Leu+(-0.1278)Trp; 0.861, 0.885, 0.781, 0.746, 0.788, 0.819, 0.
831, 0.796, (5.6127)+(-0.1249)His+(0.0234)Thr+(-0.0084)Lys+(0.
0507)Ile+(0.0838)Phe+(-0.1363)Trp; 0.861, 0.888, 0.765, 0.738, 0.
767, 0.827, 0.787, 0.780, (1.9034)+(0.0471)Ser+(-0.1367)His+(0.
0023)Val+(0.0076)Orn+(0.1144)Phe+(-0.1210)Trp; 0.861, 0.887, 0.
817, 0.821, 0.821, 0.834, 0.785, 0.815, (-0.3576)+(0.0514)Ser+(-0.
0011)Ala+(-0.0127)Arg+(-0.2661)Met+(0.1371)Phe+(-0.1421)Tr p;
0.861, 0.887, 0.790, 0.773, 0.790, 0.847, 0.794, 0.801, (-1.9425)
+(0.0526)Ser+(0.0078)Gln+(-0.1659)His+(-0.3016)Met+(-0.001
4)Lys+(0.1638)Phe; 0.861, 0.887, 0.762, 0.736, 0.778, 0.831, 0.749,
0.774, (-0.1607)+(0.0541)Ser+(-0.0016)Gly+(-0.1607)His+(0.03
06)Thr+(-0.3737)Met+(0.1711)Phe; 0.861, 0.890, 0.821, 0.829, 0.8
20, 0.833, 0.795, 0.819, (-0.9262)+(0.0466)Ser+(0.0019)Gln+(-0.
0051)Val+(-0.2928)Met+(0.1412)Phe+(-0.1425)Trp; 0.861, 0.886,
0.781, 0.762, 0.729, 0.883, 0.865, 0.810,
(1.2558)+(0.0430)Ser+(-0.0082)Ala+(0.0112)Pro+(-0.0516)Val+(-0.3203)Met+(-
0.1956)Il e; 0.861, 0.885, 0.786, 0.766, 0.773, 0.815, 0.842,
0.799,
(4.5917)+(0.0039)Gly+(-0.1006)His+(0.1083)Ile+(-0.0446)Leu+(0.0899)P
he+(-0.1218)Trp; 0.861, 0.889, 0.816, 0.821, 0.816, 0.834, 0.788,
0. 815, (-0.4831)+(0.0483)Ser+(-0.0057)Val+(-0.2859)Met+(0.005
9)Orn+(0.1402)Phe+(-0.1397)Trp; 0.861, 0.886, 0.821, 0.819, 0.82 2,
0.824, 0.825, 0.822, (-0.3110)+(0.0599)Ser+(-0.0072)Gly+(-0.
0006)Ala+(-0.2816)Met+(0.1334)Phe+(-0.1465)Trp; 0.861, 0.885,
0.829, 0.818, 0.801, 0.875, 0.883, 0.844,
(4.9134)+(0.0066)Gln+(-0.0570)Cit+(-0.0378)Val+(-0.1870)Met+(0.1670)Ile+(-
-0.1228)T rp; 0.861, 0.888, 0.778, 0.766, 0.770, 0.824, 0.792,
0.788, (1.0973)
+(0.0421)Ser+(0.0047)Gln+(-0.1408)His+(-0.0206)Tyr+(0.1286)Phe+(-
-0.1143)Trp; 0.861, 0.886, 0.820, 0.818, 0.821, 0.820, 0.824,
0.821, (-0.3653)+(0.0601)Ser+(-0.0073)Gly+(-0.2865)Met+(0.00
03)Lys+(0.1330)Phe+(-0.1474)Trp; 0.861, 0.892, 0.852, 0.845, 0.8
51, 0.860, 0.867, 0.856, (2.3965)+(0.0128)Gln+(-0.1297)His+(0.0
154)Tyr+(-0.2172)Met+(0.1374)Phe+(-0.1094)Trp; 0.861, 0.888, 0.
786, 0.766, 0.788, 0.847, 0.792, 0.798, (-1.9641)+(0.0520)Ser+(0.
0075)Gln+(-0.1672)His+(-0.3047)Met+(0.0067)Orn+(0.1609)Phe; 0.861,
0.887, 0.806, 0.787, 0.814, 0.856, 0.802, 0.815, (1.9876)+(0.
0429)Ser+(0.0035)Gln+(-0.0768)Cit+(-0.2133)Met+(0.0837)Ile+(-0.1550)Trp;
0.861, 0.881, 0.801, 0.788, 0.762, 0.889, 0.857, 0.82 4,
(4.9664)+(0.0347)Thr+(-0.0063)Ala+(-0.0603)Cit+(-0.0556)V
al+(-0.3403)Met+(0.2140)Ile; 0.861, 0.885, 0.796, 0.773, 0.789, 0.
830, 0.846, 0.810, (3.0453)+(0.0025)Gly+(0.0081)Gln+(-0.1407)H
is+(0.0485)Ile+(0.0773)Phe+(-0.1323)Trp; 0.861, 0.889, 0.812, 0.
804, 0.815, 0.832, 0.812, 0.816, (3.7194)+(0.0101)Gln+(-0.1474)H
is+(0.0244)Thr+(-0.0319)Arg+(0.1114)Phe+(-0.1300)Trp; 0.861, 0.883,
0.801, 0.778, 0.799, 0.853, 0.830, 0.815, (7.6696)+(-0.092
7)His+(0.0342)Thr+(-0.0038)Ala+(-0.1808)Met+(0.0834)Ile+(-0.
1139)Trp; 0.861, 0.886, 0.765, 0.731, 0.769, 0.821, 0.808, 0.782,
(1. 9837)+(0.0533)Ser+(-0.0035)Gly+(-0.1361)His+(0.0137)Leu+(0.
1076)Phe+(-0.1275)Trp; 0.861, 0.886, 0.834, 0.828, 0.826, 0.843, 0.
855, 0.838, (3.6642)+(-0.0551)Asn+(0.0110)Gln+(-0.1281)His+(0.
0027)Pro+(0.0996)Phe+(-0.1155)Trp; 0.861, 0.882, 0.800, 0.774, 0.
814, 0.848, 0.806, 0.811, (7.6639)+(-0.0823)His+(0.0350)Thr+(-0.
0445)Cit+(-0.1880)Met+(0.0786)Ile+(-0.1186)Trp; 0.861, 0.886,
0.801, 0.781, 0.810, 0.852, 0.796, 0.810,
(3.3523)+(0.0502)Ser+(-0.0450)Asn+(-0.0708)Cit+(-0.1609)Met+(0.0818)Ile+(-
-0.1466)T rp; 0.861, 0.885, 0.812, 0.796, 0.813, 0.860, 0.819,
0.822, (2.9654)
+(0.0423)Ser+(-0.1216)Asn+(0.0056)Gln+(-0.0904)Cit+(0.0693)Ile+(-
-0.1676)Trp; 0.861, 0.884, 0.795, 0.777, 0.749, 0.895, 0.865,
0.821, (1.8695)+(0.0424)Ser+(-0.0068)Ala+(-0.0549)Cit+(-0.04
77)Val+(-0.2786)Met+(0.2022)Ile; 0.861, 0.888, 0.820, 0.823, 0.8
20, 0.831, 0.801, 0.819, (-0.9915)+(0.0469)Ser+(0.0018)Gln+(-0.
0014)Ala+(-0.2873)Met+(0.1338)Phe+(-0.1463)Trp; 0.861, 0.886,
0.763, 0.728, 0.769, 0.830, 0.792, 0.780,
(2.0265)+(0.0506)Ser+(-0.1363)His+(-0.0081)Lys+(0.0182)Leu+(0.1113)Phe+(--
0.1214)Tr p; 0.860, 0.884, 0.762, 0.733, 0.773, 0.834, 0.764,
0.776, (-0.8079)
+(0.0664)Ser+(-0.0270)Asn+(-0.1442)His+(0.0113)Pro+(-0.310
0)Met+(0.1605)Phe; 0.860, 0.887, 0.761, 0.735, 0.785, 0.837, 0.727,
0.771, (-0.0384)+(0.0535)Ser+(-0.1543)His+(0.0332)Thr+(-0.04
31)Cit+(-0.3756)Met+(0.1756)Phe; 0.860, 0.887, 0.815, 0.819, 0.8
18, 0.824, 0.793, 0.814, (-1.1092)+(0.0473)Ser+(0.0017)Gln+(-0.
2979)Met+(0.0003)Lys+(0.1331)Phe+(-0.1479)Trp; 0.860, 0.885, 0.
782, 0.756, 0.755, 0.875, 0.839, 0.806, (1.9431)+(0.0414)Ser+(0.0
045)Gln+(-0.0927)His+(-0.0346)Val+(-0.2781)Met+(0.1652)Ile; 0.860,
0.886, 0.768, 0.733, 0.770, 0.850, 0.797, 0.788,
(-0.7431)+(0.0624)Ser+(-0.1369)His+(-0.0242)Val+(-0.3243)Met+(0.0509)Leu+-
(0.1568)Phe; 0.860, 0.886, 0.819, 0.816, 0.777, 0.848, 0.896, 0.
834, (3.8148)+(-0.1186)Asn+(0.0045)Gln+(-0.0464)Val+(0.1461)
Ile+(0.0803)Phe+(-0.1314)Trp; 0.860, 0.882, 0.755, 0.719, 0.768,
0.833, 0.766, 0.772, (-1.1575)+(0.0653)Ser+(-0.1512)His+(0.010
6)Pro+(-0.3368)Met+(0.0083)Leu+(0.1545)Phe; 0.860, 0.886, 0.79 2,
0.774, 0.789, 0.846, 0.806, 0.804, (-1.9746)+(0.0548)Ser+(-0.0
022)Gly+(0.0081)Gln+(-0.1654)His+(-0.3030)Met+(0.1611)Phe; 0. 860,
0.890, 0.785, 0.767, 0.782, 0.847, 0.792, 0.797, (2.2499)+(0.0
526)Ser+(-0.1244)His+(-0.0028)Ala+(-0.0188)Arg+(0.1339)Phe+(-0.1135)Trp;
0.860, 0.890, 0.812, 0.798, 0.770, 0.852, 0.907, 0.83 2,
(4.5275)+(-0.0096)Ala+(-0.0840)Cit+(-0.0421)Val+(0.1697)I
le+(0.0958)Phe+(-0.1450)Trp; 0.860, 0.886, 0.760, 0.734, 0.776, 0.
832, 0.742, 0.771,
(-0.2070)+(0.0521)Ser+(-0.1622)His+(0.0301)Thr+(-0.3736)Met+(0.0006)Orn+(-
0.1722)Phe; 0.860, 0.885, 0.801, 0.785, 0.788, 0.816, 0.861, 0.812,
(5.4173)+(-0.0157)Asn+(-0.088
5)His+(0.1108)Ile+(-0.0481)Leu+(0.0886)Phe+(-0.1203)Trp; 0.8 60,
0.885, 0.793, 0.775, 0.796, 0.853, 0.792, 0.804, (-2.0167)+(0.0
523)Ser+(0.0086)Gln+(-0.1570)His+(-0.0401)Cit+(-0.3072)Met+(0.1663)Phe;
0.860, 0.883, 0.818, 0.805, 0.793, 0.863, 0.874, 0.834,
(5.1525)+(0.0085)Gln+(-0.0724)His+(-0.0293)Val+(-0.1741)Met
+(0.1488)Ile+(-0.0978)Trp; 0.860, 0.887, 0.779, 0.749, 0.779, 0.8
52, 0.809, 0.797, (3.6799)+(0.0529)Ser+(-0.0928)His+(-0.0064)A
rg+(-0.1640)Met+(0.0925)Ile+(-0.1051)Trp; 0.860, 0.886, 0.792,
0.780, 0.778, 0.853, 0.810, 0.805,
(2.4785)+(0.0425)Ser+(0.0032)Pro+(-0.2281)Met+(0.1543)Ile+(-0.0565)Leu+(--
0.1313)Trp; 0.86 0, 0.885, 0.777, 0.748, 0.768, 0.850, 0.819,
0.796, (4.2991)+(0.046
3)Ser+(-0.0587)Asn+(-0.0873)His+(0.1133)Ile+(-0.0278)Leu+(-0.1114)Trp;
0.860, 0.887, 0.819, 0.817, 0.821, 0.822, 0.822, 0.820,
(-0.3656)+(0.0600)Ser+(-0.0075)Gly+(-0.2872)Met+(0.0050)Orn
+(0.1302)Phe+(-0.1473)Trp; 0.860, 0.883, 0.801, 0.787, 0.801, 0.8
23, 0.823, 0.809, (3.4603)+(0.0007)Gly+(0.0075)Gln+(-0.1445)Hi
s+(0.0153)Thr+(0.1026)Phe+(-0.1278)Trp; 0.860, 0.888, 0.821, 0.
828, 0.824, 0.832, 0.788, 0.818, (-1.0121)+(0.0489)Ser+(0.0025)G
ln+(-0.0147)Arg+(-0.2826)Met+(0.1350)Phe+(-0.1456)Trp; 0.860,
0.888, 0.764, 0.724, 0.775, 0.849, 0.786, 0.784,
(4.0850)+(0.0427)
Ser+(-0.0961)His+(-0.0781)Cit+(0.0330)Orn+(0.0735)Ile+(-0.1
376)Trp; 0.860, 0.881, 0.781, 0.753, 0.765, 0.858, 0.831, 0.802,
(4. 3682)+(0.0479)Ser+(-0.0470)Asn+(-0.0963)His+(-0.0050)Ala+(0.
0853)Ile+(-0.1108)Trp; 0.860, 0.881, 0.794, 0.773, 0.768, 0.871, 0.
844, 0.814, (4.1728)+(0.0062)Gln+(-0.0912)His+(0.0315)Thr+(-0.
0414)Val+(-0.3471)Met+(0.1758)Ile; 0.860, 0.884, 0.792, 0.780, 0.
777, 0.854, 0.810, 0.805, (2.5110)+(0.0417)Ser+(-0.2194)Met+(0.
0019)Orn+(0.1590)Ile+(-0.0575)Leu+(-0.1314)Trp; 0.860, 0.886,
0.772, 0.744, 0.774, 0.826, 0.805, 0.787,
(2.0103)+(0.0533)Ser+(-0.0037)Gly+(-0.1325)His+(0.0029)Val+(0.1158)Phe+(--
0.1234)Tr p; 0.860, 0.885, 0.789, 0.771, 0.759, 0.849, 0.858,
0.809,
(2.7917)+(0.0065)Gly+(-0.0787)His+(-0.0499)Val+(-0.3366)Met+(0.1743)Ile+(-
0.1352)Phe; 0.860, 0.887, 0.771, 0.731, 0.753, 0.877, 0.841, 0.
800,
(1.9178)+(0.0531)Ser+(-0.0836)His+(0.0452)Tyr+(-0.0437)Val+(-0.3490)Met+(-
0.1874)Ile; 0.860, 0.890, 0.821, 0.820, 0.823, 0.839, 0.805, 0.822,
(-0.6576)+(0.0498)Ser+(-0.0017)Ala+(0.014
1)Tyr+(-0.2981)Met+(0.1323)Phe+(-0.1474)Trp; 0.860, 0.884, 0.7 68,
0.737, 0.748, 0.865, 0.823, 0.793, (2.7448)+(0.0448)Ser+(-0.0
850)His+(-0.0388)Val+(-0.2722)Met+(0.0225)Orn+(0.1696)Ile; 0. 860,
0.887, 0.815, 0.817, 0.817, 0.835, 0.794, 0.816, (-0.5789)+(0.
0488)Ser+(-0.0014)Ala+(-0.2804)Met+(0.0030)Orn+(0.1335)Phe+(-0.1442)Trp;
0.860, 0.886, 0.803, 0.787, 0.778, 0.862, 0.859, 0.82 1,
(7.4713)+(-0.0934)Asn+(0.0232)Thr+(-0.0639)Cit+(-0.0405)V
al+(0.1570)Ile+(-0.1314)Trp; 0.860, 0.883, 0.778, 0.757, 0.733, 0.
882, 0.852, 0.806, (1.5906)+(0.0437)Ser+(-0.0084)Gly+(0.0244)I
hr+(-0.0590)Val+(-0.4157)Met+(0.2146)Ile; 0.860, 0.888, 0.784,
0.763, 0.783, 0.850, 0.795, 0.798, (2.1035)+(0.0517)Ser+(-0.110
7)His+(-0.0031)Ala+(-0.0577)Cit+(0.1403)Phe+(-0.1301)Trp; 0. 860,
0.884, 0.798, 0.777, 0.801, 0.823, 0.829, 0.807, (3.5421)+(0.0
077)Gln+(-0.1497)His+(0.0157)Thr+(0.0118)Leu+(0.0908)Phe+(-0.1341)Trp;
0.860, 0.883, 0.803, 0.788, 0.804, 0.823, 0.826, 0.810,
(3.5356)+(0.0076)Gln+(-0.1441)His+(0.0156)Thr+(0.0001)Pro+(0.1018)Phe+(-0-
.1282)Trp; 0.860, 0.883, 0.795, 0.773, 0.805, 0.84 8, 0.792, 0.804,
(2.9446)+(0.0478)Ser+(-0.0728)Cit+(-0.1839)Me
t+(-0.0046)Lys+(0.0870)Ile+(-0.1486)Trp; 0.860, 0.883, 0.761, 0.
733, 0.770, 0.835, 0.761, 0.775,
(-0.9537)+(0.0644)Ser+(-0.1432)His+(0.0125)Pro+(-0.0041)Val+(-0.3310)Met+-
(0.1664)Phe; 0.860, 0.889, 0.819, 0.820, 0.828, 0.835, 0.784,
0.817, (-0.5539)+(0.052
6)Ser+(-0.0134)Arg+(0.0138)Tyr+(-0.2941)Met+(0.1336)Phe+(-0.
1464)Trp; 0.860, 0.887, 0.777, 0.751, 0.775, 0.830, 0.808, 0.791,
(2. 1684)+(0.0547)Ser+(-0.0040)Gly+(-0.1270)His+(-0.0045)Lys+(0.
1231)Phe+(-0.1170)Trp; 0.859, 0.880, 0.764, 0.733, 0.744, 0.836, 0.
837, 0.787,
(4.1433)+(0.0453)Ser+(-0.0053)Gly+(-0.0866)His+(-0.0250)Val+(0.132-
2)Ile+(-0.1159)Trp; 0.859, 0.885, 0.778, 0.750, 0.746, 0.877,
0.846, 0.805,
(2.7973)+(0.0464)Ser+(-0.0762)His+(-0.0038)Ala+(-0.0362)Val+(-0.24-
46)Met+(0.1762)Ile; 0.859, 0. 887, 0.808, 0.782, 0.802, 0.839,
0.865, 0.822, (2.8036)+(0.0103)Gl
n+(-0.1235)His+(-0.0714)Cit+(0.0564)Ile+(0.0901)Phe+(-0.147 2)Trp;
0.859, 0.884, 0.793, 0.783, 0.750, 0.870, 0.855, 0.814, (3.77
77)+(0.0413)Ser+(-0.1453)Asn+(0.0022)Gln+(-0.0420)Val+(0.15
83)Ile+(-0.1132)Trp; 0.859, 0.886, 0.801, 0.804, 0.789, 0.819, 0.8
04, 0.804, (1.6061)+(0.0489)Ser+(-0.1531)Asn+(0.0071)Pro+(-0.
0111)Val+(0.1069)Phe+(-0.1366)Trp; 0.859, 0.885, 0.812, 0.816, 0.
819, 0.824, 0.775, 0.809,
(-0.5539)+(0.0514)Ser+(-0.0153)Arg+(-0.2837)Met+(0.0043)Lys+(0.1357)Phe+(-
-0.1463)Trp; 0.859, 0.882, 0.788, 0.778, 0.796, 0.860, 0.743,
0.794,
(5.9475)+(0.0386)Ser+(-0.0874)His+(0.0182)Thr+(0.0133)Pro+(-0.1731)Met+(--
0.1011)Tr p; 0.859, 0.885, 0.776, 0.742, 0.780, 0.851, 0.802,
0.794,
(4.4375)+(0.0504)Ser+(-0.0491)Asn+(-0.0844)His+(-0.0524)Cit+(0.0802)Ile+(-
-0.1253)Trp; 0.859, 0.886, 0.812, 0.796, 0.806, 0.832, 0.853,
0.822, (3.2648)+(0.0113)Gln+(-0.1398)His+(-0.0221)Arg+(0.049
7)Ile+(0.0800)Phe+(-0.1301)Trp; 0.859, 0.885, 0.835, 0.830, 0.82 7,
0.843, 0.856, 0.839, (3.6299)+(-0.0601)Asn+(0.0111)Gln+(-0.1
293)His+(0.0036)Lys+(0.1000)Phe+(-0.1157)Trp; 0.859, 0.879, 0. 765,
0.739, 0.745, 0.840, 0.823, 0.787, (3.5328)+(0.0334)Ser+(0.0
030)Gln+(-0.1001)His+(-0.0214)Val+(0.1231)Ile+(-0.1170)Trp; 0.859,
0.889, 0.766, 0.746, 0.756, 0.847, 0.783, 0.783,
(-4.1346)+(0.0541)Ser+(-0.0945)Cit+(-0.4161)Met+(0.2004)Ile+(-0.1008)Leu+-
(0.1473)Phe; 0.859, 0.887, 0.810, 0.794, 0.815, 0.835, 0.823, 0.
817,
(3.4891)+(0.0084)Gln+(-0.1318)His+(0.0202)Thr+(-0.0675)Cit+(0.1196)Phe+(--
0.1424)Trp; 0.859, 0.881, 0.794, 0.789, 0.744, 0.829, 0.886, 0.812,
(3.5371)+(0.0092)Thr+(-0.0098)Ala+(-0.045
2)Val+(0.1621)Ile+(0.0747)Phe+(-0.1514)Trp; 0.859, 0.884, 0.75 8,
0.725, 0.758, 0.824, 0.796, 0.776, (1.9404)+(0.0483)Ser+(-0.13
52)His+(-0.0130)Val+(0.0344)Leu+(0.1087)Phe+(-0.1251)Trp; 0. 859,
0.884, 0.798, 0.788, 0.781, 0.856, 0.817, 0.810, (2.0881)+(0.0
390)Ser+(0.0021)Gln+(-0.2283)Met+(0.1593)Ile+(-0.0579)Leu+(-0.1337)Trp;
0.859, 0.884, 0.784, 0.769, 0.746, 0.869, 0.844, 0.80 7,
(4.1978)+(0.0422)Ser+(-0.1479)Asn+(-0.0449)Val+(0.0207)Or
n+(0.1609)Ile+(-0.1099)Trp; 0.859, 0.884, 0.762, 0.724, 0.768, 0.
845, 0.788, 0.781, (4.1719)+(0.0423)Ser+(-0.0982)His+(0.0077)T
hr+(-0.0583)Cit+(0.0798)Ile+(-0.1361)Trp; 0.859, 0.886, 0.783,
0.761, 0.761, 0.820, 0.863, 0.801, (5.1584)+(-0.0895)His+(-0.031
9)Val+(0.0150)Orn+(0.1199)Ile+(0.0791)Phe+(-0.1185)Trp; 0.85 9,
0.889, 0.771, 0.739, 0.788, 0.840, 0.767, 0.784, (1.9869)+(0.048
5)Ser+(-0.1126)His+(-0.0888)Cit+(0.0354)Orn+(0.1271)Phe+(-0.
1413)Trp; 0.859, 0.883, 0.804, 0.787, 0.764, 0.853, 0.892, 0.824,
(6. 9809)+(-0.0104)Ala+(-0.0717)Cit+(0.0114)Pro+(-0.0379)Val+(0.
1679)Ile+(-0.1306)Trp; 0.859, 0.882, 0.797, 0.791, 0.745, 0.829, 0.
898, 0.816, (3.8111)+(-0.0102)Ala+(0.0055)Pro+(-0.0452)Val+(0.
1593)Ile+(0.0760)Phe+(-0.1458)Trp; 0.859, 0.888, 0.822, 0.819, 0.
823, 0.824, 0.826, 0.823, (-0.4105)+(0.0603)Ser+(-0.0072)Gly+(0.
0062)Tyr+(-0.2951)Met+(0.1317)Phe+(-0.1487)Trp; 0.859, 0.887,
0.811, 0.813, 0.815, 0.825, 0.786, 0.810,
(-0.7233)+(0.0492)Ser+(-0.2923)Met+(0.0014)Orn+(0.0007)Lys+(0.1335)Phe+(--
0.1464)T rp; 0.859, 0.884, 0.832, 0.824, 0.827, 0.839, 0.860,
0.837, (3.6550)
+(-0.0514)Asn+(0.0112)Gln+(-0.1331)His+(0.0098)Leu+(0.0927)Phe+(-
-0.1193)Trp; 0.859, 0.883, 0.770, 0.748, 0.748, 0.845, 0.822,
0.791, (3.4473)+(0.0335)Ser+(-0.0793)Cit+(0.0027)Pro+(-0.034
1)Val+(0.1459)Ile+(-0.1610)Trp; 0.859, 0.882, 0.771, 0.749, 0.74 9,
0.847, 0.819, 0.791, (3.5027)+(0.0324)Ser+(0.0016)Thr+(-0.07
81)Cit+(-0.0341)Val+(0.1484)Ile+(-0.1603)Trp; 0.859, 0.878, 0. 773,
0.742, 0.760, 0.851, 0.826, 0.795, (4.1357)+(0.0433)Ser+(-0.
1020)His+(-0.0054)Ala+(-0.0037)Lys+(0.0887)Ile+(-0.1147)Tr p;
0.859, 0.884, 0.794, 0.783, 0.778, 0.853, 0.811, 0.806,
(2.4701)+(0.0409)Ser+(-0.2281)Met+(0.0037)Lys+(0.1613)Ile+(-0.0597)L
eu+(-0.1341)Trp; 0.859, 0.885, 0.805, 0.796, 0.768, 0.837, 0.883,
0. 821,
(4.9586)+(-0.1011)Asn+(-0.0489)Val+(0.0164)Orn+(0.1501)Ile+(0.0759)Phe+(--
0.1251)Trp; 0.859, 0.890, 0.851, 0.849, 0.847, 0.857, 0.859, 0.853,
(2.4884)+(0.0134)Gln+(-0.1272)His+(-0.009
6)Arg+(-0.1820)Met+(0.1400)Phe+(-0.1049)Trp; 0.859, 0.887, 0.8 15,
0.806, 0.806, 0.840, 0.840, 0.823, (3.7455)+(0.0077)Gln+(-0.1
393)His+(0.0177)Thr+(-0.0042)Ala+(0.1092)Phe+(-0.1273)Trp; 0. 859,
0.881, 0.772, 0.751, 0.749, 0.848, 0.820, 0.792, (3.4953)+(0.0
332)Ser+(-0.0001)Gln+(-0.0770)Cit+(-0.0340)Val+(0.1486)Ile+(-0.1590)Trp;
0.859, 0.884, 0.808, 0.815, 0.800, 0.830, 0.793, 0.81 0,
(2.0010)+(0.0443)Ser+(-0.1634)Asn+(0.0114)Thr+(-0.0105)Va
l+(0.1101)Phe+(-0.1396)Trp; 0.859, 0.890, 0.814, 0.800, 0.785, 0.
844, 0.889, 0.830, (5.4054)+(-0.0748)Asn+(-0.0738)Cit+(-0.044
5)Val+(0.1518)Ile+(0.0955)Phe+(-0.1352)Trp; 0.859, 0.887, 0.77 5,
0.759, 0.766, 0.834, 0.793, 0.788, (1.9978)+(0.0490)Ser+(-0.12
67)His+(-0.0024)Ala+(-0.0164)Tyr+(0.1340)Phe+(-0.1118)Trp; 0. 859,
0.883, 0.772, 0.745, 0.762, 0.840, 0.816, 0.791, (3.2076)+(0.0
334)Ser+(0.0043)Gln+(-0.1132)His+(0.1031)Ile+(-0.0222)Leu+(-0.1212)Trp;
0.859, 0.881, 0.771, 0.741, 0.758, 0.853, 0.822, 0.79 3,
(4.2345)+(0.0396)Ser+(-0.1084)His+(0.0060)Thr+(-0.0058)Al
a+(0.0855)Ile+(-0.1200)Trp; 0.859, 0.885, 0.794, 0.774, 0.784, 0.
814, 0.855, 0.807, (5.1846)+(-0.0967)His+(0.0101)Orn+(0.1071)I
le+(-0.0462)Leu+(0.0834)Phe+(-0.1215)Trp; 0.859, 0.886, 0.833,
0.826, 0.827, 0.844, 0.852, 0.838, (3.7595)+(-0.0557)Asn+(0.010
6)Gln+(-0.1287)His+(0.0112)Orn+(0.0969)Phe+(-0.1137)Trp; 0.8 59,
0.883, 0.782, 0.769, 0.742, 0.867, 0.841, 0.805, (4.4002)+(0.04
04)Ser+(-0.1498)Asn+(0.0104)Thr+(-0.0441)Val+(0.1631)Ile+(-0.1147)Trp;
0.859, 0.884, 0.794, 0.772, 0.811, 0.848, 0.775, 0.802,
(4.1272)+(0.0454)Ser+(-0.1034)Asn+(-0.1118)Cit+(0.0376)Orn+(0.0583)Ile+(--
0.1654)Trp; 0.859, 0.881, 0.781, 0.757, 0.758, 0.86 1, 0.837,
0.803, (5.9442)+(-0.0778)His+(0.0386)Thr+(-0.0513)Va
l+(-0.3448)Met+(0.1714)Ile+(0.0201)Leu; 0.859, 0.888, 0.766, 0.
742, 0.773, 0.829, 0.768, 0.778, (1.9726)+(0.0533)Ser+(-0.1283)H
is+(-0.0216)Arg+(0.0063)Pro+(0.1242)Phe+(-0.1204)Trp; 0.859, 0.889,
0.819, 0.820, 0.823, 0.829, 0.799, 0.818, (-1.2157)+(0.048
0)Ser+(0.0018)Gln+(0.0117)Tyr+(-0.3145)Met+(0.1306)Phe+(-0.
1505)Trp; 0.859, 0.885, 0.765, 0.745, 0.765, 0.822, 0.779, 0.778,
(1. 8458)+(0.0487)Ser+(-0.1322)His+(-0.0232)Tyr+(0.0039)Val+(0.
1276)Phe+(-0.1152)Trp; 0.859, 0.881, 0.795, 0.777, 0.782, 0.812, 0.
858, 0.807, (5.0847)+(-0.0951)His+(0.0029)Lys+(0.1103)Ile+(-0.
0482)Leu+(0.0862)Phe+(-0.1240)Trp; 0.859, 0.882, 0.758, 0.728, 0.
770, 0.833, 0.759, 0.773, (-1.0184)+(0.0648)Ser+(-0.1479)His+(0.
0115)Pro+(-0.3292)Met+(-0.0006)Lys+(0.1612)Phe; 0.859, 0.882,
0.759, 0.730, 0.775, 0.833, 0.750, 0.772,
(-0.9528)+(0.0674)Ser+(-0.1444)His+(-0.0126)Arg+(0.0117)Pro+(-0.3182)Met+-
(0.1629)Phe; 0.859, 0.881, 0.822, 0.819, 0.851, 0.817, 0.771,
0.815, (4.431
2)+(-0.0401)Asn+(0.0450)Thr+(-0.0848)Cit+(-0.2949)Met+(0.15
00)Phe+(-0.1699)Trp; 0.859, 0.887, 0.812, 0.816, 0.819, 0.828, 0.7
75, 0.810, (-0.4575)+(0.0515)Ser+(-0.0143)Arg+(-0.2747)Met+(0.
0065)Orn+(0.1333)Phe+(-0.1429)Trp; 0.859, 0.882, 0.772, 0.740, 0.
759, 0.851, 0.826, 0.794, (4.0935)+(0.0410)Ser+(-0.1085)His+(-0.
0058)Ala+(0.0133)Orn+(0.0829)Ile+(-0.1178)Trp; 0.858, 0.884, 0.
767, 0.736, 0.744, 0.866, 0.824, 0.793, (2.7211)+(0.0481)Ser+(-0.
0802)His+(0.0060)Pro+(-0.0377)Val+(-0.2811)Met+(0.1655)Ile; 0.858,
0.883, 0.802, 0.787, 0.803, 0.823, 0.826, 0.810, (3.5610)+(0.
0075)Gln+(-0.1442)His+(0.0151)Thr+(0.0041)Orn+(0.1001)Phe+(-0.1278)Trp;
0.858, 0.886, 0.822, 0.833, 0.805, 0.836, 0.819, 0.82 3,
(1.1269)+(0.0450)Ser+(-0.1567)Asn+(0.0028)Gln+(-0.0087)Va
l+(0.1067)Phe+(-0.1387)Trp; 0.858, 0.883, 0.780, 0.759, 0.756, 0.
820, 0.856, 0.798,
(4.6904)+(0.0032)Gly+(-0.0903)His+(-0.0305)Val+(0.1205)Ile+(0.0878)Phe+(--
0.1214)Trp; 0.858, 0.882, 0.760, 0.729, 0.770, 0.833, 0.770, 0.775,
(-1.0042)+(0.0667)Ser+(-0.001
5)Gly+(-0.1469)His+(0.0116)Pro+(-0.3300)Met+(0.1598)Phe; 0.8 58,
0.885, 0.805, 0.783, 0.796, 0.832, 0.860, 0.818, (3.3138)+(0.00
88)Gln+(-0.1394)His+(-0.0026)Pro+(0.0506)Ile+(0.0762)Phe+(-0.1317)Trp;
0.858, 0.882, 0.794, 0.769, 0.795, 0.858, 0.811, 0.809,
(3.4091)+(0.0350)Ser+(-0.0097)Ala+(-0.1213)Cit+(0.0372)Orn+(0.0802)Ile+(--
0.1733)Trp; 0.858, 0.881, 0.792, 0.769, 0.782, 0.85 3, 0.829,
0.808, (3.3014)+(0.0355)Ser+(0.0039)Thr+(-0.0091)Ala
+(-0.0932)Cit+(0.0905)Ile+(-0.1728)Trp; 0.858, 0.886, 0.830, 0.
830, 0.854, 0.824, 0.783, 0.823, (1.7119)+(0.0057)Gln+(0.0396)Th
r+(-0.0908)Cit+(-0.3538)Met+(0.1541)Phe+(-0.1751)Trp; 0.858, 0.886,
0.814, 0.822, 0.801, 0.835, 0.803, 0.815,
(1.7293)+(0.0469)Ser+(-0.1517)Asn+(-0.0104)Val+(0.0135)Orn+(0.1053)Phe+(--
0.1 335)Trp; 0.858, 0.887, 0.787, 0.754, 0.795, 0.819, 0.836,
0.801, (5.
8869)+(-0.0436)Asn+(-0.1203)His+(0.0249)Thr+(0.0446)Ile+(0.
0818)Phe+(-0.1364)Trp; 0.858, 0.883, 0.821, 0.823, 0.819, 0.837, 0.
806, 0.821, (1.1634)+(0.0490)Ser+(-0.1473)Asn+(0.0049)Gln+(-0.
0981)Cit+(0.1122)Phe+(-0.1619)Trp; 0.858, 0.879, 0.777, 0.744, 0.
763, 0.850, 0.838, 0.799, (4.1338)+(0.0488)Ser+(-0.0041)Gly+(-0.
1029)His+(-0.0056)Ala+(0.0859)Ile+(-0.1178)Trp; 0.858, 0.887,
0.759, 0.725, 0.764, 0.824, 0.790, 0.776,
(1.8774)+(0.0476)Ser+(-0.1400)His+(0.0057)Orn+(0.0135)Leu+(0.1064)Phe+(-0-
.1258)Tr p; 0.858, 0.885, 0.801, 0.794, 0.816, 0.828, 0.766, 0.801,
(2.5408)+(0.0494)Ser+(-0.1515)Asn+(0.0174)Thr+(-0.1014)Cit+(0.1158)P
he+(-0.1720)Trp; 0.858, 0.881, 0.757, 0.726, 0.741, 0.837, 0.817,
0. 780,
(4.0332)+(0.0356)Ser+(-0.0943)His+(-0.0245)Val+(0.0141)Orn+(0.1279)Ile+(--
0.1150)Trp; 0.858, 0.888, 0.773, 0.745, 0.774, 0.826, 0.806, 0.787,
(2.0801)+(0.0519)Ser+(-0.0039)Gly+(-0.131
7)His+(0.0098)Orn+(0.1155)Phe+(-0.1208)Trp; 0.858, 0.882, 0.78 0,
0.769, 0.710, 0.874, 0.886, 0.810, (0.1991)+(0.0549)Ser+(-0.22
32)Asn+(-0.0085)Ala+(-0.0624)Val+(0.1893)Ile+(0.0999)Phe; 0. 858,
0.885, 0.760, 0.737, 0.774, 0.830, 0.740, 0.770, (-0.1019)+(0.
0513)Ser+(-0.1609)His+(0.0309)Thr+(-0.0093)Tyr+(-0.3611)Met
+(0.1744)Phe; 0.858, 0.884, 0.802, 0.780, 0.796, 0.827, 0.859, 0.81
5, (3.2868)+(0.0087)Gln+(-0.1390)His+(-0.0004)Orn+(0.0480)Il
e+(0.0751)Phe+(-0.1325)Trp; 0.858, 0.885, 0.772, 0.750, 0.781, 0.
831, 0.774, 0.784,
(2.0954)+(0.0526)Ser+(-0.1302)His+(-0.0198)Arg+(0.0030)Val+(0.1249)Phe+(--
0.1188)Trp; 0.858, 0.885, 0.843, 0.841, 0.829, 0.856, 0.866, 0.848,
(3.7749)+(-0.0504)Asn+(0.011
2)Gln+(-0.1257)His+(-0.0027)Ala+(0.1070)Phe+(-0.1122)Trp; 0. 858,
0.885, 0.790, 0.763, 0.742, 0.896, 0.881, 0.821, (0.2928)+(0.0
471)Ser+(-0.0070)Ala+(0.0456)Tyr+(-0.0580)Val+(-0.3851)Met+(0.2220)Ile;
0.858, 0.885, 0.802, 0.786, 0.810, 0.820, 0.816, 0.808,
(6.3084)+(-0.0575)Asn+(-0.1123)His+(0.0289)Thr+(-0.0029)Val
+(0.1099)Phe+(-0.1220)Trp; 0.858, 0.881, 0.799, 0.778, 0.787, 0.8
56, 0.841, 0.815, (2.7303)+(0.0338)Ser+(0.0023)Gln+(-0.0092)Al
a+(-0.0946)Cit+(0.0912)Ile+(-0.1746)Trp; 0.858, 0.882, 0.791, 0.
771, 0.792, 0.835, 0.812, 0.802, (2.3447)+(0.0508)Ser+(-0.0079)G
ly+(0.0168)Thr+(-0.2813)Met+(0.0775)Ile+(-0.1542)Trp; 0.858, 0.881,
0.786, 0.764, 0.765, 0.867, 0.832, 0.807, (6.1882)+(-0.066
3)His+(0.0373)Thr+(-0.0377)Cit+(-0.0453)Val+(-0.3291)Met+(0.
1859)Ile; 0.858, 0.884, 0.794, 0.782, 0.794, 0.851, 0.784, 0.803,
(-2.1711)+(0.0546)Ser+(0.0094)Gln+(-0.1644)His+(-0.0194)Arg+(-0.2873)Met+-
(0.1659)Phe; 0.858, 0.887, 0.756, 0.736, 0.754, 0.81 7, 0.773,
0.770, (1.7109)+(0.0490)Ser+(-0.1289)His+(0.0066)Pro
+(-0.0274)Tyr+(0.1291)Phe+(-0.1155)Trp; 0.858, 0.882, 0.777, 0.
744, 0.792, 0.831, 0.793, 0.790, (3.3872)+(-0.1359)His+(0.0539)T
hr+(-0.0391)Val+(-0.4050)Met+(0.0707)Leu+(0.1467)Phe; 0.858, 0.882,
0.761, 0.730, 0.779, 0.831, 0.755, 0.774, (-0.8821)+(0.065
7)Ser+(-0.1387)His+(-0.0348)Cit+(0.0119)Pro+(-0.3330)Met+(0.
1633)Phe; 0.858, 0.882, 0.756, 0.724, 0.769, 0.833, 0.758, 0.771,
(-1.0576)+(0.0639)Ser+(-0.1496)His+(0.0110)Pro+(-0.3284)Met+(0.0068)Orn+(-
0.1583)Phe; 0.858, 0.887, 0.789, 0.772, 0.790, 0.846, 0.794, 0.800,
(-1.9957)+(0.0523)Ser+(0.0078)Gln+(-0.1665)His+(0.0004)Tyr+(-0.3058)Met+(-
0.1634)Phe; 0.858, 0.879, 0.784, 0.75 9, 0.760, 0.867, 0.841,
0.807, (5.7978)+(-0.0747)His+(0.0355)Thr
+(0.0131)Tyr+(-0.0469)Val+(-0.3490)Met+(0.1867)Ile; 0.858, 0. 876,
0.789, 0.773, 0.755, 0.847, 0.859, 0.809, (7.1391)+(-0.0731)H
is+(0.0176)Thr+(-0.0063)Ala+(-0.0295)Val+(0.1474)Ile+(-0.11 69)Trp;
0.858, 0.881, 0.779, 0.756, 0.783, 0.848, 0.781, 0.792, (3.1
826)+(0.0321)Ser+(-0.1094)Cit+(0.0282)Orn+(0.1406)Ile+(-0.0
556)Leu+(-0.1687)Trp; 0.858, 0.880, 0.794, 0.768, 0.803, 0.836, 0.
816, 0.806, (7.2919)+(-0.0981)His+(0.0332)Thr+(-0.2096)Met+(0.
0048)Lys+(0.0759)Ile+(-0.1158)Trp; 0.858, 0.880, 0.783, 0.762, 0.
757, 0.862, 0.838, 0.805, (5.7417)+(-0.0770)His+(0.0341)Thr+(-0.
0463)Val+(-0.3435)Met+(0.0058)Lys+(0.1844)Ile; 0.858, 0.880, 0.
780, 0.755, 0.757, 0.861, 0.833, 0.801, (5.7754)+(-0.0777)His+(0.
0329)Thr+(-0.0460)Val+(-0.3260)Met+(0.0177)Orn+(0.1805)Ile; 0.858,
0.883, 0.788, 0.767, 0.765, 0.820, 0.871, 0.806,
(5.2198)+(-0.0850)His+(-0.0319)Val+(-0.0003)Lys+(0.1232)Ile+(0.0852)Ph
e+(-0.1200)Trp; 0.858, 0.884, 0.793, 0.769, 0.813, 0.851, 0.774, 0.
802,
(2.8545)+(0.0447)Ser+(-0.0956)Cit+(-0.1973)Met+(0.0293)Orn+(0.0742)Ile+(--
0.1540)Trp; 0.858, 0.879, 0.791, 0.765, 0.798, 0.837, 0.813, 0.803,
(7.2501)+(0.0128)Asn+(-0.0974)His+(0.033
6)Thr+(-0.2084)Met+(0.0789)Ile+(-0.1143)Trp; 0.858, 0.882, 0.7 63,
0.725, 0.770, 0.842, 0.794, 0.783, (3.9857)+(0.0454)Ser+(-0.0
939)His+(-0.0561)Cit+(0.0028)Pro+(0.0782)Ile+(-0.1350)Trp; 0. 858,
0.882, 0.779, 0.756, 0.776, 0.843, 0.804, 0.795, (3.1184)+(0.0
379)Ser+(0.0073)Gln+(-0.1247)His+(-0.0249)Arg+(0.0781)Ile+(-0.1227)Trp;
0.858, 0.888, 0.815, 0.814, 0.821, 0.828, 0.794, 0.81 4,
(-0.8209)+(0.0499)Ser+(0.0115)Tyr+(-0.3091)Met+(0.0009)Ly
s+(0.1317)Phe+(-0.1493)Trp; 0.858, 0.887, 0.816, 0.810, 0.818, 0.
819, 0.822, 0.817, (-0.5151)+(0.0608)Ser+(-0.0072)Gly+(-0.292
6)Met+(0.0065)Leu+(0.1272)Phe+(-0.1500)Trp; 0.858, 0.883, 0.82 6,
0.812, 0.800, 0.872, 0.883, 0.842, (4.5502)+(0.0053)Gln+(0.035
7)Tyr+(-0.0447)Val+(-0.2783)Met+(0.1768)Ile+(-0.1210)Trp; 0. 858,
0.880, 0.810, 0.804, 0.840, 0.807, 0.767, 0.805, (3.6186)+(0.0
419)Thr+(-0.0877)Cit+(0.0071)Pro+(-0.3424)Met+(0.1493)Phe+(-0.1742)Trp;
0.858, 0.888, 0.815, 0.820, 0.818, 0.825, 0.793, 0.81 4,
(-1.1037)+(0.0473)Ser+(0.0017)Gln+(-0.2972)Met+(0.0000)Or
n+(0.1332)Phe+(-0.1477)Trp; 0.858, 0.883, 0.768, 0.734, 0.768, 0.
844, 0.803, 0.787,
(4.5473)+(0.0450)Ser+(-0.0670)Asn+(-0.1043)His+(0.0095)Thr+(0.0738)Ile+(--
0.1181)Trp; 0.858, 0.879, 0.793, 0.768, 0.801, 0.837, 0.814, 0.805,
(7.4240)+(-0.0952)His+(0.034
0)Thr+(0.0004)Pro+(-0.1990)Met+(0.0772)Ile+(-0.1145)Trp; 0.8 57,
0.889, 0.774, 0.752, 0.780, 0.836, 0.772, 0.785, (2.1904)+(0.05
06)Ser+(-0.1292)His+(-0.0216)Arg+(0.0140)Orn+(0.1236)Phe+(-0.1160)Trp;
0.857, 0.880, 0.784, 0.771, 0.732, 0.853, 0.879, 0.809,
(3.3990)+(0.0388)Ser+(-0.0071)Gly+(-0.0086)Ala+(-0.0400)Val
+(0.1706)Ile+(-0.1366)Trp; 0.857, 0.881, 0.801, 0.797, 0.749, 0.8
32, 0.900, 0.819, (3.4636)+(0.0010)Gln+(-0.0092)Ala+(-0.0446)V
al+(0.1614)Ile+(0.0758)Phe+(-0.1471)Trp; 0.857, 0.879, 0.789, 0.
764, 0.798, 0.838, 0.803, 0.801, (7.1295)+(0.0025)Gly+(-0.0978)H
is+(0.0321)Thr+(-0.1996)Met+(0.0796)Ile+(-0.1122)Trp; 0.857, 0.883,
0.808, 0.801, 0.768, 0.836, 0.887, 0.823, (4.7636)+(-0.087
4)Asn+(-0.0411)Val+(0.1640)Ile+(-0.0203)Leu+(0.0837)Phe+(-0.
1269)Trp; 0.857, 0.883, 0.761, 0.741, 0.729, 0.813, 0.842, 0.781,
(0. 7744)+(0.0334)Ser+(-0.0419)Val+(-0.0160)Lys+(0.1465)Ile+(0.
0818)Phe+(-0.1550)Trp; 0.857, 0.882, 0.775, 0.753, 0.753, 0.854, 0.
824, 0.796,
(3.8270)+(0.0354)Ser+(-0.0752)Cit+(-0.0321)Val+(-0.0096)Lys+(0.152-
1)Ile+(-0.1491)Trp; 0.857, 0.882, 0.816, 0.816, 0.812, 0.844,
0.804, 0.819,
(2.2265)+(0.0523)Ser+(-0.1184)Asn+(-0.0039)Ala+(-0.0884)Cit+(0.122-
8)Phe+(-0.1529)Trp; 0.857, 0. 879, 0.752, 0.719, 0.720, 0.846,
0.838, 0.781, (0.7137)+(0.0607)Se
r+(-0.1708)Asn+(-0.1013)His+(-0.0429)Val+(0.1346)Ile+(0.111 4)Phe;
0.857, 0.882, 0.757, 0.729, 0.766, 0.830, 0.759, 0.771, (-0.9
490)+(0.0641)Ser+(-0.1465)His+(0.0119)Pro+(-0.0092)Tyr+(-0.
3185)Met+(0.1624)Phe; 0.857, 0.883, 0.790, 0.769, 0.799, 0.846, 0.
783, 0.800, (4.1808)+(0.0442)Ser+(-0.1059)Asn+(0.0093)Thr+(-0.
0875)Cit+(0.0684)Ile+(-0.1677)Trp; 0.857, 0.884, 0.788, 0.769, 0.
764, 0.819, 0.868, 0.805, (5.1163)+(-0.0837)His+(-0.0281)Val+(0.
1318)Ile+(-0.0133)Leu+(0.0867)Phe+(-0.1192)Trp; 0.857, 0.880,
0.783, 0.762, 0.756, 0.863, 0.839, 0.805,
(6.1606)+(-0.0168)Asn+(-0.0706)His+(0.0363)Thr+(-0.0465)Val+(-0.3175)Met+-
(0.1856)Ile; 0.857, 0.881, 0.771, 0.736, 0.779, 0.815, 0.818,
0.787, (4.923
9)+(0.0027)Gly+(-0.1303)His+(0.0180)Thr+(0.0479)Ile+(0.080
2)Phe+(-0.1368)Trp; 0.857, 0.889, 0.846, 0.840, 0.841, 0.860, 0.86
2, 0.851, (3.4876)+(-0.0572)Asn+(0.0125)Gln+(-0.1139)His+(-0.
0612)Cit+(0.1171)Phe+(-0.1225)Trp; 0.857, 0.884, 0.795, 0.778, 0.
804, 0.821, 0.801, 0.801, (5.8565)+(-0.0585)Asn+(0.0032)Gly+(-0.
1181)His+(0.0265)Thr+(0.1083)Phe+(-0.1214)Trp; 0.857, 0.883, 0.
778, 0.763, 0.736, 0.884, 0.830, 0.803, (2.7414)+(0.0389)Ser+(-0.
0969)Asn+(0.0240)Thr+(-0.0603)Val+(-0.3280)Met+(0.2153)Ile; 0.857,
0.882, 0.778, 0.766, 0.723, 0.855, 0.867, 0.803, (3.2069)+(0.
0283)Ser+(-0.0104)Ala+(0.0069)Pro+(-0.0402)Val+(0.1646)Ile+(-0.1373)Trp;
0.857, 0.880, 0.796, 0.768, 0.807, 0.843, 0.818, 0.80 9,
(7.3406)+(-0.0961)His+(0.0337)Thr+(0.0129)Tyr+(-0.2127)Me
t+(0.0765)Ile+(-0.1184)Trp; 0.857, 0.886, 0.774, 0.754, 0.779, 0.
833, 0.774, 0.785,
(2.1157)+(0.0523)Ser+(-0.1275)His+(-0.0199)Arg+(0.0004)Lys+(0.1290)Phe+(--
0.1164)Trp; 0.857, 0.884, 0.801, 0.781, 0.811, 0.821, 0.818, 0.808,
(6.2824)+(-0.0524)Asn+(-0.115
2)His+(0.0282)Thr+(-0.0006)Lys+(0.1057)Phe+(-0.1248)Trp; 0.8 57,
0.881, 0.772, 0.751, 0.749, 0.848, 0.821, 0.792, (3.4759)+(0.03
32)Ser+(-0.0772)Cit+(0.0003)Tyr+(-0.0340)Val+(0.1485)Ile+(-0.1592)Trp;
0.857, 0.887, 0.765, 0.747, 0.763, 0.822, 0.778, 0.778,
(1.9053)+(0.0468)Ser+(-0.1308)His+(-0.0243)Tyr+(0.0121)Orn+(0.1283)Phe+(--
0.1112)Trp; 0.857, 0.885, 0.802, 0.796, 0.762, 0.83 3, 0.877,
0.817, (4.3870)+(-0.1004)Asn+(0.0033)Gly+(-0.0478)Va
l+(0.1518)Ile+(0.0869)Phe+(-0.1288)Trp; 0.857, 0.884, 0.784, 0.
770, 0.743, 0.865, 0.848, 0.806, (4.1413)+(0.0437)Ser+(-0.1340)A
sn+(0.0021)Pro+(-0.0426)Val+(0.1583)Ile+(-0.1127)Trp; 0.857, 0.882,
0.789, 0.767, 0.797, 0.843, 0.791, 0.800,
(3.9350)+(0.0469)Ser+(-0.0943)Asn+(-0.0846)Cit+(0.0036)Pro+(0.0660)Ile+(--
0.1 658)Trp; 0.857, 0.882, 0.801, 0.797, 0.750, 0.834, 0.894,
0.819, (3.
7620)+(-0.0091)Ala+(-0.0360)Val+(0.1824)Ile+(-0.0292)Leu+(0.
0780)Phe+(-0.1401)Trp; 0.857, 0.884, 0.772, 0.765, 0.756, 0.821, 0.
789, 0.783, (0.2021)+(0.0422)Ser+(-0.0438)Arg+(0.1730)Ile+(-0.
0896)Leu+(0.0885)Phe+(-0.1572)Trp; 0.857, 0.881, 0.768, 0.734, 0.
760, 0.837, 0.826, 0.789, (3.9746)+(0.0466)Ser+(-0.0047)Gly+(-0.
0970)His+(0.1116)Ile+(-0.0274)Leu+(-0.1202)Trp; 0.857, 0.880,
0.814, 0.806, 0.762, 0.863, 0.907, 0.835,
(0.1328)+(0.0046)Gln+(-0.0048)Ala+(-0.0622)Val+(-0.3959)Met+(0.2046)Ile+(-
0.1205)Ph e; 0.857, 0.884, 0.804, 0.785, 0.763, 0.858, 0.899,
0.826,
(3.6725)+(-0.0654)His+(-0.0034)Ala+(-0.0511)Val+(-0.2948)Met+(0.180
1)Ile+(0.1262)Phe; 0.857, 0.882, 0.772, 0.737, 0.760, 0.853, 0.830,
0.795, (3.8712)+(0.0437)Ser+(-0.1100)His+(-0.0066)Ala+(0.018
6)Tyr+(0.0867)Ile+(-0.1250)Trp; 0.857, 0.877, 0.801, 0.777, 0.80 0,
0.843, 0.836, 0.814, (4.9636)+(0.0085)Gln+(-0.1090)His+(0.01
25)Thr+(-0.0585)Cit+(0.0712)Ile+(-0.1405)Trp; 0.857, 0.880, 0. 816,
0.807, 0.850, 0.822, 0.763, 0.811, (3.6803)+(0.0385)Thr+(-0.
1040)Cit+(-0.3120)Met+(0.0256)Orn+(0.1429)Phe+(-0.1738)Trp; 0.857,
0.879, 0.779, 0.757, 0.754, 0.860, 0.830, 0.800, (5.7873)+(0.
0016)Gly+(-0.0757)His+(0.0348)Thr+(-0.0451)Val+(-0.3314)Met
+(0.1843)Ile; 0.857, 0.886, 0.767, 0.740, 0.775, 0.830, 0.778, 0.78
1, (2.0467)+(0.0529)Ser+(-0.1333)His+(-0.0192)Arg+(0.0132)Le
u+(0.1173)Phe+(-0.1228)Trp; 0.857, 0.880, 0.803, 0.783, 0.775, 0.
862, 0.870, 0.822, (6.4478)+(-0.0085)Ala+(-0.0948)Cit+(-0.038
4)Val+(0.0473)Orn+(0.1643)Ile+(-0.1330)Trp; 0.857, 0.881, 0.80 6,
0.783, 0.793, 0.861, 0.852, 0.822, (6.6761)+(-0.0728)Cit+(-0.0
424)Val+(-0.1513)Met+(0.0443)Orn+(0.1652)Ile+(-0.1168)Trp; 0. 857,
0.881, 0.799, 0.794, 0.746, 0.832, 0.898, 0.817, (3.6635)+(0.0
007)Gly+(-0.0091)Ala+(-0.0450)Val+(0.1628)Ile+(0.0774)Phe+(-0.1455)Trp;
0.857, 0.884, 0.801, 0.781, 0.811, 0.820, 0.818, 0.80 7,
(6.2569)+(-0.0529)Asn+(-0.1152)His+(0.0279)Thr+(0.0004)Pr
o+(0.1049)Phe+(-0.1251)Trp; 0.857, 0.882, 0.799, 0.776, 0.806, 0.
845, 0.810, 0.809, (2.8223)+(0.0528)Ser+(-0.0039)Gly+(-0.0663)
Cit+(-0.2004)Met+(0.0832)Ile+(-0.1501)Trp; 0.857, 0.886, 0.793,
0.777, 0.767, 0.820, 0.869, 0.808, (5.6452)+(-0.0777)His+(-0.015
0)Arg+(-0.0351)Val+(0.1316)Ile+(0.0910)Phe+(-0.1172)Trp; 0.8 57,
0.886, 0.794, 0.768, 0.775, 0.828, 0.876, 0.812, (5.3532)+(-0.0
676)His+(-0.0594)Cit+(-0.0326)Val+(0.1297)Ile+(0.0961)Phe+(-0.1296)Trp;
0.857, 0.884, 0.795, 0.770, 0.808, 0.817, 0.818, 0.80 3,
(6.2262)+(-0.0489)Asn+(-0.1202)His+(0.0278)Thr+(0.0088)Le
u+(0.0971)Phe+(-0.1297)Trp; 0.857, 0.882, 0.785, 0.772, 0.744, 0.
867, 0.847, 0.808,
(4.1303)+(0.0431)Ser+(-0.1296)Asn+(-0.0397)Val+(0.1666)Ile+(-0.0085)Leu+(-
-0.1123)Trp; 0.857, 0.881, 0.761, 0.728, 0.755, 0.839, 0.807,
0.782, (3.8922)+(0.0384)Ser+(-0.104
0)His+(0.0102)Orn+(0.1068)Ile+(-0.0253)Leu+(-0.1193)Trp; 0.8 56,
0.884, 0.788, 0.765, 0.778, 0.833, 0.840, 0.804, (0.6766)+(0.04
08)Ser+(-0.0107)Ala+(-0.1105)Cit+(0.0798)Ile+(0.0882)Phe+(-0.1919)Trp;
0.856, 0.885, 0.760, 0.733, 0.761, 0.818, 0.786, 0.774,
(1.8354)+(0.0488)Ser+(-0.1349)His+(-0.0216)Tyr+(0.0142)Leu+(0.1197)Phe+(--
0.1191)Trp; 0.856, 0.878, 0.824, 0.817, 0.783, 0.87 0, 0.891,
0.840, (5.1343)+(0.0050)Gln+(-0.0049)Ala+(-0.0415)Va
l+(-0.1882)Met+(0.1790)Ile+(-0.1117)Trp; 0.856, 0.878, 0.778, 0.
747, 0.803, 0.839, 0.764, 0.788, (3.7507)+(0.0373)Ser+(-0.1239)C
it+(0.0421)Orn+(-0.0189)Lys+(0.0727)Ile+(-0.1728)Trp; 0.856, 0.880,
0.791, 0.776, 0.781, 0.852, 0.804, 0.803,
(2.2258)+(0.0394)Ser+(0.0140)Thr+(-0.0054)Ala+(-0.2470)Met+(0.0873)Ile+(--
0.1 465)Trp; 0.856, 0.885, 0.813, 0.821, 0.799, 0.833, 0.806,
0.815, (1.
6629)+(0.0475)Ser+(-0.1468)Asn+(-0.0089)Val+(0.0011)Lys+(0.
1087)Phe+(-0.1371)Trp; 0.856, 0.885, 0.806, 0.805, 0.811, 0.823, 0.
787, 0.807,
(-0.8499)+(0.0504)Ser+(-0.2959)Met+(-0.0007)Lys+(0.0073)Leu+(0.128-
2)Phe+(-0.1483)Trp; 0.856, 0.879, 0.793, 0.77 2, 0.783, 0.851,
0.826, 0.808, (3.2776)+(0.0381)Ser+(-0.0086)Ala
+(-0.0874)Cit+(-0.0043)Arg+(0.0909)Ile+(-0.1688)Trp; 0.856, 0. 880,
0.791, 0.764, 0.801, 0.838, 0.812, 0.803, (7.3219)+(-0.0985)H
is+(0.0324)Thr+(-0.1947)Met+(0.0117)Orn+(0.0744)Ile+(-0.114 5)Trp;
0.856, 0.886, 0.810, 0.809, 0.812, 0.829, 0.798, 0.812, (-0.7
356)+(0.0499)Ser+(-0.0018)Ala+(-0.2854)Met+(0.0083)Leu+(0.1
280)Phe+(-0.1473)Trp; 0.856, 0.883, 0.773, 0.753, 0.751, 0.850, 0.
819, 0.793, (3.4505)+(0.0332)Ser+(-0.0782)Cit+(-0.0264)Val+(0.
1665)Ile+(-0.0245)Leu+(-0.1555)Trp; 0.856, 0.877, 0.804, 0.786,
0.788, 0.849, 0.852, 0.819,
(5.4168)+(0.0075)Gln+(-0.1189)His+(0.0131)Thr+(-0.0058)Ala+(0.0745)Ile+(--
0.1286)Trp; 0.856, 0.8 80, 0.820, 0.808, 0.804, 0.859, 0.857,
0.832, (4.7648)+(0.0098)Gln
+(-0.0894)His+(-0.1441)Met+(0.1225)Ile+(-0.0340)Leu+(-0.106 7)Trp;
0.856, 0.884, 0.805, 0.803, 0.763, 0.827, 0.883, 0.819, (4.84
78)+(-0.0820)Asn+(-0.0258)Tyr+(-0.0468)Val+(0.1512)Ile+(0.0
955)Phe+(-0.1221)Trp; 0.856, 0.882, 0.795, 0.772, 0.806, 0.848, 0.
791, 0.804, (2.7543)+(0.0470)Ser+(-0.0723)Cit+(0.0006)Arg+(-0.
2001)Met+(0.0844)Ile+(-0.1507)Trp; 0.856, 0.878, 0.809, 0.795, 0.
777, 0.857, 0.877, 0.827,
(6.4757)+(-0.0051)Ala+(-0.0454)Val+(-0.1711)Met+(0.0267)Orn+(0.1819)Ile+(-
-0.1052)Trp; 0.856, 0.885, 0.798, 0.777, 0.810, 0.817, 0.814,
0.804,
(6.1891)+(-0.0531)Asn+(-0.1168)His+(0.0261)Thr+(0.0121)Orn+(0.1002)Phe+(--
0.1242)T rp; 0.856, 0.882, 0.778, 0.750, 0.800, 0.850, 0.753,
0.788, (5.1770)
+(0.0417)Ser+(-0.1148)His+(0.0263)Thr+(-0.2043)Met+(0.0405)Leu+(-
-0.1112)Trp; 0.856, 0.879, 0.823, 0.803, 0.809, 0.867, 0.872,
0.838, (5.0639)+(0.0103)Gln+(-0.0961)His+(-0.0061)Ala+(-0.06
19)Cit+(0.0861)Ile+(-0.1309)Trp; 0.856, 0.875, 0.791, 0.773, 0.7
63, 0.839, 0.864, 0.810, (7.1204)+(-0.0664)His+(-0.0059)Ala+(-0.
0319)Val+(0.0265)Orn+(0.1457)Ile+(-0.1069)Trp; 0.856, 0.885, 0.
840, 0.838, 0.833, 0.848, 0.851, 0.843, (3.6081)+(-0.0403)Asn+(0.
0126)Gln+(-0.1304)His+(-0.0168)Arg+(0.1065)Phe+(-0.1131)Tr p;
0.856, 0.878, 0.816, 0.807, 0.773, 0.865, 0.896, 0.835,
(5.1604)+(0.0048)Gln+(-0.0086)Ala+(-0.0750)Cit+(-0.0346)Val+(0.1676)Ile+(-
-0.1413)Trp; 0.856, 0.880, 0.773, 0.743, 0.767, 0.839, 0.816,
0.791, (3.2328)+(0.0357)Ser+(0.0051)Gln+(-0.1207)His+(-0.006
5)Lys+(0.0770)Ile+(-0.1201)Trp; 0.856, 0.880, 0.781, 0.759, 0.75 6,
0.862, 0.834, 0.803, (5.9125)+(-0.0736)His+(0.0356)Thr+(0.00
14)Pro+(-0.0457)Val+(-0.3334)Met+(0.1831)Ile; 0.856, 0.884, 0. 801,
0.778, 0.805, 0.831, 0.829, 0.811, (4.7474)+(0.0071)Gly+(-0.
1069)His+(-0.1966)Met+(0.0607)Ile+(0.1169)Phe+(-0.1116)Trp; 0.856,
0.883, 0.785, 0.772, 0.743, 0.866, 0.849, 0.808, (4.1340)+(0.
0434)Ser+(-0.1353)Asn+(-0.0427)Val+(0.0017)Lys+(0.1604)Ile+(-0.1133)Trp;
0.856, 0.882, 0.827, 0.807, 0.822, 0.863, 0.862, 0.83 9,
(4.6608)+(0.0116)Gln+(-0.0963)His+(-0.0517)Cit+(-0.1174)M
et+(0.0803)Ile+(-0.1208)Trp; 0.856, 0.881, 0.796, 0.775, 0.782, 0.
840, 0.852, 0.812,
(5.3343)+(0.0049)Gly+(-0.1109)His+(-0.0061)Ala+(0.0605)Ile+(0.0859)Phe+(--
0.1248)Trp; 0.856, 0.880, 0.794, 0.771, 0.783, 0.852, 0.838, 0.811,
(3.2650)+(0.0401)Ser+(-0.002
2)Gly+(-0.0087)Ala+(-0.0876)Cit+(0.0897)Ile+(-0.1696)Trp; 0. 856,
0.882, 0.774, 0.744, 0.752, 0.875, 0.826, 0.799, (3.0243)+(0.0
470)Ser+(-0.0741)His+(-0.0308)Cit+(-0.0364)Val+(-0.2578)Met
+(0.1705)Ile; 0.856, 0.885, 0.762, 0.733, 0.772, 0.828, 0.771, 0.77
6, (1.7543)+(0.0531)Ser+(-0.1148)His+(-0.0636)Cit+(0.0072)Pr
o+(0.1291)Phe+(-0.1408)Trp; 0.856, 0.884, 0.774, 0.756, 0.768, 0.
821, 0.801, 0.786,
(2.0152)+(0.0549)Ser+(-0.0046)Gly+(-0.1238)His+(-0.0259)Tyr+(0.1331)Phe+(-
-0.1130)Trp; 0.856, 0.881, 0.799, 0.793, 0.747, 0.832, 0.897,
0.817, (3.7760)+(-0.0091)Ala+(-0.045
2)Val+(0.0050)Orn+(0.1621)Ile+(0.0740)Phe+(-0.1441)Trp; 0.85 6,
0.879, 0.799, 0.780, 0.786, 0.847, 0.842, 0.814, (2.0914)+(0.053
8)Ser+(-0.0059)Gly+(-0.0046)Ala+(-0.2051)Met+(0.0860)Ile+(-0.1425)Trp;
0.856, 0.879, 0.788, 0.775, 0.789, 0.841, 0.784, 0.797,
(2.7283)+(0.0430)Ser+(-0.0549)Asn+(0.0145)Thr+(-0.2288)Met+(0.0760)Ile+(--
0.1481)Trp; 0.856, 0.885, 0.821, 0.830, 0.799, 0.84 5, 0.823,
0.824, (1.7674)+(0.0475)Ser+(-0.1363)Asn+(-0.0036)Al
a+(-0.0064)Val+(0.1117)Phe+(-0.1349)Trp; 0.856, 0.879, 0.806, 0.
792, 0.802, 0.828, 0.834, 0.814, (3.1345)+(0.0025)Gly+(0.0090)Gl
n+(-0.1445)His+(0.0123)Leu+(0.0927)Phe+(-0.1262)Trp; 0.856, 0. 877,
0.745, 0.716, 0.703, 0.850, 0.831, 0.775, (0.0706)+(0.0436)Se
r+(-0.1415)His+(-0.0088)Ala+(0.1230)Ile+(-0.0521)Leu+(0.089 6)Phe;
0.856, 0.879, 0.778, 0.747, 0.772, 0.838, 0.832, 0.797, (3.15
80)+(0.0415)Ser+(-0.0051)Gly+(0.0052)Gln+(-0.1231)His+(0.07
17)Ile+(-0.1257)Trp; 0.856, 0.884, 0.763, 0.729, 0.776, 0.828, 0.7
79, 0.778, (1.7795)+(0.0530)Ser+(-0.1211)His+(-0.0622)Cit+(0.
0171)Leu+(0.1217)Phe+(-0.1439)Trp; 0.856, 0.879, 0.743, 0.719, 0.
714, 0.794, 0.826, 0.764, (1.3803)+(0.0352)Ser+(-0.0044)Gln+(-0.
0459)Val+(0.1483)Ile+(0.0765)Phe+(-0.1594)Trp; 0.856, 0.882, 0.
823, 0.804, 0.792, 0.870, 0.903, 0.842, (6.5043)+(-0.0055)Ala+(0.
0372)Tyr+(-0.0454)Val+(-0.2031)Met+(0.1890)Ile+(-0.1131)Tr p;
0.856, 0.882, 0.794, 0.770, 0.765, 0.849, 0.880, 0.816,
(3.5114)+(-0.0722)His+(-0.0522)Val+(-0.3129)Met+(0.0187)Orn+(0.1728)Ile+(-
0.1204)Phe; 0.856, 0.881, 0.784, 0.763, 0.765, 0.820, 0.852, 0.
800,
(3.7440)+(0.0126)Thr+(-0.0913)Cit+(-0.0404)Val+(0.1414)Ile+(0.0809)Phe+(--
0.1701)Trp; 0.856, 0.878, 0.783, 0.766, 0.774, 0.849, 0.799, 0.797,
(2.8688)+(0.0318)Ser+(0.0016)Gln+(-0.090
6)Cit+(0.1499)Ile+(-0.0571)Leu+(-0.1684)Trp; 0.856, 0.879, 0.8 15,
0.807, 0.776, 0.858, 0.888, 0.832, (6.4428)+(-0.0046)Ala+(-0.
0458)Val+(-0.1913)Met+(0.0107)Lys+(0.1853)Ile+(-0.1101)Trp; 0.856,
0.878, 0.758, 0.728, 0.739, 0.837, 0.817, 0.780, (4.0982)+(0.
0361)Ser+(-0.0922)His+(0.0030)Thr+(-0.0238)Val+(0.1297)Ile+(-0.1164)Trp;
0.856, 0.881, 0.790, 0.774, 0.775, 0.849, 0.823, 0.80 5,
(1.9503)+(0.0458)Ser+(-0.0069)Ala+(0.0090)Pro+(-0.2221)Me
t+(0.0800)Ile+(-0.1397)Trp; 0.856, 0.878, 0.798, 0.780, 0.793, 0.
838, 0.830, 0.810,
(2.5591)+(0.0577)Ser+(-0.0439)Asn+(-0.0062)Gly+(-0.1939)Met+(0.0758)Ile+(-
-0.1442)Trp; 0.856, 0.879, 0.773, 0.744, 0.763, 0.851, 0.813,
0.793, (4.2656)+(0.0462)Ser+(-0.101
4)His+(-0.0051)Ala+(-0.0140)Arg+(0.0888)Ile+(-0.1155)Trp; 0. 856,
0.877, 0.762, 0.731, 0.754, 0.837, 0.807, 0.782, (3.8951)+(0.0
396)Ser+(-0.1008)His+(0.0001)Thr+(0.1096)Ile+(-0.0253)Leu+(-0.1192)Trp;
0.856, 0.882, 0.758, 0.753, 0.720, 0.795, 0.826, 0.77 4,
(0.8295)+(0.0278)Ser+(-0.0375)Tyr+(-0.0425)Val+(0.1385)Il
e+(0.0928)Phe+(-0.1572)Trp; 0.856, 0.889, 0.815, 0.814, 0.821, 0.
831,
0.794, 0.815,
(-0.7940)+(0.0500)Ser+(0.0114)Tyr+(-0.3066)Met+(0.0006)Orn+(0.1316)Phe+(--
0.1485)Trp; 0.856, 0.881, 0.792, 0.772, 0.798, 0.846, 0.794, 0.802,
(4.0859)+(0.0467)Ser+(-0.076
9)Asn+(-0.0827)Cit+(-0.0075)Lys+(0.0758)Ile+(-0.1591)Trp; 0. 856,
0.879, 0.784, 0.774, 0.738, 0.861, 0.848, 0.805, (3.6551)+(0.0
350)Ser+(-0.0075)Ala+(-0.0251)Arg+(-0.0414)Val+(0.1787)Ile+(-0.1286)Trp;
0.856, 0.882, 0.795, 0.786, 0.775, 0.814, 0.850, 0.80 6,
(5.1871)+(-0.0876)His+(-0.0315)Tyr+(0.1181)Ile+(-0.0512)L
eu+(0.1044)Phe+(-0.1116)Trp; 0.856, 0.884, 0.775, 0.751, 0.782, 0.
839, 0.780, 0.788,
(2.0499)+(0.0524)Ser+(-0.1119)His+(-0.0586)Cit+(-0.0040)Lys+(0.1377)Phe+(-
-0.1299)Trp; 0.856, 0.886, 0.809, 0.810, 0.816, 0.825, 0.779,
0.807, (-0.6155)+(0.0525)Ser+(-0.012
7)Arg+(-0.2811)Met+(0.0065)Leu+(0.1309)Phe+(-0.1462)Trp; 0.8 56,
0.884, 0.823, 0.817, 0.809, 0.841, 0.856, 0.831, (3.6143)+(0.00
93)Gln+(-0.1316)His+(-0.0050)Ala+(0.0067)Pro+(0.1038)Phe+(-0.1201)Trp;
0.856, 0.878, 0.800, 0.783, 0.778, 0.852, 0.851, 0.816,
(7.3588)+(-0.0833)His+(0.0168)Thr+(-0.0065)Ala+(0.1221)Ile+(-0.0334)Leu+(-
-0.1208)Trp; 0.856, 0.882, 0.819, 0.806, 0.784, 0.8 64, 0.894,
0.837, (7.3498)+(-0.0056)Ala+(-0.0495)Cit+(-0.0397)
Val+(-0.1089)Met+(0.1812)Ile+(-0.1101)Trp; 0.855, 0.880, 0.821,
0.816, 0.775, 0.864, 0.898, 0.838, (0.4087)+(-0.0716)Asn+(0.007
1)Gln+(-0.0643)Val+(-0.3819)Met+(0.1986)Ile+(0.1252)Phe; 0.8 55,
0.883, 0.769, 0.741, 0.780, 0.832, 0.775, 0.782, (1.8219)+(0.05
26)Ser+(-0.1188)His+(-0.0627)Cit+(0.0059)Val+(0.1282)Phe+(-0.1407)Trp;
0.855, 0.878, 0.827, 0.821, 0.793, 0.869, 0.883, 0.842,
(5.3025)+(-0.0454)Asn+(0.0064)Gln+(-0.0421)Val+(-0.1900)Met
+(0.1688)Ile+(-0.1083)Trp; 0.855, 0.886, 0.769, 0.752, 0.765, 0.8
26, 0.780, 0.781, (1.9243)+(0.0490)Ser+(-0.1276)His+(-0.0206)T
yr+(-0.0020)Lys+(0.1333)Phe+(-0.1110)Trp; 0.855, 0.879, 0.815,
0.805, 0.821, 0.850, 0.807, 0.821, (5.6439)+(0.0093)Gln+(-0.125
4)His+(0.0305)Thr+(-0.1946)Met+(0.0326)Leu+(-0.1145)Trp; 0.8 55,
0.878, 0.757, 0.726, 0.738, 0.837, 0.819, 0.780, (4.0188)+(0.03
76)Ser+(-0.0908)His+(0.0013)Pro+(-0.0239)Val+(0.1290)Ile+(-0.1157)Trp;
0.855, 0.886, 0.810, 0.795, 0.812, 0.837, 0.828, 0.818,
(6.4436)+(-0.0505)Asn+(-0.1115)His+(0.0295)Thr+(-0.0038)Ala
+(0.1120)Phe+(-0.1234)Trp; 0.855, 0.883, 0.778, 0.746, 0.791, 0.8
12, 0.813, 0.790, (5.9215)+(-0.1251)His+(0.0277)Thr+(-0.0217)A
rg+(0.0469)Ile+(0.0846)Phe+(-0.1407)Trp; 0.855, 0.881, 0.766, 0.
731, 0.771, 0.844, 0.793, 0.785, (4.1834)+(0.0460)Ser+(-0.0893)H
is+(-0.0549)Cit+(-0.0055)Lys+(0.0852)Ile+(-0.1289)Trp; 0.855,
0.882, 0.799, 0.781, 0.785, 0.818, 0.861, 0.811, (5.2599)+(-0.092
9)His+(-0.0029)Pro+(0.1150)Ile+(-0.0482)Leu+(0.0885)Phe+(-0.
1211)Trp; 0.855, 0.880, 0.801, 0.791, 0.750, 0.859, 0.889, 0.822,
(1. 2298)+(0.0042)Gly+(-0.0052)Ala+(-0.0626)Val+(-0.3692)Met+(0.
2074)Ile+(0.1218)Phe; 0.855, 0.883, 0.776, 0.754, 0.750, 0.845, 0.
839, 0.797,
(3.5460)+(0.0381)Ser+(-0.0037)Gly+(-0.0711)Cit+(-0.0342)Val+(0.147-
6)Ile+(-0.1579)Trp; 0.855, 0.877, 0.770, 0.739, 0.765, 0.841,
0.812, 0.789,
(3.1552)+(0.0344)Ser+(0.0047)Gln+(-0.1249)His+(0.0007)Thr+(0.0726)-
Ile+(-0.1247)Trp; 0.855, 0.882, 0.789, 0.775, 0.759, 0.816, 0.866,
0.804,
(5.2210)+(-0.0814)His+(-0.0232)Tyr+(-0.0318)Val+(0.1246)Ile+(0.0969)Phe+(-
-0.1136)Trp; 0.855, 0.881, 0.812, 0.799, 0.776, 0.855, 0.892,
0.831, (6.910
4)+(-0.0067)Ala+(0.0094)Pro+(-0.0436)Val+(-0.1653)Met+(0.17
80)Ile+(-0.1044)Trp; 0.855, 0.882, 0.798, 0.780, 0.765, 0.845, 0.8
83, 0.818, (3.5141)+(-0.0672)His+(-0.0463)Val+(-0.3125)Met+(0.
1883)Ile+(-0.0183)Leu+(0.1296)Phe; 0.855, 0.880, 0.785, 0.757, 0.
799, 0.813, 0.811, 0.795, (5.8701)+(-0.1288)His+(0.0256)Thr+(-0.
0067)Lys+(0.0138)Leu+(0.0961)Phe+(-0.1322)Trp; 0.855, 0.880, 0.
773, 0.738, 0.772, 0.841, 0.819, 0.793, (4.3307)+(0.0531)Ser+(-0.
0523)Asn+(-0.0036)Gly+(-0.0985)His+(0.0745)Ile+(-0.1171)Tr p;
0.855, 0.880, 0.770, 0.735, 0.771, 0.844, 0.807, 0.789,
(4.2739)+(0.0470)Ser+(-0.0602)Asn+(-0.1036)His+(0.0144)Orn+(0.0717)I
le+(-0.1155)Trp; 0.855, 0.879, 0.764, 0.731, 0.773, 0.838, 0.778,
0. 780, (-0.5779)+(0.0619)Ser+(-0.1518)His+(-0.0011)Ala+(-0.292
0)Met+(0.0147)Leu+(0.1510)Phe; 0.855, 0.882, 0.782, 0.743, 0.797,
0.821, 0.824, 0.796, (5.3148)+(-0.1087)His+(0.0240)Thr+(-0.068
0)Cit+(0.0508)Ile+(0.0941)Phe+(-0.1555)Trp; 0.855, 0.879, 0.75 7,
0.723, 0.763, 0.834, 0.778, 0.774, (4.4331)+(0.0423)Ser+(-0.11
22)His+(0.0102)Thr+(-0.0204)Arg+(0.0780)Ile+(-0.1249)Trp; 0. 855,
0.876, 0.815, 0.804, 0.788, 0.858, 0.868, 0.829, (5.2356)+(0.0
080)Gln+(-0.0952)His+(-0.0058)Ala+(0.1213)Ile+(-0.0333)Leu+(-0.1176)Trp;
0.855, 0.879, 0.769, 0.757, 0.737, 0.877, 0.790, 0.79 0,
(1.9998)+(0.0356)Ser+(0.0306)Thr+(-0.0255)Arg+(-0.0597)Va
l+(-0.4011)Met+(0.2161)Ile; 0.855, 0.878, 0.799, 0.787, 0.804, 0.
834, 0.799, 0.806, (0.7808)+(0.0102)Gln+(-0.1689)His+(0.0388)I
hr+(-0.0046)Val+(-0.3628)Met+(0.1593)Phe; 0.855, 0.878, 0.818,
0.811, 0.785, 0.858, 0.874, 0.832, (4.8797)+(0.0043)Gln+(-0.044
2)Val+(-0.2432)Met+(0.0085)Lys+(0.1728)Ile+(-0.1172)Trp; 0.8 55,
0.883, 0.786, 0.768, 0.746, 0.869, 0.853, 0.809, (3.9761)+(0.04
47)Ser+(-0.1394)Asn+(0.0119)Tyr+(-0.0437)Val+(0.1622)Ile+(-0.1163)Trp;
0.855, 0.883, 0.790, 0.769, 0.765, 0.823, 0.871, 0.807,
(5.2332)+(-0.0853)His+(-0.0011)Pro+(-0.0319)Val+(0.1242)Ile
+(0.0855)Phe+(-0.1197)Trp; 0.855, 0.882, 0.808, 0.808, 0.785, 0.8
39, 0.829, 0.815, (1.5564)+(0.0484)Ser+(-0.1360)Asn+(-0.0077)A
la+(0.0102)Pro+(0.0983)Phe+(-0.1441)Trp; 0.855, 0.884, 0.785, 0.
773, 0.748, 0.868, 0.837, 0.807, (4.3237)+(0.0457)Ser+(-0.1095)A
sn+(-0.0179)Arg+(-0.0435)Val+(0.1672)Ile+(-0.1115)Trp; 0.855,
0.883, 0.791, 0.783, 0.778, 0.857, 0.796, 0.803,
(2.8173)+(0.0457)Ser+(-0.0176)Arg+(-0.1902)Met+(0.1690)Ile+(-0.0630)Leu+(-
-0. 1267)Trp; 0.855, 0.886, 0.810, 0.811, 0.814, 0.821, 0.792,
0.810,
(-1.2236)+(0.0483)Ser+(0.0016)Gln+(-0.3036)Met+(0.0065)Leu+(0.
1275)Phe+(-0.1502)Trp; 0.855, 0.881, 0.820, 0.819, 0.848, 0.818, 0.
764, 0.812,
(3.8129)+(0.0442)Thr+(-0.0807)Cit+(-0.0050)Val+(-0.3265)Met+(0.158-
6)Phe+(-0.1672)Trp; 0.855, 0.879, 0.758, 0.742, 0.723, 0.802,
0.844, 0.778,
(0.5017)+(0.0316)Ser+(-0.0077)Thr+(-0.0434)Val+(0.1411)Ile+(0.0731-
)Phe+(-0.1641)Trp; 0.855, 0.8 80, 0.827, 0.820, 0.817, 0.844,
0.858, 0.835, (3.5149)+(0.0098)Gln
+(-0.1369)His+(-0.0037)Ala+(0.0040)Val+(0.1017)Phe+(-0.120 8)Trp;
0.855, 0.878, 0.823, 0.804, 0.817, 0.859, 0.860, 0.835, (5.06
40)+(-0.0436)Asn+(0.0116)Gln+(-0.0984)His+(-0.0571)Cit+(0.0
713)Ile+(-0.1302)Trp; 0.855, 0.883, 0.802, 0.794, 0.753, 0.835, 0.
902, 0.821,
(4.0093)+(-0.0088)Ala+(-0.0445)Val+(-0.0049)Lys+(0.1644)Ile+(0.080-
0)Phe+(-0.1407)Trp; 0.855, 0.877, 0.827, 0.81 9, 0.797, 0.873,
0.877, 0.842, (4.6565)+(0.0062)Gln+(-0.0089)Ala
+(-0.0866)Cit+(0.1725)Ile+(-0.0623)Leu+(-0.1483)Trp; 0.855, 0. 881,
0.776, 0.741, 0.784, 0.812, 0.827, 0.791, (5.3197)+(-0.1285)H
is+(0.0196)Thr+(0.0042)Orn+(0.0462)Ile+(0.0771)Phe+(-0.138 7)Trp;
0.855, 0.879, 0.817, 0.814, 0.850, 0.811, 0.758, 0.808, (3.93
25)+(0.0454)Thr+(-0.0808)Cit+(-0.0080)Arg+(-0.3232)Met+(0.1
527)Phe+(-0.1731)Trp; 0.855, 0.879, 0.769, 0.758, 0.743, 0.805, 0.
829, 0.784,
(-0.2442)+(0.0377)Ser+(-0.0166)Thr+(0.1512)Ile+(-0.0784)Leu+(0.072-
9)Phe+(-0.1578)Trp; 0.855, 0.880, 0.823, 0.819, 0.810, 0.845,
0.844, 0.829,
(3.3207)+(0.0022)Gly+(0.0092)Gln+(-0.1349)His+(-0.0032)Ala+(0.1096-
)Phe+(-0.1176)Trp; 0.855, 0.87 8, 0.824, 0.809, 0.810, 0.860,
0.865, 0.836,
(4.9673)+(0.0103)Gln+(-0.1050)His+(-0.0033)Ala+(-0.1136)Met+(0.079-
3)Ile+(-0.112 1)Trp; 0.855, 0.879, 0.807, 0.790, 0.784, 0.847,
0.870, 0.823, (7.21
86)+(-0.0504)His+(-0.0386)Val+(-0.1835)Met+(0.0134)Lys+(0.1
640)Ile+(-0.0984)Trp; 0.855, 0.885, 0.806, 0.786, 0.825, 0.833, 0.
804, 0.812,
(6.5516)+(-0.0549)Asn+(-0.0993)His+(0.0328)Thr+(-0.0646)Cit+(0.120-
7)Phe+(-0.1407)Trp; 0.855, 0.883, 0.800, 0.784, 0.788, 0.817,
0.855, 0.811,
(5.5847)+(-0.0858)His+(-0.0133)Arg+(0.1182)Ile+(-0.0526)Leu+(0.092-
1)Phe+(-0.1201)Trp; 0.855, 0.8 79, 0.816, 0.802, 0.813, 0.829,
0.847, 0.823, (3.4306)+(0.0097)Gln
+(-0.1416)His+(-0.0027)Lys+(0.0128)Leu+(0.0912)Phe+(-0.124 7)Trp;
0.855, 0.883, 0.814, 0.801, 0.812, 0.862, 0.813, 0.822, (6.36
27)+(0.0245)Thr+(-0.0673)Cit+(-0.1927)Met+(0.1422)Ile+(-0.0
505)Leu+(-0.1364)Trp; 0.855, 0.881, 0.820, 0.826, 0.809, 0.839, 0.
811, 0.821,
(1.7532)+(0.0487)Ser+(-0.1173)Asn+(-0.0044)Ala+(-0.0151)Arg+(0.106-
4)Phe+(-0.1423)Trp; 0.855, 0.882, 0.773, 0.745, 0.746, 0.871,
0.833, 0.799,
(3.1843)+(0.0489)Ser+(-0.0393)Asn+(-0.0731)His+(-0.0391)Val+(-0.23-
12)Met+(0.1739)Ile; 0.855, 0. 884, 0.799, 0.788, 0.772, 0.846,
0.852, 0.815, (0.9819)+(0.0487)Se
r+(-0.1272)Asn+(-0.0085)Ala+(0.0581)Ile+(0.0769)Phe+(-0.153 4)Trp;
0.855, 0.881, 0.792, 0.765, 0.785, 0.854, 0.834, 0.810, (2.99
27)+(0.0378)Ser+(-0.0097)Ala+(-0.0947)Cit+(0.0140)Tyr+(0.09
21)Ile+(-0.1770)Trp; 0.855, 0.874, 0.795, 0.781, 0.761, 0.883, 0.8
44, 0.817, (5.7111)+(-0.0568)Asn+(0.0367)Thr+(-0.0517)Cit+(-0.
0591)Val+(-0.3285)Met+(0.2073)Ile; 0.855, 0.882, 0.773, 0.754, 0.
751, 0.851, 0.814, 0.793, (3.7051)+(0.0364)Ser+(-0.0624)Cit+(-0.
0166)Arg+(-0.0361)Val+(0.1562)Ile+(-0.1510)Trp; 0.855, 0.881,
0.799, 0.772, 0.795, 0.856, 0.837, 0.815,
(1.1291)+(0.0496)Ser+(-0.0066)Ala+(0.0410)Tyr+(-0.2683)Met+(0.0909)Ile+(--
0.1529)Tr p; 0.855, 0.876, 0.781, 0.772, 0.727, 0.856, 0.865,
0.805,
(3.2418)+(0.0284)Ser+(-0.0009)Thr+(-0.0087)Ala+(-0.0394)Val+(0.1687)Ile+(-
-0.1366)Trp; 0.855, 0.880, 0.769, 0.735, 0.768, 0.842, 0.807,
0.788, (4.2456)+(0.0481)Ser+(-0.0554)Asn+(-0.1007)His+(0.001
6)Pro+(0.0735)Ile+(-0.1161)Trp; 0.855, 0.877, 0.798, 0.781, 0.78 6,
0.853, 0.826, 0.811, (2.4964)+(0.0477)Ser+(-0.0444)Asn+(-0.0
048)Ala+(-0.1692)Met+(0.0848)Ile+(-0.1380)Trp; 0.855, 0.882, 0.
802, 0.779, 0.794, 0.829, 0.857, 0.815, (5.2018)+(-0.0695)His+(-0.
0686)Cit+(0.1252)Ile+(-0.0543)Leu+(0.1034)Phe+(-0.1345)Trp; 0.855,
0.880, 0.809, 0.809, 0.812, 0.830, 0.791, 0.810, (2.1574)+(0.
0532)Ser+(-0.1274)Asn+(-0.0886)Cit+(-0.0030)Val+(0.1198)Phe
+(-0.1542)Trp; 0.855, 0.873, 0.805, 0.793, 0.772, 0.854, 0.872, 0.8
23,
(5.5172)+(0.0066)Gln+(-0.0844)His+(-0.0057)Ala+(-0.0246)Val+(0.1345)Ile+(-
-0.1134)Trp; 0.855, 0.884, 0.808, 0.800, 0.770, 0.835, 0.891,
0.824, (4.8756)+(-0.0904)Asn+(-0.0002)Pro+(-0.04
75)Val+(0.1509)Ile+(0.0828)Phe+(-0.1287)Trp; 0.855, 0.881, 0.7 74,
0.752, 0.736, 0.883, 0.831, 0.801, (0.7960)+(0.0372)Ser+(0.01
89)Thr+(0.0306)Tyr+(-0.0627)Val+(-0.4608)Met+(0.2203)Ile; 0. 855,
0.880, 0.790, 0.776, 0.734, 0.892, 0.869, 0.818, (2.2893)+(0.0
469)Ser+(-0.0795)Asn+(-0.0053)Ala+(-0.0530)Val+(-0.2301)Met
+(0.2058)Ile; 0.855, 0.878, 0.809, 0.791, 0.801, 0.846, 0.844, 0.82
0, (5.5425)+(-0.0677)Asn+(0.0093)Gln+(-0.1178)His+(0.0165)Th
r+(0.0616)Ile+(-0.1255)Trp; 0.855, 0.883, 0.809, 0.803, 0.771, 0.
832, 0.889, 0.824, (5.0451)+(-0.0712)Asn+(-0.0140)Arg+(-0.048
4)Val+(0.1545)Ile+(0.0859)Phe+(-0.1280)Trp; 0.855, 0.879, 0.79 8,
0.780, 0.779, 0.853, 0.844, 0.814, (3.6531)+(0.0499)Ser+(-0.10
08)Asn+(-0.0063)Gly+(0.1375)Ile+(-0.0565)Leu+(-0.1380)Trp; 0. 855,
0.879, 0.763, 0.730, 0.756, 0.838, 0.808, 0.783, (3.9448)+(0.0
402)Ser+(-0.0994)His+(-0.0023)Lys+(0.1095)Ile+(-0.0241)Leu+(-0.1175)Trp;
0.854, 0.881, 0.798, 0.776, 0.782, 0.847, 0.857, 0.81 5,
(7.2230)+(-0.0517)His+(-0.0377)Val+(-0.1522)Met+(0.0301)O
rn+(0.1593)Ile+(-0.0934)Trp; 0.854, 0.880, 0.772, 0.742, 0.747, 0.
870, 0.831, 0.797,
(2.7568)+(0.0453)Ser+(-0.0828)His+(-0.0387)Val+(-0.2825)Met+(0.0056)Lys+(-
0.1733)Ile; 0.854, 0.878, 0.757, 0.724, 0.741, 0.838, 0.819, 0.780,
(3.8920)+(0.0384)Ser+(-0.094
1)His+(0.0108)Tyr+(-0.0244)Val+(0.1304)Ile+(-0.1195)Trp; 0.8 54,
0.884, 0.795, 0.787, 0.797, 0.808, 0.800, 0.798, (6.2704)+(-0.0
546)Asn+(-0.1134)His+(0.0331)Thr+(-0.0359)Tyr+(0.1238)Phe+(-0.1154)Trp;
0.854, 0.879, 0.828, 0.821, 0.791, 0.876, 0.886, 0.84 4,
(5.6074)+(-0.0967)Asn+(0.0077)Gln+(-0.0706)Cit+(-0.0363)V
al(0.1494)Ile+(-0.1313)Trp; 0.854, 0.885, 0.823, 0.814, 0.813, 0.
835, 0.857, 0.830,
(3.8946)+(-0.0770)Cit+(-0.1943)Met+(0.1597)Ile+(-0.0756)Leu+(0.1272)Phe+(-
-0.1367)Trp; 0.854, 0.882, 0.780, 0.758, 0.775, 0.856, 0.795,
0.796, (3.5062)+(0.0364)Ser+(-0.085
8)Cit+(-0.0076)Lys+(0.1478)Ile+(-0.0513)Leu+(-0.1583)Trp; 0. 854,
0.878, 0.794, 0.780, 0.757, 0.852, 0.867, 0.814, (3.0594)+(0.0
402)Ser+(-0.0070)Gly+(-0.0092)Ala+(0.1667)Ile+(-0.0651)Leu+(-0.1445)Trp;
0.854, 0.880, 0.770, 0.740, 0.746, 0.867, 0.828, 0.79 5,
(2.8134)+(0.0467)Ser+(-0.0808)His+(-0.0372)Val+(-0.2643)M
et+(0.1712)Ile+(0.0006)Leu; 0.854, 0.877, 0.812, 0.802, 0.784, 0.
855, 0.864, 0.826,
(5.0964)+(0.0038)Gln+(-0.0440)Val+(-0.2255)Met+(0.0185)Orn+(0.1708)Ile+(--
0.1119)Trp; 0.854, 0.881, 0.819, 0.815, 0.850, 0.819, 0.764, 0.812,
(3.9846)+(0.0449)Thr+(-0.086
7)Cit+(-0.3160)Met+(-0.0047)Lys+(0.1543)Phe+(-0.1716)Trp; 0. 854,
0.878, 0.814, 0.807, 0.846, 0.807, 0.767, 0.807, (3.6467)+(0.0
431)Thr+(-0.0870)Cit+(-0.3295)Met+(0.0063)Leu+(0.1473)Phe+(-0.1770)Trp;
0.854, 0.876, 0.781, 0.771, 0.727, 0.856, 0.863, 0.80 4,
(3.2400)+(0.0268)Ser+(-0.0090)Ala+(-0.0403)Val+(0.0081)Or
n+(0.1674)Ile+(-0.1374)Trp; 0.854, 0.878, 0.792, 0.774, 0.799, 0.
826, 0.797, 0.799, (0.5273)+(0.0104)Gln+(-0.1731)His+(0.0375)I
hr+(0.0039)Pro+(-0.3739)Met+(0.1493)Phe; 0.854, 0.886, 0.835, 0.
835, 0.823, 0.841, 0.858, 0.839, (3.6089)+(-0.0519)Asn+(0.0112)G
ln+(-0.1258)His+(-0.0137)Tyr+(0.1092)Phe+(-0.1092)Trp; 0.854,
0.883, 0.808, 0.800, 0.769, 0.832, 0.890, 0.823, (4.8623)+(-0.095
3)Asn+(-0.0479)Val+(0.0022)Lys+(0.1502)Ile+(0.0818)Phe+(-0.
1291)Trp; 0.854, 0.880, 0.796, 0.776, 0.764, 0.844, 0.884, 0.817,
(3. 5104)+(0.0069)Asn+(-0.0702)His+(-0.0513)Val+(-0.3217)Met+(0.
1759)Ile+(0.1274)Phe; 0.854, 0.878, 0.769, 0.737, 0.766, 0.838, 0.
812, 0.788, (3.0663)+(0.0349)Ser+(0.0048)Gln+(-0.1268)His+(0.
0055)Tyr+(0.0721)Ile+(-0.1268)Trp; 0.854, 0.881, 0.763, 0.722, 0.
769, 0.844, 0.797, 0.783, (3.8897)+(0.0460)Ser+(-0.0970)His+(-0.
0561)Cit+(0.0104)Tyr+(0.0803)Ile+(-0.1378)Trp; 0.854, 0.881, 0.
774, 0.743, 0.746, 0.868, 0.848, 0.801, (2.8344)+(0.0527)Ser+(-0.
0044)Gly+(-0.0777)His+(-0.0378)Val+(-0.2593)Met+(0.1720)Il e;
0.854, 0.876, 0.779, 0.753, 0.764, 0.841, 0.835, 0.798,
(7.0336)+(-0.0666)His+(0.0181)Thr+(-0.0496)Cit+(-0.0280)Val+(0.1359)Ile+(-
-0.1266)Trp; 0.854, 0.880, 0.819, 0.820, 0.805, 0.828, 0.836,
0.823, (2.1097)+(0.0568)Ser+(-0.1416)Asn+(-0.0066)Gly+(-0.00
83)Val+(0.1046)Phe+(-0.1378)Trp; 0.854, 0.879, 0.811, 0.810, 0.8
43, 0.812, 0.744, 0.802, (3.2839)+(0.0028)Gly+(0.0419)Thr+(-0.0
899)Cit+(-0.3318)Met+(0.1551)Phe+(-0.1709)Trp; 0.854, 0.879, 0.
810, 0.805, 0.814, 0.825, 0.804, 0.812, (2.2035)+(0.0559)Ser+(-0.
1231)Asn+(-0.0026)Gly+(-0.0873)Cit+(0.1136)Phe+(-0.1602)Tr p;
0.854, 0.872, 0.796, 0.787, 0.759, 0.883, 0.837, 0.817,
(3.5246)+(0.0033)Gln+(0.0323)Thr+(-0.0613)Cit+(-0.0570)Val+(-0.3960)Met+(-
0.2045)Ile; 0.854, 0.878, 0.779, 0.759, 0.771, 0.849, 0.798, 0.
794,
(3.1498)+(0.0370)Ser+(-0.0052)Thr+(-0.0840)Cit+(0.1532)Ile+(-0.0582)Leu+(-
-0.1608)Trp; 0.854, 0.877, 0.802, 0.792, 0.761, 0.860, 0.872,
0.821, (6.3027)+(0.0040)Gly+(-0.0080)Ala+(-0.071
4)Cit+(-0.0361)Val+(0.1725)Ile+(-0.1320)Trp; 0.854, 0.877, 0.7 76,
0.764, 0.724, 0.854, 0.861, 0.800, (3.5806)+(0.0305)Ser+(-0.0
016)Gln+(-0.0085)Ala+(-0.0399)Val+(0.1710)Ile+(-0.1342)Trp; 0.854,
0.878, 0.790, 0.775, 0.797, 0.831, 0.783, 0.796, (0.4304)+(0.
0032)Gly+(0.0098)Gln+(-0.1764)His+(0.0370)Thr+(-0.3675)Met+(0.1564)Phe;
0.854, 0.883, 0.771, 0.748, 0.768, 0.798, 0.817, 0.783,
(5.2891)+(-0.1260)His+(0.0248)Thr+(-0.0400)Tyr+(0.0493)Ile+(0.0993)Phe+(--
0.1294)Trp; 0.854, 0.884, 0.798, 0.780, 0.796, 0.82 6, 0.826,
0.807, (5.7900)+(-0.1179)His+(0.0228)Thr+(-0.0054)Al
a+(0.0051)Pro+(0.1075)Phe+(-0.1266)Trp; 0.854, 0.880, 0.817, 0.
807, 0.813, 0.830, 0.843, 0.823, (3.3573)+(0.0096)Gln+(-0.1396)H
is+(0.0026)Val+(-0.0007)Lys+(0.0979)Phe+(-0.1217)Trp; 0.854, 0.877,
0.758, 0.727, 0.739, 0.837, 0.820, 0.781,
(4.0501)+(0.0376)Ser+(-0.0909)His+(-0.0244)Val+(0.1289)Ile+(0.0021)Leu+(--
0.1 154)Trp; 0.854, 0.882, 0.782, 0.753, 0.755, 0.888, 0.842,
0.809, (0.
8795)+(0.0469)Ser+(-0.0482)Cit+(0.0380)Tyr+(-0.0563)Val+(-0.
3958)Met+(0.2067)Ile; 0.854, 0.877, 0.770, 0.740, 0.765, 0.839, 0.
812, 0.789, (3.1302)+(0.0347)Ser+(0.0047)Gln+(-0.1247)His+(0.
0001)Pro+(0.0726)Ile+(-0.1245)Trp; 0.854, 0.878, 0.769, 0.736, 0.
767, 0.844, 0.807, 0.789, (4.2704)+(0.0480)Ser+(-0.0532)Asn+(-0.
1003)His+(-0.0008)Lys+(0.0761)Ile+(-0.1150)Trp; 0.854, 0.880,
0.779, 0.745, 0.784, 0.818, 0.829, 0.794,
(5.4488)+(-0.1299)His+(0.0219)Thr+(-0.0048)Pro+(0.0520)Ile+(0.0813)Phe+(--
0.1392)T rp; 0.854, 0.879, 0.765, 0.734, 0.775, 0.834, 0.776,
0.780, (-0.416
7)+(0.0638)Ser+(-0.0260)Asn+(-0.1484)His+(-0.2780)Met+(0.01
26)Leu+(0.1517)Phe; 0.854, 0.886, 0.775, 0.760, 0.775, 0.830, 0.77
3, 0.784, (2.0891)+(0.0525)Ser+(-0.1244)His+(-0.0188)Arg+(-0.
0188)Tyr+(0.1388)Phe+(-0.1100)Trp; 0.854, 0.879, 0.810, 0.800, 0.
806, 0.829, 0.832, 0.817, (3.1127)+(0.0023)Gly+(0.0090)Gln+(-0.
1418)His+(0.0027)Val+(0.0998)Phe+(-0.1223)Trp; 0.854, 0.878, 0.
759, 0.728, 0.741, 0.839, 0.820, 0.782, (4.1188)+(0.0381)Ser+(-0.
0880)His+(-0.0235)Val+(-0.0032)Lys+(0.1320)Ile+(-0.1129)Tr p;
0.854, 0.880, 0.808, 0.805, 0.812, 0.829, 0.788, 0.809,
(2.1909)+(0.0530)Ser+(-0.1186)Asn+(-0.0917)Cit+(-0.0036)Lys+(0.1178)Phe+(-
-0.1570)Trp; 0.854, 0.878, 0.802, 0.781, 0.785, 0.860, 0.849,
0.819, (7.3654)+(-0.0740)Asn+(-0.0876)Cit+(-0.0417)Val+(0.05
26)Orn+(0.1510)Ile+(-0.1240)Trp; 0.854, 0.882, 0.822, 0.813, 0.7
94, 0.854, 0.882, 0.836, (4.3913)+(-0.0099)Ala+(-0.0973)Cit+(0.
1736)Ile+(-0.0766)Leu+(0.1048)Phe+(-0.1499)Trp; 0.854, 0.878,
0.782, 0.773, 0.730, 0.854, 0.861, 0.805,
(3.2733)+(0.0279)Ser+(-0.0088)Ala+(-0.0324)Val+(0.1850)Ile+(-0.0231)Leu+(-
-0.1348)I rp; 0.854, 0.876, 0.810, 0.792, 0.798, 0.851, 0.852,
0.823, (4.7756)
+(0.0091)Gln+(-0.0874)His+(-0.0596)Cit+(0.1172)Ile+(-0.032
1)Leu+(-0.1301)Trp; 0.854, 0.879, 0.767, 0.738, 0.776, 0.839, 0.77
2, 0.781, (-0.4046)+(0.0589)Ser+(-0.1495)His+(-0.0005)Ala+(-0.
2769)Met+(0.0136)Orn+(0.1572)Phe; 0.854, 0.886, 0.810, 0.806, 0.
818, 0.825, 0.792, 0.810, (-0.9777)+(0.0509)Ser+(0.0119)Tyr+(-0.
3152)Met+(0.0071)Leu+(0.1255)Phe+(-0.1515)Trp; 0.854, 0.876, 0.
803, 0.793, 0.826, 0.857, 0.743, 0.805, (5.6485)+(0.0423)Ser+(-0.
1097)Asn+(-0.1136)Cit+(0.0082)Pro+(0.0503)Orn+(-0.1503)Trp; 0.854,
0.878, 0.787, 0.765, 0.772, 0.829, 0.846, 0.803,
(4.0067)+(-0.1092)Cit+(-0.0406)Val+(0.0366)Orn+(0.1365)Ile+(0.0731)Phe
+(-0.1600)Trp; 0.854, 0.882, 0.825, 0.833, 0.804, 0.846, 0.833, 0.8
29, (1.0716)+(0.0443)Ser+(-0.1424)Asn+(0.0028)Gln+(-0.0048)A
la+(0.0997)Phe+(-0.1450)Trp; 0.854, 0.880, 0.815, 0.804, 0.810, 0.
826, 0.843, 0.821, (3.3393)+(0.0094)Gln+(-0.1392)His+(0.0021)P
ro+(0.0018)Val+(0.0967)Phe+(-0.1227)Trp; 0.854, 0.876, 0.804, 0.
802, 0.800, 0.859, 0.779, 0.810, (4.1504)+(0.0367)Ser+(0.0071)Gl
n+(-0.1000)His+(0.0135)Pro+(-0.1443)Met+(-0.0962)Trp; 0.854, 0.881,
0.830, 0.826, 0.806, 0.847, 0.876, 0.839, (3.7761)+(-0.005
9)Ala+(-0.2055)Met+(0.1677)Ile+(-0.0784)Leu+(0.1105)Phe+(-0.
1244)Trp; 0.854, 0.884, 0.772, 0.754, 0.776, 0.828, 0.771, 0.782,
(1. 8983)+(0.0519)Ser+(-0.1109)His+(-0.0572)Cit+(-0.0201)Tyr+(0.
1453)Phe+(-0.1271)Trp; 0.854, 0.886, 0.778, 0.756, 0.783, 0.831, 0.
793, 0.790,
(2.2574)+(0.0563)Ser+(-0.0032)Gly+(-0.1245)His+(-0.0189)Arg+(0.127-
4)Phe+(-0.1176)Trp; 0.854, 0.872, 0.797, 0.782, 0.795, 0.833,
0.817, 0.807,
(5.3433)+(0.0099)Gln+(-0.1289)His+(0.0182)Thr+(-0.0274)Arg+(0.0676-
)Ile+(-0.1315)Trp; 0.854, 0.8 81, 0.808, 0.823, 0.789, 0.825,
0.796, 0.808, (1.6311)+(0.0486)Ser
+(-0.1366)Asn+(-0.0289)Tyr+(-0.0076)Val+(0.1228)Phe+(-0.129 7)Trp;
0.854, 0.877, 0.803, 0.795, 0.755, 0.866, 0.878, 0.824, (7.09
70)+(-0.0928)Asn+(0.0211)Thr+(-0.0069)Ala+(-0.0445)Val+(0.1
731)Ile+(-0.1189)Trp; 0.854, 0.877, 0.762, 0.731, 0.754, 0.837, 0.
807, 0.782, (3.8953)+(0.0396)Ser+(-0.1007)His+(-0.0001)Pro+(0.
1099)Ile+(-0.0254)Leu+(-0.1191)Trp; 0.854, 0.885, 0.806, 0.805,
0.811, 0.821, 0.787, 0.806,
(-0.8636)+(0.0503)Ser+(-0.2974)Met+(-0.0002)Orn+(0.0070)Leu+(0.1283)Phe+(-
-0.1487)Trp; 0.854, 0.8 82, 0.801, 0.783, 0.817, 0.822, 0.796,
0.805, (6.6511)+(-0.0395)As
n+(-0.1151)His+(0.0328)Thr+(-0.0187)Arg+(0.1099)Phe+(-0.127 3)Trp;
0.854, 0.881, 0.788, 0.764, 0.801, 0.814, 0.805, 0.796, (5.66
40)+(-0.1249)His+(0.0223)Thr+(0.0131)Orn+(-0.0041)Lys+(0.10
08)Phe+(-0.1252)Trp; 0.854, 0.878, 0.802, 0.777, 0.796, 0.856, 0.8
39, 0.817, (7.7943)+(-0.0821)His+(0.0234)Thr+(-0.0068)Ala+(-0.
0585)Cit+(0.0820)Ile+(-0.1340)Trp; 0.854, 0.878, 0.792, 0.768, 0.
801, 0.838, 0.803, 0.802, (7.7380)+(-0.0941)His+(0.0366)Thr+(-0.
0091)Arg+(-0.1902)Met+(0.0774)Ile+(-0.1153)Trp; 0.853, 0.882,
0.818, 0.801, 0.794, 0.858, 0.882, 0.834,
(5.9749)+(0.0333)Tyr+(-0.0488)Val+(-0.2732)Met+(0.0116)Lys+(0.1822)Ile+(--
0.1203)Tr p; 0.853, 0.882, 0.797, 0.791, 0.793, 0.810, 0.815,
0.802,
(3.5467)+(0.0072)Gln+(-0.1396)His+(0.0200)Thr+(-0.0305)Tyr+(0.1177)P
he+(-0.1204)Trp; 0.853, 0.883, 0.816, 0.826, 0.808, 0.833, 0.793,
0. 815, (1.8139)+(0.0494)Ser+(-0.1292)Asn+(-0.0154)Arg+(-0.007
9)Val+(0.1126)Phe+(-0.1365)Trp; 0.853, 0.883, 0.794, 0.779, 0.79 5,
0.826, 0.812, 0.803, (5.5145)+(0.0020)Gly+(-0.1222)His+(0.02
31)Thr+(-0.0040)Ala+(0.1120)Phe+(-0.1244)Trp; 0.853, 0.881, 0. 766,
0.739, 0.761, 0.838, 0.795, 0.783, (4.1722)+(0.0450)Ser+(-0.
0902)His+(-0.0209)Arg+(0.1274)Ile+(-0.0344)Leu+(-0.1159)Tr p;
0.853, 0.877, 0.758, 0.718, 0.761, 0.834, 0.799, 0.778,
(3.9897)+(0.0416)Ser+(-0.1114)His+(0.0129)Orn+(-0.0060)Lys+(0.0761)I
le+(-0.1189)Trp; 0.853, 0.881, 0.795, 0.788, 0.804, 0.820, 0.779,
0. 798, (2.0211)+(0.0545)Ser+(-0.1287)Asn+(-0.0977)Cit+(0.0075)
Pro+(0.1091)Phe+(-0.1667)Trp; 0.853, 0.879, 0.769, 0.733, 0.769,
0.844, 0.809, 0.789, (4.1621)+(0.0487)Ser+(-0.0572)Asn+(-0.103
0)His+(0.0091)Tyr+(0.0745)Ile+(-0.1192)Trp; 0.853, 0.878, 0.76 2,
0.728, 0.755, 0.837, 0.808, 0.782, (3.8342)+(0.0399)Ser+(-0.10
24)His+(0.0045)Tyr+(0.1091)Ile+(-0.0253)Leu+(-0.1211)Trp; 0. 853,
0.879, 0.787, 0.765, 0.798, 0.809, 0.808, 0.795, (5.5664)+(-0.
1241)His+(0.0224)Thr+(0.0008)Pro+(-0.0007)Val+(0.1037)Phe+(-0.1276)Trp;
0.853, 0.879, 0.796, 0.772, 0.802, 0.844, 0.810, 0.80 7,
(1.7687)+(0.0515)Ser+(-0.0472)Asn+(0.0304)Tyr+(-0.2456)Me
t+(0.0769)Ile+(-0.1522)Trp; 0.853, 0.877, 0.794, 0.775, 0.804, 0.
859, 0.775, 0.803, (5.2235)+(0.0478)Ser+(-0.0871)His+(0.0129)P
ro+(0.0338)Tyr+(-0.1721)Met+(-0.1070)Trp; 0.853, 0.880, 0.767,
0.739, 0.775, 0.838, 0.770, 0.781, (-0.4033)+(0.0585)Ser+(-0.147
5)His+(-0.0025)Val+(-0.2779)Met+(0.0150)Orn+(0.1602)Phe; 0.8 53,
0.876, 0.817, 0.810, 0.784, 0.859, 0.873, 0.831, (4.9305)+(0.00
08)Gly+(0.0047)Gln+(-0.0419)Val+(-0.2217)Met+(0.1715)Ile+(-0.1131)Trp;
0.853, 0.879, 0.826, 0.822, 0.813, 0.843, 0.855, 0.833,
(3.5052)+(0.0095)Gln+(-0.1340)His+(-0.0033)Ala+(0.0012)Lys+(0.1067)Phe+(--
0.1183)Trp; 0.853, 0.883, 0.799, 0.781, 0.800, 0.82 9, 0.823,
0.808, (5.8222)+(-0.1210)His+(0.0244)Thr+(-0.0042)Al
a+(0.0013)Val+(0.1088)Phe+(-0.1273)Trp; 0.853, 0.880, 0.805, 0.
792, 0.780, 0.858, 0.851, 0.820, (6.5462)+(0.0047)Gly+(-0.0529)C
it+(-0.0398)Val+(-0.1568)Met+(0.1732)Ile+(-0.1147)Trp; 0.853,
0.879, 0.791, 0.773, 0.735, 0.884, 0.887, 0.820, (1.3510)+(0.0500)
Ser+(-0.0061)Gly+(-0.0057)Ala+(-0.0518)Val+(-0.2988)Met+(0.
2055)Ile; 0.853, 0.877, 0.786, 0.773, 0.791, 0.849, 0.766, 0.794,
(5. 1177)+(0.0440)Ser+(-0.0892)His+(0.0149)Pro+(-0.1640)Met+(0.
0121)Lys+(-0.1050)Trp; 0.853, 0.879, 0.791, 0.769, 0.801, 0.829, 0.
802, 0.800, (0.5373)+(0.0105)Gln+(-0.1793)His+(0.0393)Thr+(-0.
3774)Met+(0.0103)Leu+(0.1432)Phe; 0.853, 0.881, 0.827, 0.839, 0.
841, 0.808, 0.781, 0.817, (1.6661)+(0.0043)Gln+(0.0376)Thr+(-0.
0102)Val+(-0.3675)Met+(0.1471)Phe+(-0.1541)Trp; 0.853, 0.879,
0.806, 0.803, 0.811, 0.826, 0.788, 0.807,
(2.1018)+(0.0529)Ser+(-0.1251)Asn+(-0.0917)Cit+(0.0000)Arg+(0.1151)Phe+(--
0.1595)Tr p; 0.853, 0.883, 0.801, 0.784, 0.801, 0.830, 0.821,
0.809,
(5.9036)+(-0.1190)His+(0.0256)Thr+(-0.0040)Ala+(-0.0026)Lys+(0.1123)
Phe+(-0.1250)Trp; 0.853, 0.880, 0.789, 0.766, 0.801, 0.814, 0.807,
0.797, (5.7142)+(-0.1235)His+(0.0240)Thr+(0.0000)Val+(-0.003
3)Lys+(0.1058)Phe+(-0.1265)Trp; 0.853, 0.880, 0.783, 0.761, 0.79 3,
0.810, 0.798, 0.791, (5.2625)+(0.0022)Gly+(-0.1268)His+(0.02
12)Thr+(-0.0001)Val+(0.1054)Phe+(-0.1261)Trp; 0.853, 0.878, 0. 789,
0.769, 0.786, 0.830, 0.821, 0.801, (1.9274)+(0.0568)Ser+(-0.
0069)Gly+(0.0056)Pro+(-0.2481)Met+(0.0714)Ile+(-0.1480)Trp; 0.853,
0.880, 0.760, 0.724, 0.774, 0.836, 0.772, 0.776,
(-0.6754)+(0.0610)Ser+(-0.1541)His+(-0.2962)Met+(0.0094)Orn+(0.0121)L
eu+(0.1492)Phe; 0.853, 0.881, 0.810, 0.817, 0.826, 0.795, 0.769, 0.
802, (3.0139)+(0.0392)Thr+(0.0082)Pro+(-0.0122)Val+(-0.3683)
Met+(0.1471)Phe+(-0.1488)Trp; 0.853, 0.881, 0.783, 0.761, 0.775,
0.848, 0.811, 0.799, (3.2888)+(0.0391)Ser+(-0.0034)Gly+(-0.082
7)Cit+(0.1481)Ile+(-0.0565)Leu+(-0.1646)Trp; 0.853, 0.884, 0.8 02,
0.784, 0.791, 0.826, 0.857, 0.814, (3.2800)+(0.0086)Gln+(-0.1
346)His+(-0.0222)Tyr+(0.0491)Ile+(0.0865)Phe+(-0.1254)Trp; 0. 853,
0.878, 0.782, 0.770, 0.732, 0.856, 0.861, 0.805, (3.4668)+(0.0
310)Ser+(-0.0084)Ala+(-0.0380)Val+(-0.0084)Lys+(0.1711)Ile+(-0.1294)Trp;
0.853, 0.879, 0.765, 0.732, 0.784, 0.847, 0.752, 0.77 9,
(-0.2887)+(0.0592)Ser+(-0.1395)His+(-0.0565)Cit+(-0.2795)
Met+(0.0290)Orn+(0.1555)Phe; 0.853, 0.878, 0.796, 0.781, 0.802, 0.
831, 0.797, 0.803, (0.8290)+(0.0106)Gln+(-0.1733)His+(0.0397)I
hr+(-0.3593)Met+(-0.0039)Lys+(0.1535)Phe; 0.853, 0.878, 0.817,
0.810, 0.785, 0.857, 0.874, 0.831, (5.0230)+(0.0048)Gln+(0.0038)
Pro+(-0.0421)Val+(-0.2294)Met+(0.1676)Ile+(-0.1133)Trp; 0.85 3,
0.873, 0.810, 0.799, 0.783, 0.854, 0.867, 0.825, (5.6444)+(-0.06
43)Asn+(0.0086)Gln+(-0.0820)His+(-0.0264)Val+(0.1260)Ile+(-0.1061)Trp;
0.853, 0.879, 0.778, 0.760, 0.771, 0.849, 0.792, 0.793,
(3.2943)+(0.0343)Ser+(-0.0864)Cit+(-0.0040)Tyr+(0.1496)Ile+(-0.0564)Leu+(-
-0.1629)Trp; 0.853, 0.875, 0.756, 0.720, 0.757, 0.8 34, 0.794,
0.776, (4.1211)+(0.0405)Ser+(-0.1107)His+(0.0050)Th
r+(-0.0057)Lys+(0.0783)Ile+(-0.1207)Trp; 0.853, 0.877, 0.785, 0.
762, 0.764, 0.843, 0.847, 0.804, (7.6402)+(-0.0653)Asn+(-0.0666)
His+(0.0222)Thr+(-0.0329)Val+(0.1409)Ile+(-0.1100)Trp; 0.853,
0.874, 0.810, 0.793, 0.794, 0.848, 0.862, 0.825,
(5.2139)+(0.0088)Gln+(-0.1137)His+(-0.0061)Ala+(0.0042)Pro+(0.0710)Ile+(--
0.1 230)Trp; 0.853, 0.880, 0.803, 0.807, 0.803, 0.823, 0.779,
0.803, (2.
0225)+(0.0538)Ser+(-0.1193)Asn+(-0.0886)Cit+(-0.0255)Tyr+(0.
1286)Phe+(-0.1510)Trp; 0.853, 0.880, 0.809, 0.796, 0.780, 0.852, 0.
871, 0.825, (6.2637)+(0.0054)Pro+(-0.0470)Val+(-0.2383)Met+(0.
0121)Lys+(0.1731)Ile+(-0.1140)Trp; 0.853, 0.881, 0.824, 0.814, 0.
813, 0.843, 0.861, 0.833, (3.5808)+(0.0097)Gln+(-0.1388)His+(-0.
0040)Ala+(0.0143)Leu+(0.0950)Phe+(-0.1241)Trp; 0.853, 0.876, 0.
763, 0.725, 0.763, 0.830, 0.815, 0.783, (4.0817)+(0.0495)Ser+(-0.
0044)Gly+(-0.1050)His+(-0.0055)Lys+(0.0785)Ile+(-0.1200)Tr p;
0.853, 0.880, 0.789, 0.766, 0.801, 0.813, 0.807, 0.797,
(5.6983)+(-0.1233)His+(0.0237)Thr+(0.0006)Pro+(-0.0033)Lys+(0.1052)P
he+(-0.1267)Trp; 0.853, 0.876, 0.780, 0.770, 0.726, 0.854, 0.866,
0. 804, (3.0792)+(0.0284)Ser+(-0.0093)Ala+(0.0087)Tyr+(-0.0403)
Val+(0.1701)Ile+(-0.1406)Trp; 0.853, 0.879, 0.825, 0.801, 0.823,
0.858, 0.865, 0.837, (4.4850)+(0.0111)Gln+(-0.1120)His+(0.027
7)Tyr+(-0.1733)Met+(0.0738)Ile+(-0.1210)Trp; 0.853, 0.881, 0.7 66,
0.728, 0.771, 0.842, 0.799, 0.785, (4.0528)+(0.0475)Ser+(-0.0
017)Gly+(-0.0939)His+(-0.0516)Cit+(0.0804)Ile+(-0.1322)Trp; 0.853,
0.879, 0.812, 0.797, 0.809, 0.826, 0.847, 0.820, (3.3749)+(0.
0094)Gln+(-0.1422)His+(0.0012)Pro+(0.0110)Leu+(0.0897)Phe+(-0.1262)Trp;
0.853, 0.884, 0.807, 0.802, 0.757, 0.837, 0.901, 0.82 4,
(4.3817)+(-0.0082)Ala+(-0.0196)Arg+(-0.0475)Val+(0.1702)I
le+(0.0862)Phe+(-0.1360)Trp; 0.853, 0.878, 0.775, 0.747, 0.788, 0.
808, 0.798, 0.785, (5.2334)+(0.0025)Gly+(-0.1326)His+(0.0211)T
hr+(0.0116)Leu+(0.0948)Phe+(-0.1319)Trp; 0.853, 0.877, 0.768, 0.
738, 0.768, 0.843, 0.796, 0.786, (4.3687)+(0.0496)Ser+(-0.0418)A
sn+(-0.0997)His+(-0.0116)Arg+(0.0778)Ile+(-0.1155)Trp; 0.853,
0.878, 0.766, 0.736, 0.776, 0.838, 0.768, 0.780, (-0.3931)+(0.059
5)Ser+(-0.1494)His+(-0.2757)Met+(0.0139)Orn+(-0.0018)Lys+(0.
1576)Phe; 0.853, 0.878, 0.765, 0.734, 0.788, 0.805, 0.769, 0.774,
(0. 7248)+(0.0373)Ser+(-0.1351)Cit+(0.0265)Orn+(0.0486)Ile+(0.0
698)Phe+(-0.2088)Trp; 0.853, 0.880, 0.814, 0.805, 0.809, 0.827, 0.
842, 0.820, (3.3601)+(0.0093)Gln+(-0.1373)His+(0.0025)Pro+(-0.
0002)Lys+(0.0993)Phe+(-0.1211)Trp; 0.853, 0.877, 0.760, 0.721, 0.
761, 0.830, 0.812, 0.781, (4.0858)+(0.0458)Ser+(-0.0044)Gly+(-0.
1125)His+(0.0049)Thr+(0.0735)Ile+(-0.1262)Trp; 0.853, 0.878, 0.
770, 0.739, 0.765, 0.838, 0.810, 0.788, (3.1649)+(0.0344)Ser+(0.0
045)Gln+(-0.1254)His+(0.0044)Orn+(0.0715)Ile+(-0.1246)Trp; 0. 853,
0.879, 0.804, 0.799, 0.810, 0.825, 0.789, 0.806, (2.0574)+(0.0
529)Ser+(-0.1248)Asn+(-0.0928)Cit+(0.0040)Leu+(0.1114)Phe+(-0.1627)Trp;
0.853, 0.881, 0.817, 0.824, 0.798, 0.842, 0.821, 0.82 1,
(1.6512)+(0.0472)Ser+(-0.1285)Asn+(-0.0046)Ala+(-0.0016)L
ys+(0.1025)Phe+(-0.1417)Trp; 0.853, 0.878, 0.827, 0.834, 0.844, 0.
811, 0.782, 0.818, (3.9635)+(-0.0513)Asn+(0.0425)Thr+(-0.0111)
Val+(-0.3070)Met+(0.1482)Phe+(-0.1449)Trp; 0.853, 0.880, 0.778,
0.758, 0.771, 0.848, 0.792, 0.792, (3.2032)+(0.0345)Ser+(-0.087
9)Cit+(0.0005)Pro+(0.1488)Ile+(-0.0565)Leu+(-0.1656)Trp; 0.8 53,
0.879, 0.779, 0.762, 0.775, 0.853, 0.782, 0.793, (3.4244)+(0.03
82)Ser+(-0.0733)Cit+(-0.0168)Arg+(0.1589)Ile+(-0.0613)Leu+(-0.1577)Trp;
0.853, 0.878, 0.783, 0.766, 0.760, 0.822, 0.849, 0.79 9,
(3.3342)+(0.0045)Gly+(-0.0908)Cit+(-0.0399)Val+(0.1444)Il
e+(0.0863)Phe+(-0.1639)Trp; 0.853, 0.880, 0.798, 0.797, 0.743, 0.
830, 0.893, 0.816, (3.8580)+(-0.0082)Ala+(-0.0189)Tyr+(-0.044
5)Val+(0.1615)Ile+(0.0863)Phe+(-0.1394)Trp; 0.853, 0.880, 0.76 4,
0.731, 0.779, 0.839, 0.768, 0.779, (-0.5166)+(0.0631)Ser+(-0.1
441)His+(-0.0353)Cit+(-0.2997)Met+(0.0146)Leu+(0.1543)Phe; 0. 853,
0.879, 0.800, 0.783, 0.812, 0.837, 0.791, 0.806, (0.7194)+(0.0
112)Gln+(-0.1660)His+(0.0394)Thr+(-0.0460)Cit+(-0.3655)Met+(0.1558)Phe;
0.853, 0.876, 0.804, 0.796, 0.761, 0.850, 0.883, 0.822,
(-0.2433)+(0.0023)Gly+(0.0041)Gln+(-0.0636)Val+(-0.4370)Met
+(0.1997)Ile+(0.1242)Phe; 0.853, 0.880, 0.764, 0.728, 0.771, 0.84
2, 0.788, 0.782, (4.1408)+(0.0468)Ser+(-0.0937)His+(-0.0484)Ci
t+(-0.0076)Arg+(0.0823)Ile+(-0.1306)Trp; 0.853, 0.879, 0.814, 0.
798, 0.806, 0.852, 0.844, 0.825, (4.5941)+(0.0028)Gly+(0.0100)Gl
n+(-0.1091)His+(-0.1396)Met+(0.0768)Ile+(-0.1114)Trp; 0.853, 0.877,
0.784, 0.767, 0.731, 0.885, 0.864, 0.812, (1.2558)+(0.0413)
Ser+(-0.0001)Gln+(-0.0059)Ala+(-0.0515)Val+(-0.3037)Met+(0.
2054)Ile; 0.853, 0.877, 0.759, 0.723, 0.765, 0.835, 0.785, 0.777,
(4. 1643)+(0.0446)Ser+(-0.1109)His+(-0.0183)Arg+(0.0158)Orn+(0.
0754)Ile+(-0.1217)Trp; 0.852, 0.878, 0.762, 0.729, 0.773, 0.833, 0.
778, 0.778,
(-0.6323)+(0.0632)Ser+(-0.0009)Gly+(-0.1518)His+(-0.2972)Met+(0.01-
36)Leu+(0.1509)Phe; 0.852, 0.879, 0.761, 0.72 8, 0.774, 0.835,
0.771, 0.777, (-0.5887)+(0.0630)Ser+(-0.1515)Hi
s+(-0.2914)Met+(-0.0030)Lys+(0.0148)Leu+(0.1517)Phe; 0.852, 0. 878,
0.768, 0.752, 0.730, 0.872, 0.816, 0.793, (1.3742)+(0.0335)Se
r+(0.0207)Thr+(0.0039)Pro+(-0.0585)Val+(-0.4193)Met+(0.206 4)Ile;
0.852, 0.877, 0.811, 0.801, 0.773, 0.860, 0.879, 0.828, (6.47
16)+(0.0025)Gly+(-0.0048)Ala+(-0.0429)Val+(-0.1624)Met+(0.1
843)Ile+(-0.1053)Trp; 0.852, 0.878, 0.781, 0.763, 0.732, 0.883, 0.
859, 0.809,
(1.1897)+(0.0392)Ser+(-0.0061)Ala+(-0.0532)Val+(-0.3108)Met+(0.016-
3)Orn+(0.2038)Ile; 0.852, 0.877, 0.785, 0.763, 0.794, 0.838, 0.789,
0.796, (1.3956)+(0.0438)Ser+(0.0107)Thr+(0.
0265)Tyr+(-0.3095)Met+(0.0781)Ile+(-0.1584)Trp; 0.852, 0.877,
0.808, 0.787, 0.788, 0.854, 0.871, 0.825,
(6.0830)+(0.0274)Tyr+(-0.0477)Val+(-0.2427)Met+(0.0224)Orn+(0.1787)Ile+(--
0.1119)Tr p; 0.852, 0.883, 0.799, 0.796, 0.779, 0.833, 0.826,
0.808,
(1.7192)+(0.0501)Ser+(-0.1603)Asn+(-0.0338)Val+(0.0531)Leu+(0.1032)P
he+(-0.1381)Trp; 0.852, 0.874, 0.741, 0.706, 0.723, 0.831, 0.803,
0. 766, (0.2788)+(0.0567)Ser+(-0.1190)Asn+(-0.1350)His+(0.1092)
Ile+(-0.0537)Leu+(0.1080)Phe; 0.852, 0.880, 0.797, 0.779, 0.761,
0.844, 0.886, 0.817, (3.1454)+(-0.0745)His+(-0.0547)Val+(-0.35
00)Met+(0.0122)Lys+(0.1769)Ile+(0.1281)Phe; 0.852, 0.877, 0.80 4,
0.776, 0.810, 0.847, 0.832, 0.816, (4.9631)+(0.0087)Gln+(-0.10
38)His+(-0.0743)Cit+(0.0301)Orn+(0.0646)Ile+(-0.1374)Trp; 0. 852,
0.876, 0.805, 0.792, 0.780, 0.848, 0.862, 0.820, (6.0536)+(-0.
0476)Val+(-0.2262)Met+(0.0210)Orn+(0.0084)Lys+(0.1759)Ile+(-0.1117)Trp;
0.852, 0.875, 0.794, 0.777, 0.758, 0.843, 0.877, 0.81 4,
(7.3653)+(-0.0580)His+(-0.0071)Ala+(0.0066)Pro+(-0.0320)V
al(0.1483)Ile+(-0.1074)Trp; 0.852, 0.879, 0.763, 0.745, 0.725, 0.
803, 0.859, 0.783, (0.9591)+(0.0391)Ser+(-0.0079)Gly+(-0.0443)
Val+(0.1422)Ile+(0.0645)Phe+(-0.1623)Trp; 0.852, 0.879, 0.810,
0.791, 0.788, 0.860, 0.870, 0.827,
(5.7756)+(0.0039)Gly+(0.0383)Tyr+(-0.0467)Val+(-0.2569)Met+(0.1836)Ile+(--
0.1143)Trp; 0.85 2, 0.881, 0.824, 0.817, 0.814, 0.843, 0.851,
0.831, (3.6460)+(0.009
0)Gln+(-0.1340)His+(-0.0036)Ala+(0.0128)Orn+(0.1016)Phe+(-0.
1170)Trp; 0.852, 0.879, 0.791, 0.783, 0.760, 0.859, 0.824, 0.807,
(3. 3329)+(0.0378)Ser+(-0.0079)Ala+(-0.0279)Arg+(0.1839)Ile+(-0.
0729)Leu+(-0.1355)Trp; 0.852, 0.872, 0.808, 0.791, 0.792, 0.853, 0.
855, 0.823, (5.0919)+(0.0015)Gly+(0.0086)Gln+(-0.1152)His+(-0.
0052)Ala+(0.0749)Ile+(-0.1217)Trp; 0.852, 0.872, 0.794, 0.776, 0.
783, 0.834, 0.835, 0.807, (4.9946)+(0.0071)Gln+(-0.1122)His+(0.
0082)Thr+(0.0973)Ile+(-0.0242)Leu+(-0.1247)Trp; 0.852, 0.880,
0.785, 0.770, 0.793, 0.854, 0.757, 0.793,
(5.2454)+(0.0427)Ser+(-0.0893)His+(0.0128)Pro+(-0.1353)Met+(0.0258)Orn+(--
0.0967)Tr p; 0.852, 0.876, 0.778, 0.763, 0.781, 0.830, 0.772,
0.787,
(1.9164)+(0.0412)Ser+(0.0121)Thr+(0.0039)Pro+(-0.2827)Met+(0.0736)Il
e+(-0.1507)Trp; 0.852, 0.881, 0.814, 0.818, 0.799, 0.842, 0.813, 0.
818, (1.9232)+(0.0435)Ser+(-0.1443)Asn+(0.0099)Thr+(-0.0054)
Ala+(0.1007)Phe+(-0.1471)Trp; 0.852, 0.878, 0.800, 0.784, 0.806,
0.834, 0.804, 0.807, (0.8099)+(-0.0227)Asn+(0.0109)Gln+(-0.171
4)His+(0.0386)Thr+(-0.3481)Met+(0.1501)Phe; 0.852, 0.880, 0.79 5,
0.774, 0.763, 0.843, 0.882, 0.816, (3.5896)+(-0.0679)His+(0.00
29)Pro+(-0.0520)Val+(-0.3232)Met+(0.1738)Ile+(0.1267)Phe; 0. 852,
0.879, 0.808, 0.799, 0.804, 0.826, 0.829, 0.814, (3.1456)+(0.0
021)Gly+(0.0088)Gln+(-0.1388)His+(0.0023)Pro+(0.1017)Phe+(-0.1212)Trp;
0.852, 0.878, 0.811, 0.796, 0.809, 0.828, 0.842, 0.819,
(3.4528)+(0.0091)Gln+(-0.1427)His+(0.0078)Orn+(0.0107)Leu+(0.0876)Phe+(-0-
.1253)Trp; 0.852, 0.879, 0.777, 0.748, 0.784, 0.81 3, 0.816, 0.790,
(5.6002)+(-0.1272)His+(0.0250)Thr+(-0.0200)Va
l+(0.0420)Leu+(0.0955)Phe+(-0.1319)Trp; 0.852, 0.874, 0.820, 0.
806, 0.804, 0.859, 0.866, 0.834, (5.3744)+(-0.0314)Asn+(0.0100)G
ln+(-0.1099)His+(-0.0046)Ala+(0.0719)Ile+(-0.1187)Trp; 0.852,
0.879, 0.819, 0.803, 0.810, 0.853, 0.856, 0.831,
(4.7484)+(0.0105)Gln+(-0.1072)His+(0.0028)Pro+(-0.1402)Met+(0.0718)Ile+(--
0.1 131)Trp; 0.852, 0.884, 0.775, 0.753, 0.784, 0.837, 0.773,
0.787, (2.
0608)+(0.0535)Ser+(-0.1137)His+(-0.0506)Cit+(-0.0114)Arg+(0.
1377)Phe+(-0.1297)Trp; 0.852, 0.882, 0.813, 0.820, 0.804, 0.822, 0.
808, 0.813, (0.9136)+(0.0449)Ser+(-0.1460)Asn+(0.0028)Gln+(-0.
0037)Lys+(0.0930)Phe+(-0.1491)Trp; 0.852, 0.878, 0.811, 0.804, 0.
806, 0.829, 0.831, 0.817, (3.1491)+(0.0022)Gly+(0.0089)Gln+(-0.
1389)His+(0.0001)Lys+(0.1040)Phe+(-0.1199)Trp; 0.852, 0.877, 0.
755, 0.741, 0.719, 0.803, 0.833, 0.774, (0.4912)+(0.0276)Ser+(-0.
0361)Val+(0.1617)Ile+(-0.0281)Leu+(0.0717)Phe+(-0.1623)Trp; 0.852,
0.873, 0.801, 0.782, 0.781, 0.848, 0.857, 0.817, (5.1363)+(0.
0079)Gln+(-0.0813)His+(-0.0542)Cit+(-0.0222)Val+(0.1252)Ile
+(-0.1256)Trp; 0.852, 0.877, 0.797, 0.782, 0.770, 0.825, 0.871, 0.8
12, (3.2245)+(0.0026)Gln+(-0.0878)Cit+(-0.0389)Val+(0.1398)I
le+(0.0798)Phe+(-0.1658)Trp; 0.852, 0.877, 0.762, 0.766, 0.734, 0.
788, 0.792, 0.770, (0.3870)+(0.0286)Ser+(-0.0492)Tyr+(0.1432)I
le+(-0.0761)Leu+(0.0967)Phe+(-0.1513)Trp; 0.852, 0.875, 0.815,
0.803, 0.798, 0.850, 0.854, 0.826, (5.2074)+(-0.0474)Asn+(0.009
6)Gln+(-0.0978)His+(0.1047)Ile+(-0.0303)Leu+(-0.1153)Trp; 0. 852,
0.877, 0.796, 0.769, 0.800, 0.836, 0.832, 0.809, (1.3947)+(0.0
575)Ser+(-0.0061)Gly+(0.0278)Tyr+(-0.2791)Met+(0.0783)Ile+(-0.1559)Trp;
0.852, 0.873, 0.790, 0.766, 0.779, 0.842, 0.841, 0.80 7,
(7.4444)+(-0.1007)His+(0.0196)Thr+(-0.0064)Ala+(0.0028)Pr
o+(0.0730)Ile+(-0.1269)Trp; 0.852, 0.876, 0.784, 0.754, 0.776, 0.
843, 0.835, 0.802, (6.9960)+(-0.0578)His+(-0.0728)Cit+(-0.031
0)Val+(0.0466)Orn+(0.1347)Ile+(-0.1209)Trp; 0.852, 0.878, 0.79 7,
0.782, 0.803, 0.831, 0.800, 0.804, (0.6370)+(0.0106)Gln+(-0.17
44)His+(0.0392)Thr+(-0.3678)Met+(-0.0054)Orn+(0.1546)Phe; 0. 852,
0.879, 0.791, 0.771, 0.797, 0.844, 0.793, 0.801, (3.9162)+(0.0
465)Ser+(-0.0915)Asn+(-0.0822)Cit+(-0.0002)Arg+(0.0699)Ile+(-0.1634)Trp;
0.852, 0.877, 0.798, 0.788, 0.809, 0.833, 0.774, 0.80 1,
(0.6978)+(0.0125)Gln+(-0.1732)His+(0.0460)Thr+(-0.0267)Ar
g+(-0.3707)Met+(0.1570)Phe; 0.852, 0.877, 0.779, 0.764, 0.783, 0.
832, 0.775, 0.788, (2.0330)+(0.0403)Ser+(0.0138)Thr+(-0.2739)M
et+(-0.0048)Orn+(0.0800)Ile+(-0.1513)Trp; 0.852, 0.876, 0.792,
0.776, 0.778, 0.850, 0.821, 0.806, (2.0378)+(0.0455)Ser+(-0.005
1)Ala+(-0.1965)Met+(-0.0034)Lys+(0.0891)Ile+(-0.1389)Trp; 0. 852,
0.880, 0.791, 0.770, 0.798, 0.845, 0.796, 0.802, (3.8552)+(0.0
468)Ser+(-0.0941)Asn+(-0.0835)Cit+(0.0047)Tyr+(0.0695)Ile+(-0.1656)Trp;
0.852, 0.876, 0.818, 0.814, 0.783, 0.860, 0.873, 0.83 3,
(4.9377)+(0.0050)Gln+(-0.0373)Val+(-0.2160)Met+(0.1805)Il
e+(-0.0146)Leu+(-0.1124)Trp; 0.852, 0.879, 0.819, 0.804, 0.835, 0.
849, 0.801, 0.823, (4.3746)+(0.0057)Gln+(0.0253)Thr+(-0.0817)C
it+(-0.2352)Met+(0.0731)Ile+(-0.1647)Trp; 0.852, 0.880, 0.785,
0.764, 0.795, 0.812, 0.797, 0.792, (5.3883)+(0.0021)Gly+(-0.125
7)His+(0.0224)Thr+(-0.0028)Lys+(0.1072)Phe+(-0.1249)Trp; 0.8 52,
0.881, 0.775, 0.748, 0.758, 0.865, 0.815, 0.796, (1.2623)+(0.04
12)Ser+(0.0060)Gln+(-0.1237)His+(-0.2381)Met+(0.1300)Ile+(-0.0348)Leu;
0.852, 0.879, 0.767, 0.736, 0.776, 0.838, 0.777, 0.782,
(-0.4055)+(0.0610)Ser+(-0.0015)Gly+(-0.1489)His+(-0.2792)Me
t+(0.0138)Orn+(0.1556)Phe; 0.852, 0.879, 0.823, 0.821, 0.845, 0.8
23, 0.778, 0.817, (3.9070)+(0.0434)Thr+(-0.0031)Ala+(-0.0843)C
it+(-0.3053)Met+(0.1543)Phe+(-0.1708)Trp; 0.852, 0.876, 0.806,
0.797, 0.775, 0.849, 0.862, 0.821, (5.9610)+(0.0023)Gly+(-0.046
3)Val+(-0.2302)Met+(0.0112)Lys+(0.1788)Ile+(-0.1132)Trp; 0.8 52,
0.876, 0.761, 0.722, 0.761, 0.829, 0.813, 0.781, (3.9413)+(0.04
79)Ser+(-0.0042)Gly+(-0.1096)His+(0.0012)Pro+(0.0732)Ile+(-0.1246)Trp;
0.852, 0.881, 0.797, 0.777, 0.774, 0.827, 0.875, 0.813,
(4.4418)+(-0.0828)Cit+(-0.0391)Val+(-0.0083)Lys+(0.1468)Ile
+(0.0897)Phe+(-0.1526)Trp; 0.852, 0.876, 0.787, 0.773, 0.785, 0.8
35, 0.795, 0.797, (2.3472)+(0.0493)Ser+(-0.0490)Asn+(0.0049)Pr
o+(-0.2083)Met+(0.0706)Ile+(-0.1424)Trp; 0.852, 0.875, 0.815, 0.
803, 0.773, 0.864, 0.896, 0.834,
(7.5019)+(-0.0309)Asn+(-0.0069)Ala+(-0.0582)Cit+(-0.0383)Val+(0.1722)Ile+-
(-0.1194)Trp; 0.85 2, 0.879, 0.823, 0.807, 0.814, 0.856, 0.860,
0.834, (4.8460)+(-0.00
99)Asn+(0.0108)Gln+(-0.1066)His+(-0.1262)Met+(0.0737)Ile+(-0.1124)Trp;
0.852, 0.879, 0.808, 0.797, 0.805, 0.831, 0.829, 0.815,
(3.2440)+(0.0020)Gly+(0.0085)Gln+(-0.1395)His+(0.0098)Orn+(0.0992)Phe+(-0-
.1195)Trp; 0.852, 0.873, 0.789, 0.763, 0.782, 0.83 9, 0.835, 0.805,
(7.3684)+(-0.1059)His+(0.0183)Thr+(-0.0060)Al
a+(0.0163)Orn+(0.0713)Ile+(-0.1264)Trp; 0.852, 0.876, 0.768, 0.
743, 0.775, 0.835, 0.770, 0.781,
(-0.3541)+(0.0601)Ser+(-0.1466)His+(0.0001)Ala+(-0.0006)Val+(-0.2801)Met+-
(0.1633)Phe; 0.852, 0.875, 0.800, 0.778, 0.799, 0.847, 0.829,
0.813,
(4.5386)+(0.0039)Gly+(0.0092)Gln+(-0.1055)His+(-0.0620)Cit+(0.0754)Ile+(--
0.1 355)Trp; 0.852, 0.879, 0.783, 0.756, 0.743, 0.891, 0.856,
0.812, (1.
5799)+(0.0508)Ser+(-0.0815)Asn+(0.0362)Tyr+(-0.0607)Val+(-0.
3299)Met+(0.2119)Ile; 0.852, 0.875, 0.791, 0.772, 0.787, 0.833, 0.
822, 0.803,
(2.0568)+(0.0559)Ser+(-0.0066)Gly+(-0.2220)Met+(-0.0032)Lys+(0.079-
4)Ile+(-0.1451)Trp; 0.852, 0.875, 0.754, 0.718, 0.756, 0.830,
0.793, 0.774,
(3.9426)+(0.0401)Ser+(-0.1143)His+(0.0033)Thr+(0.0002)Pro+(0.0746)-
Ile+(-0.1241)Trp; 0.852, 0.87 6, 0.816, 0.807, 0.783, 0.855, 0.877,
0.831, (6.7732)+(-0.0293)Asn
+(-0.0472)Val+(-0.2023)Met+(0.0130)Lys+(0.1772)Ile+(-0.109 6)Trp;
0.852, 0.873, 0.806, 0.792, 0.781, 0.850, 0.861, 0.821, (6.78
59)+(-0.0303)Asn+(-0.0466)Val+(-0.1775)Met+(0.0287)Orn+(0.1
739)Ile+(-0.1025)Trp; 0.852, 0.871, 0.800, 0.786, 0.764, 0.849, 0.
878, 0.819,
(7.6985)+(-0.0179)Asn+(-0.0532)His+(-0.0053)Ala+(-0.0328)Val+(0.15-
41)Ile+(-0.1033)Trp; 0.852, 0.879, 0.768, 0.7 41, 0.778, 0.838,
0.770, 0.782, (-0.1745)+(0.0615)Ser+(-0.0340)A
sn+(-0.1450)His+(-0.2560)Met+(0.0135)Orn+(0.1559)Phe; 0.852, 0.877,
0.793, 0.781, 0.797, 0.827, 0.793, 0.799, (0.7834)+(0.0101)
Gln+(-0.1708)His+(0.0391)Thr+(-0.0172)Tyr+(-0.3430)Met+(0.1
564)Phe; 0.852, 0.878, 0.771, 0.748, 0.777, 0.838, 0.775, 0.784,
(-0.
0644)+(0.0625)Ser+(-0.0332)Asn+(-0.1421)His+(-0.0003)Ala+(-0.2542)Met+(0.-
1614)Phe; 0.852, 0.874, 0.798, 0.787, 0.750, 0.885, 0.865, 0.822,
(5.2881)+(-0.0564)Asn+(0.0341)Thr+(-0.0049)Ala+(-0.0600)Val+(-0.3106)Met+-
(0.2147)Ile; 0.852, 0.880, 0.773, 0.7 59, 0.750, 0.796, 0.841,
0.786, (0.4540)+(0.0398)Ser+(-0.0085)Gl
y+(0.1380)Ile+(-0.0723)Leu+(0.0645)Phe+(-0.1674)Trp; 0.852, 0. 879,
0.814, 0.802, 0.812, 0.831, 0.840, 0.821, (3.4315)+(0.0090)Gl
n+(-0.1396)His+(0.0015)Val+(0.0094)Orn+(0.0948)Phe+(-0.121 0)Trp;
0.852, 0.879, 0.813, 0.802, 0.773, 0.861, 0.893, 0.832, (-0.4
061)+(0.0067)Gln+(-0.0587)Cit+(-0.0616)Val+(-0.4239)Met+(0.
1981)Ile+(0.1297)Phe; 0.852, 0.873, 0.788, 0.766, 0.768, 0.835, 0.
850, 0.805,
(7.3995)+(-0.0418)Asn+(-0.0643)His+(-0.0341)Val+(0.0297)Orn+(0.137-
8)Ile+(-0.1024)Trp; 0.852, 0.879, 0.793, 0.78 7, 0.760, 0.816,
0.864, 0.807, (4.2104)+(-0.0802)Cit+(-0.0345)Ty
r+(-0.0405)Val+(0.1468)Ile+(0.1029)Phe+(-0.1473)Trp; 0.852, 0. 878,
0.811, 0.798, 0.802, 0.831, 0.852, 0.821, (3.5271)+(0.0091)Gl
n+(-0.1383)His+(-0.0119)Val+(0.0302)Leu+(0.0917)Phe+(-0.124 7)Trp;
0.852, 0.882, 0.818, 0.828, 0.813, 0.824, 0.795, 0.815, (0.91
68)+(0.0459)Ser+(-0.1370)Asn+(0.0035)Gln+(-0.0190)Arg+(0.09
65)Phe+(-0.1512)Trp; 0.852, 0.873, 0.806, 0.805, 0.798, 0.855, 0.7
92, 0.812, (4.6410)+(0.0370)Ser+(-0.0852)Asn+(0.0080)Gln+(-0.
1015)His+(0.0097)Pro+(-0.0994)Trp; 0.852, 0.875, 0.800, 0.793, 0.
778, 0.852, 0.828, 0.813, (2.9510)+(0.0376)Ser+(-0.1224)Asn+(0.
0031)Gln+(0.1383)Ile+(-0.0580)Leu+(-0.1368)Trp; 0.852, 0.883,
0.798, 0.779, 0.800, 0.829, 0.820, 0.807,
(5.7516)+(-0.1216)His+(0.0224)Thr+(-0.0042)Ala+(0.0134)Orn+(0.1049)Phe+(--
0.1251)T rp; 0.851, 0.878, 0.787, 0.770, 0.815, 0.826, 0.745,
0.789, (2.0021)
+(0.0389)Ser+(-0.1405)Cit+(0.0490)Orn+(-0.0184)Lys+(0.1042)Phe+(-
-0.1758)Trp; 0.851, 0.879, 0.762, 0.735, 0.745, 0.845, 0.810,
0.784, (4.4039)+(0.0428)Ser+(-0.0811)His+(-0.0219)Arg+(-0.02
71)Val+(0.1440)Ile+(-0.1118)Trp; 0.851, 0.877, 0.772, 0.751, 0.7
77, 0.839, 0.773, 0.785, (-0.0102)+(0.0625)Ser+(-0.0367)Asn+(-0.
1396)His+(-0.0020)Val+(-0.2513)Met+(0.1643)Phe; 0.851, 0.881,
0.811, 0.794, 0.789, 0.852, 0.873, 0.827,
(7.1486)+(-0.0460)Cit+(0.0055)Pro+(-0.0406)Val+(-0.1585)Met+(0.1664)Ile+(-
-0.1138)Trp; 0.851, 0.875, 0.796, 0.787, 0.752, 0.847, 0.871,
0.814, (1.980
7)+(-0.0542)Asn+(0.0051)Gly+(-0.0650)Val+(-0.3525)Met+(0.20
17)Ile+(0.1246)Phe; 0.851, 0.876, 0.779, 0.764, 0.781, 0.835, 0.77
2, 0.788, (2.1648)+(0.0408)Ser+(0.0145)Thr+(-0.2629)Met+(-0.0
055)Lys+(0.0807)Ile+(-0.1477)Trp; 0.851, 0.888, 0.783, 0.773, 0.
738, 0.854, 0.849, 0.804,
(-4.0834)+(0.0480)Ser+(-0.0079)Ala+(-0.3698)Met+(0.1997)Ile+(-0.0977)Leu+-
(0.1268)Phe; 0.851, 0.877, 0.809, 0.794, 0.779, 0.854, 0.883,
0.827,
(7.6850)+(-0.0422)His+(-0.0038)Ala+(-0.0359)Val+(-0.1162)Met+(0.1687)Ile+-
(-0.094 3)Trp; 0.851, 0.879, 0.780, 0.750, 0.795, 0.808, 0.808,
0.790, (5.55
69)+(-0.1309)His+(0.0213)Thr+(0.0102)Orn+(0.0100)Leu+(0.089
8)Phe+(-0.1327)Trp; 0.851, 0.870, 0.791, 0.770, 0.787, 0.829, 0.82
7, 0.803, (5.0167)+(0.0004)Gly+(0.0074)Gln+(-0.1265)His+(0.01
06)Thr+(0.0640)Ile+(-0.1293)Trp; 0.851, 0.879, 0.780, 0.755, 0.7
56, 0.885, 0.818, 0.803, (1.6919)+(0.0391)Ser+(-0.0696)Cit+(-0.
0527)Val+(-0.3268)Met+(0.0328)Orn+(0.1885)Ile; 0.851, 0.879, 0.
794, 0.772, 0.798, 0.842, 0.807, 0.805, (3.9604)+(0.0498)Ser+(-0.
0904)Asn+(-0.0025)Gly+(-0.0784)Cit+(0.0687)Ile+(-0.1634)Tr p;
0.851, 0.874, 0.814, 0.809, 0.792, 0.858, 0.842, 0.825,
(6.0479)+(0.0216)Thr+(-0.0062)Ala+(-0.1864)Met+(0.1574)Ile+(-0.0579)Leu+(-
-0.1307)Trp; 0.851, 0.877, 0.830, 0.823, 0.817, 0.866, 0.850,
0.839, (4.2629)+(0.0076)Gln+(-0.0721)Cit+(-0.1497)Met+(0.156
2)Ile+(-0.0593)Leu+(-0.1396)Trp; 0.851, 0.878, 0.796, 0.779, 0.8
03, 0.830, 0.799, 0.803, (0.6681)+(0.0104)Gln+(-0.1742)His+(0.0
382)Thr+(-0.0001)Ala+(-0.3632)Met+(0.1519)Phe; 0.851, 0.871, 0.
793, 0.783, 0.744, 0.878, 0.862, 0.817, (4.2961)+(-0.0004)Gly+(0.
0317)Thr+(-0.0054)Ala+(-0.0588)Val+(-0.3584)Met+(0.2143)Il e;
0.851, 0.883, 0.766, 0.753, 0.748, 0.803, 0.811, 0.778,
(0.3092)+(0.0331)Ser+(-0.0136)Lys+(0.1358)Ile+(-0.0650)Leu+(0.0741)P
he+(-0.1596)Trp; 0.851, 0.880, 0.783, 0.766, 0.757, 0.830, 0.848,
0. 800,
(0.4951)+(0.0384)Ser+(-0.0098)Ala+(-0.0168)Lys+(0.0710)Ile+(0.0694)Phe+(--
0.1642)Trp; 0.851, 0.882, 0.795, 0.771, 0.796, 0.831, 0.827, 0.806,
(5.8685)+(-0.1258)His+(0.0249)Thr+(-0.004
8)Ala+(0.0143)Leu+(0.0990)Phe+(-0.1330)Trp; 0.851, 0.877, 0.76 5,
0.748, 0.727, 0.874, 0.813, 0.791, (1.7317)+(0.0344)Ser+(-0.00
13)Gln+(0.0219)Thr+(-0.0587)Val+(-0.4059)Met+(0.2130)Ile; 0. 851,
0.877, 0.817, 0.803, 0.820, 0.857, 0.818, 0.825, (6.5034)+(0.0
293)Thr+(-0.0066)Ala+(-0.0787)Cit+(-0.1750)Met+(0.0828)Ile+(-0.1511)Trp;
0.851, 0.877, 0.799, 0.782, 0.792, 0.836, 0.831, 0.81 0,
(1.4012)+(0.0531)Ser+(-0.0070)Gly+(0.0024)Gln+(-0.2424)Me
t+(0.0768)Ile+(-0.1501)Trp; 0.851, 0.880, 0.799, 0.801, 0.796, 0.
817, 0.788, 0.800, (1.7343)+(0.0447)Ser+(-0.1437)Asn+(0.0082)T
hr+(-0.0051)Lys+(0.0941)Phe+(-0.1497)Trp; 0.851, 0.875, 0.806,
0.796, 0.764, 0.851, 0.889, 0.825, (-0.0565)+(0.0044)Gln+(-0.063
9)Val+(-0.4315)Met+(0.0049)Orn+(0.1988)Ile+(0.1210)Phe; 0.85 1,
0.880, 0.815, 0.804, 0.813, 0.833, 0.839, 0.822, (3.4671)+(0.008
9)Gln+(-0.1378)His+(0.0107)Orn+(-0.0008)Lys+(0.0970)Phe+(-0.
1189)Trp; 0.851, 0.879, 0.786, 0.763, 0.798, 0.812, 0.805, 0.795,
(5. 5054)+(-0.1253)His+(0.0208)Thr+(-0.0013)Val+(0.0127)Orn+(0.
0999)Phe+(-0.1259)Trp; 0.851, 0.878, 0.782, 0.754, 0.797, 0.808, 0.
810, 0.792, (5.6269)+(-0.1303)His+(0.0232)Thr+(-0.0007)Pro+(0.
0113)Leu+(0.0938)Phe+(-0.1337)Trp; 0.851, 0.877, 0.761, 0.721, 0.
763, 0.833, 0.814, 0.783, (3.9640)+(0.0465)Ser+(-0.0041)Gly+(-0.
1125)His+(0.0105)Orn+(0.0717)Ile+(-0.1244)Trp; 0.851, 0.875, 0.
815, 0.805, 0.776, 0.858, 0.890, 0.832, (6.9793)+(-0.0083)Asn+(-0.
0047)Ala+(-0.0430)Val+(-0.1454)Met+(0.1826)Ile+(-0.1040)Tr p;
0.851, 0.873, 0.816, 0.821, 0.808, 0.868, 0.786, 0.821,
(5.4461)+(0.0299)Ser+(-0.0887)Asn+(0.0080)Gln+(-0.1021)His+(0.0132)T
hr+(-0.1009)Trp; 0.851, 0.873, 0.791, 0.781, 0.794, 0.854, 0.768,
0. 799,
(5.8291)+(0.0466)Ser+(-0.0335)Asn+(-0.0781)His+(0.0141)Pro+(-0.1006)Met+(-
-0.0962)Trp; 0.851, 0.871, 0.783, 0.764, 0.762, 0.831, 0.841,
0.799, (5.3017)+(0.0054)Gln+(-0.0992)His+(0.010
6)Thr+(-0.0234)Val+(0.1197)Ile+(-0.1201)Trp; 0.851, 0.881, 0.8 21,
0.818, 0.814, 0.841, 0.826, 0.825, (3.0865)+(0.0029)Gly+(0.01
12)Gln+(-0.1395)His+(-0.0212)Arg+(0.1112)Phe+(-0.1170)Trp; 0. 851,
0.881, 0.824, 0.820, 0.820, 0.834, 0.838, 0.828, (3.3690)+(0.0
116)Gln+(-0.1376)His+(-0.0211)Arg+(0.0036)Pro+(0.1040)Phe+(-0.1189)Trp;
0.851, 0.876, 0.758, 0.723, 0.763, 0.832, 0.786, 0.77 6,
(4.1042)+(0.0462)Ser+(-0.1074)His+(-0.0167)Arg+(0.0022)Pr
o+(0.0766)Ile+(-0.1218)Trp; 0.851, 0.873, 0.791, 0.768, 0.780, 0.
843, 0.839, 0.808,
(7.5912)+(-0.1003)His+(0.0213)Thr+(-0.0058)Ala+(-0.0026)Lys+(0.0766)Ile+(-
-0.1258)Trp; 0.851, 0.875, 0.805, 0.795, 0.762, 0.849, 0.887,
0.823, (-0.0824)+(0.0046)Gln+(0.002
2)Pro+(-0.0636)Val+(-0.4385)Met+(0.1972)Ile+(0.1225)Phe; 0.8 51,
0.880, 0.782, 0.760, 0.792, 0.810, 0.798, 0.790, (5.2454)+(0.00
22)Gly+(-0.1267)His+(0.0209)Thr+(0.0006)Pro+(0.1046)Phe+(-0.
1263)Trp; 0.851, 0.874, 0.805, 0.799, 0.760, 0.848, 0.885, 0.823,
(-0.2290)+(0.0047)Gln+(-0.0552)Val+(-0.4250)Met+(0.2188)Ile+(-0.0279)Leu+-
(0.1251)Phe; 0.851, 0.876, 0.780, 0.766, 0.789, 0.83 6, 0.757,
0.787,
(2.4262)+(0.0414)Ser+(0.0179)Thr+(-0.0170)Arg
+(-0.2644)Met+(0.0788)Ile+(-0.1496)Trp; 0.851, 0.873, 0.813, 0.
793, 0.798, 0.854, 0.867, 0.828, (5.1283)+(0.0090)Gln+(-0.1180)H
is+(-0.0058)Ala+(0.0126)Tyr+(0.0737)Ile+(-0.1270)Trp; 0.851, 0.877,
0.755, 0.738, 0.720, 0.799, 0.837, 0.774,
(0.5779)+(0.0291)Ser+(-0.0439)Val+(-0.0092)Orn+(0.1428)Ile+(0.0747)Phe+(--
0.1 692)Trp; 0.851, 0.873, 0.813, 0.796, 0.797, 0.853, 0.861,
0.827, (5.
2317)+(0.0090)Gln+(-0.1137)His+(-0.0051)Ala+(-0.0012)Lys+(0.
0748)Ile+(-0.1214)Trp; 0.851, 0.880, 0.781, 0.757, 0.792, 0.811, 0.
797, 0.789, (5.2102)+(0.0021)Gly+(-0.1283)His+(0.0194)Thr+(0.
0117)Orn+(0.1001)Phe+(-0.1254)Trp; 0.851, 0.874, 0.809, 0.805, 0.
794, 0.817, 0.846, 0.816, (4.3123)+(-0.0885)Asn+(0.0106)Thr+(0.
1282)Ile+(-0.0692)Leu+(0.0732)Phe+(-0.1469)Trp; 0.851, 0.876,
0.792, 0.766, 0.792, 0.845, 0.823, 0.806,
(7.1411)+(-0.0729)His+(0.0167)Thr+(-0.0534)Cit+(0.1111)Ile+(-0.0310)Leu+(-
-0.1311)Trp; 0.851, 0.875, 0.742, 0.710, 0.695, 0.849, 0.849,
0.776, (0.446
9)+(0.0407)Ser+(-0.1301)His+(-0.0082)Ala+(-0.0306)Val+(0.12
15)Ile+(0.0814)Phe; 0.851, 0.880, 0.810, 0.785, 0.794, 0.855, 0.87
8, 0.828, (7.3511)+(-0.0459)His+(0.0320)Tyr+(-0.0383)Val+(-0.
1833)Met+(0.1663)Ile+(-0.1019)Trp; 0.851, 0.877, 0.769, 0.742, 0.
776, 0.835, 0.775, 0.782,
(-0.3309)+(0.0615)Ser+(-0.0011)Gly+(-0.1463)His+(0.0000)Ala+(-0.2791)Met+-
(0.1613)Phe; 0.851, 0.880, 0.814, 0.795, 0.790, 0.853, 0.883,
0.830, (6.3936)+(0.0032)Pro+(0.
0306)Tyr+(-0.0459)Val+(-0.2384)Met+(0.1768)Ile+(-0.1129)Tr p;
0.851, 0.881, 0.784, 0.771, 0.775, 0.818, 0.813, 0.794,
(0.9148)+(0.0494)Ser+(-0.1255)Asn+(-0.0095)Lys+(0.0479)Ile+(0.0732)P
he+(-0.1565)Trp; 0.851, 0.878, 0.780, 0.769, 0.784, 0.796, 0.791,
0. 785,
(5.5484)+(-0.1228)His+(0.0272)Thr+(-0.0349)Tyr+(0.0006)Val+(0.1206)Phe+(--
0.1197)Trp; 0.851, 0.872, 0.794, 0.773, 0.789, 0.830, 0.831, 0.806,
(5.2285)+(0.0077)Gln+(-0.1239)His+(0.012
6)Thr+(-0.0055)Lys+(0.0669)Ile+(-0.1273)Trp; 0.851, 0.880, 0.7 86,
0.768, 0.748, 0.886, 0.839, 0.810, (2.7468)+(0.0476)Ser+(-0.0
793)Asn+(-0.0445)Cit+(-0.0519)Val+(-0.2464)Met+(0.1946)Ile; 0.851,
0.875, 0.833, 0.828, 0.814, 0.868, 0.860, 0.843,
(4.8479)+(-0.0763)Asn+(0.0085)Gln+(-0.0834)Cit+(0.1455)Ile+(-0.0584)Le
u+(-0.1487)Trp; 0.851, 0.871, 0.791, 0.778, 0.754, 0.844, 0.864, 0.
810, (7.0906)+(0.0024)Gly+(-0.0624)His+(-0.0056)Ala+(-0.030
4)Val+(0.1505)Ile+(-0.1068)Trp; 0.851, 0.878, 0.814, 0.813, 0.84 5,
0.807, 0.759, 0.806, (3.7261)+(0.0437)Thr+(-0.0850)Cit+(-0.0
065)Tyr+(-0.3192)Met+(0.1540)Phe+(-0.1719)Trp; 0.851, 0.878, 0.
761, 0.729, 0.772, 0.832, 0.772, 0.776, (-0.6177)+(0.0618)Ser+(-0.
1521)His+(-0.0036)Tyr+(-0.2930)Met+(0.0137)Leu+(0.1524)Phe; 0.851,
0.876, 0.756, 0.717, 0.759, 0.833, 0.794, 0.776, (3.9180)+(0.
0395)Ser+(-0.1163)His+(0.0021)Thr+(0.0094)Orn+(0.0725)Ile+(-0.1240)Trp;
0.851, 0.875, 0.768, 0.737, 0.782, 0.797, 0.800, 0.77 9,
(0.6560)+(0.0427)Ser+(-0.0028)Gly+(-0.1095)Cit+(0.0543)Il
e+(0.0736)Phe+(-0.2055)Trp; 0.851, 0.874, 0.805, 0.796, 0.761, 0.
857, 0.883, 0.824, (6.8920)+(-0.0692)Asn+(-0.0067)Ala+(-0.045
0)Val+(0.0271)Orn+(0.1680)Ile+(-0.1099)Trp; 0.851, 0.874, 0.81 4,
0.805, 0.776, 0.856, 0.886, 0.831, (6.8277)+(-0.0049)Ala+(-0.0
383)Val+(-0.1479)Met+(0.1921)Ile+(-0.0143)Leu+(-0.1044)Trp; 0.851,
0.878, 0.764, 0.734, 0.777, 0.834, 0.766, 0.778,
(-0.5475)+(0.0641)Ser+(-0.1493)His+(-0.0106)Arg+(-0.2849)Met+(0.0127)Leu+-
(0.1540)Phe; 0.851, 0.876, 0.809, 0.799, 0.758, 0.859, 0.907, 0.
831, (2.5979)+(-0.0349)Asn+(-0.0047)Ala+(-0.0632)Val+(-0.317
9)Met+(0.2059)Ile+(0.1191)Phe; 0.851, 0.874, 0.812, 0.791, 0.808,
0.847, 0.852, 0.825, (4.9215)+(0.0105)Gln+(-0.1017)His+(-0.058
7)Cit+(-0.0051)Lys+(0.0764)Ile+(-0.1325)Trp; 0.851, 0.871, 0.7 88,
0.765, 0.775, 0.841, 0.833, 0.804, (7.2283)+(0.0018)Gly+(-0.1
031)His+(0.0189)Thr+(-0.0058)Ala+(0.0762)Ile+(-0.1254)Trp; 0. 851,
0.878, 0.817, 0.799, 0.811, 0.854, 0.852, 0.829, (4.8284)+(0.0
100)Gln+(-0.1091)His+(-0.1330)Met+(0.0094)Orn+(0.0716)Ile+(-0.1126)Trp;
0.851, 0.882, 0.807, 0.813, 0.800, 0.812, 0.800, 0.80 6,
(1.0933)+(0.0426)Ser+(-0.1601)Asn+(0.0025)Gln+(0.0055)Thr
+(0.0897)Phe+(-0.1540)Trp; 0.851, 0.882, 0.799, 0.786, 0.816, 0.7
83, 0.806, 0.798, (2.3486)+(0.0402)Thr+(-0.3781)Met+(-0.0258)O
rn+(0.0577)Ile+(0.1213)Phe+(-0.1712)Trp; 0.851, 0.877, 0.817, 0.
798, 0.794, 0.858, 0.885, 0.834, (6.5750)+(-0.0108)Asn+(0.0321)T
yr+(-0.0457)Val+(-0.2222)Met+(0.1791)Ile+(-0.1118)Trp; 0.851,
0.870, 0.788, 0.775, 0.755, 0.878, 0.824, 0.808,
(4.4898)+(0.0015)Gly+(0.0335)Thr+(-0.0572)Cit+(-0.0577)Val+(-0.3796)Met+(-
0.2 061)Ile; 0.851, 0.874, 0.809, 0.790, 0.795, 0.852, 0.858,
0.824, (5.
2890)+(0.0084)Gln+(-0.1162)His+(-0.0054)Ala+(0.0119)Orn+(0.
0709)Ile+(-0.1221)Trp; 0.851, 0.874, 0.795, 0.772, 0.785, 0.845, 0.
842, 0.811,
(7.7870)+(-0.0216)Asn+(-0.0979)His+(0.0227)Thr+(-0.0056)Ala+(0.073-
8)Ile+(-0.1252)Trp; 0.851, 0.877, 0.820, 0.803, 0.812, 0.850,
0.858, 0.831,
(4.6917)+(0.0103)Gln+(-0.1097)His+(-0.1439)Met+(0.0044)Lys+(0.0727-
)Ile+(-0.1143)Trp; 0.851, 0.8 75, 0.757, 0.720, 0.758, 0.833,
0.797, 0.777, (3.9599)+(0.0428)Ser
+(-0.1086)His+(0.0008)Pro+(-0.0047)Lys+(0.0779)Ile+(-0.119 6)Trp;
0.851, 0.870, 0.795, 0.780, 0.759, 0.845, 0.872, 0.814, (7.25
63)+(-0.0621)His+(-0.0057)Ala+(-0.0315)Val+(0.0041)Lys+(0.1
498)Ile+(-0.1093)Trp; 0.851, 0.876, 0.758, 0.742, 0.724, 0.803, 0.
838, 0.777, (0.6936)+(0.0274)Ser+(-0.0029)Pro+(-0.0442)Val+(0.
1442)Ile+(0.0707)Phe+(-0.1660)Trp; 0.851, 0.878, 0.824, 0.825, 0.
800, 0.831, 0.864, 0.830, (3.0094)+(-0.0979)Asn+(0.0053)Gln+(0.
1337)Ile+(-0.0717)Leu+(0.0707)Phe+(-0.1472)Trp; 0.851, 0.878,
0.778, 0.766, 0.783, 0.798, 0.786, 0.783,
(5.4138)+(0.0009)Gly+(-0.1233)His+(0.0265)Thr+(-0.0335)Tyr+(0.1213)Phe+(--
0.1187)Tr p; 0.851, 0.880, 0.827, 0.823, 0.822, 0.837, 0.839,
0.830,
(3.3666)+(0.0118)Gln+(-0.1392)His+(-0.0201)Arg+(0.0018)Val+(0.1041)P
he+(-0.1185)Trp; 0.851, 0.876, 0.792, 0.776, 0.779, 0.849, 0.819,
0. 806,
(1.9068)+(0.0444)Ser+(-0.0052)Ala+(-0.2068)Met+(0.0033)Orn+(0.0860)Ile+(--
0.1415)Trp; 0.850, 0.873, 0.804, 0.788, 0.770, 0.854, 0.881, 0.823,
(7.7361)+(-0.0414)His+(-0.0062)Ala+(-0.04
80)Cit+(-0.0317)Val+(0.1599)Ile+(-0.1121)Trp; 0.850, 0.879, 0. 769,
0.740, 0.745, 0.869, 0.821, 0.794, (2.9195)+(0.0484)Ser+(-0.
0788)His+(-0.0086)Arg+(-0.0371)Val+(-0.2499)Met+(0.1714)Il e;
0.850, 0.877, 0.772, 0.748, 0.779, 0.836, 0.778, 0.785, (-0.0697)
+(0.0637)Ser+(-0.0323)Asn+(-0.0009)Gly+(-0.1417)His+(-0.256
0)Met+(0.1605)Phe; 0.850, 0.883, 0.806, 0.800, 0.817, 0.798, 0.805,
0.805, (0.9631)+(0.0040)Gln+(0.0320)Thr+(-0.3834)Met+(0.049
7)Ile+(0.1063)Phe+(-0.1683)Trp; 0.850, 0.880, 0.825, 0.822, 0.79 0,
0.851, 0.886, 0.837, (4.5654)+(-0.0476)Asn+(-0.0086)Ala+(0.1
569)Ile+(-0.0762)Leu+(0.0802)Phe+(-0.1352)Trp; 0.850, 0.879, 0.
813, 0.801, 0.784, 0.855, 0.872, 0.828, (6.7508)+(-0.0406)Cit+(-0.
0431)Val+(-0.1861)Met+(0.0096)Lys+(0.1734)Ile+(-0.1157)Trp; 0.850,
0.876, 0.767, 0.742, 0.776, 0.835, 0.770, 0.781,
(-0.3597)+(0.0602)Ser+(-0.1472)His+(-0.0000)Ala+(-0.2799)Met+(-0.000
1)Lys+(0.1624)Phe; 0.850, 0.883, 0.833, 0.841, 0.847, 0.812, 0.799,
0.825, (1.8994)+(-0.0663)Asn+(0.0060)Gln+(0.0361)Thr+(-0.319
2)Met+(0.1275)Phe+(-0.1595)Trp; 0.850, 0.878, 0.802, 0.790, 0.75 2,
0.855, 0.900, 0.824, (1.7946)+(-0.0050)Ala+(-0.0633)Val+(-0.
3537)Met+(0.0134)Orn+(0.2046)Ile+(0.1127)Phe; 0.850, 0.874, 0. 762,
0.732, 0.780, 0.799, 0.781, 0.773, (0.5142)+(0.0392)Ser+(-0.
1143)Cit+(0.0007)Pro+(0.0547)Ile+(0.0743)Phe+(-0.2063)Trp; 0. 850,
0.874, 0.810, 0.803, 0.809, 0.857, 0.800, 0.817, (4.2182)+(0.0
364)Ser+(-0.0703)Asn+(0.0087)Gln+(-0.1175)His+(0.0116)Val+(-0.1084)Trp;
0.850, 0.871, 0.818, 0.813, 0.834, 0.874, 0.755, 0.81 9,
(6.1616)+(0.0395)Ser+(-0.0954)Asn+(-0.0032)Ala+(-0.1138)C
it+(0.0591)Orn+(-0.1351)Trp; 0.850, 0.880, 0.812, 0.799, 0.810, 0.
828, 0.839, 0.819, (3.4320)+(0.0088)Gln+(-0.1381)His+(0.0019)P
ro+(0.0094)Orn+(0.0952)Phe+(-0.1206)Trp; 0.850, 0.879, 0.805, 0.
781, 0.793, 0.836, 0.874, 0.821,
(6.0874)+(-0.1021)His+(-0.0069)Ala+(0.0039)Pro+(0.0559)Ile+(0.0809)Phe+(--
0.1266)Trp; 0.850, 0.878, 0.771, 0.742, 0.748, 0.866, 0.824, 0.795,
(2.5498)+(0.0480)Ser+(-0.1025)His+(-0.0053)Ala+(-0.1954)Met+(0.1464)Ile+(-
-0. 0392)Leu; 0.850, 0.876, 0.800, 0.791, 0.793, 0.843, 0.812,
0.810, (1.
7097)+(0.0452)Ser+(-0.0637)Asn+(0.0036)Gln+(-0.1980)Met+(0.
0746)Ile+(-0.1454)Trp; 0.850, 0.881, 0.815, 0.820, 0.797, 0.843, 0.
820, 0.820, (1.6419)+(0.0464)Ser+(-0.1343)Asn+(-0.0050)Ala+(0.
0087)Orn+(0.0974)Phe+(-0.1419)Trp; 0.850, 0.876, 0.797, 0.783, 0.
782, 0.851, 0.826, 0.810, (1.5211)+(0.0425)Ser+(0.0017)Gln+(-0.
0051)Ala+(-0.2131)Met+(0.0864)Ile+(-0.1435)Trp; 0.850, 0.874,
0.808, 0.796, 0.767, 0.858, 0.889, 0.827,
(6.9248)+(-0.0077)Ala+(-0.0627)Cit+(-0.0369)Val+(-0.0010)Lys+(0.1719)Ile+-
(-0.127 8)Trp; 0.850, 0.875, 0.810, 0.802, 0.778, 0.851, 0.868,
0.825, (6.22
70)+(-0.0411)Val+(-0.2202)Met+(0.0122)Lys+(0.1894)Ile+(-0.0
176)Leu+(-0.1124)Trp; 0.850, 0.882, 0.773, 0.747, 0.780, 0.831, 0.
783, 0.785,
(1.9568)+(0.0529)Ser+(-0.0010)Gly+(-0.1138)His+(-0.0566)Cit+(0.133-
9)Phe+(-0.1335)Trp; 0.850, 0.877, 0.801, 0.785, 0.801, 0.851,
0.810, 0.812,
(3.8707)+(0.0396)Ser+(-0.0791)Asn+(0.0083)Gln+(-0.1211)His+(0.0297-
)Leu+(-0.1099)Trp; 0.850, 0.8 81, 0.797, 0.777, 0.764, 0.844,
0.886, 0.818, (3.5827)+(-0.0688)Hi
s+(0.0008)Arg+(-0.0516)Val+(-0.3172)Met+(0.1761)Ile+(0.127 2)Phe;
0.850, 0.875, 0.789, 0.781, 0.750, 0.851, 0.845, 0.807, (2.88
99)+(0.0293)Ser+(-0.0103)Ala+(0.0045)Pro+(0.1609)Ile+(-0.06
45)Leu+(-0.1448)Trp; 0.850, 0.875, 0.785, 0.761, 0.795, 0.840, 0.7
90, 0.796, (3.0176)+(0.0360)Ser+(0.0025)Gln+(-0.0959)Cit+(-0.
0156)Lys+(0.0809)Ile+(-0.1757)Trp; 0.850, 0.875, 0.802, 0.786, 0.
779, 0.845, 0.860, 0.817, (6.3016)+(0.0027)Pro+(-0.0458)Val+(-0.
2084)Met+(0.0239)Orn+(0.1721)Ile+(-0.1069)Trp; 0.850, 0.873, 0.
801, 0.787, 0.777, 0.846, 0.855, 0.816, (6.1184)+(0.0013)Gly+(-0.
0457)Val+(-0.2062)Met+(0.0239)Orn+(0.1752)Ile+(-0.1070)Trp; 0.850,
0.872, 0.796, 0.787, 0.746, 0.883, 0.865, 0.820, (3.6212)+(0.
0018)Gln+(0.0301)Thr+(-0.0055)Ala+(-0.0584)Val+(-0.3671)Met
+(0.2129)Ile; 0.850, 0.879, 0.803, 0.778, 0.795, 0.837, 0.866, 0.81
9, (6.1174)+(-0.1072)His+(-0.0061)Ala+(0.0146)Orn+(0.0557)Il
e+(0.0767)Phe+(-0.1253)Trp; 0.850, 0.877, 0.769, 0.754, 0.729, 0.
873, 0.817, 0.793, (1.3818)+(0.0327)Ser+(0.0218)Thr+(-0.0595)V
al+(-0.4144)Met+(0.2093)Ile+(0.0035)Leu; 0.850, 0.876, 0.762, 0.
723, 0.763, 0.830, 0.813, 0.782, (3.9286)+(0.0478)Ser+(-0.0040)G
ly+(-0.1103)His+(0.0022)Tyr+(0.0745)Ile+(-0.1248)Trp; 0.850, 0.880,
0.786, 0.762, 0.798, 0.810, 0.806, 0.794, (5.5158)+(-0.126
3)His+(0.0207)Thr+(0.0001)Pro+(0.0121)Orn+(0.0982)Phe+(-0.1
272)Trp; 0.850, 0.874, 0.804, 0.795, 0.752, 0.854, 0.899, 0.825,
(1.
8321)+(-0.0050)Ala+(-0.0540)Val+(-0.3433)Met+(0.2247)Ile+(-0.0278)Leu+(0.-
1202)Phe; 0.850, 0.874, 0.762, 0.731, 0.779, 0.798, 0.782, 0.773,
(0.5921)+(0.0397)Ser+(-0.0004)Gln+(-0.1134)Cit+(0.0555)Ile+(0.0750)Phe+(--
0.2054)Trp; 0.850, 0.883, 0.807, 0.78 9, 0.817, 0.844, 0.810,
0.815, (6.1079)+(-0.1038)His+(0.0297)Thr
+(-0.0048)Ala+(-0.0672)Cit+(0.1290)Phe+(-0.1420)Trp; 0.850, 0. 878,
0.817, 0.812, 0.806, 0.826, 0.842, 0.822, (3.3097)+(0.0096)Gl
n+(-0.1366)His+(-0.0178)Tyr+(0.0030)Val+(0.1061)Phe+(-0.116 6)Trp;
0.850, 0.877, 0.766, 0.739, 0.780, 0.838, 0.757, 0.778, (-0.3
211)+(0.0614)Ser+(-0.1466)His+(-0.0132)Arg+(-0.2654)Met+(0.
0151)Orn+(0.1580)Phe; 0.850, 0.875, 0.770, 0.744, 0.782, 0.840, 0.
765, 0.783,
(-0.2172)+(0.0610)Ser+(-0.1396)His+(-0.0335)Cit+(0.0008)Val+(-0.28-
06)Met+(0.1639)Phe; 0.850, 0.878, 0.778, 0.76 7, 0.781, 0.794,
0.789, 0.783, (5.4813)+(-0.1216)His+(0.0264)Thr
+(0.0025)Pro+(-0.0364)Tyr+(0.1195)Phe+(-0.1192)Trp; 0.850, 0. 876,
0.800, 0.787, 0.749, 0.854, 0.900, 0.823, (2.0275)+(-0.0066)A
la+(0.0082)Pro+(-0.0625)Val+(-0.3621)Met+(0.2006)Ile+(0.116 4)Phe;
0.850, 0.877, 0.769, 0.743, 0.776, 0.836, 0.775, 0.783, (-0.3
105)+(0.0614)Ser+(-0.0011)Gly+(-0.1455)His+(-0.0006)Val+(-0.
2782)Met+(0.1622)Phe; 0.850, 0.875, 0.791, 0.779, 0.743, 0.878, 0.
859, 0.815, (4.3085)+(0.0306)Thr+(-0.0068)Ala+(0.0070)Pro+(-0.
0583)Val+(-0.3630)Met+(0.2072)Ile; 0.850, 0.875, 0.787, 0.761, 0.
776, 0.848, 0.836, 0.805, (6.3778)+(-0.0987)Cit+(-0.0364)Val+(0.
0503)Orn+(-0.0094)Lys+(0.1464)Ile+(-0.1393)Trp; 0.850, 0.879,
0.814, 0.809, 0.802, 0.824, 0.845, 0.820,
(2.8738)+(0.0030)Gly+(-0.2531)Met+(0.1595)Ile+(-0.0782)Leu+(0.1134)Phe+(--
0.1275)Tr p; 0.850, 0.877, 0.778, 0.759, 0.753, 0.860, 0.819,
0.798,
(6.4120)+(-0.0704)His+(0.0411)Thr+(-0.0162)Arg+(-0.0475)Val+(-0.321
6)Met+(0.1891)Ile; 0.850, 0.878, 0.770, 0.747, 0.776, 0.835, 0.773,
0.783, (-0.1149)+(0.0624)Ser+(-0.0332)Asn+(-0.1426)His+(-0.2
580)Met+(0.0006)Lys+(0.1612)Phe; 0.850, 0.872, 0.787, 0.769, 0.7
61, 0.879, 0.826, 0.808, (4.4153)+(0.0298)Thr+(-0.0688)Cit+(-0.
0586)Val+(-0.3688)Met+(0.0270)Orn+(0.1998)Ile; 0.850, 0.875, 0.
792, 0.771, 0.790, 0.832, 0.822, 0.804, (1.9264)+(0.0551)Ser+(-0.
0067)Gly+(-0.2333)Met+(0.0043)Orn+(0.0761)Ile+(-0.1477)Trp; 0.850,
0.875, 0.764, 0.747, 0.769, 0.794, 0.781, 0.773, (0.5898)+(0.
0399)Ser+(-0.1090)Cit+(-0.0378)Tyr+(0.0560)Ile+(0.0965)Phe+(-0.1921)Trp;
0.850, 0.878, 0.813, 0.805, 0.804, 0.825, 0.845, 0.82 0,
(3.3598)+(0.0095)Gln+(-0.1390)His+(-0.0173)Tyr+(0.0118)Le
u+(0.0994)Phe+(-0.1202)Trp; 0.850, 0.878, 0.775, 0.758, 0.780, 0.
798, 0.793, 0.782,
(5.5806)+(-0.1281)His+(0.0275)Thr+(-0.0357)Tyr+(0.0117)Leu+(0.1114)Phe+(--
0.1251)Trp; 0.850, 0.876, 0.772, 0.746, 0.782, 0.841, 0.767, 0.784,
(-0.1681)+(0.0608)Ser+(-0.138
3)His+(-0.0003)Ala+(-0.0331)Cit+(-0.2776)Met+(0.1649)Phe; 0. 850,
0.872, 0.803, 0.784, 0.786, 0.843, 0.856, 0.818, (7.3380)+(-0.
0745)His+(-0.0060)Ala+(0.0228)Orn+(0.1261)Ile+(-0.0410)Leu+(-0.1111)Trp;
0.850, 0.879, 0.774, 0.751, 0.783, 0.842, 0.766, 0.78 6,
(0.0909)+(0.0635)Ser+(-0.0347)Asn+(-0.1337)His+(-0.0335)C
it+(-0.2541)Met+(0.1641)Phe; 0.850, 0.875, 0.756, 0.742, 0.739, 0.
794, 0.799, 0.768, (0.6559)+(0.0315)Ser+(-0.0025)Gln+(0.1380)I
le+(-0.0724)Leu+(0.0689)Phe+(-0.1646)Trp; 0.850, 0.881, 0.820,
0.803, 0.820, 0.844, 0.851, 0.829, (3.1785)+(0.0107)Gln+(-0.129
3)His+(-0.0615)Cit+(0.0136)Leu+(0.1038)Phe+(-0.1364)Trp; 0.8 50,
0.879, 0.782, 0.771, 0.786, 0.802, 0.791, 0.787, (5.6383)+(-0.1
212)His+(0.0284)Thr+(-0.0344)Tyr+(-0.0026)Lys+(0.1229)Phe+(-0.1182)Trp;
0.850, 0.877, 0.793, 0.778, 0.768, 0.825, 0.862, 0.80 8,
(3.9218)+(-0.0869)Cit+(-0.0291)Val+(0.1697)Ile+(-0.0375)L
eu+(0.0891)Phe+(-0.1540)Trp; 0.850, 0.874, 0.790, 0.779, 0.769, 0.
847, 0.820, 0.804,
(3.4041)+(0.0414)Ser+(-0.1018)Asn+(-0.0021)Thr+(0.1405)Ile+(-0.0582)Leu+(-
-0.1342)Trp; 0.850, 0.875, 0.758, 0.724, 0.762, 0.833, 0.787,
0.777, (4.1380)+(0.0463)Ser+(-0.106
5)His+(-0.0153)Arg+(-0.0013)Lys+(0.0801)Ile+(-0.1198)Trp; 0. 850,
0.874, 0.754, 0.716, 0.757, 0.831, 0.794, 0.775, (3.9002)+(0.0
404)Ser+(-0.1150)His+(0.0029)Thr+(0.0029)Tyr+(0.0746)Ile+(-0.1252)Trp;
0.850, 0.877, 0.815, 0.797, 0.791, 0.854, 0.883, 0.831,
(6.3750)+(0.0315)Tyr+(-0.0433)Val+(-0.2292)Met+(0.1845)Ile+(-0.0076)Leu+(-
-0.1126)Trp; 0.850, 0.881, 0.803, 0.807, 0.795, 0.8 09, 0.805,
0.804, (0.8832)+(0.0451)Ser+(-0.1548)Asn+(0.0024)Gl
n+(0.0036)Pro+(0.0876)Phe+(-0.1530)Trp; 0.850, 0.878, 0.801, 0.
794, 0.797, 0.805, 0.826, 0.806, (1.8218)+(0.0566)Ser+(-0.1413)A
sn+(-0.0068)Gly+(0.0043)Pro+(0.0850)Phe+(-0.1528)Trp; 0.850, 0.872,
0.809, 0.793, 0.800, 0.847, 0.845, 0.821, (5.0483)+(-0.046
4)Asn+(0.0024)Gly+(0.0099)Gln+(-0.1159)His+(0.0642)Ile+(-0.
1189)Trp; 0.850, 0.880, 0.797, 0.777, 0.765, 0.845, 0.885, 0.818,
(3. 6045)+(-0.0686)His+(0.0002)Tyr+(-0.0517)Val+(-0.3159)Met+(0.
1762)Ile+(0.1272)Phe; 0.850, 0.880, 0.798, 0.776, 0.766, 0.850, 0.
886, 0.820,
(3.7214)+(-0.0626)His+(-0.0301)Cit+(-0.0519)Val+(-0.3057)Met+(0.17-
74)Ile+(0.1294)Phe; 0.850, 0.875, 0.790, 0.77 9, 0.772, 0.846,
0.817, 0.803, (3.4481)+(0.0402)Ser+(-0.1079)Asn
+(0.0045)Orn+(0.1376)Ile+(-0.0576)Leu+(-0.1349)Trp; 0.850, 0. 874,
0.810, 0.798, 0.771, 0.860, 0.886, 0.829, (6.8927)+(-0.0077)A
la+(-0.0638)Cit+(-0.0293)Val+(0.1878)Ile+(-0.0244)Leu+(-0.1
256)Trp;
0.850, 0.870, 0.792, 0.772, 0.788, 0.831, 0.829, 0.805, (5.
0990)+(0.0075)Gln+(-0.1265)His+(0.0115)Thr+(-0.0022)Pro+(0.
0664)Ile+(-0.1293)Trp; 0.850, 0.880, 0.824, 0.816, 0.820, 0.838, 0.
844, 0.829, (3.3774)+(0.0117)Gln+(-0.1420)His+(-0.0196)Arg+(0.
0102)Leu+(0.0969)Phe+(-0.1221)Trp; 0.850, 0.874, 0.790, 0.775, 0.
786, 0.841, 0.798, 0.800, (2.3839)+(0.0486)Ser+(-0.0469)Asn+(-0.
1917)Met+(-0.0011)Lys+(0.0769)Ile+(-0.1418)Trp; 0.850, 0.881,
0.824, 0.801, 0.820, 0.846, 0.874, 0.835,
(6.0142)+(-0.0922)His+(-0.0039)Ala+(-0.1520)Met+(0.0621)Ile+(0.1084)Phe+(-
-0.1168)Trp; 0.850, 0.876, 0.819, 0.813, 0.806, 0.822, 0.857,
0.824, (3.330
9)+(0.0043)Asn+(-0.2450)Met+(0.1582)Ile+(-0.0778)Leu+(0.111
0)Phe+(-0.1284)Trp; 0.850, 0.878, 0.794, 0.795, 0.791, 0.806, 0.79
1, 0.795, (1.4981)+(0.0456)Ser+(-0.1511)Asn+(0.0046)Thr+(0.00
34)Pro+(0.0884)Phe+(-0.1531)Trp; 0.850, 0.877, 0.784, 0.769, 0.7
30, 0.884, 0.863, 0.811, (1.2949)+(0.0405)Ser+(-0.0060)Ala+(-0.
0475)Val+(-0.2975)Met+(0.2168)Ile+(-0.0147)Leu; 0.850, 0.874,
0.789, 0.779, 0.786, 0.856, 0.772, 0.798,
(5.6071)+(0.0445)Ser+(-0.0808)His+(-0.0024)Ala+(0.0162)Pro+(-0.1163)Met+(-
-0.0943)I rp; 0.850, 0.878, 0.821, 0.820, 0.804, 0.838, 0.845,
0.827, (1.9949)
+(0.0555)Ser+(-0.1290)Asn+(-0.0062)Gly+(-0.0044)Ala+(0.098
4)Phe+(-0.1436)Trp; 0.850, 0.878, 0.806, 0.778, 0.812, 0.823, 0.85
5, 0.817, (5.1465)+(0.0400)Asn+(-0.1038)His+(-0.2076)Met+(0.0
608)Ile+(0.1128)Phe+(-0.1189)Trp; 0.850, 0.874, 0.809, 0.786, 0.
806, 0.843, 0.849, 0.821, (4.7956)+(0.0100)Gln+(-0.1052)His+(-0.
0566)Cit+(0.0011)Pro+(0.0713)Ile+(-0.1355)Trp; 0.850, 0.871, 0.
788, 0.774, 0.755, 0.877, 0.829, 0.809, (4.6427)+(0.0342)Thr+(-0.
0547)Cit+(0.0022)Pro+(-0.0580)Val+(-0.3831)Met+(0.2037)Ile
[0530] Although the invention has been described with respect to
specific embodiments for a complete and clear disclosure, the
appended claims are not to be thus limited but are to be construed
as embodying all modifications and alternative constructions that
may occur to one skilled in the art that fairly fall within the
basic teaching herein set forth.
* * * * *